<SEC-DOCUMENT>0001019687-14-002904.txt : 20140731
<SEC-HEADER>0001019687-14-002904.hdr.sgml : 20140731
<ACCEPTANCE-DATETIME>20140731144522
ACCESSION NUMBER:		0001019687-14-002904
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20140731
DATE AS OF CHANGE:		20140731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RestorGenex Corp
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-197409
		FILM NUMBER:		141005856

	BUSINESS ADDRESS:	
		STREET 1:		1800 CENTURY PARK EAST, 6TH FLOOR
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310.526.8700

	MAIL ADDRESS:	
		STREET 1:		1800 CENTURY PARK EAST, 6TH FLOOR
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TITAN MOTORCYCLE CO OF AMERICA INC
		DATE OF NAME CHANGE:	19980615
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>restorgenex_424b3-073114.htm
<DESCRIPTION>RESTORGENEX CORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to Rule 424(b)(3)<BR>
Registration No. 333-197409</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RestorGenex Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>11,633,885 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus relates to the sale of up
to 8,949,142 shares of our currently outstanding shares of common stock that are owned by some of our stockholders, and 2,684,743
shares issuable upon the exercise of currently outstanding common stock purchase warrants held by some of the warrant holders.
For a list of the selling stockholders, please see &ldquo;Selling Stockholders.&rdquo; The selling stockholders may sell these
shares from time to time in the principal market on which our common stock is traded at the prevailing market price or in negotiated
transactions. The selling stockholders may be deemed underwriters within the meaning of the Securities Act of 1933, as amended,
of the shares of common stock that they are offering. We will pay the expenses of registering these shares. We will not receive
proceeds from the sale of our shares by the selling stockholders that are covered by this prospectus. However, we will receive
payment in cash upon any exercise of the warrants for cash, and any proceeds we receive will be used for general corporate purposes
and for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The securities are being registered to permit
the selling stockholders to sell the securities from time to time in the public market. The selling stockholders may sell the securities
through ordinary brokerage transactions or through any other means described in the section titled &ldquo;Plan of Distribution.&rdquo;
We do not know when or in what amount the selling stockholders may offer the securities for sale. The selling stockholders may
sell some, all or none of the securities offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed for quotation
on the OTC QB, under the symbol &ldquo;RESX&rdquo;. There is limited trading in our common stock.&nbsp; On July 8, 2014, the last
reported price per share of our common stock was $4.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>You should understand the risks associated
with investing in our common stock. Before making an investment, read the &ldquo;Risk Factors,&rdquo; which begin on page 4 of
this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>We may amend or supplement this prospectus
from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or
supplements carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>RESTORGENEX CORPORATION HAS NOT REGISTERED
THE SHARES FOR SALE BY THE SELLING STOCKHOLDERS UNDER THE SECURITIES LAWS OF ANY STATE. BROKERS OR DEALERS EFFECTING TRANSACTIONS
IN THE SHARES SHOULD CONFIRM THAT THE SHARES HAVE BEEN REGISTERED UNDER THE SECURITIES LAWS OF THE STATE OR STATES IN WHICH SALES
OF THE SHARES OCCUR AS OF THE TIME OF SUCH SALES, OR THAT THERE IS AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF
THE SECURITIES LAWS OF SUCH STATES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is July
31, 2014</B></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">TABLE OF CONTENTS</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 95%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Page</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUMMARY</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BUSINESS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF OUR DERMATOLOGY BUSINESS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF OUR OPHTHALMOLOGY BUSINESS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF OUR WOMEN&rsquo;S HEALTH BUSINESS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MARKET PRICE OF AND DIVIDENDS ON COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">46</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">51</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">52</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SELLING STOCKHOLDERS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SECURITIES</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DISCLOSURE OF SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INDEX TO FINANCIAL STATEMENTS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-1</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">This prospectus is part of a registration statement
we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).&nbsp;&nbsp;You should rely only on the information
provided in this prospectus.&nbsp;&nbsp;We have not authorized anyone to provide you with information different from that contained
in this prospectus.&nbsp;&nbsp;This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities
other than the common stock offered by this prospectus.&nbsp;&nbsp;This prospectus does not constitute an offer to sell or a solicitation
of an offer to buy any common stock in any circumstances in which such offer or solicitation is unlawful.&nbsp;&nbsp;The selling
stockholders are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales
are permitted.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances,
create any implication that there has been no change in our affairs since the date of this prospectus or that the information
contained by reference to this prospectus is correct as of any time after its date.&nbsp;&nbsp;The information in this prospectus
is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common
stock.&nbsp;&nbsp;The rules of the SEC may require us to update this prospectus in the future.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">PROSPECTUS SUMMARY</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">This summary highlights information
contained elsewhere in this prospectus; it does not contain all of the information you should consider before investing in our
common stock. You should read the entire prospectus before making an investment decision.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Throughout this prospectus,
the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;our company&rdquo; refer to RestorGenex Corporation,
a Nevada corporation, formerly known as Stratus Media Group, Inc.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">All references to the number
of shares issued or outstanding in this prospectus, and all per share and other similar data, reflect a <FONT STYLE="font-size: 10pt">1-for-100
reverse stock split that we effected on March 7, 2014. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are a specialty biopharmaceutical
company initially focused on developing products for dermatology, ophthalmology and women&rsquo;s health.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">RestorGenex History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Prior to our repositioning as a specialty
biopharmaceutical company, on March 14, 2008, pursuant to an Agreement and Plan of Merger dated August 20, 2007 between Feris International,
Inc. (&ldquo;Feris&rdquo;) and Pro Sports &amp; Entertainment, Inc. (&ldquo;PSEI&rdquo;), Feris issued 49,500,000 shares of its
common stock for all issued and outstanding shares of PSEI, resulting in PSEI becoming a wholly-owned subsidiary of Feris and the
surviving entity for accounting purposes (&ldquo;Reverse Merger&rdquo;). In July 2008, Feris&rsquo; corporate name was changed
to Stratus Media Group, Inc. PSEI, a California corporation, was organized on November 23, 1998 and specialized in various sports
events that it owned and operated. PSEI also owned Stratus Rewards LLC (&ldquo;Stratus White&rdquo;) that planned to operate a
credit card rewards program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In June 2011, we acquired Series A
Convertible Preferred Stock of ProElite, Inc., a New Jersey corporation (&ldquo;ProElite&rdquo; or &ldquo;PEI&rdquo;), that organizes
and promotes mixed martial arts (&ldquo;MMA&rdquo;) matches. These holdings of Series A Convertible Preferred Stock provide us
voting rights on an as-converted basis equivalent to a 95% ownership in ProElite. On February 5, 2009, PEI entered into an Asset
Purchase Agreement and other related agreements with Explosion Entertainment, LLC (&ldquo;Strikeforce&rdquo;). Under the terms
of the Purchase Agreement, Strikeforce acquired from PEI certain PEI fighter contracts, a library of televised PEI events and specified
related assets. Consideration paid for the assets consisted of (i) $3 million in cash paid at closing, (ii) the assumption of certain
liabilities relating to the assets sold and (iii) contingent consideration in the form of rights to receive a portion of the license
fee earned by Strikeforce under a distribution agreement between Strikeforce and Showtime Networks Inc. (&ldquo;Showtime&rdquo;).
PEI was informed in March 2013 that Strikeforce was no longer conducting these Showtime events and there will be no further license
fees received by PEI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">During the first quarter of 2013, we
decided to focus on the MMA business and temporarily suspended development of our other businesses. Because of lack of working
capital, effective June 30, 2013, we suspended operations of ProElite. Following our repositioning as a specialty biopharmaceutical
company as discussed below, our board of directors voted to discontinue operations of PEI effective March&nbsp;31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Effective September 30, 2013, we entered
into an Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;) with Canterbury Acquisition LLC, Hygeia Acquisition,
Inc., Canterbury Laboratories, LLC (&ldquo;Canterbury&rdquo;), Hygeia Therapeutics, Inc. (&ldquo;Hygeia&rdquo;) and Yael Schwartz,
Ph.D., as Holder Representative, pursuant to which we agreed to acquire all of the capital stock of Canterbury and Hygeia with
Canterbury and Hygeia becoming our wholly owned subsidiaries. The consideration for the mergers was the issuance by us of an aggregate
of 1,150,116 restricted shares of our common stock issued to the stakeholders of Canterbury and Hygeia. Effective November 18,
2013, the mergers were completed, and Canterbury and Hygeia became our wholly owned subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On March 3, 2014, we entered into
an Agreement and Plan of Merger with Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. (&ldquo;Paloma&rdquo;) and David Sherris,
Ph.D., as founding stockholder and Holder Representative pursuant to which we agreed to acquire all of the capital stock of Paloma
with Paloma becoming our wholly owned subsidiary. On March 28, 2014, the merger with Paloma was closed and we issued an aggregate
of 2,500,000 common shares to the holders of Paloma Common Stock and its derivative securities and assumed promissory notes of
Paloma in the aggregate amount (principal and interest) currently of approximately $1,130,500 to be paid on the first anniversary
of the closing of the Paloma merger.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Also on March 3, 2014, we entered into
an Agreement and Plan of Merger with VasculoMedics Acquisition, Inc., VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;) and Dr.
Sherris pursuant to which we agreed to acquire all of the capital stock of VasculoMedics with VasculoMedics becoming our wholly
owned subsidiary. The VasculoMedics merger was concurrently closed with and as a condition to the closing of the Paloma Merger
on March 28, 2014, with our company issuing an aggregate of 220,000 common shares to the VasculoMedics stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On March 7, 2014, we effected a reverse
stock split of 1 to 100 with respect to our Common Stock and we changed our corporate name from Stratus Media Group, Inc. to RestorGenex
Corporation. All stock numbers herein are post reverse split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As part of our repositioning as a specialty
biopharmaceutical company, effective March&nbsp;5, 2014 we appointed Stephen M. Simes as our Chief Executive Officer and effective
May 27, 2014 we appointed Phillip Donenberg as our Chief Financial Officer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">Hygeia and Canterbury History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Hygeia is a Delaware Corporation based
in Holden, Massachusetts and was formerly known as Orcas Therapeutics, Inc. It was incorporated on November 14, 2005 to acquire
and develop biodegradable hormone receptor modulators for topical indications. Hygeia is focused on developing topical therapies
for conditions for which localized treatments offer advantages over systemic therapies. Hygeia has signed an Exclusive License
Agreement (the &ldquo;Yale License&rdquo;) with Yale University (&ldquo;Yale&rdquo;) under U.S. Patent 7,015,211 &ldquo;<I>15.alpha.-Substituted
Estradiol Carboxylic Acid Esters as Locally Active Estrogens</I>,&rdquo; U.S. Patent 6,476,012 &ldquo;<I>Estradiol-16.alpha Carboxylic
Acid Esters as Locally Active Estrogens</I>&rdquo; and U.S. Patent 8,552,061 &ldquo;<I>Locally active &quot;soft&quot; antiandrogens</I>&rdquo;
(together the &ldquo;Yale Patents&rdquo;). Hygeia agreed to pay royalty fees to Yale quarterly beginning in the first calendar
quarter in which net sales occur. Canterbury is a Delaware limited liability company that was formed on October 14, 2011 and began
operations on February 22, 2012. Initially, Canterbury was a wholly owned subsidiary of Hygeia. Canterbury is engaged in the premium
cosmeceutical business. Cosmeceuticals are the latest addition to the health industry and are sometimes described as cosmetic products
with &ldquo;drug-like benefits.&rdquo; Generally, cosmeceuticals are products sold over-the-counter, without the requirement of
the Food and Drug Administration (&ldquo;FDA&rdquo;) approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">A reorganization and separation agreement
was signed on October 14, 2011 between Canterbury and Hygeia under which Hygeia received 100% of all issued and outstanding units
of all classes of limited liability company membership interests of Canterbury. Hygeia distributed these profit units to holders
of its common and preferred stock. Further, shares were issued to the Hygeia&rsquo;s non-qualifying stock option (&ldquo;NSO&rdquo;)
holders to liquidate the outstanding NSO&rsquo;s. Holders of Hygeia stock purchase warrants exchanged their warrants for an equal
number of units of Canterbury stock purchase warrants. Pursuant to the license agreement shares of Series A convertible preferred
stock was issued to Yale University for the Yale License. In February 2012, Hygeia assigned its rights and obligations related
to non-prescription products under the Yale License to Canterbury.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">Paloma and VasculoMedics History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Both Paloma and VasculoMedics are Delaware
corporations and are based in Jamaica Plain, Massachusetts. Paloma was founded in January 2005 and VasculoMedics was founded in
November 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Paloma has developed a non-steroidal,
synthetic, small molecule drug library for dermatology (psoriasis, atopic dermatitis, rosacea, actinic keratosis, keloid and hypertrophic
scarring, Dupuytren&rsquo;s disease, bullous blistering diseases), ocular disease, cancer, pulmonary fibrosis, CNS (Huntington&rsquo;s
disease and infantile spasm, a form of childhood epilepsy), biodefense and anti-viral application. The lead product, P529, targets
and inhibits the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dual TORC1/TORC2 dissociative
inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">VasculoMedics was founded as a platform
epigenetic company to develop orally available small molecular inhibitors of zinc finger transcription factors. Zinc finger transcription
factors are a subset of transcription factors utilizing zinc at its core for activity. Transcription factors are proteins that
bind to specific parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs the protein
making machinery to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of a transcription
factor, one can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription factor. Many
diseases can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors. Inhibition
of such transcription factors could then be able to control disease pathology.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">Recent Developments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-indent: 0.5in">We have entered into securities purchase
agreements (the &ldquo;Securities Purchase Agreements&rdquo;) with various institutional and individual accredited investors to
raise gross proceeds of $35,582,740 in a private placement (the &ldquo;Private Placement&rdquo;). On July 10, 2014, we completed
the Private Placement. In connection with the Private Placement, we issued (i) an aggregate of 8,895,685 shares of our common stock,
and (ii)&nbsp;warrants (&ldquo;Warrants&rdquo;) to purchase a total of 2,668,706 shares of common stock. The purchasers of common
stock received warrants to purchase 0.3 shares of Common Stock for each share of common stock that such investors purchased in
the Private Placement. The purchase price of each common stock/Warrant unit was $4.00. Each warrant is exercisable into a share
of common stock at an initial exercise price of $4.80 per share. We received net proceeds of approximately $31.3 million from the
Private Placement, after paying placement agent fees, estimated offering expenses, and certain accounts payable, which we will
use to fund our research and development and for working capital purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-indent: 0.5in">Maxim Group, LLC acted as placement
agent for the Private Placement. As compensation for the services of Maxim Group, LLC, we paid $3,558,274 of placement agent
fees and issued common stock purchase warrants to purchase up to 927,069 shares of our common stock with the same initial
exercise price and terms as the Warrants. The shares underlying the warrants that we issued to the placement agent are not
included in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-indent: 0.5in">We filed the registration statement of
which this prospectus is a part to fulfill certain of our contractual obligations to the investors in the Private Placement under
registration rights agreements we entered into pursuant to the Securities Purchase Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at 1800 Century Park East, 6th Floor, Los Angeles, California 90067, and our telephone number at that address is (805) 229-1829.
 Our website is located at www.RestorGenex.com. Information on our website is not, and should not be considered, part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-align: center">The Offering</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 8.1pt; padding-bottom: 12pt">Common Stock offered by the selling stockholders</td>
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">11,633,885 shares (1)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 8.1pt; padding-bottom: 12pt">Common Stock offered by us</td>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">None</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 8.1pt; padding-bottom: 12pt">Common Stock currently outstanding</td>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">18,360,025 shares (2)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 8.1pt; padding-bottom: 12pt">Common Stock to be outstanding after the offering</td>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">9,410,883 shares (2)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 8.1pt; padding-bottom: 12pt">OTC QB trading symbol</td>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">RESX</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 8.1pt; padding-bottom: 12pt">Use of proceeds</td>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">We will not receive any proceeds from the sale of the common stock offered hereby.&nbsp;However, we may receive up to a maximum of approximately $12,886,766 of gross proceeds from the exercise of Warrants in cash by selling stockholders, which proceeds we expect to use for general working capital.&nbsp;No assurances can be given, however, that all or any portion of such warrants will ever be exercised.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 8.1pt; padding-bottom: 12pt">Risk Factors</td>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt">An investment in our common stock involves significant risks.&nbsp;See &ldquo;Risk Factors&rdquo; beginning on page 4, below.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt">_________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 3pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in">(1)</TD><TD><P STYLE="margin: 0pt 0">Includes 8,949,142 shares of common stock issued to investors and our law firm in connection with the
Private Placement a<FONT STYLE="font: 10pt Times New Roman, Times, Serif">nd 2,684,743 shares of common stock issuable upon the
exercise of the warrants issued in the Private Placement to investors and our law firm.</FONT></P>


</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>(2)</TD><TD><P STYLE="margin: 0pt 0">Does not include (i) 1,594,680 shares of common stock issuable upon the exercise of outstanding options
(with exercise prices ranging from $2.50 to $155.00 per share), (ii) 872,567 shares of common stock issuable upon the exercise
of all of the warrants issued previous to the Private Placement (with exercise prices ranging from $3.00 to $200.00 per share)
or (iii) the 3,611,812 shares of common stock issuable upon the exercise of all of the warrants issued in the Private Placement.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.15pt; text-indent: -20.15pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.15pt; text-indent: -20.15pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.15pt; text-indent: -20.15pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">RISK FACTORS</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">You should carefully consider
the risks described below before deciding whether to invest in our common stock. The risks described below are not the only ones
we face. Additional risks not presently known to us or that we currently believe are immaterial may also impair our business operations
and financial results. If any of the following risks actually occurs, our business, financial condition or results of operations
could be adversely affected. In such case, the trading price of our common stock could decline and you could lose all or part of
your investment. Our filings with the SEC also contain forward-looking statements that involve risks or uncertainties. Our actual
results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including
the risks we face described below.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">RISKS RELATING TO OUR BUSINESS</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We will require a significant amount of cash
to fully implement our business plan, and any failure to generate and raise sufficient cash would impair our ability to implement
fully our business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We will require a significant amount
of cash to fully implement our business plan. Our ability to fund working capital needs will depend on our ability to obtain sufficient
financing in the form of equity or debt or a combination thereof, the amount of which will depend in part on our ability to generate
cash flow in the future. Our ability to generate future cash flow is subject to general economic, financial, competitive, legislative,
regulatory and other factors that are beyond our control. We cannot assure you that our business will generate cash flow from operations
or that our cash needs will not increase beyond what we currently anticipate our cash needs to be. Equity or debt financing may
not be available at all or may be available only on terms that are not favorable to us. In addition, any debt financing, if available,
may involve restrictions on our ability to pay dividends or the manner in which we conduct our business. Our ability to obtain
additional financing depends on many factors beyond our control, including our net assets and the prospects for our business. The
inability to timely obtain sufficient funds will require us to delay, scale back or eliminate all or some of our research and development,
personnel recruitment and marketing, among other corporate activities. There is no assurance that we will be able to raise sufficient
capital or generate sufficient cash flow to permit us to timely discharge our obligations or to successfully operate as a going
concern.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We have a history of losses and expect to incur
losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Because of our focus on research and
development, we have not yet established many of the necessary functions and systems that will be central to conducting business,
including an administrative structure, sales and marketing activities and personnel recruitment. The likelihood of our success
must be considered in light of the problems, expenses, difficulties, complications, competition and delays frequently encountered
in connection with the development of a new business and new products. There can be no assurance that we will be able to generate
sufficient funds from operations or be able to raise sufficient capital to enable us to continue with our business plan and develop
new products or, if developed, that the products will be commercially successful. Any factor adversely affecting the sale of future
products, including delays in product development, flaws or lack of acceptance of the products would have a material adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are subject to all of the risks
inherent in both the creation of a new business structure and the development of new products, including the absence of a history
of significant operations and the absence of established products.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We have no operating history, no products and
no revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have not generated any significant
revenues or profits from our life science business. The likelihood of our success must be considered in light of the risks, costs,
difficulties and delays frequently encountered in developing new products and services. There can be no assurance that our products
will prove to be commercially feasible, successful or profitable in the foreseeable future.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our products may not generate revenues in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our development of current and future
product candidates is subject to the risks of failure inherent in the development of new pharmaceutical products and products based
on new technologies. These risks include but are not limited to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Delays in product development, clinical testing or manufacturing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Unplanned expenditures in product development, clinical testing, manufacturing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Failure in clinical trials or failure to receive regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Emergence of superior or equivalent products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Inability to manufacture on our own, or through others, product candidates on a commercial scale;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Inability to market products due to third party proprietary rights; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Failure to achieve market acceptance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Because of these risks, our research
and development efforts may not result in any commercially viable products. If significant portions of these development efforts
are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful,
our business, financial condition and results of operations will be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As an early stage company, our revenue
and profit potential is unproven and our limited operating history makes it difficult for an investor to evaluate our business
and prospects. Our technology may not result in any meaningful benefits to our current or potential patients or business partners.
Our products may not generate revenues in the future. Further, due to our limited operating history, we have difficulty accurately
forecasting revenue or determining whether there will be any revenue. Our business and prospects should be considered in light
of the heightened risks and unexpected expenses and problems we may face as a company in an early stage of development in a new
and rapidly evolving industry.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We anticipate future losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The costs associated with clinical
trials and product manufacturing are very expensive and the time frame necessary to achieve market recognition and success for
our product candidates is long and uncertain. We do not expect to generate material product revenues for several years, and we
may never generate product revenues sufficient to become profitable or to sustain profitability.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our product development efforts may not be
successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our product candidates have not received
regulatory approval and many of our product candidates are generally in research and pre-clinical stages of development. If the
results from any of the laboratory research, and preclinical and clinical trials are poor, those results may adversely affect our
ability to raise additional capital, which will affect our ability to continue full-scale research and development for our products
and technologies. In addition, our product candidates may take longer than anticipated to progress to and through clinical trials,
or patient enrollment in the clinical trials may be delayed or prolonged significantly, thus delaying the clinical trials. Patient
enrollment is a function of many factors, including the size of the patient population, the nature of the protocols, the proximity
of patients to the clinical sites, the eligibility criteria for the study, and the availability of insurance coverage.</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Clinical trials required for our product candidates
are expensive and time consuming, and their outcome is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In order to obtain FDA approval to
market a new drug product, we must demonstrate proof of safety and efficacy in humans. To meet these requirements, we will have
to conduct extensive pre-clinical testing and adequate and well-controlled clinical trials. Conducting clinical trials is a lengthy,
time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and
intended use of the product candidate, and often can be several years or more per trial. Delays associated with products for which
we are directly conducting pre-clinical or clinical trials may cause us to incur additional operating expenses. The commencement
and rate of completion of clinical trials may be delayed by many factors, including, for example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The inability to obtain additional funding to finance our operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The inability to manufacture sufficient quantities of qualified materials under current good manufacturing practices, or cGMPs,
for use in clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Slower than expected rates of patient recruitment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The need or desire to modify our manufacturing processes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The inability to adequately observe patients after treatment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Changes in regulatory requirements for clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The lack of effectiveness during the clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Unforeseen safety issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Delays, suspension, or termination of the clinical trials due to the institutional review board responsible for overseeing
the study at a particular study site; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Government or regulatory delays or &ldquo;clinical holds&rdquo; requiring suspension or termination of the trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Even if we obtain positive results
from pre-clinical or clinical trials, we may not achieve the same success in future trials. Clinical trials may not demonstrate
statistically sufficient safety and effectiveness to obtain the requisite regulatory approvals for product candidates employing
our technology. The failure of clinical trials to demonstrate safety and effectiveness for our desired indications could harm the
development of that product candidate as well as other product candidates. Any change in, or termination of, our clinical trials
could materially harm our business, financial condition and results of operations.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Third-party manufacturing facilities may not
continue to meet regulatory requirements and have limited capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Before approving a new drug or biologic
product, the FDA requires that the facilities at which the product will be manufactured be in compliance with current good manufacturing
practices, or cGMP requirements. To be successful, our products must be manufactured for development and, following approval, in
commercial quantities, in compliance with regulatory requirements and at acceptable costs. We do have any manufacturing facilities.
We do not propose to establish them in the future as we intend to use third-party providers to meet our manufacturing requirements.
We may also encounter problems with the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Production yields;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Quality control and assurance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Shortages of qualified personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Compliance with FDA regulations, including the demonstration of purity and potency;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Changes in FDA requirements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Production costs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Development of advanced manufacturing techniques and process controls.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In addition, any third-party manufacturer
and we will be required to register manufacturing facilities with the FDA and other regulatory authorities. The facilities will
be subject to inspections confirming compliance with cGMP or other regulations. If any of our third-party manufacturers or we fail
to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a
pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business,
financial condition and results of operations may be materially harmed.</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Since we will be administering some of our
products in human clinical trials and thereafter to patients, we will be subject to potential product liability risks which are
inherent in the testing, manufacturing, marketing and sale of therapeutic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Clinical trials on humans create a
risk of liability for serious side effects to participants resulting from an adverse reaction to the products being tested or resulting
from negligence or misconduct and the associated adverse publicity. We intend to manage our liability risks by trying to follow
proper protocols and obtain an appropriate level of clinical trial liability insurance. Such insurance is expensive and difficult
to obtain. In the future, insurance coverage might not be available to us on acceptable terms, if at all. If we are unable to obtain
sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims we might not
be able to commercialize our products. If we face a future product liability claim or a product withdrawal, we may suffer a material
adverse effect on our financial condition.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We are dependent upon the performance of various
corporate and academic collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have and will continue to enter
into various arrangements with corporate and academic collaborators, licensors, licensees and others for the research, development,
clinical testing, manufacturing, marketing and commercialization of our products. We will not have control over how they perform
their contractual obligations. Accordingly, we will suffer if they do not fulfill their contractual obligations. We may enter into
additional corporate agreements to develop and commercialize product candidates. We might not be able to establish such additional
collaborations on favorable terms, if at all, or that our current or future collaborative arrangements will be successful. In addition,
third party arrangements may require us to grant certain rights to third parties, including exclusive marketing rights to one or
more products, or may have other terms that are burdensome to us. Also, various third parties might not fulfill their obligations
in a manner which maximizes our revenues. These arrangements may also require us to transfer certain material rights or issue equity
securities to corporate investors, licensees and others. If we license or sublicense our commercial rights to others, we might
realize reduced product revenue compared to our direct commercial exploitation. Moreover, we might not derive any revenue or profit
from these arrangements. Collaborators might also pursue alternative technologies or drug candidates, either on their own or in
collaboration with others, and compete directly with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In addition, we have limited direct
experience in marketing, sales or distribution, and we do not intend to develop a sales and marketing infrastructure to commercialize
pharmaceutical products in the near future. If we develop product candidates eligible for commercial sales, we intend to rely on
third parties such as licensees, collaborators, joint venture partners or independent distributors to market and sell these products.
We might not be able to obtain access to a marketing and sales force with sufficient technical expertise and distribution capability.
We also will not be able to control the resources and effort that a third party will devote to marketing our product candidates.
If we are unable to develop and maintain relationships with third parties with the necessary marketing and sales force, we may
fail to gain market acceptance of our product candidates, and our revenues could be impaired.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Difficulties managing growth could adversely
affect our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">If we achieve growth in our operations
in the next few years, such growth could place a strain on our management, and our administrative, operational and financial infrastructure.
Our ability to manage our operations and growth requires the continued improvement of operational, financial and management controls,
reporting systems and procedures. In addition, we will need to hire additional management, financial and sales and marketing personnel
to manage our future operations. If we are unable to manage our growth effectively or if we are unable to attract additional highly
qualified personnel, our business, operating results and financial condition may be materially adversely affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Since the manufacture and marketing of human
pharmaceutical products requires the approval of the Food and Drug Administration (&ldquo;FDA&rdquo;) in the United States and
similar agencies in other countries, and since we do not yet have such approval, we may not be able to successfully develop and
market some of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The manufacture and marketing of human
pharmaceutical products in the United States require the approval from the FDA. The process that our pharmaceutical product candidates
must undergo to obtain these approvals includes preclinical testing and clinical trials to demonstrate safety and efficacy. Such
process is expensive and time consuming. Investors are at risk that we will be unable to successfully develop future products,
prove safety and effectiveness in clinical trials, or receive applicable regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have no experience in manufacturing
pharmaceuticals and the applicable GMP regulations for the manufacture of our products, nor do we have a manufacturing facility.
These regulations include requirements relating to quality control, quality assurance and maintenance of records and documentation.
If we cannot establish and demonstrate the proper manufacturing techniques and controls, we will not receive regulatory approval
to manufacture and market our products.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Regulatory authorities have the power to withdraw
a previously approved product from the market upon a change in regulations or upon receipt of newly discovered information and/or
require additional, and potentially expensive, additional testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We might face newly discovered information
that comes to light after initial approval of our product candidates. Unanticipated changes in existing regulations or the adoption
of new regulations could adversely affect the development, manufacture and marketing of our products. Since we have no operating
history, ongoing government regulation could cause unexpected delays and adversely impact our business in areas where our inexperience
might lead to failure in complying with applicable requirements. Such failure to comply might also result in criminal prosecution,
civil penalties, recall or seizure of products, or partial or total suspension of production. Any of these penalties could delay
or prevent the promotion, marketing or sale of our products. Furthermore, the laws, regulations, policies or current administrative
practices of any governmental body, organization or regulatory agency in the United States might be changed, or applied or interpreted
in a manner which will fundamentally alter the ability of us or our collaborative partners to develop, operate, export or market
the products or services which we may provide. We do not have lobbying or other resources to affect the course of such changes.
If such future changes have an adverse impact on our products or their manufacture and marketing, the likelihood of our success
could be damaged.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We are engaged in a rapidly changing field
characterized by intense competition that we expect to increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As a small pre-clinical and clinical
stage company we will experience a competitive disadvantage in the market environment with many of our competitors having significant
products that have been approved or are in development and operate large, well-funded discovery and development programs. We are
engaged in a rapidly changing field characterized by rapid technological change, new and improved product introductions, changes
in regulatory requirements and evolving industry standards. Other drugs and therapies that will compete directly with the products
that we are seeking to develop currently exist or are being developed. We expect competition from fully integrated pharmaceutical
companies and more established biotechnology companies to be intense and to increase. These companies have significantly greater
financial resources and expertise in discovery and development, manufacturing, preclinical and clinical testing, obtaining regulatory
approvals and marketing than we do. Many of our competitors have significant products that have been approved or are in development
and operate large, well-funded discovery and development programs. Academic institutions, governmental agencies and other public
and private research organizations also conduct research, seek patent protection and establish collaborative arrangements for therapeutic
products and clinical development and marketing. In addition, we will face competition based on product efficacy and safety, the
timing and scope of regulatory approvals, availability of supply, marketing and sales capability, reimbursement coverage, pricing
and barriers from patent positions of larger companies. We limited experience in these areas at this time and therefore we are
at a competitive disadvantage.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If our competitors succeed in developing competing
products earlier than we do, in obtaining regulatory approvals for such products more rapidly than we do, or in developing products
that are more effective, safer or less expensive than the products we develop, we may have difficulty competing with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Since many of our competitors keep
their product research and development information confidential, we do not know where they stand in developing competing products.
As a result, we might be using our resources to develop products that will face such competing products and our products might
not be successful in the marketplace. Our future success depends on our ability to timely identify new market trends and to develop,
introduce and support new and enhanced products on a successful and timely basis. We might not be successful in developing or introducing
to the market our products. If we fail to develop and deploy new products on a successful and timely basis, we may be non-competitive
and unable to recoup the research and development and other expenses we incur to develop and test new product candidates.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our success may depend in part on the extent
to which reimbursement for the cost of our products will be available from government health administration authorities, private
health coverage insurers and other organizations, since potential customers might not use our products if such reimbursement is
not available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">At the present time, we have not established
that such governmental authorities or non-governmental providers will reimburse physicians and patients for the use of some of
our product candidates. Recently, the prices of medical products and services have increasingly been examined and challenged by
third parties and consumers of such products and services. We anticipate that new federal or state legislation will be proposed
to attempt to provide broader and better health care and to manage and contain costs. Since we have not yet established reimbursement
coverage, we face significant uncertainty as to the reimbursement status of newly approved health-care products and whether third
party reimbursement will be available at price levels sufficient for us to realize our desired returns.</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our discovery and development processes may
involve the controlled use of hazardous and radioactive materials, which are subject to certain laws and regulations. We cannot
eliminate the risk of accidental contamination or injury from these materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are subject to federal, provincial
and local laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste
products. We cannot eliminate the risk of accidental contamination or injury from these materials. If such an accident occurs,
we might be held liable for any damages that result and any such liability could exceed our resources. We are not specifically
insured with respect to this liability.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">RISKS RELATING TO GOVERNMENT REGULATION</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Regulations governing our industry could have
a significant negative effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our business is subject to numerous
laws and regulations. The formulation, manufacturing, packaging, labeling, registration, advertising, distribution, importation,
storage and sale of our products are subject to extensive regulation by various federal agencies, including the FDA, the U.S. Federal
Trade Commission (&ldquo;FTC&rdquo;), or the U.S. Environmental Protection Agency (&ldquo;EPA&rdquo;) and by various agencies of
the states, localities and foreign countries in which our products are manufactured, distributed and sold. Failure by us or our
manufacturers to comply with those laws and regulations could lead to enforcement action and the imposition of significant penalties
or claims, resulting in significant loss of sales, and could have a negative effect on our business, results of operations and
financial condition. If we fail to comply with federal, state or foreign laws and regulations, we could be required to suspend
manufacturing operations, change product formulations, suspend the sale of certain products, initiate product recalls, change product
labeling, packaging or advertising or take other corrective actions. Any of these actions could harm our business, financial condition
and results of operations. In addition, the adoption of new laws or regulations or changes in the interpretations of existing laws
or regulations may result in significant compliance costs or discontinuation of products. Our failure to comply with FDA, FTC,
EPA or state laws and regulations, or with laws and regulations in foreign markets, that cover our advertising, including direct
claims and advertising by us, may result in enforcement actions and imposition of penalties or otherwise materially adversely affect
the distribution and sale of our products and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Under the Federal Food, Drug, and Cosmetic
Act (&ldquo;FDCA&rdquo;) cosmetics/cosmeceuticals are defined as articles or components of articles that are applied to the human
body and intended to cleanse, beautify or alter its appearance, with the exception of soap. Cosmeceuticals, unlike prescription
drugs, are not subject to pre-market approval by the FDA but the product and ingredients must be tested to assure safety. If safety
has not been adequately substantiated, a specific label warning is required. The FDA monitors compliance of cosmeceutical products
through random inspection of cosmeceutical manufacturers and distributors to ensure that the products neither contain false or
misleading labeling nor are manufactured under unsanitary conditions. Inspections also may occur from consumer or competitor complaints
filed with the FDA. In the event the FDA does find false or misleading labeling or unsanitary conditions or otherwise a failure
to comply with FDA requirements, our distribution channel may be affected by a possible product recall or insufficient product
in the marketplace resulting in reduced product sales and revenue to us and increased costs to our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We may also, at some point in the future,
be subject to a variety of other laws and regulations. Our failure to comply, or assertions that we have failed to comply, with
these laws and regulations could have a material adverse effect on our business in a particular market or in general. To the extent
we decide to commence or expand operations in additional countries, laws and regulations in those countries, or the cost of complying
with such laws and regulations, may prevent or delay entry into or expansion of operations in those markets or could have a negative
effect on our operating margins for products sold in those countries. Regulatory requirements can vary widely from country to country
and could further delay the introduction of our products into those countries. We may not be able to enter into acceptable agreements
to market and commercialize our products in international markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our ability to sustain satisfactory
levels of sales in our markets is dependent in significant part on our ability to introduce additional products into those markets.
Government laws and regulations in both our domestic and international markets can delay or prevent the introduction, or require
the reformulation or withdrawal, of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">The regulatory status of our cosmeceutical
products could change, and we may be required to conduct clinical trials to establish efficacy and safety or cease to market some
or all of our products, which would require significant time and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The FDA does not have a pre-market
approval system for cosmetics/cosmeceuticals, and we believe we are permitted to market our cosmeceuticals and have them manufactured
without submitting safety or efficacy data to the FDA. However, the FDA may in the future determine to regulate our cosmetics or
the ingredients included in our cosmetics as drugs or biologics. If certain of our products are deemed to be drugs or biologics,
rather than cosmetics, we would be required to conduct clinical trials to demonstrate the safety and efficacy of these products
in order to continue to market and sell them. In such event, we may not have sufficient resources to conduct the required clinical
trials, we may not be able to establish sufficient efficacy or safety to resume the sale of these products, we may not gain regulatory
approval of the trial design, the clinical trials may be subject to unanticipated delays due to their time-consuming nature and
the outcome of any clinical trial is uncertain. Any inquiries by the FDA or any foreign regulatory authorities into the regulatory
status of our cosmetics and any related interruption in the marketing and sale of these products could severely damage our brand
reputation and image in the marketplace, as well as our relationships with retailer customers, which would harm our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Some of our cosmeceuticals may be considered
over-the-counter (&ldquo;OTC&rdquo;) drug products by the FDA. The FDA regulates the formulation, manufacturing, packaging, labeling
and distribution of OTC drug products pursuant to a monograph system that specifies active drug ingredients and acceptable product
claims that are generally recognized as safe and effective for particular uses. If any of these products that are OTC drugs are
not in compliance with the applicable FDA monograph, we would be required to (i) reformulate such product, (ii) cease to make certain
use claims relating to such product or (iii) cease to sell such product until we receive further FDA approval. If more stringent
regulations are promulgated, we may not be able to comply with such statutes or regulations without incurring substantial expense.
In addition, OTC drug products must be manufactured in accordance with pharmaceutical good manufacturing practice regulations.
Our OTC drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA as well as regular and ongoing inspections.
In addition, inspections may be commenced as a result of consumer or competitor complaints related to our products. Corresponding
state agencies may also inspect our facility to ensure strict compliance with drug good manufacturing practices and other government
regulations and corresponding foreign standards. We have minimal control over third-party manufacturers&rsquo; compliance with
these regulations and standards. If the FDA finds a violation of drug good manufacturing practices, it may enjoin the manufacturer&rsquo;s
operations, seize products, or criminally prosecute the manufacturer, any of which could require us to find alternative manufacturers,
resulting in additional time and expense.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">RISKS RELATING TO OUR STRATEGY</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our strategy includes plans for expansion by
acquisition, which will require additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We may need to raise additional capital
to complete any further acquisitions, and there can be no assurances we will be able to do so, or will choose to do so. While we
intend that the value added by acquisitions will more than offset the dilution created by the issuance of shares for acquisitions,
there can be no assurance that this offset will occur. Additional financing for future acquisitions may be unavailable and, depending
on the terms of the proposed acquisitions, financings may be restricted by the terms of credit agreements and privately placed
debt securities contained in the financing. Any debt financing would require payments of principal and interest and would adversely
impact our cash flow. Furthermore, future acquisitions may result in charges to operations relating to losses to the acquired events,
interest expense, impairment of intangible assets or the write down of goodwill, thereby increasing our losses or reducing or eliminating
our earnings, if any.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We may investigate potential acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Although management continues to investigate
potential acquisitions, any acquisitions consummated by the Company involve substantial expenditures and risks on our part. There
can be no assurance that acquisitions will be identified or completed successfully or, if completed, will yield the expected benefits
to us, or will not materially and adversely affect our business, financial condition or results of operations. There can be no
assurance that the value attributed by the market to acquisitions will offset the dilution created by the issuance of any additional
shares issued in connection with an acquisition. As a result of the foregoing, there can be no assurance as to when the intended
acquisitions will be consummated or that they will be consummated. Furthermore, the results of the intended acquisitions may fail
to conform to the assumptions of management. Therefore, in analyzing the information in this document, stockholders should consider
that the intended acquisitions may not be consummated at all.</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Future acquisitions by us could result
in (a) potentially dilutive issuances of equity securities, (b) the incurrence of substantial additional indebtedness and/or (c)
incurrence of expenses for interest, operating losses and the write down of goodwill and other intangible assets, any or all of
which could materially and adversely affect our business, financial condition and results of operations. Acquisitions involve numerous
risks, including difficulties in the assimilation of the operations, technologies, services and products of the acquired companies
and the diversion of management&rsquo;s attention from other business concerns. In the event that such acquisitions were to occur,
there can be no assurance that our business, financial condition and results of operations would not be materially and adversely
affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Stockholders may suffer substantial dilution
as the result of subsequent financings or if we issue additional securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We will require substantial additional
funds to complete our research and development and operate our businesses. However, there can be no assurance that any financing
will occur, or, if it does, that it will occur in a timely fashion or that it will result in raising sufficient additional funds.
If we are unable to raise funds on terms favorable to existing stockholders, our stockholders&rsquo; position and the value of
their investment may be materially adversely affected, significantly diminished, and possibly liquidated.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">RISKS RELATING TO OUR INTELLECTUAL PROPERTY</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If we are unable to protect our intellectual
property our ability to compete would be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We will attempt to protect our intellectual
property under the patent and trademark laws. The market for our products depends to a significant extent upon protecting our trademarks,
trade names and the goodwill associated therewith. We plan to own the material trademarks and trade name rights to be used in connection
with the packaging, marketing and sale of our products. Although we plan to register or apply to register many of our trademarks
in the United States and in certain foreign countries, we cannot assure you that all of our trademark applications will be approved
or successfully defended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We also own or license patents that
relate to some of our products. The patents we own or license could be challenged, invalidated or circumvented by others and may
not be of sufficient scope or strength to provide us with any meaningful protection or commercial advantage. Although we have registered
or applied to register additional patents in the United States and in certain foreign countries, we cannot assure you that any
of our patent applications will be approved. In addition, we do not own any formula patents. Our suppliers or other third parties
may hold certain formula patents for the manufacture of our products. If our relationships with our suppliers were interrupted
or terminated, or if we are unable to use formulas covered by third-party patents, our business could be harmed and it would negatively
impact our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Third parties may also oppose our trademark
and patent applications, or otherwise challenge our use of our trademarks or patents. We cannot assure you that competitors will
not infringe our trademarks or our patents, or that we will have adequate time and resources to enforce our trademarks and patents
and to protect our rights through litigation or otherwise, or that we will be successful in doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We also face the risk of claims that
we have infringed third parties&rsquo; intellectual property rights. Any claims of intellectual property infringement, even those
without merit, could expose us to the following risks, among others:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may be required to defend against infringement claims which are expensive and time-consuming;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may be required to cease making, licensing or using products that incorporate the challenged intellectual property;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may be required to re-design, re-engineer or re-brand our products or packaging;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may be required to enter into royalty or licensing agreements in order to obtain the right to use a third party&rsquo;s
intellectual property; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Any of these outcomes would negatively impact our business, results of operations and financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our trade secrets may be difficult to protect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Confidentiality agreements with employees
and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately
protect our intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our success depends upon the skills,
knowledge and experience of our scientific and technical personnel, our consultants and advisors as well as our licensors and contractors.
We rely in part on trade secrets to protect our proprietary technology and processes. However, trade secrets are difficult to protect.
We enter into confidentiality agreements with our employees, consultants, outside scientific collaborators, and other advisors.
These agreements generally require that the receiving party keep confidential and not disclose to third parties any confidential
information developed by the receiving party or made known to the receiving party by us during the course of the receiving party&rsquo;s
relationship with us. Our agreements also provide that any inventions made based solely upon our technology are our exclusive property,
and we enter into assignment agreements to perfect our rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">These confidentiality, inventions and
assignment agreements may be breached and may not effectively assign intellectual property rights to us. Our trade secrets also
could be independently discovered by competitors, in which case we would not be able to prevent use of such trade secrets by our
competitors. The enforcement of a claim alleging that a party illegally obtained and was using our trade secrets could be difficult,
expensive and time consuming and the outcome would be unpredictable. In addition, courts outside the United States may be less
willing to protect trade secrets. The failure to obtain or maintain meaningful trade secret protection could adversely affect our
competitive position.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We may be subject to claims that our employees
have wrongfully used or disclosed alleged trade secrets of their former employers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As is common in the biotechnology and
pharmaceutical industries, we may employ individuals who were previously employed at other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently,
deliberately or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation
may be necessary to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use
valuable intellectual property rights, which could adversely affect our business, financial condition, results of operations, and
prospects.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">From time to time we may need to rely on licenses
to proprietary technologies, which may be difficult or expensive to obtain or we may lose certain licenses which may be difficult
to replace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We may need to obtain licenses to patents
and other proprietary rights held by third parties to develop, manufacture and market products. If we are unable to timely obtain
these licenses on commercially reasonable terms, our ability to commercially market our products may be inhibited or prevented,
which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If we are unable to obtain and maintain protection
for our intellectual property and proprietary technology, the value of our technology and future products may be adversely affected,
and we may not be able to protect our technology from unauthorized use by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our long-term success largely depends
on our ability to market technologically competitive product candidates and to protect those technological creations. In order
to do so we must:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Obtain, maintain and protect commercially valuable patents or the rights to patents both domestically and abroad;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Operate without infringing upon the proprietary rights of others; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Prevent others from successfully challenging or infringing our proprietary rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">If we fail to obtain or maintain these
protections, we may not be able to prevent third parties from using our proprietary rights. We will be able to protect our proprietary
rights from unauthorized use only to the extent that these rights are covered by valid and enforceable patents or are effectively
maintained as trade secrets.</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Patent protection involves complex
legal and factual questions. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical
fields are still evolving. Accordingly, the degree of future protection for our patent rights is uncertain. Other risks and uncertainties
that we face with respect to our patents and other proprietary rights include the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The patent applications we intend to file may not result in issued patents or may take longer than we expect to result in issued
patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The claims of any patents that issue may not provide meaningful protection;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may be unable to develop additional proprietary technologies that are patentable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Any patents that may be issued to us may not provide a competitive advantage;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Other parties may challenge patents licensed or issued to us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Disputes may arise regarding the invention and corresponding ownership rights in inventions and know-how resulting from the
joint creation or use of intellectual property by us, our third-party vendors, corporate partners and other scientific collaborators;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Other parties may design around our patented technologies.</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We may become involved in lawsuits to protect
or enforce our patents that would be expensive and time consuming.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In order to protect or enforce our
intellectual property rights, we may initiate patent litigation against third parties. In addition, we may become subject to interference
or opposition proceedings conducted in patent and trademark offices to determine the priority of inventions. The defense of intellectual
property rights, including patent rights through lawsuits, interference or opposition proceedings, and other legal and administrative
proceedings, would be costly and divert our technical and management personnel from their normal responsibilities. An adverse determination
of any litigation or defense proceedings could put our patent application at risk of not being issued. Furthermore, because of
the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
our confidential information could be compromised by disclosure during this type of litigation. For example, during the course
of this kind of litigation, confidential information may be inadvertently disclosed in the form of documents or testimony in connection
with discovery requests, depositions or trial testimony. This disclosure could materially adversely affect our business and financial
results.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">The high level of competition in our industry
could harm our business, financial performance, market share and profitability. Many of our competitors have substantially greater
resources than we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The business of developing prescription
drugs for many of our potential indications and selling cosmeceuticals for aging skin is highly competitive. These markets include
numerous manufacturers, distributors, marketers and retailers that actively compete for consumers both in the United States and
abroad. In particular, the cosmeceutical market is highly sensitive to the introduction of new products, which may rapidly capture
a significant share of the market. In addition, our products may be, or are at the risk of becoming, obsolete due to new product
introductions or new technologies. Our competitors may foresee the course of market development more accurately than we do, develop
products and technologies that are superior to ours, produce similar products at a lower cost than we can or adapt more quickly
to consumer preferences. Any of these developments could harm our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We plan to compete in select product
categories against a number of multinational manufacturers and pharmaceutical companies, many of which are larger and have substantially
greater resources than we do. Therefore, these larger competitors have the ability to spend more aggressively on advertising, marketing
and research and to grow more quickly through acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our competitors may attempt to gain
market share by offering products at prices at or below the prices at which our products may be offered. Competitive pricing may
require us to reduce our prices, which would decrease our profitability or result in lost sales. Our competitors, many of whom
have greater resources than ours, may be better able to withstand these price reductions and lost sales. We cannot assure you that
future price or product changes by our competitors will not adversely affect our net sales or that we will be able to react with
price or product changes of our own to maintain our current market position.</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If our products do not appeal to a broad range
of consumers, our sales and our business would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our success will depend on our products&rsquo;
(as and when available for sale) appeal to a broad range of consumers whose preferences cannot be predicted with certainty and
are subject to change. If our products do not meet consumer demands, our sales will suffer. In addition, our growth depends upon
our ability to develop new products through new product lines, product line extensions and product improvements, which involve
numerous risks. New product launches are essential to our growth. As we grow, our reliance on new products will increase. We may
not be able to accurately identify consumer preferences, translate our knowledge into consumer-accepted products or successfully
integrate new products with our existing product platform or operations. We may also experience increased expenses incurred in
connection with product development or marketing and advertising that are not subsequently supported by a sufficient level of sales,
which would negatively affect our margins. Furthermore, product development may divert management&rsquo;s attention from other
business concerns, which could cause sales of our then existing products to suffer. We may not be able to successfully develop
new products in the future, and our newly developed products may not contribute favorably to our operating results.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We are a small company that relies on a few
key employees to ensure that our business operates efficiently. If we were to lose the services of any of these key employees,
we would experience difficulty in replacing them, which would affect our business operations and harm our business and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our success depends to a significant
degree upon the business expertise and continued contributions of our senior management team, any one of whom would be difficult
to replace. As a result, our future results will depend significantly upon the efforts and retention of key employees, including
but not limited to Stephen M. Simes, Yael Schwartz, Ph.D., and David Sherris, Ph.D. We rely on these individuals for managing/developing
our products, developing our business strategy and maintaining strategic relationships. Any of these employees could, with little
or no prior notice, voluntarily terminate their employment with us at any time. The loss of service of any of these key employees
would harm our business and results of operations. We do not retain key-person life insurance on any employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In addition, our senior management
team may not be able to successfully manage our company as it grows larger. If they are unable to handle these increased responsibilities
and we are unable to identify, hire and integrate new personnel, our business, results of operations and financial condition would
suffer. Even if we are able to identify new personnel, the integration of new personnel into our business will inevitably occur
over an extended period of time. During that time, the lack of sufficient senior management personnel would cause our results of
operations to suffer.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our initiatives to develop new products may
not be successful and any failure to develop new products would harm our business, results of operations, financial condition and
future growth potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In order to expand our business, we
plan to further develop new products. We may not be successful in our efforts. Each of our product initiatives involves significant
risks, as well as the possibility of unexpected consequences, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our prescription based products may fail at any stage of development and/or not obtain FDA approval for commercialization;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our prescription products may not be successful even if FDA approved;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Sales of the new non-prescription products to retailer customers may not be as high as we anticipate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The rate of purchases by consumers may not be as high as we or our retailer customers anticipate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Returns of new products by retailer customers may exceed our expectations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our marketing strategies and merchandising efforts may be ineffective and fail to reach the targeted consumer base or engender
the desired consumption;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may incur unexpected costs as a result of the continued development and launch of new products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our pricing strategies may not be accepted by retailer customers and/or their consumers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may experience a decrease in sales of our existing products as a result of introducing new products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There may be delays or other difficulties impacting our ability, or the ability of our third-party manufacturers and suppliers,
to timely manufacture, distribute and ship products in connection with launching new products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Each of the risks referred to above
could delay or impede our ability to successfully develop new products, which would harm our business, results of operations, financial
condition and future growth potential.</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We may be unable to increase our sales through
new and existing distribution channels which would limit our growth and harm our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Products similar to our potential non-prescription
products are sold via multiple avenues, including department stores, door-to-door, Internet, home shopping television shows, mail-order
and telemarketing by representatives of direct sales companies. Our growth strategy may include entering new distribution channels
such as home shopping television. Any failure to successfully enter new distribution channels could limit our growth. In addition,
consumers could choose to purchase cosmetics through distribution channels in which we do not participate. Our ability to continue
to grow and achieve similar profit margins is dependent on our continued expansion through multiple distribution channels.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Consumers may reduce discretionary purchases
of our consumer products as a result of a general economic downturn or sudden disruption in the economy, which would negatively
affect our net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We believe that consumer spending on
cosmetics products is influenced by a number of factors, including general economic conditions, inflation, interest rates, energy
costs and the availability of discretionary income, all of which are beyond our control. Consumer purchases of discretionary items
tend to decline during recessionary periods, when disposable income is lower. Any resulting material reduction in our sales would
negatively affect our business, financial condition and results of operations. In addition, sudden disruptions in the economy or
adverse weather conditions can have a short or long-term impact on consumer spending. A downturn in the economy or a sudden disruption
of business conditions would likely negatively affect our net sales.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If we are unable to successfully execute any
material part of our growth strategy, our future growth and ability to make profitable investments in our business could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We may not be able to be profitable
and if we are profitable we may not be able to sustain our growth or profitability on a quarterly or annual basis in future periods.
Our future growth and profitability will depend upon a number of factors, including, without limitation:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to develop, gain regulatory approval for, and market successfully our prescription products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The level of competition in both the cosmeceutical and prescription dermatology industry;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to continue to successfully execute our growth strategy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to continuously offer new products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to maintain efficient, timely and cost-effective research, development, production and delivery of our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to obtain sufficient production capacity for our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The efficiency and effectiveness of our sales and marketing efforts in building product and brand awareness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to identify and respond successfully to emerging trends in the dermatology and skincare beauty industry;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The level of physician and consumer acceptance of our products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>General economic conditions and consumer confidence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We may not be successful in executing
our growth strategy, and even if we achieve targeted growth, we may not be able to sustain profitability. Failure to successfully
execute any material part of our growth strategy could significantly impair our future growth and our ability to make profitable
investments in our business.</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our future products, both prescription and
cosmeceutical, may cause unexpected and undesirable side effects that would limit their use, require their removal from the market
or prevent their further development. Product liability claims resulting from these undesirable side effects would hurt our business.
In addition, we are vulnerable to claims that such products are not as effective as we claim them to be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Unexpected and undesirable side effects
caused by our future products for which we have not provided sufficient label warnings could result in the recall or discontinuance
of sales of some or all of our products. Unexpected and undesirable side effects could prevent us from achieving or maintaining
market acceptance of the affected products or could substantially increase the costs and expenses in marketing new products. In
the future, we may be subject to various product liability claims resulting from those undesirable side effects caused by our products.
Product liability claims may result in negative publicity regarding our company, brand or products that may harm our reputation
and sales. In addition, if one of our products is found to be defective we may be required to recall it, which may result in substantial
expense, adverse publicity and loss of sales, which would substantially harm our brand. Although we intend to maintain product
liability insurance coverage, potential product liability claims may exceed the amount of our insurance coverage or potential product
liability claims may be excluded under the terms of our policy, which would cause our financial condition to suffer. In addition,
we may be required to pay higher premiums and accept higher deductibles in order to secure adequate insurance coverage in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Consumer or industry analysts may assert
claims that our products are not as effective as we claim. Unexpected and undesirable side effects associated with our products
or assertions that our products are not as effective as we claim them to be also could cause negative publicity regarding our company,
brand or products, which could in turn harm our reputation and our business.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If we cannot obtain additional funding, our
drug development and commercialization efforts may be reduced or discontinued and we may not be able to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We expect to expend substantial funds
on the research, development and clinical trials of our product candidates. We expect negative cash flows from operations for the
foreseeable future unless and until we are able to generate sufficient revenues to maintain our research and operations. We will
need to obtain funding to continue the research and development and to complete clinical trials of our product candidates. There
can be no assurance that we will be successful in raising funds on terms acceptable to us, or at all, or that sufficient additional
capital will be raised to complete the research, development, and clinical testing of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We will require substantial funds for
additional research and commencement of pre-clinical and clinical trials, working capital and general corporate purposes. There
is no assurance that we will be successful in the completion of any future financings. Our failure to obtain funds may cause us
to reduce or cease operations.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Even if our drugs and products are approved
for sale by the regulatory authorities, we have not yet demonstrated their market acceptance and they might not gain market acceptance
among physicians, patients, healthcare payers and the medical community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have no commercial products at this
time. However, if and when we develop such candidates, the degree of market acceptance of such product candidates will depend on
a number of factors, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Demonstration of the clinical efficacy and safety of the products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Cost-effectiveness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Potential advantage over alternative treatment methods;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The effectiveness of marketing and distribution support for the products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Reimbursement policies of government and third party payers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">If our products do not achieve significant
market acceptance, our business and financial condition will be materially adversely affected.</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our future revenue and operating results are
unpredictable and may fluctuate significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">It is difficult to accurately forecast
our revenues and operating results and they could fluctuate in the future due to a number of factors. These factors may include:
our ability to further develop products; acceptance of products; the amount and timing of operating costs and capital expenditures;
competition from other market venues that may reduce market share and create pricing pressure; and adverse changes in general economic,
industry and regulatory conditions and requirements. Our operating results may fluctuate from year to year due to the factors listed
above and others not listed. At times, these fluctuations may be significant.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We may be unable to successfully defend our
patent claims and other proprietary rights and may unintentionally infringe on the proprietary rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our profitability may depend in part
on our ability to effectively protect our proprietary rights, including, for example, obtaining patent protection for our methods
of producing and administering small molecule drug zinc-finger transcription factor inhibitors/activators, maintaining the secrecy
of our internal workings and preserving our trade secrets, as well as its ability to operate without inadvertently infringing on
the proprietary rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">There can be no assurance that (i)
any small molecular inhibitors of zinc finger transcription factors - related patents will be issued from any pending or future
patent applications; (ii) the scope of any patent protection will be sufficient to provide competitive advantages; (iii) any patents
we obtain will be held valid if subsequently challenged; or (iv) others will not claim rights in or ownership of our patents and
its other proprietary rights. Unauthorized parties may try to copy aspects of our products and technologies or obtain and use information
it considers proprietary. Policing the unauthorized use of proprietary rights is difficult and time-consuming. We cannot guarantee
that no harm or threat will be made to our intellectual property. In addition, the laws of certain countries are not expected to
protect our intellectual property rights to the same extent as do the laws of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Administrative proceedings or litigation,
which could result in substantial costs and uncertainty, may be necessary to enforce its patent or other intellectual property
rights or to determine the scope and validity of the proprietary rights of others. There can be no assurance that third parties
will not assert patent infringement claims in the future with respect to its products or technologies. Any such claims could ultimately
require us to enter into license arrangements or result in litigation, regardless of the merits of such claims. Litigation with
respect to any infringement claims or any other patent or intellectual property rights could be expensive and time consuming and
could have a material adverse effect on our business, operating results and financial condition, regardless of the outcome of such
litigation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">RISKS RELATING TO OUR ORGANIZATION AND OUR COMMON
STOCK</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">The price of our common stock has fluctuated
in the past and the stock is thinly traded. Future fluctuations in price could be greater than those experienced in the past.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Based upon a post reverse split calculation,
from January 1, 2011 to June 30, 2014, the average price of our common stock was $34.00 per share, with a low of $2.50 and a high
of $100.00, on an average trading volume per day of 1,434 shares. The closing price of our common stock on July 3, 2014 was $4.00
per share. It is possible that trading volumes could increase or decrease significantly, and such changes in volume could lead
to significant fluctuations in the price of our stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We are the result of a &ldquo;reverse merger&rdquo;
with a shell entity in 2008, resulting in a limitation on shareholder&rsquo;s use of Rule 144 exemptions for resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Since we had a &ldquo;reverse merger&rdquo;
with a shell entity in 2008, resale of our shares under Rule 144 may be limited. The use of Rule 144 is the most common method
of selling restricted shares. Rule 144(i) pertains to shares issued by a former shell company that executed a reverse merger. Under
Rule 144(i), sales of shares may only be made under certain conditions, including a sale or intended sale of the stock and if we
have filed all annual and quarterly reports required under the securities laws. Therefore permission may be granted to remove the
restrictive legend on stock certificates only for a specified sale of securities and not as a &ldquo;blanket&rdquo; removal of
the restrictive legend.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our management will be able to exert significant
influence over us to the detriment of minority stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our directors and officers beneficially
own almost 26.34% of our outstanding common stock. These stockholders, if they act together, will continue to be able to exert
significant influence on our management and affairs and all matters requiring stockholder approval, including significant corporate
transactions. This concentration of ownership may have the effect of delaying or preventing our change in control and might affect
the market price of our common stock.</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Exercise of options and warrants will dilute
our existing shareholder&rsquo;s percentage of ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of July 10, 2014, we have outstanding
options and warrants to purchase 6,079,059 shares of our common stock including warrants to purchase 3,611,812 shares issued in
connection with the Private Placement. In the future, we may grant additional stock options, warrants and convertible securities.
The exercise or conversion of stock options, warrants or convertible securities will dilute the percentage ownership of our other
stockholders. The dilutive effect of the exercise or conversion of these securities may adversely affect our ability to obtain
additional capital. The holders of these securities may be expected to exercise or convert them when we would be able to obtain
additional equity capital on terms more favorable than these securities.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our stock price may be volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The stock market in general, and the
stock prices of life sciences companies in particular, have experienced volatility that often has been unrelated to the operating
performance of any specific public company. The market price of our common stock is likely to be highly volatile and could fluctuate
widely in price in response to various factors, many of which are beyond our control, including the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Changes in our industry;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Competitive pricing pressures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to obtain working capital financing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Additions or departures of key personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Sales of our common stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to execute our business plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Operating results that fall below expectations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Loss of any strategic relationship;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Regulatory developments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Economic and other external factors; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Period-to-period fluctuations in our financial results.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In addition, the securities markets
have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of
particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">We have not paid dividends in the past and
do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have never paid cash dividends on
our common stock and do not anticipate doing so in the foreseeable future. The payment of dividends on our common stock will depend
on earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may
consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only
occur if our stock price appreciates.</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">There is currently a limited trading market
for our common stock and we cannot ensure that one will ever develop or be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">To date, there has been a limited trading
market for our common stock and since January 1, 2011 daily trading volume has ranged from zero to 93,026 shares with an average
daily volume of 1,434 shares. We cannot predict how liquid the market for our common stock might become. Our common stock is quoted
for trading on the OTCQB under the symbol RESX, and as soon as is practicable, we intend to apply for listing of our common stock
on the New York Stock Exchange (&ldquo;NYSE MKT&rdquo;), The Nasdaq Capital Market or other national securities exchanges, assuming
that we can satisfy the initial listing standards for such exchanges. We cannot ensure that we will be able to satisfy such listing
standards or that our common stock will be accepted for listing on any such exchanges. Additionally, because we may be considered
a shell company, we may be subject to the &ldquo;seasoning&rdquo; rules adopted by NASDAQ and NYSE which could further delay any
listing. If we fail to satisfy the initial listing standards of such Mergers, or our common stock is otherwise rejected for listing
and remain listed on the OTCQB, the trading price of our common stock could suffer and the trading market for our common stock
may be less liquid and our common stock price may be subject to increased volatility. Furthermore, for companies whose securities
are traded in the OTCQB, it is more difficult (1) to obtain coverage for significant news events because major wire services generally
do not publish press releases about such companies, and (2) to obtain needed capital.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Our common stock may be deemed a &ldquo;penny
stock,&rdquo; which makes it more difficult for our investors to sell their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our common stock may be subject to
the &ldquo;penny stock&rdquo; rules adopted under Section 15(g) of the Exchange Act. The penny stock rules generally apply to companies
whose common stock is not listed on The Nasdaq Stock Market or other national securities exchange and trades at less than $5.00
per share, other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible
net worth of at least $5,000,000 ($2,000,000 if the company has been operating for three or more years). While our common stock
has traded above $5.00 for several days in 2014, there can be no assurances that it will continue to do so and we may be subject
to the &ldquo;penny stock&rdquo; rules if our stock does not stay above $5.00. These rules require, among other things, that brokers
who trade penny stock to persons other than &ldquo;established customers&rdquo; complete certain documentation, make suitability
inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure
document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the
requirements of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities
is limited. If we remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market,
if any, for our securities. If our securities are subject to the penny stock rules, investors will find it more difficult to dispose
of our securities.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Offers or availability for sale of a substantial
number of shares of our common stock may cause the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">If our stockholders sell substantial
amounts of our common stock in the public market upon the effectiveness of the registration statement of which this prospectus
is a part, upon the expiration of any statutory holding period under Rule 144, or issued upon the exercise of outstanding options
or warrants, it could create a circumstance commonly referred to as an &ldquo;overhang&rdquo; and in anticipation of which the
market price of our common stock could fall. Additionally, the former equity holders of Canterbury, Hygeia, Paloma and VasculoMedics
who received shares of our Common Stock are subject to a lock-up on the sale of their shares for one year, but thereafter may sell
their shares under Rule 144. The existence of an overhang, whether or not sales have occurred or are occurring, also could make
more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future
at a time and price that we deem reasonable or appropriate.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">If we were to dissolve our company the holders
of our securities may lose substantial amounts of their investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">If we were to dissolve, as part of
ceasing to do business or otherwise, we may be required to pay all amounts owed to any creditors before distributing any assets
to our shareholders. There is no assurance that in the event of such a dissolution, there will be sufficient assets to distribute
to our shareholders.</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">This prospectus contains forward-looking
statements, which reflect the views of our management with respect to future events and financial performance. These forward-looking
statements are subject to a number of uncertainties and other factors that could cause actual results to differ materially from
such statements. Forward-looking statements are identified by words such as &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;targets&rdquo;
and similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based
on the information available to management at this time and which speak only as of this date. We undertake no obligation to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a discussion
of some of the factors that may cause actual results to differ materially from those suggested by the forward-looking statements,
please read carefully the information under &ldquo;Risk Factors&rdquo; beginning on page 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The identification in this document
of factors that may affect future performance and the accuracy of forward-looking statements is meant to be illustrative and by
no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. You
may rely only on the information contained in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have not authorized anyone to provide
information different from that contained in this prospectus. Neither the delivery of this prospectus nor the sale of common stock
means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer
to sell or solicitation of an offer to buy these securities in any circumstances under which the offer or solicitation is unlawful.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are registering these shares pursuant
to the registration rights granted to the investors and placement agent in the Private Placement. As a result, we will not receive
any proceeds from the sale of the common stock by the selling stockholders pursuant to this prospectus. All proceeds from the sale
of the shares will be for the account of the selling stockholders. The selling stockholders may sell these shares in the over-the-counter
market or otherwise, at market prices prevailing at the time of sale, at prices related to the prevailing market price, or at negotiated
prices. However, we may receive proceeds upon the cash exercise of the common stock purchase warrant, the underlying shares of
which are offered by this prospectus. If all of the warrants issued in connection with the Private Placement are exercised for
cash at the initial exercise price of $4.80 per share (which exercise price is subject to adjustment under customary anti-dilution
protections), then we will receive gross proceeds of approximately $12,886,766. Any such proceeds will be used for working capital
and general corporate purposes. No assurance can be given, however, that all or any portion of such warrants will be exercised.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are a specialty biopharmaceutical
company initially focused on developing products for dermatology, ophthalmology and women&rsquo;s health.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">RestorGenex History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Prior to our repositioning as a specialty
biopharmaceutical company, on March 14, 2008, pursuant to an Agreement and Plan of Merger dated August 20, 2007 between Feris International,
Inc. (&ldquo;Feris&rdquo;) and Pro Sports &amp; Entertainment, Inc. (&ldquo;PSEI&rdquo;), Feris issued 49,500,000 shares of its
common stock for all issued and outstanding shares of PSEI, resulting in PSEI becoming a wholly-owned subsidiary of Feris and the
surviving entity for accounting purposes (&ldquo;Reverse Merger&rdquo;). In July 2008, Feris&rsquo; corporate name was changed
to Stratus Media Group, Inc. PSEI, a California corporation, was organized on November 23, 1998 and specialized in various sports
events that it owned and operated. PSEI also owned Stratus Rewards LLC (&ldquo;Stratus White&rdquo;) that planned to operate a
credit card rewards program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In June 2011, we acquired Series A
Convertible Preferred Stock of ProElite, Inc., a New Jersey corporation (&ldquo;ProElite&rdquo; or &ldquo;PEI&rdquo;), that organizes
and promotes mixed martial arts (&ldquo;MMA&rdquo;) matches. These holdings of Series A Convertible Preferred Stock provide us
voting rights on an as-converted basis equivalent to a 95% ownership in ProElite. On February 5, 2009 PEI entered into an Asset
Purchase Agreement and other related agreements with Explosion Entertainment, LLC (&ldquo;Strikeforce&rdquo;). Under the terms
of the Purchase Agreement, Strikeforce acquired from PEI certain fighter contracts, a library of televised PEI events and specified
related assets. Consideration paid for the assets consisted of (i) $3 million in cash paid at closing, (ii) the assumption of certain
liabilities relating to the assets sold and (iii) contingent consideration in the form of rights to receive a portion of the license
fee earned by Strikeforce under a distribution agreement between Strikeforce and Showtime Networks Inc. (&ldquo;Showtime&rdquo;).
PEI was informed in March 2013 that Strikeforce was no longer conducting these Showtime events and there will be no further license
fees received by PEI. During the first quarter of 2013, we decided to focus on the MMA business and temporarily suspended development
of our other businesses. Because of lack of working capital, effective June 30, 2013, we suspended operations of ProElite. Following
our repositioning as a specialty biopharmaceutical company, our board of directors voted to discontinue operations of PEI effective
March&nbsp;31, 2014.</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Effective September 30, 2013, we entered
into an Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;) with Canterbury Acquisition LLC, Hygeia Acquisition,
Inc., Canterbury Laboratories, LLC (&ldquo;Canterbury&rdquo;), Hygeia Therapeutics, Inc. (&ldquo;Hygeia&rdquo;) and Yael Schwartz,
Ph.D., as Holder Representative, pursuant to which we agreed to acquire all of the capital stock of Canterbury and Hygeia with
Canterbury and Hygeia becoming our wholly owned subsidiaries. The consideration for the mergers was the issuance by us of an aggregate
of 1,150,116 restricted shares of our common stock issued to the stakeholders of Canterbury and Hygeia. Effective November 18,
2013, the mergers were completed, and Canterbury and Hygeia became our wholly owned subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On March 3, 2014, we entered into an
Agreement and Plan of Merger with Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. (&ldquo;Paloma&rdquo;) and David Sherris,
Ph.D., as founding stockholder and Holder Representative pursuant to which we agreed to acquire all of the capital stock of Paloma
with Paloma becoming our wholly owned subsidiary. On March 28, 2014, the merger with Paloma was closed and we issued an aggregate
of 2,500,000 common shares to the holders of Paloma Common Stock and its derivative securities and assumed promissory notes of
Paloma in the aggregate amount (principal and interest) of approximately $1,130,500 to be paid on the first anniversary of the
closing of the Paloma merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Also on March 3, 2014, we entered into
an Agreement and Plan of Merger with VasculoMedics Acquisition, Inc., VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;) and Dr.
Sherris pursuant to which we agreed to acquire all of the capital stock of VasculoMedics with VasculoMedics becoming our wholly
owned subsidiary. The VasculoMedics merger was concurrently closed with and as a condition to the closing of the Paloma Merger
on March 28, 2014, with our company issuing an aggregate of 220,000 common shares to the VasculoMedics stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On March 7, 2014, we effected a reverse
stock split of 1 to 100 with respect to our Common Stock and we changed our corporate name from Stratus Media Group, Inc. to RestorGenex
Corporation. All stock numbers herein are post reverse split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As part of our repositioning as a specialty
biopharmaceutical company, effective March&nbsp;5, 2014, we appointed Stephen M. Simes as our Chief Executive Officer and effective
May 27, 2014 we appointed Phillip Donenberg as our Chief Financial Officer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">Hygeia and Canterbury History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Hygeia is a Delaware Corporation based
in Holden, Massachusetts and was formerly known as Orcas Therapeutics, Inc. It was incorporated on November 14, 2005 to acquire
and develop biodegradable hormone receptor modulators for topical indications. Hygeia is focused on developing topical therapies
for conditions where localized treatments offer advantages over systemic therapies. Hygeia has signed an Exclusive License Agreement
(the &ldquo;Yale License&rdquo;) with Yale University (&ldquo;Yale&rdquo;) under U.S. Patent 7,015,211 &ldquo;<I>15.alpha.-Substituted
Estradiol Carboxylic Acid Esters as Locally Active Estrogens</I>,&rdquo; U.S. Patent 6,476,012 &ldquo;<I>Estradiol-16.alpha Carboxylic
Acid Esters as Locally Active Estrogens</I>&rdquo; and U.S. Patent 8,552,061 &ldquo;<I>Locally active &quot;soft&quot; antiandrogens</I>&rdquo;
(together the &ldquo;Yale Patents&rdquo;). Hygeia agreed to pay royalty fees to Yale quarterly beginning in the first calendar
quarter in which net sales occur. Canterbury is a Delaware limited liability company that was formed on October 14, 2011 and began
operations on February 22, 2012. Initially, Canterbury was a wholly owned subsidiary of Hygeia. Canterbury is engaged in the premium
cosmeceutical business. Cosmeceuticals are the latest addition to the health industry and are sometimes described as cosmetic products
with &ldquo;drug-like benefits.&rdquo; Generally, cosmeceuticals are products sold over-the-counter, without the requirement of
the Food and Drug Administration (&ldquo;FDA&rdquo;) approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">A reorganization and separation agreement
was signed on October 14, 2011 between Canterbury and Hygeia under which Hygeia received 100% of all issued and outstanding units
of all classes of limited liability company membership interests of Canterbury. Hygeia distributed these profit units to holders
of its common and preferred stock. Further, the shares were issued to the Hygeia&rsquo;s non-qualifying stock option (&ldquo;NSO&rdquo;)
holders to liquidate the outstanding NSO&rsquo;s. Holders of Hygeia stock purchase warrants exchanged their warrants for an equal
number of units of Canterbury stock purchase warrants. Pursuant to the license agreement shares of Series A convertible preferred
stock was issued to Yale University for the Yale License. In February 2012, Hygeia assigned its rights and obligations related
to non-prescription products under the Yale License to Canterbury.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">Paloma and VasculoMedics History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Both Paloma and VasculoMedics are Delaware
corporations and are based in Jamaica Plain, Massachusetts. Paloma was founded in January 2005 and VasculoMedics was founded in
November 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Paloma has developed a non-steroidal,
synthetic, small molecule drug library for dermatology (psoriasis, atopic dermatitis, rosacea, actinic keratosis, keloid and hypertrophic
scarring, Dupuytren&rsquo;s disease, bullous blistering diseases), ocular disease, cancer, pulmonary fibrosis, CNS (Huntington&rsquo;s
disease and infantile spasm, a form of childhood epilepsy), biodefense and anti-viral application. The lead product, P529, targets
and inhibits the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dual TORC1/TORC2 dissociative
inhibitor.</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">VasculoMedics was founded as a platform
epigenetic company to develop orally available small molecular inhibitors of zinc finger transcription factors. Zinc finger transcription
factors are a subset of transcription factors utilizing zinc at its core for activity. Transcription factors are proteins that
bind to specific parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs the protein
making machinery to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of a transcription
factor, one can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription factor. Many
diseases can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors. Inhibition
of such transcription factors could then be able to control disease pathology.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">DESCRIPTION OF
OUR DERMATOLOGY BUSINESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Prescription Dermatology and Woman&rsquo;s Health
Products</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Development Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">RES-102, our lead &ldquo;soft&rdquo;
estrogenic candidate, a member of the 15-alpha-carboxylic acid esters of estrogen, RES-102, is under development for the topical
treatment of skin aging (thinning and fragility) and vulvar and vaginal atrophy (&ldquo;VVA&rdquo;). RES-102 is the first estrogenic
drug candidate engineered to be rapidly deactivated to non-estrogenic metabolites by hydrolytic enzymes and represents a new generation
of effective estrogens. In animal models, RES-102 has strong estrogenic effects at the site of application but no effect on the
most estrogen-sensitive systemic tissues even at high multiples of the locally effective dose. These observations are consistent
with rapid formation of inactive metabolites. The expected major metabolite, RES-103, has no detectable estrogenic effects in the
test tube (&ldquo;<I>in vitro&rdquo;)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Key findings to date in estrogen-deficient
animals demonstrate superior safety over estradiol. Preclinical proof of concept for efficacy and safety have been demonstrated.
We performed the proof of concept study for vaginal atrophy in ovariectomized rats to reproduce the thinning of the vaginal wall
epithelium seen in postmenopausal women. The vaginal wall thickness was measured to determine efficacy following application of
different intravaginal doses. Because the uterus is the most estrogen-sensitive organ in rats, as well as humans, we measured uterine
weights to assess unwanted systemic effects. The results are shown in the figure below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="changefromcontrol.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The data in the figure support a therapeutic
index, (&ldquo;TI&rdquo;), of greater than 300 (Max Safe Dose/Min Effective Dose = 100/0.3). The currently marketed Vagifem<SUP>&reg;</SUP>
10 &micro;g estradiol vaginal tablet for the treatment of VVA is weakly effective at reducing symptoms or increasing vaginal wall
cells (13.2% increase in superficial cells above baseline) but also increases systemic exposure to estradiol according to the most
recent Vagifem<SUP>&reg;</SUP> Package Insert (2009). RES-102 will have a much larger TI than currently marketed drug products
by increasing efficacy while maintaining safety. These studies indicate a favorable therapeutic index relative to currently marketed
estrogen containing products. Metabolism studies in human hepatocytes, liver cells which contain a full complement of metabolizing
enzymes showed that the half-life is very short i.e. 7 minutes.</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="table2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">RES-102 is the first estrogenic drug
candidate engineered to be rapidly deactivated to a non-estrogenic metabolite by hydrolytic esterase enzymes and represents a new
generation of topically effective estrogens with reduced systemic liability. Rapid degradation to an inactive metabolite makes
RES-102&rsquo;s safety profile superior to the currently marketed estrogen-replacement products. This permits higher dosing for
greater efficacy. In human keratinocytes, which comprise 90% of epithelium, RES-102 was significantly proliferative as shown below:</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 10.5pt"><IMG SRC="table3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">A proprietary model of human skin
thickness (Living Skin Equivalency Model), shown below, demonstrated that RES-102 elicited a positive trend toward increased thickness
by greater than 30% over control. These studies bode well for the efficacy of RES-102 in the treatment of age-related skin fragility/thinning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="table4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">RES-440 is our lead &ldquo;soft&rdquo;
anti-androgenic candidate for the topical treatment of acne, hirsutism and androgenic alopecia. <B>RES-440</B> is a racemic mixture
of (S)-and (R)-RES-440. In a separate androgen receptor binding experiment, <B>(S)-RES-440</B> was shown to have 20% the affinity
as T and approximately a70-fold more affinity than (<I>R</I>)-RES-440 as shown below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="table5.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The expected major metabolite has no
detectable androgen-receptor affinity or ability to interfere with the androgenic effects of endogenous androgens. <I>In vivo</I>
proof-of-concept studies in the Golden Syrian Hamster showed local activity without affecting internal androgen sensitive tissues.
The Golden Syrian Hamster model has long been validated as a model for topical anti-androgens. Since acne, seborrhea, hirsutism
and alopecia are all caused by excess androgens in the skin or scalp, the Golden Syrian Hamster model is a good predictor of androgen-sensitive
functional activity. The sebaceous gland flank organ spots are visible as a dark raised spot on each flank. In castrated animals,
these flank gland organs will gradually diminish and disappear over 14-21 days. The application of DHT or other androgens can restore
the flank gland spots in castrated hamsters. Topical doses of (S)-<B>RES-440</B> from 10 to 300 &micro;g/day were administered
to male Golden Syrian Hamsters following the same protocol described above for the flutamide experiment. In addition to monitoring
the untreated flank organ size for systemic effects, androgen-sensitive tissues collected at the end of the experiment were weighed
and compared to vehicle-treated intact animals and castrated controls. The results of the Golden Syrian Hamster study with (S)-<B>RES-440</B>
are shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 10.5pt"><IMG SRC="table6.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Flank organ sizes were measured on
Days 0, 4, 7, 10, 14, 18, and 21. The differences between right and left flank organs appeared to plateau after Day 7. As shown
above, <B>RES-440</B> treatment resulted in a significant dose-related reduction in flank organ size. Moreover, the untreated flank
organ size was unaffected by <B>RES-440</B> over the course of the study and there was no evidence of systemic anti-androgen effects
on any of the five most androgen sensitive internal tissues analyzed at the end of the 21-day study. The melting point of <B>RES-440</B>
is 40-42&deg;C, just above body temperature, making it ideal for permeation into the pilosebaceous unit where the androgen receptors
are found. In summary, RES-440 has the ideal topical anti-androgenic drug profile for the treatment of acne, seborrhea, alopecia
and hirsutism; it is very potent at the androgen receptor, has a short half-life with no active anti-androgenic metabolites, and
is very soluble in a variety of solvents including ethanol and methylene chloride. We recently shortened the synthesis route of
RES-440 from 7 steps to 2 steps creating a potential for a new process patent.</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">RES-102440 is a combination product
of RES-102 and RES-440 and will be developed for the topical treatment of hair loss due to increased hair follicle sensitivity
to androgens and the positive effects of estrogen on the hair growth cycle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">P529 is part of our non<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>steroidal,
synthetic, small molecule drug library developed through computational design, synthetic and medicinal chemistry, resulting in
a family of agents, &ldquo;Palomids.&rdquo; All Palomids are wholly synthetic with a molecular weight ranging from 300 to 500 Daltons.
We are focused on developing its Palomid library to combat a wide variety of diseases. Palomid 529 (P529) is the result of three
generations of Palomid design work. P529&rsquo;s activity has been shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR
signal transduction pathway, specifically as an allosteric, dual TORC1/TORC2 dissociative inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have submitted patents (currently
16 issued patents and 29 pending applications) covering our ownership of intellectual property relating to a series of novel, proprietary,
small molecule drugs created through an integrated design platform incorporating proprietary, customized and industry standard
computational tools that the Company believes may have therapeutic potential for among other indications, keloid and hypertrophic
scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren&rsquo;s disease and bullous diseases. These small
molecule drugs, &ldquo;Palomids,&rdquo; have shown activity <I>in vitro </I>and in animal (&ldquo;<I>in vivo&rdquo;</I>) models
of disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In <I>in vitro </I>skin models, P529
was shown to inhibit keratinocyte proliferation (growth of keratinocytes) and induce apoptosis (cause death of hyperproliferating
keratinocytes). P529 has been shown to inhibit signaling which promote keloid scar formation. This work has shown significant
destabilization of human keloid scars in organ culture and is the lead application for P529 in dermatology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10.5pt; text-align: center"><IMG SRC="table7.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Human keloid fibroblasts are plated
and cell index is observed over time. After P529 treatment, Keloid fibroblasts are inhibited in a dose-dependent manner showing
inhibition of &ldquo;scar formation&rdquo; in real time down to baseline. P529 shows greater reduction in &ldquo;scar formation&rdquo;
compared to other PI3K inhibitors, rapamycin (Rapa) and wortmannin (Wort). P529 shows sustained effect after drug removal not seen
with Rapamycin or Wortmannin.</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As P529 has been shown to inhibit neovascularization,
together with its effect on keratinocytes, P529 is expected to show activity in psoriasis and atopic dermatitis. We are aware of
two potentially competing products of similar modality being Elidel and Protopic primarily used for atopic dermatitis. Revenues
for Elidel in 2010 were approximately $210 million and revenues for Protopic were approximately $220 million in 2011. Both Elidel
and Protopic are Rapamycin analogs. However both drugs have a black box cancer warning. We believe that P529 will not have such
a black box warning. This is due to P529 being a broad acting anti<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>cancer
agent that inhibits both TORC1 and TORC2, as opposed to Rapamycin analogs only inhibiting TORC1, so it would not be expected to
have the drawback of the IRS1 negative feedback loop, which could be the reason for Elidel and Protopic having a black box warning.
Management is not aware of any companies developing anti<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>angiogenesis
agents in the clinic for skin disease nor is the Company aware of any companies developing PI3K/Akt/mTOR inhibitors for fibrotic
(keloid scarring, pulmonary fibrosis) or anti<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>viral diseases.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Product Rationale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>RES-102</B>: Estrogens are known
to support skin health by maintaining skin thickness, elasticity and moisture content in both men and women. As estrogen levels
decline with age, skin thickness, elasticity and moisture content also decline. Skin loses half of its elasticity by age 60 and
continues to decline with age. Clinically, thinning skin leads to delicate wrinkles, ease of bruising and tearing, poor wound healing
and sensitivity to cold. The profound effects of estrogens on skin were known long before it was discovered that estrogen receptors
are present in all epithelial tissues but most abundant in skin and the uterus. Decades after estrogens were first used over-the-counter
(OTC) in facial creams, shampoos and hair conditioners to restore and maintain skin and hair health, unwanted estrogenic side effects
were linked to the use of those products. In 1994, safety concerns finally led to the removal of all estrogens and other hormone-containing
OTC products in the U.S. Less than ten (10) years later, the use of estrogen-containing prescription products was associated with
an increased risk of cancer and cardiovascular disease. These risks associated with estrogen use have made many doctors and patients
hesitant to use estrogens for these indications. Therefore, our RES-102, a &ldquo;soft&rdquo; estrogen, which we believe will have
the positive effects and efficacy of estrogen on skin without the local and systemic safety issues has strong rationale for use
on skin in various potential indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>RES-440</B>: Excess androgens (testosterone-like
hormones) in the skin of both men and women can lead to the overproduction of sebum which can block skin pores and lead to localized
infection and inflammation. An anti-androgen applied to the skin can block the actions of androgens and heal acne. In some women,
excess skin androgen can lead to unwanted localized hair growth (hirsutism). An anti-androgen applied to those skin areas can greatly
minimize excess body hair growth caused by excess androgens in the skin. Paradoxically, excess androgen in the scalp can cause
androgenic alopecia or baldness and is the most common cause of hair loss affecting both men and women. An anti-androgen applied
to the scalp at the first signs of thinning can block the actions of testosterone-like hormones. Hair thinning in some women coincides
with menopause when estrogen levels decrease and androgen levels increase. Therefore, a combination product of RES-102 and RES-440
(RES-102440) would be expected (but has not yet been established), to be more effective in those women than an anti-androgen alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>P529</B>: There currently is no
FDA-approved product for the treatment of scarring, especially keloid/hypertrophic scarring, our first dermatologic target indication
for P529. In view of the unmet medical need and the proposed mechanism of action of P529 to treat and prevent keloid/hypertrophic
scarring, development of the product for this indication has strong rationale.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Market Potential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Aging Skin (Skin Fragility)</B>:
Currently, there are no preventative treatments for age-related skin fragility (thinning), bruising, and slow healing. Severe skin-thinning
seen in nursing home patients often leads to skin tearing which can take 10-21 days to heal and increases nursing care costs for
institutions, individuals and the community. Estrogen-containing hormone therapy has been shown to improve skin thickness and elasticity,
but is not approved for this purpose due to systemic side effects. RES-102 has the potential to penetrate and expand the world-wide
aging skin market in all adult age groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Vulvar and Vaginal Atrophy</B>:
We believe the market size in 2012 world-wide was $1.1 billion and is expected to grow to $2.1 billion by 2022. Only 1 in 4 women
are currently seeking treatment for their vulvar vaginal atrophy symptoms because of fears associated with currently marketed estradiol
containing products. RES-102 is expected to achieve significant market share because of its safety profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Acne, Alopecia and Hirsutism</B>:
We believe that the world-wide anti-acne market is $2.8 billion and constitutes the largest prescription market in dermatology.
Currently available prescription anti-acne products are associated with undesirable side effects e.g., skin irritation, photosensitivity,
hypopigmentation and GI-upset. There are no other known non-systemic &ldquo;soft&rdquo; topical anti-androgens in development.
Hirsutism affects about 10% of the female population and Americans spend $1 billion annually for the removal of unwanted hair.
Androgenic baldness is a greatly underserved market and is primed for a safe, effective, non-invasive treatment. It affects both
men and women; women constitute nearly half of the hair-loss market. In the U.S. alone, consumers spend $1.2 billion annually on
topical treatments for thinning hair. We believe that this market is greatly underserved for safe and non-invasive remedies.</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Keloid Scarring/Hypertrophic Scarring</B>:
We believe that this market is a true unmet medical need today. In the U.S. alone there are at least 42 million procedures every
year which could benefit from products that reduce scarring in the skin, giving an estimated potential market size of over $4 billion.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Current Status of Dermatology Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our &ldquo;soft estrogen&rdquo; and
&ldquo;soft anti-androgen&rdquo; have completed <I>in vitro</I> and <I>in vivo</I> proof-of-concept studies in widely accepted
tissue and animal models. Our objective for RES-102 and RES-440 is to move into clinical trials as soon as possible after closing
on the current financing. We currently are working on synthesis and formulations of products. With regard to RES-102 we plan to
enter a Phase I/II clinical trial in Q3 2015 for the treatment of skin fragility/thinning and for RES-440 in Q2 2015 for the treatment
of acne. With regard to P529, we are currently working toward entering the clinic in a Phase I/II clinical trial for the treatment
of keloid scarring/hypertrophic scarring in Q1 2015.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-align: justify">Cosmeceutical Products (non-prescription
products)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On March 28, 2011, we entered into
an Exclusive Development Collaboration Agreement with Ferndale Pharma Group, Inc. (&ldquo;Ferndale&rdquo;), an experienced developer,
manufacturer and formulator of cosmeceutical products. Ferndale is a privately owned company located in Ferndale, Michigan. Established
in 1897, Ferndale is a holding company operating through six (6) specialty healthcare companies all focused on offering high-value
prescription and over-the-counter products treating a wide variety of medical disorders ranging from benign anorectal disorders
to skin conditions. Ferndale has over thirty (30) years of experience manufacturing topical Rx and OTC drugs, medical devices and
cosmeceuticals for both domestic and international distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Ferndale performed early development
studies on the Company&rsquo;s portfolio to identify a lead cosmeceutical candidate suitable for aging skin. As a result of the
studies, a lead product, which the Company refers to as &ldquo;CL-214&rdquo; was selected. On March 22, 2012, we entered into a
Sublicense Agreement (the &ldquo;Sublicense&rdquo;) with Ferndale for the formulation, manufacture, sale and marketing of CL-214
within Ferndale&rsquo;s established marketing channel for cosmeceuticals, which are the offices of surgeons, physicians and other
health care providers (the &ldquo;Distribution Channel&rdquo;). Ferndale is responsible for all costs and expenses associated with
developing marketing products for sale through the Distribution Channel. The territory is the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In consideration of our entering into
the Sublicense, Ferndale has agreed to pay us the following amounts on a country-by-country basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Royalties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Ten percent of net sales of products
sold within the territory where the Yale Patent is valid and in force; Four and one-half percent of net sales sold within the territory
when the Yale Patent has expired and two percent of net sales when the Yale Patent has been held invalid by final judgment of a
court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Use Fee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$100,000 payable within
thirty days following the first commercial sale of a product in the United States and Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$20,000 payable within
thirty days following the first commercial sale of a product in each of the following countries: Germany, France, United
Kingdom, Japan and Brazil; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fees received by
Ferndale from a distributor or other comparable party during the term shall be divided equally and paid by Ferndale to
Canterbury when received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Sales Milestone Payments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$100,000 at such time as the
trailing twelve months of net sales in any country in the territory first exceeds $1,000,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$200,000 at such time as the
trailing twelve months of net sales in any country in the territory first exceeds $5,000,000; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$400,000 at such time as
the trailing twelve months of net sales in any country in the territory first exceeds $10,000,000.</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">For purposes of the Ferndale Sublicense
Agreement, the United States and Canada are considered to be one country. Net sales has the customary definition with the usual
and standard permitted deductions provided, however, that under no circumstances can the aggregate deductions from gross sales
exceed seven and one-half percent of the gross amount actually received by Ferndale or an Affiliate. None of the amounts described
above have yet been paid to us. Ferndale has, to date, neither developed nor begun marketing any product covered by the Sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In addition to the Sublicense, we and
Ferndale have agreed to enter into a Supply Agreement on commercially reasonable terms pursuant to which Ferndale has committed
to purchase all of its required supply of CL-214 from us at cost of raw material and directly related costs and expenses. The Supply
Agreement has not yet been executed and the terms have not been finalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The term of the Sublicense, which is
subject to the terms and conditions of the Yale License, will continue in full force and effect until the last of the claims in
the Yale Patents expire, lapse or are declared to be invalid by a non-appealable decision of a court of competent jurisdiction.
Ferndale may voluntarily terminate the license upon ninety days prior written notice to us. Further, either party, upon thirty
days prior written notice and the failure to correct within that time period, may terminate the Sublicense upon the occurrence
of a material breach or a default by the other party. Finally, either party may immediately terminate the Agreement if the other
party is adjudged bankrupt, becomes insolvent or enters into a composition with its creditors or if a receiver is appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The Sublicense with Ferndale is our
first collaboration. We believe, but have not established, that there are multiple distribution and marketing channels available
for its cosmeceutical products, from direct retail sales to consumers to infomercials and the internet. With additional resources
and qualified partners and collaborators, we intend to explore all of these options. To date, we have not negotiated any agreements
other than the Sublicense with Ferndale.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">The Cosmeceutical Market for Aging Skin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Management believes that skin care
is one of the most important categories in the global beauty and personal care industry. Anti-aging products continue to be a significant
market performer, showing consistently high increases in revenue over the last five years. While spending has curbed since the
economic decline in late 2008, skin care products are one area of consumption that has not generally been negatively affected.
Growth in the cosmeceuticals market worldwide is primarily attributed to the aging population in the United States and across the
globe. Market gains are driven by a highly receptive, fast-expanding group of middle-aged customers who want to prevent and redress
visible damage to the skin caused by aging, sun damage and other environmental stressors. There is also an increase in disposable
income in emerging markets like Asia and South America. (Euromonitor: 2011).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">For women in their late forties and
early fifties, aging accelerates due to the hormonal changes of menopause. Management believes that women&rsquo;s top fear of aging
is losing attractiveness. Many women are experiencing these fears, with 51 million U.S. women between the ages of forty-five and
seventy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Anti-aging is no longer just about
reducing fine lines and minimizing wrinkles but in having skin that is hydrated, evenly toned, textured and supple. Management
believes that today&rsquo;s consumer wants a product that addresses all seven signs of aging: dehydration, fine lines, wrinkles,
skin discoloration, large pores, loss of elasticity and fullness. We believe that the product(s) that can address all of these
issues and is correctly priced will succeed. Anti-aging is fueling the fast-growing cosmeceutical market; these women are actively
seeking solutions for aging skin and hair. Anti-aging is the fastest growing segment of the personal care and cosmeceutical industries.
Cosmeceutical anti-aging skincare is the fastest growing segment in the skincare market, projected to grow to $3.7 billion by 2016
with +8.3% Compound Annual Growth Rate (&ldquo;CAGR&rdquo;) (2010-2016, according to the research firm Mintel Group Ltd.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We believe that the science and technology
behind the development of CL-214, and other members of our product portfolio, have the potential to make us a market leader by
focusing on a plan that maximizes the value of its unique portfolio of assets:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Need: For women in their late forties and early fifties, skin aging accelerates due to the
hormonal changes of menopause. Women&rsquo;s top fear of aging is losing attractiveness. Many women are experiencing these fears,
with 51 million U.S. women between the ages of forty-five and seventy.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Solution: the proprietary ingredients bring a new, differentiated benefit to the anti-aging
market. Our ingredients potentially safely halt and reverse age-related hormonal changes in women&rsquo;s skin and hair. Unlike
other anti-aging topical cosmeceuticals, the Company&rsquo;s ingredients act only at the point of application, are non-irritating
and spare internal organs from unnecessary systemic exposure.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Anti-aging is fueling the fast-growing cosmeceutical market: These women are actively seeking solutions
for aging skin and hair. Management believes that anti-aging is the fastest growing segment of the personal care and cosmeceutical
industries.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Competition: Despite the growth in cosmeceuticals, many of the current anti-aging topical products
are either ineffective, unsafe or both. As is the case with the retinoids, their effectiveness is limited by constraints on how
much can be applied to skin without causing photo-sensitivity to the sun&rsquo;s rays and irritation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our products can fit multiple product segments: these ingredients can be formulated for multiple
cosmeceutical applications where we believe the total addressable U.S. market is $5.5 billion. We are focused on the cosmeceutical
skin and hair care segments where we believe the addressable U.S. market is $2.3 billion and $550 million, respectively.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our business plan maximizes the value of the ingredients and creates a large and growing business
in skin and hair care: the plan is sequenced to attack the largest cosmeceutical market quickly with a unique benefit of halting
and reversing the effects of aging, then accelerating growth in other key segments while leveraging current brand and channel assets.</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Current Status of Our Over-The-Counter Dermatology
Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our first product for aging skin, CL-214,
will be developed and initially be sold and marketed by Ferndale Pharma Group through physician offices and medi-spas world-wide.
Preparation for manufacturing was completed in the first quarter of 2014 and the first batch of CL-214 started formulation development
in February 2014. Management believes that CL-214 will be launched by Ferndale in the fourth quarter of 2015, following human skin
assessment studies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">DESCRIPTION OF
OUR OPHTHALMOLOGY BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have submitted patents (currently
16 issued patents and 29 pending applications) covering its ownership of intellectual property relating to a series of novel, proprietary,
small molecule drugs created through an integrated design platform incorporating proprietary, customized and industry standard
computational tools that we believe may have therapeutic potential for the treatment of certain ophthalmic disease (age<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>related
macular degeneration, diabetic macular edema, proliferative vitreoretinopathy and uveitis). These small molecule drugs, &ldquo;Palomids,&rdquo;
have shown activity <I>in vitro</I> and <I>in vivo</I>models of disease. Palomid 529 (P529), lead drug of the Palomid series, entered
the clinic in 2010 for age<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>related macular degeneration in two
Phase I/II clinical trials. We sponsored a trial using intravitreal administration that was completed in December of 2011. The
National Eye Institute (NEI) sponsored trial using subconjunctival administration, was completed in July of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We believe that age-related macular
degeneration is an important potential use of P529 and we are planning to initiate a Phase I/II clinical trial in Q1 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Example of human Phase I Results.
P529 was shown to reduce fluid pockets in patients. In the presence of Lucentis&trade;, in Lucentis&trade; refractory patients, P529
was shown to reduce cyst and thin retina.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 10.5pt"><IMG SRC="table8.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In ocular diseases, P529 may improve
vision by simultaneously inhibiting growth, reducing edema and hemorrhage, and, possibly, regress existing disease<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>causing
ocular vessels. P529 has shown activity in animal models of macular degeneration and diabetic retinopathy. In a retinal detachment
fibrotic animal model, it has shown nearly complete elimination of retinal scar formation.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">P529 is a first-in-class PI3K/Akt/mTOR
pathway inhibitor.<B> </B>Other companies also are developing drugs to target this pathway, notably AstraZeneca, OSI Pharmaceuticals,
Wyeth Pharmaceuticals, Ariad and Intellikine (recently merged with Takeda) having small molecule drug inhibitors in the clinic.
Although such companies may have their drugs approved prior to that of our company, we will be able to observe how these companies
are progressing through the clinic and learn by example how to develop its own drugs. By this ability, we expect to move quickly,
effectively and efficiently through the clinic. We believe that success in the development of other PI3K/Akt/mTOR acting inhibitor
drugs will increase the value of the drugs in our pipeline. Our therapeutic indication areas have large market sizes. In addition,
business development deals have been quite lucrative in this space notably for anti<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>angiogenesis
agents to treat ocular diseases.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Current Status of Ophthalmology Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are developing our Palomid series
of compounds targeting several disease indications including ophthalmology. We have completed two Phase I studies in age<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>related
macular degeneration. Both studies showed a lack of toxicity and preliminary evidence of activity. We plan to engage in Phase II
studies with either macular degeneration (as a Lucentis<SUP>&trade;</SUP>/Eylea<SUP>&trade;</SUP> companion drug) and/or proliferative vitreoretinopathy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are conducting early development
of P529 and its analogs for a variety of diseases where the PI3K/Akt/mTOR pathway shows aberrant up<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>regulation.
Our preclinical work is divided into research and development. Research has traditionally been out<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>sourced
to academic laboratories. Development work may be divided into two areas. First, process development for the manufacture of both
active pharmaceutical ingredients (&ldquo;API&rdquo;) and drug product along with the final good manufacturing practice (&ldquo;GMP&rdquo;)
manufacturing of API and drug product, and second, good laboratory practice (&ldquo;GLP&rdquo;) and non<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>GLP
toxicology work to support toxicology studies.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Product Rationale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As discussed above, P529 has completed
Phase I studies in age<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>related macular degeneration. Data from
these studies have shown P529 to be safe and lacking toxicity, even at the injection site for both the intravitreal and subconjunctival
clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Although the Phase I studies were
designed to assess safety, some patients exhibited what may be considered as preliminary activity. This activity manifested itself
in reducing retinal thickness and fluid pocket size, as well as some degree of vision improvement. However, as these studies were
not designed to statistically evaluate efficacy statistically, a larger Phase II study is in the planning stage for subconjunctival
administration in either or both age<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>related macular degeneration
and diabetic macular edema in both the presence and absence of standard of care Lucentis&trade;. As P529 has shown augmentation
of activity with anti<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>VEGF in preclinical studies and possibly
in our clinical studies, P529 is being considered as a companion drug for Lucentis&trade; as opposed to attempting to supersede
Lucentis&trade;<SUP> </SUP>as monotherapy which is considered a very high bar to hurdle.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">The Market for Therapeutic Indications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We believe the ophthalmology indication
for P529 falls within a therapeutic area that exhibits certain unmet needs with a potential market size of $7 billion.</P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">DESCRIPTION OF
OUR WOMEN&rsquo;S HEALTH BUSINESS</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Development Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">RES-102, the lead &ldquo;soft&rdquo;
estrogenic candidate, is a member of the 15-alpha-carboxylic acid esters of estrogen, RES-102, is under development for the topical/vaginal
treatment of VVA.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Product Rationale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>RES-102</B>: Estrogens are known
to support skin and mucous membrane health by maintaining thickness, elasticity and moisture content in women. As estrogen levels
decline with age, skin and mucous membrane thickness, elasticity and moisture content also decline. Skin loses half of its elasticity
by age 60 and continues to decline with age. Vaginal wall atrophy, a condition that significantly reduces quality of life, affects
47% of women within three years of menopause and approaches 100% over time. The profound effects of estrogens on skin were known
long before it was discovered that estrogen receptors are present in all epithelial tissues but most abundant in skin and the uterus.
Decades after estrogens were first used OTC in facial creams, shampoos and hair conditioners to restore and maintain skin and hair
health, unwanted estrogenic side effects were linked to the use of those products. In 1994, safety concerns finally led to the
removal of all estrogens and other hormone-containing OTC products in the U.S. Less than ten years later, the use of estrogen-containing
prescription products was associated with an increased risk of cancer and cardiovascular disease. These risks associated with estrogen
use have made many doctors and patients hesitant to use estrogens to manage VVA associated with low estrogen.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Market Potential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>VVA</B>: VVA is a urogenital disorder
caused by a decrease in estrogen, typically occurring during menopause. When estrogen levels are low, the tissues of the vulvar
vaginal region become less moist and the elastic and collagen fibers that give the vaginal wall stretch and stretchiness decreases
in number. The skin of the opening becomes thinner and less protective. Thus, the vulvar and vaginal region becomes painful during
intercourse and there is an increased incidence of urinary tract infections. In extreme cases, thinning of the tissue can lead
to tiny abrasions that cause the sides of the vaginal opening to stick together and the opening may become fused closed. The VVA
market is in need of a product with lower systemic activity since treatment guidelines issued by the FDA favor estrogenic products
with lower systemic effects. We believe that only 1 in 4 women with VVA symptoms seek treatment because of safety concerns of currently
marketed estrogen-containing products. Prevalence, severity and awareness of the condition are increasing as the population ages
and women spend one third of their lives in menopause. We believe that the post-menopausal VVA market in the U.S. is currently
over $1 billion. The CAGR has grown by 8.8% over the past 5 years and the world-wide market is expected to grow to over $2 billion
dollars by 2022.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Current Status of Women&rsquo;s Health Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our &ldquo;soft estrogen&rdquo; has
completed <I>in vitro</I> and <I>in vivo</I> proof-of-concept studies in widely accepted tissue and animal models. Our objective
for RES-102 is to move into clinical trials as soon as possible after closing on the current financing and final synthesis and
formulation development. With regard to RES-102 we plan to enter a Phase I/II clinical trial in 2015 for the treatment of VVA.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left">DESCRIPTION OF OTHER INDICATIONS/PRODUCTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have rights to and own technologies
and potential products beyond just those described above. It is our strategy to focus at the current time on dermatology, ophthalmology
and women&rsquo;s health as described in this document. Beyond those products described, we will review our technologies and potential
products on a regular basis and consider internal development in the future and the potential to out-license portions of our technology
and potential products to other biopharmaceutical companies with greater resources than us. The technologies and products that
could be licensed are those included in the following indications with what we believe are the respective potential market sizes.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Dermatology ($10 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Ophthalmology ($5 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Oncology ($30 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Central Nervous System (&ldquo;CNS&rdquo;) ($100 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">Infantile Spasm (epilepsy)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">Aberrant protein accumulation</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Huntington&rsquo;s/Parkinson&rsquo;s disease</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Amyotrophic lateral sclerosis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Alzheimer&rsquo;s disease</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Schizophrenia</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Fibrosis ($4 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">Pulmonary/Renal</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Infectious disease ($20 billion</B>)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">HIV/AIDS</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">HCV</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Biodefense ($50 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">Radiation protectant/mitigant</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Cardiovascular ($5 billion)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">Drug eluting stent</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><B>Orphan Disease</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: justify">Progeria (systemic)</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In addition, we believe we may be
the only company that has developed and may develop further small molecule drug zinc<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>finger
transcription factor inhibitors/activators. We have the potential of being an epigenetic company having the ability to affect
DNA function without changing its structure. This modality has recently become a major interest for academics, biotechnology and
pharmaceutical companies. We potentially could focus on a variety of indications where a zinc<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>finger
transcription factor has been implicated in disease.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Zinc finger transcription factors are
a subset of transcription factors utilizing zinc at its core for activity. Transcription factors are proteins that bind to specific
parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs the protein making machinery
to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of a transcription factor, one
can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription factor. Many diseases
can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors. Inhibition of such
transcription factors could then be able to control disease pathology. Since transcription factors are functionally closer to the
ultimate pathological protein(s), specific inhibition of transcription factors may result in a greater degree of disease fighting
activity along with reduced level of toxicity. This may have advantage over conventional small molecule drugs that directly inhibit
their target protein through a one<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>to<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>one
interaction as transcription factor inhibitors will literally turn off pathological protein manufacturing capability at its source.
Our disease area of focus could include dermatology, cancer and ophthalmic diseases of retinal origin.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Development Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Subject to management&rsquo;s decision
and available resources, we may plan to expand and continue or out-license its work with vascular endothelial zinc finger (&ldquo;VEZF1&rdquo;)
small molecule drug development to allow Phase I clinical development for oncology as well as its pipeline aimed at other zinc-finger
targets in a variety of indication areas. We are currently evaluating our product ZNF750 for its dermatology program for common
and rare human skin disorders, including atopic dermatitis, psoriasis, ichthyosis vulgaris, and epidermal cancers, which in lifetime
aggregate afflict a large portion of the U.S. population.</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Product Rationale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Since transcription factors are functionally
closer to the ultimate pathological protein(s), specific inhibition of transcription factors may result in a greater degree of
disease fighting activity along with reduced level of toxicity. Our compounds may have an advantage over conventional small molecule
drugs that directly inhibit their target protein through a one-to-one interaction as transcription factor inhibitors. We are not
aware of any other company developing small molecule drugs targeting the disruption of the zinc finger transcription factor and
DNA interaction.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Market Potential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Management believes
that angiogenesis inhibitors are an effective and safe treatment for a number of diseases that <FONT STYLE="background-color: white">involve
a proliferation of blood vessels, like cancer. </FONT>The number of cancer<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>cases
globally is expected to grow to 22.2 million in 2030, from 12.8 million in 2008 according to <I>Bloomberg</I>. The world&rsquo;s
aging population is one reason oncology is a hot prospect for drug makers. Cancer drugs also carry bigger price tags than many
other types of treatments. Increasing numbers of patients plus lucrative pricing equals big growth for the oncology market, with
sales expected to surpass $114 billion by 2018, according to EvaluatePharma, a forecast and analysis report of the biotech and
pharmaceutical sector by Evaluate Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of 2006, the market for all products
regulating angiogenesis was predicted to reach $2.4 billion and was growing at an average annual growth rate (AAGR) of over 88%.
Global Industry Analysts, Inc., a publisher of specialty market research, recently released a comprehensive global report on angiogenesis
inhibitors and stimulators markets and forecasted that the global market for angiogenesis inhibitors and stimulators is expected
to reach $53.5 billion by the year 2015. The report cited aging population worldwide, increasing incidence of cancer patients and
heart diseases, changing lifestyles, and unmet needs in present oncology therapeutic area as the key factors driving growth in
the angiogenesis inhibitors and stimulators market. Increased adoption of approved anti-angiogenic drugs as well as robust pipeline
of efficacious new drugs across diverse cancer indications are expected to drive future growth in the angiogenesis inhibitors market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Oncology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">There is consensus that demand exists
for novel and effective cancer treatments, however no one knows whether the ideal agent will be an angiogenesis inhibitor or not.
Angiogenesis inhibitors are unique cancer-fighting agents because they tend to inhibit the growth of blood vessels rather than
tumor cells. In some cancers, angiogenesis inhibitors are most effective when combined with additional therapies, especially chemotherapy.
It has been hypothesized that these drugs help normalize the blood vessels that supply the tumor, facilitating the delivery of
other anticancer agents, but this possibility is still being investigated. That being said, there is the potential to use our technology
independently or in conjunction with other treatments to address many types of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="background-color: white">The
global consulting and market research firm Lucintel reported that the global oncology drugs industry experienced significant growth
during the past five years and is expected to continue that momentum to reach an estimated $100.6 billion in 2018. Lucintel&rsquo;s
study points to </FONT>an aging population, changing lifestyles, more effective diagnosing, unhealthy eating habits, and an increasing
incidence of chronic diseases across the entire global population as supporting growth opportunities for the oncology drugs industry
players.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Ophthalmology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="background-color: white">Angiogenesis
in the eye underlies the major causes of blindness in both developed and developing nations, including exudative age-related macular
degeneration (&ldquo;AMD&rdquo;), proliferative diabetic retinopathy (&ldquo;PDR&rdquo;), diabetic macular edema (&ldquo;DME&rdquo;),
central retinal vein occlusion (&ldquo;CRVO&rdquo;), neovascular glaucoma, corneal neovascularization (trachoma), and pterygium.&nbsp;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The global ophthalmology drug and devices
market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia,
macular degeneration, and diabetic retinopathy among the aging population. According to the market research firm MarketsandMarkets.com,
the global ophthalmology drug and devices market is expected to reach a market size of $36 billion by the year 2014, at a CAGR
of 5.4% from 2009-2014 and the pharmaceutical drug market is expected to reach a size of $19.8 billion by the year 2014 growing
at a CAGR of 4% from 2009-2014.</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Dermatology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Today, there are an estimated 9,600
dermatologists and 7,800 dermatology practices in the U.S according to IMS Health. Harris Williams &amp; Company published a 2013
study projecting that the $10.1 billion U.S. dermatology market is expected to grow to $13.1 million by 2017, representing a 5.3%
CAGR. BCC research estimated the global dermatological therapeutics market was worth an estimated $25.0 billion in 2008 and should
reach $38.0 million in 2013, for CAGR of 8.7%.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">GOVERNMENT REGULATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Government authorities in the U.S.,
at the federal, state and local level, and other countries extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution,
marketing and export and import of products such as those we are developing. Our business is subject to numerous laws and regulations.
The formulation, manufacturing, packaging, labeling, registration, advertising, distribution, importation, storage and sale of
our cosmetic products are subject to extensive regulation by various Federal agencies, including the U.S. Food and Drug Administration,
or the &ldquo;FDA,&rdquo; the U.S. Federal Trade Commission, or the &ldquo;FTC,&rdquo; the U.S. Environmental Protection Agency,
or the &ldquo;EPA,&rdquo; and by various agencies of the states, localities and foreign countries in which our products are manufactured,
distributed and sold. Failure by us or our manufacturers to comply with those laws and regulations could lead to enforcement action
and the imposition of significant penalties or claims, resulting in significant loss of sales, and could have a negative effect
on our business, results of operations and financial condition. If we fail to comply with Federal, state or foreign laws and regulations,
we could be required to suspend manufacturing operations, change product formulations, suspend the sale of certain products, initiate
product recalls, change product labeling, packaging or advertising or take other corrective actions. Any of these actions could
harm our business, financial condition and results of operations. In addition, the adoption of new laws or regulations or changes
in the interpretations of existing laws or regulations may result in significant compliance costs or discontinuation of products.
Our failure to comply with FDA, FTC, EPA or state laws and regulations, or with laws and regulations in foreign markets, that cover
our advertising, including direct claims and advertising by us, may result in enforcement actions and imposition of penalties or
otherwise materially adversely affect the distribution and sale of our products and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Under the Federal Food, Drug, and Cosmetic
Act (&ldquo;FDCA&rdquo;) cosmetics/cosmeceuticals are defined as articles or components of articles that are applied to the human
body and intended to cleanse, beautify or alter its appearance, with the exception of soap. Cosmeceuticals, unlike prescription
drugs, are not subject to pre-market approval by the FDA but the product and ingredients must be tested to assure safety. If safety
has not been adequately substantiated, a specific label warning is required. The FDA monitors compliance of cosmeceutical products
through random inspection of cosmeceutical manufacturers and distributors to ensure that the products neither contain false or
misleading labeling nor are manufactured under unsanitary conditions. Inspections also may occur from consumer or competitor complaints
filed with the FDA. In the event the FDA does find false or misleading labeling or unsanitary conditions or otherwise a failure
to comply with FDA requirements, our distribution channel may be affected by a possible product recall or insufficient product
in the marketplace resulting in reduced product sales and revenue to us and increased costs to our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We may also, at some point in the future,
be subject to a variety of other laws and regulations. Our failure to comply, or assertions that we have failed to comply, with
these laws and regulations could have a material adverse effect on our business in a particular market or in general. To the extent
we decide to commence or expand operations in additional countries, laws and regulations in those countries, or the cost of complying
with such laws and regulations, may prevent or delay entry into or expansion of operations in those markets or could have a negative
effect on our operating margins for products sold in those countries. Regulatory requirements can vary widely from country to country
and could further delay the introduction of our products into those countries. We may not be able to enter into acceptable agreements
to market and commercialize our products in international markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our ability to sustain satisfactory
levels of sales in our markets is dependent in significant part on our ability to introduce additional products into those markets.
Government laws and regulations in both our domestic and international markets can delay or prevent the introduction, or require
the reformulation or withdrawal, of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The FDA does not have a pre-market
approval system for cosmetics/cosmeceuticals, and we believe we are permitted to market our cosmeceuticals and have them manufactured
without submitting safety or efficacy data to the FDA. However, the FDA may in the future determine to regulate our cosmetics or
the ingredients included in our cosmetics as drugs or biologics. If certain of our products are deemed to be drugs or biologics,
rather than cosmetics, we would be required to conduct clinical trials to demonstrate the safety and efficacy of these products
in order to continue to market and sell them. In such event, we may not have sufficient resources to conduct the required clinical
trials, we may not be able to establish sufficient efficacy or safety to resume the sale of these products, we may not gain regulatory
approval of the trial design, the clinical trials may be subject to unanticipated delays due to their time-consuming nature and
the outcome of any clinical trial is uncertain. Any inquiries by the FDA or any foreign regulatory authorities into the regulatory
status of our cosmetics and any related interruption in the marketing and sale of these products could severely damage our brand
reputation and image in the marketplace, as well as our relationships with retailer customers, which would harm our business, results
of operations and financial condition.</P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Some of our cosmeceuticals may be considered
OTC drug products by the FDA. The FDA regulates the formulation, manufacturing, packaging, labeling and distribution of OTC drug
products pursuant to a monograph system that specifies active drug ingredients and acceptable product claims that are generally
recognized as safe and effective for particular uses. If any of these products that are OTC drugs are not in compliance with the
applicable FDA monograph, we would be required to (i) reformulate such product, (ii) cease to make certain use claims relating
to such product or (iii) cease to sell such product until we receive further FDA approval. If more stringent regulations are promulgated,
we may not be able to comply with such statutes or regulations without incurring substantial expense. In addition, OTC drug products
must be manufactured in accordance with pharmaceutical GMP regulations. Our OTC drug manufacturers are subject to ongoing periodic
unannounced inspection by the FDA as well as regular and ongoing inspections. In addition, inspections may be commenced as a result
of consumer or competitor complaints related to our products. Corresponding state agencies may also inspect our facility to ensure
strict compliance with drug good manufacturing practices and other government regulations and corresponding foreign standards.
We have minimal control over third-party manufacturers&rsquo; compliance with these regulations and standards. If the FDA finds
a violation of drug good manufacturing practices, it may enjoin the manufacturer&rsquo;s operations, seize products, or criminally
prosecute the manufacturer, any of which could require us to find alternative manufacturers, resulting in additional time and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Preparing drug candidates for FDA approval
has been historically a costly and time-consuming process. In order to gain FDA permission to test our drugs, we must first conduct
preclinical studies in the laboratory and in animal model systems to gain preliminary information on an agent&rsquo;s effectiveness
and to identify any safety problems. The results of these studies are submitted as a part of an investigational new drug (IND)
application for our drugs, which the FDA must review before human clinical trials of an investigational drug can begin. The IND
includes a detailed description of the clinical investigations to be undertaken. In order to commercialize any products, we must
sponsor and file an IND and conduct clinical studies to demonstrate the safety and effectiveness necessary to obtain FDA approval
of such products. For INDs sponsored by us, we are required to select qualified investigators (usually physicians within medical
institutions) to supervise the administration of the products, and ensure that the investigations are conducted and monitored in
accordance with FDA regulations, including the general investigational plan and protocols contained in the IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Clinical trials of drugs are normally
done in three phases, although the phases may overlap. Phase I trials are concerned primarily with the safety and preliminary effectiveness
of the drug, involve a small group ranging from 15-20 subjects, and may take from six months to over one year to complete. Phase
II trials normally involve 30-200 patients and are designed primarily to demonstrate effectiveness in treating or diagnosing the
disease or condition for which the drug is intended, although short-term side effects and risks in people whose health is impaired
may also be examined. Phase III trials are expanded clinical trials with larger numbers of patients which are intended to evaluate
the overall benefit-risk relationship of the drug and to gather additional information for proper dosage and labeling of the drug.
Phase III clinical trials generally take two to five years to complete, but may take longer. The FDA receives reports on the progress
of each phase of clinical testing, and it may require the modification, suspension, or termination of the clinical trials, if it
concludes that an unwarranted risk is presented to patients, or, in Phase II and III, if it concludes that the study protocols
are deficient in design to meet their stated objectives.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Properties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are operating in multiple &ldquo;virtual
office&rdquo; settings. We believe this virtual office structure is adequate for our current needs and suitable additional or substitute
space will be available as needed.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We currently have six full time employees.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In July 2013, the Company received
notice that a complaint for property damage had been filed by the Truck Insurance Exchange against the Company for $393,592 related
to water damage incurred by a printing company on the ground floor of the Company&rsquo;s former office space in Los Angeles. This
damage is alleged to have occurred in connection with a water leak in the Company&rsquo;s former office in February 2013. The Company
has filed an answer to this complaint that includes, but not be limited to, the defense of culpability of the building&rsquo;s
management in this leak. The Company has a dispute with its insurance carrier at that time regarding coverage for this incident
and the Company intends to pursue this dispute to ensure that it had proper insurance coverage at that time. The $300,000 accrued
for this matter as of December 31, 2012 was increased to $393,592 in the Company&rsquo;s financial statements as of December 31,
2013.</P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">MARKET PRICE OF
AND DIVIDENDS ON COMMON EQUITY<BR>
AND RELATED STOCKHOLDER MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Market Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth the
high and low prices of our common stock during the past two years, for each period indicated, as reported by the OTCBB or OTCQB
for the dates indicated. Such quotations reflect prices between dealers in securities and do not include any retail mark-up, markdowns
or commissions and may not necessarily represent actual transactions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Fiscal Period</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b><u>High</u></b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b><u>Low</u></b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 46%; text-align: justify"><font style="font-size: 10pt"><b><u>2014</u></b></font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 13%; text-align: right">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 13%; text-align: right">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">&nbsp;&nbsp;First quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">6.30</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt"><b>&nbsp; </b>Second quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">6.20</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">3.90</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt"><b><u>2013</u></b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">First quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">20.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">8.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Second quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">24.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">14.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Third quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">19.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">6.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Fourth quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">10.50</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">2.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt"><b><u>2012</u></b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">First quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">54.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">40.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Second quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">55.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">31.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Third quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">50.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">30.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Fourth quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">44.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">12.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt"><b><u>2011</u></b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">First quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">65.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">27.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Second quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">100.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">33.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Third quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">89.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">48.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Fourth quarter</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">81.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">40.00</font></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of June 30, 2014, there
were approximately 1,300 stockholders of record of our common stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Since our inception, we have never
declared or paid any cash dividends. We currently expect to retain earnings for use in the operation and expansion of our business,
and therefore do not anticipate paying any cash dividends in the foreseeable future.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Securities Authorized for Issuance Under Equity Compensation
Plans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table provides information
as of March&nbsp;5, 2014 regarding compensation plans (including individual compensation arrangements) under which our securities
are authorized for issuance. Information is included for both equity compensation plans approved by our stockholders and equity
compensation plans not approved by our stockholders.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Plan Category</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average Exercise Price of Outstanding Options, Warrants and Rights</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities in the first column)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Equity compensation plans approved by stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD></TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 49%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Equity compensation plans not approved by stockholders</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: right">1,403,725</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.10</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,403,725</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The above-referenced stock option grants
were issued without registration in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act, based on certain
representations made to us by the recipients.</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">You should read the following
information together with our financial statements and notes thereto that are included in this prospectus. This discussion contains
forward-looking statements that involve risks, uncertainties, and assumptions. Actual results may differ materially from those
anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those presented
under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following discussion relates to
the operations of RestorGenex Corporation and should be read in conjunction with the Notes to Financial Statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Background on the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are a specialty biopharmaceutical
company initially focused on developing products for dermatology, ophthalmology and women&rsquo;s health. On March 7, 2014, we
effected a reverse stock split of 1 to 100 with respect to our Common Stock and we changed our corporate name from Stratus Media
Group, Inc. to RestorGenex Corporation. All stock numbers herein are post reverse split.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">RestorGenex History</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Prior to our repositioning as a specialty
biopharmaceutical company, on March 14, 2008, pursuant to an Agreement and Plan of Merger dated August 20, 2007 between Feris International,
Inc. (&ldquo;Feris&rdquo;) and Pro Sports &amp; Entertainment, Inc. (&ldquo;PSEI&rdquo;), Feris issued 495,000 shares of its common
stock for all issued and outstanding shares of PSEI, resulting in PSEI becoming a wholly-owned subsidiary of Feris and the surviving
entity for accounting purposes (&ldquo;Reverse Merger&rdquo;). In July 2008, Feris&rsquo; corporate name was changed to Stratus
Media Group, Inc. PSEI, a California corporation, was organized on November 23, 1998 and specialized in various sports events that
it owned and operated. PSEI also owned Stratus Rewards LLC (&ldquo;Stratus White&rdquo;) that planned to operate a credit card
rewards program. In June 2011, we acquired shares of Series A Convertible Preferred Stock of ProElite, Inc., a New Jersey corporation
(&ldquo;ProElite&rdquo; or &ldquo;PEI&rdquo;), that organized and promoted mixed martial arts (&ldquo;MMA&rdquo;) matches. These
holdings of Series A Convertible Preferred Stock provide us voting rights on an as-converted basis equivalent to a 95% ownership
in ProElite. During the first quarter of 2013, we decided to focus on the MMA business and temporarily suspended development of
our other businesses. Because of lack of working capital, we suspended operations of ProElite effective June 30, 2013. Following
the repositioning of our company as a specialty biopharmaceutical company, our Board of Directors voted to discontinue operations
of ProElite effective March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Effective September 30, 2013, we entered
into an Agreement and Plan of Merger with Canterbury Acquisition LLC, Hygeia Acquisition, Inc., Canterbury Laboratories, LLC (&ldquo;Canterbury&rdquo;),
Hygeia Therapeutics, Inc. (&ldquo;Hygeia&rdquo;) and Yael Schwartz, Ph.D., as Holder Representative, pursuant to which we acquired
all of the capital stock of Canterbury and Hygeia with Canterbury and Hygeia becoming our wholly-owned subsidiaries. The consideration
for the mergers was the issuance by us of an aggregate of 1,150,116 restricted shares of our common stock issued to the stakeholders
of Canterbury and Hygeia. Closing of the mergers occurred on November 18, 2013. For the three months ended March 31, 2014, there
were no revenues associated with Canterbury and Hygeia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Canterbury and Hygeia (the &ldquo;Canterbury
Group&rdquo;) are related companies engaged in the development of pharmaceuticals and cosmeceuticals (cosmetic products with &ldquo;drug-like&rdquo;
benefits) which, depending on the specific product involved, may treat acne, hirsutism (unwanted hair) and alopecia (thinning hair)
and that may revitalize hormonally-aged skin and hair in women over the age of 45. The Canterbury Group has an exclusive license
with Yale University to develop and market 23 synthetic estrogenic ingredients for the treatment of aging skin and four classes
of anti-androgenic ingredients for hair loss, excess facial hair, seborrhea and acne. The license from Yale covers 24 patent-protected
compounds under U.S. Patent 7,015,211 &ldquo;Estradiol 15-&alpha;-Carboxylic Acid Esters as Locally Active Estrogens,&rdquo; U.S.
Patent 6,476,012 &ldquo;Estradiol 16-alpha Carboxylic Acid Esters as Locally Active Estrogens&rdquo; and U.S. Patent 8,552,061
&ldquo;Locally active &quot;soft&quot; antiandrogens&rdquo; (together the &ldquo;Yale Patents&rdquo;).</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The acquisitions of Canterbury and
Hygeia were steps in the implementation of our plan to reposition the Company as a specialty biopharmaceutical company. The total
consideration was $12,421,249 based on the issuance of 1,150,116 shares of common stock at the market value of $10.80 as of the
execution of the Merger Agreements on September 30, 2013. Based on the third-party valuation of the Yale Patents of $7,779,000,
$4,642,249 of the purchase price was initially allocated to goodwill, which is not tax deductible. The value of the Yale Patents
at the time of purchase was $132,571 as reflected on the books of Canterbury, giving rise to an adjustment of $7,646,429 to us
for the $7,779,000 allocated to the Yale Patents at the time of acquisition less the $132,571 on the books of Canterbury. When
tax effected at a combined U.S. Federal and California tax rate of 40%, the net result of this adjustment is a deferred tax liability
of $3,000,576. Total goodwill of $7,642,825 as of December 31, 2013 consisted of the $4,642,249 initial allocation of the purchase
price plus the deferred tax liability of $3,000,576.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Hygeia, a Delaware Corporation based
in Holden, Massachusetts, was incorporated in November 2005 and was formerly known as Orcas Therapeutics, Inc. Canterbury is a
Delaware Limited Liability Company that was formed in October 2011 and began operations in February 22, 2012. Initially, Canterbury
was a wholly-owned subsidiary of Hygeia and shareholders of Hygeia owned 94% of Canterbury at the time of the mergers with our
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On March 3, 2014, we entered into an
Agreement and Plan of Merger with Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. (&ldquo;Paloma&rdquo;) and David Sherris,
Ph.D., as founding stockholder and Holder Representative pursuant to which we agreed to acquire all of the capital stock of Paloma
with Paloma becoming our wholly owned subsidiary. On March 28, 2014, the merger with Paloma was closed and we issued an aggregate
of 2,500,000 common shares to all the holders of Paloma Common Stock and its derivative securities and assumed promissory notes
of Paloma in the aggregate amount (principal and interest at that time) of approximately $1,151,315 to be paid on the first anniversary
of the closing of the Paloma merger. The 2,500,000 shares were valued at $2.50 per share, which was the closing market price of
our common stock on March 3, 2014, resulting in $6,250,000 of stock consideration, resulting in total consideration of $7,401,315.
Of this total consideration, 30%, or $2,220,395, was allocated to intangible assets based on our assessment and $5,180,920 was
allocated to goodwill. We are planning to have a third-party valuation of the intangible assets and when that valuation is completed
the allocation to intangibles may change. These intangible assets had a value of $763,131 on Paloma&rsquo;s books, resulting in
an adjustment of $1,457,082. When tax effected at a combined U.S. Federal and California tax rate of 40%, the net result of this
adjustment is a deferred tax liability of $582,833. Total goodwill of $5,763,753 as of March 31, 2014 consists of the $5,180,920
initial allocation of the purchase price, plus the deferred tax liability of $582,833 plus net assets acquired of $190,567. Since
Paloma was acquired at the end of the quarter, there were no expenses for Paloma included in the consolidated loss of $1,376,137.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Also on March 3, 2014, we entered into
an Agreement and Plan of Merger with VasculoMedics Acquisition, Inc., VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;) and Dr.
Sherris pursuant to which we agreed to acquire all of the capital stock of VasculoMedics with VasculoMedics becoming our wholly
owned subsidiary. The VasculoMedics Merger was concurrently closed with and was a condition to the closing of the Paloma Merger
on March 28, 2013, with our company issuing an aggregate of 220,000 common shares to the VasculoMedics stockholders. These shares
were valued at $2.50 per share, which was the closing price of our common stock on March 3, 2014, resulting in $550,000 of consideration,
all of which was allocated to goodwill. Since VasculoMedics was acquired at the end of the quarter, there were no expenses for
VasculoMedics included in the consolidated loss of $1,376,137. The mergers with Paloma and VasculoMedics were completed as part
of our plan to reposition itself as a specialty biopharmaceutical company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Both Paloma and VasculoMedics are Delaware
corporations and are based in Jamaica Plain, Massachusetts. Paloma was founded in January 2005 and VasculoMedics was founded in
November 2007. Dr. Sherris, the founder and Chief Executive Officer of both companies, owned 56% of the outstanding stock of Paloma
at the time of the Mergers and owned 89% of the outstanding stock of VasculoMedics, with Paloma owning the other 11% of the outstanding
stock of VasculoMedics. For accounting purposes Paloma and VasculoMedics are considered to be under common control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Paloma has developed a non-steroidal,
synthetic, small molecule drug library for dermatology (psoriasis, atopic dermatitis, rosacea, actinic keratosis, keloid and hypertrophic
scarring, Dupuytren&rsquo;s disease, bullous blistering diseases), ocular disease, cancer, pulmonary fibrosis, CNS (Huntington&rsquo;s
disease and infantile spasm, a form of childhood epilepsy), biodefense and anti-viral application. The lead product, P529, targets
and inhibits the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dual TORC1/TORC2 dissociative
inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">VasculoMedics was founded as a platform
epigenetic company to develop orally available small molecular inhibitors of zinc finger transcription factors. Zinc finger transcription
factors are a subset of transcription factors utilizing zinc at its core for activity. Transcription factors are proteins that
bind to specific parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs the protein
making machinery to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of a transcription
factor, one can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription factor. Many
diseases can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors. Inhibition
of such transcription factors could then be able to control disease pathology.</P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">OPERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are a specialty biopharmaceutical
company initially focused on developing products for dermatology, ophthalmology and women&rsquo;s health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><U>Dermatology</U>: </B>Our prescription
dermatology business primarily is based upon three compounds. The first is RES-102, a &ldquo;soft&rdquo; estrogen, which is under
development for the treatment of aging skin fragility/thinning. The second is RES-440, a &ldquo;soft&rdquo; anti-androgen, which
is under development for the treatment of androgen excess, e.g. acne, androgenic alopecia and hirsutism (unwanted excess hair).
The third prescription dermatology compound is P529. This compound is under development for the treatment of keloid scarring, psoriasis,
atopic dermatitis, rosacea, actinic keratosis, Dupuytren&rsquo;s disease and the bullous blistering diseases. Our first product
for aging skin, CL-214, initially will be sold and marketed by Ferndale Pharma Group through physician offices and medi-spas world-wide.
Management believes that the product will be ready for Ferndale&rsquo;s launch in the fourth quarter of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><U>Ophthalmology:</U></B> Our ophthalmology
business is based upon developing a non-steroidal, synthetic, small molecule drug library through computational design, and synthetic
and medicinal chemistry, resulting in a family of agents, called &ldquo;Palomids.&rdquo; Our Palomids have shown significant activity
in <I>in vitro</I> (&ldquo;test tube&rdquo;) and <I>in vivo</I> (&ldquo;animal&rdquo;) models of disease. The specific focus is
on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway in the area of ophthalmology. We have completed two
human Phase I clinical studies with one of our Palomids (&ldquo;P529&rdquo;) for age-related macular degeneration (&ldquo;AMD&rdquo;),
both of which showed preliminary evidence of activity and no toxicity. We are planning Phase II studies for age-related macular
degeneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><U>Women&rsquo;s Health:</U></B>
We also are engaged in the prescription women&rsquo;s health business. We have a &ldquo;soft&rdquo; estrogen compound, RES-102,
under development for vulvar and vaginal atrophy (VVA), a condition affecting peri- and post-menopausal women due to declining
levels of estrogen. RES-102 targets hormonal aging in women which radically affects the mucous membranes, skin and hair of women
in menopause due to loss of estrogen which affects how women look and feel, and their sexual activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><U>Other Indications/Products:</U></B>
In addition to the potential products and indications described above, we also have other potential products in its portfolio for
a host of other indications that can be developed either internally or through license to other biopharmaceutical companies which
may have greater resources than RestorGenex. These other indications include the use of our Palomids in areas like oncology, CNS
disorders, cardiovascular medicine and biodefense. We also may develop orally available small molecular inhibitors. In order to
create novel, patentable inhibitors of zinc-finger transcription factors, we have initially targeted the zinc finger transcription
factor vascular endothelial zinc finger (&ldquo;VEZF1&rdquo;). VEZF1 is essential for embryonic blood vessel formation and regulates
the synthesis of important growth factors such as IL3, endothelin-1 and neuropilin-1. Notably, VEZF1 is thought to control at least
in part the creation of lymphatic vessels, called lymphangiogenesis. Lymphatic vessels support cancer metastasis. Thus far, we
have undertaken a novel approach to design inhibitors of VEZF1/DNA binding using homology structural modeling and computer modeling
(&ldquo;<I>in silico</I>&rdquo;) targeting of small molecules to the VEZF1/DNA interface. Previous modeling work undertaken by
us has identified a first generation series of small molecule antagonists which show activity in in vitro assay of VEZF1, a VEZF1
responsive promoter-reporter gene cell-active luciferase assay quantitatively establishing VEZF1 transcription activity and in
vivo by inhibiting angiogenesis in the murine oxygen-induced retinopathy model. Since transcription factors are functionally closer
to the ultimate pathological protein(s), specific inhibition of transcription factors may result in a greater degree of disease
fighting activity along with reduced level of toxicity. We believe that this may have advantage over conventional small molecule
drugs that directly inhibit their target protein through a one-to-one interaction as transcription factor inhibitors will turn
off pathological protein manufacturing capability at its source in pathological conditions such as dermatologic diseases, cancer
and retinal diseases of neovasculature.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Description of our Revenues, Costs and Expenses</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Prior to the mergers with Canterbury,
Hygeia, Paloma and VasculoMedics, our past revenues were from television licensing for MMA events. Future revenues will be derived
from sales and licensing revenue from our dermatology, ophthalmology and women&rsquo;s health products and intellectual property.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Gross Margin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our gross profit represents revenues
less the cost of sales.</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our selling, general and administrative
expenses include personnel, rent, travel, office and other costs for selling and promoting events and running our administrative
functions. Legal and professional services are paid to outside attorneys, auditors and consultants are broken out separately given
the size of these expenses relative to selling, general and administrative expenses. Operating expenses also include expenses for
impairment of goodwill, fair value expenses for issuing common stock for consideration less than the number of shares issued valued
at market closing price on the day of issuance, and Black-Scholes expenses for options and warrants.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our interest expense results from accruing
interest on loans payable and notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0in"><B>Basic and Diluted Earnings/(Loss)
Per Share (&ldquo;EPS&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Basic EPS is computed by dividing income/loss
available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed
similar to basic net income per share except that the denominator is increased to include the number of additional common shares
that would have been outstanding if all the potential common shares, warrants and stock options had been issued and if the additional
common shares were dilutive. Diluted EPS is based on the assumption that all dilutive convertible shares were converted into common
stock. Dilution is computed by applying the if-converted method for the outstanding convertible preferred shares. Under the if-converted
method, convertible outstanding instruments are assumed to be converted into common stock at the beginning of the period (or at
the time of issuance, if later).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Critical Accounting Policies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Goodwill and Intangible Assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Goodwill is the excess of the cost
of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. We apply
ASC 350 &ldquo;Goodwill and Other Intangible Assets,&rdquo; which requires allocating goodwill to each reporting unit and testing
for impairment using a two-step approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Goodwill and intangible assets as of
March 31, 2014 and December 31, 2013 were as follows:</P>


<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>March 31, 2014 (unaudited)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>December 31, 2013</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Intangible</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Intangible</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Goodwill</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Goodwill</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; width: 31%"><font style="font-size: 10pt">Canterbury</font></td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">7,504,863</font></td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">7,642,825</font></td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">7,691,682</font></td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right"><font style="font-size: 10pt">7,642,825</font></td>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</td>
    </tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><font style="font-size: 10pt">Paloma</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,220,395</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">5,770,055</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    </tr>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><font style="font-size: 10pt">VasculoMedics</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">550,000</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</td>
    </tr>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>9,725,258</b></font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>13,962,880</b></font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>7,691,682</b></font></td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>7,642,825</b></font></td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt">&nbsp;</td>
    </tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The Company reviews the value of intangible
assets and related goodwill as part of its annual reporting process, which generally occurs in February or March of each calendar
year. In between valuations, the Company conducts additional tests if circumstances warrant such testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">To review the value of intangible assets
and related goodwill as December 31, 2013, we followed Accounting Standards Update (&ldquo;ASU&rdquo;) 2011-08 and first examined
the facts and circumstances for each event or business to determine if it was more likely than not that an impairment had occurred.
If this examination suggested it was more likely that an impairment had occurred, we then compare discounted cash flow forecasts
related to the asset with the stated value of the asset on the balance sheet. The objective is to determine the value of each asset
to an industry participant who is a willing buyer not under compulsion to buy and we are a willing seller not under compulsion
to sell. Revenues from these assets are forecasted based on the assumption they are standalone entities. These forecasts are discounted
at a range of discount rates determined by taking the risk-free interest rate at the time of valuation, plus premiums for equity
risk to small companies in general, for factors specific to us and the business. As of March 31, 2014, we determined that the fair
value of its businesses for accounting purposes was equal to its market capitalization of approximately $34,900,000, which was
147% of the $23,688,138 total for goodwill and intangible assets on the balance sheet as of March 31, 2014 on a company-wide basis.
However, it is possible that impairment may have occurred on a reporting-unit basis and we intend to test impairment on a reporting-unit
basis beginning with the three months ending June 30, 2014. Based on this determination, we concluded that no impairment had occurred
as of March 31, 2014. As of December 31, 2013, we determined that the fair value of its businesses for accounting purposes was
equal to its market capitalization of approximately $19,600,000, which was 128% of the $15,334,507 goodwill and intangible assets
on the balance sheet as of December 31, 2013.</P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">If we determine the discount factor
for cash flows should be substantially increased, or the event will not be able to begin operations when planned, or that facts
and circumstances for each asset have changed, it is possible that the values for the intangible assets currently on the balance
sheet could be substantially reduced or eliminated, which could result in a maximum charge to operations equal to the current carrying
value of the intangible assets and goodwill of $23,688,138 as of March 31, 2014.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Anti-dilution provision of Series E Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">On May 24, 2011, we entered into a
Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with eight investors (collectively, the &ldquo;Investors&rdquo;)
pursuant to which we sold 8,700 shares of a new series of convertible preferred stock designated as Series E Convertible Preferred
Stock (&ldquo;Original Series E&rdquo;), the terms of which are set forth in the Certificate of Designations of Series E Preferred
Stock (the &ldquo;Certificate&rdquo;), for $1,000 per share, or $8,700,000 in the aggregate. In October 2012, we sold 1,000 shares
of Series E for $1,000,000 (&ldquo;New Series E&rdquo;). The Original Series E and New Series E together are referred to herein
as &ldquo;Series E&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">These Series E contained &ldquo;full
ratchet-down&rdquo; liquidity protection that provides that if we issue securities for less than the existing conversion price
for the Series E or the strike price of the Series E warrants, then the conversion price for Series E will be lowered to that lower
price. Also, the strike price for Series E warrants will be decreased to that lower price and the number of Series E warrants will
be increased such that the product of the original strike price times the original quantity equals the lower strike price times
the higher quantity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Subsequent to the issuance of this
Series E, we determined that the warrants for these financings included certain embedded derivative features as set forth in ASC
815 &ldquo;Derivatives and Hedging&rdquo; (&ldquo;ASC 815&rdquo;) and that this conversion feature of the Series E was not an embedded
derivative because this feature was clearly and closely related to the host (Series E) as defined in ASC 815. These derivative
liabilities were initially recorded at their estimated fair value on the date of issuance and were subsequently adjusted each quarter
to reflect the estimated fair value at the end of each period, with any decrease or increase in the estimated fair value of the
derivative liability for each period being recorded as other income or expense. Since the value of the embedded derivative feature
for the related warrants was higher than the value of both Series E transactions, there was no beneficial conversion feature recorded
for either transaction, and the excess of the value of the embedded derivative feature over the value of the transaction was recorded
in each year on the Statement of Operations as a separate line item for each year presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The fair value of these derivative
liabilities was calculated using the Black Scholes pricing model that is based on the following as of the date of calculation:
the closing price of the common stock, the strike price of the underlying instrument, the risk-free interest rate for the applicable
remaining life of the underlying instrument (i.e., the U.S. treasury rate for that period) and the historical volatility of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">During the second quarter 2013, these
derivative liabilities were extinguished and the derivative liability was reversed.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Income Taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We utilize ASC 740 &ldquo;Accounting
for Income Taxes,&rdquo; which requires recognition of deferred tax assets and liabilities for the expected future tax consequences
of events that were included in the financial statements or tax returns. Under this method, deferred income taxes are recognized
for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting
amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are
expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount
expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period
in deferred tax assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of December 31, 2013, we had a deferred
tax asset of $26,274,933, that was fully reserved and a net operating loss carryforward of $47,728,300 for Federal tax purposes
and $44,482,850 for state tax purposes. We will continue to monitor all available evidence and reassess the potential realization
of its deferred tax assets. The net operating loss carry-forwards for 2013 begin expiring in 2021. From December 31, 2012 to March
31, 2014, the outstanding shares of common stock increased from 890,837 to 8,683,785. This increase in the number of shares outstanding
constitutes a change of ownership, under the provisions of Internal Revenue Code Section 382 and similar state provisions, and
is likely to significantly limit our ability to utilize these net operating loss carryforwards to offset future income. Accordingly,
the company recorded a 100% valuation allowance of the deferred tax assets at March 31, 2014 and December 31, 2013.</P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of March 31, 2014 and December 31,
2013, we had a net operating loss carryforwards as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Combined NOL Carryforwards:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%">Federal</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">48,480,486</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">47,728,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>California</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,235,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">44,482,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Stock-Based Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We adopted ASC 718 &ldquo;Share Based
Payment&rdquo; using the modified prospective transition method. New awards and awards modified, repurchased or cancelled after
January 1, 2006 trigger compensation expense based on the fair value of the stock option as determined by the Black-Scholes option
pricing model. We amortize stock-based compensation for such awards on a straight-line method over the related service period of
the awards taking into account the effects of the employees&rsquo; expected exercise and post-vesting employment termination behavior.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We account for equity instruments issued
to non-employees in accordance with ASC 718 and EITF Issue No. 96-18. The fair value of each option granted is estimated as of
the grant date using the Black-Scholes option pricing model.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Results of Continuing Operations for the Three Months
Ended March 31, 2014</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Net loss for the three months ended
March 31, 2014 (&ldquo;Current Period&rdquo;) was $1,380,175, compared to the net loss for the three months ended March 31, 2013
(&ldquo;Prior Period&rdquo;) of $2,601,155. There were no revenues for the Current Period and operating expenses of $1,371,520,
other income of $49,639, interest expense of $58,294, which resulted in the net loss of $1,380,175. There were no revenues in the
Prior Period and operating expenses of $2,092,612, loss on adjustments to fair value of derivative liability of $236,850, other
income of $2,564, interest expense of $22,971, loss from discontinued operations of $126,911 and preferred dividends of $124,375,
which resulted in a net loss attributable to holders of RestorGenex common stock of $2,601,155.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">There were no revenues for the Current
Period or Prior Period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Gross Profit (Loss)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">There were no gross profits or losses
for the Current Period or the Prior Period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Overall operating expenses in the Current
Period were $1,371,520, a decrease of $721,092 from $2,092,612 in the Prior Period. General and administrative expenses in the
Current Period of $611,845 were comparable to $624,674 in the Prior Period. Warrants, options and stock expense in the Current
Period of $149,885 was a decrease of $1,166,263 from $1,316,148 in the Prior Period. Most of this decrease was related primarily
to $1,287,000 in Black Scholes expense for options and warrants that vested during the Prior Period to purchase 483,917 shares,
of which 310,000 shares were granted to two officers and 173,917 shares were granted to financial advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Legal and professional expense in the
Current Period was $131,686, which was comparable to $143,103 in the Prior Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Depreciation and amortization of $478,104
in the Current Period increased by $469,417 from $8,687 in the Prior Period. Of this increase, $262,813 is related to amortization
of $3,153,750 of total expense related to a July 2013 agreement with Maxim Group LLC to provide general financial advisory and
investment banking services to the Company for three years on a non-exclusive basis. In addition, $186,819 of this increase is
related to amortizing the amount attributed to intangible assets of Canterbury over the lives of those intangible assets.</P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Loss on adjustments to fair value of derivative liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The loss on adjustments to fair value
of derivative liability was $0 in the Current Period and $236,850 in the Prior Period because the derivative liability was eliminated
in May 2013, resulting in no further adjustments to the fair value of the derivative liability past that point.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Other Income</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Other income for the Current Period
was $49,639, an increase of $47,075 from $2,564 from the Prior Period. This increase is primarily related to a $51,659 reduction
in deferred taxes related to the amortization of the intangible assets at Canterbury during the Current Period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Interest expense was $58,294 in the
Current Period, an increase of $35,323 from $22,971 in the Prior Period, primarily related to $33,365 of interest expense in the
Prior Period that was removed from interest expense in the Prior Period and reclassified into Loss from Discontinued Operations
in the Prior Period as the result of the decision by the Company&rsquo;s Board of Directors to discontinue operations of ProElite
effective March 31, 2014. Operations of ProElite had been suspended since June 30, 2013.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Net Loss from Discontinued Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">There was no loss from discontinued
operations in the Current Period and a loss of $126,911 in the Prior Period, when ProElite had $71,667 in revenues and $198,578
in expenses.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Dividends on Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Dividends in the Prior Period were
$124,375 related to dividends on Series D and Series E Preferred Stock, which were extinguished in the three months ended June
30, 2013. As a result, there were no dividends on preferred stock in the Current Period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Results of Operations for the Year Ended December 31,
2013</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Revenues
for 2013 were $71,667, a decrease of $302,875 from $374,542 in 2012. Event revenues were $0 in the 2013, a decrease of $89,542
from 2012 when ProElite conducted one small MMA event. Licensing revenues in 2013 were $71,667, a decrease of $213,333 from $285,000
in 2012. The Company received one license payment of $71,667 from Strikeforce in January 2013, however, Strikeforce is not planning
any additional events and these license payments will not be a future source of revenue.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Gross Profit (Loss)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
overall gross margin for 2013 was $71,667, a decrease of $67,072 compared to $138,739 for 2012.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Overall
operating expenses in 2013 were $12,988,997, an increase of $1,058,389 from $11,930,608 in 2012. General and administrative expenses
in 2013 of $2,008,118 decreased by $2,562,043 from $4,570,161 in 2012. This decrease is primarily related to a reduction in personnel
expenses of $3,188,879 offset by an increase in other general administrative expenses from 2012 to 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Impairment
of intangible asset expenses was $1,935,621 in 2013, an increase of $511,777 from $1,423,844 in 2012. The amount of impairment
of intangible asset expenses in both years was based on the Company&rsquo;s annual review for impairment. For 2013, the goodwill
of $1,935,621 for its MMA business was deemed to be fully impaired at June 30, 2013 when the Company decided to suspend its MMA
business. For 2012, $1,423,844 of intangible assets related to several events were deemed to be fully impaired as of December 31,
2013 when the Company decided to suspend these events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Legal
and professional services were $1,071,392 in 2013, a reduction of $1,057,506 from $2,128,898 in 2012. This reduction was primarily
from reduced consulting fees of $969,355 related to a reduction of $814,000 in consulting fees for Perugia International Film Festival
since that event was canceled in 2012.</FONT></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Warrants,
option and stock expense in 2013 was $4,228,317, an increase of $584,655 from $3,643,662 in the Prior Period, primarily from $1,287,000
in Black Scholes expense for options and warrants that vested during Current Period to purchase 483,917 shares, of which 310,000
shares were granted to two officers and 173,917 shares were granted to three financial advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Fair
value of common stock issued for warrants was $3,069,792 in the 2013 compared with no expense in the 2012. In May 2013, we issued
1,023,264 shares of common stock in exchange for Series E Warrants that contained a full-ratchet down provision and were extinguished.
These shares of common stock were valued at $3.00 per share, which was the price at which we sold 139,167 shares from April 2013
to June 2013, resulting in the charge of $3,069,792.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Depreciation
and amortization of $675,757 in 2013 increased by $511,714 from $164,043 in 2012. This increase is related to amortization of stock
issued in connection with an advisory agreement that resulted in approximately $525,000 of amortization in 2013 that was not present
in 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">In
October 2012, we issued $1,000,000 of Series E Preferred (&ldquo;Series E&rdquo;). In May 2011, the Company issued $8,700,000 of
Series E. The warrants issued in conjunction with the Series E were determined to have an embedded derivative liability, which
is revalued using Black Scholes models upon the earlier of events that affect the value of this liability or the end of every quarter.
These warrants were extinguished in May 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
total gain on adjustments to fair value of derivative liability for 2013 was $8,980,077, which is the sum of the reductions between
the value of this derivative liability at December 31, 2012 and March 31, 2013 of $236,850 plus the decrease in the value of this
derivative liability between March 31, 2013 and May 6, 2013 of $9,216,927. During 2012, the fair value of the derivative liability
was reduced by $6,907,748, which was recorded as a gain. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Gain on Extinguishment of Derivative Liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">In
May 2013, the warrants that gave rise to the derivative liability were exchanged for common stock and extinguished. Following the
$8,980,077 decrease in the derivative liability mentioned above, the value of the derivative liability was $1,635,967 and a gain
of this amount resulted in 2013 when the liability was extinguished.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Other (Income)/Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Other
(income)/expense for 2013 was a net other income of $71,631, an increase of $450,819 from the net other expense of $379,188 in
2012. A gain of $713,479 was realized when 180,500 shares of common stock were issued at $3.00 to extinguish $1,083,000 of debt
and accrued interest of $171,979. This gain was offset by: an expense of $466,347 to record the 20% discount received by the third
party who assumed liabilities of $1,856,386 in exchange for stock; an additional accrual of $100,000 estimated to be needed to
settle a dispute with a vendor in Europe; and an additional accrual of $93,592 for water damage in the building formerly occupied
by us for which we may be liable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Other
(income)/expense for 2012 was a net other expense of $379,188 that resulted from the offset of a $538,515 receivable from Paul
Feller, our former chairman and president (see Footnote 6 to the Financial Statements for more information). Other expenses in
2012 were increased by an accrual of $300,000 estimated to be needed to settle a dispute with a vendor in Europe, and $300,000
accrued for water damage in the building formerly occupied by us for which we may be liable. These expenses were offset by: the
reduction of $346,974 reduction in accrued liabilities related to Paul Feller to calculated values; $256,449 in reductions in accrued
interest related to debt that has been paid or settled; $102,435 in accrued interest related to preferred stock that has been converted
to common stock and $72,078 in gains on negotiated settlement of certain payables for less than book value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
following is a table of the components of other (income)/expense for 2013 and 2012:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">Other (Income)/Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">Gain on issuance of&nbsp;shares to retire debt and accrued interest</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(713,479</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Discount expense on transfer of liabilities to third party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">466,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrual to settle dispute with vendor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrual for damage that Company may be liable for</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Reduction in interest for debt and preferred stock converted into common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(358,884</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on negotiated settlement of accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72,078</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments related to Paul Feller, former CEO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,610</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;&nbsp;Net other (income)/expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(71,631</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">379,188</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt"><B>Interest Expense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Interest
expense was $228,294 in 2013, an increase of $60,400 from $167,894 in 2012, primarily related to higher levels of interest-bearing
promissory notes in 2013 and an increase in interest rate on one note that is in default.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Dividends on Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Dividends
in 2013 were $171,625, a decrease of $325,542 from $497,167 in 2012. This decrease was the result of all preferred stock being
extinguished in May 2013 versus being outstanding for the full year in 2012.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Liquidity and Capital Resources</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">We
have suffered losses from operations and lacked liquidity to meet our then-current obligations as of March 31, 2014. We had net
losses of $1,380,175 and $2,601,155 for the three months ended March 31, 2014 and 2013, respectively and net losses for 2013 and
2012 of $2,635,975 and $7,366,061, respectively. As of March 31, 2014, we had negative working capital of $8,016,821 and an accumulated
deficit of $62,464,074. We had a total of $717,002 of promissory notes that were in default as of March 31, 2014. We raised $400,000
and $200,000 from the issuance of promissory notes during the three months ended March 31, 2014 and 2013, respectively. In 2013,
we raised $700,000 through the issuance of two promissory notes and $427,501 through the sale of common stock.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt 0.5in">Recent Developments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-indent: 0.5in">We have entered into securities purchase
agreements (the &ldquo;Securities Purchase Agreements&rdquo;) with various institutional and individual accredited investors to
raise gross proceeds of $35,582,740 in a private placement (the &ldquo;Private Placement&rdquo;). On July 10, 2014, we completed
the Private Placement. In the Private Placement, we issued (i) an aggregate of 8,895,685 shares of our common stock, and (ii) warrants
(&ldquo;Warrants&rdquo;) to purchase a total of 2,668,706 shares of common stock. The purchasers of common stock received warrants
to purchase 0.3 shares of common stock for each share of common stock that such investors purchased in the Private Placement. The
purchase price of each common stock/Warrant unit was $4.00. Each warrant is exercisable into a share of common stock at an initial
exercise price of $4.80 per share. These warrants are exercisable immediately and expire four years from the date of grant. We
received net proceeds of approximately $31.3 million from the Private Placement, after paying placement agent fees, estimated offering
expenses, and certain accounts payable, which we will use to fund our research and development and for working capital purposes.
However, given our plans to grow its existing businesses and potentially pursue acquisitions, this funding may not be sufficient
and we may need to raise additional capital in the future to fully implement its business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts
or the amount and classification of liabilities that might result if the Company is unable to continue as a going concern.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
following table sets forth our cash flows for the three months ended March 31, 2014 and 2013:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(432,893</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(306,183</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(94,475</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total intangible assets and goodwill</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(32,893</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(200,658</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Operating Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Negative
operating cash flows for the Current Period reflect our net loss from continuing operations of $1,380,175, offset by non-cash items
of $478,104 of depreciation and amortization and $149,885 of expense for warrants, options and stock. Further, there was a net
increase during the Current Period in other items providing cash of $319,293.</FONT></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Negative
operating cash flows for the Prior Period reflect our net loss from continuing operations of $2,349,869, offset by non-cash items
totaling $1,698,635, primarily related to $236,850 for a loss on adjustment to fair value of derivative liabilities and $1,323,098
for warrant, stock and option expenses. Cash was further adjusted by a source of funds from working capital of $345,051, primarily
related to $181,555 in deferred salaries and $194,293 from an increase in other accrued expenses and liabilities, offset by a decrease
in deposits and prepaid expenses of $36,100. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Investing Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Capital
constraints resulted in no cash used in investing activities during the three months ended March 31, 2014 or 2013.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 9pt">Summary of Contractual Obligations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Set
forth below is information concerning our known contractual obligations as of March 31, 2014 that are fixed and determinable by
year starting with the year ending December 31, 2014.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2018 and</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Later</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 30%; text-align: left">Notes payable</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,931,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,931,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred Salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">838,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">838,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Rent obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,260,644</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">677,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued board fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,515,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,515,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Employee contracts:&nbsp;&nbsp;other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,931,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,181,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,341,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,273,732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">634,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">634,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,112,059</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,779,407</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,680,958</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,516,681</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">135,013</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Off-Balance Sheet Arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">At March 31, 2014, we had no obligations
that would require disclosure as off-balance sheet arrangements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">DIRECTORS, EXECUTIVE
OFFICERS,<BR>
PROMOTERS AND CONTROL PERSONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Executive Officers and Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth, as
of the July 8, 2014, the names of, and certain information concerning, our directors:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD  STYLE="width: 20%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 1%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 4%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 1%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 56%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 1%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 8%; text-align: justify"><font style="font-size: 10pt"><b>Director</b></font></td>
    <TD  STYLE="width: 1%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 8%; text-align: justify"><font style="font-size: 10pt"><b>End of</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD  STYLE="border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Name</b></font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Age</b></font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Position</b></font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Since</b></font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Term</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Sol J. Barer</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">65</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Chairman of the Board</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2013</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2014</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Isaac Blech</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">63</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Vice Chairman of the Board</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2013</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2014</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Stephen M. Simes</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">62</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Chief Executive Officer and Director</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2014</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2017</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Nelson Stacks</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">43</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Director and Chair of Compensation Committee</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2013</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2014</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Rex Bright</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">74</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Director and Chair of Audit Committee</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2014</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2015</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Yael Schwartz</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">65</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Director and Executive Vice President of Preclinical Development</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2013</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">2014</font></td></tr>
<tr style="background-color: white">
    <TD  STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">David Sherris</font></td>
    <TD  STYLE="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <TD  STYLE="vertical-align: top; text-align: justify"><font style="font-size: 10pt">61</font></td>
    <TD  STYLE="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Director and Chief Scientific Officer</font></td>
    <TD  STYLE="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <TD  STYLE="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">2014</font></td>
    <TD  STYLE="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <TD  STYLE="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">2015</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>Sol J. Barer, Ph.D.</I></B> &ndash;
Dr. Barer became our director and Chairman of the Board on November 1, 2013. He is currently the Managing Partner of SJBarer Consulting
LLC. He previously served in various positions at Celgene Corporation (a biopharmaceutical company focused on the treatment of
cancer and inflammatory diseases), including Chairman and Chief Executive Officer from May 2006 until June 2010, Executive Chairman
from June 2010 until December 2010 and Non-Executive Chairman from January 2011 until June 2011. Prior to that, he held several
other positions within Celgene, including President and Chief Operating Officer. Dr. Barer joined the Celanese Research Company
in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer currently serves on the Boards
of Directors of Amicus Therapeutics (a biopharmaceutical company focused on the development of novel small molecule drugs for the
treatment of genetic diseases), InspireMD, Inc. (a medical device company focused on the development and commercialization of stent
system technology), Medgenics (a gene therapy company) and Aegerian Pharmaceuticals, Inc. (a company focused on the development
of novel, life-altering therapies for patients with debilitating, often fatal diseases) and several privately held biotechnology
companies including Edge Therapeutics, Inc., a biopharmaceutics company. Dr. Barer holds a B.S. degree from Brooklyn College and
a Ph.D. degree in Organic Chemistry from Rutgers University.</P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>Isaac Blech</I></B> &ndash; Isaac
Blech became our director and Vice Chairman of the Board on November 1, 2013. Mr. Blech has established some of the leading biotechnology
companies in the world during the past 30 years. These include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation,
Pathogenesis Corporation, and Genetics Systems Corporation. Collectively, these companies have produced major advances in a broad
array of diseases including the diagnosis and/or treatment of cancer, chlamydia, sexual dysfunction, cystic fibrosis, and AIDS.
Celgene Corporation introduced two major cancer drugs. ICOS Corporation discovered the drug Cialis, and was acquired by Eli Lilly
for over $2 billion. Nova Pharmaceutical Corporation developed a new treatment for brain cancer, and after merging with Scios Corporation,
was purchased for $2 billion. Pathogeneses Corporation created TOBI&reg; for cystic fibrosis, the first inhaled antibiotic approved
by the FDA, and was acquired by Chiron Corp for $660 million. Genetics Systems developed the first inexpensive and accurate test
to diagnosis chlamydia, allowing thousands of babies to be born to women who otherwise would have become sterile from pelvic inflammatory
disease. Genetics Systems was acquired for 3% of Bristol Myers&rsquo; stock. Mr. Blech is currently a major shareholder and board
member of ContraFect Corporation, which is creating new therapies for infectious diseases, is a director and major shareholder
of Medgenics, Inc., and is the Vice Chairman of Premier Alliance Group, Inc., and is the Vice Chairman of Spendsmart, Inc. Mr.
Blech is also a director of Edge Therapeutics, Inc., a biopharmaceutics company. Mr. Blech is also the Founder, Vice Chairman and
a major shareholder of Cerecor, Inc., a neuroscience company developing new treatments for cough and other medical implications.
Mr. Blech received a Bachelor of Arts degree from City University of New York, Baruch College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>Stephen M. Simes</I></B> &ndash;
Mr. Simes was appointed our Chief Executive Officer and a director on March 5, 2014. Mr. Simes served as Vice Chairman, President,
Chief Executive Officer and a director of BioSante Pharmaceuticals, Inc. from 1998 until June 19, 2013 when BioSante merged with
ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. BioSante, whose stock was listed on The NASDAQ Global Markets, was a
specialty pharmaceutical company focused on developing products for women&rsquo;s and men&rsquo;s health and oncology. From 1994
to 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., (currently a wholly owned
subsidiary of AbbVie, Inc.) a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989
to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated
on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly
Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals
Inc. Mr. Simes' career in the pharmaceutical industry started in 1974 with G.D. Searle &amp; Co. (now a part of Pfizer Inc.). Mr.
Simes earned his MBA in Marketing and Finance from New York University, having earlier received a Bachelor of Science degree in
Chemistry at Brooklyn College of the City University of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>Nelson K. Stacks </I></B>&ndash;
Mr. Stacks served as Chairman of the Board of Canterbury prior to their mergers with the Company. From December 2011 to present,
Mr. Stacks has been the CEO and Director of WaveGuide Technology, maker of the world&rsquo;s smallest and most sensitive handheld
NMR for detection of cancer, infectious diseases, oil and gas exploration and industrial anti-counterfeiting. From December 2011
to January 2013, Mr. Stacks was CEO and Director of Molecular Insight Pharmaceuticals, a biotechnology company focused on cancer
diagnostics and therapeutic treatments as well as orphan neuroendocrine cancers. From July 2009 to August 2011, Mr. Stacks served
as the, CEO and Director of Vascular Pathways Incorporated where he raised $14 million from venture capitalists and brought a revolutionary
peripheral IV catheter to the market and sold products to the U.S. Military and various U.S. and international hospitals. Prior
to this position, from March 2006 to July 2009, he served as a venture partner and turnaround CEO for various portfolio companies
with Queensland Investment Corporation, Queensland Biocapital Funds, a $70 billion superannuation and venture fund. Over his career,
Mr. Stacks has been a venture capitalist in the United States as the General Partner at 3i Ventures and earlier at Oak Investment
Partners. Mr. Stacks is a member of the fourth class of Kauffman Fellows and has invested in all areas of healthcare and information
technology. He also previously served as the Chairman of Xbio Systems, a clinical trial software management system, and as CEO,
and Executive Director of Xenome Limited, a venom peptide company focused on cancer pain therapy. Mr. Stacks received an MBA from
the F.W. Olin Graduate School of Business at Babson College and a BA from The University of Rochester.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>Rex Bright </I></B>&ndash; Mr.
Bright became a director of the Company in February, 2014 and Chairman of the Audit Committee in July, 2014.&nbsp; He has held
Chief Executive Officer positions in the health care industry for over 20 years.&nbsp; His career includes 18 years with Johnson
&amp; Johnson (J&amp;J).&nbsp; Subsequently, he was hired by GlaxoSmithKline to build a dermatological business within the Allergan
business unit.&nbsp; After building Allergan Skin Care into a profitable and growing dermatologist business at GSK, he spent several
years as CEO of startup healthcare companies and as a turnaround CEO in the pharmaceutical/biotech sector.&nbsp; He co-founded
and served as President &amp; CEO of SkinMedica from 2002 until 2009 and as a member of the Board of Directors until 2012.&nbsp;
In 2012, SkinMedica was named the fastest growing medical aesthetic company for the sixth year in a row by the Kline &amp; Company.&nbsp;
Rex played a key role in the process which resulted in SkinMedica being acquired by Allergan, Inc. for $375 million in 2012.&nbsp;
He has been a speaker at various industry meetings and university and college MBA programs.&nbsp; He is a member of the American
Academy of Dermatology, China Biotechnology &amp; Pharmaceutical Association, International Society of Caricature Artists, Rotary
International, The Chief Executive Officer Global Leaders Network and Vistage International.</P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>Yael Schwartz,
Ph.D.</I></B> &ndash; Dr. Yael Schwartz has more than 25 years&rsquo; experience in drug discovery and product development.
Dr. Schwartz is a director and our Executive Vice President of Preclinical Development. Previously, Dr. Schwartz was
President of  our Hygeia/Canterbury wholly owned subsidiaries. From 1998 to 2007 Dr. Schwartz had positions of
increasing responsibility at Sepracor, Inc. (now Sunovion) where she played key leadership roles on teams that launched 3
drugs that are currently in clinical practice for the treatment of asthma (Xopenex), insomnia (Lunesta) and chronic
obstructive pulmonary disease (Brovana). Prior to that she contributed to the development of drugs for the treatment of
urinary bladder cancer (Valstar) and hypertension (Carvedilol). Since 2007, Dr. Schwartz has been the Founder, President, CEO
and Director of Hygeia. Dr. Schwartz adapted and streamlined development strategies and budgets to ensure effective
achievement of scientific and business objectives. In 2011, Dr. Schwartz founded Canterbury where she has been President, CEO
and Director. Dr. Schwartz received her doctorate degree with honors in Endocrine Physiology from a joint program at the
University of Massachusetts Medical School and Worcester Polytechnic Institute (WPI).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B><I>David Sherris, Ph.D.</I></B>
&ndash; Dr. Sherris is a director and our Chief Scientific Officer.&nbsp; Previously, Dr. Sherris was Chief Scientific Officer
and President of RestorGenex&rsquo;s Paloma/VasculoMedics wholly owned subsidiaries.&nbsp; Dr. Sherris was the founder and CEO
of both Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc. He has over 30 years of experience in biopharmaceuticals and diagnostics.&nbsp;
Dr. Sherris was CEO and founder of a consulting/out-sourcing concern, Sherris Pharma Partners, with a focus on business development
and R&amp;D strategy, including a niche focus in angiogenesis and vascular targeting.&nbsp; In addition, Dr. Sherris has worked
with venture capital companies where he has both advised and raised seed money for biotech startups.&nbsp; Prior to his starting
Sherris Pharma Partners, Dr. Sherris had been employed by pharmaceutical and biotechnology companies to manage external R&amp;D
(academic groups and contract research organizations) to augment and expand internal scientific programs, and to lead internal
pharmaceutical development teams.&nbsp; Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business
and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas.&nbsp; Dr. Sherris has
held positions of increasing responsibility at Centocor, Unilever Research, Serono and OXiGENE where he was Chief Operating Officer
and Vice President of Research and Development, as well as Chief Operating Officer of a joint venture between OXiGENE and Peregrine
Pharmaceuticals called Arcus LLC.&nbsp; Dr. Sherris received his Ph.D. in Biochemistry and Molecular Genetics from the University
of Utah, held a postdoctoral position in cellular immunology at the Jackson Laboratory and a faculty position in the Department
of Medicine, Division of Clinical Immunology at the Mt. Sinai Medical Center, New York, NY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth, as
of July 8, 2014, the name of, and certain information concerning, each of our executive officers other than Mr. Simes, Dr. Schwartz,
and Dr. Sherris:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD  STYLE="width: 28%; border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Name</b></font></td>
    <TD  STYLE="width: 1%; text-align: justify">&nbsp;</td>
    <TD  STYLE="width: 6%; border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Age</b></font></td>
    <TD  STYLE="width: 1%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 64%; border-bottom: black 1pt solid; text-align: justify"><font style="font-size: 10pt"><b>Position</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Phillip Donenberg</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">53</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Chief Financial Officer</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">Timothy Boris</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD  STYLE="text-align: justify"><font style="font-size: 10pt">45</font></td>
    <TD  STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">General Counsel and Vice President of Legal Affairs</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Phillip Donenberg</B><FONT STYLE="font-size: 10pt">
&ndash; </FONT>Mr. Donenberg joined our company as Chief Financial Officer on May&nbsp;27, 2014 and previously served as BioSante
Pharmaceuticals, Inc.&rsquo;s Senior Vice President of Finance from 2010 until June 19, 2013 and Chief Financial Officer and Secretary
from 1998 until June&nbsp;19, 2013 when BioSante merged with ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. BioSante,
whose stock was listed on the NASDAQ Global Markets, was a specialty pharmaceutical company focused on developing products for
women&rsquo;s and men&rsquo;s health and oncology. From 1995 to 1998, Mr.&nbsp;Donenberg was Controller of Unimed Pharmaceuticals,
Inc. (currently a wholly owned subsidiary of AbbVie Inc.), a company with a product focus on infectious diseases, AIDS, endocrinology
and oncology. Prior to Unimed Pharmaceuticals, Inc., Mr.&nbsp;Donenberg held similar positions with several other pharmaceutical
companies. Mr.&nbsp;Donenberg earned his BS in Accountancy from the University of Illinois Champaign-Urbana, College of Business
and is a Certified Public Accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>Timothy Boris</B> &ndash; Mr. Boris
joined our company in August 2011. He has been practicing law for more than sixteen years. From 2005 to 2011, he was in private
practice representing corporate and entertainment clients. He is a former partner at the firm of Hager &amp; Dowling. His areas
of practice have included litigation, entertainment and corporate law. He received a Bachelor&rsquo;s of Business Administration
from the University of Michigan and a juris doctorate from the University of San Diego School of Law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Family Relationships</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">There are no family relationships among
the directors and officers.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">The Board of Directors and Committees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The Board of Directors
is responsible for the supervision of our overall affairs. The Board met eight times during the year ended December 31,
2013. The Audit Committee is chaired by Rex Bright and includes Nelson Stacks and Isaac Blech. The Compensation Committee
is chaired by Nelson Stacks and includes Sol J. Barer and Isaac Blech. The Nominating and Governance Committee is chaired by
Isaac Blech and includes Sol J. Barer, Rex Bright and Nelson Stacks.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Term of Office</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our directors and officers hold office
until the earlier of their death, resignation, removal or the end of their stated term.</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The Audit Committee&rsquo;s responsibilities
include, but are not limited to, the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Appointing, evaluating and retaining the independent registered public accounting firm;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial
statements and disclosures;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Discussing our systems of internal control over financial reporting; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Meeting separately with the independent registered public accounting firm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The audit committee currently consists
of Rex Bright, who is the Chairman and who we believe qualifies as a financial expert, Nelson Stacks, and Isaac Blech. We believe
that Messrs. Stacks, Blech and Bright are independent under Rule 10A-3(b)(i) of the Securities Exchange Act of 1934.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The Compensation Committee administers
our compensation and benefit plans, in particular, the incentive compensation and equity-based plans, and will approve salaries,
bonuses, and other compensation arrangements and policies for our officers, including the Chief Executive Officer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Nominating &amp;
Governance Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The
Nominating and Governance Committee (i) identifies, evaluates and nominates candidates for election as directors and for
appointment to serve on the Board&rsquo;s committees; (ii) oversees the evaluation of the Board and its committees and (iii)
reviews and considers developments in corporate governance practices and recommend to the Board a set of effective corporate
governance policies and procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Code of Ethics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have adopted a code of ethics applicable
to our principal executive officer, principal financial officer and persons performing significant functions. A copy of the code
is filed as Exhibit 14 to this Annual Report and will be provided without charge to any person so requesting a copy by requesting
same from the Company&rsquo;s Secretary.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth information
concerning the compensation earned by certain of our Executive Officers during fiscal 2013 and 2012:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Name and Principal Position</b></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Year</b></font></td>
    <TD>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Salary</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Bonus</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Stock Award Shares</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Non-equity Incentive Plan Compensation</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>All Other Compensation</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 39%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Jerold Rubinstein, Former Chief</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%; text-align: center"><font style="font-size: 10pt">2013</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 6%; text-align: right"><font style="font-size: 10pt">250,000</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 6%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">$</td>
    <TD STYLE="width: 6%; text-align: right"><font style="font-size: 10pt">250,000</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 6%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 6%; text-align: right"><font style="font-size: 10pt">157,800</font></td>
    <TD STYLE="width: 2%"><font style="font-size: 10pt">(b)</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 6%; text-align: right"><font style="font-size: 10pt">407,800</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Executive Officer and Chairman of the Board(a)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">2012</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">125,000</font></td>
    <TD><font style="font-size: 10pt">(a)</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>$</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">23,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">173,900</font></td>
    <TD><font style="font-size: 10pt">(b)</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">298,900</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">John Moynahan,</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">2013</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">220,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>$</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">220,000</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Chief Financial Officer(c)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">2012</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">220,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>$</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">20,466</font></td>
    <TD><font style="font-size: 10pt">(d)</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">240,466</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Timothy Boris,</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">2013</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">180,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>$</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">60,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">180,000</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">General Counsel and Vice President of Legal Affairs</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">2012</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">180,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>$</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">3,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">180,000</font></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in">(a)</TD><TD>Mr. Rubinstein started as Chief Executive Officer on June 28, 2012 and resigned effective March 5, 2014.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>(b)</TD><TD>Represents $100,000 as chairman of the audit committee up to June 28, 2012, $100,000 as chairman of the board following that
date, $50,000 as member of the board of directors, twelve months of an auto allowance of $650 per month and $20,000 as consulting
fee for May and June 2012.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>(c)</TD><TD>Mr. Moynahan resigned as Chief Financial Officer on May 27, 2014.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>(d)</TD><TD>Represents cost of living increases earned in that year but not paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Previously and effective June 28, 2012,
Jerold Rubinstein was elected by our board of directors as Chairman of the Board, CEO and a director of our subsidiaries. The Board
of Directors of PEI also elected him as Chairman of the Board and CEO. Under the terms of an employment agreement dated June 28,
2012, Mr. Rubinstein received an annual salary of $250,000 per year and continued to serve on our board of directors and as Chairman
of our Audit Committee and continued to receive his compensation for such services. The term of this agreement was six months with
an automatic six month extension unless we provided written notice of non-renewal 30 days prior to the end of the initial six-month
term. This executive was granted options to purchase 23,000 shares of our common stock at $3.50 per share, which was the closing
price of our common stock on the day of option grant. These options vested monthly over a twelve-month period. In the event we
did not renew the second six month period, the executive resigned or we terminated the executive&rsquo;s employment without cause,
all options would immediately vest and the executive would receive all unpaid salary for the full twelve month period. Mr. Rubinstein
resigned as Chief Executive Officer on March 5, 2014 and as Chairman of the Board on November 1, 2013 and a director on July 7,
2014.</P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 18, 2013, we entered into an
Employment Agreement with Yael Schwartz, Ph.D. pursuant to which she is to be employed for an initial period of three years. During
the initial year of her employment term, she is to receive a base salary of $330,000. Thereafter, her base salary will be subject
to mutually agreed upon increases. Our board of directors or Compensation Committee may grant Dr. Schwartz bonuses in its sole
discretion. Dr. Schwartz is also eligible for grants of awards under our Incentive Compensation Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 5, 2014, we entered into an Employment
Agreement with Stephen M. Simes (the &ldquo;Simes Employment Agreement&rdquo;) pursuant to which Mr. Simes was appointed our Chief
Executive Officer. The Simes Employment Agreement is for an initial term of three years, subject to extension as provided therein.
Mr. Simes is to receive a base salary at an annual rate of $425,000 with at least annual review and base salary increases as approved
by the Board of Director or its Compensation Committee. He will have the opportunity to earn a bonus with respect to each year
during his employment based upon achievement of performance objectives set by the Board or the Compensation Committee after consultation
with Mr. Simes with a target bonus opportunity of 60% of base salary for each year. He also has received an initial grant of options
to purchase 500,000 shares at an exercise price of $2.50 which will vest quarterly over the initial three-year term of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the closing of the mergers
with Paloma and VasculoMedics, we entered into an employment agreement on March 31, 2014 with David Sherris, Ph.D. pursuant to
which Dr. Sherris was appointed our Chief Scientific Officer and President of our Paloma/VasculoMedics divisions. Under the agreement,
he is to be employed for an initial period of three years. During the term he is to receive a base salary of $345,000 and is eligible
for a bonus of up to 50% of his base salary upon meeting certain milestones established by the Board of Directors or Compensation
Committee upon consultation with Dr. Sherris. Dr. Sherris is also eligible for grants under our Incentive Compensation Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May&nbsp;27, 2014, we entered into an
Employment Agreement with Phillip B. Donenberg (the &ldquo;Donenberg Employment Agreement&rdquo;) pursuant to which Mr. Donenberg
was appointed Chief Financial Officer of the Company. The Donenberg Employment Agreement is for an initial term of three years,
subject to extension as provided therein. Mr. Donenberg is to receive a base salary at an annual rate of $335,000 with at least
an annual review and base salary increases as approved by the Board of Directors or its Compensation Committee. He will have the
opportunity to earn a bonus with respect to each year during his employment based upon achievement of performance objectives set
by the Board or the Compensation Committee after consultation with Mr. Donenberg with a target bonus opportunity of 45% of base
salary for each year. He will also receive an initial grant of ten-year options to purchase 250,000 shares at an exercise price
of $4.00 per share which will vest quarterly over the initial three-year term of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 9, 2014, we entered into
an Employment Agreement with Tim Boris (the &ldquo;Boris Employment Agreement&rdquo;) pursuant to which Mr. Boris was appointed
General Counsel and Vice President of Legal Affairs. The Boris Employment Agreement is for a period of one year. Mr. Boris is
to receive a base salary of $235,000. He will have the opportunity to earn a target annual bonus of up to 30% of base salary.</P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in"><B>OUTSTANDING EQUITY AWARDS AT JULY
1, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth certain
information relating to unexercised and outstanding options for each named executive officer as of July 1, 2014. No other equity
awards otherwise reportable in this table had been granted to any of our executive officers as of that date.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Unexercised</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Options</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Option</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">that are</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Expiration</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: justify">Stephen Simes</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">41,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">3/7/2019</font></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Timothy Boris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">3/27/2018</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify">Timothy Boris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">12/29/2016</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Timothy Boris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">38.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">8/20/2017</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify">Timothy Boris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">6/2/19</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Yael Schwartz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">6/2/19</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify">David Sherris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">6/2/19</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Phillip Donenberg</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">5/26/19</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Employment Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Future minimum payments under the employment
agreements with Stephen M. Simes, Yael Schwartz, Timothy Boris, David Sherris and Phillip Donenberg are as follows:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>Years Ending December 31,</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Amount</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 33%"><font style="font-size: 10pt">2014</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">1,272,479</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">2015</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,538,014</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">2016</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,435,000</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Total</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,245,493</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Option Plans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are intending to adopt, but has
not yet completed, its Stock Compensation Program (the &ldquo;Stock Compensation Program&rdquo;). This program is intended to provide
key employees, vendors, directors, consultants and other key contributors to our growth an opportunity to participate in the Company&rsquo;s
success. It is estimated that 15% of total shares outstanding will be authorized in options and reserved for this program. Awards
under the program may be made in the form of incentive stock options, nonqualified stock options, restricted shares, rights to
purchase shares under an employee stock plan, grants of options to non-employee directors, and or other specified stock rights
as defined under the plan. Subject to Shareholder approval, we plan to adopt a new stock option plan in 2014.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">CERTAIN RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Director Independence</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in">Independent Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of July 8, 2014, the independent
directors Of the Board were Sol Barer, Isaac Blech, Nelson Stacks and Rex Bright. In addition, we have made a subjective determination
as to each independent director and determined that no relationship exists which, in the opinion of our Board, would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director.</P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">SECURITY OWNERSHIP
OF CERTAIN<BR>
BENEFICIAL OWNERS AND MANAGEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth, as
of July&nbsp;8, 2014, the number and percentage of shares of Common Stock beneficially owned, directly or indirectly, by each
of our directors and executive officers, beneficial owners known by the Company of more than five percent of the outstanding shares
of our Common Stock and by our directors and executive officers as a group. Beneficial ownership is determined in accordance with
the Rule 13d-3(a) of the Securities Exchange Act of 1934, as amended, and does not necessarily indicate ownership for any other
purpose, and generally includes voting or investment power with respect to the shares and shares which such person has the right
to acquire within 60 days of July&nbsp;8, 2014.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Beneficial Owner (a)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount
and Nature </B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>of Beneficial Ownership (b)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Percent of Class(c)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 65%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>5% Stockholders:</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 13%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 13%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.2in; text-indent: -0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">River Charitable Remainder Unitrust, West Charitable Remainder Unitrust, Liberty Charitable Remainder Trust, Isaac Blech, Vice Chairman of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,737,975</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.49%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sol J. Barer, Chairman of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,380,589</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.39%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABG II - USLI Limited</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,625,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.70%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shamus, LLC</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">975,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.26%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ernest W. Moody, Revocable Trust</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">975,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.26%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Other Directors and Executive Officers:</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.2in; text-indent: -0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yael
    Schwartz, Executive Vice President of Preclinical Development and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23,977</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.13%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nelson Stacks, Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,021</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.04%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">David Sherris, Chief Scientific Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,585,509</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(k)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.66%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rex Bright, Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,142</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(l)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.04%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stephen M. Simes, Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">41,667</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.23%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phillip Donenberg, Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">___</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">___</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Timothy Boris, General Counsel and Vice President of Legal Affairs</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">66,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(n)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.36%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All Directors and Executive Officers as a Group (9 persons)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,849,880</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.2in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">26.22%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.2in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify; width: 96%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless otherwise indicated, the address for each Beneficial Owner is c/o RestorGenex Corporation, 1800 Century Park East, 6<SUP>th</SUP> Floor, Los Angeles, California 90067.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The persons named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to applicable community property laws.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on 18,310,025 shares deemed outstanding as of July&nbsp;8, 2014.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This amount consists of (i) 714,285 shares of Common Stock held by Liberty Charitable Remainder Unitrust; (ii) 714,285 shares of Common Stock held by West Charitable Remainder Unitrust; (iii) 119,048 shares of Common Stock held by River Charitable Remainder Unitrust; and (iv) 183,333 shares of Common Stock held by Isaac Blech.&nbsp;&nbsp;Mr. Blech is the sole trustee of each of the Trusts and has the sole voting and dispositive power of each of the Trusts.&nbsp;&nbsp;Mr. Blech disclaims beneficial ownership of the Common Stock owned by each of the Trusts except to the extent of his pecuniary interest therein.&nbsp;&nbsp;This amount does not include 119,047 shares held by Miriam Wimpfheimer Blech, Mr. Blech&rsquo;s wife.&nbsp;&nbsp;Mr. Blech disclaims beneficial ownership of the shares owned by Ms. Blech and Ms. Blech disclaims beneficial ownership of the shares owned by Mr. Blech and the Trusts.&nbsp;&nbsp;The amount also includes 7,021 shares issuable upon exercise of options.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes 355,699 shares issuable upon exercise of warrants and 3,818 shares issuable upon exercise of options.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes 375,000 shares issuable upon exercise of warrants.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes 225,000 shares issuable upon exercise of warrants.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes 225,000 shares issuable upon exercise of warrants.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consists of 23,977 shares received in the acquisition of Canterbury and Hygeia.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consists of 7,021 shares issuable upon exercise of warrants.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(k)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consists of 1,584,056 shares received in the acquisition of Paloma and VasculoMedics.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(l)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consists of 7,142 shares issuable upon exercise of options.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consists of 41,667 shares issuable upon exercise of options.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(n)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consists of 66,000 shares issuable upon exercise of stock options.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">SELLING STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Selling stockholders Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">This prospectus covers an aggregate
of 11,633,885 of our common stock, consisting of (i) 8,949,142 outstanding shares of common stock, and (ii) 2,684,743 shares issuable
upon the exercise of the Warrants but does not include common stock issuable upon the exercise of the common stock purchase warrants
that we issued to the placement agent who participated in the Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are registering the shares of common
stock in accordance with the terms of a Registration Rights Agreement we entered into with the selling stockholders as part of
the Private Placement in order to permit the selling stockholders to offer the shares of common stock for resale from time to time.
The selling stockholders may from time to time offer and sell pursuant to this prospectus any or all of the below listed shares
of common stock owned by them. The registration of these shares does not require that any of the shares be offered or sold by the
selling stockholders. The selling stockholders may from time to time offer and sell all or a portion of their shares in the over-the-counter
market, in negotiated transactions, or otherwise, at prices then prevailing or related to the then current market price or at negotiated
prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The registered shares may be sold directly
or through brokers or dealers, or in a distribution by one or more underwriters on a firm commitment or best efforts basis. To
the extent required, the names of any agent or broker-dealer and applicable commissions or discounts and any other required information
with respect to any particular offer will be set forth in a prospectus supplement. Please see &ldquo;Plan of Distribution.&rdquo;
The selling stockholders and any agents or broker-dealers that participate with the selling stockholders in the distribution of
registered shares may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act, and any commissions
received by them and any profit on the resale of the registered shares may be deemed to be underwriting commissions or discounts
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">No estimate can be given as to the
amount or percentage of common stock that will be held by the selling stockholders after any sales made pursuant to this prospectus
because the selling stockholders are not required to sell any of the shares being registered under this prospectus. The following
table assumes that the selling stockholders will sell all of the shares listed in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Additional selling security holders
not named in this prospectus will not be able to use this prospectus for resales until they are named in the table below by prospectus
supplement or post-effective amendment. Transferees, successors and donees of identified selling stockholders will not be able
to use this prospectus for resales until they are named in the table below by prospectus supplement or post-effective amendment.
If required, we will add transferees, successors and donees by prospectus supplement in instances where the transferee, successor
or donee has acquired its shares from holders named in this prospectus after the effective date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following table sets forth the
beneficial ownership of the selling stockholders. The term &ldquo;selling stockholder&rdquo; or &ldquo;selling stockholders&rdquo;
includes the stockholders listed below and their respective transferees, assignees, pledges, donees or other successors. Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect
to securities. Shares of common stock subject to options, warrants and convertible securities currently exercisable or convertible,
or exercisable or convertible within 60 days are deemed outstanding, including for purposes of computing the percentage ownership
of the person holding the option, warrant or convertible security, but not for purposes of computing the percentage of any other
holder.</P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">SELLING SECURITYHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Selling Securityholder Table</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><B>Beneficial Ownership Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><B>Beneficial Ownership After Offering<SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><U>&nbsp;</U></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><B>Number of Shares
    Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><U>&nbsp;</U></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">A R PROPERTIES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">650,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">3.51%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">650,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (3)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DOMINICK ABEL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ACNYC, LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">487,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.76%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">487,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (4)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ALLENWOOD VENTURES, INC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (5)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THE AMERIAN FAMILY TRUST UAD 07/26/99 ROGER AMERIAN &amp; MARY LEE AMERIAN TTEES AMD 04/28/13</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">58,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">58,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MONTE D. ANGLIN &amp; JANET S. ANGLIN JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MICHAEL J. ARKO &amp; PATRICIA ARKO JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ARZT, LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (6)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">EVAN B. AZRILIANT</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT BAHR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">29,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">29,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THE BAHR FAMILY LIMITED PARTNERSHIP</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">35,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">35,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (7)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARTIN A. BECKER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BES INVESTMENTS LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (8)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT CHARLES BOURGE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD I. BOWLING JR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD F. BRAUN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">52,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">52,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CHARLES BRINKLEY</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ADOLFO CARMONA &amp; DONNA CARMONA JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CHAD CARROLL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARC COHEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD D. COHEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">130,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">130,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MICHAEL COHN &amp; PAULA COHN JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID COOPER &amp; YVONNE COOPER JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CHARLES J. COSTICH III &amp; KARIN J. COSTICH JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">C. BARNES DARWIN II</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES M. DIASIO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">19,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (9)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">SCOTT ALLEN EDELBACH &amp; MICHELLE LYNNE EDELBACH JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership
    Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership</B><BR>
    <B>After Offering <SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-right: Black 1pt solid; text-align: center"><B>Number of Shares Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PAUL D. EHRMAN</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THOMAS L. EISENBERG</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">13,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">13,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RON ELLER &amp; BETH ELLER JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">EZ COLONY PARTNERS LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (10)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">EZ MM &amp; B HOLDINGS LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (11)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PAUL A. FEGLEY</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HENRY PERRY FELL JR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GARY M. FERMAN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">FORTEZZA INVESTMENTS, LP</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">162,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">162,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (12)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID &amp; DEBORAH FRANZETTA TRUST UAD 01/29/98 P. D. FRANZETTA &amp; D. F. FRANZETTA TTEES AMD 01/21/04</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES B. FRYFOGLE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">KEITH GELLES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ALBERT GENTILE &amp; HIEDI LYN GENTILE JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEVEN GLASSMAN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES B. &amp; KAREN A. GLAVIN FAMILY TRUST UAD 10/30/98 JAMES B GLAVIN &amp; KAREN A GLAVIN TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BRUCE DONALD GOETHE &amp; LAURA K. GOETHE COMM PROP WROS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT GRINBERG</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HENRY HERZING REVOCABLE LIVING TRUST UAD 10/27/93 HENRY HERZING TTEE AMD 05/22/00</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">195,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.06%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">195,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DONALD E. HINKLE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TE-SHAO HSU</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM HUFF</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BRUCE P. INGLIS &amp; NANCY M. INGLIS JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JORDAN FAMILY LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (13)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">VICTOR F. KEEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM H. KIMBALL FAMILY TRUST UAD 04/08/13 WILLIAM H. KIMBALL TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES A. KLUGE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THOMAS KOTYK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JEFF KURTZ</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARK J. LEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEVEN K. LUMINAIS &amp; ELIZABETH KINDWALL LUMINAIS JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>


<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership
    Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership</B><BR>
    <B>After Offering <SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-right: Black 1pt solid; text-align: center"><B>Number of Shares Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICK D. MACE</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARKETPLACE LOFTS LIMITED PARTNERSHIP</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">243,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.32%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">243,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (14)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STANLEY M. MARKS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">REED C. MOSKOWITZ</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">325,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.76%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">325,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEVEN H. ORAM REVOCABLE TRUST UAD 05/17/06 &nbsp;STEVEN H. ORAM &amp; TERRI ORAM TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ANDREW W. O&rsquo;SHAUGHNESSY</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PANELLA LIVING TRUST UAD 05/11/04 JOSEPH PANELLA &amp; PAMELA PANELLA TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JONATHAN PATRONIK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,450</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,450</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEPHEN M. PAYNE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JOHN PERAGINE &amp; ALISA C. PERAGINE JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DANIEL P. PETRO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BRIAN POTIKER REVOCABLE TRUST UAD 08/07/96 BRIAN POTIKER TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARK REUTLINGER &amp; ANALEE REUTLINGER COMM PROP</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MICHAEL P. ROSS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">SHELDON SANDERS &amp; DELORES SANDERS JTWROS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD SAXE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ANIL K. SHARMA &amp; PRAGATI G. SHARMA JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">162,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">162,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PARESH SONI &amp; MANJULA SONI JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ARNOLD E. SPANGLER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CLAY STRUVE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TROY TAYLOR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES W. THOMAS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,875</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,875</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HENRY M. TUFO &amp; CARLEEN TUFO JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TED VANVICK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LOUIS VIGDEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JOHN V. WAGNER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TRUST U/W WEISS DTD 05-09-90 PETER H. WEISS TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WIDELITZ FAMILY TRUST UAD 04/15/94 KENNETH WIDELITZ &amp; HEIDI WIDELITZ TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RANDE R. WILLISON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>


<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership
    Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership</B><BR>
    <B>After Offering <SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-right: Black 1pt solid; text-align: center"><B>Number of Shares Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HOWARD J. WORMAN</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEVEN &amp; KAYE YOST FAMILY TRUST UAD 02/07/92 STEVEN A. YOST &amp; KAYE YOST TTEES AMD 06/04/97</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LIZABETH ZLATKUS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES D. ALLARD</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAY R. ANGLE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BARCLAY M. ARMITAGE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (15)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEPHEN BENDER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MILES BLACKSBERG</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRWIN BLITT REVOCABLE TRUST UAD 01/28/78 IRWIN BLITT TTEE AMD 01/11/07</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">EDWARD M. COHEN &amp; LORI COHEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARIO COVO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ANTHONY DIMAGGIO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,875</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,875</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MICHAEL T. DOLEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES L. DRITZ</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">19,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">19,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RUSSELL S. DRITZ</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">3,900</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">3,900</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LAWRENCE FEINBERG</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID FRYDRYCH</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">195,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.06%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">195,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WALTER G. GANS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CRAIG GEERS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PHILLIP M. GENDELMAN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM F. GRIECO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARK GRINBAUM &amp; TATYANA GRINBAUM</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ARNOLD T. HAGLER SEPARATE PROPERTY TRUST UAD 09/17/97 ARNOLD T. HAGLER TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">NATHAN HALEGUA</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JOHN HAWK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DANIEL H HILDEBRAND</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">10,400</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">10,400</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LARRY HOPFENSPIRGER REVOCABLE TRUST UAD 04/13/12 LARRY HOPFENSPIRGER TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JOHN K. HOSKINSON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ITASCA CAPITAL PARTNERS, LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (16)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GEORGE KALIL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT KANTOR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT KARGMAN &amp; MARJIE KARGMAN JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">325,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.76%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">325,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership
    Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership</B><BR>
    <B>After Offering <SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-right: Black 1pt solid; text-align: center"><B>Number of Shares Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">KF BUSINESS VENTURES, LP</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">650,000</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">3.51%</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">650,000</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (17)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PATRICK T. LEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CLAUDE M. MCQUARRIE III</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ERNEST W. MOODY REVOCABLE TRUST UAD 01/14/09 ERNEST W MOODY TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">975,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">5.25%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">975,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PETER A. MORGAN REVOCABLE TRUST UAD 12/22/87 PETER MORGAN TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEVEN M. NELSON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THE OAKS FAMILY LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">162,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">162,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (18)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">OSPREY I, LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (19)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM C. PURDON &amp; DEBRA B PURDON JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARC ROTTER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">KENNETH RUDES GRANDCHILDREN TRUST UAD 02/27/03 LISA RUDES SANDEL TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LESLIE RUDES GRANDCHILDREN TRUST UAD 02/27/03 LISA RUDES SANDEL TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LISA RUDES GRANDCHILDREN TRUST UAD 02/13/03 LISA RUDES SANDEL TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LISA SANDEL GRANDCHILDREN TRUST UAD 09/03/08 ALEX SANDEL TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">40,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ALYSON D. SCHLOSSER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HENRY SCOVERN &amp; LAURA PAKAROW TEN ENT</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">12,513</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">12,513</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">SHAMUS, LLC&nbsp;&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">975,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">5.25%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">975,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (20)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DENNIS SHASHA</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GRAHAM R. SMITH</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MIN SUN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES W. SWISTOCK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">52,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">52,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT E. TRUSKOWSKI</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">G. JAN VAN HEEK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">VIVARI, LTD</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (21)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">KAZUAKI YONEMOTO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">26,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">26,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT A. YOST &amp; MARGARET L. YOST LIVING TRUST UAD 09/22/00 ROBERT A. YOST &amp; MARGARET L. YOST TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">KEITH ZAR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>


<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership
    Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership</B><BR>
    <B>After Offering <SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-right: Black 1pt solid; text-align: center"><B>Number of Shares Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ADVANCED AMBULATORY ANESTHESIOLOGISTS, LLC DEFINED BENEFIT PLAN RICHARD I. STILLMAN TTEE</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">81,250</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (22)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GILYA ALCHITS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JEFFREY C. ALLARD</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO BARCLAY M. ARMITAGE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (15)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JIM AUKSTUOLIS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">26,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">26,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THE STANFORD BARATZ REVOCABLE TRUST UAD 09/07/94 STANFORD BARATZ &amp; AMY BARATZ TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HOWARD B. BRODSKY REVOCABLE TRUST OF 1988 UAD 10/24/88 HOWARD BRODSKY BRODSKY TTEE AMD 09/04/12</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">45,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">45,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO GEORGE E. CONNIFF PERSHING LLC AS CUSTODIAN ROTH ACCOUNT</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID D. DEATKINE JR</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PATRICK DECAVAIGNAC &amp; NANCY J. CONNOLY JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">FRANCESCA DIMAGGIO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,875</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,875</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DJ&amp;J LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (23)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ADAM T. DROBOT &amp; LUCY S. DROBOT JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD DVORAK</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">5,200</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">5,200</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ELEVADO INVESTMENTS COMPANY LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (24)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO MARSHALL S. EZRALOW PERSHING LLC AS CUSTODIAN ROTH ACCOUNT</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD FILIP</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JACK R. FRANK II</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GBS VENTURES INC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,503</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,503</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (25)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">J MICHAEL HAMILTON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TIMOTHY P. HANLEY &amp; MONICA HANLEY TEN COM</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DANIEL J. HARTUNG &amp; JULIE A. HARTUNG JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BENJAMIN R. HASTY</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO THOMAS HUANG PERSHING LLC AS CUSTODIAN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership
    Before Offering</B></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><B>Beneficial Ownership</B><BR>
    <B>After Offering <SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; text-align: center"><B>Number</B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 12%; border-right: Black 1pt solid; text-align: center"><B>Number of Shares Being Offered</B></TD>
    <TD  STYLE="width: 7%; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Number </B><BR>
    <B>of Shares</B></TD>
    <TD STYLE="width: 9%; border-right: Black 1pt solid; text-align: center"><B>Percent</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LIBERTY TRUST COMPANY LTD CUSTODIAN FBO PEDRO VERGNE-MARINI IRA TC 002152</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM LURIE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO STEPHEN R MEYER PERSHING LLC AS CUSTODIAN ROLLOVER ACCOUNT</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">29,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">29,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT C. MONKS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">19,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">19,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID Y. NORTON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RICHARD MARTIN REITER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PAUL G. ROBERTS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DYKE ROGERS&nbsp;&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JOSHUA SCHEIN 2009 SPEARFISH TRUST UAD 12/28/09 BRANDON SCHEIN &amp; JACLYN T. SCHEIN TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID E. SCHWARTZ</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">46,800</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">46,800</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES F. SPALLINO &amp; MARY E. SPALLINO COMM PROP WROS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEPHENS INC CUSTODIAN FBO JAMES C. GILSTRAP / JAMES C. GILSTRAP IRA</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">97,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">97,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BARRY S. STRAUCH &amp; EVELYN M. STRAUCH JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TERRENCE E TROY</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TRUST OF DAVID BENADERET UAD 01/15/13 DAVID BENADERET TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID R. VICTOR REVOCABLE TRUST UAD 03/29/00 DAVID R. VICTOR TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO NEIL H. WASSERMAN PERSHING LLC AS CUSTODIAN ROTH ACCOUNT</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PETER ZABOROWSKI &amp; TIFFANY ZABOROWSKI JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ABGII - USL1 LIMITED</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,625,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">8.67%</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,625,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (26)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID ABRAHAM &amp; JOANN ABRAHAM</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (27)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">AVAVODHA, INC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">RONALD A. BOWLING</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BEN CROWN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JAMES M. DIASIO IRA</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">22,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">3,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (9)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PAUL EHRLICH CPA DEFINED BENEFIT PLAN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GEORGE ELEFTHER &amp; KARIN ALEXA ELEFTHER JT TEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">14,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">14,625</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DANIEL B. ERLANGER &amp; BETH L. ERLANGER TEN COM</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">HOSSEIN ESLAMBOLCHI &amp; FARNAZ ESLAMBOLCHI JT TEN</TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM FILON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LEON FRENKEL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THE DIANA &amp; DAVID FRESHWATER LIVING TRUST UAD 01/20/04 DAVID FRESHWATER &amp; DIANA FRESHWATER TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">GARFINKLE REVOCABLE TRUST UAD 05/15/08 MORRIS GARFINKLE &amp; STEPHANIE GARFINKLE TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ROBERT GIESEN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">JOEL L. HOCHMAN REVOCABLE TRUST UAD 12/08/94 JOEL HOCHMAN TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">24,375</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">BOMAN K. NAJMI REVOCABLE TRUST UAD 04/16/13 BOMAN K NAJMI TTEE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID OLSHANSKY</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">OSI HOLDINGS, LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (28)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ANDREW LOUIS PERITO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">PORTSMOUTH SQUARE INC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (29)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TODD A. RATHE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">MARK SALMON</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">SANTA FE FINANCIAL CORP.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (30)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">DAVID SCHNEIDER</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">65,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">WILLIAM SHEPPARD</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">LAWRENCE I. SILVERSTEIN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">THE INTERGROUP CORPORATION</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2) (31)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">KIM H TIETZ</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8,125</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">STEVEN J. VALKO</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">IRA FBO JOHN V. WINFIELD PERSHING LLC AS CUSTODIAN</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TROYGOULD PC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">36,994</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">36,994</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(32)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">FICKSMAN FAMILY TRUST, DAVID FICKSMAN &amp; MAXINE FICKSMAN, TTEES</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">32,500</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><SUP>(33)</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">CRANSHIRE CAPITAL MASTER FUND LTD<B>.</B></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">48,750</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><SUP>(2) (34)</SUP></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">EQUITEC SPECIALISTS LLC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">*</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,250</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><SUP>(2) (35)</SUP></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">* Less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD>Assumes the selling securityholder sells all of the shares of common stock included in this prospectus.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD>Represents shares of our common stock and shares of our common stock issuable upon exercise of warrants, of which 77% is shares
of our common stock and 23% is shares of our common stock issuable upon exercise of warrants.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD>Randall J. Repp has voting and investment power over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD>Andrew Cader, Managing Member, has voting and investment power over the securities..</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD><TD>James Ramo, President of Allenwood Ventures, Inc., has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)</FONT></TD><TD>R. K. Ahuja, CEO of ARZT LLC, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)</FONT></TD><TD>Robert L. Bahr, Trustee of the General Partner, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)</FONT></TD><TD STYLE="text-align: justify">Jeffrey Enslin and James Bergin, Managers of BES Investments LLC, have voting and investment powers
over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9)</FONT></TD><TD>James M. Diasio owns a total of 19,500 shares of our common stock and shares of our common stock issuable upon exercise of
warrants directly in his name and a total of 3,250 shares of common stock and shares of our common stock issuable upon exercise
of warrants in the James M. Diasio IRA account also listed in this prospectus. Beneficial ownership after offering assumes that
all of the related parties in this footnote will sell all of the shares covered by this prospectus.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10)</FONT></TD><TD>Bryan Ezralow<B> </B>has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11)</FONT></TD><TD>Bryan Ezralow has voting and investment powers over the securities.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12)</FONT></TD><TD>Michael J. Morocco, Managing Member, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13)</FONT></TD><TD>Patricia J. Jordan, Chief Manager, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14)</FONT></TD><TD>Jeffrey Stonberg, President of Stonberg Holding Corp, general partner of Marketplace Lofts Limitted Partnership, has voting
power investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15)</FONT></TD><TD>Barclay M. Armitage owns a total of 16,250 shares of our common stock and shares of our common stock issuable upon exercise
of warrants directly in his name and a total of 16,250 shares of common stock and shares of our common stock issuable upon exercise
of warrants in the IRA FBO Barclay M. account also listed in this prospectus. Beneficial ownership after offering assumes that
all of the related parties in this footnote will sell all of the shares covered by this prospectus.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16)</FONT></TD><TD>Michael S. Wallace, Maging Member, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17)</FONT></TD><TD>Robert Kopple, President of Kopple Financial, Inc., general partner of KF Business Ventures, LP, has voting and investment
powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18)</FONT></TD><TD>Robert Kargman, Managing Partner, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19)</FONT></TD><TD>Dale Burns, Manager of Osprey I, LLC, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20)</FONT></TD><TD>David E. Smith, President of Coast Asset Management, LLC, who is trading advisor to Shamus LLC, has voting and investment powers
over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(21)</FONT></TD><TD>Richard Jackson, President of Vivari, Ltd., has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(22)</FONT></TD><TD>Richard Stillman, Trustee of Advanced Ambulatory Anesthesiologists, LLC DBP, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23)</FONT></TD><TD>David Victor, Manager of DJ&amp;J LLC, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(24)</FONT></TD><TD>Marc Ezralow, Trustee of the Ezralow Family Trust, who is Managing Member of Elevado Investments Company LLC, has voting and
investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(25)</FONT></TD><TD>George Salem, President of GBS Ventures, Inc., has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(26)</FONT></TD><TD>Chun Ka-Yee Angela, Director of ABG II-USL1 Limited, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(27)</FONT></TD><TD>Mark Ast, President of Avavodha, Inc., has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28)</FONT></TD><TD>Kevin P. McCarthy, Principal Member of OSI Holdings, LLC, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29)</FONT></TD><TD>John V. Winfield, President &amp; CEO of Portsmouth Square, Inc., has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30)</FONT></TD><TD>John V. Winfield, President &amp; CEO of Santa Fe Financial Corp, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(31)</FONT></TD><TD>John V. Winfield, President &amp; CEO of The Intergroup Corporation, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32)</FONT></TD><TD>Represents 28,457 shares of our common stock and 8,537 shares of our common stock issuable upon exercise of warrants. Sanford
J. Hillsberg, Managing Partner, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(33)</FONT></TD><TD>Represents 25,000 shares of our common stock and 7,500 shares of our common stock issuable upon exercise of warrants.
                                                                                                                            David Ficksman, as trustee, has voting and investment powers over the securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(34)</TD><TD>Cranshire Capital Advisors, LLC (&ldquo;CCA&rdquo;) is the investment manager of Cranshire Capital Master Fund, Ltd. (&ldquo;Cranshire
Master Fund&rdquo;) and has voting control and investment discretion over securities held by Cranshire Master Fund. Mitchell P.
Kopin (&ldquo;Mr. Kopin&rdquo;), the president, the sole member and the sole member of the Board of Managers of CCA, has voting
control over CCA. As a result, each of Mr. Kopin and CCA may be deemed to have beneficial ownership (as determined under Section
13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Cranshire Master Fund.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">CCA is also the investment manager for managed accounts
for Equitec Specialists, LLC (&ldquo;Equitec&rdquo;) and CCA has voting control and investment discretion over securities held
in the managed accounts for Equitec. Mr. Kopin, the president, the sole member and the sole member of the Board of Managers of
CCA, has voting control over CCA. As a result, each of Mr. Kopin and CCA also may be deemed to have beneficial ownership (as determined
under Section 13(d) of the Securities Exchange Act of 1934, as amended) of an additional 12,500 shares of common stock owned by
Equitec and 3,750 shares of common stock that are issuable upon exercise of warrants held owned by Equitec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(35)</TD><TD>Cranshire Capital Advisors, LLC (&ldquo;CCA&rdquo;) is the investment manager of a managed account for Equitec Specialists,
LLC (&ldquo;Equitec&rdquo;) and has voting control and investment discretion over securities held in by Equitec in such managed
account. Mitchell P. Kopin (&ldquo;Mr. Kopin&rdquo;), the president, the sole member and the sole member of the Board of Managers
of CCA, has voting control over CCA. As a result, each of Mr. Kopin and CCA may be deemed to have beneficial ownership (as determined
under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Equitec in such managed account.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in">CCA is also the investment manager of Cranshire Capital
Master Fund, Ltd. (&ldquo;Cranshire Master Fund&rdquo;). Mr. Kopin, the president, the sole member and the sole member of the Board
of Managers of CCA, has voting control over CCA. As a result, each of Mr. Kopin and CCA may be deemed to have beneficial ownership
(as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Cranshire Master
Fund, that are described in footnote 34.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD>Equitec is an affiliate of a broker-dealer. Equitec acquired the shares being registered hereunder in the ordinary course of
business, and at the time of the acquisition of the shares and warrants described herein, Equitec did not have any arrangements
or understandings with any person to distribute such securities</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The information in the above table is as of the date of this prospectus.
Information concerning the selling securityholders may change from time to time and any such changed information will be described
in supplements to this prospectus if and when necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Relationships with Selling Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">All stockholders, other than those
discussed below, are investors who acquired their securities in the Private Placement and who have had no position, office, or
other material relationship (other than as purchasers of securities) with us or any of our affiliates within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Maxim Group, LLC acted as
placement agent in the Private Placement. As compensation for its services, Maxim Group, LLC received warrants to purchase
927,069 shares of common stock and $3,558,274 of cash compensation. All of the shares of common stock underlying the
foregoing warrants are not included in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">David Ficksman, one of the trustees
of the Ficksman Family Trust, is a member at TroyGould PC, a law firm. TroyGould PC, since 2004 has acted as our corporate/securities
law firm. TroyGould PC and the Ficksman Family Trust received shares of common stock and Warrants in connection with the Private
Placement as part of a settlement of outstanding amounts due to TroyGould PC and are selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The information in the above table
is as of the date of this prospectus. Information concerning the selling stockholder may change from time to time and any such
changed information will be described in supplements to this prospectus if and when necessary.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The selling stockholders, which used
herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares
of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or
interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private
transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to
the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The selling stockholders may use any
one or more of the following methods when disposing of shares or interests therein:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of
the block as principal to facilitate the transaction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>short sales effected after the date the registration statement of which this prospectus is a part is declared effective by
the SEC;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per
share;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>a combination of any such methods of sale; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>any other method permitted by applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The selling stockholders may, from
time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default
in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock,
from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision
of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest
as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances,
in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.</P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In connection with the sale of our
common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The
selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also
enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus,
which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The aggregate proceeds to the selling
stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or
commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to
time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not
receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive
the exercise price of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The selling stockholders also may resell
all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided
that they meet the criteria and conform to the requirements of that rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The selling stockholders and any underwriters,
broker-dealers or agents that participate in the sale of the common stock or interests therein may be &quot;underwriters&quot;
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &quot;underwriters&quot;
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">To the extent required, the shares
of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices,
the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will
be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In order to comply with the securities
laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers
or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or
an exemption from registration or qualification requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have advised the selling stockholders
that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities
of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus
(as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the
prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates
in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have agreed to indemnify the selling
stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration
of the shares offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have agreed with the selling stockholders
to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as
all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement
or (2) the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act.</P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">DESCRIPTION OF
SECURITIES</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The following is a summary of
all material characteristics of our capital stock as set forth in our amended and restated articles of incorporation and bylaws,
as amended. Copies of these documents are filed or incorporated by reference as exhibits to the registration statement, of which
this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We are presently authorized to issue
1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of the date
of this prospectus, we had 9,464,340 shares of common stock issued and outstanding and no shares of Preferred Stock outstanding.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">The holders of our common stock are
entitled to equal dividends and distributions per share with respect to the common stock when, as and if declared by the Board
of Directors from funds legally available therefore. No holder of any shares of common stock has a preemptive right to subscribe
for any of our securities, nor are any common shares subject to redemption or convertible into other securities. Upon liquidation,
dissolution or winding-up of our company, and after payment of creditors and preferred stockholders, if any, the assets will be
divided pro rata on a share-for-share basis among the holders of the shares of common stock. All shares of common stock now outstanding
are fully paid, validly issued and non-assessable. Each share of our common stock is entitled to one vote with respect to the election
of any director or any other matter upon which stockholders are required or permitted to vote.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Under our articles of incorporation,
the Board of Directors has the power, without further action by the holders of the common stock, to designate the relative rights
and preferences of the preferred stock, and to issue the preferred stock in one or more series as designated by the Board of Directors.
The designation of rights and preferences could include preferences as to liquidation, redemption and conversion rights, voting
rights, dividends or other preferences, any of which may be dilutive of the interest of the holders of the common stock or the
preferred stock of any other series. The issuance of preferred stock may have the effect of delaying or preventing a change in
control of the company without further stockholder action and may adversely affect the rights and powers, including voting rights,
of the holders of the common stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Each Warrant issued in the Private
Placement entitles the holder thereof to purchase 0.3 of the number of shares of common stock purchased by such investor in the
Private Placement. The Warrants are exercisable in whole or in part, at an initial exercise price per share of $4.80 for a period
of four years from the date of grant, and may be exercised in a cashless exercise if there is no effective registration statement
registering, or no current prospectus available for, the resale of the Warrant shares. The exercise price and number of shares
of common stock issuable under the Warrants are subject to adjustments for stock dividends, splits, combinations and similar events.
The Warrants may be exercised at any time upon the election of the holder, beginning on the date of issuance and ending on the
fifth anniversary of the date of issuance.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Rule 144</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">In general, under Rule 144 as currently
in effect, a person (or persons whose shares are aggregated) who has beneficially owned restricted securities for at least six
months, including persons who may be deemed our &ldquo;affiliates,&rdquo; as that term is defined under the Securities Act, would
be entitled to sell such securities. Sales under Rule 144 are subject to the availability of current public information about the
company. A person who has not been our affiliate at any time during the three months preceding a sale, and who has beneficially
owned his shares for at least one year, would be entitled under Rule 144 to sell such shares without regard to any limitations
under Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">As of the date of this prospectus,
approximately 12,775,549<B> </B>of our outstanding shares of common stock are or will be eligible for public resale under Rule&nbsp;144.
The sale, or availability for sale, of substantial amounts of common stock could, in the future, adversely affect the market price
of the common stock and could impair our ability to raise additional capital through the sale of our equity securities or debt
financing. The future availability of Rule 144 to our holders of restricted securities would be conditioned on, among other factors,
the availability of certain public information concerning the company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt">Transfer Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">Our transfer agent currently is Registrar
and Transfer Company, 10 Commerce Drive, Cranford NJ 07016-3572, 1-800-866-1340.</P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">DISCLOSURE OF
SEC POSITION ON INDEMNIFICATION<BR>
FOR SECURITIES ACT LIABILITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Our Amended and Restated Articles of
Incorporation provide to the maximum extent permitted under applicable law, there shall be no personal liability of a director
or an officer to this corporation or its stockholders for damages for breach of fiduciary duty as a director or an officer. Our
bylaws and Amended and Restated Articles of Incorporation also provide that we shall indemnify and hold harmless each person who
serves at any time as a director or officer of this company from and against any and all claims, judgments and liabilities to which
such person shall become subject by reason of the fact that he is or was a director or officer, and shall reimburse such person
for all legal and other expenses reasonably incurred by him or her in connection with any such claim or liability. We also have
the power to defend such person from all suits or claims in accordance with the Nevada Revised Statutes. The rights accruing to
any person under our bylaws and Amended and Restated Articles of Incorporation do not exclude any other right to which any such
person may lawfully be entitled, and we may indemnify or reimburse such person in any proper case, even though not specifically
provided for by the bylaws and Amended and Restated Articles of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers or persons controlling this company pursuant to the foregoing
provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in
the Securities Act and is, therefore, unenforceable.&nbsp;&nbsp;In the event a claim for indemnification against such liabilities
(other than payment by us for expenses incurred or paid by a director, officer or controlling person of our company in successful
defense of any action, suit, or proceeding) is asserted by a director, officer or controlling person in connection with the securities
being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction, the question of whether such indemnification by it is against public policy in the Securities
Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">LEGAL MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">TroyGould PC, Los Angeles, California,
has rendered an opinion with respect to the validity of the shares of common stock covered by this prospectus. TroyGould PC and
one member of that firm beneficially own in the aggregate 53,457 shares and warrants to acquire 16,037 shares of our common stock,
all of which shares are covered by this registration statement. The beneficial ownership of our shares described above includes
all warrants that may be exercised within 60 days from the date of this prospectus.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">EXPERTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Our consolidated financial statements
for the years ended December 31, 2013 and December 31, 2012 have been audited by Goldman Kurland and Mohidin LLP, an independent
registered public accounting firm, as stated in their reports appearing herein, and are included in reliance upon such reports
given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">WHERE YOU CAN
FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We have filed with the SEC a registration
statement on Form S-1 with respect to this offering of our common stock. This prospectus, which constitutes a part of the registration
statement, does not contain all of the information set forth in the registration statement, some items of which are contained in
exhibits to the registration statement as permitted by the rules and regulations of the SEC. Statements contained in this prospectus
as to the contents of any contract, agreement or other document are summaries of the material terms of that contract, agreement
or other document. With respect to each of these contracts, agreements or other documents filed or incorporated by reference as
an exhibit to the registration statement, reference is made to the exhibits for a more complete description of the matter involved.
A copy of the registration statement, and the exhibits and schedules thereto, may be inspected without charge at the public reference
facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. Copies of these materials may be obtained by writing
to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330
for further information on the operation of the public reference facilities. The SEC maintains a website that contains reports,
proxy and information statements and other information regarding registrants that file electronically with the SEC. The address
of the SEC&rsquo;s website is http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt; text-indent: 0.5in">We file periodic reports and other
information with the SEC. Such periodic reports and other information are available for inspection and copying at the public reference
room and website of the SEC referred to above. We maintain a website at http://www.restorgenex.com. You may access our annual reports
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant
to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the SEC. The information and other content contained on our
website are not part of the prospectus.</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RestorGenex Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Index to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Financial Statements for the Years Ended December&nbsp;31, 2013
and 2012:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 95%; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: center">Page</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>Report of Independent Registered Public Accounting Firm</td>
    <TD STYLE="text-align: right">F-1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Balance Sheets as of December 31, 2013 and 2012</td>
    <TD STYLE="text-align: right">F-2</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>Statements of Operations for the years 2013 and 2012</td>
    <TD STYLE="text-align: right">F-3</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Statements of Shareholders Equity/(Deficit) for the years 2013 and 2012</td>
    <TD STYLE="text-align: right">F-4</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>Statements of Cash Flows for the years 2013 and 2012</td>
    <TD STYLE="text-align: right">F-5</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Notes to Consolidated Financial Statements</td>
    <TD STYLE="text-align: right">F-6</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Unaudited Financial Statements for the Three Months Ended March
31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="width: 95%">Balance Sheets as of December 31, 2013 and March 31, 2014 (unaudited)</td>
    <TD STYLE="width: 5%; text-align: right">F-27</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Statements of Operations for the Three Months Ended March 31, 2014 (unaudited) and 2013 (unaudited) </td>
    <TD STYLE="text-align: right">F-28</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>Statements of Cash Flows for the Three Months Ended March 31, 2014 (unaudited) and 2013 (unaudited) </td>
    <TD STYLE="text-align: right">F-29</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Notes to Unaudited Condensed Financial Statements</td>
    <TD STYLE="text-align: right">F-30</td></tr>
</table>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>To the Board of Directors and Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>RestorGenex Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Los Angeles, California&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated balance sheets of RestorGenex Corporation (&ldquo;Company&rdquo;) as of December 31, 2013 and 2012, and the related
consolidated statements of operations, stockholders&rsquo; equity/(deficit) and cash flows for each of the two years in the period
ended December 31, 2013. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility
is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We conducted our audits
in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial
reporting.&nbsp;&nbsp;Our audits considered internal control over financial reporting as a basis for designing audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our opinion, the consolidated
financial statements referred to above present fairly, in all material respects, the financial position of RestorGenex Corporation
as of December 31, 2013 and 2012, and the results of its operations and its cash flows for each of the two years in the period
ended December 31, 2013 in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements were prepared assuming RestorGenex Corporation will continue as a going concern. As discussed in Note 2 to
the consolidated financial statements, RestorGenex Corporation has suffered recurring losses and has negative cash flow from operations.
These conditions raise substantial doubt as to the ability of RestorGenex Corporation to continue as a going concern. These consolidated
financial statements do not include any adjustments that might result from such uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Goldman Kurland and Mohidin LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Goldman Kurland and Mohidin LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Encino, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">April 15, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">Cash and equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">254,964</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">312,093</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Receivable from former officer, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,946</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,741,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77,599</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,998,283</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">461,638</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,262</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,691,682</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,642,825</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,935,621</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">18,344,052</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,446,297</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt">LIABILITIES AND SHAREHOLDERS' DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,520,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,203,382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,152,933</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,472</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,260</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued preferred stock dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">733,840</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other accrued expenses and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,697,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,683,508</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Payable to officer and former officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,358</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Rent liability for facilities no longer occupied</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,121,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,260,645</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,004,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Obligation to issue stock for transfer of liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,854,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Derivative liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,389,607</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8,878,318</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">20,852,636</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Long-term liability - deferred taxes on acquisition</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,000,576</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">Shareholders' surplus/(deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Series C 10% Preferred Stock, $0.001 par value: 1,000,000 shares authorized, 0 and 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Series D 10% Preferred Stock, $0.001 par value: 500,000 shares authorized, 0 and 18,999 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Series E 5% Preferred Stock, $0.001 par value: 10,000 shares authorized; 0 and 9,450 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 5,813,785 and 890,837 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,814</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,390,493</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,329,046</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60,937,550</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(56,717,225</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total RestorGenex shareholders' surplus/(deficit)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,458,757</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(18,387,260</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Non-controlling interest surplus/(deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,401</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(19,079</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total shareholders' surplus/(deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,465,158</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(18,406,339</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders' surplus/(deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">18,344,052</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,446,297</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; font-weight: bold">Revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">71,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">374,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">235,803</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross profit</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">71,667</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">138,739</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">General, administrative, research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,008,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,570,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Impairment of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,935,621</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,423,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Warrants, options and stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,228,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,643,662</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Fair value of common stock exchanged for warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,069,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Legal and professional services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,071,392</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,128,898</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">675,757</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">164,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">12,988,997</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">11,930,608</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(12,917,330</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(11,791,869</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Other (income)/expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Fair value of derivative liabilities in excess of proceeds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">408,501</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">(Gain)/loss on adjustments to fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,980,077</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,907,748</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on extinguishment of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,635,967</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Other (income)/expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71,631</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">379,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Present value of remaining lease payments for facilities no longer occupied</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,010,111</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">228,294</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">167,894</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,459,381</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,942,054</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,457,949</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,849,815</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net loss attributed to non-controlling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,401</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss attributed to RestorGenex Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,464,350</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,868,894</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Preferred dividends</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">171,625</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">497,167</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to RestorGenex Corporation common shareholders</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,635,975</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(7,366,061</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1.00</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(8.16</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Basic weighted average shares outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,646,603</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">903,139</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Fully-diluted weighted average shares outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,646,603</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,121,987</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDER&rsquo;S
EQUITY / (DEFICIT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">Additional</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="10" style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">Common Stock</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">Paid-In</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">Accumulated</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Preferred Stock Series</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Amount</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Capital</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Deficit</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">C</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">D</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">E</font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 23%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Balance at December 31, 2011</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="width: 7%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>866,571</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>867</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>33,322,207</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(49,385,387</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>19</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 6%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>9</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="width: 7%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(16,062,285</b></font></td>
    <td style="width: 1%; padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Issuance of common stock for cash</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,114</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">144,237</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">144,241</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Issuance of Series E preferred stock for cash</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">869,999</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">869,999</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Stock expense, value of warrants and options</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9,000</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,284,346</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,284,355</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Conversion of preferred to common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">16,667</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">17</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(17</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Stock for services</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,000</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,588,236</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,588,243</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Cancellation and reissue of shares, net</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(213</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Reduction in shares accrued for issuance</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(21,613</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(22</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">22</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Shares issued in settlement of contract</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,861</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">8</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">117,910</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">117,918</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Shares issued as dividends on preferred stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,450</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Adjustments related to acquisition of ProElite</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,106</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(482,023</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(479,917</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Derivative liability</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(999,999</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(999,999</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(6,849,815</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(6,849,815</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Balance at December 31, 2012</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>890,837</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>891</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>38,329,046</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(56,717,225</b></font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>19</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>9</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(18,387,260</b></font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Issuance of common stock for cash</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">142,501</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">143</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">427,358</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">427,501</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Stock expense, value of warrants and options</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,527,067</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,527,067</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Payment of preferred stock dividends with common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,202</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">99,789</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">99,793</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Conversion of Series D Preferred to common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11,611</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">12</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(12</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(19</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(19</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Conversion of Series E Preferred to common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,575,000</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,575</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,575</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Conversion of debt to common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">576,331</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">577</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,915,922</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,916,500</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Conversion of warrants to common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,023,264</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,023</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,023</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Shares issued in settlement of contract</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,000</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">31,998</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">32,000</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Remove accrued dividends for Series E extinguishment</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">802,994</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">802,994</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Remove accrued interest for notes exchanged for stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">63,602</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">63,602</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Shares issued as part of board compensation</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(6,827</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(8</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">41,757</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">41,749</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Fair value charge for warrants retired</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,069,792</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,069,792</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Adjustments related to ProElite</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">942,600</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,584,350</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(641,750</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Shares issued for acquisition</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,150,116</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,150</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">12,420,099</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">12,421,249</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Issuance of shares for advisory agreements</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">243,250</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">243</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,231,482</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,231,725</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Shares issued as fee</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,500</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,498</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,500</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Issuance of shares to third party for assumption of liabilities</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">200,000</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">200</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">479,099</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">479,299</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(2,635,975</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(2,635,975</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Balance at December 31, 2013</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>5,813,785</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>5,814</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>67,390,493</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(60,937,550</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>6,458,757</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; font-weight: bold; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 13%; font-weight: bold; text-align: right">(2,457,949</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 13%; font-weight: bold; text-align: right">(6,849,815</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164,043</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Impairment of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,935,621</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,423,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Fair value of derivative liabilities in excess of proceeds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">408,501</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">(Gain)/loss on adjustments to fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,980,077</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,907,748</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on extinguishment of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,635,967</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Warrants, options and stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,228,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,643,662</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Fair value of common stock exchanged for warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,069,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Note issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,813</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Non-cash gain on reversal of liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Increase / (decrease) in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Receivable from former officer and director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,946</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,903</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Advances to acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414,361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(581,605</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,152,933</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(123,788</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">559,694</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Rent liability for facilities no longer occupied</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,260,645</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expense for potential property damage</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Estimated cost of vendor settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Obligation to issue stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,854,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other accrued expenses and liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">130,963</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(401,834</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,184,630</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,310,483</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds on notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">700,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,483,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Increase in payables to officers and a director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">427,501</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,829</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Proceeds from issuance of preferred stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">870,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,127,501</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,524,127</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Decrease in cash and equivalents</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(57,129</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">213,644</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Cash and equivalents, beginning of period</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">312,093</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">98,449</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and equivalents, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">254,964</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">312,093</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Cash paid during the period for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Cash paid during the period for income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DECEMBER 31, 2013 AND 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 14, 2008, pursuant
to an Agreement and Plan of Merger dated August 20, 2007 between Feris International, Inc. (&ldquo;Feris&rdquo;) and Pro Sports
&amp; Entertainment, Inc. (&ldquo;PSEI&rdquo;), Feris issued 49,500,000 shares of its common stock for all issued and outstanding
shares of PSEI, resulting in PSEI becoming a wholly-owned subsidiary of Feris and the surviving entity for accounting purposes
(&ldquo;Reverse Merger&rdquo;). In July 2008, Feris&rsquo; corporate name was changed to Stratus Media Group, Inc. (&ldquo;Company,&rdquo;
&ldquo;Stratus,&rdquo; or &ldquo;SMDI&rdquo;). PSEI, a California corporation, was organized on November 23, 1998. PSEI acquired
the business of Stratus White, LLC (&ldquo;Stratus White&rdquo;) in August 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2011, the Company
acquired shares of Series&nbsp;A Convertible Preferred Stock of&nbsp;ProElite, Inc., a New Jersey corporation (&ldquo;ProElite&rdquo;
or &ldquo;PEI&rdquo;), that organized and promoted mixed martial arts (&ldquo;MMA&rdquo;) matches. These holdings of Series A Convertible
Preferred Stock provide the Company voting rights on an as-converted basis equivalent to a 95% ownership in ProElite.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 7, 2014, the Company
effected a reverse stock split 1 to 100 with respect to its Common Stock and the Company changed its corporate name from Stratus
Media Group, Inc. to RestorGenex Corporation, a biopharmaceutical company. All stock numbers herein are post reverse split. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective September 30,
2013, Stratus entered into an Agreement and Plan of Merger with Canterbury Acquisition LLC, a wholly owned subsidiary of the Company,
Hygeia Acquisition, Inc., a wholly-owned subsidiary of the Company, Canterbury Laboratories, LLC (&ldquo;Canterbury&rdquo;), Hygeia
Therapeutics, Inc. (&ldquo;Hygeia&rdquo;) and Yael Schwartz, Ph.D., as Holder Representative, pursuant to which Stratus will acquire
all of the capital stock of Canterbury and Hygeia (the &ldquo;Mergers&rdquo;) with Canterbury and Hygeia becoming wholly-owned
subsidiaries of Stratus. The consideration for the Mergers was the issuance by Stratus of an aggregate of 1,150,116 restricted
shares of Stratus common stock issued to the stakeholders of Canterbury and Hygeia. Closing of the Mergers occurred on November
18, 2013 and is subject to rescission if Stratus has not raised $7.5 million or more in gross financing proceeds by April 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Canterbury and Hygeia (the
&ldquo;Canterbury Group&rdquo;) are related companies engaged in the development of cosmeceuticals that revitalize hormonally-aged
skin and hair in women over the age of 45. Cosmeceuticals are the latest addition to the health industry and are sometimes described
as cosmetic products with &ldquo;drug-like benefits.&rdquo; Generally, cosmeceuticals are products sold over-the-counter, without
the regulatory requirement of FDA approval. The Canterbury Group has an exclusive license with Yale University to develop and market
23 synthetic estrogenic ingredients for the treatment of aging skin and four classes of anti-androgenic ingredients for hair loss,
excess facial hair, seborrhea and acne. The license from Yale covers 24 patent-protected compounds under U.S. Patent 7,015,211<I>
&ldquo;Estradiol 15-&alpha;-Carboxylic Acid Esters as Locally Active Estrogens,&rdquo; </I>U.S. Patent 6,476,012<I> &ldquo;Estradiol
16-alpha Carboxylic Acid Esters as Locally Active Estrogens&rdquo;</I> and U.S. Patent 8,552,061 <I>&ldquo;Locally active &quot;soft&quot;
antiandrogens&rdquo; </I>(&ldquo;Yale Patents&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The acquisition of Canterbury
and Hygeia was the first step in the Company&rsquo;s plan to reposition itself as a life sciences company. The total consideration
was $12,421,249 for 1,150,116 shares of common stock at the market value of $10.80 as of the execution of the Merger Agreements
on September 30, 2013. Based on the valuation of the Yale Patents of $7,779,000, $4,642,249 of the purchase price was allocated
to goodwill, which is not tax deductible. The book value of the Yale Patents at the time of purchase was $132,571, giving rise
to a gain of $7,646,429. When tax effected at a combined U.S. Federal and California taxe rate, the net result of this gain is
a deferred tax liability of $3,058,572. Total goodwill of $7,642,825 as of December 31, 2013 consists of the $4,642,249 initial
allocation of the purchase price, plus the deferred tax liability of $3,000,576 plus net assets acquired of $190,567. For 2013,
additional expenses for Canterbury and Hygeia of $138,320 after the Mergers were included in the consolidated loss attributable
to RestorGenex shareholders for 2013 of $2,635,975 and there were no revenues for Canterbury and Hygeia following the Mergers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Hygeia is a Delaware Corporation,
based in Holden, Massachusetts was incorporated in November 2005 and was formerly known as Orcas Therapeutics, Inc. Canterbury
is a Delaware Limited Liability Company that was formed in October 2011 and began operations in February 22, 2012. Initially, Canterbury
was a wholly-owned subsidiary of Hygeia and shareholders of Hygeia currently own 94% of Canterbury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 3, 2014, the Company
entered into an Agreement and Plan of Merger with Paloma Acquisition, Inc., a wholly owned subsidiary of the Company, Paloma Pharmaceuticals,
Inc. (&ldquo;Paloma&rdquo;) and David Sherris, Ph.D., as founding stockholder and Holder Representative pursuant to which the Company
agreed to acquire all of the capital stock of Paloma with Paloma becoming a wholly owned subsidiary of the Company. On March 28,
2014, the merger with Paloma was closed and the Company issued an aggregate of 2,500,000 post-reverse stock split common shares
to the holders of Paloma Common Stock and its derivative securities and assumed promissory notes of Paloma in the aggregate amount
(principal and interest) currently of approximately $1,130,500 to be paid on the first anniversary of the closing of the Paloma
merger. The merger with Paloma is subject to rescission if the Company has not raised gross proceeds of at least $7.5 million by
May 27, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also on March 3, 2014,
the Company entered into an Agreement and Plan of Merger with VasculoMedics Acquisition, Inc., a wholly owned subsidiary of the
Company, VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;) and Dr. Sherris pursuant to which the Company agreed to acquire all
of the capital stock of VasculoMedics with VasculoMedics becoming a wholly owned subsidiary of the Company. The VasculoMedics Merger
was concurrently closed with and as a condition to the closing of the Paloma Merger on March 28, 2013, with the Company issuing
an aggregate of 220,000 post-reverse stock split common shares to the VasculoMedics stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Both Paloma and Vasculomedics
are Delaware corporations and both are based in Jamaica Plain, Massachusetts. Paloma was founded in January 2005 and VasculoMedics
was founded in November 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Paloma has developed a
non-steroidal, synthetic, small molecule drug library for dermatology (psoriasis, atopic dermatitis, rosacea, actinic keratosis,
keloid and hypertrophic scarring, Dupuytren&rsquo;s disease, bullous blistering diseases), ocular disease, cancer, pulmonary fibrosis,
CNS (Huntington&rsquo;s disease and infantile spasm, a form of childhood epilepsy), biodefense and anti-viral application. The
lead product, P529, targets and inhibits the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric,
dual TORC1/TORC2 dissociative inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">VasculoMedics was founded
as a platform epigenetic company to develop orally available small molecular inhibitors of zinc finger transcription factors. Zinc
finger transcription factors are a subset of transcription factors utilizing zinc at its core for activity. Transcription factors
are proteins that bind to specific parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs
the protein making machinery to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of
a transcription factor, one can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription
factor. Many diseases can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors.
Inhibition of such transcription factors could then be able to control disease pathology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has suffered
losses from operations and, without additional capital,&nbsp;currently lacks liquidity to meet its current obligations. The Company
had net losses for 2013 and 2012 of $2,635,975 and $7,366,061, respectively. As of December 31, 2013, the Company had negative
working capital of $5,880,035 and an accumulated deficit of $60,937,550. The Company had a total of $667,002 of promissory notes
that were in default as of December 31, 2013. Unless additional financing is obtained, the Company may not be able to continue
as a going concern. In 2013, the Company raised $700,000 through the issuance of two promissory notes and $427,501 through the
sale of common stock. In 2012, the Company raised $870,000 through issuance of preferred stock, $143,829 through the issuance of
common stock and received $3,483,103 through issuance of promissory notes. The Company is seeking additional capital in connection
with current and potential acquisitions. However, due to the current economic environment and the Company&rsquo;s current financial
condition, there can be no assurance that adequate capital will be available when needed and on acceptable terms.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements
were prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities in the normal
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of
asset carrying amounts or the amount and classification of liabilities that might result if the Company is unable to continue as
a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of
Presentation and Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Basis of Presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements
were prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;),
pursuant to the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The balance sheets at December
31, 2013 and December 31, 2012 and the income statements for the years ended December 31, 2013 and 2012 consolidate the accounts
of PEI, Canterbury and Hygeia reflecting the acquisition of these entities (see Note 19). All significant intercompany balances
were eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Basic and Diluted Earnings/(Loss) Per Share (&ldquo;EPS&rdquo;)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic EPS is computed by
dividing the income/(loss) available to common shareholders by the weighted average number of common shares outstanding for the
period. Diluted EPS is computed similar to basic income/(loss) per share except that the denominator is increased to include the
number of additional common shares that would have been outstanding if all the potential common shares, warrants and stock options
had been issued and if the additional common shares were dilutive. Diluted EPS is based on the assumption that all dilutive convertible
shares were converted into common stock. Dilution is computed by applying the if-converted method for the outstanding convertible
preferred shares. Under the if-converted method, convertible outstanding instruments are assumed to be converted into common stock
at the beginning of the period (or at the time of issuance, if later).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of calculating
EPS, the number of common shares on December 31, 2012 did not include 281,667 shares of common stock issuable upon conversion by
the holders of Series E Preferred. These conversion shares were not included in the EPS calculation because they were antidilutive
given the losses by the Company for the year ended December 31, 2012. As of June 30, 2013 the Series E Preferred had been extinguished
and the basic and fully-diluted shares are the same from that point forward and the number of shares used for basic and fully-diluted
EPS calculations in 2013 are the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Non-controlling Interest</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company follows Accounting
Standards Codification (&ldquo;ASC&rdquo;) Topic 810 <I>&ldquo;Consolidation,&rdquo;</I> which governs the accounting for and reporting
of Non-Controlling Interests (&ldquo;NCIs&rdquo;) in partially owned consolidated subsidiaries and the loss of control of subsidiaries.
Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as
a liability, that increases and decreases in the parent&rsquo;s ownership interest that leave control intact be treated as equity
transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary
be allocated to the NCI even when such allocation might result in a deficit balance. This standard also required changes to certain
presentation and disclosure requirements. The net income (loss) attributed to the NCI is separately designated in the accompanying
statements of operations and other comprehensive income (loss). Losses attributable to the NCI in a subsidiary may exceed the NCI&rsquo;s
interests in the subsidiary&rsquo;s equity. The excess attributable to the NCI is attributed to those interests. The NCI shall
continue to attribute its share of losses even if that attribution results in a deficit NCI balance. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Use of Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of our
consolidated financial statements in accordance with U.S.&nbsp;GAAP requires us to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated
financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions
we may undertake in the future, actual results may differ from such estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Derivative Liabilities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2011, the Company
entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with eight investors (collectively, the &ldquo;Investors&rdquo;)
pursuant to which the Company sold 8,700 shares of a new series of convertible preferred stock designated as Series E Convertible
Preferred Stock (&ldquo;Original Series E&rdquo;), the terms of which are set forth in the Certificate of Designations of Series
E Preferred Stock (the &ldquo;Certificate&rdquo;), for $1,000 per share, or $8,700,000. In October 2012, the Company sold 1,000
shares of Series E for $1,000,000 (&ldquo;New Series E&rdquo;). The Original Series E and New Series E together are referred to
herein as &ldquo;Series E.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These Series E contained
&ldquo;full ratchet-down&rdquo; liquidity protection, which provided that if the Company issues securities for less than the existing
conversion price for the Series E Preferred Stock or the strike price of the Series E warrants, then the conversion price for Series
E Preferred Stock will be lowered to that lower price. Also, the strike price for Series E warrants would be decreased to that
lower price and the number of Series E warrants would be increased such that the product of the original strike price times the
original quantity equals the lower strike price times the higher quantity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequent to the issuance
of this Series E, the Company determined that the warrants for these financings included certain embedded derivative features as
set forth in ASC Topic 815 &ldquo;<I>Derivatives and Hedging</I>,&rdquo; (&ldquo;ASC 815&rdquo;) and that this conversion feature
of the Series E was not an embedded derivative because this feature was clearly and closely related to the host (Series E) as defined
in ASC 815. These derivative liabilities were initially recorded at their estimated Fair Value (&ldquo;FV&rdquo;) on the date of
issuance and were subsequently adjusted each quarter to reflect the estimated FV at the end of each period, with any decrease or
increase in the estimated FV of the derivative liability for each period being recorded as other income or expense. Since the value
of the embedded derivative feature for the related warrants was higher than the value of both Series E transactions, there was
no beneficial conversion feature recorded for either transaction, and the excess of the value of the embedded derivative feature
over the value of the transaction was recorded in each period on the Statement of Operations as a separate line item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FV of these derivative
liabilities was calculated using the Black Scholes pricing model that was based on the closing price of the common stock, the strike
price of the underlying instrument, the risk-free interest rate for the applicable remaining life of the underlying instrument
(i.e., the U.S. treasury rate for that period) and the historical volatility of the Company&rsquo;s common stock. These FV results
were extremely sensitive to all these input variables, particularly the closing price of the company&rsquo;s common stock and the
volatility of the Company&rsquo;s common stock. Accordingly, the FV of these derivative liabilities was subject to significant
changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Series E and related
warrants were extinguished in May 2013 when the Series E and related warrants were exchanged for common stock, at which time the
derivative liability was extinguished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Allowance for Uncollectible Receivables</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accounts receivable are
recorded at their face amount, less an allowance for doubtful accounts. We review the status of our uncollected receivables on
a regular basis. In determining the need for an allowance for uncollectible receivables, we consider our customers financial stability,
past payment history and other factors that bear on the ultimate collection of such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cash Equivalents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider all highly
liquid investments purchased with maturities of three months or less to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Fair Value of Financial Instruments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our financial instruments
include cash and equivalents, receivables, accounts payable and accrued liabilities. The carrying amounts of financial instruments
approximate FV due to their short maturities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Property and Equipment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation. We record depreciation using the straight-line method over the following estimated
useful lives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: top; width: 53%"><font style="font-size: 10pt">Equipment</font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 46%"><font style="font-size: 10pt">3 &ndash; 5 years</font></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><font style="font-size: 10pt">Furniture and fixtures</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">5 years</font></td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><font style="font-size: 10pt">Software</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">3 years</font></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">Lesser&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;life&nbsp;of&nbsp;improvements</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Goodwill and Intangible Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Intangible assets as of
December 31, 2013 consisted of goodwill and intangible assets related to the acquisition of Canterbury and Hygeia in November 2013.
Goodwill as of December 31, 2012 was related to goodwill for ProElite that we acquired in June 2011 but suspended development of
this business in June 2013. Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible
and intangible assets acquired and liabilities assumed. We apply ASC Topic 350 &ldquo;<I>Goodwill and Other Intangible Assets,</I>&rdquo;
which requires allocating goodwill to each reporting unit and testing for impairment using a two-step approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company reviewed the
value of intangible assets and related goodwill as part of its annual reporting process, which occurs in February or March of each
year. In between valuations, the Company conducted additional tests to determine if circumstances warranted additional testing
for impairment. The Company decided to suspend development of its ProElite business as of June 30, 2013 and the goodwill was considered
to be fully impaired at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To review the value of
intangible assets and related goodwill as of December 31, 2013, the Company followed ASC Topic 350 &ldquo;<I>Intangibles-Goodwill
and Other</I>&rdquo; and first examined the facts and circumstances for each event or business to determine if it was more likely
than not that an impairment had occurred. If this examination suggested it was more likely that impairment had occurred, the Company
then compared discounted cash flow forecasts related to the asset with the stated value of the asset on the balance sheet. The
objective was to determine the value of each asset to an industry participant who is a willing buyer not under compulsion to buy
and the Company is a willing seller not under compulsion to sell. Revenue from goodwill and intangible assets were forecasted based
on the assumption they are standalone entities. These forecasts were discounted at a range of discount rates determined by taking
the risk-free interest rate at the time of valuation, plus premiums for equity risk to small companies in general, for factors
specific to the Company and the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2013,
Company Management determined that the fair value of its businesses for accounting purposes was equal to its market capitalization
of approximately $19,600,000, which was 128% of the $15,334,507 goodwill and intangible assets on the balance sheet as of December
31, 2013. Based on this determination, Company Management concluded that no impairment had occurred as of December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company utilizes ASC
Topic 740 <I>&ldquo;Accounting for Income Taxes,&rdquo;</I> which requires recognition of deferred tax assets and liabilities for
the expected future tax consequences of events included in the financial statements or tax returns. Under this method, deferred
income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities
and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods
in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce
deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period
and the change during the period in deferred tax assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2013,
the Company had a deferred tax asset of $26,274,933 that was fully reserved and a net operating loss carryforward of $47,728,300
for Federal purposes and $44,482,850 for state tax purposes. The Company will continue to monitor all available evidence and reassess
the potential realization of its deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The net operating loss
carry-forwards for 2013 and 2012 begin expiring in 2021 and 2020, respectively. During 2013, the outstanding shares of common stock
increased from 890,837 to 5,813,785. The utilization of net operating loss carry-forwards is likely to be limited due to this ownership
change under the provisions of Internal Revenue Code Section 382 and similar state provisions. The Company recorded a 100% valuation
allowance on the deferred tax assets at December 31, 2013 and 2012 because of the uncertainty of their realization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock-Based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We follow ASC Topic 718
&ldquo;<I>Share Based Payment,&rdquo;</I> using the modified prospective transition method. New awards and awards modified, repurchased
or cancelled after January&nbsp;1, 2006 trigger compensation expense based on the FV of the stock option as determined by the Black-Scholes
option pricing model. We amortize stock-based compensation for such awards on a straight-line method over the related service period
of the awards taking into account the effects of the employees&rsquo; expected exercise and post-vesting employment termination
behavior. We account for equity instruments issued to non-employees in accordance with ASC Topic 718 and EITF Issue No.&nbsp;96-18.
The FV of each option granted is estimated as of the grant date using the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Advertising</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expense the cost of
advertising as incurred. Such amounts have not historically been significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Reclassifications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain prior year amounts
were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the
net loss or the shareholder&rsquo;s deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Recent Accounting Pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 27, 2012, the FASB
issued ASC 2012-02 &ldquo;<I>Intangibles-Goodwill and Other (Topic 350)&rdquo;</I> Testing Indefinite-Lived Intangible Assets for
Impairment. The ASC provides entities with an option to first assess qualitative factors to determine whether events or circumstances
indicate that it is more likely than not that the indefinite-lived intangible asset is impaired.&nbsp; If an entity concludes that
it is more than 50% likely that an indefinite-lived intangible asset is not impaired, no further analysis is required.&nbsp; However,
if an entity concludes otherwise, it would be required to determine the FV of the indefinite-lived intangible asset to measure
the amount of actual impairment, if any, as currently required under U.S. GAAP. The ASC is effective for annual and interim impairment
tests performed for fiscal years beginning after September 15, 2012.&nbsp; Early adoption is permitted. The adoption of this pronouncement
did not have a material impact on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FASB has issued ASU
No. 2013-04, Liabilities (Topic 405), &ldquo;<I>Obligations Resulting from Joint and Several Liability Arrangements for Which the
Total Amount of the Obligation Is Fixed at the Reporting Date</I>.&rdquo; ASU 2013-04 provides guidance for the recognition, measurement,
and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation
within the scope of this ASU is fixed at the reporting date, except for obligations addressed within existing guidance in US GAAP.
The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the
basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors.
The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15,
2013. The Company does not expect the adoption of this guidance to have a material impact on the Company&rsquo;s consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2013, the FASB
issued ASU 213-11, Income Taxes (Topic 740): &ldquo;<I>Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward,
A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force)</I>&rdquo;. ASU 2013-11
provides guidance on financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar
tax loss, or a tax credit carryforward exists. The FASB&rsquo;s objective in issuing this ASU is to eliminate diversity in practice
resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits
that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This amendment is effective
for public entities for fiscal years beginning after December 15, 2013 and interim periods within those years. The company does
not expect the adoption of this standard to have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed
by management to have a material impact on the Company&rsquo;s present or future consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2013, the Company
signed a term sheet (&ldquo;Term Sheet&rdquo;) with an outside financial firm (&ldquo;Financial Firm&rdquo;) to have that firm
acquire certain portions of the Company&rsquo;s liabilities to creditors, employees and former employees (&ldquo;Creditors&rdquo;).
The Financial Firm entered into agreements in July 2013 with such Creditors to acquire $1,865,386 in liabilities (&ldquo;Liability
Settlement&rdquo;) of the Company and filed a complaint on July 29, 2013 with the Second Judicial Circuit, Leon County, Florida
seeking a judgment against the Company for the Liability Settlement. A court order based on this complaint was issued on October
7, 2013. Based on conditions agreed to in the Term Sheet, the Company will settle that judgment by issuing common stock to the
Financial Firm. Under an exemption from registration in the SEC regulations, common stock issued pursuant to this court order is
tradable without restrictions. This common stock will be issued in tranches such that the Financial Firm will not own more than
9.99% of outstanding shares at any time and will be priced at 80% of average closing bids during such period of time in which the
dollar trading volume of the stock is three times the Liability Settlement (&ldquo;Settlement Period&rdquo;). The Financial Firm
will sell the shares to generate proceeds to pay the Creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until the Financial
Firm repays all the creditors, the Company will have a liability on its balance sheet for the value of amount still owed by
the Financial Firm to the creditors plus 20% to recognize the discount stock owed to the Financial Firm. The selling
activities of the Financial Firm could put downward pressure on the stock price. As of December 31, 2013, the Company had a
liability of $1,854,743 on its balance sheet, which would have required the issuance of 618,248 shares to satisfy this
liability given the $3.00 price for the Company&rsquo;s common stock on that date, or 10.6% of the 5,813,785 shares
outstanding at that time. The Financial Firm held a promissory note for $50,000 that was converted into 8,333 shares of
common stock on October 3, 2013 and received a fee of 1,500 shares of common stock on October 7, 2013 and both were recorded
as consulting fees. An initial tranche of 200,000 shares was issued to the Financial Firm in November 2013 and a subsequent
tranche of 150,000 shares was issued in February 2014. In July 2013, the Company received notice that a complaint for
property damage had been filed by the Truck Insurance Exchange against the Company for $393,592 related to water damage
incurred by a printing company on the ground floor of the Company&rsquo;s former office space in Los Angeles. This damage is
alleged to have occurred in connection with a water leak in the Company&rsquo;s former office in February 2013. The Company
has filed an answer to this complaint that includes, but not be limited to, the defense of culpability of the
building&rsquo;s management in this leak. The Company has a dispute with its insurance carrier at that time regarding
coverage for this incident and the Company intends to pursue this dispute to ensure that it had proper insurance coverage at
that time. The $300,000 accrued for this issue as of December 31, 2012 was increased to $393,592 in the Company&rsquo;s
financial statements as of June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid
Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2013, the Company
entered into an agreement with Maxim Group LLC to provide general financial advisory and investment banking services to the Company
for three years on a non-exclusive basis. Under this agreement, Maxim received common stock equal to 4.99% of the outstanding common
stock of the Company as of that date, or 21,025,000 shares of common stock. These shares were valued at $0.15, which was the closing
price of the Company&rsquo;s common stock on the date of the agreement, for a total expense of $3,153,750. This expense is being
recognized ratably over the life of the three-year term of the agreement at $262,813 per quarter. As of December 31, 2013, $2,628,125
remained in prepaid expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivable
From Former Chairman and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to an investigation
directed by the Company&rsquo;s Board of Directors (&ldquo;Board&rdquo;) in March 2012, it was determined that Paul Feller, the
Company&rsquo;s former chairman and Chief Executive Officer (&ldquo;CEO&rdquo;), received $640,000 in December 2010 in connection
with a sale of the Company&rsquo;s common stock he arranged with outside investors and he caused 25,400 shares of common stock
to be issued directly by the Company while Mr. Feller kept the cash proceeds (the &ldquo;European Transactions&rdquo;). Accordingly,
the Company recorded a gross receivable of $640,000 from Mr. Feller in connection with the European Transactions. Mr. Feller resigned
from the Company on June 28, 2012. During 2012, it was determined that Mr. Feller kept in his possession a vintage automobile that
the Company paid $38,100 for, increasing his receivable to $678,100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2012,
this receivable of $678,100 was increased by $71,946, which is the value of 3,787 shares owed by Mr. Feller to the Company at the
$19.00 closing price of common stock on December 31, 2012, along with $4,622 of personal expenses for Mr. Feller paid with Company
funds. This receivable of $754,668 was presented net of the offset of $538,515 of the receivable related to stock issuance (see
below), $30,540 of approved business expenses and $113,667 in deferred salary. As of December 31, 2013, this receivable was reduced
to $2,020, which is the value of the 673 shares owed by Mr. Feller to the Company at the $3.00 closing price of the Company&rsquo;s
shares as of December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These impacts are summarized
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Gross receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">Sale of Company common stock, net proceeds retained by Mr. Feller</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">640,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">640,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Value of 3,787 shares of common stock owed by Mr. Feller to the Company valued at December 31, 2012 price of $19.00 and 673 shares valued at December 31, 2013 price of $3.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,946</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Vintage automobile retained by Mr. Feller</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;&nbsp;Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">684,742</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">754,668</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Offsets to receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(113,667</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(113,667</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Expense reports submitted and approved</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Net amount owed</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">540,535</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">610,461</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Write off receivable based on stock offsets (a)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(538,515</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(538,515</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net receivable</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,020</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">71,946</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to a Separation
and Release Agreement dated June 28, 2012 and signed by Mr. Feller on August 9, 2012 (&ldquo;Separation Agreement&rdquo;), Mr.
Feller agreed to waive his rights to any deferred salary prior to October 1, 2011. Accordingly, the amount of deferred salary eligible
for an offset to the gross receivable was reduced from $398,790 at December 31, 2011 to $113,667 at December 31, 2012, which is
$125,000 in deferred salary between October 1, 2011 and June 28, 2012, less $11,333 paid in salary during that period. In addition,
Mr. Feller did not submit expense reports to support the $133,770 of expenses in the time provided for in the Separation Agreement,
so that amount was removed as an offset to his receivable as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This offset of the $538,515
receivable from Mr. Feller resulted from the decision by the Company to treat 21,613 shares of stock owed to Mr. Feller from 2008
and 2009 that were approved by the Board but never issued, as having been satisfied when he had the Company issue 25,400 shares
of stock in connection with the European Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The 21,613 shares were
due to Mr. Feller as payment for $2,768,652 in accrued salary, interest, vacation and rental payments for 2008, 2009 and prior
years, and repayment of $729,439 of outstanding loans made by Mr. Feller to the Company in those periods. The Company is satisfied
that it properly recorded and disclosed the 2008 and 2009 transactions in its financial reports filed with the SEC and the only
adjustment needed was to reduce shares outstanding as of December 31 2012 by these 21,613 shares. The Company has accrued the employer
taxes on this taxable income as of December 31, 2012. While Mr. Feller was owed 21,613 shares from 2008 and 2009, he had the Company
issue 25,400 shares related to the European Transactions, leaving a balance due to the Company of 3,787 shares.&nbsp;In consideration
for a legal judgment paid by Mr. Feller, the Company agreed to reduce the number of shares of common stock owed by him to the Company
from 3,787 shares to 673 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2013,
the Company had recorded an accrued expense of $375,000 pursuant to Mr. Feller&rsquo;s consulting agreement that provides for $62,500
per quarter through June 30, 2014, subject to certain conditions. These consulting payments were conditioned on the Company raising
$2,000,000 of equity and that Mr. Feller provide consulting services under this agreement at the direction of the Company&rsquo;s
board of directors. Given that the Company has not raised this amount of equity and given that Mr. Feller has not provided any
consulting services to the Company, the Company elected to reverse this accrued expense, resulting in a gain of $375,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property
and Equipment, Net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Property and equipment were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 36%; text-align: left; text-indent: -10pt; padding-left: 10pt">Computers, peripherals and office machines</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">145,245</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">147,030</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Furniture and fixtures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,833</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">73,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220,935</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(212,816</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(171,897</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Property and equipment, net</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,262</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">49,038</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2013 and 2012, depreciation expense was $40,919 and $26,771, respectively, reflecting accelerated depreciation in 2013 for
assets deemed to have shorter useful lives given the Company&rsquo;s financial situation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Goodwill was $7,642,825
at December 31, 2013 and $1,935,621 at December 31, 2012.&nbsp; Given the Company&rsquo;s decision as of June 30, 2013 to suspend
development of its MMA business, the goodwill for ProElite was considered to be fully impaired as of that date. In accordance with
ASC Topic 350, &ldquo;<I>Intangibles-Goodwill and Other</I>,&rdquo; the Company&rsquo;s goodwill is considered to have indefinite
lives and were therefore not amortized, but rather is subject to annual impairment tests. As of December 31, 2013, Company Management
determined that the fair value of its businesses for accounting purposes was equal to its market capitalization of approximately
$19,600,000, which was 128% of the $15,334,507 goodwill and intangible assets on the balance sheet as of December 31, 2013. Based
on this determination, Company Management concluded that goodwill was not impaired as of December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
Salary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Capital constraints necessitated
that the Company reduce staff starting February 16, 2013 and the Company has not been able to pay employees on a regular basis
since that point, resulting in unpaid salaries of $571,328 and $1,152,933 as of December 31, 2013 and December 31, 2012, respectively,
net of any advances. During 2013 $1,035,514 of deferred salary liability was transferred to a third party</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;Other Accrued
Expenses and Other Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other accrued expenses
and other liabilities consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Payroll related</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">479,087</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">329,191</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Estimated damage liability that may not be covered by insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">393,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Estimated settlement with vendor in Europe</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued board fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,011</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Consultant fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,777</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">109,819</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,697,714</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,683,508</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The estimated damage liability
that may not be covered by insurance was increased to the amount of the legal complaint disclosed in footnote 4 that is related
to this amount. The estimated settlement with vendor in Europe was transferred to a third party. As of December 31, 2013, the Company
had recorded an accrued expense of $375,000 pursuant to Mr. Feller&rsquo;s consulting agreement that provides for $62,500 per quarter
through June 30, 2014, subject to certain conditions. These consulting payments were conditioned on the Company raising $2,000,000
of equity and that Mr. Feller provide consulting services under this agreement at the direction of the Company&rsquo;s board of
directors. Given that the Company has not raised this amount of equity and given that Mr. Feller has not provided any consulting
services to the Company, the Company elected to reverse this accrued consulting liability as of December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payable to Officer and Former
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The amounts payable to an officer and a former
officer pursuant to their employment agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 36%; text-align: left">Officer pursuant to employment agreement</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">156,358</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">156,358</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Promissory note to former officer</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">55,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">156,358</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">211,358</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
2010 employment agreement for its then Senior Vice President and Chief Operating Officer, the Company owed this former officer
$55,000, which is the remaining portion of a promissory note assumed by the Company in connection with this employment agreement.
This liability was transferred to a third party during 2013. In connection with the 2010 employment agreement for the Company&rsquo;s
Chief Financial Officer, the Company owes this officer $156,358 for unpaid amounts consisting of consulting fees prior to employment,
expenses, salary increases and signing bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes Payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Notes payable were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Notes payable from ProElite to various individuals dated October 20, 2011 with
    maturity of July 20, 2012, plus interest at 8%, convertible into common stock of ProElite at noteholder's
    election.&nbsp;Secured by the assets of ProElite. These notes were converted into common stock in November 2013.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,063,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to a shareholder with original maturity of May 24, 2012, plus interest at 0.19%, that was secured by the assets of ProElite.&nbsp;This note was converted into common stock in May 2013.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable from ProElite to one party dated October 19, 2012 with original maturity of October 19, 2013.&nbsp;Bears interest at 7% and was secured by the assets of ProElite.&nbsp;This note was converted into common stock in May 2013.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's outside law firm and represents the corporate and litigation fees due as of June 30, 2012.&nbsp;This note originally bore interest at 3% and was due December 31, 2012.&nbsp;Starting on January 1, 2013, this note bears interest at 10%.&nbsp;This note is currently in default.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">486,104</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Notes payable to three holders dated May 11, 2012 with original maturity of the earlier of November 11, 2012 and was secured by the assets of the Company.&nbsp;This note was converted into common stock in May 2013.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Notes payable to 11 investors dated July 9, 2012 with maturity date on the earlier of a $2 million capital raise by the company, or February 6, 2013 and bears interest at 8%.&nbsp;$225,000 of these notes were converted by 9 investors to common stock in November 2013.&nbsp;The remaining two notes are currently in default.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Notes payable to one holder dated April 4, 2012 with original maturity on October 4, 2012 that was changed to January 4, 2013.&nbsp;This note was converted into common stock in May 2013.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,999</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Notes payable to a director of the Company dated March 5, 2013 with maturity on the earlier of September 5, 2013 or receipt by the Company of $200,000 in net proceeds from a private placement of Company securities.&nbsp;This note does not bear interest and is not secured.&nbsp;This note is currently in default.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to a high-yield fund.&nbsp;This note bears interest at 10% and matures on June 19,
    2014. Upon the closing of a financing of at least $7,500,000 on or before the applicable maturity date, this note will be
    converted into securities issued in such financing at a conversion price equal to 50% of the purchase price per share or unit
    of the securities.&nbsp;This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's chairman of the board dated August 9, 2013. Bears interest at 7% and matures on August 9, 2014. Contains mandatory conversion into security or securities totaling $10 million or more at the lesser of 50% of the selling price of such securities or the equivalent of $0.04 per share of common stock. This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's chairman of the board dated December 19, 2013.&nbsp;This note bears interest at 10% and matures on June 19, 2014.&nbsp;Upon the closing of a financing&nbsp;of at least $7,500,000 on or before the applicable maturity date, this note will be converted into securities issued in such financing at a conversion price equal to 50% of the purchase price per share or unit of the securities.&nbsp;This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to a shareholder dated January 14, 2005, with original maturity of May 14, 2005, plus interest at 10%.&nbsp;Unsecured.&nbsp;This note was written off in June 2013.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Note payable to a shareholder dated February 1, 2005 with original maturity of June 1, 2005, plus interest at 10%.&nbsp;Unsecured.&nbsp;This note was written off in June 2013.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,867,002</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,004,103</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The notes of $70,000 and
$10,000 outstanding as of December 31, 2012 were written off in June 2013 since there have been no actions taken to collect on
these notes and the statute of limitations for collecting on these notes has passed. The gain of $80,000 for the writeoff of these
notes was reflected in other income for the year ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expense on these
notes was $228,294 in 2013 and $167,894 in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation to issue stock for
transfer of liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2013, the Company
signed a term sheet (&ldquo;Term Sheet&rdquo;) with an outside financial firm (&ldquo;Financial Firm&rdquo;) to have that firm
acquire certain portions of the Company&rsquo;s liabilities to creditors, employees and former employees (&ldquo;Creditors&rdquo;).
The Financial Firm entered into agreements in July 2013 with such Creditors to acquire $1,865,386 in liabilities (&ldquo;Liability
Settlement&rdquo;) of the Company and filed a complaint on July 29, 2013 with the Second Judicial Circuit, Leon County, Florida
seeking a judgment against the Company for the Liability Settlement. A court order based on this complaint was issued on October
7, 2013, resulting in the transfer of these $1,865,386 million of liabilities to the Financial Firm (see Footnote 4 for additional
information). Of the amount transferred to the Financial Firm, $1,035,514 was related to deferred salary and paid time off for
current and former employees and $829,872 was for amounts owed to vendors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on conditions agreed
to in the Term Sheet, the Company will settle that judgment by issuing common stock to the Financial Firm. Under an exemption from
registration in the SEC regulations, common stock issued pursuant to this court order is tradable without restrictions. This common
stock will be issued in tranches such that the Financial Firm will not own more than 9.99% of outstanding shares at any time and
will be priced at 80% of average closing bids during such period of time in which the dollar trading volume of the stock is three
times the Liability Settlement (&ldquo;Settlement Period&rdquo;). The Financial Firm will sell the shares to generate proceeds
to pay the Creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until the Financial Firm
repays all the creditors, the Company will have a liability on its balance sheet for the value of amount still owed by the Financial
Firm to the creditors plus 20% to recognize the discount stock owed to the Financial Firm. The selling activities of the Financial
Firm could put downward pressure on the stock price. As of December 31, 2013, the Company had a liability of $1,854,743 on its
balance sheet, which would have required the issuance of 618,248 shares to satisfy this liability given the $3.00 price for the
Company&rsquo;s common stock on that date, or 10.6% of the 5,813,785 shares outstanding at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Financial Firm held
a promissory note for $50,000 that was converted into 8,333 shares of common stock on October 3, 2013 and received a fee of 1,500
shares of common stock on October 7, 2013 and both were recorded as consulting fees. An initial tranche of 200,000 shares was issued
to the Financial Firm in November 2013 and a subsequent tranche of 150,000 shares was issued in February 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2011, the Company
entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with eight investors (collectively, the &ldquo;Investors&rdquo;)
pursuant to which the Company sold 8,700 shares of a new series of convertible preferred stock designated as Series E Convertible
Preferred Stock (&ldquo;Original Series E&rdquo;), the terms of which are set forth in the Certificate of Designations of Series
E Preferred Stock (the &ldquo;Certificate&rdquo;), for $1,000 per share, or $8,700,000. In October 2012, the Company sold 1,000
shares of Series E for $1,000,000 (&ldquo;New Series E&rdquo;). The Original Series E and New Series E together are referred to
herein as &ldquo;Series E.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These Series E contained
&ldquo;full ratchet-down&rdquo; liquidity protection that provided that if the Company issues securities for less than the existing
conversion price for the Series E Preferred Stock or the strike price of the Series E warrants, then the conversion price for Series
E Preferred Stock will be lowered to that lower price. Also, the strike price for Series E warrants were decreased to that lower
price and the number of Series E warrants will be increased such that the product of the original strike price times the original
quantity equaled the lower strike price times the higher quantity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequent to the issuance
of this Series E, the Company determined that the warrants for these financings included certain embedded derivative features as
set forth in ASC Topic 815 and that this conversion feature of the Series E was not an embedded derivative because this feature
was clearly and closely related to the host (Series E) as defined in ASC 815. These derivative liabilities were initially recorded
at their estimated FV on the date of issuance and were subsequently adjusted each quarter to reflect the estimated fair value at
the end of each period, with any decrease or increase in the estimated FV of the derivative liability for each period being recorded
as other income or expense. Since the value of the embedded derivative feature for the related warrants was higher than the value
of both Series E transactions, there was no beneficial conversion feature recorded for either transaction, and the excess of the
value of the embedded derivative feature over the value of the transaction was recorded in each period on the Statement of Operations
as a separate line item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of these
derivative liabilities was calculated using the Black Scholes pricing model that was based on the closing price of the common stock,
the strike price of the underlying instrument, the risk-free interest rate for the applicable remaining life of the underlying
instrument (i.e., the U.S. treasury rate for that period) and the historical volatility of the Company&rsquo;s common stock. These
fair value results were extremely sensitive to all these input variables, particularly the closing price of the company&rsquo;s
common stock and the volatility of the Company&rsquo;s common stock. Accordingly, the fair value of these derivative liabilities
were subject to significant changes.&nbsp; During 2013, the Series E and related warrants were converted into common stock and
extinguished and the company recorded a gain of $8,980,077 on the decrease in fair value for the derivative security and recorded
a gain of $1,635,967 on extinguishment of the derivative liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following assumptions
were used to calculate the Black Scholes values of this derivative liability as of the measurement dates of March 31, 2013 and
as of May 6, 2013. The fair value of the underlying common stock was based on the sale of 139,166 shares of common stock at $3.00
by the Company during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 82%"><font style="font-size: 10pt">Remaining life in years</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">3.05 - 3.15</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.35% - 0.38%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">141% - 142%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder&rsquo;s
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following a majority vote
of shareholders to approve, an information statement was distributed to shareholders of record as of June 30, 2013. After the appropriate
waiting period after such mailing, the authorized number of shares was increased from 500,000,000 to 1,000,000,000 in August 2013.
During the 2013, the Company issued a total of 4,922,948 shares of Common Stock, resulting in an increase in outstanding shares
from 890,836 shares as of December 31, 2012 to 5,813,785 shares as of December 31, 2013:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of Common Shares</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 63%"><font style="font-size: 10pt">Balance at December 31, 2012</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">890,837</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Conversion of Series E Preferred to common stock</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,575,000</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Shares issued for acquisition</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,150,116</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Conversion of warrants to common stock</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,023,264</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Conversion of debt to common stock</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">576,331</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Issuance of shares for advisory agreements</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">243,250</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Issuance of shares to third party for assumption of liabilities</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">200,000</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Issuance of common stock for cash</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">142,501</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Other</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">12,486</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at December 31, 2013</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,813,785</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="color: red; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Series C 10% Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no shares of
Series C 10% Preferred Stock outstanding as of December 31, 2013 or December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Series D 10% Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2013
and 2012, 0 and 18,999 shares of Series D were outstanding, respectively. Each share of Series D sold for $30, could be converted
at any time into 0.6 shares of common stock and had voting rights equal to 0.6 shares of common stock. In connection with the issuance
of Series D, the Company issued warrants to purchase 1,799 shares of common stock. The warrants have a life of five years to purchase
a share of common stock for $100 per share. The Series D had liquidation preference over common stock at a liquidation value equal
to its par value of $30 and paid a cumulative dividend of 10% per year. Given the losses recorded by the Company, the stock equivalents
related to the Series D are not included in the calculation of earnings per share since the effect of such inclusion would be antidilutive.
During 2013, 18,999 shares of Series D were converted into a total of 14,138 shares of common stock: 11,399 shares for direct conversion
of the Series D into common stock, 2,528 shares for dividends and 211 shares for the price protection feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Series E 5% Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2013
and December 31, 2012, there were 0 and 9,450 shares of Series E were outstanding, respectively. On May 6, 2013 all shares of Series
E were exchanged for 1,575,000 shares of common stock and were extinguished, thereby removing the &ldquo;overhang&rdquo; created
by the terms of the Series E that provided for the conversion price into common stock to be reduced to the price of any subsequent
financing done at a lower price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October 2012, the Company
raised $870,000 through the issuance of 1,000 shares of Series E 5% Preferred Stock (&ldquo;Series E&rdquo;) and common stock and
warrants to purchase shares of common stock at $0.65 to $1.00.&nbsp; On May 24, 2011, the Company entered into a Securities Purchase
Agreement (the &ldquo;Purchase Agreement&rdquo;) with eight investors (collectively, the &ldquo;Investors&rdquo;) pursuant to which
the Company sold 8,700 shares of a new series of convertible preferred stock designated as Series E Convertible Preferred Stock
(&ldquo;Original Series E&rdquo;), the terms of which are set forth in the Certificate of Designations of Series E Preferred Stock
(the &ldquo;Certificate&rdquo;), for $1,000 per share, or $8,700,000. In October 2012, the Company sold 1,000 shares of Series
E for $1,000,000 (&ldquo;New Series E&rdquo;). The Original Series E and New Series E together are referred to herein as &ldquo;Series
E&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
sale of the Series E, the Company also agreed to issue to the Investors (a) warrants (&ldquo;A Warrants&rdquo;) to purchase up
to one additional share of Common Stock for each share of Common Stock issuable upon conversion of the Preferred Shares, and (b)
warrants (&ldquo;B Warrants&rdquo;) to purchase up to 0.50 additional shares of Common Stock for each share of Common Stock issuable
upon conversion of the Preferred Shares. The Warrants were exercisable for five years commencing on the date of first issuance.
For the Original Series E, exercise price of the A Warrant was $65.00 per share and the B Warrant had an exercise price of $100.00
per share, subject in each case to full ratchet anti-dilution protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Original Series E were
adjusted pursuant to the full ratchet anti-dilution protection when $249,999 of notes were issued on April 4, 2012 that contained
a $3.00 conversion feature, so that the Original Series E had a conversion price of $3.00 and an exercise price of $3.00 for the
warrants. The New Series E were issued with a conversion and exercise price of $30.00 for the warrants. The impact of this ratchet-down
provision in April 2012 increased the number of shares that would be issued upon conversion on that date from 211,250 shares of
common stock to 281,667 and to increase the number of shares that would be issued upon full exercise of the warrants on that date
from 379,750 shares of common stock to 949,667. All of the Series E have been converted into the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 27, 2013 the Board
approved an option to the Company&rsquo;s CEO to purchase 250,000 shares of common stock at $3.00 and an option to the Company&rsquo;s
General Counsel to purchase 60,000 shares of common stock at $3.00. These options have a five-year life and vested in the three
months ended June 30, 2013, resulting in Black Scholes option expense of $824,600 for this quarter. The Black Scholes expense for
these March 27, 2013 options was calculated using the following assumptions. The fair value of the underlying common stock was
based on the sale of 139,167 shares of common stock at $3.00 by the Company during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 82%"><font style="font-size: 10pt">Remaining life</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.35%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">141%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2012, the Company
cancelled 46,609 options for employees whose employment had been terminated and granted 23,000 options to Jerold Rubinstein, the
Company&rsquo;s new Chairman of the Board and CEO on June 28, 2012, pursuant to an employment contract, 4,500 options to a director
and 3,000 options to an officer. These options have a strike price of $35.00 - $38.00, which were the closing prices of the Company&rsquo;s
common stock on the day of grant and a five-year life. Mr. Rubinstein&rsquo;s options vest monthly over a 12-month period unless
the employment contract is terminated for any reason, at which time the options vest in full. The director&rsquo;s options vest
ratably over a 36-month period, and the officer&rsquo;s options vest one third at grant, one third after the first year and one
third after the second year. The Black Scholes value of these options was $706,250 which is being amortized over the respective
vesting periods. The Black Scholes expense for these 2012 options was calculated using the following assumptions. The fair value
of the underlying common stock was determined by closing price on the Bulletin Board stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$35.00 - $38.00</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 82%"><font style="font-size: 10pt">Remaining life</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.69% - 0.80%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80% - 89%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth the activity
of our stock options to purchase common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Options&nbsp;Outstanding</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Options&nbsp;Exercisable</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Range&nbsp;of</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Options</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Options</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Outstanding</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Prices</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Price</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercisable</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Price</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt"><b>As of December 31, 2011</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>121,699</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>$14.00 - $150.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>2.9</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$49.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>87,577</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>2.9</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>40.00</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="width: 26%"><font style="font-size: 10pt">Cancelled</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">(72,763</font></td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">)</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">(46,610</font></td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">)</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD><font style="font-size: 10pt">Granted</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">30,500</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt">$35.00 - $38.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$36.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">16,343</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">36.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt"><b>As of December 31, 2012</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>79,436</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>$35.00 - $54.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.0</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$46.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>57,310</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>2.6</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>48.00</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD><font style="font-size: 10pt">Cancelled</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD><font style="font-size: 10pt">Granted</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">310,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">310,000</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt"><b>As of December 31, 2013</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>389,436</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$0.03 - $0.54</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.9</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$11.77</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>367,310</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.9</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$11.10</b></font></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2013 the Board approved
warrants to three financial advisors to purchase 173,917 shares of common stock at $3.00. These warrants have a five-year life
and vested immediately, resulting in Black Scholes warrant expense of $462,618. The Black Scholes expense for these March 27, 2013
warrants was calculated using the following assumptions. The fair value of the underlying common stock was based on the sale of
139,167 shares of common stock at $3.00 by the Company during the three months ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 82%"><font style="font-size: 10pt">Remaining life</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.35%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">141%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2013 Series E warrants,
along with related warrants with similar terms, were exchanged for 1,023,264 shares of common stock and these warrants were extinguished,
thereby removing the &ldquo;overhang&rdquo; created by the full-ratchet provisions of these warrants that would have increased
the number of warrants outstanding and reduced the strike price of these warrants to the price of any subsequent financing done
at a lower price. This exchange of common stock for the Series E warrants resulted in a fair value charge of $3,069,792 in 2013.
These 1,023,264 shares of common stock were valued at $3.00 per share, which was the price at which the Company sold 139,167 shares
during 2013, resulting in the fair value charge for $3,069,792.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2012, the Company
issued warrants to purchase 50,000 shares of common stock at $30.00 in connection with the sale of 1,000 shares of Series E. The
Original Series E were adjusted pursuant to the full ratchet anti-dilution protection when $249,999 of notes were issued on April
4, 2012 that contained a $30.00 conversion feature, so that the Original Series E now has an exercise price of $0.30 for the warrants.
The New Series E was issued with an exercise price of $30.00 for the warrants. The Company also issued six five-year warrants to
purchase 135,300 shares at $38.00 to $75.00 in connection with consulting and advisory contracts. The Black Scholes value of these
warrants is $4,133,690, which is being recognized over the 12 months of the contracts. The Black Scholes expense for these 2012
warrants was calculated using the following assumptions. The fair value of the underlying common stock was determined by closing
price on the Bulletin Board stock exchange.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 82%"><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">$38.00 - $75.00</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Remaining life</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.74% - 1.80%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84% - 132%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of the warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Warrants&nbsp;Outstanding </b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Warrants&nbsp;Exercisable </b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted&nbsp;&nbsp;</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Weighted </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Range of</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Remaining </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Average </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Warrants </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Exercise </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Warrants </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Life&nbsp;in </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Exercise </b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Outstanding </b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Prices</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Price </b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercisable </b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Years </b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Price </b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>As of December 31, 2011</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>595,302</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>$65.00 - $200.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.2</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$200.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>595,302</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.2</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$200.00</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="width: 26%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercised</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Ratchet-down impact</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">569,917</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">569,917</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">157,633</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt">$30.00 - $75.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.3</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$38.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">103,883</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.3</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>As of December 31, 2012</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>1,322,852</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>$30.00 - $200.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.2</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$40.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>1,269,102</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.2</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$38.00</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(978,700</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(939,950</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Ratchet-down impact</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Granted</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">173,917</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">173,917</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>As of December 31, 2013</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>518,069</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>$3.00 - $200.00</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.3</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$44.07</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>503,069</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.3</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$44.07</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Office Space Rental</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 1, 2009, we entered
into a lease for 1,800 square feet of office space in Santa Barbara, California for use as our executive offices. This lease was
amended on July 21, 2009 and expired on December 31, 2013 with a three-year renewal term available at an initial rent plus common
area charges of $5,767 per month. This property was vacated in August 2012 and the Company has recorded a liability of $139,000
to cover unpaid rent and the present value of rents due for the remainder of the lease term. During 2013, a settlement amount of
$110,700 was negotiated with the lease holder and transferred to a third party, resulting in a reduction of the accrued liability
of $139,150.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2011, we entered
into a lease for&nbsp;7,000 square feet of office space in Los Angeles, California. The lease continues through November 30, 2014.
Initially, the lease had a fixed monthly rent of $19,326 and was subject to annual increases of 3%. The Company was not required
to pay a fixed monthly rent for months two through five. Prior to this, the Company was leasing the same office space on a month-to-month
basis. This property was vacated in April 2012 and the Company recorded a liability of $892,000 to cover unpaid rent and the present
value of rents due for the remainder of the lease term. As of April 2013, this space was released, but the terms and conditions
of the new lease are unknown, so the Company did not adjust the accrued liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp; &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2011, we
entered into a lease for 3,000 square feet of office space in Santa Barbara, California for use by our operating units. This lease
expires on October 31, 2014 with two additional three-year renewal terms available. The initial rent plus common area charges were
$7,157 per month. This property was vacated in June 2012 and the Company recorded a liability of $229,000 to cover unpaid rent
and the present value of rents due for the remainder of the lease term. As of June 2013, this space was released, but the terms
and conditions of the new lease are unknown, so the Company did not adjust the accrued liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From May 2012 to May 2013,
the Company was in a month-to-month lease for office space in Los Angeles, California. Rent for this facility was $2,300 per month.
Given reductions in staff, the Company is now operating with a &ldquo;virtual office.&rdquo; The Company believes this virtual
office structure is adequate for our current needs and suitable additional or substitute space will be available as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Contractual Obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Set forth below is information
concerning our known contractual obligations as of December 31, 2013 that are fixed and determinable by year starting with the
year ending December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2017 and</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Later</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 30%; text-align: left; text-indent: -10pt; padding-left: 10pt">Notes Payable</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,867,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,867,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Rent Obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,121,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">878,546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred Salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,472</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,472</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Employee Contracts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,931,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,181,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,341,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,273,732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Employee Contracts: Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">156,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">156,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,736,811</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,744,117</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,583,949</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,273,732</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">135,013</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Employment Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective June 28, 2012,
Jerold Rubinstein was elected by the Board as Chairman of the Board, CEO and a director of the Company&rsquo;s subsidiaries. The
Board of Directors of PEI also elected him as Chairman of the Board and CEO of PEI. Under the terms of an employment agreement
dated June 28, 2012, Mr. Rubinstein will receive an annual salary of $250,000 per year. Mr. Rubinstein continues to serve on the
Board and receive $50,000 annually for such services, along with $100,000 annually as Chairman of the Board. The term of this agreement
is six months with an automatic six month extension unless the Company provides written notice of non-renewal 30 days prior to
the end of the initial six-month term. This executive was granted options to purchase 2,300,000 shares of the Company&rsquo;s common
stock at $0.35 per share, which was the closing price of the Company&rsquo;s common stock on the day of option grant. These options
vest monthly over a 12-month period. In the event the Company does not renew the second six month period, the executive resigns
or the Company terminates the executive&rsquo;s employment without cause, all options will immediately vest and the executive will
receive all unpaid salary for the full 12 month period. In March 2013, Mr. Rubinstein received an option grant to purchase 25,000,000
shares at $0.03 with a five-year life and vesting occurring in the three months ended June 30, 2013. Mr. Rubinstein&rsquo;s contract
expired on June 28, 2013 and he is currently working without a contract. As of December 31, 2013, Mr. Rubinstein was owed unpaid
salary of $36,458 and unpaid board fees of $199,771.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2011, the
Company entered into any employment contract with Timothy Boris as the Company&rsquo;s General Counsel and Vice President of Legal
Affairs at an annual salary of $180,000. In December 2011 received options to purchase 300,000 shares of common stock at $0.54
that had 100,000 shares vested upon grant, 100,000 shares vested at the end of year one and 100,000 shares vest at the end of year
two. This contract expired on August 8, 2012 and was renewed under the same terms until August 8, 2013. In August 2012 Mr. Boris
received options to purchase 300,000 shares of common stock at $0.38 that had 100,000 shares vest upon grant, 100,000 shares vest
at the end of year one and 100,000 shares vest at the end of year two. Both of these option grants have a five-year life. In March
2013, Mr. Boris received an option grant to purchase 6,000,000 shares at $0.03 with a five-year life and vesting occurring in the
three months ended June 30, 2013. Mr. Boris&rsquo;s contract expired on August 8, 2013 and he is currently working without a contract.
As of December 31, 2013, Mr. Boris was owed unpaid salary of $75,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2010, the
Company entered into an employment agreement with John Moynahan, who provided accounting and financial services to the Company
as a consultant pursuant to a consulting agreement dated November 14, 2007. Under the agreement, Mr. Moynahan was to receive an
annual salary of&nbsp;$220,000 for the first year of the contract, subject to an annual increase of the Consumer Price Index plus
2%, and will be eligible for a $50,000 bonus in the first year of this contract. Under this agreement, Mr. Moynahan received a
grant of 3,000 shares and a five-year stock option grant to purchase 15,600 shares of common stock at $200.00 per share, with 10,400
shares that vested upon the signing of the agreement and 5,200 shares that vested on September 1, 2011. The strike price on these
options was adjusted to $54.00 in December 2011 by the Board. After a review of this contract during 2012, the Company determined
that the non-salary amounts due to Mr. Moynahan were $156,358 as of December 31, 2012.&nbsp; Mr. Moynahan&rsquo;s contract expired
on August 1, 2012 and he is currently working without a contract. As of December 31, 2013, Mr. Moynahan was owed the $156,358 under
his employment contract and $87,083 in unpaid salary, not including any other claims that Mr. Moynahan may have under his employment
contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 22, 2010, the
Company entered into an employment contract with William Kelly, the Company&rsquo;s former Senior Vice President and Chief Operating
Officer of ProElite, and the Chief Operating Officer of the Company whose employment was terminated in March 2013. In connection
with Mr. Kelly&rsquo;s employment, the Company assumed a promissory note of $231,525 formerly owed to Mr. Kelly by ProElite, Inc.
and agreed to pay the promissory note with $121,525 payable to Mr. Kelly upon the closing of the acquisition of ProElite by the
Company, $55,000 due 90 days after the closing of the acquisition, and $55,000 due 180 days after the closing of the acquisition.
In 2011, $176,525 of these amounts were paid to Mr. Kelly. During 2013, this $55,000 obligation to Mr. Kelly was transferred to
a third party.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Consulting Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 28, 2012, Paul
Feller, the Company&rsquo;s former Chairman of the Board and CEO, resigned from all positions with the Company and its subsidiaries,
including PEI. In connection therewith, pursuant to a Separation and Release Agreement, the Company and Mr. Feller entered into
a new Consulting Agreement for a term of two years at an annual compensation of $250,000, As of December 31, 2013, the Company
had recorded an accrued expense of $375,000 pursuant to Mr. Feller&rsquo;s consulting agreement that provides for $62,500 per quarter
through June 30, 2014. These consulting payments were conditioned on the Company raising $2,000,000 of equity and that Mr. Feller
provide consulting services under this agreement at the direction of the Company&rsquo;s board of directors. Given that the Company
has not raised this amount of equity and given that Mr. Feller has not provided any consulting services to the Company, the Company
elected to reverse this accrued expense.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment
Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2013, ProElite, Stratus
White and Hygeia/Canterbury were considered operating segments pursuant to ASC Topic 280 <I>&ldquo;Segment Reporting&rdquo; </I>since
each was budgeted separately and tracked separately to provide the chief operating decision maker information to assess and manage
ProElite, Stratus White and Hygeia/Canterbury. In 2012, ProElite and Stratus White were considered operating segments. In 2012,
the Company decided to suspend development of all business activities other than ProElite and effective June 30, 2013, the Company
decided to suspend development of its ProElite business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of results by segments is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">As of/for the Year Ended December 31, 2013</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">As of /for the Year
    Ended December 31, 2012</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stratus Rewards </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;ProElite </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Life Sciences</FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;Other </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;Total </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stratus Rewards </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;ProElite </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Other Events </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;Other </FONT></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;Total </FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="width: 20%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>

<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Revenues</FONT></td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">375</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">375</FONT></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Cost of sales</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">236</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">236</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Gross margin</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">139</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">139</FONT></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Deprec. &amp; Amort</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">87</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">587</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">676</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Segment profit</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(87</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(587</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(604</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">137</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(32</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">105</FONT></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Operating expenses</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">85</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">192</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">80</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12,371</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12,728</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,724</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">990</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9,183</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11,897</FONT></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Other (income) expenses</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(714</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">643</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(71</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">97</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,763</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,859</FONT></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Impact of derivative
    securities</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(10,459</FONT></td>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(10,459</FONT></td>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,801</FONT></td>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,801</FONT></td>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(85</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">592</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(167</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(3,142</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,802</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(1,724</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(950</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,177</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,850</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Net loss attributable to non-controlling
    interests</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;(19</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;(19</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Preferred dividend</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(172</FONT></td>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(172</FONT></td>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">497</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">497</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Net loss attributable
    to common shareholders</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(85</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">592</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(167</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,976</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,636</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(1,724</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(950 </FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,693</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(7,366</FONT></td>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Assets</FONT></td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">230</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">572</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,542</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18,344</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,161</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">285</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,446</FONT></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Liabilities</FONT></td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">52</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,779</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">587</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,460</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,878</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">122</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,632</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,271</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15,828</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,853</FONT></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Significant components
of the Company's deferred tax assets for federal income taxes consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 36%; text-align: left">Net operating loss carryforward</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">21,492,311</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">18,050,294</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(823,367</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(580,145</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,841,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">904,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">883,794</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Deferred state tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,904,277</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(477,307</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449,209</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,274,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,230,179</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company had net operating loss carry-forwards
(&ldquo;NOL&rdquo;) for federal and state income tax purposes of approximately:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2013</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt"><b>Combined NOL Carryforwards:</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 36%"><font style="font-size: 10pt">Federal</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">47,728,300</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">40,240,679</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">California</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">44,482,850</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">36,995,229</font></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The net operating loss
carry-forwards for 2013 and 2012 begin expiring in 2021 and 2020, respectively. During 2013, the outstanding shares of common stock
increased from 890,837 to 5,813,785. The utilization of net operating loss carry-forwards is likely to be limited due to this ownership
change under the provisions of Internal Revenue Code Section 382 and similar state provisions. The Company recorded a 100% valuation
allowance on the deferred tax assets at December 31, 2013 and 2012 because of the uncertainty of their realization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation of the
income tax credit computed at the federal statutory rate to that recorded in the financial statements for 2013 and 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2013</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt"><b>Rate reconciliation:</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%"><font style="font-size: 10pt">Federal tax benefit at statutory rate</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">(922,591</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">(&nbsp;&nbsp;35.0%</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">(2,578,121</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">( 35.0%</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">State tax, net of Federal benefit</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(761,237</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">28.9%</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(782,767</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10.6%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Change in valuation allowance</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,044,754</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(267.3%</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,495,845</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(74.6%</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Derivative accounting and other</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(5,360,926</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">273.4%</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(2,134,957</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)&nbsp;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">99.0%</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total provision</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&ndash;%</font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&ndash;%</font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro Forma Financials for Acquisition
of Canterbury and Hygeia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective September 30,
2013, the Company entered into a Merger Agreement with Canterbury Acquisition LLC, a wholly owned subsidiary of the Company, Hygeia
Acquisition, Inc., a wholly-owned subsidiary of the Company, Canterbury, Hygeia and Yael Schwartz, Ph.D., as Holder Representative,
pursuant to which the Company acquired all of the capital stock of Canterbury and Hygeia with Canterbury and Hygeia becoming wholly-owned
subsidiaries of the Company. The Mergers were closed on November 18, 2013 and 1,150,115 shares were issued to the stakeholders
of Canterbury and Hygeia. The Mergers are subject to rescission if RestorGenex has not raised $7.5 million or more in gross financing
proceeds by April 30, 2014. The Company has consolidated the balance sheets of Canterbury and Hygeia as of December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Mergers had occurred
on January 1, 2012, the combined statement of operations for the year ended December 31, 2013 would be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RestorGenex Corporation, Canterbury and Hygeia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pro Forma Income Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Year Ended December 31, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31, 2013 (a)</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Adjustments</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Other</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>for&nbsp;Canterbury</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>RestorGenex</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>and Hygeia (b)</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Adjustments</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Combined</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Audited)&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 51%"><font style="font-size: 10pt"><b>Revenues</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">71,667</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">127,167</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">198,834</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt"><b>Cost of revenues</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">89,387</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">89,387</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt"><b>Gross profit</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>71,667</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>37,780</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>109,447</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt"><b>Operating expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">General, administrative, research and development</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">2,008,118</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">265,260</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">503,732</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(c)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">2,777,110</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">Impairment of intangible assets</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,935,621</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,935,621</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">Warrants, options and stock</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4,228,317</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4,228,317</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">Fair value of common stock exchanged for warrants</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">3,069,792</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">3,069,792</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">Legal and professional services</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,071,392</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">326,646</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,398,038</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">Depreciation and amortization</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">675,757</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">14,781</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">659,958</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">(d)</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,350,496</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Total operating expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>12,988,997</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>606,687</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>1,163,690</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>14,759,374</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt"><b>Loss from operations</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(12,917,330</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(568,907</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(1,163,690</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(14,649,927</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt"><b>Other (income)/expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt"><font style="font-size: 10pt">(Gain)/loss on adjustments to fair value of derivative liability</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(8,980,077</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(8,980,077</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">Gain on extinguishment of derivative liability</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,183,093</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,183,093</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt">Other (income)/expenses</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(524,505</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(524,505</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">Interest expense</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">228,294</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">20,267</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">248,561</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Total other (income)/expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(10,459,381</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>20,267</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(10,439,114</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt"><b>Net loss</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(2,457,949</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(589,174</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,163,690</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(4,210,813</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">Net loss attributed to non-controlling interests</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(6,401</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(6,401</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Net loss attributed to RestorGenex Corporation</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(2,464,350</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(589,174</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(1,163,690</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(4,217,214</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Preferred dividends</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">171,625</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">171,625</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Net income/(loss) attributable to RestorGenex Corporation common shareholders</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(2,635,975</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(589,174</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,163,690</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(4,388,839</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Basic and diluted earnings per share</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1.00</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1.20</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt"><b>Basic and fully-diluted weighted average shares outstanding</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,646,603</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>1,014,623</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">(e)</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,661,226</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <TD STYLE="width: 4%"><font style="font-size: 10pt">(a)</font></td>
    <TD STYLE="width: 96%; text-align: justify"><font style="font-size: 10pt">Assumes the mergers with Canterbury and Hygeia occurred on January 1, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(b)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Results of operations from January 1, 2013 to November 18, 2013, when the mergers were closed.</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(c)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact of employment agreements from January 1, 2013 to November 18, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(d)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact of amortization of intangible assets from January 1, 2013 to November 18, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(e)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact on weighted average shares if the 1,150,116 shares issued for the mergers were outstanding for the full year.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Mergers had occurred
on January 1, 2012, the combined statement of operations for the year ended December 31, 2012 would be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RestorGenex Corporation, Canterbury and Hygeia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pro Forma Income Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Year Ended December 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31, 2012 (a)</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Other</b></font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Canterbury</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>RestorGenex</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>and Hygeia</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Adjustments</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Combined</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(Audited)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 51%"><font style="font-size: 10pt"><b>Revenues</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">374,542</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">246,731</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 2%; text-align: right">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt">621,273</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>Cost of revenues</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">235,803</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">123,374</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">359,177</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>Gross profit</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>138,739</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>123,357</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>262,096</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Operating expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">General, administrative, research and development</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">4,570,161</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">324,261</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">503,732</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(b)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">5,398,154</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Impairment of intangible assets</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,423,844</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,423,844</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Warrants, options and stock</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">3,643,662</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">3,643,662</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Legal and professional services</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">2,128,898</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">77,965</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">2,206,863</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Depreciation and amortization</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">164,043</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">17,196</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">747,276</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">(c)</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">928,515</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt; padding-left: 11pt"><font style="font-size: 10pt"><b>Total operating expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>11,930,608</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>419,422</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>1,251,008</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>13,601,038</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Loss from operations</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(11,791,869</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(296,065</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(1,251,008</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(13,338,942</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Other (income)/expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Fair value of derivative liabilities in excess of proceeds</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">408,501</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">(Gain)/loss on adjustments to fair value of derivative liability</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(6,907,748</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(6,907,748</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Other (income)/expenses</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">379,188</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">379,188</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Present value of remaining lease payments for facilities no longer occupied</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,010,111</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Interest expense</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">167,894</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">167,894</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt; padding-left: 11pt"><font style="font-size: 10pt"><b>Total other (income)/expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(4,942,054</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(6,360,666</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt"><b>Net loss</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(6,849,815</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(296,065</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,251,008</font></td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(6,978,276</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 22pt; text-indent: -11pt"><font style="font-size: 10pt">Net loss attributed to non-controlling interests</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,079</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,079</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Net loss attributed to RestorGenex Corporation</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(6,868,894</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(296,065</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(1,251,008</b></font></td>
    <TD STYLE="text-align: left"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(6,997,355</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Preferred dividends</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">497,167</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">497,167</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Net income/(loss) attributable to RestorGenex Corporation common shareholders</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(7,366,061</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(296,065</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,251,008</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(7,494,522</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Basic and diluted earnings per share</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(8.16</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(3.65</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Basic and fully-diluted weighted average shares outstanding</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>903,139</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>1,150,116</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>(d)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,053,255</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt; text-indent: -11pt"><font style="font-size: 10pt"><b>Fully-diluted weighted average shares outstanding</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,121,987</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>1,150,116</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>(d)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,272,103</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><font style="font-size: 10pt">(a)</font></td>
    <TD STYLE="width: 96%; text-align: justify"><font style="font-size: 10pt">Assumes the mergers with Canterbury and Hygeia occurred on January 1, 2012.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">(b)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact of employment agreements for the full year.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">(c)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact of amortization of intangible assets for the full year.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">(d)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact on weighted average shares if the 1,150,116 shares issued for the mergers were outstanding for the full year.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>20(a).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reverse Split and Name Change</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 7, 2014, the Company
effected a reverse stock split of 1&nbsp;to&nbsp;100 with respect to its Common Stock and the Company changed its corporate name
from Stratus Media Group, Inc. to RestorGenex Corporation, a biopharmaceutical company. All stock numbers herein are post reverse
split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Issuance of Note and Settlement of Amounts
Owed (Unaudited)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2014, the Company
agreed to issue to our law firm a non-interest bearing convertible note in the aggregate principal amount of $875,000 (the &ldquo;<U>Note</U>&rdquo;)
as payment in full for the amounts owed to them at that time, contingent on the Company successfully concluding a Cash Proceeds
Event, including the $467,200 note that was issued on July 1, 2012. The Note is due in full on March 31, 2015, provided that the
Company is required to prepay (i) $1.00 in principal amount of the Note for each $15.00 raised by the Company in all Cash Proceeds
Events (as defined in the Note), up to the first $7.5 million raised, for total repayments of up to $500,000; (b) an additional
$100,000 in principal amount of the Note when the cumulative amounts so raised in all Cash Proceeds Events equal $10.0 million;
and (c) the balance due under the Note when the cumulative amounts so raised in all Cash Proceeds Events equal $12.5 million. The
Note also provides that the holder may, at its option, convert all or any portion of the outstanding balance thereunder into the
securities issued and sold in certain securities offerings by the Company, including the offering currently underway by the Company
(the &ldquo;<U>Offering</U>&rdquo;). In connection with the issuance of the Note, the Company also agreed to issue to the holder
of the Note, for no additional consideration, $213,827 worth of the Company&rsquo;s securities sold in the Offering (valued at
the offering price of the securities) upon the closing of the Offering. The holder will be entitled to the same registration and
other rights with respect to such securities as are granted to the purchasers of securities in the Offering. In the event that
the Company does not repay at least $500,000 principal amount of the Note by July 1, 2014, the Note will be deemed to be in default
and will automatically convert into a non-convertible note in the principal amount of $1,188,827, which note will bear interest
at the annual rate of 10% and be due and payable upon demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is currently
in negotiations with other vendors, former directors and employees to reduce the amounts owed to them and use a combination of
stock and cash to settle these reduced amounts, but there can be no assurance that the Company will be successful in doing so or
that such settlements will amount to a material reduction in the amounts owed to these vendors, former directors and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Acquisitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">On March&nbsp;28,
2014, the Company acquired Paloma Pharmaceuticals, Inc. (&ldquo;Paloma&rdquo;) for consideration of 2,500,000 shares of common
stock and VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;) for consideration of 220,000 shares of common stock. In connection
with the acquisition of Paloma, the Company agreed to assume three promissory notes which have been extended to a maturity date
of March 28, 2015. The notes have a current balance (principal and interest) of approximately $1,132,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>20(b).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
Event (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Completed Financings with Net Proceeds
of $31,250,466</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 29,
2014, the Company closed the initial round of a private placement in the aggregate sum of $11,106,000 of a private placement
resulting in $9,222,900 of net proceeds after payment of fees, expenses and certain accounts payable. On May 6, 2014, the
Company closed the second round of this private placement in the aggregate sum of $13,672,500 resulting in $12,305,250 of net
proceeds after payment of fees and certain accounts payable. On May 21, 2014, the Company closed the third round of this
private placement in the aggregate sum of $3,489,240 resulting in $3,140,316 of net proceeds after payment of fees. On June
13, 2014, the Company closed the fourth round of this private placement in the aggregate sum of $7,115,000 resulting in
$6,403,000 of net proceeds after payment of fees. On July 10, 2014, the Company closed a fifth round of this private
placement in the aggregate sum of $200,000 resulting in $179,500 of net proceeds after payment of fees. However, given the
Company&rsquo;s plans to grow its existing businesses and potentially pursue acquisitions, this funding may not be sufficient
and the Company may need to raise additional capital in the future to fully implement its business plan. The following is a
summary of these five rounds of financing (amounts presented in thousands (000s) except per share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>First Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>April 29, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Second Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>May 6, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Third Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>May 21, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fourth Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>June 13, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fifth Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>July 10, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 23%">Shares sold</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,777</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3,418</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,779</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">8,896</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Price per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Gross Proceeds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,583</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt; padding-bottom: 1pt">Fees, expenses and payment of certain accounts payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,883</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,367</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(349</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(712</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(21</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(4,332</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net proceeds</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">9,223</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">12,305</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">3,140</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">6,403</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">180</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">31,250</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Warrants issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,110.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(a)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,367.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(b)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">348.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(c)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(d)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(e)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Strike price of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 5%; border-top: black 1pt solid"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 95%; border-top: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 832,950 shares of common stock issued with the financing and warrants to purchase 277,650 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 1,025,438 shares of common stock issued with the financing and warrants to purchase 341,813 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 261,693 shares of common stock issued with the financing and warrants to purchase 87,231 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 533,625 shares of common stock issued with the financing and warrants to purchase 177,875 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(e) </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 15,000 shares of common stock issued with the financing and warrants to purchase 5,000 shares of common stock issued to the placement agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchasers of
Common Stock received warrants to purchase three shares of Common Stock for every ten shares of Common Stock such Investors purchased
in the Private Placement at a strike price of $4.80. The purchase price of each share of Common Stock was $4.00, which was minimum
price under the terms of the Private Placement and approximated the volume weighted average market price for ten days prior to
the close.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">Cash and equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">222,071</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">254,964</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,455,881</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,743,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,677,952</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,998,283</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,262</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,725,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,691,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,962,880</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,642,825</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">26,447,653</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">18,344,052</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt">LIABILITIES AND SHAREHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,601,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,520,206</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">838,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,328</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">633,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,472</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other accrued expenses and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,829,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,697,714</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Payable to officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,358</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Rent liability for facilities no longer occupied</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,121,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,121,495</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,932,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867,002</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Obligation to issue stock for transfer of liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,581,641</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,854,743</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">10,694,773</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8,878,318</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Long-term liability - deferred taxes on acquisition</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,538,051</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,000,576</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Series C 10% Preferred Stock, $0.001 par value: 1,000,000 shares authorized, 0 and 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Series D 10% Preferred Stock, $0.001 par value: 500,000 shares authorized, 0 and 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Series E 5% Preferred Stock, $0.001 par value: 10,000 shares authorized; 0 and 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 8,683,785 and 5,813,785&nbsp;&nbsp;shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,684</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,814</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,670,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,390,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(62,464,074</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60,937,550</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total RestorGenex shareholders' equity</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">12,214,829</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,458,757</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Non-controlling interest equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,401</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total shareholders' equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">12,214,829</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,465,158</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders' equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">26,447,653</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">18,344,052</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross margin</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">611,845</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">624,674</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Warrants, options and stock compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,316,148</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Legal and professional services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">478,104</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,687</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,371,520</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,092,612</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,371,520</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,092,612</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Other (income)/expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Loss on adjustments to fair value of&nbsp;&nbsp;derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,639</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,564</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,294</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,971</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">8,655</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">257,257</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss from continuing operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,380,175</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,349,869</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss from discontinued operations</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(126,911</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,380,175</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,476,780</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Preferred dividends</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">124,375</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to holders of RestorGenex Corporation common stock</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,380,175</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,601,155</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Basic and diluted loss per share for continuing operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.23</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(2.77</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Basic and diluted loss per share for discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total basic and diluted loss per share</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2.91</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Basic weighted average shares outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,934,474</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">892,534</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Fully-diluted weighted average shares outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,934,474</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,207,534</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31, </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="color: red; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: red; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="color: red; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-weight: bold; text-align: left; padding-left: 10pt">Net loss from continuing operations</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 11%; font-weight: bold; text-align: right">(1,380,175</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 11%; font-weight: bold; text-align: right">(2,349,869</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 20pt; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in
    operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">478,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Gain on adjustments to fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Warrants, options and stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,323,098</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Stock issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Increase / (decrease) in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,100</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,515</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Deferred salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">267,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,975</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Other accrued expenses and liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(87,664</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">194,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(432,893</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(306,183</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Proceeds from notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">400,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">400,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Decrease in cash and equivalents from continuing operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(32,893</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(106,183</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Decrease in cash and equivalents from discontinued operations</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(94,475</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Total decrease in cash and equivalents</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(32,893</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(200,658</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Cash and equivalents, beginning of period</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">254,964</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">312,093</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and equivalents, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">222,071</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">111,435</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Cash paid during the period for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Cash paid during the period for income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Financial Statements.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTORGENEX CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MARCH 31, 2014 (UNAUDITED) AND DECEMBER 31,
2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">RestorGenex is a specialty
biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women&rsquo;s health.&nbsp;On
March 7, 2014, the Company effected a reverse stock split 1 to 100 with respect to its Common Stock and the Company changed its
corporate name from Stratus Media Group, Inc. to RestorGenex Corporation (&ldquo;Company&rdquo;). All stock numbers herein are
post reverse split. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 14, 2008, pursuant
to an Agreement and Plan of Merger dated August 20, 2007 between Feris International, Inc. (&ldquo;Feris&rdquo;) and Pro Sports
&amp; Entertainment, Inc. (&ldquo;PSEI&rdquo;), Feris issued 495,000 shares of its common stock for all issued and outstanding
shares of PSEI, resulting in PSEI becoming a wholly-owned subsidiary of Feris and the surviving entity for accounting purposes
(&ldquo;Reverse Merger&rdquo;). In July 2008, Feris&rsquo; corporate name was changed to Stratus Media Group, Inc. (&ldquo;Stratus&rdquo;
or &ldquo;SMDI&rdquo;). PSEI, a California corporation, was organized on November 23, 1998.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2011, the Company
acquired shares of Series&nbsp;A Convertible Preferred Stock of&nbsp;ProElite, Inc., a New Jersey corporation (&ldquo;ProElite&rdquo;
or &ldquo;PEI&rdquo;), that organized and promoted mixed martial arts (&ldquo;MMA&rdquo;) matches. These holdings of Series A Convertible
Preferred Stock provide the Company voting rights on an as-converted basis equivalent to a 95% ownership in ProElite. The Company
suspended operations of ProElite effective June 30, 2013. Following the repositioning of the Company as a specialty biopharmaceutical
company, the Company&rsquo;s Board of Directors voted to discontinue operations of ProElite effective March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective September 30,
2013, Stratus entered into an Agreement and Plan of Merger with Canterbury Acquisition LLC, a wholly owned subsidiary of the Company,
Hygeia Acquisition, Inc., a wholly-owned subsidiary of the Company, Canterbury Laboratories, LLC (&ldquo;Canterbury&rdquo;), Hygeia
Therapeutics, Inc. (&ldquo;Hygeia&rdquo;) and Yael Schwartz, Ph.D., as Holder Representative, pursuant to which Stratus acquired
all of the capital stock of Canterbury and Hygeia (the &ldquo;Mergers&rdquo;) with Canterbury and Hygeia becoming wholly-owned
subsidiaries of Stratus. The consideration for the Mergers was the issuance by Stratus of an aggregate of 1,150,116 restricted
shares of Stratus common stock issued to the stakeholders of Canterbury and Hygeia. Closing of the Mergers occurred on November
18, 2013. For the three months ended March 31, 2014, there were no revenues associated with Canterbury and Hygeia. For the three
months ended March 31, 2014, expenses associated with Canterbury and Hygeia were approximately $185,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Canterbury and Hygeia (the
&ldquo;Canterbury Group&rdquo;) are related companies engaged in the development of pharmaceuticals and cosmeceuticals (cosmetic
products with &ldquo;drug-like&rdquo; benefits) which, depending on the specific product involved, may treat acne, hirsutism (unwanted
hair) and alopecia (thinning hair) and that may revitalize hormonally-aged skin and hair in women over the age of 45. The Canterbury
Group has an exclusive license with Yale University to develop and market 23 synthetic estrogenic ingredients for the treatment
of aging skin and four classes of anti-androgenic ingredients for hair loss, excess facial hair, seborrhea and acne. The license
from Yale covers 24 patent-protected compounds under U.S. Patent 7,015,211<I> &ldquo;Estradiol 15-&alpha;-Carboxylic Acid Esters
as Locally Active Estrogens,&rdquo; </I>U.S. Patent 6,476,012<I> &ldquo;Estradiol 16-alpha Carboxylic Acid Esters as Locally Active
Estrogens&rdquo;</I> and U.S. Patent 8,552,061 <I>&ldquo;Locally active &quot;soft&quot; antiandrogens&rdquo; </I>(&ldquo;Yale
Patents&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The acquisition of the
Canterbury Group was a step in the implementation of the Company&rsquo;s plan to reposition itself as a specialty biopharmaceutical
company. The total consideration for the acquisition of the Canterbury Group was $12,421,249 based on the issuance of 1,150,116
shares of common stock at the market value of $10.80 as of the execution of the Merger Agreements on September 30, 2013. Based
on the third-party valuation of the Yale Patents of $7,779,000, $4,642,249 of the purchase price was initially allocated to goodwill,
which is not tax deductible. The value of the Yale Patents at the time of purchase was $132,571 as reflected on the books of Canterbury,
giving rise to an adjustment of $7,646,429 to the Company for the $7,779,000 allocated to the Yale Patents at the time of acquisition
less the $132,571 on the books of Canterbury. When tax effected at a combined U.S. Federal and California tax rate of 40%, the
net result of this adjustment is a deferred tax liability of $3,000,576. Total goodwill of $7,642,825 as of December 31, 2013 consisted
of the $4,642,249 initial allocation of the purchase price plus the deferred tax liability of $3,000,576. For the three months
ended March 31, 2014, expenses for Canterbury and Hygeia of approximately $184,000 were included in the consolidated loss of $1,376,137.
There were no revenues for Canterbury and Hygeia for the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Hygeia, a Delaware Corporation
based in Holden, Massachusetts, was incorporated in November 2005 and was formerly known as Orcas Therapeutics, Inc. Canterbury
is a Delaware Limited Liability Company that was formed in October 2011 and began operations in February 22, 2012. Initially, Canterbury
was a wholly-owned subsidiary of Hygeia and shareholders of Hygeia owned 94% of Canterbury at the time of the Mergers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 3, 2014, the Company
entered into an Agreement and Plan of Merger with Paloma Acquisition, Inc., a wholly owned subsidiary of the Company, Paloma Pharmaceuticals,
Inc. (&ldquo;Paloma&rdquo;) and David Sherris, Ph.D., as founding stockholder and Holder Representative pursuant to which the Company
agreed to acquire all of the capital stock of Paloma with Paloma becoming a wholly owned subsidiary of the Company. On March 28,
2014, the merger with Paloma was closed and the Company issued an aggregate of 2,500,000 common shares to all the holders of Paloma
Common Stock and its derivative securities and assumed promissory notes of Paloma in the aggregate amount (principal and interest)
of approximately $1,151,315 to be paid on the first anniversary of the closing of the Paloma merger. The 2,500,000 shares were
valued at $2.50 per share, which was the closing market price of the Company&rsquo;s common stock on March 3, 2014, resulting in
$6,250,000 of stock consideration, for a total consideration of $7,401,315. Of this total consideration, 30%, or $2,220,395, was
allocated to intangible assets based on management&rsquo;s preliminary assessment. The excess of the purchase consideration over
the fair value of the assets and liabilities acquired of $5,180,920 was initially allocated to goodwill. The Company is planning
to have a third-party valuation of the intangible assets and when that valuation is completed the allocation to intangibles may
change. These intangible assets had a value of $763,131 on Paloma&rsquo;s books, resulting in an adjustment of $1,457,082. When
tax effected at a combined U.S. Federal and California tax rate of 40%, the net result of this adjustment is a deferred tax liability
of $582,833. Total goodwill of $5,763,753 as of March 31, 2014 consists of the $5,180,920 initial allocation of the purchase price,
plus the deferred tax liability of $582,833. Since Paloma was acquired at the end of the quarter, there were no expenses for Paloma
included in the consolidated loss. There were no revenues for Paloma for the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also on March 3, 2014,
the Company entered into an Agreement and Plan of Merger with VasculoMedics Acquisition, Inc., a wholly owned subsidiary of the
Company, VasculoMedics, Inc. (&ldquo;VasculoMedics&rdquo;) and Dr. Sherris pursuant to which the Company agreed to acquire all
of the capital stock of VasculoMedics with VasculoMedics becoming a wholly owned subsidiary of the Company. The VasculoMedics Merger
was concurrently closed with and as a condition to the closing of the Paloma Merger on March 28, 2013, with the Company issuing
an aggregate of 220,000 post-reverse stock split common shares to the VasculoMedics stockholders. These shares, valued at $2.50
per share, which was the closing price of the Company&rsquo;s common stock on March 3, 2014, results in $550,000 of consideration,
all of which was allocated to goodwill. Since VasculoMedics was acquired at the end of the quarter, there were no expenses for
VasculoMedics included in the consolidated loss. There were no revenues for VasculoMedics for the three months ended March 31,
2014. The Mergers with Paloma and VasculoMedics were completed as part of the Company&rsquo;s plan to reposition itself as a specialty
biopharmaceutical company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Both Paloma and VasculoMedics
are Delaware corporations and based in Jamaica Plain, Massachusetts. Paloma was founded in January 2005 and VasculoMedics was founded
in November 2007. At the time of the Mergers, Dr. David Sherris, the founder and Chief Executive Officer of both companies, owned
56% of the outstanding stock of Paloma and 89% of the outstanding stock of VasculoMedics, with Paloma owning the other 11%. For
accounting purposes Paloma and VasculoMedics are considered to be under common control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Paloma has developed a
non-steroidal, synthetic, small molecule drug library for dermatology (psoriasis, atopic dermatitis, rosacea, actinic keratosis,
keloid and hypertrophic scarring, Dupuytren&rsquo;s disease, bullous blistering diseases), ocular disease, cancer, pulmonary fibrosis,
CNS (Huntington&rsquo;s disease and infantile spasm, a form of childhood epilepsy), biodefense and anti-viral application. The
lead product, P529, targets and inhibits the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric,
dual TORC1/TORC2 dissociative inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">VasculoMedics was founded
as a platform epigenetic company to develop orally available small molecular inhibitors of zinc finger transcription factors. Zinc
finger transcription factors are a subset of transcription factors utilizing zinc at its core for activity. Transcription factors
are proteins that bind to specific parts of DNA that control the transfer of genetic information from DNA to RNA. RNA in turn directs
the protein making machinery to manufacture one or more proteins controlled by the transcription factor. Hence, by inhibition of
a transcription factor, one can specifically inhibit the synthesis of one or more proteins controlled by the particular transcription
factor. Many diseases can be linked to the activation of particular proteins whose synthesis is controlled by transcription factors.
Inhibition of such transcription factors could then be able to control disease pathology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has suffered
losses from operations and lacked liquidity to meet its then-current obligations at March 31, 2014. The Company had net losses
of $1,380,175 and $2,601,155 for the three months ended March 31, 2014 and 2013, respectively and net losses for 2013 and 2012
of $2,635,975 and $7,366,061, respectively. As of March 31, 2014, the Company had negative working capital of $8,016,821 and an
accumulated deficit of $62,464,074. The Company had a total of $717,002 of promissory notes that were in default as of March 31,
2014. The Company raised $400,000 and $200,000 from the issuance of promissory notes during the three months ended March 31, 2014
and 2013, respectively. In 2013, the Company raised $700,000 through the issuance of two promissory notes and $427,501 through
the sale of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 29, 2014 and May
6, 2014, the Company sold a total of 6,194,625 shares of common stock at $4.00 per share and warrants to purchase 2,477,851 shares
of common stock at an exercise price of $4.80, for total proceeds of $24,778,500 and net proceeds of $21,528,150 after payment
of fees, expenses and certain accounts payable (for additional details please see Footnote 20 &ldquo;Subsequent Events&rdquo;).
However, given the Company&rsquo;s plans to grow its existing businesses and potentially pursue acquisitions, this funding may
not be sufficient and the Company may need to raise additional capital in the future to fully implement its business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements
were prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities in the normal
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of
asset carrying amounts or the amount and classification of liabilities that might result if the Company is unable to continue as
a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of
Presentation and Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Basis of Presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements
were prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;),
pursuant to the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The balance sheet at March
31, 2014 consolidates the accounts of ProElite, Canterbury, Hygeia, Paloma and VasculoMedics and the balance sheet at December
31, 2013 consolidates the accounts of ProElite, Canterbury, and Hygeia. The income statements and statements of cash flow for the
three months ended March 31, 2014 consolidate the accounts of Canterbury, Hygeia, along with results of Paloma and VasculoMedics
from the date of acquisition, and includes ProElite as discontinued operations. The income statements and statements of cash flow
for the three months ended March 31, 2013 includes ProElite as discontinued operations. All significant intercompany balances were
eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Basic and Diluted Earnings/(Loss) Per Share
(&ldquo;EPS&rdquo;)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic EPS is computed by
dividing the income/(loss) available to common shareholders by the weighted average number of common shares outstanding for the
period. Diluted EPS is computed similar to basic income/(loss) per share except that the denominator is increased to include the
number of additional common shares that would have been outstanding if all the potential common shares, warrants and stock options
had been issued and if the additional common shares were dilutive. Diluted EPS is based on the assumption that all dilutive convertible
shares were converted into common stock. Dilution is computed by applying the if-converted method for the outstanding convertible
preferred shares. Under the if-converted method, convertible outstanding instruments are assumed to be converted into common stock
at the beginning of the period (or at the time of issuance, if later).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of calculating
EPS, the number of common shares on March 31, 2013 did not include 315,000 shares of common stock issuable upon conversion by the
holders of Series E Preferred. These conversion shares were not included in the EPS calculation because they were antidilutive
given the losses by the Company for the three months ended March 31, 2013. During 2013 the Series E Preferred were extinguished
and the basic and fully-diluted shares are the same from that point forward and the number of shares used for basic and fully-diluted
EPS calculations are the same for the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company suspended operations
of ProElite effective June 30, 2013. Following the repositioning of the Company as a specialty biopharmaceutical company, the Company&rsquo;s
Board of Directors voted to discontinue operations of ProElite effective March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Use of Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of our
consolidated financial statements in accordance with U.S.&nbsp;GAAP requires us to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated
financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions
we may undertake in the future, actual results may differ from such estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Derivative Liabilities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2011, the Company
entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with eight investors (collectively, the &ldquo;Investors&rdquo;)
pursuant to which the Company sold 8,700 shares of a new series of convertible preferred stock designated as Series E Convertible
Preferred Stock (&ldquo;Original Series E&rdquo;) for $8,700,000. In October 2012, the Company sold 1,000 shares of Series E for
$1,000,000 (&ldquo;New Series E&rdquo;). The Original Series E and New Series E together are referred to herein as &ldquo;Series
E.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequent to the issuance
of this Series E, the Company determined that the warrants for these financings included certain embedded derivative features as
set forth in ASC Topic 815 &ldquo;<I>Derivatives and Hedging</I>,&rdquo; (&ldquo;ASC 815&rdquo;) and that this conversion feature
of the Series E was not an embedded derivative because this feature was clearly and closely related to the host (Series E) as defined
in ASC 815. These derivative liabilities were initially recorded at their estimated fair value on the date of issuance and were
subsequently adjusted each quarter to reflect the estimated fair value at the end of each period, with any decrease or increase
in the estimated fair value of the derivative liability for each period being recorded as other income or expense. Since the value
of the embedded derivative feature for the related warrants was higher than the value of both Series E transactions, there was
no beneficial conversion feature recorded for either transaction, and the excess of the value of the embedded derivative feature
over the value of the transaction was recorded in each period on the Statement of Operations as a separate line item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Allowance for Uncollectible Receivables</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accounts receivable are
recorded at their face amount, less an allowance for doubtful accounts. We review the status of our uncollected receivables on
a regular basis. In determining the need for an allowance for uncollectible receivables, we consider our customers financial stability,
past payment history and other factors that bear on the ultimate collection of such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cash Equivalents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider all highly
liquid investments purchased with maturities of three months or less to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Fair Value of Financial Instruments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our financial instruments
include cash and equivalents, receivables, accounts payable and accrued liabilities. The carrying amounts of financial instruments
approximate fair value due to their short maturities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Property and Equipment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation. We record depreciation using the straight-line method over the following estimated
useful lives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: top; width: 53%"><font style="font-size: 10pt">Equipment</font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 46%"><font style="font-size: 10pt">3 &ndash; 5 years</font></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><font style="font-size: 10pt">Furniture and fixtures</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">5 years</font></td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><font style="font-size: 10pt">Software</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">3 years</font></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">Lesser of lease term or life of improvements</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Goodwill and Intangible Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Intangible assets as of
March 31, 2014 consisted of goodwill and intangible assets arising from the acquisitions of Canterbury, Hygeia, Paloma and VasculoMedics.
Goodwill as of December 31, 2013 arose from goodwill for the acquisitions of Canterbury and Hygeia. Goodwill is the excess of the
cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. We
apply ASC Topic 350 &ldquo;<I>Goodwill and Other Intangible Assets,</I>&rdquo; which requires allocating goodwill to each reporting
unit and testing for impairment using a two-step approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company reviewed the
value of intangible assets and related goodwill as part of its annual reporting process, which occurs in February or March of each
year. In between valuations, the Company conducted additional tests to determine if circumstances warranted additional testing
for impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To review the value of
intangible assets and related goodwill as of December 31, 2013, the Company followed ASC Topic 350 &ldquo;<I>Intangibles-Goodwill
and Other</I>&rdquo; and first examined the facts and circumstances for each event or business to determine if it was more likely
than not that an impairment had occurred. If this examination suggested it was more likely that impairment had occurred, the Company
then compared discounted cash flow forecasts related to the asset with the stated value of the asset on the balance sheet. The
objective was to determine the value of each asset to an industry participant who is a willing buyer not under compulsion to buy
and the Company is a willing seller not under compulsion to sell. Revenue from goodwill and intangible assets were forecasted based
on the assumption they are standalone entities. These forecasts were discounted at a range of discount rates determined by taking
the risk-free interest rate at the time of valuation, plus premiums for equity risk to small companies in general, for factors
specific to the Company and the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2014, Company
management determined that the fair value of its businesses for accounting purposes was equal to its market capitalization of approximately
$34,900,000, which was 147% of the $23,688,138 total for goodwill and intangible assets on the balance sheet as of March 31, 2014.
Based on this determination, Company management concluded that no impairment had occurred as of March 31, 2014 on a Company-wide
basis. However, it is possible that impairment may have occurred on a reporting-unit basis and the Company intends to test impairment
on a reporting-unit basis beginning with the three months ending June 30, 2014. As of December 31, 2013, Company management determined
that the fair value of its businesses for accounting purposes was equal to its market capitalization of approximately $19,600,000,
which was 128% of the $15,334,507 goodwill and intangible assets on the balance sheet as of December 31, 2013. Based on this determination,
Company management concluded that no impairment had occurred as of December 31, 2013. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company utilizes ASC
Topic 740 <I>&ldquo;Accounting for Income Taxes,&rdquo;</I> which requires recognition of deferred tax assets and liabilities for
the expected future tax consequences of events included in the financial statements or tax returns. Under this method, deferred
income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities
and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods
in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce
deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period
and the change during the period in deferred tax assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2014 and
December 31, 2013, the Company had net operating loss carryforwards as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Combined NOL Carryforwards:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%">Federal</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">48,480,486</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">47,728,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>California</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,235,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,482,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The net operating loss
carryforwards for 2014 and 2013 begin expiring in 2022 and 2021, respectively. From December 31, 2012 to March 31, 2014, the outstanding
shares of common stock increased from 890,837 to 5,813,785. This increase in the number of shares outstanding constitutes a change
of ownership, under the provisions of Internal Revenue Code Section 382 and similar state provisions, and is likely to significantly
limit the ability of the Company to utilize these net operating loss carryforwards to offset future income. Accordingly, the company
recorded a 100% valuation allowance of the deferred tax assets at March 31, 2014 and December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock-Based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We follow ASC Topic 718
&ldquo;<I>Share Based Payment,&rdquo;</I> using the modified prospective transition method. New awards and awards modified, repurchased
or cancelled after January&nbsp;1, 2006 trigger compensation expense based on the fair value of the stock option as determined
by the Black-Scholes option pricing model. We amortize stock-based compensation for such awards on a straight-line method over
the related service period of the awards taking into account the effects of the employees&rsquo; expected exercise and post-vesting
employment termination behavior. We account for equity instruments issued to non-employees in accordance with ASC Topic 718 and
EITF Issue No.&nbsp;96-18. The fair value of each option granted is estimated as of the grant date using the Black-Scholes option
pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Advertising</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expense the cost of
advertising as incurred. Such amounts have not historically been significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Reclassifications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain prior year amounts
were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the
net loss or the shareholder&rsquo;s deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Recent Accounting Pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FASB has issued ASU
No. 2013-04, Liabilities (Topic 405), &ldquo;<I>Obligations Resulting from Joint and Several Liability Arrangements for Which the
Total Amount of the Obligation Is Fixed at the Reporting Date</I>.&rdquo; ASU 2013-04 provides guidance for the recognition, measurement,
and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation
within the scope of this ASU is fixed at the reporting date, except for obligations addressed within existing guidance in US GAAP.
The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the
basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors.
The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15,
2013. Adoption of this guidance did not have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2013, the FASB
issued ASU 213-11, Income Taxes (Topic 740): &ldquo;<I>Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward,
A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force)</I>&rdquo;. ASU 2013-11
provides guidance on financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar
tax loss, or a tax credit carryforward exists. The FASB&rsquo;s objective in issuing this ASU is to eliminate diversity in practice
resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits
that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This amendment is effective
for public entities for fiscal years beginning after December 15, 2013 and interim periods within those years. Adoption of this
guidance did not have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed
by management to have a material impact on the Company&rsquo;s present or future consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2013, the Company
signed a term sheet with an outside financial firm (&ldquo;Financial Firm&rdquo;) to have that firm acquire certain portions of
the Company&rsquo;s liabilities to creditors, employees and former employees (&ldquo;Creditors&rdquo;). The Financial Firm entered
into agreements in July 2013 with such Creditors to acquire $1,865,386 in liabilities (&ldquo;Liability Settlement&rdquo;) of the
Company and filed a complaint on July 29, 2013 with the Second Judicial Circuit, Leon County, Florida seeking a judgment against
the Company for the Liability Settlement. A court order based on this complaint was issued on October 7, 2013. Based on conditions
agreed to in the Term Sheet, the Company will settle that judgment by issuing common stock to the Financial Firm. Under an exemption
from registration in the SEC regulations, common stock issued pursuant to this court order is tradable without restrictions. This
common stock will be issued in tranches such that the Financial Firm will not own more than 9.99% of outstanding shares at any
time and will be priced at 80% of average closing bids during such period of time in which the dollar trading volume of the stock
is three times the Liability Settlement (&ldquo;Settlement Period&rdquo;). The Financial Firm will sell the shares to generate
proceeds to pay the Creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until the Financial Firm
repays all the creditors, the Company will have a liability on its balance sheet for the value of amount still owed by the Financial
Firm to the creditors plus 20% to recognize the discount stock owed to the Financial Firm. The selling activities of the Financial
Firm could put downward pressure on the stock price. As of March 31, 2014, the Company had a liability of $1,581,641 on its balance
sheet, which would have required the issuance of 263,607 shares to satisfy this liability given the $6.00 price for the Company&rsquo;s
common stock on that date, or 4.5% of the 5,813,785 shares outstanding at that time. An initial tranche of 200,000 shares was issued
to the Financial Firm in November 2013 and a subsequent tranche of 150,000 shares was issued in February 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2013, the Company
received notice that a complaint for property damage had been filed by the Truck Insurance Exchange against the Company for $393,592
related to water damage incurred by a printing company on the ground floor of the Company&rsquo;s former office space in Los Angeles.
This damage is alleged to have occurred in connection with a water leak in the Company&rsquo;s former office in February 2013.
The Company has filed an answer to this complaint that includes, but not be limited to, the defense of culpability of the building&rsquo;s
management in this leak. The Company has a dispute with its insurance carrier at that time regarding coverage for this incident
and the Company intends to pursue this dispute to ensure that it had proper insurance coverage at that time. The Company has accrued
$393,592 for this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid
Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2013, the Company
entered into an agreement with Maxim Group LLC to provide general financial advisory and investment banking services to the Company
for three years on a non-exclusive basis. Under this agreement, Maxim received common stock equal to 4.99% of the outstanding common
stock of the Company as of that date, or 210,250 shares of common stock. These shares were valued at $15.00, which was the closing
price of the Company&rsquo;s common stock on the date of the agreement, for a total expense of $3,153,750. This expense is being
recognized ratably over the life of the three-year term of the agreement at $262,813 per quarter. As of March 31, 2014, $2,442,449
remained in prepaid expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property
and Equipment, Net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Property and equipment were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Computing equipment and office machines</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">231,830</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">145,245</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Furniture and fixtures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100,479</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,833</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">332,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(250,746</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(212,816</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">81,563</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,262</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the three months ended
March 31, 2014 and 2013, depreciation expense was $4,511 and $8,687, respectively. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Goodwill was $13,962,880
at March 31, 2014 and $7,642,825 at December 31, 2013, with the increase arising from the acquisition of Paloma and VasculoMedics
in the three months ended March 31, 2014. In accordance with ASC Topic 350, &ldquo;<I>Intangibles-Goodwill and Other</I>,&rdquo;
the Company&rsquo;s goodwill is considered to have indefinite lives and was therefore not amortized, but rather is subject to annual
impairment tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2014, Company
management determined that the fair value of its businesses for accounting purposes was equal to its market capitalization of approximately
$34,900,000, which was 147% of the $23,688,138 total for goodwill and intangible assets on the balance sheet as of March 31, 2014.
Based on this determination, Company management concluded that no impairment had occurred as of March 31, 2014 on a Company-wide
basis. However, it is possible that impairment may have occurred on a reporting-unit basis and the Company intends to test impairment
on a reporting-unit basis beginning with the three months ending June 30, 2014. As of December 31, 2013, Company management determined
that the fair value of its businesses for accounting purposes was equal to its market capitalization of approximately $19,600,000,
which was 128% of the $15,334,507 goodwill and intangible assets on the balance sheet as of December 31, 2013. Based on this determination,
Company management concluded that no impairment had occurred as of December 31, 2013. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
Salary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From February 2013 through
March 31, 2014, the Company had not been able to pay employees on a regular basis, resulting in unpaid salaries of $838,476 as
of March 31, 2014 and $571,328 as of December 31, 2013, net of advances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Accrued
Expenses and Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other accrued expenses
and liabilities consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Payroll related</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">599,706</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">479,087</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Estimated property damage liability that may not be covered by insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">393,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">393,592</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Board fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">751,660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,839</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,829,119</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,697,714</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payable to Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
2010 employment agreement for the Company&rsquo;s Chief Financial Officer, the Company owes this officer $156,358 for unpaid amounts
consisting of consulting fees prior to employment, expenses, salary increases and signing bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes Payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Notes payable were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Note payable to the Company's outside law firm and represents the corporate and litigation fees due as of June 30, 2012. This note originally bore interest at 3% and was due December 31, 2012. Starting on January 1, 2013, this note bears interest at 10%. This note is currently in default.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">467,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">467,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Notes payable to 11 investors dated July 9, 2012 with maturity date on the earlier of a $2 million capital raise by the company, or February 6, 2013 and bears interest at 8%. $225,000 of these notes were converted by 9 investors to common stock in November 2013. The remaining two notes are currently in default.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Notes payable to a director of the Company dated March 5, 2013 with maturity on the earlier of September 5, 2013 or receipt by the Company of $200,000 in net proceeds from a private placement of Company securities. This note does not bear interest and is not secured. This note is currently in default.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to a high-yield fund. This note bears interest at 10% and matures on June 19, 2014. Upon the closing of a financing of at least $7,500,000 on or before the applicable maturity date, this note will be converted into securities issued in such financing at a conversion price equal to 50% of the purchase price per share or unit of the securities. This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's chairman of the board dated August 9, 2013. Bears interest at 7% and matures on August 9, 2014. Contains mandatory conversion into security or securities totaling $10 million or more at the lesser of 50% of the selling price of such securities or the equivalent of $4.00 per share of common stock. This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's chairman of the board dated December 19, 2013. This note bears interest at 10% and matures on June 19, 2014. Upon the closing of a financing of at least $7,500,000 on or before the applicable maturity date, this note will be converted into securities issued in such financing at a conversion price equal to 50% of the purchase price per share or unit of the securities. This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's chairman of the board dated February 4, 2014.&nbsp;&nbsp;This note bears interest at 7% and matures on February 4, 2015. Upon the closing of a financing of at least $7,000,000 on or before the applicable maturity date, this note plus accrued interest will be converted into securities issued in such financing at a conversion price equal to 50% of the purchase price per share or unit of the securities or $4.00 at the holder's election.&nbsp;&nbsp;This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Note payable to the Company's chairman of the board dated March 19, 2014. This note bears interest at 7% and matures on February 4, 2015. Upon the closing of a financing of at least $7,000,000 on or before the applicable maturity date, this note plus accrued interest will be converted into securities issued in such financing at a conversion price equal to 50% of the purchase price per share or unit of the securities or $4.00 at the holder's election. This note is secured by the assets of the Company.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Note payable to three holders issued June 30, 2009 by Paloma and assumed by the Company on March 28, 2014, with repayment to occur by March 28, 2015. These notes bear interest at 18%. Accrued interest on these notes as of March 31, 2014 was $486,315.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">665,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,932,002</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,867,002</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expense on these
notes was $58,294 and $22,971 for the three months ended March 31, 2014 and 2013, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obligation to issue stock for
transfer of liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2013, the Company
signed a term sheet (&ldquo;Term Sheet&rdquo;) with the Financial Firm to have that firm acquire certain portions of the Company&rsquo;s
liabilities to creditors, employees and former employees (&ldquo;Creditors&rdquo;). The Financial Firm entered into agreements
in July 2013 with such Creditors to acquire $1,865,386 in liabilities of the Company and filed a complaint on July 29, 2013 with
the Second Judicial Circuit, Leon County, Florida seeking a judgment against the Company for the Liability Settlement. A court
order based on this complaint was issued on October 7, 2013, resulting in the transfer of these $1,865,386 million of liabilities
to the Financial Firm (see Footnote 4 for additional information).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2014, the
Company had a liability of $1,581,641 on its balance sheet, which would have required the issuance of 263,607 shares to satisfy
this liability given the $6.00 price for the Company&rsquo;s common stock on that date, or 4.5% of the 5,813,785 shares outstanding
at that time. An initial tranche of 200,000 shares was issued to the Financial Firm in November 2013 and a subsequent tranche of
150,000 shares was issued in February 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2011, the Company
entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with eight investors (collectively, the &ldquo;Investors&rdquo;)
pursuant to which the Company sold 8,700 shares of a new series of convertible preferred stock designated as Series E Convertible
Preferred Stock (&ldquo;Original Series E&rdquo;), the terms of which are set forth in the Certificate of Designations of Series
E Preferred Stock (the &ldquo;Certificate&rdquo;), for $1,000 per share, or $8,700,000. In October 2012, the Company sold 1,000
shares of Series E for $1,000,000 (&ldquo;New Series E&rdquo;). The Original Series E and New Series E together are referred to
herein as &ldquo;Series E.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These Series E contained
&ldquo;full ratchet-down&rdquo; liquidity protection that provided that if the Company issues securities for less than the existing
conversion price for the Series E Preferred Stock or the strike price of the Series E warrants, then the conversion price for Series
E Preferred Stock will be lowered to that lower price. Also, the strike price for Series E warrants were decreased to that lower
price and the number of Series E warrants will be increased such that the product of the original strike price times the original
quantity equaled the lower strike price times the higher quantity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequent to the issuance
of this Series E, the Company determined that the warrants for these financings included certain embedded derivative features as
set forth in ASC Topic 815 and that this conversion feature of the Series E was not an embedded derivative because this feature
was clearly and closely related to the host (Series E) as defined in ASC 815. These derivative liabilities were initially recorded
at their estimated fair value on the date of issuance and were subsequently adjusted each quarter to reflect the estimated fair
value at the end of each period, with any decrease or increase in the estimated fair value of the derivative liability for each
period being recorded as other income or expense. Since the value of the embedded derivative feature for the related warrants was
higher than the value of both Series E transactions, there was no beneficial conversion feature recorded for either transaction,
and the excess of the value of the embedded derivative feature over the value of the transaction was recorded in each period on
the Statement of Operations as a separate line item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of these
derivative liabilities was calculated using the Black Scholes pricing model that was based on the closing price of the common stock,
the strike price of the underlying instrument, the risk-free interest rate for the applicable remaining life of the underlying
instrument (i.e., the U.S. treasury rate for that period) and the historical volatility of the Company&rsquo;s common stock. These
fair value results were extremely sensitive to all these input variables, particularly the closing price of the company&rsquo;s
common stock and the volatility of the Company&rsquo;s common stock. Accordingly, the fair value of these derivative liabilities
were subject to significant changes.&nbsp; During 2013, the Series E and related warrants were converted into common stock and
extinguished and the company recorded a gain of $8,980,077 on the decrease in fair value for the derivative security and recorded
a gain of $1,635,967 on extinguishment of the derivative liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following assumptions
were used to calculate the Black Scholes values of this derivative liability as of the measurement dates of March 31, 2013. The
fair value of the underlying common stock was based on the sale of 139,166 shares of common stock at $3.00 by the Company during
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 87%"><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Remaining life in years</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.15</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.38</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">142</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The number of shares of
common stock has increased from 890,837 shares as of December 31, 2012 to 8,683,785 shares as of March 31, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">Common Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; font-weight: bold">Balance at December 31, 2012</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-weight: bold; text-align: right">890,837</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Conversion of Series E Preferred to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,575,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares issued for acquisition of Canterbury and Hygeia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,116</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Conversion of warrants to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,023,264</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversion of debt to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">576,331</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Issuance of shares for advisory agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of shares to third party for assumption of liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Issuance of common stock for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,501</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,486</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">Balance at December 31, 2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,813,785</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Issuance of shares to third party for assumption of liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares issued for acquisition of Paloma</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Shares issued for acquisition of VasculoMedics</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">220,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2014 (Unaudited)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">8,683,785</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;<FONT STYLE="color: red">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three months
ended March 31, 2013, the Company issued five-year options to purchase a total of 116,627 to five members of the Company&rsquo;s
Board of Directors at a strike price of $3.00, which was the closing market price on the date of the grants. These options vested
25% at time of grant with the remainder vesting ratably over three years. On March 5, 2014, the Company issued five-year options
to its Chief Executive Officer to purchase 500,000 shares at a strike price of $2.50, which was the closing market price on the
date of the grant. This option vests ratably over three years. These options were valued using the Black Scholes model and resulted
in a total expense of $1,468,100, of which $128,000 was recognized in the three months ended March 31, 2014 and the remaining $1,340,100
will be recognized ratably over the coming three years. The assumptions used to value the options granted during the first three
months of 2014 was:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$2.50 - $3.00</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 82%"><font style="font-size: 10pt">Remaining life</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.50% - 1.72%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">153% - 155%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth the activity
of our stock options to purchase common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Options&nbsp;Outstanding</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Options&nbsp;Exercisable</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Range&nbsp;of</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Options</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Options</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Outstanding</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Prices</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Price</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Exercisable</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Price</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 22%; padding-left: 5pt"><font style="font-size: 10pt"><b>As of December 31, 2012</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt"><b>79,436&nbsp;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 11%; text-align: right"><font style="font-size: 10pt"><b>$35.00 -$54.00&nbsp;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>3.0</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>46.00</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt"><b>57,310&nbsp;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>2.6</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>48.00</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Canceled</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Granted</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">310,000&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">310,000&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5pt"><font style="font-size: 10pt"><b>As of December 31, 2013</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>389,436&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&nbsp;$3.00 -$54.00&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>3.9</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>11.77</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>367,310&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>3.9</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>11.10</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="vertical-align: bottom"><font style="font-size: 10pt">Canceled</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(3,585)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">43.27</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(3,585)</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">43.27</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Granted</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">600,586&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">$2.50 - $3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">4.9</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">91,128&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">4.9</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5pt"><font style="font-size: 10pt"><b>As of March 31, 2014</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>986,437&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&nbsp;$3.00 -$54.00&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>4.4</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>6.74</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>454,853&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>3.8</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>11.11</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2013 the Board approved
warrants to three financial advisors to purchase 173,917 shares of common stock at $3.00. These warrants have a five-year life
and vested immediately, resulting in Black Scholes warrant expense of $462,618. The Black Scholes expense for these March 27, 2013
warrants was calculated using the following assumptions. The fair value of the underlying common stock was based on the sale of
139,167 shares of common stock at $3.00 by the Company during the three months ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Estimated fair value of underlying common stock</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 82%"><font style="font-size: 10pt">Remaining life</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.35%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">141%</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2013 Series E warrants,
along with related warrants with similar terms, were exchanged for 1,023,264 shares of common stock and these warrants were extinguished,
thereby removing the &ldquo;overhang&rdquo; created by the full-ratchet provisions of these warrants that would have increased
the number of warrants outstanding and reduced the strike price of these warrants to the price of any subsequent financing done
at a lower price. This exchange of common stock for the Series E warrants resulted in a fair value charge of $3,069,792 in 2013.
These 1,023,264 shares of common stock were valued at $3.00 per share, which was the price at which the Company sold 139,167 shares
during 2013, resulting in the fair value charge for $3,069,792.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of the warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Warrants&nbsp;Outstanding</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Warrants&nbsp;Exercisable</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Range of</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Remaining</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Average</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Warrants</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Warrants</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Life&nbsp;in</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Outstanding</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Prices</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Price</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Exercisable</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Years</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Price</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 22%; padding-left: 5pt"><font style="font-size: 10pt"><b>As of December 31, 2012</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt"><b>1,322,852&nbsp;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 11%; text-align: right"><font style="font-size: 10pt"><b>$30.00 - $200.00</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>3.2</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>40.00</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 9%; text-align: right"><font style="font-size: 10pt"><b>1,269,102&nbsp;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>3.2</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 7%; text-align: right"><font style="font-size: 10pt"><b>38.00</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Canceled</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(978,700)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">$30.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">30.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(939,950)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">30.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Granted</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">173,917&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">$3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">173,917&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">4.2</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5pt"><font style="font-size: 10pt"><b>As of December 31, 2013</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>518,069&nbsp;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>$3.00 - $200.00</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.3</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>44.07</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>503,069&nbsp;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>3.3</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>44.07</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Canceled</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(198)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">200.00</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(198)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">200.00</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Exercised</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Granted</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 5pt"><font style="font-size: 10pt"><b>As of March 31, 2014</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>517,871&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>$3.00 - $200.00</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>3.0</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>44.01</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>502,871&nbsp;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>3.0</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>44.01</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Office Space Rental</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 1, 2009, the Company
entered into a lease for 1,800 square feet of office space in Santa Barbara, California for use as our executive offices. This
lease was amended on July 21, 2009 and expired on December 31, 2013. This property was vacated in August 2012 and the Company has
recorded a liability of $139,000 to cover unpaid rent and the present value of rents due for the remainder of the lease. During
2013, a settlement amount of $110,700 was negotiated with the lease holder and transferred to a third party, resulting in a reduction
of the accrued liability of $139,150.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2011, the
Company entered into a lease for&nbsp;7,000 square feet of office space in Los Angeles, California. The lease continues through
November 30, 2014. Initially, the lease had a fixed monthly rent of $19,326 and was subject to annual increases of 3%. The Company
was not required to pay a fixed monthly rent for months two through five. Prior to this, the Company was leasing the same office
space on a month-to-month basis. This property was vacated in April 2012 and the Company recorded a liability of $892,000 to cover
unpaid rent and the present value of rents due for the remainder of the lease term. As of April 2013, this space was released,
but the terms and conditions of the new lease are unknown, so the Company did not adjust the accrued liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp; &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2011, the
Company entered into a lease for 3,000 square feet of office space in Santa Barbara, California for use by our operating units.
This lease expires on October 31, 2014 with two additional three-year renewal terms available. The initial rent plus common area
charges were $7,157 per month. This property was vacated in June 2012 and the Company recorded a liability of $229,000 to cover
unpaid rent and the present value of rents due for the remainder of the lease term. As of June 2013, this space was released, but
the terms and conditions of the new lease are unknown, so the Company did not adjust the accrued liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From May 2012 to May 2013,
the Company was in a month-to-month lease for office space in Los Angeles, California. Rent for this facility was $2,300 per month.
Given reductions in staff, the Company has been operating with a &ldquo;virtual office.&rdquo; The Company believes this virtual
office structure was adequate for our past needs but given the Company&rsquo;s growth plans it is anticipated that laboratory and
office space will be needed in the future. The Company believes that suitable space will be available as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Contractual Obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Set forth below is information
concerning our known contractual obligations as of March 31, 2014 that are fixed and determinable by year starting with the year
ending December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>2018 and</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Later</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 30%"><font style="font-size: 10pt">Notes payable</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,931,593</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,931,593</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Deferred Salary</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">838,476</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">838,476</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Rent obligations</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,260,644</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">677,737</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">339,958</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">242,949</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Accrued board fees</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,515,820</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,515,820</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Employee contracts:&nbsp;&nbsp;other</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,931,156</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,181,411</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,341,000</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,273,732</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">135,013</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Accrued interest</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">634,370</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">634,370</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>11,112,059</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>7,779,407</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,680,958</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,516,681</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>135,013</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Employment Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective June 28, 2012,
Jerold Rubinstein was elected by the Board as Chairman of the Board, CEO and a director of the Company&rsquo;s subsidiaries. The
Board of Directors of ProElite also elected him as Chairman of the Board and CEO of ProElite. Under the terms of an employment
agreement dated June 28, 2012, Mr. Rubinstein was to receive an annual salary of $250,000 per year. Mr. Rubinstein continues to
serve on the Board and receive $50,000 annually for such services, along with $100,000 annually as Chairman of the Board. This
executive was granted options to purchase 230,000 shares of the Company&rsquo;s common stock at $35.00 per share, which was the
closing price of the Company&rsquo;s common stock on the day of option grant. These options vest monthly over a 12-month period.
In March 2013, Mr. Rubinstein received an option grant to purchase 250,000 shares at $3.00 with a five-year life that vested in
full in the three months ended June 30, 2013. Mr. Rubinstein&rsquo;s contract expired on June 28, 2013 and he resigned as CEO on
March 5, 2014. As of March 31, 2014, Mr. Rubinstein was owed unpaid salary of $39,883 and unpaid board fees of $214,458.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2011, the
Company entered into any employment contract with Timothy Boris as the Company&rsquo;s General Counsel and Vice President of Legal
Affairs at an annual salary of $180,000. In December 2011 he received options to purchase 3,000 shares of common stock at $54.00
that had 1,000 shares vested upon grant, 1,000 shares vested at the end of year one and 1,000 shares vest at the end of year two.
This contract expired on August 8, 2012 and was renewed under the same terms until August 8, 2013. In August 2012 Mr. Boris received
options to purchase 3,000 shares of common stock at $38.00 that had 1,000 shares vest upon grant, 1,000 shares vest at the end
of year one and 1,000 shares vest at the end of year two. Both of these option grants have a five-year life. In March 2013, Mr.
Boris received an option grant to purchase 60,000 shares at $3.00 with a five-year life that vested in full in the three months
ended June 30, 2013. Mr. Boris&rsquo;s contract expired on August 8, 2013 and he is currently working without a contract. As of
March 31, 2014, Mr. Boris was owed unpaid salary of $90,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2010, the
Company entered into an employment agreement with John Moynahan, who provided accounting and financial services to the Company
as a consultant pursuant to a consulting agreement dated November 14, 2007. Under the agreement, Mr. Moynahan was to receive an
annual salary of&nbsp;$220,000 for the first year of the contract, subject to an annual increase of the Consumer Price Index plus
2%, and will be eligible for a $50,000 bonus in the first year of this contract. Under this agreement, Mr. Moynahan received a
grant of 3,000 shares and a five-year stock option grant to purchase 15,600 shares of common stock at $200.00 per share, with 10,400
shares that vested upon the signing of the agreement and 5,200 shares that vested on September 1, 2011. The strike price on these
options was adjusted to $54.00 in December 2011 by the Board. After a review of this contract during 2012, the Company determined
that the non-salary amounts due to Mr. Moynahan were $156,358 as of December 31, 2012.&nbsp; Mr. Moynahan&rsquo;s contract expired
on August 1, 2012 and he is currently working without a contract. As of March 31, 2014, Mr. Moynahan was owed the $156,358 under
his employment contract and $110,000 in unpaid salary, not including any other claims that Mr. Moynahan may have under his employment
contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective as of November&nbsp;18,
2013, the Company entered into employment agreements with Yael Schwartz and Craig Abolin as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the Employment Agreement
with Dr. Schwartz, she is to be employed for an initial period of three years. During the initial year of her employment term,
she is to receive a base salary of $330,000. Thereafter, her base salary will be subject to mutually agreed upon increases. The
Company&rsquo;s Board of Directors or Compensation Committee may grant Dr. Schwartz bonuses in its sole discretion. Dr. Schwartz
is also eligible for grants of awards under the Company&rsquo;s Incentive Compensation Plan. As of March 31, 2014, Dr. Schwartz
was owed $80,849 in unpaid salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the Employment Agreement with Dr. Abolin, he is to be employed for an initial period of
three years. During the initial year, he is to receive a base salary of $241,000. Thereafter his base salary will be subject to
mutually agreed upon increases. The Company&rsquo;s Board or Compensation Committee may grant Dr. Abolin bonuses in its sole discretion.
Dr. Abolin is also eligible for grants of awards under the Company&rsquo;s Incentive Compensation Plan. As of March 31, 2014,
Dr. Abolin was owed $58,257 in unpaid salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 5, 2014, the Company
entered into an Employment Agreement with Stephen M. Simes (the &ldquo;Simes Employment Agreement&rdquo;) pursuant to which Mr.
Simes was appointed Chief Executive Officer of the Company. The Simes Employment Agreement is for an initial term of three years,
subject to extension as provided therein. Mr. Simes is to receive a base salary at an annual rate of $425,000 with at least annual
review and base salary increases as approved by the Board of Director or its Compensation Committee. He will have the opportunity
to earn a bonus with respect to each year during his employment based upon achievement of performance objectives set by the Board
or the Compensation Committee after consultation with Mr. Simes with a target bonus opportunity of 60% of base salary for each
year. He also has received an initial grant of options to purchase 500,000 shares at an exercise price of $2.50 which will vest
quarterly over the initial three-year term of his employment. As of March 31, 2014, Mr. Simes was owed $31,057 in unpaid salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
closing of the mergers with Paloma and VasculoMedics, the Company entered into an employment agreement on March 31, 2014 with David
Sherris, Ph.D. pursuant to which Dr. Sherris was appointed Chief Scientific Officer of the Company and President of the Company&rsquo;s
Paloma/VasculoMedics divisions. Under the agreement, he is to be employed for an initial period of three years. During the term
he is to receive an annual base salary of $345,000 and is eligible for a bonus of up to 50% of his base salary upon meeting certain
milestones established by the Board of Directors or Compensation Committee upon consultation with Dr. Sherris. Dr. Sherris is also
eligible for grants under the Company&rsquo;s Incentive Compensation Plan.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment
Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2013, ProElite was considered
to be an operating segment pursuant to ASC Topic 280 <I>&ldquo;Segment Reporting&rdquo; </I>since each was budgeted separately
and tracked separately to provide the chief operating decision maker information to assess and manage ProElite, Stratus White and
Hygeia/Canterbury. The Company suspended operations of ProElite effective June 30, 2013. Following the repositioning of the Company
as a specialty biopharmaceutical company, the Company&rsquo;s Board of Directors voted to discontinue operations of ProElite effective
March 31, 2014. The following segment information is presented to provide a comparison for the three months ended March 31, 2014
and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of results by segments is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended March 31, 2014 ($000)</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended March 31, 2013 ($000)</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Bio-</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>ProElite</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Bio-</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>ProElite</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Pharma</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(Discont.)</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Other</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Pharma</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(Discont.)</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Other</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Revenues</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Cost of sales</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Gross margin</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%; padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Deprec. &amp; Amort</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">477</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">478</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">9</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">9</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Segment profit</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(477</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(478</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Operating expenses</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">183</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">710</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">893</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,084</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,084</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Other (income)/expenses</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">20</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">20</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Impact of derivative securities</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">237</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">237</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss from continuing ops.</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(184</b></font></td>
    <td><font style="font-size: 10pt"><b>)</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(1,192</b></font></td>
    <td><font style="font-size: 10pt"><b>)</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(1,376</b></font></td>
    <td><font style="font-size: 10pt"><b>)</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(2,350</b></font></td>
    <td><font style="font-size: 10pt"><b>)</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>(2,350</b></font></td>
    <td><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Loss from discontinued ops.</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(127</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(127</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Preferred dividends</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">124</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">124</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss attributable to common shareholders</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(184</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,192</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,376</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(127</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(2,474</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(2,601</b></font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Assets at End of Period</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">230</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">344</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">25,878</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">26,452</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,677</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">511</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2,188</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 5pt"><font style="font-size: 10pt">Liabilities at End of Period</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2,779</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">625</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7,291</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">10,695</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,998</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">19,927</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">21,925</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company suspended operations
of ProElite effective June 30, 2013. Following the repositioning of the Company as a specialty biopharmaceutical company, the Company&rsquo;s
Board of Directors voted to discontinue operations of ProElite effective March 31, 2014. The assets and liabilities of ProElite
are consolidated into the Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013 and are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>March 31,</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>December 31,</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2014</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2013</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(Unaudited</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total assets</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 68%"><font style="font-size: 10pt">Accounts payable</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">167,244</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt">167,244</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><font style="font-size: 10pt">Other accrued</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">16,250</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">16,250</font></td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Equity, net</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(183,494</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(183,494</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total liabilities and shareholder's deficit</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The income statement details
for ProElite that are summarized in the discontinued operations line in the Consolidated Statements of Operations are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended March 31,</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2014</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2013</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 68%"><font style="font-size: 10pt"><b>Revenues</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt"><b>71,667</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Cost of revenues</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 11pt"><font style="font-size: 10pt"><b>Gross profit</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>71,667</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Operating expenses</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">171,892</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD><font style="font-size: 10pt">Interest expense</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">33,365</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Net loss attributed to non-controlling interests</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(6,679</font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 11pt"><font style="font-size: 10pt"><b>Total expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>198,578</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Net Loss</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(126,911</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Consolidated Statements
of Operations for the periods ended March 31, 2014 and 2013 do not consolidate the results for ProElite but present them on a net
basis in a discontinued operations line. The income statement details for ProElite that are summarized in the discontinued operations
line in the statement of cash flows are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended March 31,</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2014</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2013</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 68%"><font style="font-size: 10pt"><b>Net Loss</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="width: 13%; text-align: right"><font style="font-size: 10pt"><b>(126,911</b></font></td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Working capital and other adjustments</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">32,436</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 11pt"><font style="font-size: 10pt"><b>Cash used by operating activities</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt"><b>(94,475</b></font></td>
    <TD><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD><font style="font-size: 10pt">Investing activities</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">Financing activities</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 11pt"><font style="font-size: 10pt"><b>Net impact on cash flows</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(94,475</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro Forma Financials for Acquisition
of Canterbury, Hygeia, Paloma and VasculoMedics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company acquired Canterbury
and Hygeia on November 18, 2013 and 1,150,115 shares were issued to the stakeholders of Canterbury and Hygeia. On March 28, 2014,
the Company acquired Paloma and issued an aggregate of 2,500,000 common shares to the holders of Paloma Common Stock and its derivative
securities and assumed promissory notes of Paloma in the aggregate amount (principal and interest) currently of approximately $1,130,500
to be paid on the first anniversary of the closing of the Paloma merger. The VasculoMedics Merger also closed on March 28, 2014,
with the Company issuing an aggregate of 220,000 common shares to the VasculoMedics stakeholders. The balance sheet as of December
31, 2013 consolidated the accounts of Canterbury and Hygeia and the balance sheet as of March 31, 2014 consolidated the accounts
of Canterbury, Hygeia, Paloma and VasculoMedics. The income statement for the three months ended March 31, 2014 consolidated the
accounts of Canterbury and Hygeia, along with the accounts of Paloma and VasculoMedics for activity between March 28, 2014 and
March 31, 2014. The income statement for the three months ended March 31, 2013 did not include Canterbury, Hygeia, Paloma or VasculoMedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following pro forma
financial information has been prepared as if the mergers with Paloma and VasculoMedics had occurred on January 1, 2014. The information
in these pro forma financials for Paloma and VasculoMedics has been derived from the unaudited financial statements for Paloma
and VasculoMedics for the three months ended March 31, 2014. The information in these pro forma financials for RestorGenics has
been derived from the unaudited financial statements for the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RestorGenex Corporation, Canterbury and Hygeia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pro Forma Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Three Months Ended March 31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="18" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended March 31, 2014 (a)</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>RestorGenex</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Paloma</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>VasculoMedics</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Adjustments</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Combined</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Revenues</b></font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">$</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Cost of revenues</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Gross profit</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Operating expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 32%; padding-left: 20pt"><font style="font-size: 10pt">General, administrative, research and development</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">611,845</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">102,153</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">81,250</font></td>
    <TD STYLE="width: 2%; text-align: right"><font style="font-size: 10pt">&nbsp;(b)</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 10%; text-align: right"><font style="font-size: 10pt">795,248</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Warrants, options and stock compensation</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">149,885</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">149,885</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Legal and professional services</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">131,686</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,725</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">133,411</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Depreciation and amortization</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">478,104</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">634</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">27,755</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">&nbsp;(c)</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">506,493</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 20pt"><font style="font-size: 10pt"><b>Total operating expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>1,371,520</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>104,512</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>109,005</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>1,585,037</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Loss from operations</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(1,371,520</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(104,512</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(109,005</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(1,585,037</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Other (income)/expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Other income</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(49,639</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(25,397</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(75,036</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Interest expense</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">58,294</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">29,925</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">88,219</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 1pt; padding-left: 20pt"><font style="font-size: 10pt"><b>Total other expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>8,655</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>4,528</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>13,183</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss from continuing operations</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,380,175</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(109,040</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(109,005</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,598,220</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss from discontinued operations</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,380,175</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(109,040</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(109,005</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,598,220</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Basic and diluted loss per share</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(0.23</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(0.18</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Basic and fully-diluted weighted average shares outstanding</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>5,934,474</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,500,000</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&nbsp;(d)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>220,000</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&nbsp;(d)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>8,654,474</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><font style="font-size: 10pt">(a)</font></td>
    <TD STYLE="width: 96%; text-align: justify"><font style="font-size: 10pt">Assumes the mergers with Paloma and VasculoMedics occurred on January 1, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">(b)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact of employment agreements from January 1, 2014 to March 31, 2014.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">(c)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Amortization of intangible assets for Paloma assuming a 20-year amortization period.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">(d)</font></td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Impact on weighted average shares outstanding for the acquisition shares being outstanding for the entire quarter.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following pro forma
financial information has been prepared as if the mergers with Canterbury, Hygeia, Paloma and VasculoMedics had occurred on January
1, 2014. The information in these pro forma financials for Paloma and VasculoMedics has been derived from the unaudited financial
statements for Canterbury, Hygeia, Paloma and VasculoMedics for the three months ended March 31, 2014. The information in these
pro forma financials for RestorGenex has been derived from the unaudited financial statements for the three months ended March
31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RestorGenex Corporation, Canterbury, Hygeia,
Paloma and VasculoMedics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pro Forma Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Three Months Ended March 31, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="26" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended March 31, 2013 (a)</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>RestorGenex</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Canterbury</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Hygeia</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Paloma</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>VasculoMedics</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Adjustments</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Combined</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 19%; padding-left: 10pt"><font style="font-size: 10pt"><b>Revenues</b></font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">46,155</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%"><font style="font-size: 10pt">$</font></td>
    <TD STYLE="width: 8%; text-align: right"><font style="font-size: 10pt">46,155</font></td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Cost of revenues</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">54,765</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">54,765</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Gross profit</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(8,610</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(8,610</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Operating expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">General, administrative, research and development</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">624,674</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">31,331</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">47,880</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">848,732</font></td>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(b)</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,552,617</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Warrants, options and stock</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,316,148</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">1,316,148</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Legal and professional services</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">143,103</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">25,435</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">17,254</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">185,792</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Depreciation and amortization</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">8,687</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">4,212</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">687,713</font></td>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">(c)</FONT></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">700,612</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt"><b>Total operating expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2,092,612</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>60,978</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>65,134</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>1,536,445</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>3,755,169</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Loss from operations</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(2,092,612</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(69,588</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(65,134</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(1,536,445</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(3,763,779</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Other (income)/expenses</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Loss on adjustments to fair value of derivative liability</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">236,850</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;&nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">236,850</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Other income</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(2,564</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(63,910</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(66,474</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt">Interest expense</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">22,971</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,358</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">20,781</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">46,110</font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt"><font style="font-size: 10pt"><b>Total other (income)/expenses</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>257,257</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>2,358</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(43,129</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(216,486</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss from continuing operations</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(2,349,869</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(71,946</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(22,005</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(1,536,445</font></td>
    <TD><font style="font-size: 10pt">)</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(3,980,265</font></td>
    <TD><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss from discontinued operations</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(126,911</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>(126,911</b></font></td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Net loss</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(2,476,780</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(71,946</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(22,005</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(1,536,445</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(4,107,176</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><font style="font-size: 10pt"><b>Basic and diluted loss per share</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(2.77</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(0.86</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Basic weighted average shares outstanding</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>892,534</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,150,116</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,500,000</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>(d)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>220,000</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>4,762,650</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Fully-diluted weighted average shares outstanding</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,207,534</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,150,116</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt"><b>(d)</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,500,000</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>220,000</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</td>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>5,077,650</b></font></td>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 5%"><font style="font-size: 10pt">(a)</font></td>
    <td style="width: 95%; text-align: justify"><font style="font-size: 10pt">Assumes the mergers with Canterbury, Hygeia, Paloma and VasculoMedics occurred on January 1, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(b)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Adds the $848,732 of expenses associated with employment agreements for Canterbury and Paloma executives that would be incurred from January 1, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(c)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Adds $659,958 of additional amortization for intangible assets at Canterbury and $27,755 for Paloma (assuming at 20-year amortization period) that would be incurred if amortization began on January 1, 2013.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">(d)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Impact on weighted average shares if the 1,150,116 shares issued for the mergers with Canterbury and Hygeia, the 2,500,000 shares issued for the Paloma merger and the 220,000 shares issued for the VasculoMedics merger were outstanding for the quarter.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Completed Financings with Net Proceeds
of $31,250,466</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 29, 2014,
the Company closed the initial round of a private placement in the aggregate sum of $11,106,000 of a private placement resulting
in $9,222,900 of net proceeds after payment of fees, expenses and certain accounts payable. On May 6, 2014, the Company closed
the second round of this private placement in the aggregate sum of $13,672,500 resulting in $12,305,250 of net proceeds after
payment of fees and certain accounts payable. On May 21, 2014, the Company closed the third round of this private placement in
the aggregate sum of $3,489,240 resulting in $3,140,316 of net proceeds after payment of fees. On June 13, 2014, the Company closed
the fourth round of this private placement in the aggregate sum of $7,115,000 resulting in $6,403,000 of net proceeds after payment
of fees. On July 10, 2014, the Company closed a fifth round of this private placement in the aggregate sum of $200,000 resulting
in $179,500 of net proceeds after payment of fees. However, given the Company&rsquo;s plans to grow its existing businesses and
potentially pursue acquisitions, this funding may not be sufficient and the Company may need to raise additional capital in the
future to fully implement its business plan. The following is a summary of these five rounds of financing (amounts presented in
thousands (000s) except per share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>First Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>April 29, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Second Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>May 6, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Third Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>May 21, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fourth Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>June 13, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fifth Round</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>July 10, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 23%">Shares sold</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,777</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3,418</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,779</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">8,896</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Price per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Gross Proceeds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,583</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt; padding-bottom: 1pt">Fees, expenses and payment of certain accounts payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,883</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,367</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(349</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(712</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(21</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(4,332</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net proceeds</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">9,223</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">12,305</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">3,140</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">6,403</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">180</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">31,250</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Warrants issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,110.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(a)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,367.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(b)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">348.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(c)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(d)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>(e)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Strike price of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 5%; border-top: black 1pt solid"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 95%; border-top: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 832,950 shares of common stock issued with the financing and warrants to purchase 277,650 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 1,025,438 shares of common stock issued with the financing and warrants to purchase 341,813 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 261,693 shares of common stock issued with the financing and warrants to purchase 87,231 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 533,625 shares of common stock issued with the financing and warrants to purchase 177,875 shares of common stock issued to the placement agent.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(e) </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 15,000 shares of common stock issued with the financing and warrants to purchase 5,000 shares of common stock issued to the placement agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchasers of
Common Stock received warrants to purchase three shares of Common Stock for every ten shares of Common Stock such Investors purchased
in the Private Placement at a strike price of $4.80. The purchase price of each share of Common Stock was $4.00, which was minimum
price under the terms of the Private Placement and approximated the volume weighted average market price for ten days prior to
the close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following pro forma
financial information has been prepared as if the above financings had occurred on March 31, 2014. The information in these pro
forma financials for RestorGenex has been derived from the unaudited balance sheets as of March 31, 2014 and the information presented
above on the financings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RestorGenex Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pro Forma Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>March 31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2014 (a)</b></font></td>
    <td style="padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right"><font style="font-size: 10pt"><b>Pro Forma</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>As Reported</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Adjustments</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>Adjusted</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-align: center"><font style="font-size: 10pt"><b>ASSETS</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt"><b>Current assets</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 51%; padding-left: 22pt"><font style="font-size: 10pt">Cash and equivalents</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">222,071</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">31,250,466</font></td>
    <TD STYLE="width: 2%; text-align: right"><FONT STYLE="font-size: 10pt">(b)</FONT></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">31,472,537</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Prepaid expenses and deposits</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,455,881</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">2,455,881</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 11pt"><font style="font-size: 10pt"><b>Total current assets</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>2,677,952</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>31,250,466</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>33,928,418</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Property and equipment, net</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">81,563</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">81,563</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Intangible assets</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9,725,258</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9,725,258</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">Goodwill</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">13,962,880</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">13,962,880</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 11pt"><font style="font-size: 10pt"><b>Total assets</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>26,447,653</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>31,250,466</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>57,698,119</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-align: center"><font style="font-size: 10pt"><b>LIABILITIES AND SHAREHOLDERS' EQUITY</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt"><b>Current liabilities</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Accounts payable</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,601,721</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,601,721</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Deferred salary</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">838,476</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">838,476</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Accrued interest</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">633,961</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">633,961</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Other accrued expenses and liabilities</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,829,119</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,829,119</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Payable to officer and former officer</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">156,358</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">156,358</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Rent liability for facilities no longer occupied</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,121,495</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,121,495</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Notes payable</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,932,002</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,932,002</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Obligation to issue stock for transfer of liabilities</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,581,641</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,581,641</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 11pt"><font style="font-size: 10pt"><b>Total current liabilities</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>10,694,773</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>10,694,773</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt"><b>Long-term liability - deferred taxes on acquisition</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>3,538,051</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>&ndash;</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt"><b>3,538,051</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt"><b>Commitments and contingencies</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt"><b>Shareholders' equity</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Series C 10% Preferred Stock, $0.001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Series D 10% Preferred Stock, $0.001 par value: 500,000 shares authorized, 0 shares issued and outstanding</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Series E 5% Preferred Stock, $0.001 par value: 10,000 shares authorized; 0 shares issued and outstanding</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">&ndash;</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 8,683,785 shares issued and outstanding</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">8,684</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">8,896</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">(c)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&nbsp;</font><br>
<font style="font-size: 10pt">17,580</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Additional paid-in capital</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">74,670,219</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">31,241,570</font></td>
    <TD STYLE="text-align: right"><font style="font-size: 10pt">(d)</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">105,911,789</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt"><font style="font-size: 10pt">Accumulated deficit</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(62,464,074</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&ndash;</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(62,464,074</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 11pt"><font style="font-size: 10pt"><b>Total shareholders' equity</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>12,214,829</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>31,250,466</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt"><b>43,465,295</b></font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt"><b>Total liabilities and shareholders' equity</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>26,447,653</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>31,250,466</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>57,698,119</b></font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 4%; border-top: black 1pt solid"><font style="font-size: 10pt">(a)</font></td>
    <TD STYLE="border-top: black 1pt solid; width: 96%"><font style="font-size: 10pt">Assumes the financings occurred on March 31, 2014</font></td></tr>

<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(b)</font></td>
    <TD><font style="font-size: 10pt">Net cash proceeds to the Company from financings</font></td></tr>

<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(c)</font></td>
    <TD><font style="font-size: 10pt">Value of 8,895,685 shares sold in the financings at a par value of $0.001</font></td></tr>

<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">(d)</font></td>
    <TD><font style="font-size: 10pt">Difference between net cash proceeds and value of shares sold</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Issuance of Note </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2014, the Company
agreed to issue to our law firm a non-interest bearing convertible note in the aggregate principal amount of $875,000 (the &ldquo;Note&rdquo;)
as payment in full for the amounts owed to them at that time, contingent on the Company successfully concluding a Cash Proceeds
Event, including the $467,200 note that was issued on July 1, 2012. The Note was due in full on March 31, 2015. Based on the terms
of the Note, on May 6, 2014 the Company repaid the note in full upon the receipt of the $21,528,150 in funding mentioned above.
As part of this settlement, the Company also agreed to issue to the holder of the Note 53,457 shares of the Company&rsquo;s Common
Stock sold in the Offering. The holder will be entitled to the same registration and other rights with respect to such securities
as are granted to the purchasers of securities in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Settlement of Amounts Owed</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After March 31, 2014, the
Company has reached a number of settlements with vendors, former directors and employees whereby $875,000 of liabilities were settled
for $225,000 in cash and the issuance of 160,000 shares of common stock valued at $870,000 at the market price on the date of the
settlement for total consideration of $1,095,000, resulting in a loss on settling these liabilities of $220,000. The Company is
currently in negotiations with other vendors, former directors and employees to reduce the amounts owed to them and use a combination
of stock and cash to settle these reduced amounts, but there can be no assurance that the Company will be successful in doing so,
or that such settlements will amount to a material reduction in the amounts owed to these vendors, former directors and employees,
or that these negotiations will not result in further losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 117; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>changefromcontrol.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 changefromcontrol.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`#J`5(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]C/VCOVCO
M'W@+X^^!?AU\.O`O@_Q?K?B_P_KGB2>?Q)XNN?#UK86^F7.DV[(K0:=?/+)(
M^K1D`H@40M\Q)`K/_P"%C_M3?]$;^`'_`(>35_\`YF*/B-_RE-^#?_9*O'G_
M`*=_!E?0%`'S_P#\+'_:F_Z(W\`/_#R:O_\`,Q1_PL?]J;_HC?P`_P##R:O_
M`/,Q7T!10!\__P#"Q_VIO^B-_`#_`,/)J_\`\S%'_"Q_VIO^B-_`#_P\FK__
M`#,5]`44`?/_`/PL?]J;_HC?P`_\/)J__P`S%'_"Q_VIO^B-_`#_`,/)J_\`
M\S%?0%%`'S__`,+'_:F_Z(W\`/\`P\FK_P#S,4?\+'_:F_Z(W\`/_#R:O_\`
M,Q7T!10!\_\`_"Q_VIO^B-_`#_P\FK__`#,4?\+'_:F_Z(W\`/\`P\FK_P#S
M,5]`44`?/_\`PL?]J;_HC?P`_P##R:O_`/,Q1_PL?]J;_HC?P`_\/)J__P`S
M%?0%%`'S_P#\+'_:F_Z(W\`/_#R:O_\`,Q1_PL?]J;_HC?P`_P##R:O_`/,Q
M7T!10!\__P#"Q_VIO^B-_`#_`,/)J_\`\S%'_"Q_VIO^B-_`#_P\FK__`#,5
M]`44`?/_`/PL?]J;_HC?P`_\/)J__P`S%'_"Q_VIO^B-_`#_`,/)J_\`\S%?
M0%%`'S__`,+'_:F_Z(W\`/\`P\FK_P#S,4?\+'_:F_Z(W\`/_#R:O_\`,Q7T
M!10!\_\`_"Q_VIO^B-_`#_P\FK__`#,4?\+'_:F_Z(W\`/\`P\FK_P#S,5]`
M44`?/_\`PL?]J;_HC?P`_P##R:O_`/,Q1_PL?]J;_HC?P`_\/)J__P`S%?0%
M%`'S_P#\+'_:F_Z(W\`/_#R:O_\`,Q1_PL?]J;_HC?P`_P##R:O_`/,Q7T!1
M0!\__P#"Q_VIO^B-_`#_`,/)J_\`\S%'_"Q_VIO^B-_`#_P\FK__`#,5]`44
M`?/_`/PL?]J;_HC?P`_\/)J__P`S%'_"Q_VIO^B-_`#_`,/)J_\`\S%?0%%`
M'S__`,+'_:F_Z(W\`/\`P\FK_P#S,4?\+'_:F_Z(W\`/_#R:O_\`,Q7T!10!
M\_\`_"Q_VIO^B-_`#_P\FK__`#,4?\+'_:F_Z(W\`/\`P\FK_P#S,5]`44`?
M/_\`PL?]J;_HC?P`_P##R:O_`/,Q1_PL?]J;_HC?P`_\/)J__P`S%?0%%`'S
M_P#\+'_:F_Z(W\`/_#R:O_\`,Q1_PL?]J;_HC?P`_P##R:O_`/,Q7T!10!\_
M_P#"Q_VIO^B-_`#_`,/)J_\`\S%<_P#$3]JCX^_`ZU\/ZOXU^$'P@M_#.J>*
M_#_AB\N-$^*FHZA?VG]K:Q9Z5'/';R^'[>.7RY+Q'*--'E4;#9Q7U!7S_P#\
M%+/^3=?#G_95?AQ_ZF^A4`?0%%%%`'S_`/$;_E*;\&_^R5>//_3OX,KZ`KY_
M^(W_`"E-^#?_`&2KQY_Z=_!E?0%`!1110`4444`%%%%`!1110`5YK^V'XD\:
M^$/V8/&^I_#JTFO?&EGI<DFEQP6HNIU?C<\4)R)ID3>Z1$$.ZJN#NP?2JK:Q
M%=SZ1=)I\]M;7[PNMM-<0-/#%*5.QGC5T+J#@E0ZD@$;ESD14NX-+?\`KT_-
M%1MS*_\`7Y_D?F5X0_;6^-UY\0M/\.>*/CAX?^''PWTS7VNM3\6^.?`=OX:\
M4KH0N2NGQW<U[/#90:AJ<D<\4=N=)AD%K!)<;8W,2O\`67_!1_\`;8US]CWX
M;^$K7P-X/'CWXG?%/Q'#X0\&Z1-<_9;!KZ:*68W%W-U2VABADD?;\S!0H*@E
MTY'QS_P2UEU?X=Z$=#\<V-G\2;;4]5UG7O$^L^&QJ]KXEO-5L6L;^:6R-Q'L
M(@9([95G*V\<,46)8@R-T7[37_!,+PM^T3^R1X!^&%OXG\6^$]3^$C:;>^!_
M%^G7"'6-!U#3[?R+:Z)9=DV4R)8R`'5V`*':RT_X:@^CA>V\EISV>EFDK)^Z
MFVVHPZQ&ZJ.2ZJ=K[1>O)=:]7K\5DDG*9XYXC^/7[;_P/_9S^-NI_&7PW\"+
M?^P/ASKGB/P[XS^&NHWC1:-J-I:2/#;W%AJB,\[.W[Q77]THA*NK;QB+_@GO
M_P`%U/`/QV^'&GZ-X^M_B+X5\4^&OA?:^/\`6?$GBCPJVD:3XHLHK>+^T-1T
MXJ`9H4F9N5A16Y\H.HXW_"/_``3`^.?BOP+\3-+^,W[7WBOXK2^.?!.I^"].
MMH/!.G>'M%TE+Z%HY+R>QMF/VNX0[#&_FQ%5\Q,D2<7-3_X(R:'XSO\`P9;^
M)O&5QJGA_P`.?`^Y^"FHV-OI8MIM4@G%NKWZ3&5Q`X$'$120`L#O.W!;<TIV
MLVXZ>JC6:_\`)O91E:UT[MOE<BDH/D3NK2=_1NBOR]HU>]FG:W,D-_9@_P""
MZ'P\_:B^-O@7P';_``P^/O@C5/B6E[=>&;SQAX._LC3]:L[6T^U->V\[3,LL
M#QE0ICW-ETW*JL&KDO@;_P`')GP%^-'B#1([OPU\8_`?AOQ%INJZAI_BSQ3X
M5%KX?NVTR*6:]MHKJ*:42SQ10R.1$KKP%W;R$-[]FW_@D'\5OAK^T1\)?'/Q
M*_:FU_XO6?P7AU&P\.:->>"[+2HX;.[L!9A9)H)3)-.H5&,\QD+A<;4+,QY;
MQ?\`\$&=,C_8I^#?PTUKQ9K7CC2?@E!XH>[L='T6WLM1\8QZO:WL)M[<W%X(
M+29/M7R/+(Z%D&[8"2%B)*$)3IZV6E_62N_1<K:6[NHNV@4%S/EJZ/RVV;:5
M^CE9)NUD]==5Z!^S3_P7E^&W[2WQU\#^`4^&?QZ\!ZA\1[:_U'P]J/C/PBFC
MZ9JEA:6HNFOH9WG/FV[QD;6C#')&Y4#*3I?LP?\`!<[X1?M6?'G0_!6C>&_B
MWH&F^-9+J'P5XR\1^$Y=,\+^.Y+;<TD>FW;L6D;8DC@21Q\1L.&PI^#O^":O
MP;_:$_:9_P""@OPDN/B%_P`-*:]\,/@OH6N:?+<?%SX;V7@2*TM+RP%C;6ML
MMO/.^IW+`-YMQ))D(@X&_+_57_!/W_@WXT;]A#]HRQ\4+XX\)>+_``=X6$I\
M+Z/<_"+PS::]I[L2(I+K7TMC?74D:LWSJ869MI)V@HV\8PYXM_`TW_Y-):I;
M2LHVM[M[MOEL8R<^64?MII6\[)Z7WC>][VE:RMS<ULC_`(+&?\%4_&_[#7[=
MGP/\-:3!\3;3X=0Z/J?C/QS)X:\$6>NCQ!86A7-FLUQ+']G$2QR-/*C(85N+
M=B6#X'2:A_P<;_"^'1[.XT_X-?M.Z]=WEG+KG]FZ7X"%Q?6V@KM$>O31?:`8
M=.F)<12/M=A$[>6%*,WK_P#P4'_X)G_\-W^,-.U7_A-?^$5^P>!?%7@KRO['
M^W>9_;=M!!]ISY\>/(\G=Y>/WF[&Y,9/GO[0_P#P1\\9^+O%VA^*/@_^T)K?
MP4\5R>!K/X>^+[RV\*VFMV_BK3+52(66&XD'V2X4O+B:-V8*X`Q@EN2FZD:?
M*]7=O7S=2UWORKEI)VVC*3BN9,Z:G(YJ4=-+/Y<FWF^:HUYQBI/EL=I^TK_P
M6<^%/[.WACX1:M9:+\1_BC;_`!TTR]U3P7#X#\/G6+O5TMH()VC6W+I*)'2=
M2`5PNR3S#'MKBOV:?^#A'X)_M5?%?X;>&?#GAGXQ6=C\4G:PTGQ-JWA%[+P_
M'JR122RZ/)=M)AKV,1D,(5EBRRXE/)'H_@?_`():^&?A-\0_V9+[PKK5Q8>'
M?V9]"UC0].TN[LQ=7&L+?VD%OYSW&]!%(IB9V(B8.92`$`KC/AU_P1X3X??#
M+X">'5^(*W!^"/Q,U+XC-<C0/+_MTWDVHR?9"OV@^24%^%\W,F[R?N#=A>GW
M%576+E\U'G:OYOV;YO5)6W3Y_?>&3VJ6^7-RR?W<RC'TE)WV<;G[9W[:WQPO
M/VL[?X`_LS^#OA_JGQ`L/#D7C#Q)XE^(5S=P^&]#L)9Y8+>W$=G_`*1-<S/%
M(1M(5%3D/EC'T7AG]M?X@?LJ?L=>+_'_`.UQX;\(>"]3\#78M#=>!M0FU:P\
M7"3RUMWL+:51<122S2BW6"8EBZ[BRHWRU/VV?^"9WB#X\?'W2OC)\'?C-X@^
M`?QCL-&_X1F[UVST2UU_3M:TGS6F%O=Z?<E8Y'21BT<NX%-S9#80IEZE_P`$
MI_$7Q9_8A\5_"_XM?'WQ]\3/&?B?6(?$L/C2:PM-./AW5+:2*6SETZQB&RW@
MC>")FMS(RLQF(,?F''/#F5%W^+6_5_'HX=-*>EI-)RW6O,MIV=56VTMO;X->
M;KK/K%-J-K=8O&M/^"^7PFL_V;_BA\0?$G@CXT>`K[X0'3I/$G@OQ5X772O%
M-O:W]Q';VMXEK)/Y;P.\A^82[@(V^7E`_A?[=G_!P2FI?L'?&/6OA'X2^-OP
M]^*7PYU?0+*6U\2^!XK>^L;34+I6BU!K:X,J"TN(8IHD>10_F30_(N]&KT/Q
M!_P0K\4?&'X(_%^T^*O[0>I?$?XM_%RWT72KCQO/X.M=-MM)TO2[^*^@LX=,
MMIDC^:19-\GFC)=3MRK;^S_:\_X(U_\`#57B3X^ZA_PL?^P?^%Y:/X5TGR_^
M$?\`M7]B?V)>"Y\S/VE//\_&W&(_+ZY?I6MM87?VE>VR2Y7?7>]G%KNY6NN5
MA3:6KZ/KU5XKIVO-KNE&]FVGE^+O^#@_X4?#CQ7XAT;Q!\/?CII<O@K3K*^\
M2W<_A2,6N@R7MA;W=E9W#"XRMY<R7"VL=N%+F=)`0L:F6N8_:)_X+4)\4OV`
M/C?XA^&VD_$SX,?%[X71Z7-<>'OB#X5BTS7=/M[R]@CBN_LDWG1/!*AF16Y(
M*G(7*$^I?&3_`((_Z1\<--_:$@U7QOJ=G-\:]=T3Q-I5YIU@(;KP=J.DVMO%
M:3HS2,+C$ULDA!6/*LR?[=<"_P#P1"\4?$;X._&.+XJ_'_4OB9\6_C#I^EZ%
M<>-I_"%KI=MI&EZ?=I=06L.F6TJQ\R>87?S1N+J<`JV]0?,US*VS?W)M+S4K
MQ=[1Y%=-R=B%>*C;R_/5OR<=5;7FT:27,_T"M)#+:1,W)9`2??%24RWB\B!$
MSG8H7/KBGTWOH33NHI2W"BBBD6%%%%`!1110`4444`%?/_\`P4L_Y-U\.?\`
M95?AQ_ZF^A5]`5\__P#!2S_DW7PY_P!E5^''_J;Z%0!]`4444`?/_P`1O^4I
MOP;_`.R5>//_`$[^#*^@*^?_`(C?\I3?@W_V2KQY_P"G?P97T!0`5X5\:_\`
M@H5X#^!?CG4O#>HV_B/4]9TDQ-=6VEV(N7AA:+S7N&&\$0Q)M+N0!\XV[BK[
M?=:^3/VFO'7C_3_CCXCL_#'P/\.>)#!86LI\0:IH<EPFIV2E7:T6:,$R3&<H
M$C.%B\HR/E3E/GN(L=B,+3IO#RY7*5G[DIZ6;V6VVK?2]M3YCBW,<3@L#[;"
MRY97M?D=3=/[,=;WM9O1.W-HSZPMYUNH$D0Y210RG'4'D4^N"_:3DUO_`(9S
M\87&AZ]J'A#7;71KB[MM3L8;6YN+"6.,R91;F*6!C\NWYXW&">.E?'^@?M7_
M`!3^,G[.?[$>A6WCJ]\+>*?VA-`CU+Q/XOT[2]/EU&-K?0/[0D^SP7%O)9QM
M-/MW$P,JIO5%4LK)]`Y:3DOL<M_^W^:WW<CO\K7/IE\,7)_$I/JOA46]-U?F
M5OQL??M%?EI'_P`%%/C9\>/@QX-FTOQE_P`(#KFD_!/Q!\3]7OM/T*RG_P"$
MCU+3+T64-O+#=1S+%92F.25U@*3-YJ!)H@OS?6'[0'[:'Q&^$_["-A\<?#?P
M[\(>*=.TWP%/XZ\4:?K'BVZ\/W5E%#IZ7IAM$CTZ]6>1E$Z[97A"E(QN;>Q2
MHI24I1=TG_[=.-_OIR\]-M4)RY9*#W?_`,C"5ONJ1^_R9]-T5\__`/"Q_P!J
M;_HC?P`_\/)J_P#\S%'_``L?]J;_`*(W\`/_``\FK_\`S,4BCZ`HKY__`.%C
M_M3?]$;^`'_AY-7_`/F8H_X6/^U-_P!$;^`'_AY-7_\`F8H`^@**^?\`_A8_
M[4W_`$1OX`?^'DU?_P"9BC_A8_[4W_1&_@!_X>35_P#YF*`/H"BOG_\`X6/^
MU-_T1OX`?^'DU?\`^9BC_A8_[4W_`$1OX`?^'DU?_P"9B@#Z`HKY_P#^%C_M
M3?\`1&_@!_X>35__`)F*/^%C_M3?]$;^`'_AY-7_`/F8H`^@**^?_P#A8_[4
MW_1&_@!_X>35_P#YF*/^%C_M3?\`1&_@!_X>35__`)F*`/H"BOG_`/X6/^U-
M_P!$;^`'_AY-7_\`F8H_X6/^U-_T1OX`?^'DU?\`^9B@#Z`HKY__`.%C_M3?
M]$;^`'_AY-7_`/F8H_X6/^U-_P!$;^`'_AY-7_\`F8H`^@**^?\`_A8_[4W_
M`$1OX`?^'DU?_P"9BC_A8_[4W_1&_@!_X>35_P#YF*`/H"BOG_\`X6/^U-_T
M1OX`?^'DU?\`^9BC_A8_[4W_`$1OX`?^'DU?_P"9B@#Z`HKY_P#^%C_M3?\`
M1&_@!_X>35__`)F*/^%C_M3?]$;^`'_AY-7_`/F8H`^@**^?_P#A8_[4W_1&
M_@!_X>35_P#YF*/^%C_M3?\`1&_@!_X>35__`)F*`/H"BOG_`/X6/^U-_P!$
M;^`'_AY-7_\`F8KC_P!H7]K']I+]FOX!>./B+KOP3^"%WHG@'P_?^)-0@L/C
M!JCW4UO9VTEQ*D2OX:1#(4C8*&=021E@.:`/K"BO"=>_::\=_L__`+/_`,2/
MB-\;/!G@?PIHG@+1I=:B3PCXOO/$DM_'#%+),KB?2['R6&R,)M\W<9&W;-@W
M?`.F_P#!2[XX_$SP[K7A/7/'^H_!GXD?#?P#XJ\?^+%FT;0[I%U&W:SO+#2%
MDVW,$VFPV.HVY>2+;=2`QEI87WK6;J13DOY4Y/R23;?W1>WDMVKW[.346OM-
M)>K:7YRBM>_9.WZZ45^97PA_X*(?%_XF_%;PAXRO_$W]BV.K_%?1OAM=_"_^
MR[/[.MG>^'X+^6\,QA:_%W').TX)F2'R(-K0@[GK]-:Z)4I15WWM_P"2QG_Z
M3.+^=MTSGA6C-VCVO\N:4?SC)?+LPHHHK,U"OG__`(*6?\FZ^'/^RJ_#C_U-
M]"KZ`KY__P""EG_)NOAS_LJOPX_]3?0J`/H"BBB@#Y_^(W_*4WX-_P#9*O'G
M_IW\&5]`5\__`!&_Y2F_!O\`[)5X\_\`3OX,KZ`H`*_/;_@H#X+UT?MD07J^
M(_!=LNIZ=]ELKO6/&UOI4GARWFA,#-]EDD60@2AY@T2L7(VGIBOT)KY&^/7[
M*GCG4_C]XO\`&FD^'OV=]=T'5DM'>7QU8W%W=:>+>`*[!EC*Q@]3\V,*IP#G
M/Q?&F"J8FEAX0BVE4N[=(\LD[Z:)WLVFFKZ-79\)XB9?5QN5*A1A*3YXOW=6
MN6\D[6:>J2LUHVI;I'U1JOA^T\5^$KC2M0'VZQU*T:TN0&*_:(W0J_*G(W`G
MD'//!KRWQ;^P-\*O&GP-\$?#FZ\/:A:^%_AK';1>%AINOZCINHZ$MO;-:Q^1
M?V\\=XA^SN\3'SLNCL'+`FO7;#_CQA_U7^K7_5?<Z?P^WI4U?:3BG=/K:_G:
M]ONN[=KNQ]Q1;Y(V[?FE?[[*_>VIX5\1_P#@FG\$OBIX,\(^'M4\$)!HO@;2
MI=!TBTTK5;[2$CTV41B:PF^R31&YM)?)B\RWG,D4A0%U8UG_`/!5*P@TK_@E
M'^T?:VL,5M;6WPF\310PQ($CB1='N@JJHX`````Z8KZ%KY__`."L7_*++]I;
M_LE7BC_TT75-R;O?KJ_7N59:>6GR/H"BBBD,****`"BBB@`HHHH`****`"BB
MB@`HHHH`\4U36?B[IOQ=T/PK_P`)9\.'_MG1]1U7[5_PAEZ/)^R36,7E[/[4
MYW_;<YW#'EXP=V1[%HT5W!I%JFH3VUS?I"BW,UO`T$,LH4;V2-G<HI;)"EV(
M!`+-C)X'Q/\`\G=>!_\`L4/$/_I;H=>CUY67TE"K62;=I)*\I/3EB^K?5L\7
M*Z"IU\0E*3Y9)*\I2LN2#^TWU;UW^04445ZI[04444`%%%%`!1110`5\_P#_
M``5B_P"467[2W_9*O%'_`*:+JOH"OG__`(*Q?\HLOVEO^R5>*/\`TT75`'N^
ML:/:>(M(NM/U"UMKZPOH7M[FVN(A+#<1.I5T=&!#*P)!!&""<UY8_P"P%\")
M?`^C^&6^"GPD;PWX>O7U/2M)/@_3S8Z9=OC?<00^3LBE;:N70!C@9/%>N44+
M1W6^GX.Z^YZKS!ZJS_J^C^]:'%O^SA\/)/C2GQ(;P'X,;XB1V_V1?%)T2V.M
M+#L*>4+S9YVS82NW?C!(QBNTHHHZ6_KN'6X4444`%?/_`/P4L_Y-U\.?]E5^
M''_J;Z%7T!7S_P#\%+/^3=?#G_95?AQ_ZF^A4`?0%%%%`'S_`/$;_E*;\&_^
MR5>//_3OX,KZ`KY_^(W_`"E-^#?_`&2KQY_Z=_!E?0%`"."R'!P<<''2O@?X
MT?L577B'XG:YXG\7?M!^'YM3\,):S:PL_P`/;)X8XIF9;87<2R>5.1@A3*CE
M``?E&#7WP3@5^;O[9WBGXC6?QYU*U6TTGP?X>\:VED_BO0+SXB:':RZU&@V?
MNC<%9;?**8F=%(?9WQBO@..7A8/#5,12E4ESVC9U>6,FG:4N1I63M=N\N6ZB
MG=GYQXG/!QRN-3&T9U8I_#!U5TT;]G**=I<K]Y_#S<OO:'Z/647D642;E?8B
MKN50H;`Z@#@5Y)^U_P#MG:#^QSHWA:34]"\3>*M8\;:NVBZ'HN@K:"\O[A;:
M>[DP]Y<6]N@2"WE8^9,I.T*H9B%/K.F8_LVWVJ$7REPH?>%&!QGO]:^:?^"E
M'[&VO_M<0?#633-&\#>.M'\%Z]/J>L^!?&M_/9:!XJBDL9[>(SR16MW^\MY9
M$FC#VTBDJ?N,%<?=XES2?)O=?GK^'_#]3]&PG)R+FVY7]_+IOYVW*GC'_@KK
M\.M`^%W@;Q7H_A[Q_P",K7QOX+D^(OV/1-/MFO-#\/1)$T^HWB3W$0"QF9%\
MJ%I9G8-Y4<@4D;?_``4\\1V7C'_@D=^T-J^FW"W>G:I\(?$EY:3J"!-%)HUR
MZ.`<'!4@\CO7SG=?\$I_C/X(^#O@+3O#_BCP/XI\40_![5/A#XFN/$>IW\%O
M807LT<T=W9.EO-+<BUP\*P3>3YL:19EB(;/HW_!4?]C/X<?\.?\`XBZ;XC\&
M^$O&6H?!_P"#NNVWA;5=:T2WO+S19;?175;BUDE5WMY2UM`^Z-@VZ)#DE01T
MRY+SMWT].:HO_2%2=^\I*^EHYKG7(M]-?_`8?G)U%;M&.BO>7VG17S__`,.G
M?V6?^C:?@!_X;S2/_D>C_AT[^RS_`-&T_`#_`,-YI'_R/61J?0%%?/\`_P`.
MG?V6?^C:?@!_X;S2/_D>C_AT[^RS_P!&T_`#_P`-YI'_`,CT`?0%%?/_`/PZ
M=_99_P"C:?@!_P"&\TC_`.1Z/^'3O[+/_1M/P`_\-YI'_P`CT`?0%%?/_P#P
MZ=_99_Z-I^`'_AO-(_\`D>C_`(=._LL_]&T_`#_PWFD?_(]`'T!17S__`,.G
M?V6?^C:?@!_X;S2/_D>C_AT[^RS_`-&T_`#_`,-YI'_R/0!]`45\N?$#_@GC
M^R+\,_LG]H_LP?".Y^V[_+_LKX-P:MMV;<[_`++8R^7]X8WXW8.,[3C-^%?[
M#W[&OQH\EO#_`.S1\(YK:YLUO[>[O/@Q%I]I<P-MVO'/<6$<3[@ZE0K$LN2`
M0"1RO'895?J[J1Y_Y;J_W;G'+,<)&O\`5I58^T_EYES?=>_5'UK17S__`,.G
M?V6?^C:?@!_X;S2/_D>L[Q;_`,$S_P!D+P!X>N-6UW]G[]F[1=*M-OGWM_X%
MT6VMX=S!%W2/`%7+,JC)Y+`=ZZ)SC"+E)V2.J<XPBYS=DM6WLD>E>)_^3NO`
M_P#V*'B'_P!+=#KT>OYR_%OASP%JOQ>UKQ-HWPH^%6A6&IZBU[;Z"/!NDW&E
M6B!)(H(VM6M1;2M%%*RB1H=Q9F?AV)K]H_!W_!+#]FG6O".E7FK?LK?`#1=5
MN[.&:]T[_A!=&N?L$[(#)#YJV^V38Q*[UX;;D=:^$X,XPPF>5\6L-&2Y9)W:
MT:<5%/R;Y6[/IM?6WYKX?\>8'B+$8U8.$ER33NUHXN*BG?HWR-\KMHU:]G;Z
M1HKY_P#^'3O[+/\`T;3\`/\`PWFD?_(]'_#IW]EG_HVGX`?^&\TC_P"1Z^]/
MTP^@**^?_P#AT[^RS_T;3\`/_#>:1_\`(]'_``Z=_99_Z-I^`'_AO-(_^1Z`
M/H"BOG__`(=._LL_]&T_`#_PWFD?_(]'_#IW]EG_`*-I^`'_`(;S2/\`Y'H`
M^@**^?\`_AT[^RS_`-&T_`#_`,-YI'_R/1_PZ=_99_Z-I^`'_AO-(_\`D>@#
MZ`KY!_X*J_M6_"[4O^"?/[2'@ZW^)/@&?Q=/\//$^C1:''XAM&U*2^.FW4(M
M%MQ)YAG,IV",+NW?+C/%=]_PZ=_99_Z-I^`'_AO-(_\`D>OD;_@M3_P3V^`7
MP?\`V*]=U'PE\#_A!X7U"31O%>^ZTCP;IUE,_D>"_$5Y#EXH5)\NZMK:=.?E
MEMXG&&12.7%SJ0@I4VMTM5?=I=UW/=X?PN#Q->=+&1DTH3DN62C\$)3L[PGO
MRVZ6O?78_2[0-?L?%>A66J:7>VFI:9J4$=U:7=K,LT%U"ZADDC=25=&4@A@2
M"""*MT45U*]M3Q)\KD^7;[_\OR04444$GQ]\6OVQ_P!I_P`)?M!6^@>'OV7?
M[<\+M/J4<%]_PEUL/[8AA=!;W/V@#RK#<IW^3<!GDW[4(,;Y]_\`V;/B-X\^
M)W@.YU#XB?#C_A5^MQWSP1:3_P`)!;ZWYUN$C99_.@4(NYF==A&1Y>>C"OC7
M]O;X=_&?]KCXKZ+I^N_LLW?C'X>>"-4U+R+,?%.RTVW\3HX\JVO66,QS02*J
M[U5BV%FD0C)R/HG_`()L?!W_`(4A\!]1TG_A37_"CO.UR:Z_L#_A+?\`A)OM
M.Z"W7[7]IW-MW;-GEYX\G/\`%7S.3U\3/%U(5)3E!+3GBXWVZ>R@NZ^-]^7J
MOW7C#*<EI<)8?$TZ.%IXJT>94*T:DE[\_B_X4:LN9QY927U5J-U'VD+<L?H.
MOG__`(*6?\FZ^'/^RJ_#C_U-]"KZ`KY__P""EG_)NOAS_LJOPX_]3?0J^F/P
MH^@****`/G_XC?\`*4WX-_\`9*O'G_IW\&5]`5\__$;_`)2F_!O_`+)5X\_]
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M_P#!6+_E%E^TM_V2KQ1_Z:+JOH"OG_\`X*Q?\HLOVEO^R5>*/_31=4C0^@**
M**`"BBB@`HHHH`****`"BBB@`KR_]E/6;3P[^Q=\-M0U"ZMK&PL?!6EW%S<W
M$HBAMXDL8F=W=B`JJH)))P`"37R__P`%Q_CQJ7@GX<^%_".A^)[;2YM<FGGU
M;3[6ZGBU&ZM/*:)0PC(3[(Y>9767_6,L>P,(Y=OSU_P2L^`L_P"V'XNO_#GC
MB[\1ZW\+?!%F;U-%_MN6'3XM0G=UA'DJX9<JUY)NBV_,OS-ARK_F.:<;NGQ'
M')L)1]I4Y7%/FLKRY9:V4FE%1N^OD?CV<^(DJ7%D,@P.']I647%-RM'FGR3U
MM&348QBW)V;\NI]J^.O^"C7_``G7B&_\*_`GPCJ7Q:\3VFZ&?4(?]&T#2Y-M
MQM,UTY57^:$%0&2.96PDV[BCP+_P3E_X3GQ#8>*OCMXNU+XM>)[3;-!I\W^C
M:!I<FVWW"&U0*K_-"0Q*I',K9>'=S7T=X2\':1X`\/6^DZ%I6G:+I5IN\BRL
M+9+:WAW,7;;&@"KEF9C@<EB>]:5?40X?EB9*KG$_;-:J%K4H_P#;MWS/^]-R
M_NJ.I]E#A>6,DJV?5/;M:J"7+1B_\%WSM?S5'+O%0NSP.Z_9K^'7A;]KKP)_
M9G@'P5IWE>'-:U!/LNAVL.RY@O=&\F<;4&)(_,DV/]Y=[8(R:]\KSCQ/_P`G
M=>!_^Q0\0_\`I;H=>CUZ&68>E1JUXTHJ*YULK?8AV/4RC"T:%;$QH045SK9)
M?\NZ?8****]8]L****`"BBB@`KFOB=\8_"OP6T6/4/%GB'2?#UI.YBA>^N5B
M-PX1G*1J3EV"*S$*"=JL>@)KI:Y3XO?`WP?\?O#*Z-XU\.:3XGTI)/.6TU&`
M3PI(`0)`IX#@$@,.0&.#R:QQ'M?9OV%N;I>]OP\C.K[3D?LK<W2^U_,S;S]J
M7X;6&N:+ILGCWPB+WQ&EO+ID2ZK`QO4N,_9W3#$%9BK",])",+N/%?(W_!:S
MQVGQ9_8U^(=GX9TO7=:L/!&@^+6U_6H+%QI6G/+X5US2DB$[[1<,+R\6.9K?
MS4M/)G-T]N(S7UIJ?[)_PVUGQ3X>UNZ\%>'[C6/"4<4.B7SVH-QI4<7^JC@?
MK&B9RJJ0%/(`/-?EU^W5\7_$9^%_QN\,V8\8W_P6^'_AKXD>!K74_#UY#`=<
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M;BW2ZCM;B6\2R7!>0Q6T>UV6-7WA01^<'P/_`."47[1'[,7C?XT277P.TSQM
MHOQ`\-^(?"NF0V/Q!LM8E>_U33]&2;5[N?4([&1K>XN+*9IY%7[09"^VUV*D
MDOKT:E25^>-FH<WK+I%/;7:_2ZEJDSXW'4</3K2CAI\T.?EB[?8O\;6CVM*W
M6SCHVC]B)_VB/A_:_&:'X<R^.?!T?Q"N;4WT/A=M:MAK,MN%9O.6TW^<8]JL
M=P3&%)SQ78U^8_P=_P"">?QA^&OQ8\*>#-0\+/J]CHOQ9T;XCW/Q1.J67V:6
MRLO#T%A+:>3YPOS=22PO;@-`T7DS;FE)RM?IQ77*,5&Z=]?_`&V+O\FW'SY>
M;:22\V$Y-VDK:?K)6^Y*7ES<NZ;?Q3_P5K_9_P!/^*7CGX1>)O%/PK\5_%CP
M!X3FU:'7=+\*^?+K2-=00K;-'#%+&TD/FQ`OM964HASMWH_E_P#P3;_8Y\1_
M`W]H/PCXK\.?#SQ3\./#WBG4/$MWJUCJ-[.S)X?*0_V1;7T<DC*M\EP[E$`W
MB+>79V#-6U_P54^$_P"SW\!-"M+O7?@Q>_$?Q/XDO];\71:=%XHO=*B+".U?
M5+R2<387]W';XB1&R5PBKEC7OW_!,NR^&&A?"#Q=H_PK\*R^#]'T#QE?Z7J5
MDVIS:BLE_$D"O*DLKNV&B\C*Y&U@RXR"3\+@L'2JYS4G/E4XKF]W5J_+?5TX
MW6C5U)V3E&WO.W]43XDQN6^&=*GA/;3H5%4I>_%1HN,I54Y<BQD_>C4JWC4>
M'2E*$%>]-M_1U?/_`/P4L_Y-U\.?]E5^''_J;Z%7T!7S_P#\%+/^3=?#G_95
M?AQ_ZF^A5]L?RX?0%%%%`'S_`/$;_E*;\&_^R5>//_3OX,KZ`KY_^(W_`"E-
M^#?_`&2KQY_Z=_!E?0%`!7PY^V7^TA\0?AS^T!XDT72OBMJOA&<Q6;>%?#*>
M!8]4;Q(\D:AUANC&V/WN5^8_>)&!BON&0%HV`QDCC/2OSC^)_P"PIK]W\1;:
M/Q'I/[+=OJ]U$&L[>\\3^([:[GMHOE#+']I7=M`Y(&,]37PG&L\>Y8:E@D[<
MUY-2G'2S5O<W>MUS7CIK&2/SOQ*J9BLLC#+$^=RW4ZD+=$FZ=I:N6BYDN9*Z
MDKH_1FR+FRB\PL9-B[BRA23CG('`KY,_X+"_&[QWX%^!WACP#\,KB+2O''QD
MUT^&K+6;C59=(ATFWBM+B_O&6]CCE>WN9+:TEA@=8W*RRJX4[*^LK"`VMC#&
M0H,<:J0A.T8&.,\X^M<_\6_@MX.^/_@N;PWX[\)>&?&OAVXD2:72]>TN#4K*
M5T.Y&:&960E3R"1D'I7W%>,I*T';5?G_`)'Z)A)<L4YKI^-M'??1ZGYM_M,_
MMBZA^U3X?\)>)=*\6>/OAGX-N/V<=;^+6A0V'B.XT>Z_MJ!K40M<SPNOVU+9
M'R89"\$GG;I(W#)CVK_@I#J7Q4^*/_!%SQKXBT_Q!X/\.&_^"FLZEXST_6/#
M$^J76H>;H322PVDT-]:QV<@_TA=[PW"Y>,^6`A63ZG^(?[,7PU^+NF>'K+Q9
M\/?`_B>S\(RI/H4&K:#:WL6BR(%5'M5E1A`RA5`,>"`HQT%><?\`!6+_`)19
M?M+?]DJ\4?\`IHNJVYHKG45HW=>2YJDOOM.,'Y4XZ[*.:A+W&WLK/_P&"^Y.
M$I+SJ2TZR/\`A7/[4W_19/@!_P"&;U?_`.:>C_A7/[4W_19/@!_X9O5__FGK
MZ`HJ#0^?_P#A7/[4W_19/@!_X9O5_P#YIZ/^%<_M3?\`19/@!_X9O5__`)IZ
M^@**`/G_`/X5S^U-_P!%D^`'_AF]7_\`FGH_X5S^U-_T63X`?^&;U?\`^:>O
MH"B@#Y__`.%<_M3?]%D^`'_AF]7_`/FGH_X5S^U-_P!%D^`'_AF]7_\`FGKV
M[Q;H=SXD\/7%E9ZQJ6@7,VW9?V"6[W$&&#':)XI8N0"IW1MPQQ@X(\F^$/AG
MQ;K?Q'\9P:A\4O&M[9^#O$EO806TEEHR)?0'3=/O&28I8*_S/<R*3&R'9MP0
MPW'AQ.-=&I"G[.4N9VNN6U[-ZWDGLNQYV+S!T*U.E[*4N=V37+:]F];R3VBW
MLS*_X5S^U-_T63X`?^&;U?\`^:>O$_C1^T;^U%\.OC7H_P`/?!WC#X(?%;QO
M*/M^JZ'IWPQU+2QI=@JAB\]Y+XCDC@D<%`@=#_K%)^_$LOJOQI_:6\6?&;XS
M/\)?@C=VUOK&CS(_C#QC+;)=V/A2(-S;QHX*37;E678<@89>&$KV_H_[*W[*
MVA_LK^!Y[*RGN=:\0ZU-]N\0>(+[+7VNW9)+2R,22%#,^U-QV[F)+.SN_BU\
M?B,QJO"Y:W&$7:=732V\:=[WET<FG&.JUDK+Y[$9EBLUK/!93)PIQ;52NK.S
M6\*2=U*=])3<7"&J]Z:LOGSX9?\`!/KXX^`?$GBSQ%)\5/@OKOB#X@PJFO7/
MBCX7:AKUR8FA19;%9DURTB:TW*V$6UB!01JRXC15T_V4?A3^T-IW[,W@$>%?
MB;\!]"\/7&@6=W8V%Q\(]2N;BWCFA67$TT?B*%)IB7)DE6*,2.7?8N[`^G/B
M!X'U/QG]D_L[QCXC\)_9M_F?V5!82?:MVW&_[5;3XVX.-FW[YSGC&+\$O@9/
M\$=(T_2X?&OBS7M$TC38]+L=-U2+3O)M8HU18R'@M(I6943;EY&!#$D$X(WP
MF70P>(IPPU%J$8R7->.KDXRNVY<SNTW)M7;UUW.G`Y53P&*I4\)0:IPC./->
M+NYN$FVW+GDVTW)M7<G?6]SSW_A7/[4W_19/@!_X9O5__FGH_P"%<_M3?]%D
M^`'_`(9O5_\`YIZ^@**^A/J3X3U7QY\>[KXQ:%K!\>>%Y9K'1M2LUU)/V:?&
M*6MHLT]@Y@DMCJYDEDE,"LDJR*D0MY59',T;1^QZ-X._:BUW2+6]A^,/P)2&
M\A2>-;CX)ZW;S*K*&`>*3Q,KQM@\JZAE.00",5]$T5P83#5J4YSJS4N9WTBU
MK9+^9]$>;@<)B*-2I.M-2YW?2+C9V4>LI:6BOGU/G_\`X5S^U-_T63X`?^&;
MU?\`^:>C_A7/[4W_`$63X`?^&;U?_P":>OH"BN\](^?_`/A7/[4W_19/@!_X
M9O5__FGH_P"%<_M3?]%D^`'_`(9O5_\`YIZ^@**`/G__`(5S^U-_T63X`?\`
MAF]7_P#FGH_X5S^U-_T63X`?^&;U?_YIZ^@**`/G_P#X5S^U-_T63X`?^&;U
M?_YIZ/\`A7/[4W_19/@!_P"&;U?_`.:>OH"B@#X4_;C^-G[3'[+WPYTVWM_C
M!\!=6\<^.M2M_#WA30++X7W^G:EJ]W<310LUO-<>(+B"(PK+YGFSPO`K>6K@
M^8JM\_?\%)?V2?BG^R)_P3(/@2W^(?PPU+P3X>T'Q?%86UO\/]1M=0.[P?XD
MGNI)KF37)D>2:%KQ1LAC2.:XCD"&*(VTGUS^RM_QF/\`MD>,_CE<_P"E^"?`
M_G>!/AON_>6]SL;_`(FNLP9\R)O.F`MXKJVD7S((I(Y$RM<E_P`%B?@E\0_&
M_P"P[\8M>U3QMX,/AGP5X2\5:];:5:^$+F*_N+=_#VJV3VSW;:D\?F?9;R4"
M86^!*J/Y14&)OG?WF)D\9&+DKI0M;X5).4M6OB:^Z,3]ED\)DU"'#E:M&C-0
MJ5,0Y*;YJU2A.%*E:$)->PC-IWU52K65[))?<%%5-`AOK;0K*/5+BTO-32"-
M;NXM;9K:">8*-[QQ,\C1H6R0AD<J"`6;&3;KZ):H_')I*32=_/O]]F%%%%!)
M\H?MX^(/AI\2_%5CX!^+WP(^*OC#PS;L+^W\4Z5X>EU'2[`;`SR?:-/F:\@`
M(V.GEJ6VYVLF&/H?[`7CKX+^-/V?((/@,UH?`6@7DFF*MO975L([A5260-]I
M199'(E1C(VXL6^\2#CYG_;9_80\0?&?]N"Y\5^%_A-K.L3:MI<6F7GB37O$O
MAY_#L+*@*R1Z=?6&I3@+A$9HXHCN5]JX=I7^D/\`@GC\$?'_`.SQ^SNGA;XC
M'X=/K5GJ-Q);R>#--33[&6V?:ZF2&.WMXQ-O,H)CB4%1&3EMQ/S&43KRQ]:5
M6DHK7WN2S=FE%<UHW7+K\+\I.Q^Z<3X7**/`V%CALPE*I^[E]75=.$924O:3
M=!2JVFG9-N=*6M_96=E[I7S_`/\`!2S_`)-U\.?]E5^''_J;Z%7T!7S_`/\`
M!2S_`)-U\.?]E5^''_J;Z%7TY^%GT!1110!\_P#Q&_Y2F_!O_LE7CS_T[^#*
M^@*^?_B-_P`I3?@W_P!DJ\>?^G?P97T!0`5^:7_!0'PKK?B']M[5%\*^'?%'
MBJVEM(+7Q%>:7X5EU.?1$GMO),,3APK'R?WJJQ0*[9#$@X_2N;_4MC.<'H<?
MK7Y(P^(?%&A?&#Q4UQKGQ`L;NXN;?+'X^:/ITLT/E[H]TLD6+I0'8J4X0,4^
M\":_,?$/$4Y5<'A*BE9SYKI2>R:Y=$]^;7K:]K'Y-XO8BFLMHX:I&5IU+\T5
M)N/(FTURIZMZ:]+VUU7ZU:<H33X`!*`(U`$GWQQ_%[^M35!IA+:;;DDDF)<D
MOO)X'\0X/U[UP?[5O[4/@[]B_P#9Z\5?$[Q[J/\`9OA;PC9->7DB`-+,>%2&
M)20'ED<JB+D99U&1UK]-K3C"\IO1'ZMA8N<(1@M6D>AU\_\`_!6+_E%E^TM_
MV2KQ1_Z:+JN6\6_\%<O`/AWX3^`?%EAX4^(GB6/QYX'/Q);3-)L;-[_P_P"'
M4BADFU"]62Z1`L?GHIB@>:9V#"*.3:Q&7_P6#_:H^&?@W_@EQ\7X=<^('@W0
M+GXE_"SQ(GA*VU;6+>PN?$KR:3($CLXIF5YW)N(!L12V9HQC+`&Y0E%M-;.S
M];M?G&2]8R6\79J:=FNNJ^Y/\FGZ2B]FK_7M%?/_`/P]B_99_P"CEO@!_P"'
M#TC_`.2*/^'L7[+/_1RWP`_\.'I'_P`D5)1]`45\_P#_``]B_99_Z.6^`'_A
MP](_^2*\_P#B/_P6.^%&@ZK+_P`(O\5?V8_%NG^?;Q1>7\8K.._\MVC6:XDM
MX[>54A@#22R.)&"PPO(<8*CFQ>+IX:FZM6_*NR;\]DFSDQN.I82DZ]>_*M[1
ME*VE[VBF[:;GV!17S+X$_P""N/[/FH:1(_B?]H']F72+\3%8X=+^+&FZC"T6
MU<,9)/((;=N&W80``=QS@5_C7_P6(^`'PO\`A%J?BG0OB7X(^(7V.&=H8/#.
MNV^HP-+$J,RSW,#20VJJLBNS2L#L#%5<KM.6*S+#8;#O%XB7)!=977RL];OH
MK7;T2,<9FV$PF$>-Q<^2FNLKKT5GK=[)6NWHE<]2_;/^/EW^S#^S+XJ\<:?8
M6VIW^BPPK;6]P[+"99IXX$9]O)56E#%006"E0RYW#\R/V:_VH_B1^UM\59?A
M9XF\9ZE::+\6M8BF\0WVEZ0G]H3)%9B%X8_(C`CCFBMX(Y'*%$6+>_[OSQ)Z
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M!1EV)"JJC"J`.MKY_P#^'L7[+/\`T<M\`/\`PX>D?_)%'_#V+]EG_HY;X`?^
M'#TC_P"2*_5J-"G1IJE1BHQ6B25DEV26Q^UX?#TL/2C0H14815DDDDEV26B1
M]`45\_\`_#V+]EG_`*.6^`'_`(</2/\`Y(H_X>Q?LL_]'+?`#_PX>D?_`"16
MIL?0%%?/_P#P]B_99_Z.6^`'_AP](_\`DBC_`(>Q?LL_]'+?`#_PX>D?_)%`
M'T!17S__`,/8OV6?^CEO@!_X</2/_DBC_A[%^RS_`-'+?`#_`,.'I'_R10!]
M`45\_P#_``]B_99_Z.6^`'_AP](_^2*/^'L7[+/_`$<M\`/_``X>D?\`R10!
M]`45\_\`_#V+]EG_`*.6^`'_`(</2/\`Y(H_X>Q?LL_]'+?`#_PX>D?_`"10
M!]`45\__`/#V+]EG_HY;X`?^'#TC_P"2*/\`A[%^RS_T<M\`/_#AZ1_\D4`?
M0%?-O_!1[XX>+/#'A'PW\+/AF+0_%3XUSW>AZ)/<WDUDFC6D=LTE]J8FC&0]
MM$4*A6$FZ17193&8VU[+_@JK^R_J5Y%;V_[2'P%GN)W$<44?Q`TEGD8G`50+
MC)))P`*^9_V5_P#@H3\`O&_[6'Q0^-OC_P".'P@\)ZA>;?!/@K2-;\9:=IU_
M9>'K63S6N9())HIE^VW),XCNH%FB5%"LT<BD^7F524^7!TG:53>VZBOB?_MJ
M?24DS[O@K!TL/[;B+&TU*CA$G%2^&I7E=4:;[I-.K..G-2I3C=-H^YO@1\%=
M"_9S^#?AOP-X:M_L^B>%[".PMMR1I)/M'SS2^6J*TTCEI)&"C<[NV,FO+/\`
M@K%_RBR_:6_[)5XH_P#31=4?\/8OV6?^CEO@!_X</2/_`)(KQ#_@IK_P4V_9
MN\>_\$V_V@]"T+]H/X(:UK>M?#7Q'8:?I]AXZTNYNK^XETNY2*&*))R\DCNR
MJJJ"6)``)->E"$814(*R6B/C,7BJV*KSQ.(DY3FW*3>[;=VWYMZGW?1115'.
M%%%%`'SQ_P`%`OV_;?\`8;\+Z8]OX4O?&GB+6;:^O[738KY+");2Q1)+N>2=
MU;;L212%5&9R<`=2.Z_9>_:;TW]J#PYXFOM/LI;&3PIXDO/#5[&TRS*9[?8Q
M9'7J"DJ$@@%6W*?NY/S9_P`%G;K2/%EG\-?`FJ:5\%I/^$GN[^[CU?XDZQ<Z
M78:6+6*-BD<UK+%<(\ID4;E;R_W81@2Z5ZG_`,$N-,_X1S]EY-'BN_@E=V6B
MZG-:69^%VI7&H:1'%Y<3[9IIW>5KLL[LY9B2K1DG)-?.X'&8FIFM>C.2=.*5
ME;9Z7Z7Z]WWTV7[-F'#.34O#S"YO&A)8R<Y7GS.TH>TE%-+F:5N1QY>2,KWF
MYM<L3Z-KY_\`^"EG_)NOAS_LJOPX_P#4WT*OH"OG_P#X*6?\FZ^'/^RJ_#C_
M`-3?0J^B/QD^@****`/G_P"(W_*4WX-_]DJ\>?\`IW\&5]`5\_\`Q&_Y2F_!
MO_LE7CS_`-._@ROH"@`(R*_-[]N/X@^#/AU^T3XEMWO/A;X=N/"%O9/I_AZZ
M^&L&JGQ+NB61DFO#$6MP,A!L(PN".<U^C\V[RFV_>P<?6OCC_A9W[7,&E7MG
M_P`*P\^ZDTC^S[?4?^$CT9?)O1(Y_M#RMN#E60>2?E^3.<DU\)QI!UI4*,%-
M23<E*-*=1*T79/DE"UW:RDW%NW,N52:_/_$2FJV`CAK5+R;=X4JE6UNC5*4)
M1NVI)\R3Y&G=>Z_J#X,_%OP]\<?ASI_B7PM?)J6B7P98)TMY8%8HQ1@$D57`
M#*1RHZ5Y%_P4*_8#MOV\_!OAZUE\;>+_``C?^"[NXU?1TTEM/:RNM0:V>&&2
M[BO+.Z218O,8H50,C.74[U0K]`6'F_88?/\`]=Y:^9T^]CGIQUJ:OMJE'VD/
M9U7=]6M->ZWMKJM7;S/NLMG7IT:;JM.=E>T>5/37W6Y63[<SMW/SD/\`P2C^
M,7@#X$?"_1O#6O\`@+Q!XFTOX'77P6\4RZ_J%Q:VME'<"W*W]BUO9$W(MVCD
M18)D@,L8B+3(X=F]X_X*`?#BW^#G_!%;XV>$;.5KBT\*_!+7='@E9<&1+?0I
MX58C)P2$!ZGZU]1UX'_P5*TS4_$W_!.GXW:!I.E76IWGB?P)KNC*\4L,<>G_
M`&C3+F,7,YDD0^2A(W>4)),'Y8WYK3$XM4XU*]5V3;D]/[TY].BE4F_^WGT2
M2SK3I8:E[:II&FM]7HHQBWIK\,()_P"&^[;?OE%<W\/_`!QJ?C+[7_:/@[Q'
MX3^S;/+_`+5GL)/M6[=G9]EN9\;<#._;]\8SSCI*BE552*G&]O--/[G9FM&M
M&K!5(WL^Z:?W-)_@%?+_`/P4;_;2\#_L_:-HWAO69]2N?$4VL:'KRZ?96A=Q
M96VJQ7,DI=RL7(LY4"[]V]DR`I+CM?VE/VY?#'[/VIQ>'K"SU+QW\0+[S4L_
M"GAY1=Z@'6W,X:=%RT$94H=Q5GVL65'56Q\#_ML_L)?'#XO^+M1^+FN^'?#F
MEWGBW6+/31X=L]72:[TWS'CL+022-B!]Q%NK.DI^:8,4C7<(_P`]XXXDQ%+!
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M<^)/#UQ96>L:EH%S-MV7]@EN]Q!A@QVB>*6+D`J=T;<,<8.".!\%?LX:CX(\
M57VJP_$[Q]=MJ^I1:IJ=O<6^C>3J,J0P08?98*Z*8;>)"(F0X4D$,2U>H45]
M#7P5*M.-2=[QVM*2[]$TNK7IIL?58C+Z->I&K4O>.UI226^MDTKZM7MMIL%%
M%%=9VA1110`4444`%%%%`!1110`4444`%>,?%^Z^.T?Q^\-CP5;^`I/AMYD'
M]M/J/G#5%7<_VCRU#;'!0Q^6=T960-N#H:]GKYB_;=_:1^(?[/']N:AX8U[P
MGJD>E6":W+X?'@2_U.^T[2X^;R[N;U-3@M8L10WLL"SB`7#6S01L\BLU<&85
M8TJ:K3;M%IZ-:VZ.^Z?9:OH>ID_#5?/L2LMPU3V<Y6L_>[KK&,N5=Y22BE=N
M2*G_``49U^^^-NN^"_V<?#5[=VVI_%6<W7BR[L9F2?0_"ULP:]D+QEF@>Z8+
M:Q-+$\$I>:)L9KZ=T#0+'PIH5EI>EV5IINF:;!':VEI:PK#!:PHH5(XT4!41
M5``4````"OD#_@D=_;O[2/A;7?VEO'G]DS>,?BCMTK38+#S&M=!TC3W:W^S6
MZS;Y;?SKN.XFE197C<^2^%?<*^RJY\J?MT\>_P#EY;E\H+X?ONY?.W0^OX^I
M_P!E3I\*0:?U-R55K:6(E;VOJH<L:*Z/V;DOB85\_P#_``5B_P"467[2W_9*
MO%'_`*:+JOH"OG__`(*Q?\HLOVEO^R5>*/\`TT75>N?GAT7AS]KRT^*OPZ\7
MZKX!\$_$SQ#K?ABS$UOHFN>#]4\&3:Q.ZR>5#!-K5O:1/EHR'=681`J6QN0-
M\K7/_!;#QA)\0/B#X!TSX*:+KGQ$^$=CJFM>+;:P\>L^AK86$%I+*NGWYTX2
M75[NNUB-O);0(DD,JM,N%+?<7QA^'L_Q9^%VN^&;?Q+XD\'2ZY9R68UKP_-#
M#JFG!Q@R6\DL<J))C.'*$KG(PP!'R'X:_P""%/@OPC\,]-\+:?\`%SXS65CI
MNA7_`(5$UG_PCUG<7>C7YB:]L9V@TE!+Y\D2RO<L#>>8SL+@%VSG^\YY6VY7
M:_\`-K9Z:V3MS=XM\OO)*6GN<L;[WUM_+I??K:_+_>MS:;:G@3_@KS#\3OBC
MH,NA^`FNOA%KOC"P\`)XM?6]NI1:O>Z;'?P9TP6[+]DS-#`TINED65V_<[%W
MG[-KYDT#_@E)\._"GQMTSQ3INK^,;+P[H^O6OBNT\"QW5K_PC<6L6VG+IT%\
M%-N;L.D"1XC%SY/F1J_E[AFOINNB3AR^[O?\.6/_`+=SM?W7&^MSFA[2_O\`
M;\;R_#EY5_B4K:6/@W_@H)XJ\7:;XT\-Z3XXB_8Q:35-3UJ3PR_Q,TZ_EA32
MXA9&/$[H88;HEV\X;U5\0>6&*MCV_P#X)L?\D'U'_DWS_D.3?\D=_P"0#_J+
M?_6_]/7][_8\FO)?^"T7[0>B?`OP=X2%Y\-OA;XWUR_AU.ZTV]\>Z;'>:;IJ
M6T<,DT$:D;VN;@%%CC5T#-'DD[0*]5_X)J?$_P`,?%3X,^)KOP?X.\)>$-!T
M[Q;J&FVQ\,V"6>F:VL0B`O8E155]RE8RXW!F@.&Q@#Y#*I06;5Z"G>48Z[WL
MW'?H_/U/Z'SRCBJGAKA<=]6<*<I-<R<>1N-22NDGS*^UFFW*,Y?#8^B*^?\`
M_@I9_P`FZ^'/^RJ_#C_U-]"KZ`KY_P#^"EG_`";KX<_[*K\./_4WT*OJS^?3
MZ`HHHH`^?_B-_P`I3?@W_P!DJ\>?^G?P97T!7S_\1O\`E*;\&_\`LE7CS_T[
M^#*^@*`$?.P[<9QQGIFOA'XP_P#!0;XJ?`OXFWGA;Q+XN_9VTO5;-T+VK:5X
MFG=$<!DR\4+1DE6!X/>ON^OA7]L75;JZ_:/\5Z#X?OOC3?Z3K4%A%XSTWPKX
M(M]:MY/W?[N)+N217M7,.#\JL`6W`DY4?$<95L51^KU,+4<6Y\K71IIO5<\=
MFE=KF:3=HL^`\1J^+P^61KX*JX34K:=;IZ6YZ=]4G\6D>9VDU8^Y+"<W5C#(
M2I,D:L2@.TY&>,\X^M35%9'=91<2CY%XD^^./XO?UKXE_P""[OQ_^!_P!_9=
MTB]^,/A[0_'>JWNJ&W\#^$-;U(6VE:YK#Q-#&]ZDKK:&U@$OF237BM%!PXQ)
MY>?M,14<%>*N[V2[W=K+S[>?;<^_PD'4C&+?3?Y7N^R[OHM=3[?KR_\`;:UF
MTT+]CSXHS7MU;6<+^%M1MUDGE$:M++;211("2!N>1T11U9F4#)(K\L/VE-$\
M,^#?@G\(-$^+/CWPU\2O#&G?LY:S;>"?$G]I+J&E:QXXB:U2&729T_UVHJF$
MM73_`$DJ&\OYC+7NO_!4[X0?$;Q[^RC\"-=U#0M7U;4_#/AZ0^+IX(7F?3[J
M2SLY)9)EYD5-UO<%I&&U=OS$%ESX/&.-G@LFQ>)H0=1PO&W>\YT[]=E'G:_E
M<=5>Z^,X[SBME_#^(Q5"DZDG#X5?[2IW>B;M%5+[:\DUI:Y]Q_$#]K[X8?"_
MX>VGBK6/'/AR+0=1W_8;JVNUO/[1V2+%)]G2'>\VQV`?RU;9R6P`37A=GX[^
M/?[=FD)<>$H[;X'_``TU:%GMM<O5%[XBU>W=;A$EAA4@0*Z^0WWD=<K)%/(I
MQ7S+_P`$Q?V(OB5K^FZEXYTVR\#^$[R.6RDT'4_'G@>Z\0QW$>&G:>R@CU&Q
M,;`_966Y^<$9$9'[ROM7_A7/[4W_`$63X`?^&;U?_P":>O"R6IF'$.#IXS&M
MT*4E_#@VI2Z7E/22B[-I1Y79ZR:/%X>JYKQ3@*6/S%O#49K^%!N,YZVO.II)
M1=FXQ@HNS3<Y([#]G#]C?X>?LIZ0L/@_P_;6U^\/DW.K7'[_`%&\!6,/OF;D
M*S1(YC3;$&!*HN:Q/VJ_BA9_V-#H$&D^-;_4K#Q)X?OYOL'A'5;VW\B#5;*[
MF=9XK=H7VPQNQ"N3E2N-_P`M97_"N?VIO^BR?`#_`,,WJ_\`\T]'_"N?VIO^
MBR?`#_PS>K__`#3U]34RNG#!O!8)1IP::LHZ6:L[)-:^?X'V=3)J4,`\OR]1
MHP::LHZ)--.R3CKYZ^:9[+X$\?V/Q&TB2]T^#6K>&*8P,NJ:->:7,6"JV1%=
M11N5PP^8*5)R`<@@;=?/_P#PKG]J;_HLGP`_\,WJ_P#\T]'_``KG]J;_`*+)
M\`/_``S>K_\`S3UZ5/G44IN[\E;\+O\`,]>DIJ"51IOK967W7?YL^@**^?\`
M_A7/[4W_`$63X`?^&;U?_P":>C_A7/[4W_19/@!_X9O5_P#YIZLL^@**^?\`
M_A7/[4W_`$63X`?^&;U?_P":>C_A7/[4W_19/@!_X9O5_P#YIZ`/H"BOG_\`
MX5S^U-_T63X`?^&;U?\`^:>C_A7/[4W_`$63X`?^&;U?_P":>@#Z`HKY_P#^
M%<_M3?\`19/@!_X9O5__`)IZ/^%<_M3?]%D^`'_AF]7_`/FGH`^@**^?_P#A
M7/[4W_19/@!_X9O5_P#YIZ/^%<_M3?\`19/@!_X9O5__`)IZ`/H"BOG_`/X5
MS^U-_P!%D^`'_AF]7_\`FGH_X5S^U-_T63X`?^&;U?\`^:>@#Z`HKY__`.%<
M_M3?]%D^`'_AF]7_`/FGKP3]M7]LCXW?L6V=MI=_\9/@7XE^(FOP;O#?@W2O
M@MK<VI:Y,\JPQ)\GB5A"CRM@.XRWERB-970QG#$XJEAZ;JUY*,5U?];]ENSU
MLDR+,,XQD,ORNC*K5GM&*OZM]%%+64G:,5=MI)L^SOC5\>/!O[.?@6?Q+XY\
M2:3X7T2WW+]IOYQ'Y[K&\GE1)]Z:8I&Y6*,,[;3M4FORD^+G[0MI^UAXUU/Q
M?\3=8M/#7P5\5^)=/N3\/K?Q-IEKXY\16*6]K%I8OEN;NW%KHQE,EZ$23]VU
M_/.`T;I?Q>_G_@FA\?/VE/'7A?XH_%WXC_"G4O$UG87:0^!?$_P]F\2>'/"_
MVF3>(X8[?5;..:9(\1M),)\D)\\IABFKZ)_X5S^U-_T63X`?^&;U?_YIZ\#$
MX+%9I"]7]U3W46KMZ?;UT7]V^J?O=E^MY)Q-D7`M>4<"OKV+:Y9U82Y*=.TK
M\N';@W*5TG[?ECRRBG1T_>2V_P!C3Q)I'Q(TGQSXWTC7?#VKIXZ\2C5)[72-
M6MM530VCTS3[)+2:XMW>)KCR;2&:148K&UP45Y419Y?9:^?_`/A7/[4W_19/
M@!_X9O5__FGH_P"%<_M3?]%D^`'_`(9O5_\`YIZ^@H4G3IJ#=WU?=O5O[S\@
MS;'QQF*EB(1Y8Z*,;WY8Q2C&-[*_+%)7:N[:MN[?T!7S_P#\%8O^467[2W_9
M*O%'_IHNJ/\`A7/[4W_19/@!_P"&;U?_`.:>O$/^"FO@+]I*S_X)M_M!RZ[\
M5_@AJ.B1?#7Q&^H6EA\)]4LKJZMQI=R98XIW\13)%(R;@LC12!202C@;3L>:
M?=]%%%`!1110!\1?M.?#+]KWXN?%^'1X_#W[-/B?X8/=ZA+;V.OV%Q>V30JZ
MFR;4HY5:7[2$^X;0>6'\W?QY=?1G[(7A3X@^!OA"FD?$73?A=H^HZ?<M#IME
MX`M[FWTBVL`D?EH(YP&5P_FY"@+MV8YS7R#^W#^QI_PM3]J/Q3KW_#%__"UO
MMYM3_P`)5_PMW^PO[5V6L*?\>?F+Y7E[?*Z?-Y6[^*OHC_@F3\"_%?[/G[-]
MQHOBK2O^$86YUZ]U#1O#']KG5_\`A%-.E9?)T_[5DB;:PD?<"?\`6^N:^6R5
M5%C*BG&6SUDYM:-67O4X?*SEHGY'[]QG/!U.#,*Z57#QDE3?LX1PZFW).4I?
MNL97J<T;\LG5H46XI*7+)<A]#U\__P#!2S_DW7PY_P!E5^''_J;Z%7T!7S__
M`,%+/^3=?#G_`&57X<?^IOH5?4GX"?0%%%%`'S_\1O\`E*;\&_\`LE7CS_T[
M^#*^@*^?_B-_RE-^#?\`V2KQY_Z=_!E?0%`"$X%?G#^U1XHUVQ_:/UC4Y#XG
M\':OJ<%F=1M--^.VB:`B[(@$5K:2(R<`D@L2#N)&`:_1^OAK]L[X/Z-XE^/G
MB6*?QG^SEI\?BR&SAU)_&'DCQ'X>"1A-UF-P!+)AQYFW)(&<`&O@>/,/7J4\
M/*A)W4]O<2ORNWQ)^FC5DVV?GGB9AJU;*4Z,FFI+9P71V^.+]-.DFWHM/M;P
MMK%KXA\-6%]974%]:7=O'+#<0SK/'.C*"&61?E<'^\.#UJ_7G_[+_P`(9?@7
M\%M+\.37=E=O;RW%SFRB,=K")YY)A%"I/$2>9M7V4<#I7H%?=TISG",ZD>63
M2;79]5\MC[3*ZE:>#I3Q,>6;BN97O9VU5T%><?MB_P#)HOQ3_P"Q0U;_`-(I
MJ]'KYY_X*R>%(/$__!-'X\R'38=0U31_A]X@U/1F-N);BQOXM*NO(N+<X+).
MC'Y'3#@G@USYA2E5PM2E"UY1:UVU5C3,,+5Q6%J86@KRFG%>LE;HF^O8^AJ*
MY#X0?#SP%X1T)=4\`Z'X1TS3/$4$%TMWX?LK>&#4X=I:&0/"`LJ;9"4;)&')
M'6NOK>C*<H)U$D_)W7WV7Y'1!5DN7$1Y9K=)MV^;47^""BBBM"PHHHH`****
M`"BBB@`HHHH`****`"BOGGQC_P`%#]&\`>%E\8ZWX7U;1/AFU_+I\/BC4=6T
MJWCU4!Y?+O+"W-T9;NT>&WGF4H!<2HULUO;W*RNT7G>J?\%F?"WQ*U&72/@1
M\/\`XA_';6T^R(9=(TJ;3M&LI;B=HUCO+RX0-:_(DCB1H3$0.74!VC\NIG6"
MIZ3J6?1:W?HK7?R3/N\%X9<3XM.IA\(Y03M*?-#V<'>UJE1R]G3:;LU4E%KJ
M?95</^TM\<+']FK]G[QCX]U$6DEOX4TFXU%+>YO%LTOID0^3;"5@0KS2[(E^
M5B6D4!6)`/S;I?@_]M/]HK48M0U;QA\//V=M$'VN2#3-(TF+Q3K/,ZK!#>-.
M3:MMB5F$MO(F2_S1`MMB/#7_``1%^%OB#R]0^+>O?$/XX>)OL%M9MJ?BKQ)=
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M`$[PU9Z+I&D6,TL%TM]#-<_8[2)C,EZ!*#;&VB98H5DBD/GR7'N%9Y=EM7VG
MUC&7E)?"GM'>_*KRZ65VW+?961V<9\:X'ZE_9'#48TJ,[^UE!6E6BN7D]K+V
M=+:2E+V<(1I).-_:34IA1117OGY$%%%%`!7S_P#\%8O^467[2W_9*O%'_IHN
MJ^@*^?\`_@K%_P`HLOVEO^R5>*/_`$T75`'T!1110`4444`%%%%`!7S_`/\`
M!2S_`)-U\.?]E5^''_J;Z%7T!7S_`/\`!2S_`)-U\.?]E5^''_J;Z%0!]`44
M44`?/_Q&_P"4IOP;_P"R5>//_3OX,KZ`KY_^(W_*4WX-_P#9*O'G_IW\&5]`
M4`(3M'_UJ^'/B?\`!JT_;%^./BY_`VL?!K5H]=$-KK:^)-#F7Q9X5^S8MY'M
MH7577L0TJH"Q`SC!K[C/3CKVKYT\9_L<^(_VE_&%EK'Q2UCPY86^D3E].T[P
MIIJB\A5+A982VJW"&Y!PN'6W6`$G@^ORO$6`GC*V'I*G[2*;;5^6W2[G?:S:
MY5&4I;IQLV?'<:Y=5QV#CAJ=+VMW?E^&^EOCNE!6;NW&;:^&-TFOHBUA^S6T
M<><[%"Y"@9P/0<"I*;&GE1A1G"C`R23^9Y-.KZI[GU\%RQ2/F;]MC_@H)J?[
M,'Q`'A?PMX"A\=ZSIG@W4OB%KL=UKW]C1V.B6#QQRF!_L\_VB\=Y"(X6$49V
M,7FC^7=X=_P69^)O@SQU^QK=>*/%&D>(==^&?BOX/^*9--:U\.W&L16VM:A#
MI4>C3$11316UV1<7*07$NU8S+*!(H9L^W?ML_P#!/G5_VG_B.GBGPKX_MO`>
MJZEX,U3X>:^UWX?_`+92_P!&OY(I)/LZ_:(!;W<;1L8YF\U/WAWPR87'JO[,
M_P`1OAIXD\")X6^&?C/PIXMT[X=1P^&[J/1M9MM1?27MXQ$MO<>0Q\J4+'RC
M!3P>!7+4H.OAI4INTKIKKM.?X<OLEWYG+R/;R3-EEF94\9R<\$IIJ_+?FIJ.
M]G9W=1[-64?,_+_X??\`!2?XP^`;+Q7\5?#UI\)]/^'GB33?[;U'7-/^$OQ$
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M1:C'EG"3E904=9PE3E>RNG'E:TL^I^7EG_P<A>-]1_L[[/\`L?\`Q?G_`+8U
M6[T*P\NPUMOMVHVGVG[59Q8T?Y[B'['>>9$N73[)/N`\M\>;>-/^"[WC/XN3
MVFOZS^S_`/'R7P7K-II5[H.G^&;[7M%M7BU&7[+IUU)>66EK=SR7ESYT4`\]
M+></"J6\DJ+,_P"OEG\)_"VG?V=]G\->'X/['U6[UVP\O3H5^PZC=_:?M5Y%
MA?DN)OMEYYDJX=_M<^XGS'SX=^U?^S?^SAJ>B?#_`,+>/_\`A7?@42:CHNC^
M%K.273]*;6(M.OK>[M=`BAE79=63211J;$(Z#<K1K'*D4J3B<JQ-2*C'$S>N
MS]FK]+:4WUZ-.YMD?'^1X6M*I4R7#T_==I0>,E*+NG=<V-C;1-7C*,E>][7B
M_E?]D[_@N%\0X_"T5K\0OV:OVG/$MM%)J*IXBT7P'?ZE>SRQZC-$MI<6\6G6
MD$<D"H\$C`JQ>WR85\P[?4/%G_!>7PMX"\*ZEKNN_LY_MDZ+HFBVDM_J&H7_
M`,(KZVM;"WB0O+-+*[!(XT169F8@*`22`*^TO`W@'0OA?X6M=#\-:+I/A[1+
M'?\`9M/TRSCM+6WWNSOLBC`5=SLS'`Y+$]34_BSPGI?CWPKJ6A:[IFGZUHFM
M6DMAJ&GW]NES:W]O*A26&6)P4DC=&965@0P)!!!KKPN"KTZ485*\FUU]W\^7
M7U>K/G<^XGRO&8^KB<+E="G"3;48NNEOOR^W:C?^6+Y8[1T1\,_$C_@N8FD^
M#[A](_9N_:RTS5)Y(;2TNO$'PDU"WL(99IDB4L-ZF:3+CR[=71KB4QPK)&TH
M=?-_`O\`P6LOO#'Q8T[3++P1^V)XXL5U:;2/$FF>*O@W'#J=E.FDRZC%;V+V
M$5JJW9B:"=[>XCE:2V821F/&)OO?XC?$[X5_$7Q7J?P3\0^+_!USXG\5Z-<1
M77@YM>AAUF]T^:%UE9;99%N1&8_,_>(!@`D,,9KA9OAS\#OV*?&UKXF\5>,M
M.\-ZCXHU8)I$WC3QB<76H/:QVH\DWDV;J^,"&(7$IFNQ`_V991;)%!'C7P.)
ME5C*%65M+:I:WUT4;2OMZZ'I95Q3D=#`U*5?`4N?W[KDG*\7!<MIRK<U-Q=Y
M-I6Y7?5I)_/GB;_@X7\(:;\)_$GBW3_V??VKKC3/#D&HM<W][\,[VUTFTFL6
MFCNDNKQ?,6W2":"6.=RK&$Q2;ERA6O,/$?\`P<A>-_!W]O\`]K_L?_%_2O\`
MA%-*77=;^V6&MP?V-IS?:-MY<[M''DVY^R76)7PA^S3<_NVQ^F<_PG\+7/@3
M5_"TGAKP_)X9\0?;O[4TAM.A-AJ7VZ266]\^#;Y<GVB2>9Y=P/F--(7W%B2>
M(_A/X6\8_P!O_P!K^&O#^J_\)7I2Z%K?VS3H9_[9TY?M&VSN=RGSK<?:[K$3
MY0?:9N/WC9Z*F"K2?NXB<?14_P!8,\?`\3Y;0BU5RC#U;]92Q:MZ<F*@OON?
MD]\:/^"_OCGXBQ6FB7/[,WQK\,6>G>)8-'URSM7U_2]0U.[FL_-MM(CN(M,B
MN8+MVNK&[$<+>=)"@!0PS.:R?V9_^"G_`,9/$GB[5]>^%?PYU'P?X&\1Z3IM
M]I?ASQ'X-^(/BFTTBQ*R-9W=BME9.D5I>^9<K#]EB2V6/3%3;'MC:X_4+4XO
M@CX\^,6L>`[Q?A7K/Q`?=XFU7P[,+"XUAO-L!I;:A/:G,WSV,BV9F=>8)!#N
MV-MK$_8PT/X+_L^^&%^!_P`,O%/A#4M<^'%A:6VOZ=:ZE8S>(&ECMXH!?:K%
M;A7^U3+'&9)I(U+L<^@KS7DE:==5)8B4NJ^!/31I<L%IO?5)=4WJ?;4/%'+,
M/E<L)0RBA3;7*X_[1.G)N7,I-5<3-*2M&S<)3DDDJD8>X?&.B_M&?'?Q19OJ
M.N_'[XO>$]3O9YII-'T+]D;Q5J>FZ<IE<QQ07%SI,<\B"/9S(NX<@L^-[8FC
M>$_A+\1?"VK>&]8_:`_X*&>+;O3XUT3Q5:6_@7QJUK]HEM(I9;>:U;193"LD
M%Q%(()7<^5<1DEU8,WZLUS/B+4?!WP+T#Q/XMU:?PSX.TN>3^V/$6M7;P:?;
MR.D$5O\`:KN=MJDK!!!%YDC9$<,:YVHH'6\DPEKU>:7^*<WZ[RLO.R1\\O%/
MB"$O]A]E0UO:CAL/3>FRYH4E.7+?3FE)];WNS\E++X8?L_\`PM^(\_AO0/@[
MXAN->U=-7O?#^N:_\-_B->:E96+R^6;E?#USH$]I>C31?VL(\R8K*RV[R/"\
MXV_=?PX_X*/_``1^'FG6/P]\.Z+\;[;_`(0S1;".+1D^"WC>:ZTW3B);>S>1
M6TMI?+?[).B2/G>;>7YF*-CU77OVB/@MIOP_TGXS:IXY^%\'A5+673]+\=76
MM6*Z>MO=31>;!#J+/Y?ES36L&Y%DP[VT>03&N.YT#2=`U/57\5Z7;:/<7NO:
M?:P/K-K'&\NHV41FEMD,Z\R0H;J=XQN*J;B0KC>Q/1@<IP^#<O804>CLDK>6
MB6OK=NRN]#R>*>/LZXCC36;5Y5>6[3E.<N9OK[\I)+>T8<L(\TN6,>9W^=[/
M_@L)\$=1_L[[.WQ?G_MC5;O0K#R_@UXR;[=J-I]I^U6<6-+^>XA^QWGF1+ET
M^R3[@/+?!9_\%A/@CJ/]G?9V^+\_]L:K=Z%8>7\&O&3?;M1M/M/VJSBQI?SW
M$/V.\\R)<NGV2?<!Y;X^@+/X3^%M._L[[/X:\/P?V/JMWKMAY>G0K]AU&[^T
M_:KR+"_)<3?;+SS)5P[_`&N?<3YCYY;X>ZU\(/'/C/4?#GA2[^&VL>(?AMK<
M^K7^EZ3+97%[X5U6^^U^?<RPQDO:W5Q]IOM\C!9)?M%SDMO?/H;NR/C]E<\H
M^'7_``6$^"/Q@T=]1\)-\7_%&GQ^1ONM(^#7C*]A3S[6"\AR\6EL!YEK<VTZ
M<_-%<1.,JZD]!_P\L^'7_0N?'_\`\,3XW_\`E35S]D6'X)>"Q\4)_A-XR\%Z
MGI#:[!=:_8:%JUA-IW@^:ST?3])2R6.VPMG%':Z3!^ZDY5A)C"[47TSX0_&_
MP7^T'X-3Q'X"\7^%_&_AZ25X$U30-5@U*S>1.'030LR%E)Y&<CO0M=NU_D]G
MZ,'IOZ?-;H\7N?\`@JQ\);/Q59Z%+I_QOBUO4;2>_M-/?X(^-5NKJW@>%)YH
MXCI6]HXWN;=78`A3/$"077)XE_X*L?"7P7IT=YK&G_&_2;2:[MK".>\^"/C6
M"-[BYGCM[>$,VE`&26>6*)%ZN\B*H+,`?6OC)X]^'/P-M(?B#\0=:\$^#X-&
M@DTN'Q+XAO+73TL8KN2!I+9;N<J(UFDM[8L@8!V@BR"47&9\7_CE\(-#\&>&
M+OQ]XP^&UGX>\57]C<>'9O$&JV4=EK%Y'+'=V3VC3.$FF62.&:(QY8,B.G(!
MH6NW>WS>R]6#TW]?DMW\CSC6?^"K'PE\.:CI-GJ&G_&^QN]>NVL-,@N/@CXU
MBDU&X6"6X:&%6TH&20003RE5R0D,C8VHQ!;?\%6/A+>>*KS0HM/^-\NMZ=:0
M7]WIZ?!'QJUU:V\[S)!-)$-*WK'(]M<*C$`,8)0"2C8]2^)7Q4^%WAWXI^"?
M#OC#Q'X!L?&U]>27OA#3-9U"TBU6XN?)EMGEL(I6$K2>3<3Q%H1NV3R*3AV!
MZZV\)Z79^*KS78M,T^+6]1M(+"[U!+=%NKJW@>9X(9)0-[1QO<W#(I)"F>4@
M`NV1:JZV#9V>Y\OVW_!;#]GR\\*WFNQ:K\3Y=$T[P_!XLN]03X1>+VM;71IT
MF>#4Y)1IFQ;.1+:X9)R1&P@E(8A&QYA_P4)_X*9_"[XX_L4?'#X9>%K/XOZI
MX]\8>%=>\#:1HO\`PJ#Q=!<W>N7.@7%U!IW[S35"7#6KK<;'*D0'S3B/+U](
M>&O%?[-VM_!'Q=J6CZE\$+OX;Z'HZ^"?%%W9W&ER:)I^F64<JKI%ZZGR([:W
MCNY@+:4A(UNI!L`D.:'Q.U7X"W7AWP1\<-2\?>`?#7A/0_%/_":6WBR#7-.L
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M5OFG?7_+1K>_04K34+=+OU35M/NWU[!1110,****`"OG_P#X*6?\FZ^'/^RJ
M_#C_`-3?0J^@*^?_`/@I9_R;KX<_[*K\./\`U-]"H`^@****`/G_`.(W_*4W
MX-_]DJ\>?^G?P97T!7S_`/$;_E*;\&_^R5>//_3OX,KZ`H`****`"BBB@#E/
MCOX8U3QM\#_&6C:'+Y&M:OH=[9:?)YIB\NXDMW2)MXY7#LOS#IUK\]O^"?4O
MB'X+7=K\1&^$OQ7L='^$O[/6B>#-<T*/P7/9:OKFN6,\LTEGI]O.(C?-$HD"
MR0EH'-R`DK'./TTHI4UR5'4CN[?>HU(K\*LOGROHTW.TXJ$ME^7-"7YTX_+F
M[IK\^?CUI7_"U?\`@HI\(]1\)_"#XCZ;XB\,^/H]0\0)J_@H6?AJ_LWTB2)_
M$IU>V41S7L,#I:0PW%V[@AT:S!"2K^@U%%.-HPY%WO\`@E^45^-K1Y8QEW<^
M=]DON;?YM_AUO)E?+W_!5GX=:W\1OA/\,(M`T+5-=O-.^+G@W4+A-/LI+J6U
MLX=:MI;B=PBDK%&B%W<X557)(`S7T+\1?B9X<^#_`(/NO$/BWQ!HGA;0+$QK
M<ZGJ]]%8V=N9)%C0/+*RHNYW11D\LR@<D5MJP=01R#R".].#M4A57V)1E\XR
M4K?.WW,;UC*'\T91_P#`DU^%Q:*X?X(_M(>"_P!HU?%9\&:S_;(\$>(KSPGK
M?^B3V_V+4[0J+BW_`'J)OV%E^=-R'/RL:[BET3[I->C5T_1K5>0=6NJ;3]5H
MUZIZ,^`/VC?#O_"P_P#@I+\*[GPG\)?B#:^(O"/Q"6\\0'4?!HM?"NJ6;:3+
M"_B8:S;*(Y[N*!TM(8KBZ9Q\R-9`A)5XK]O#5]?^,GQ=UKQH?@_\7K[0/$WP
MB\;?"K2-.E\&W-]=QZXVHQ11/)!"LHMK2]2(/%>2E(7B13(\8VBOTTHK%T8R
MIJE+^]_Y/#V;_P#)+VWM+^ZE!:*K)5/:+?W?_))\Z_\`)K7VO%6^)N3X[]G?
MPGJW@+]G_P`#:%KTOGZYHOAZPL-1ER#YES%;1I*V02.75CP<5V-%<#)^U!X&
MB_:=C^#;:YCXD2^&SXO31_L5QSI8N?LIN//\OR/]=\NSS-_?;CFNNM5E6K.;
M^*3;LOG)V]$F_17.>C15*DH1VBDOR2OZNR]6>.>+OAUK<O\`P62\!^*8-"U1
MO#=O\(]?T^ZU>.RD-C%>2:MI#QP/.%V"5HXG94)W%8V(&%./FC_@GS\$O&N@
M?M&?!;0M1\%>,-$UCX.WOQ$E\;:UJ/A^XM=.U%=5U(R6?V;4)46*_P#M!,=Q
MFW>0J(?WOEM@5^G%9'C_`,=:5\+O`FM>)==NOL.B>'K&?4]0N?*>7[/;PQM)
M(^Q`6;"*QPH)..`36"E&E"',_=@I^7Q2E*]^B7,_DC64'5F^5:R<?_)8J%OG
M;[S7KRO]LK7-&T#X&74_B'P-XG\>Z.;ZS6>U\/\`AV#Q#?Z4WGH8M32QE5S/
M]DE$<^(H9Y5,8989"N*VI/VFOA_9?`*P^*>H>,-!T+X=ZEIUKJT/B#6KM=*L
M5M;D(8))'N?+\K?YL8`DVG+A<9.*G^"?[1OP]_:6\/76K_#GQWX-\?Z397!M
M+F]\-ZW;:K;V\P56\IY('=5?:RG:3G#`XYJITY7<'HX[^5GUV:_!]FF*$XV4
MUJGMYZ=.C[]5W5C\T_@G\*_%GP5\&?`7QKK?PY^(5[X`\"_%?QKJ5R$\(ZC>
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ME6I1K0E1?6+O;>S]UO\`\F6O=KN;0JNG[R[Q^]24TOGR_=?L?E3:?LP_$;XV
M_LC^,].\)_#7QSX<N?#W[-6A_#G4]*U;PW/H<VM:W9W;3W%C;+.L9O`L"SH)
M(M]O(;L*LK;FQ]P_\$ZM)U#Q+\?_`-H#XBV_AGQ1X4\%>/-3T-="M=?\.W'A
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MGL[4R1QL@D=$W'+`1J\;.4$B%O3ZY?8QG&?:6CM_U[E!K_%RU6T^EXMIK1]/
MM7&<&MXI-?*<9)^G-32:ZV=FG=GY+?'O]F7XEZ%KOCOP/?\`@_QAXB\8_$OP
ME\,-,\,:_I^@3:EIME=Z-=[M0-S?(K6UCY$@>YQ/)&K^8#&7<E:_6DC(KSWX
M_P#[5'@3]EN+PQ+X\UJ70+7QCK=OX<TRZ;3KJXM6O[AML$4TT4;QVX=N`\[(
MA/&[->A5U3JNKS3ENY2;MM=V=ODFODTSFITHTK0CTC'?>R7+?YV^],_+_P")
M/P"\;:=H/QNU?_A!O%MWHND_M2:!XXFT^UT2YGN-;T&TM=$$UQ9VJ(7O8XWB
M9PL*N2;9P@9T"U2\)_#/Q7\-_$GPS^+>L^`/B!/\.;?XV>./%C:):>#[V\UG
M2].U6QNH+"\DT>&)[M=\QE8AH1-%]M!=$!<K^IM%8*-J?LU_*H_=&C%_>J,+
M=KRWNK:U;5).4NK;^]U6ON]M*_>T=K._XZM^S/\`$+X'?L__``^M?%OPT\<>
M(AKG[/'BGX?Z?I6D^&IM9ET36-0OH[BTL;J*V61+-7MVBB,\A2!3:D22)M7/
MZL_L[^$]6\!?L_\`@;0M>E\_7-%\/6%AJ,N0?,N8K:-)6R"1RZL>#BNQHK6+
MY5**V;_]NJ3_`#JR^7+I=-N9+FDIO=?K&$?RIQ^?-KJDBBBBI*"BBB@`KY__
M`."EG_)NOAS_`+*K\./_`%-]"KZ`KY__`."EG_)NOAS_`+*K\./_`%-]"H`^
M@****`/G_P"(W_*4WX-_]DJ\>?\`IW\&5]`5\_\`Q&_Y2F_!O_LE7CS_`-._
M@ROH"@`HHHH`****`"BBB@`HHHH`^)/^#BO_`)0_?%3_`*^=!_\`3[I]?!G_
M``EGQ>T7XB^(_C3#^T'\:L^&OVNF^&]EX-?Q"TGA=M$N-0BBE@EM7!,F$D*Q
M@OLB4?(BM\U?N=110_=U%-ZVE?\`\FI-KYQIN/I-]M75?/0]CZZ^L)17W-J7
M_;MO-?@5\$?@5XM\'MXE\)>%/CM\<_"H^(W[8NK>!-6U2Q\3E;X6$-C?F::-
MM@47=P'!DF96'F06\@4-$M<7^U1^TMX@^"5M\:]%U_\`:E_:W\,?M&^!_$?]
M@^'?`$-WJ$FAW'A6&]M(+349IA;E'::S_>O?M<Q2O(YR'W9E_HIHHH?NW"^O
M*HI^?+"E%>G\.71Z5)1\QUY>TE*6UVW]\ZDG_P"EQ736$9>1^7OQ[U;XYZ!_
MP4XB_9RT;Q#X];P%\=M=TSXEVWB>+7+I;CPIHVG(O]NZ1#<"0S6\4]Q!8B-8
MBB(-2D08#<_&/[=G[97B3PSXU_:&F\2_M+?M/>`OVDM#\93V&@?#/0DO;7PG
M'X774+6.UO%$5N851[-MYO/M$,A9L8?=F7^A"BBC[DJ;>O+?YZQMZ6A",-4[
MIS;UFR9:IKOR_@G>_7WI2<M&K-0Z1U_#?_@K?^U9JG@7]KCX^6/Q$_:*_:2^
M"GB;PYX6AF^"?ACP'!=QZ)XO@;2GDN+F?R8'2X<7?FJ[RRP&`1Y67Y/W7JOB
M']I/XBP^!TE3Q]XU67_AARY\6[UURY#?VR$0C4\[_P#C\&>+C_6?[5?77[:7
M_!'KPM^W'\2KK6O$7QA_:1\.^']8M8[/7/!7ASXAW-IX6U^)>)$GL9%D"++'
MB.18&B5@-V!(S.WU-X*\&Z7\.?!VE>']#L;?3-%T.SBT^PLX%VQ6MO$@2.-1
MV554`?2LH4W]7=.3LW=?^4ZL+^K=12>NKCM#0TYU&O":U4;?A.E*WI:FX^2E
MO+4_`[Q[\2_VCOV1O`^@3^$OCW\>/B'>?&']GNP\=>(VU:]_MRY\+D:CID5]
M?:/;[1Y+PV-Q=,,-O)!D>0LJLO;?LQ?M"Z%\0/B/\=/#GPM_:-_:!^/WP>3]
MF_Q%J5O>?$BYO9`NJ?:6CF,+W%O;&XV(0N\QL8][()",JO[G45>(BJL9QV4E
M47HI^T23[J"FK+1MQO>SLHH-T^1[N+@_5P]FV_)RY'?=)2M;1M_EQ_P4!O-/
MT[_@UM\.7&K")M*@\$>!)+T2Q>:AA%[I!DW)@[AMSD8.>F*\8^'OQ;\%_$_]
MJ/XF_%/_`()P^"(H='\,?!76K'7+KP_X2GT+P[K?B(2Q2Z3:16$L$*3ZA"OG
MR\1`LLJ*68-MK]KJ*TQ4W6JU:J]US<VK;IS@X:OJDG=;:D86*HT*=!Z\O+>^
MSY7&6BZ7<;/?1VMU/PN_8?\`VL;G7-0\?P?#C]K+]H+Q=\.O^%/ZEJGQ7\:?
M$'3KS4_^%2^)%11;OIZ2P1.)`S7?^AP&0,(<K(Y12G$-^V[XZ_X=++=?#CXQ
M?M!:[X)LOBO%I/Q#^*>K^)]5O)(=)-AYC2:9JYT0ZC8V9G6!9"=/DDMYI/+!
MECF#R?T$45,_>O;2Z2\M*G/_`.`V]Q1O\.C<K*U07+:[;LV[]=:?)O\`S7]]
MRM\6RC=W^`O^"%7Q%^(OC_\`81\5:SJGQ&E^+7ADZI>-X`UV_N]7U+5I;,1\
MP75[J6E:9)?%+C>%G6WVG+1[AY6U?G?X9?M;:]^PQ_P0"_9$\9^$_$=OX1M=
M6\::):^,M1>RM[B/[#=ZA=2:L93*L@3+^86E&'&"0RGBOV%(R*^5O#G_``21
M\"^#]"\/:+I/C'XEZ9X:\)?$P_%'1-$M=2M(K'3+QI)IGT^,"VWG3FEGED\E
MG9@S?+(HXJW.];F6BO2>NNE.7O)[7YXMN7>UG=LF,>6ERO5_O/+XXNS6]G%V
M4>W,WHE8^";O_@LQXW_:<_9;_;:L?AM\2=6\3^)/A_XV8^'=1\+^'A<7.@^"
M&NK6WGOK.6*!(KB1(OMSQL\IE(C,@8*JN+G_``21_:Y\(#_@HSXMA\"_M,_'
M_P".?P,\/?!JY\12:A\2[R]D2VNXM57[3)$;B&W,^Q`R^:T.4RT8D8#:GZQ_
M'OX-VO[0/PBUSPA=Z[XO\,1:U;F%=6\+:Y<:+J^G/U2:WNH&5T=6`.#N1L;7
M1T+*?!/V0?\`@D)\./V4?$?B[7]4\2_$OXW^*O&VFQZ'J.O?%775\37_`/9:
M-O&G(7B1!;>82Y0H26/)(``SP]X2UZ0M?=M^S<$W\[3:T?-S2YG=15XCWX67
M6=[;67/&;2?HG%;JUERJSD_F'_@H1X<\<>$?V)?@;XLTK2--O?BU\0?CQH7C
M-=/U>X:VMSJ%TT[V-E<2(I*K;VZV=H2HZ6V<Y):O$_B%^U-X@T/_`()UV5SK
M?QT^.V@^,;CXDV-E^TQJEM<S_P#"4?"JTD%RSI8:?&TJ:7IYF6%(KBS0K+$0
MP,QS$/VUKR_]KC]ERU_:Z^$,WA.?QQ\3_AU*UQ'<V^N^`O%%QH&KV;H>=LL1
M*2(REE:.9)$^;<%#JCK#CRQG&"NG)-)]$O9KEZ7BU3M):77*ERJ+YFO>G&4W
M9J+3:[MU'S=;-.=X[\NKM*ZY?Q-M?C3IOQE_X)]_\%"[/3_C5\8/C1\-/"&A
M>%;SP'KOQ#N+G^T8Y/*,T,L2S)$P+W*1$3>3$TNU6.3B1OWH^&UY?ZC\.]`N
M-54KJ<^G6\EXI&"LQB4N/^^LU\?^$O\`@@]\*O#GPQD\,WWC3XO^*_[;\7:?
MXQ\7ZOXB\00ZEJ_C^>P96L[35;F2W+26D.Q`L4/DD[1N8G)/VU72Y*SMUY%_
MX#!)OIK)MIZ:\D7U,%%W5^G-_P"3-65NB2C=*[MS-=-2BBBLC4****`"BBB@
M`HHHH`*^?_\`@I9_R;KX<_[*K\./_4WT*OH"OG__`(*6?\FZ^'/^RJ_#C_U-
M]"H`^@****`/F_\`:?@\;^`OVT/A9\1?#7PO\8?$[1-%\%>*_#>I0>&[_1K:
MZL+B_OO#EQ;.RZE?6:-&R:9=`F-W*D+E0&S6A_PV1\1?^C3OC_\`^#?P1_\`
M-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T-'_#9'Q%_P"C3OC_`/\`@W\$
M?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$?_-#1_PV1\1?^C3OC_\`^#?P
M1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T-'_#9'Q%_P"C3OC_`/\`
M@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$?_-#1_PV1\1?^C3OC_\`
M^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T-'_#9'Q%_P"C3OC_
M`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$?_-#1_PV1\1?^C3O
MC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T-'_#9'Q%_P"C
M3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$?_-#1_PV1\1?
M^C3OC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T-'_#9'Q%
M_P"C3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$?_-#1_PV
M1\1?^C3OC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T-'_#
M9'Q%_P"C3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$?_-#
M1_PV1\1?^C3OC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'_P`T
M-'_#9'Q%_P"C3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`@W\$
M?_-#1_PV1\1?^C3OC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X-_!'
M_P`T-'_#9'Q%_P"C3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_`/\`
M@W\$?_-#1_PV1\1?^C3OC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/_P#X
M-_!'_P`T-'_#9'Q%_P"C3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C3OC_
M`/\`@W\$?_-#1_PV1\1?^C3OC_\`^#?P1_\`-#7T!10!\_\`_#9'Q%_Z-.^/
M_P#X-_!'_P`T-'_#9'Q%_P"C3OC_`/\`@W\$?_-#7T!10!\__P##9'Q%_P"C
M3OC_`/\`@W\$?_-#7`?M'_$3XH_M0>$O"_A*S_9L^+_A?_BX'@[6[O5M;UCP
GC]@T^STWQ+IFI74L@M=;GG;%O:2X6.)V9MH`YS7U_10`4444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>table2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`#-`/$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]P/B=^T_\
M/_@UXCBTCQ/XJTK1]4FMEO%M)G)F\EF=%D*@$A2T;@$]2C8Z&N=_X;U^#_\`
MT/FC?^1/_B:T/#+'_ALSQL,G'_"%^'SC_M^UNO3J`/(?^&]?@_\`]#YHW_D3
M_P")H_X;U^#_`/T/FC?^1/\`XFO7J*`/(?\`AO7X/_\`0^:-_P"1/_B:/^&]
M?@__`-#YHW_D3_XFO7J*`/(?^&]?@_\`]#YHW_D3_P")H_X;U^#_`/T/FC?^
M1/\`XFO7J*`/(?\`AO7X/_\`0^:-_P"1/_B:/^&]?@__`-#YHW_D3_XFO7J*
M`/(?^&]?@_\`]#YHW_D3_P")H_X;U^#_`/T/FC?^1/\`XFO7J*`/(?\`AO7X
M/_\`0^:-_P"1/_B:/^&]?@__`-#YHW_D3_XFO7J*`/(?^&]?@_\`]#YHW_D3
M_P")H_X;U^#_`/T/FC?^1/\`XFO7J*`/(?\`AO7X/_\`0^:-_P"1/_B:/^&]
M?@__`-#YHW_D3_XFO7J*`/(?^&]?@_\`]#YHW_D3_P")H_X;U^#_`/T/FC?^
M1/\`XFO7J*`/(?\`AO7X/_\`0^:-_P"1/_B:/^&]?@__`-#YHW_D3_XFO7J*
M`/(?^&]?@_\`]#YHW_D3_P")H_X;U^#_`/T/FC?^1/\`XFO7J*`/(?\`AO7X
M/_\`0^:-_P"1/_B:/^&]?@__`-#YHW_D3_XFO7J*`/(?^&]?@_\`]#YHW_D3
M_P")H_X;U^#_`/T/FC?^1/\`XFO7J*`/(?\`AO7X/_\`0^:-_P"1/_B:WOAI
M^U1\//C%XL.A>&?%ND:OK(M)+_[%#(1.;>-XTDE"L`2JO-$I(Z&1,_>%>@5Y
M/XP/_&<OPZ_[$7Q3_P"G#PY0!ZQ1110!YAX9_P"3SO&O_8E>'_\`TNUNO3Z\
MP\,_\GG>-?\`L2O#_P#Z7:W7I]`!1110`5\V?'C]N76OV??VR=-\$:SX8TIO
M`.H>`=;\9+KD&I2/J2R:5Y+7$)M?*"!"DZ;6$A)(;@<9^DZ\]^('[+_A#XH?
M&70O'6MV4]YK?A[1-2\/6R-.PMGL]0\G[2DD7W7W>1&`3T&?6HGS?9\_R=OQ
ML7#E^UY?FK_A<^6_V0?^"MOBKXGIK"_$_P"%<_AZY;P5HGQ)T*U\&SW'B>YN
MM$U:6>*!9H4@21;F)H"90BM&%;(;`K['^%?Q.T7XT_#70?%WAR[^WZ#XEL(=
M2T^X\MH_.@E0.C%6`93@C@@$5\V_#G_@EY\./V-?@K\3$\"V/B[7]1\2>%CH
M$2:WJ/\`PD5Q:Z;;Q3?9=*M([YQ"MK&99-D#L$)?YFQT[7_@EE%Y'_!-WX&I
ML:/9X)TM=C($*8MD&"HR`1TP.!T%:NW3^M?\K&:OU_K^F>^4445(PHHKA?&U
MK')XRD;6K;6+S2?LD?V%;%)Y$28,_F;EA^8.08]K'@8."#G.-:K[.-_^&^;.
M?$U_91YK?HEZO6W^9W5%>*6/@WXWZA;`P^-?"6DV39-M%=>'Y+N^ABS\BS2?
M:%1Y0N-Q"@$YJ9?@_P#&*Z'[[XR6$'M:^#K?C\7E:N!9E6>L<--_^`+\YH\M
M9OB&KQPE1_\`@M?G43/9:*\:/[//Q$O/^/KXW^*!Z_9-$TV#^<+TX?LI:U=?
M\?GQC^*L^>OE7=G;_P#HNV&*/KV*>V&E\Y0_23'_`&EC'\.$G\Y4_P!)L],7
MQYHSZ_\`V6-2M#?AMGD^8-V[^[Z;O]GK[5KUYA-\&]:N?ALG@HW_`)6FH0!K
MT=TPU7`DWB4#9M%SGDR[OO9;;DXK*;]EGQ'9_P#'A\:/B=;^@G>PNA_X_;$_
MK1]<Q2_Y<N7HTK/M[S5[=UHP^OXV/_,.Y>CBK/JO>:O;^9.SZ'LE%>-#X#_%
M&R/^B?&[4V'_`$^^&;"?/_?(2D/PU^-VG_ZCXH^%+[T^V>$=F?KY=P*/[1KK
M?#3^^G_\L#^UL2M\'4^^E_\`+3V:BO'(]-^/UAQ_:_PDU$#O)IFH6I/Y3./T
MI'U[X^:?]_PW\*M1'_3#7+VW)_![=A^M']J)?'2FO^W;_P#I-P_MM+^)0J+_
M`+<O_P"DN1[)17C0^*OQHL3^_P#A)H-[[V?C"-<_A)`*7_AH'XD6/_'Y\$/$
M)]?L6OZ=<?END2C^V,/UC/\`\%U/_D0_M_"]8U%_W!J__('LE%>-C]J[6+3_
M`(_O@[\5K;'4Q65I=?EY5PV:T_!?[0EW\5O$1T?2O#7B3PS>10&ZEE\4:1+9
MJT88+B%=W[ULD9PP"C&>H%5'-\+*2A%N[V5FG^*1<,^P4Y*$9/F>R<9)O[TC
MU&BL7P1XDG\1Z=<_:HH8[NPNI+.?R6+1.Z8^9"><$$<'D'([5M5Z,)J<5*)Z
MM.I&I%3CLPKR?QC_`,GS?#K_`+$3Q3_Z</#E>L5Y/XQ_Y/F^'7_8B>*?_3AX
M<JBSUBBBB@#S#PS_`,GG>-?^Q*\/_P#I=K=>GUYAX9_Y/.\:_P#8E>'_`/TN
MUNI/VLO'WQ)^'?PAEN_A-X&T[X@>-KJ\@L[/3]2U9=+L;99&P]U<3%6;RHER
MQ5%+MP%Y-`'I=%?G]KGQ]_;=^&?B"TCNM4_8R\?:[=+++'X`TG5M2T;6M2"`
MNT5E<W,LBR2!`<F2%%XR<"OO?0[Z;4]%M+FXM7L;BX@266V=@S6[,H)0D<$J
M3C(]*.EQ7UL6J***!GD/[=/P=\2_'G]F3Q%X9\)ZDNFZQ?+&R[Y3$EU&KAG@
M9QRH=01GIV/!->!?\$1=4NXO@AK5AJ&J73/=/::UINEW!/\`HVGW,`:&>/)(
M\N4AN%X5HR#S7UI\:AHC?!_Q0/$T,ESX>.E7(U.*.&:5I;?RF\Q0D(,K$KGA
M!N/;FOD/]FKPK>>!_P#@GQ^SU\6O"EI//JG@;P1IT6HV,2MYFL:&T$9GM]IY
M,D0`FC!Y#(P_B-?+YKE=.GCH9Y&[G35FKZ.&MVEW5^;SM:U[-?&9WDM*CF5/
MB2',YTH\LHW=G3=^9J/\T;\WFE:W-9K[CHK/\)^*M/\`'/AC3]9TFZBOM,U6
MW2ZM;B,Y6:-U#*P^H(K0KZ>,E)*47=,^QA.,XJ<'=/8****904444`%%%%`!
M1110`4444`%%%%`!1110`5G>(?"FG^*H8DO[5+CR&WQ-DJ\1Z$JP((X]#6C1
M2E%27+)71,X1FN6:NBMI&CVN@:=%:64$=M;0C"1QK@#N?Q)R2>Y-6:**$DE9
M#2459;!7D_C'_D^;X=?]B)XI_P#3AX<KUBO)_&/_`"?-\.O^Q$\4_P#IP\.4
MQGK%%%%`'F'AG_D\[QK_`-B5X?\`_2[6ZXW_`(*D:)X=\0_L)>/K7Q7X1^)?
MCK0GM86N-$^'_G?\)#>[9XV46WE.C<,`S<XV*^01D'LO#/\`R>=XU_[$KP__
M`.EVMUY7_P`%??%.@>$_V/))?$M]X;TS3+K7=/M/M>O^*]4\+Z=;R22X1I=0
MTU6GA&<#)Q&21O(%1./,N7N5&7*[GY/_`/!O5%X7\(_\%#X].\.V7@7P-HLL
MVH1:=X;^)7AW[5\5BXAE,HAU)+&W5$!4ED:5V$>Y<$G(_H#K\V?V"?B]X5_X
M)I_"'Q'<?$WQ]^SSH/PSU#4+SQ/;:OI_Q*N?$VJRW$R6Z+$);F(37K$)*0X9
MI,-'&JL%S7Z.:+J\'B#1K2_MBS6U["EQ"S(5)1U#*2#R.".#S6SE>*78S2M)
MON6J***@HR/'_BJQ\#>!M8UG4[G[%IVE64UW=7&QG\F-$+,V%!8X`)P`3Z"O
M'/\`@EW<)J'_``3D^"<J$/%<>#--D4XX96MT(.,#J#Z"O<M58KI=R1P1$Q!'
M;@UXI_P3*X_X)[?!GK_R*.G]?^N"T`0?!AC^S)\<KSX8W&8_"7BEI]9\%R-G
M9:OG?>:8#VV%C-&/[CN/X*]ZK@/VD_@N?C?\-);&SNO[,\1:7.FJ:!J0'S:=
M?PG=#)_NDY5AW1V'>G_LX_&<?''X90:G<6ITW7+&:33=<TUOOZ9?PG;-"?;=
M\RGNC*>]>-@?]EK/`OX?BAZ=8_\`;K>G]UI+X6?/9;_L.(>62^!WE2_P_:A_
MVXWI_<:2^%G>4445[)]"%%%%`!1110`445RWCSXW^#OA=K&GZ?XC\3Z%H=[J
MIQ:07U['"]QSCY0Q'&>,],UG5K4Z4>>K))=V[&5?$4J,/:5I**[MV7XG4T4@
M;<,CD'H:Y#4OV@O`NCO<K=>,?#-NUG>W&FSK)J40,-U;VYN9X&&[B2.`&5DZ
MJ@W$`<UI=+5FR3>QV%%>?ZU^U=\,/#GA35M=OOB'X+M=%T&WM+K4;Z36;<6]
ME%=QB2U:1]^U1,A5H\G]X&4KG(SM_"SXR>$OCAX(A\2^#?$NA>*?#]P76/4=
M*OH[NV9D.'7>A*AE/#`G((P0*.Z["_4Z6BO,]9_;/^$7A[P!I7BN^^)W@.S\
M,:[?MI>G:M-KMLEG?72LR-#'*7VLZLCA@#\NULXP:V_"_P"T/X#\;?%'6?!&
MC^,O#&J>,?#L:S:IHEKJ4,M_8(<8,L*L74?,N<CC>N?O#(&QV-%%%`!1110`
M5Y/XQ_Y/F^'7_8B>*?\`TX>'*]8KR?QC_P`GS?#K_L1/%/\`Z</#E`'K%%%%
M`'F'AG_D\[QK_P!B5X?_`/2[6Z[OQKH>E>)?"6HV6N:;::QI$\#"[LKJU6ZB
MN8P,E&B8$.#CH0<UPGAG_D\[QK_V)7A__P!+M;KT?59/*TNY;R7N-L3'RD^]
M+P?E'N>E3/X65'XD?F=_P3>@^#?[27Q*\*>./`?[`OA'P-X,\1&XN]*\?RIX
M862WC3S-DGV.*1KN)W=-NT(&4MDX`)K].:_"#_@D7XO\!0_M[_!76_#WP_\`
MV=(/$'Q%N->COO"/@[2=0M_%OPA%M!.`^H2R7#J^X+Y$OFPQ9DF7R\@5^[]:
MOX(_U_P/NT(^V_Z_KYZA2-R..M+14#/C#]F?]K'XFV7[/O[0&I>,)]/^)FK_
M``I^(FL>'HIT%MX<C.EVT-M+O<G=&IB260DG+,%'4UZI_P`$M;T:E_P3A^!]
MRH`6X\%Z9*`""`&MD/4``]>N*['XO>!M!^'/P(^),^CVV@^%?[9L[_5M3O1=
M/HL,MT\&)+NXNK=?-C;"+NG4%P$!&2!7&_\`!+$Y_P"";GP-)97SX)TL[DD,
MBM_HR<ACRP/8GD]32C?E2>Z2OZI:OYL'\3:ZMOY-Z+Y'OE>"?%M?^&8/CU:_
M$>`>5X.\9O!H_C%`/DLKC(2SU(]@`2(93_=:,G[M>]UF>,O"&G?$#PGJ6AZO
M:QWNEZM;26EU!(,K+&ZE6'Y'\*X<QPDJ]+]V[3B[Q?:2_1ZI^39YF:X&6)H_
MNG:I!\T'VDN_DU>,N\6T:8.117BW[*'B_4?"MYJ_PH\3W4MUXA\"JAL+R;[^
MMZ.Y(M;K/=U`\F3T>//\5>TUI@L6L3155*SV:ZIK1I^CT-<NQT<7AXUTK/9I
M[QDM)1?FG=?BM`HHHKK.X****`"OD?\`;A_X)<K^U[\9;'Q9!XM;1-UI'8:A
M;RVGVC,:%B&A.X;6PQ!!R,X/K7UQ7GGC'Q`L7BG4XM4\17OAY;-4;3(X-JBZ
M!0%I`"I\YO,W+Y8Z!!Q\V:\7/LNP6.PWU?'0YH-IVO;5>=T?/<3Y3E^98/ZK
MF=/GIN2=K\NJN[WNK=5OK>QVOAG0H_"WAO3],A>62'3K:.UC>1MSLJ*%!8]S
M@<U\0>#_`/@D5K6@?MU-\9+GQ:US%/\`$_5O%\VAG5;QM*.F7>A'3D46)'V<
M7WFG+S8^:+Y=QZ5]N^$[R\U#POI\^HP_9[^:VC>XB`QY<A4%ACMSGBOSST+]
MLS]H7QI^W9=_#UHHM+^&EW\7->\'VWBF%H6OH;>+PT;N"U%FUMC9%<8F%T93
MO/[LKCKZD>7E7*NBM_X%&RU\[?D?18?_`'?W-(V_#E?Z7-[P]_P1PO/@M^SM
MX;T?X?+\/HO%7@GXI7_Q%T^PURWN+K0=7CD:ZM[.TN3@RQM;6$T"0R(K^3):
MH55A7KO["O['WQ:^!7@FV_X6-\7[G7]7F\1ZCKE_IVF:;8#3IX+E56*S>;['
M#+-Y94R&<)$\CRMN!`%?,=O^UC^T9X>_9,L?%GQ+^(=GX4LM7^)4G@KQ'XJT
M'PLMU%X,T;3!<V4VI+$\;;7U"_M06GE5X;9;M,(`O'O'_!,3]M#Q/^T/\$["
M:]T#XM>);.]\2:II%IXMU[3]&ME^RVX4QW#M9S+%<0$L8DGAC/F/$Y*KU.\=
MVH^7Y0_3E^Y^=U/=<V^OYRO^/-MW7D>;?M#_`/!)/XB>-OA)!H_A34_A>VH/
MJOC^&:'7K2Y:PMM-\42RL)X1&A(O+9&0!=H1]TB[U!R>\_9*_8$^(_P;_;OU
M3Q]XIC^%D_@?2O#TWA[PBFAFYM]5LEE>V:YN[N,P+%/=7IMHGFE:1BGD1(@(
MW,?GC]I_]N_XR?!K]F70[B[^*6K^'[ZV\1_$'3T\2GPI;W,^O7^D7$Z:%I4D
M*P&)!=E,'8BM+Y.U6!;->P_LB?MG>//B/_P5&UCP+J/BZ^\0>&KGP=-J&K>'
MVT-;4^!M:@EL@;-\PI+'$8YW,<TDLRW19MFP0_,J+LUR_P`OX<NGX7^_7=#K
M[OG_`)G]_,K_`(V^2TV9]\4444""BBB@`KR?QC_R?-\.O^Q$\4_^G#PY7K%>
M3^,?^3YOAU_V(GBG_P!.'AR@#UBBBB@#S#PS_P`GG>-?^Q*\/_\`I=K=<]_P
M4.\#^._'O[,>H6OPWC\37'BZTU"QO[.VT+Q7'X8N;P0W*2/$U[)#,J1,JD.A
M3YURN1G-=#X9_P"3SO&O_8E>'_\`TNUNO0O$1QX?OOFD3_1Y/FC0.R_*>0IX
M)]CUJ*OP-HN'Q(_)#_@D=\/OC1:_M6>$O%7Q`_X2:SU+78+B7Q&MQ\:]#U<7
M$A@E*+-IEOIZW,NT[,*;IMA`8D[<5^OE?@U_P1-^!G@+Q7^T/^SE?>&-<_96
MTFX^&IUF\_MWP[KP_P"$_P#B0+BVN8EAO=*D19K5D21I95D:388L1;4)K]Y:
MWE;D5C&/QO\`K^OQ"BBBLRSF_C#>C3?A1XDN&US3_#(ATRX<ZO?Q1RVNF8C8
M^?*DC*C(GWB&8`@')`KRK_@ER_F_\$Y?@BWFI/N\&:8?-0`++_HZ?,`.`#U&
M..:]?^)%Z^G?#[6[B/2)_$#PV,SKID'E>9J!"$^2OFLL>6Z#>P7GD@5Y#_P2
M\)/_``3H^">4:(GP;II*-UC_`-'3Y3R>1TZGIUH`]XHHHH`\>_:P^'NJ"TTC
MXB>$K8W'C+X?N]U%;1\-K-@P'VNP/KO0;D])(TQU->C?#GX@Z7\5O`FD^)-$
MN!=Z5K5LEW;2CJ589P1V8<@CL01VK;KY1\2?'SPQ_P`$ZOCEJ>@>(KYK;P'X
MY$GB#2([>(SOHEX9`MW$8T!802,?-0@8#&45X&-KT\MK_6ZLE&E4LIMZ*,MH
MR^?PO_MWS/E\PQ-+*,3]?K24:%6RFV[*,]HS])*T)>:ATNSZNHJCX;\1V/C#
MP]9:KI=U#?:=J4"7-K<1'*31N`RL#Z$$5>KWHR4ES1U3/IHRC**E%W3"BBBF
M4%&,T44`%%%%``>:0#`I:*`$(S1CFEHH`****`"BBB@`KR?QC_R?-\.O^Q$\
M4_\`IP\.5ZQ7D_C'_D^;X=?]B)XI_P#3AX<H`]8HHHH`\P\,_P#)YWC7_L2O
M#_\`Z7:W6A^T]\*K_P"-'P3UG0-,\;>,/AY=W"+*NN>%VA&J6HC8.5B\V.1#
MN"E2-I)#'!!YK/\`#/\`R>=XU_[$KP__`.EVMUZ-J\IATFZ<6[716%R(%ZS<
M'Y1[GI^-15^!E0=I(_&C_@A1\*_%.I_$+X5>,--L?B]J?P_-I>"TU[7_`!/X
M/^S7<7ESHKRZ?;Q'5(V+?P&9G4XWDJ#7[05^"G_!&KX[_#[Q#_P4$\$VFA_!
MSX$Z=X^U77KQ;VP\,>'+ZPUSX>V#:1/+*LKR,07@N5%K/)*`'><","OWKK:5
MW!7_`*_KRT[&2MSNW]?U]X4445!9D>/];?PWX&UC4(]/U'5GLK*:=;+3XUDN
MKLJA/EQ*S*I=L8`+`$D<BO(/^"84OG_\$[?@J^QH]_@[36V,!N3-NAP<<9'?
M%>VZQ_R";K_KB_\`(UXE_P`$PF+_`/!._P""Y/4^$-./_D!?<_SH`]VHHHH`
M*\#_`&R_^">_A3]LR^TW4=5U#5=%UK2K=[6"\LF4AXF)8*Z,""`QR,8/)&>:
M]\HKBS#+L-CJ#PV+@IP>Z?D>?FF4X3,L-+"8ZFITY;I^6J/&OV+?&*V_PY_X
M5[J-C!HOBKX:I%H^HZ?$3Y<D2K^XNX<\M#.@W`]FWJ>5KV6O&_VG/AQJ^DZO
MIOQ/\%6K7'C#PC$T=U81G'_"1Z63NFLF]9!CS(B>DBXZ,:]'^&?Q'TCXN^`M
M+\2Z#="\TG6(%N+>3&#@]58?PLI!5E/(((/2N3+)RHO^SZOQ07NO^:&R?JMI
M>=GHI)'!DU26'?\`9=?XJ:]U_P`U/9/UC\,[=;.R4DC=HHHKV#WPHHHH`***
M*`"BBB@`HHHH`****`"BBB@`KR?QC_R?-\.O^Q$\4_\`IP\.5ZQ7D_C'_D^;
MX=?]B)XI_P#3AX<H`]8HHHH`\P\,_P#)YWC7_L2O#_\`Z7:W7I.H^?\`V?/]
ME\O[3Y;>3YGW=^/ES[9Q7FWAG_D\[QK_`-B5X?\`_2[6Z]&UBV6]TBZA=@B2
MPNC,6*A05()R,$?7-3/X78J/Q(_(_P#X)[?MV>/_`(L_M/?`+X7W%SXFM_B_
MX3O=?C^.]QJNG:;;6.M((;CR%CNH@#=M'/Y/V<6Y.V)7,O(S7Z\U^)7_``1'
M_P"$.^$G[3OPW\!Z7KWP#\16EHNJVV@>+H_@GJ&BZUXS,"3"X_L_Q#.?*NY(
MR6\QER9(U?!;K7[:UJ_@B_Z^7D1KSM'%_M'7_B72_P!GGQY<^#(Y)O&%OX=U
M"70HXXQ([WZVTAMPJGAB90F`>#7YP?\`!%+]IV'0O&VL0WOC_P"*OB3P7XCT
M'PAIEQ=>-3J=[)!X_NXKLZI8V[W*;XN(XC(BX@B?`!7.#^J=%3#23;Z_\'_/
M[TGTL.6L;?UT_P`ON;74^%_V0=0^)'PY_9^_:8MM"U;6?$&I^#?BGKD.B-XW
MEO\`6Y)-.C@M)?)B+2I+(#NE$8$@0,W7&:]O_P""7,C2_P#!.7X(NXVR/X+T
MQG`&,,;="1CMS7H_[1%A%JOP%\9VT\,D\,^BW<;Q)HXUAI%,+`@61XN3_P!,
M3]_[O>O-/^"5^/\`AVU\#-H(4>"=*`#1>40/LR<%.=O^[VZ=JF-U&,7T27W*
MU_F#UDWW;?WNY[[1113`****`"OGZ^_XPW^.)O!^Z^%_Q(U`"Y'2+PUK4IP)
M?1;>Z/#=EEP>`]?0-9'C[P)I7Q/\%ZGX>URSCO\`2=8MWM;J"0<2(PP?H1U!
M'((!'2O/S#"2K04Z3M4AK%^?9_W9+1_>M4CR\UP$L1"-2@[58.\'Y]4_[LEI
M+RU6J36O17BW[,_CS5?!?B2^^$WC&[DN_$7AJ`7&C:G-PWB/2<[8Y\]YHN(Y
M1ZA6Z/7M-:X+%QQ-)5(JSV:>Z:W3]/N>ZT9MEV/AC*"JQ5GLT]XR6CB_-/Y/
M=733"BBBNL[@HHHH`****`"BBB@`HHHH`****`"O)_&/_)\WPZ_[$3Q3_P"G
M#PY7K%>3^,?^3YOAU_V(GBG_`-.'AR@#UBBBB@#S#PS_`,GG>-?^Q*\/_P#I
M=K=8?_!0;]KJP_8C_9;UKQU>^'KOQ?/]IL]&T[0;6=8)=9O;ZYCM(+<2/E4#
M/*,L1PH)P:W/#/\`R>=XU_[$KP__`.EVMU=_:I_9@\(_ME?`;7_ASXXLY[OP
M[XAB193;3F"YM98W66&>&4<QS1R(CHPZ,HX(R*F:;C;^O,J+L[GP#X)_8R\/
M_P#!/_\`;U_9;\+Z]XB^+'BOP'=SZY;?#71M3U.RDT;X=ZJ;%Y?LC>5$MS=Y
MM6O(XI)798PN.=V1^H%?)/[._P#P2CB^%_Q[\.?$?XA_&3XJ_'+Q%X$M9K3P
M@/%]U;?9O#HFC,4TZ1V\48EN7C^0SR;FVY[\U];5HW[J7K_3\_/M9:VN\];W
M]/Z7EY=[O2]@HHHJ2CF?C/)!#\(O$[74^OVMLNEW)EFT)9&U.)?+;+6PC#2&
M8#[FP%MV,`FO*_\`@ELBQ_\`!.+X'A6E91X+TP*TN?,8?9TP6R`=WKD`YSQ7
ML?CZ75(/`VL/HD5A/K"V4QL8[Z5XK9YMAV"5T5F5"V,E5)`S@5X__P`$P&D?
M_@G9\%#*$$I\'::9`A)4-]G3.">2,YQF@#W>BBB@`HHHH`****`/-/VF/@K>
M?%+PW8:KX=N(]-\=^$9SJ7AV^?[JS8P]O+ZP3IF-QZ$'JHK6^`/QJL_CQ\.8
M-9@MY=.OX9'LM5TV?_7Z5>Q';-;R#U5NA_B4JPX-=K7@GQQT^?\`9C^*+?%K
M2(9'\,ZH([3QW80@G$*_+%JJ*/XX,[9,<M$<]4KQ<8G@ZWUZ'P/2HO+I/UCM
M+O'_``I'SN8)X"N\RA_#=E57DMJGK':7>&OV$CWNBH=/U"#5K"&ZMIH[BVN8
MUEBEC8,DJ,,JRD<$$$$&IJ]I.ZNCZ%--704444#"BBB@`HHHH`****`"BBB@
M`KR?QC_R?-\.O^Q$\4_^G#PY7K%>3^,?^3YOAU_V(GBG_P!.'AR@#UBBBB@#
MS#PS_P`GG>-?^Q*\/_\`I=K=>GUYAX9_Y/.\:_\`8E>'_P#TNUNO3Z`"BBB@
M`HI-XW[<C=C.,\XHW@/MR-V,XSSB@#)\?W&I6G@;6)=&M+._U:.RF:SMKNY-
MM!/,$.Q'E"N44G`+!6('.#7CW_!+P./^"=/P3\P!9/\`A#=-WJ#D*WV=,@'`
MR,]\#Z"O<-7_`.03<_\`7)_Y&O%/^"97_*/7X,_]BAIW_HA?K0![G1110`44
M44`%%%%`!45Y9Q:C9RV]Q%'/!.ACDCD4,LBD8*D'@@CM4M%&^C!JZLS\ZOV?
MOVN/B'\'?VT(O@II^AO-X'L_$%QIMGIMW;N][IE@TC,DB3YYAC7YEW`@)A<\
M"OT5J/[)$+GSO*C\[;M\S:-V/3/7%25X60Y17R^E.E5K.HG*\;JW+'I%:O1?
M)=DCYGAC(L3E5&I0KXAUHN3<$U;DCT@M7HODNR04445[I],%%%%`!1110`44
M44`%%%%`!7D_C'_D^;X=?]B)XI_].'ARO6*\G\8_\GS?#K_L1/%/_IP\.4`>
ML4444`>8>&?^3SO&O_8E>'__`$NUNO3Z\P\,_P#)YWC7_L2O#_\`Z7:W7I]`
M!1110!^3GQB^!7CM?^"O]SXF'PZ^*-_XSA^*.BZ[HOCBSMKF30K/P'!H834-
M-^T*WDJ7N1<K]D*^9)+/&P!X-8_Q)^%WCOXR_P#!4O1/'UC\,/C'#XH\0^/?
M!WB#PKXKNM,N['3O#O@F/3@NL:;=L7$=I*9#=++:R@22//&0IX(_7NBG3ER\
MO]UI_E^=E?UE_-H2UYO-6_/_`#?X=CXG_P""?'[*'B7P!^S_`/'#P-IESXN^
M$=O-\7?$-UX;NX+6-YUTMIHC`]N+V.5'MY`&`;:<C.T@\UT?[*7[!GQ3^$'[
M-/@3PMJWQ^\<Z=JGA_1+6PN[72]/T6:R@DCC"LD+RV!D9`1P6.<`9KY-_:1\
M2>/++_@L5\FH?%Z+QO;_`!)\+#PM96']I?\`",2^`O[.+:U)(B`V+@3?:O,,
MG[X2+#L]*Q?&7QD\3_%__@JAH'B7PSJWQFE\0:_\0O"=UX(MX+;5[3PY<_#V
M33=VK2S6\B+:K^^^U>;]H59UD6';BBDN905^R_)?KKVM+L55TE*7J_O;?_#>
MJ[GZ%K^RC\0A_P`W&?%$\`?\@K0/_E?1_P`,H_$+_HXWXH]O^85H'_ROKW:B
MD2>%']E+XA'_`)N,^*';_F%:!_\`*^N9^)W[*WQOCLM&_P"$0_:)\;/.=:LQ
MJG]I:5H>T::91]J\K;I_^N$6=F>-V,U]`_$A]4C^'>O-H@)UI=.N#IX4`DW'
ME-Y>,\??V]:_+'_@C%\=I/AAX[N+S5=6^-=WH6K>"O#.F>,5\76>M7SCXCW-
MU=I>06Z7*,R,5">:8<6R?NOF&:(ZRY?ZZ_Y6]7%=0EI'F_KI_G?T4GT/O+_A
ME'XA_P#1QOQ1[_\`,*T#_P"5]#?LH_$(C_DXSXH#@C_D%:!_\KZ^0/\`@A9X
MO\3^(?VDOC9_;<WB?QE%J.-9N/%NHP>)-+2QN[G4+QVT*33]5;R(Y[:/RSNL
MHU0(R*Q8X-?IK19\J;ZK^OZ^[0/M./9_U_7WZGA)_91^(1'_`"<9\4.F/^05
MH''_`)3Z/^&4?B%S_P`9&?%#G_J%:!Q_Y3Z]VKPS_@IIX0N/&W_!/CXS6ME/
MXBMM3M_!VIW^G/H5]<V>H"[M[62>W\I[=EE)\V-/D4_/]T@AB#,Y<L7+L73@
MYS4%U.63]E;XX_\`"YI5/[1/C;_A`O[&1HV&E:'_`&C_`&GY[;@?^)?M\CR=
MF.^[/:NF/[*/Q")_Y.,^*'7/_(*T#_Y7U\N_MW_&N\;]@'X0^$+O4OB+;.(?
M!>L_$Y]#L]475HO"TLL<.H2BYMT\W>95`F6)_/6,R-M`.:]N_P"",U_XCU']
MAC3I-=G\676F_P#"0ZXOA2;Q-YYU6;P\-2N!I33FX`G)-IY.#+\Y7;FKMK+R
M_&UO\_PEV,[Z1??];_Y?BNYVB_LH_$,#_DXWXH'ZZ5H'/_E/H'[*/Q#'_-QO
MQ1Z8_P"05H'_`,KZ]VHI#/"?^&4?B$3_`,G&?%'IC_D%:!_\KZYKX5?LJ?&^
M7PU=_P#"9_M%>-TU;^U+X6_]EZ5H?D_81=2_8RV[3\^:;;RO,[;R^.,5D_MU
M^$]53]MS]E#Q#H]QXP39XPO]*U6+3[^\73'L9-'O93]KMXV\AAYT<.V25<@A
M0#SBOE/_`(+`?M%W_P`5/CU\&[[P'<>-O$VE:%=WULO@FTTOQ3HP\<:A_:EO
M8S117]CY*1S6@@F=1=,82CE\.C@T0?,TEWM^"=_Q^\<O=3?E?\6K?A]Q]T?\
M,I?$+_HXSXH=?^@5H'_ROH'[*7Q"S_R<9\4.N?\`D%:!_P#*^O=`>*6@1X3_
M`,,H_$/C_C(SXH<?]0K0.?\`RGU@_$_]F+XVZ3X%OKGP1^T!XOU#Q5;".33[
M77=+T4:=<NLBEDG,5@)-C+N!V$'G@BOI2OR=_9A_:0\*>'?^"M?Q5\36OC'X
MVVO@WP5HVLS>);GQ1;:Y?P^-;N2[B*_8+)8#:V]EIB1F&)HD6:;S>%D4%V%K
M+E\F_N!Z1OZ?B?K%17Y._P#!.;Q'XXU/_@IU8B[OOC!/XVFOO'1^+=IKG]I#
MP]:Z>-03_A&S;).!9H3;F'ROLOS%#+O[U^L5.WNQEW5Q7O*2[.P5Y/XQ_P"3
MYOAU_P!B)XI_].'ARO6*\G\8_P#)\WPZ_P"Q$\4_^G#PY2&>L4444`>8>&?^
M3SO&O_8E>'__`$NUNO3Z\P\,_P#)YWC7_L2O#_\`Z7:W7I]`!1110`4444`%
M%%%`!1110!X1\//^"E7P9\<_#B3Q3?>-]"\%Z4FM:GH,9\5:A;:1)<W&GW;6
M=R8UED&]!,N`P_O+D#.*[KQA^U3\,?AYXAT32=?^(O@;1-4\2QI-I%G?Z]:V
M\^IH_P!QX$=P9%;L5!![5\`:+_P0N\1:UJNA_P#"9#X9^)].T:T^)HCM[Z*6
M[2*Z\2:@+C3YD62#`:&/>)&ZJ6^3?UK"^$/_``1;^+_[._B&P>S\._LQ_%N'
MQ#X9\)Z/K5U\1;"\OI_"LVD6<-K,FG`0GSK:01&6-6:!ED(+9`Q13]Z,>;1V
M5_5WO]UK_-%3LI2Y=M;?A;\'^!^F,WQK\'PDK_PE/AUY1J;Z((DU*$R/J*(7
M:R"[LFX"@DQ??QSC%>:?L9?\%%OA3^W3X`TC6/!7BC2O[3U2P;49/#=WJ-K_
M`&YIL(D>,M<6L<KM'RG?C!7UKY;TO_@E1\7K;]M07TVM_#C_`(4Q:?&6]^-L
M%Q']J'B26_GTYK1=.:$Q_9UA5V+&82;BH'R@\5XM^SI_P0"^+FFZ!X`\*^,;
MOX(>!M,^'6B^*;)/%W@2WNV\4>))M9L[JT47DDD4*[(1<^8QW.9&AC`"8S4I
MODNUK;;Y:_\`DUUZ*_4&ES63T_X+_2S]7Y'Z+^+?^"B'P4\,?#?QGXFMOB9X
M(\0VO@+2KW6-6M=&UZSO;R*&T0M,!$LN=P.U0#CYG49&17+?`3_@JI\)_CWI
MWBS5X=3/AGPCX2TO1-6G\3:_=V=GH]U%JMJ;B%(Y_/8"2/!CD5]NV0%1NQ7Q
M)\)_^"'/Q=AU:YC\2^'OV9_#>G:;\$=;^$]D_A&VNXIO$%W<QQ+:ZCJ"R6P'
MWH@[`%V1F<@N6^5+[_@@1\1O#?B6W\2:*?@OK+^&[KP;J-AX/URVN'\.>(I=
M*\/2:7?)>HD'[LF>5[B"01R_-\SH"36EHI7OV_\`2I)_@D[>=B'?2WG^46OQ
M;7RN?I3XG_:^^$_@GP;I7B+6/B=\/M*T#7H6GTS4KOQ#:0VFI1J0K/!*T@64
M`LH)0G!8>M<=^VU_P4(\&?L)?`RQ^(_B/1_&GBCPA>S1QM?^$=(.L1V<<H'E
M3S,C!4A<LBJ^<%I$`ZU\6?!W_@@EK^EZSX(O_',7PFUNUL6\?ZQJ7ANWL9'T
M'P[J'B%+-;6VTJ"6(@6MO]GDRS!&!E)5,GCW#QU_P3=\;^)O^"'N@?LT0:OX
M93QQI7A+0]`EU"2:?^RVFL9K5Y6#B/S-A$#;3Y8/(R!VFW?R_6Z^7?J-/WK=
M-?TL_GV/1?@S_P`%4/AE\3(O%\GB7^UO@]'X.O;>QN/^%BFU\/R7,LUFEWMC
M22<MNCC<;U<*RGMCFO5_!/[5/PQ^)7B*;2/#OQ%\"Z]JMO8KJ<MGIVO6MU/%
M:,,BX9$<L(R"#OQC!'/(KX?\1_\`!%OQ!\0?^"E%U\5?%(^'7B3X>7GQ(F\9
M3Z)J44EU+/;'PTFF1*\,D)A:5+M%D`+%0JA@=PVUYKX%_P"#=?7_``]^SQ\.
M?!MOJ?P]\(ZUI?@CQ]X5\4Z_H-M(MS?2:Y*K6$BGRHVN$AC78XE92JDJF0:G
MF;CS-:VV\^6__I6@[+GY+Z=_G_EJ?IO\)?V@_`?Q]M[^;P-XU\*>,HM*F^SW
MKZ'JT&H+:2<X60Q,VTG!P#UP:^=]=_X+,?"WPUX]UK3KZR\16GAK0OB/;_"R
M?Q;<?9(-$.LO:S7,X\V2=6$%LL)261E`#LH4-R1Y-_P1K_X)$>+?V"OBUX@\
M9>-AX;@U6?PQ8^$[/^P_%.H:LEW!`P9I)8[BW@2-=RKY2*KM&&D4NP-><?!7
M_@GUXI^,LFJ_"/Q7X5M+>R^%/[3MU\4KZ3Q%ITKZ3XT\/7OVRYA:U<QM%<3!
M[E4>-CA##\Q&0#;7OI)]/_;HK_TEM_\`#$7ERMVZ_P#MK?YV7_#GV_J?_!1+
MP!8_M!_"SP-!+/JVG?&:RO9_"?B[3)[>\\/ZC<VB^9+8_:(Y21.8PSJ-NUMK
M`-N!%>\U^67A?]A;QK\$_C1^S%\&[#PW'=6'A#XO>*?B[J>N:-93)H7AO1I)
M-1-E8F9HT19Y/MJ1^0@^7RC_``X8_J;2CK!2_KI^3;7R*>DK?UNU^*2?S"BB
MB@`HHHH`*\G\8_\`)\WPZ_[$3Q3_`.G#PY7K%>3^,?\`D^;X=?\`8B>*?_3A
MX<H`]8HHHH`\2\3^/XOA-^UGXBU/5-%\8W.FZOX1T:UM;O2?#.H:M"\L%YJS
M2QLUK#($95GA.&QQ(,9K=_X:X\-?]`3XG_\`AO->_P#D2O4**`/+_P#AKCPU
M_P!`3XG_`/AO->_^1*/^&N/#7_0$^)__`(;S7O\`Y$KU"B@#R_\`X:X\-?\`
M0$^)_P#X;S7O_D2C_AKCPU_T!/B?_P"&\U[_`.1*]0HH`\O_`.&N/#7_`$!/
MB?\`^&\U[_Y$H_X:X\-?]`3XG_\`AO->_P#D2O4**`/+_P#AKCPU_P!`3XG_
M`/AO->_^1*/^&N/#7_0$^)__`(;S7O\`Y$KU"B@#R_\`X:X\-?\`0$^)_P#X
M;S7O_D2C_AKCPU_T!/B?_P"&\U[_`.1*]0HH`\O_`.&N/#7_`$!/B?\`^&\U
M[_Y$H_X:X\-?]`3XG_\`AO->_P#D2O4**`/+_P#AKCPU_P!`3XG_`/AO->_^
M1*/^&N/#7_0$^)__`(;S7O\`Y$KU"B@#R_\`X:X\-?\`0$^)_P#X;S7O_D2C
M_AKCPU_T!/B?_P"&\U[_`.1*]0HH`\O_`.&N/#7_`$!/B?\`^&\U[_Y$H_X:
MX\-?]`3XG_\`AO->_P#D2O4**`/+_P#AKCPU_P!`3XG_`/AO->_^1*/^&N/#
M7_0$^)__`(;S7O\`Y$KU"B@#R_\`X:X\-?\`0$^)_P#X;S7O_D2C_AKCPU_T
M!/B?_P"&\U[_`.1*]0HH`\O_`.&N/#7_`$!/B?\`^&\U[_Y$H_X:X\-?]`3X
MG_\`AO->_P#D2O4**`/+_P#AKCPU_P!`3XG_`/AO->_^1*/^&N/#7_0$^)__
M`(;S7O\`Y$KU"B@#R_\`X:X\-?\`0$^)_P#X;S7O_D2N9T+Q_'\6_P!LSP?J
M6E:'XSM],T7P7XAM;R\U;POJ.E6\<UQ?:$T,0>ZAC5G=;><A5).(F/:O=J*`
'"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>table3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$$`0T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]B/\`@I/^
MV;-_P3Z_8N\8_%NW\+?\)K/X5-DL6B_VF--^W-<WL%H!]H,4HCP9]V2ASMQQ
MG(\#^"W_``7;\':-%XYTG]ICPW!^S)XX^'^HV-CJ>D:EXA@\163+?6%S?V92
M^LTV&22"SN#Y;*I#")`7>55KV3_@K)^R!XB_;S_8&\<?"KPI?:/INN^)Y---
MO<ZI<S6UK&MOJ-K=2;I(8Y)%)CA<*54_,5Y'4>:>/_\`@CKX.\*Z]\()?A3X
M?\/:'#X6^+%M\2?&5WK>HWNI:IXC>.UO(VE>\N?M%Q<W`FN5=//E"K\Y#*>"
MJ5]5+K))>2;A>5M-$G.]V[VM9;ESY?9IK=*;[7M&\5UW>BLEO>[MROT#Q7_P
M6,_9D\#?%#P'X,U?XQ>%;#Q+\2K*VU'0;.7SAYL%S$DMLUQ)Y>RS,J2(8UNF
MB9]P"@GBO.O@?_P5^C\9_$N71O%FB^&O#VE0Z[X^LY[\:K=-<VUCX8GB0SK;
M+:2+*7CE#/NGBV[&V+(2%KS?]JG_`()*_&#XN>(/VCO"'AO5/AI_PK7]IGQ)
MH6OZGK^K:A>Q^(O"HM!:I<QV]G':O!=G;:(T#-<P>6S-N#8!KI?V4/\`@E/\
M0?@-^UYX3\>ZIK7@^ZT30/$GQ#U>:*VO+E[N2'Q!=6LUD%#6ZJ718&\X%@%)
M&PR<D*%Y>]M>,]];2M!Q72[4N:-]%.S:23)GI%+>THWMI>/O)OK;FT=K-PT3
M<GJ<K^QS_P`'(_PA^*/[.'C#XN_%WQCX#^''@Y?&DWAWPO86O]IWVM^0D494
M7EN+7=),P(G+VHDBCBN8D<K)&Q;ZL\5?\%2/V?/!?Q-\'>#K_P"*WA4>(OB#
M!IUWX:M;>9[E=;@U"2:.TF@DB5HWB=H)`7#;4&PN5$B%OC+0_P#@B;\4/`G@
M[X`W<.H^&_$FN?"S3_%&BZWHUI\1_$/@FUO[;5M0:\BFMM5TRW-VKH1&LD+P
M^7(,C/R*Q]T_8\_X)G:W^S)^T<GC'3+'P+X.T:U^#UA\/]*TS2]1OM:?0;Z+
M4+J[EV37D:RSVH\^+#R.KR&,[HT&,5S*R;6V]M[1A+O:\IN,;/9<]GK'526L
M[/T[7<X]%=\L(REIN^6Z=F9WQ0_X./OV0?AU\-O''B.Q^*=OXQ/@"_ATW4=,
MT&QFEOKJ669HE:T$RQ1W4(*,3/%(T(`7Y\O&&]`\"_\`!6KX7>.O&6H7L?B;
MPC9?"RU^'-C\1HO%U]J=S9R-:75[/:*);6>TC2%0\!`+7'FL[JHAYS7Q%XG_
M`."&'[27Q@T/Q-=^,O&?@R_\9:O\+[CPA-J^J?$+7_$JZSK#:UI^IB\,-S91
MQZ9:/]EDC^S6:%(OD($F3M]E_;7_`."47Q@_;,^(_B'QV]]\-?"_B&^\&>%[
M.QTG^U[W4M..L:-KLNJ&&XE^QPN]C*A1/,6,2!B3Y6%&X2:Y%)[M\SW45::Y
MK:.5VHS2TE9J+5W<<_M\JVV6EV^:F[7U2T<XMZJZ<EHD>\^#O^"V7[*OCKX&
MV7Q)L/C5X43P5?:PWA]=2O5N+'[/?"">X$$\4\:2VY:*WE9#,B+)A0A8N@;U
MOX`_MC_"_P#:A_9]@^*G@7QKHFN?#Z:":Y?6_--M!:)""9OM`F"/;F,`EUE5
M"HY(`KXGE_X)*_%GXL?MKP_'7QO<?##2-6U'XG^&O%FH>&=)U2\U*QLM,T72
M+VRC:.YFLH6N+Z2:[5OF@A1$A3#DBO2M`_X)=^(K_P#8;_:F^$.KZ_HNES_'
MCQ?XLUS2+[2VEFCTZUU5@UNLZM'&=ZXQ(B;EP2%<YS4S;5*I-+WE&\5YI4W;
MSNY3MM;D:UO<<4G4IQO[K:4GY-U+ORY>6*Z\W-?38YS]HO\`X..?V;/A[^R+
M\2OB3\._'F@_$O5?`%TFDQZ%;M<V<M_J$K%854R0[FMF*N?M,:O"1&P5R<"N
MP\4_\%67^$__``3S^#GQ-O="TOXG_$CXT#3='\*Z!X)GGM--\4ZU>1,T:03Z
MA''):6IV,[/<INA4$,'*_-X#\:O^"/\`\>OVK=!\3:IXPN_@[X2\4#X3:1\+
MM#T_P_K.HWNFWWV?5K;4+B^NYY;&&2%?]&VPP)%+M\U]TIZGZH_X*:?L7>-O
MVI?`OPWUSX7ZWX5T/XJ?!SQ9:^+_``T_B6WFET:_ECBD@EM;HP_ODBDCF;YH
MP6!1<`9W+I*,8JSE>\XIM=(*33:6NLHOGMJXZ1:;1G"4IO:UHRT?63C%Q3>F
MD97A?2^LKI-6V?V8?VW_`!!XWN/#7A?XW?#2;X#_`!9\82:G-HOA"3Q!;^)A
MJ5C8);O-=I>V2^2BC[0@V3>6^X-M#@9KRJ]_X+@?#?3O&?C;7A=0W_P6\)_"
MNS^(\/B2SMKC[=J#3:G=V!MDMI51@2]NB*'"G>QW$+R,_P"+'[,_[6/Q/_:.
M^&GQB6R_9WTWQ5X`;Q%H\.@'7]8N-/32M2L;)(IFO/L*23W45W;RR,@MX(WA
M9(PZOF:N!_8J_P""+_Q(_9X\`>(M!\1>)O!%S_;7P/F^&"7.G2W3[+^34M5N
MOM!C>%,0>7?1?Q%]RN-N`&;"O*IR<\%[R4M%M?V=6WXJEUMS2:6B:6U!4V^6
M;=FXZ]E[2"E_Y+SV_NJ[U9]0?LF?\%6?@A^VIX7^'NH^!_%-Q<7'Q-M=1N=&
MTZ[TRY@N]VG"$W\4OR&.-X#/&IR^UR<QM(.:JZ!_P6$_9K\3>)/`>CV?Q6T9
MM7^)R64GA>QDM+N*YUA;NYN;6`I&\08`SVDZ-N`\LJOF;!(A;PG1_P!@S]I+
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MIO@W4;^\8O:7*S_:9'N;6`;79IL*!F-?+3,F#(<Y;M)WM%Z[7ERU;/75>\J=
MHO6\M6TM74D_9-Q5I-KSLN:G==FW%S][:T=KM69X`_X+)_\`"<_L=_LZ_%G_
M`(5Q]E_X7[\0[7P%_97_``D&_P#L+SKF]@^U^=]F'G[?L>[R]D>?,QO&W)]]
MC_;]^$4MA870\8P"VU/QS/\`#:VE:PN@DOB"`S"6RR8L#!MY1YIQ$=O#G*Y^
M%_@G_P`&_<OPB_9K_9FL;?P]\%++XO\`PG^)EGXN\7^+K"P,=YK>F0W5[,UO
M'>BT6YG<K-;`),$3,/W@%4G9E_X)1?'QOB#I^AKJWP@'PQT'X^WOQDL[TW^H
MG7KRWN7F;[%)#]F\B*2+[1.=ZR.),QC$6QF>ZK2E*,%]IV_PWHI:]K.JTWJV
MNRL]*J2;<-DM/7]_;\526^SONVU[:W_!P#^QJFGZE<G]H'P,J:5HT6NSH6G$
MK6\A(6../R]\MT,?-:1AKA/XHES73Z-_P6<_9<\1?'?PI\-+#XT^$+WQCXVL
M+?4M&M('ED@NHKB,RP*UT$^SQ32)@K!)(LK;T`3+J#XS^R5_P29\;?``?LJ#
M4;[P+(/@7X)\3^']<%C-.?M5]JGDF.:UW6Z[E^23S&?RV^?@-DU\V_!K_@A%
M^U!X9^'WPW\(>,O'G@?Q)I?P[\7^'-=TN>#X@:_:Z;I.FZ=,DT]A%H260LIY
MWD:=Q>SN96.Q=L0/RS+2;C'57_#GG&_RBH3\US*]^5"M>+DM-';UM%J^W7FC
MIK=I[*3/T/\`V:/^"K_[.O[8OQ37P3\,_BSX8\6^*WTB/7%TVU:5)FM6S_ST
M11YJ8_>09\V+(\Q$R*\C^-__``6?A^%?[2_Q2^#VD_#I_%7Q)\*:UX>\/>#-
M#M]?6&X\<7>J67VV5CF`_8K>TA5WFG;S555!.TLJG'_9!_X)2^-?V=KW]C66
M_OO`Y_X9Z\/>)]*\3?V?-/G4)]4CC$3VF;=?,7>KM(9?+/S9`8DUS7QU_P""
M._Q'\1?M\?%?]I'P'XC\&:!\39M:\-ZO\/+NYN;D)+;6>G"QU72M6"0$K:7B
M$@>3YK*4C<;2"ITE&"JI7]W6[]*B2:]:>MM=VTF[(2NX3:6MO=7G9:-[;W[+
MHVM9'T_X7_X*B?`?Q)^U9=?`I?B=X3_X7!IMJT]]X>AN)76*2-0TUO'=-&L$
ML\8W%H5;S@J.S1J%;;Q-Q_P79_9*MOA!K_CS_A=GAJ3PMX8ET^WU&[AM;R5X
MY[Y'DMH$A6$RRS%(Y"\4:,\0BD\Q4V-CPW]FG_@CKXQ^#_Q@,OB?0_"?C#1+
M/Q_JWCK1M>N/BUXH$NBR7OGRKM\.BW&EO<QR7$L1N/,3?&Q=H]Q*'I_#G_!-
MWXW_``A_X)N_L_\`P?\`!_B7P[:ZE\.]067QQI^D>,=4\(V_BJUVW3F&#6;&
MT>^M\W,L$C[(4:4*ZEU!^;%.3HJ4M)^YIT]Y^]Y^Y\/77WDVG8KW?:.*NXKF
MMT;M>WE>5DUM:]FD]3M?"G_!>[]F?XC?M3>%/A#X8\<C7?$GCO0XM9T'4+>T
ME.CWCRJSQ6;W`4M#<%%9F5XPL>THS"4>56EH?_!:+X)^#/V4?AS\3OBWXT\*
M?#1?B1H%WXAT^S%Y>:A%/#:R1I-';R-:0RSRKYT6(A`LCDOY:2*C-7AW_!/O
M_@DU\:/V)?B9\/=7N+SX:>(+&Q\&>(?!WB-/^$AU(7%FM_XBN-6M[JUDELW:
M\98Y5CD2=H6+9;S&QENR_9)_X)3^-O@?JO[(\_B*_P#!&HK\`/!?B/P]K8MY
MYYC<7>HB!89+/S+==R!4D5V?RV`?`5@33E=4VUO>7X>ULM-V^6GJM'S:*Z;)
M6E1J6J5MM+Z0N]=E?F:6ZL[MW5O8OC3_`,%C/V8OV>O"_@'6O%WQF\(:9IGQ
M.CBN/#4T<DMW]O@E)5;AA"CM#;[@RM-,$C1E9692I`K_`+1/_!:']EO]E'XC
M0^$O'GQH\)Z/XAGTU=6%I#YU^4MG19(V=[:.1$:2-T>.-B'D1U9%92#7QG\$
M?^"*/[0/[+WP@U30O"][\%/%%]X]^$$_PO\`$(US6=2MK?0I3?7\T5U9&.PD
M-U"8;]O,@D6W)DC7$F,UZ?\`LR?\$DOB5^R+9_$7X9VM]\._'_P6^+.FZ3IW
MB36==O+Z'Q-;6]MH::5=Q16<5N\%QYBP1O"S7,?E;W!67`RZC4>=QV3ER]+^
M]))-_9]U1FYM6:?*E=#2LXQ?E=KII%MI==7*"ANFN9NVA[S^V]_P6*^!/[`?
MA[Q%<^-_$E]=ZEX9LM,U"ZT?1]/DNKR2'4998[0HQVP$OY$[X,H(2(DCYDW+
MXW_X+3?LN_#3P=\,=>\0_&'PYHNE_&&&*Y\*R7D-S&UY!(_EK<3(8M]I!ORI
MFN1%&I5MS#:V/B/]A?\`X)5_%3XO?\$:OB_H7B:YDTWXS?%R2TTK3;[QGIES
MI4T.DZ"UO9Z1#=PF,W$*/%9O+@H6'VLL5))S[%^T_P#\$L?B;^T'^TIJOQ+U
M3PYX)\2V_P`0/AY:^#_%/@X_&3Q1X5TZRGMYIR-EUIEBK:G9R17#AX;JWBPV
M2OWFHFN62BM;M/\`EM%Q<K-:VE>T&]HRU:LT*&JO+2UUW]Y2C%M/^764DMY1
M6]SZQL/^"C'P1U?]KZ/X"V?Q&T&]^+4NG'5!H%MYDSK"$\PAIE0P++Y?[SR6
MD$OED/LVD-7M=?"GPI_X)S?$OX3?\%!?#_Q`\(/X4^&'P]@$R>+['0?&FKZC
M%\0(ET^&TL1<:+=6PM;2Y@\B(?:XKEY75"6!,AV_==6U'DBUOU^_MTT[N_6R
MNB(N3D[^7_!]===K6:6][%%%%06%%%%`!1110`4444`%%%%`!1110`4444`%
M?.WQ/_X*S?LY?!;X^)\+O%?Q;\+:#X^?6;?0#HMVTJ3Q7<]M'<PASLVI$\<L
M>)F(BWMY>_S`4'T37Y]_M/?\$E_&_P`;-$_:S33+_P`"PW_QX\4>$M:T&>[G
MN%:TM](^P><ETRV[%&)MI_+$?F#]X,E-S8*>M:,9?#I?_P`"@G_Y*Y/Y!+X&
MUOT^YZORO;MN?5WQA_;N^!_[/'C#_A'O'_QE^%/@;7Q`ER=,\0>+;#3+P1/G
M9)Y4\JOM;!P<8.#7%_M__MC>._V3?@K<^/?`?POT7XF^'-%T._\`$>MZC?>-
M[;P[96%I;1)*BQ2-#.T\LRLY0!%CQ$VZ52R*W:?&']GCQ=\3/&']IZ+\=_BM
M\/++R$B_LGP_I_AJ>S#+G,F[4-)NI]S9&?WNW@84<Y\?_P""GG[(7C;]KCX8
MQ^#]'^&O[/WQ3TV;P]J-BM]\3;JYM+[0-4FC2*'4+1K6PN.B>:7$1MI-PC*2
MIC%85O:>R?)\6MON?_`ZK6U[)NVU'D]JN?X=+_>O3SZ/3OU^A/V=_C%!^T/\
M`O!/CZVTS4-%MO&VA66NQ6%^H6ZLDN8$F6*0#C>H<`X[BNRKS#]B[X+>(_V<
M_P!E#X?^!O%_BV\\>>)_"VB6^GZGK]T\CRZG.BX>0M(6=AG@%R6(4$\UZ?7=
MBO9JM-4OAN[>E]#CPSFZ,'5^*ROZVU"BBBL#8****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BO//VM?B#XK^$_P"R]\0O$_@71?\`A)/&GA_P]?:AH>E?
M8IKW^T;V*!WAA\B%EEEWN%79&0S9P"":^$KW_@K%\5/$-UXK\*^"_%GPOU_Q
MI\//!^N>._$TNN?"GQ'X5-C%8PV;0:.VE7VHK=13SFY,GVUI3&(RFVWD)+5#
MJ13?,]DW\DFV_DDWY[*\FD[]G)J+7VG9>K<4E\W))?-[)M?IA17SQ\!_^"F?
MPY^.6H>`-*6S^(GA_7OB-$JZ3%K/P_U_3]-N[D6$U_);PZG/9)8S$6]M<2*T
M<[+*L+-&7!&?H>MJM.5.;ISW3L_D8TJD:D%4ALU=?,****@L****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"OS
M>^.O_!PMH_P!_:$\=?#G7O"_P[TC5=$US^P_#\^K_%&TL$OF2_L+66?4XC;-
M/I</EWWVB-_+N/,BM+AL*J;C^D-?EW\6(/C)^TS_`,%`=9T/QS\1_%_A_P"%
M_A_QY%I>F>`KC]EFZ\4^'?$>E-!'#+*/$$MK+'`MU#<W=K-.SHL0>?'[DAFB
M"E+$PIIZ-/3IO%7OJ]+[13;NW;W2Y<JH2F]TU^4G;M9VU;:VM>[1][?"#QQI
MG[;'[(OA?Q+-!J^BZ7\2?#=IJ;P:9K=Q97EFES"DA2&^M'BF4KNPLT+H6`#*
M0#7F&L?\$<_V>?$-C/'?>#-:O+R^DNFU+59O&6N/K&N)=1PQ7%OJ&H&\^UWU
MM)';P(;>ZEDAVPH-F`!7TKI.DVN@:5;6-C;6]E964206]O!&(XH(U`5411@*
MH````P`*L5M4Y'4E.FK)_E>Z1G'FY%&?]/N?/7[7-A!I7Q[_`&2+6UABMK:V
M^*-Y%##$@2.)%\#^*@JJHX`````Z8KZ%KY__`&R/^3BOV3O^RJWW_J$>*Z^@
M*EMMW8TDE9!1112`****`"BBB@`HHHH`****`"BBB@#QWQW_`,%`/@W\-/B-
M'X4UGQ_HMMK;S"WDB3S)X;24RM$4GGC5HH&5U(<2NI0#+;0<U[%7XW_M/?\`
M!./XR7?[6WB73]-\,ZUXL7Q'J5UJUEK:)&MK=Q2O)-NGN-L5O#/PP="(QOX1
M2KQEOU;_`&;_`(;:A\'/@#X.\*ZKJ']J:CX>T>VL+BX&W87CC52D96./,:8V
M(64.452Y9MS'X'A+B3-LQQN)P^887V4*;M&5FNNSNVI.VMXZ6]4?F7`_%N>9
MMF&,PN:8/V-.D[1E:2OK;E;;:D[6=XZ)>J9K>,?B=H?@#7/#.FZM>_9+WQCJ
M;:/H\?DR2?;+I;6XNS'E5(3]Q:SON<JO[O&=S*#B:1^TGX*UWQS%X;MM:W:Q
M/J5[HT<+VD\:27EG$DUQ;B1D$9D6*0.!N^=5D*[A'(5\^_;B^`'BWX^Z[\&H
M_">NZ_X3;PSXX?6-3U[1/[.:^T>U_L35K;S(TOX9X)-TUS#$5,$C!9BP"[=Z
M^/\`B+]A/QW?_L;_`!6\)76J>*?$/CBZ\=W'B/PSXAGOM-L=9NPWV=!<^9:1
MP6T#/!]IA8+'%F-G!7+9/WL;N379-_/F@ORE)VW=M-$V?I]:T5!QUO:_6W\7
MT_EAZ<VN\3WKQ%^WI\+/#?AS0M3/B"_U-/$J2W&F6FC:!J.KZC=6D4IADOA9
MVL$EP+%7"@WC1BW'FQ'S,2QENX\7?&_P9X`^%$OCS7/%GAO2/!$-G'J#^(+S
M4H8=,6VDVF.;[0S"/8^]-K;L-N7&<BOEK]H+X+?$GX%?%7Q9J'PI\)^/+S2/
M&7A#1=!TF^^'LOAB'5?!TFCR77E6KPZ^Z6KV<R7G!1970I,-J;HWKT[P-X3^
M*?PG^`-WXC\5:W\2/B]XTU3P]8QW?@RU3PU:Q6&H-$B77V&7RK%2OF,[-]IO
M'7:AV<X5HJR?LJDZ6\=KK?XK::OI9O;5/9IBA?VM.,]I;V>WPWUT2W=O)/JF
MCI?&/[=/PL\!_#GPAXLU+Q1LT'QW8KJVCW$&F7ER\NGF))7OYHHHFDMK**.6
M)IKJ=8X8!+'YKQ[ESHI^U_\`#J3XZV?PW_X2(#Q7J,3/91M8W(L;V18A.UK#
M?&/[))=K`PG-JDIG$)\TQ^7\]?)/PT^'_P`8_AU\(?AG=O\``?QAJ6K:=\))
MOAE?Z(^M>'OM&E7R"TV7DC'4?(>PF,3;C%,]P!$F;<Y^7L_AWX%^)>D_M(_"
MCPGXG^%WCK4/A[\%=*LK'0/%%AJ>AR:=J>JG2S97&JW@DU%+X1112SP1Q)9L
M[--+(V?W:KU.-/VDHK:[2]+S2U](P?GSVTY6S)SERK36VOK:#V[7<EN_@OKS
M)'V;1116)H%%%%`!1110`4444`4/%7AZ#Q=X8U'2KI[^.UU.VDM9GL;Z:QNE
M1U*L8IX726%\$[9(W5U."K`@&OR+T;]M2SO?VIH?!Z^'/'OA/XK6'Q6T[0H]
M+\9_M*OI]G9Z.MU:C=-HW_"6RS7MV]N3LCBLY;>X>1#B8%D?]@Z_,S5[?]G+
MXV_MH7>@0_M"-\+?&W@GXL3KX@\$ZWJF@1W?C*ZEGT_48(+$/NG$;7UO9O'-
M$3<C_2K8["R^483_`'^%]K7??2<+>;W:?6ST#$?[I*V]].VL)W\M;)JZM=*^
MA^F=%%%`'S_^V1_R<5^R=_V56^_]0CQ77T!7S_\`MD?\G%?LG?\`95;[_P!0
MCQ77T!0`4444`%%%%`!1110`45S?Q`U3Q=IOV3_A%=#\.:SOW_:O[5UR;3/)
MQMV;/+M+C?G+9SLQ@8W9..<_9Z^*GB[XQ^$=$\1ZMX8\.:%H/B'1X-5LFL_$
M,U_=CSDCDCCDB:SA1?D<[BLC890`"#N''+'4HUUAG?F?]V5NG6UNJZG!+,J$
M<2L(^;G>J]R5M+7]ZW+I==>IZ/11178=X4444`?-_AK_`(*L?"7QIITEYH^G
M_&_5K2&[N;"2>S^"/C6>-+BVGDM[B$LNE$"2*>*6)UZH\;JP#*0/</A/\4M"
M^./PL\->-?"U]_:GAGQAI5KK>D7GDR0?:[.YA2:"7RY%61-T;JVUU5AG!`.1
M7RA\?O"?C[X7?&7Q#\(O`.F>,+7PI^TU=F_M?$^A6]REM\+[C`'B>9KN$"/2
MY+JS"W>F,$E,VMW-_+.=D@KZ_P#"?A/2_`7A73="T+3-/T71-%M(K#3]/L+=
M+:UL+>)`D4,42`)'&B*JJJ@!0```!0`[Q+XFTWP7X>O=7UC4+'2=*TV%KF[O
M;R=8+>UB49:221B%10`222``*XGXX?M>_";]F2XTV+XD_%#X=_#Z764>33T\
M2^)+/26OE3:':(3R)Y@7>N2N<;AGJ*\G_P""OWASP[XO_8*\;Z5KG@?5/'U_
M?V4\7AW3].\&7GBFY@U;[/*;6XCAM;>=X&1@=MR518RP^=2PSK?M.Z_J?[17
M[-?AOPKX/T[Q5;6_QANX=!U"]O-#U'2KC0=(='DU&:XBEBBGM)&M89H(O.$9
M\^XA^A7O->[O=+RUVN^FN^]EKZ5[L6N?:S?GIO9==-N[T]?2A^U/\,3\4=&\
M#_\`"QO`?_":^([)=2TGP_\`V_:?VIJEJR/(MQ!;>9YLL12.1@Z*5*HQS@&E
M^.'[4?PS_9DM-.G^)/Q%\"_#Z#5W>*PD\2Z_:Z2EZZ`%UB,\B!RH9<A<XW#/
M6OA/QBN[]L?XG>&?"VE^-M5UW0_B[X7U2Q\.6G@F\N/"M]##HGAO]]=ZO';+
M%92V<,5Q+$IOHAG`DM[H2)"_:_M4ZG\;O@E^UW\+?%FJ^)M%U.TAT?Q/IYU7
MPU\!_$_B:WL+:>YT.2*RN+73=2N)EN9!;2LMVSI%B%QY!)!&D5&?LVG93_+D
M4U\]>72^U]VH!R24N672*>G>S;^6BL]-^RN?=UM=1WMM'-#(DL,JAT=&#*ZD
M9!!'!!%25^?_`.T)I_BCXP?$?]I3P6FG?%WQ98^*?AYJK:9?PP^*/#VGZ*Z6
MMNMOH\$#Q1Z=>2RRF247EE,;B022V\T7EQAGD\/Z#XBT?0O%GB_P[!^T7J7A
MKP/\*-)?PEX<NM3\0Z9<7^J'^V(;S?'>127D]VJ&$%9H;AU!MY$@DD6V(SO[
MCJ/163^_GT?IRVT33;TO&TG-M5%:N[6GER)??SWU=TEK[UXK[\KG_"/Q8\+?
M$#4KBST'Q+H&MWEI;QW<\%AJ,-S)##))-$DC*C$JC26\Z!CP6@D`Y1@/SR^%
M/Q&^)M_\#M)C\<:3\?/#GPU7XCW5K<0>'T\7ZYXDMM(&B)/9@75QI]MXBGMC
MJA<O,\&X,H@<O;;A3/@+!\8_A9^SK?VUS8_&BRT1-+\+IJ>S1KDZW!92^(=9
M.L2VMI;Q#_3GLV@,OV*(3(DB/$H98:J2M;SY=]$N9)^\];<M_?WLM5<F,KIO
MR;TZVE;W5IS7^S;?3T?Z0S>*-,MO$MOHTFHV*:Q=VTMY!8M<(+F>")HTDE6/
M.YD1I8@S`8!D0$_,,WZ^*/V-=$\8ZQ^UIHFN7=E\0+CX>6.@^)]/\)7_`(MT
MW48-6M]-:Y\/F"&^>_47?G--#?F,WG^D20Q*[;OO5]KT^7]W";WDKVZKWFK-
M='9*ZZ.Z!2O*4>SMY/1:KR[/L%%%%24%%%%`'/?%KXK:!\"_A?XA\9^*K_\`
MLKPUX5T^?5=5O3#)-]EMH4,DLFR-6=MJJ3A5)..`:_)'PE^T-:_&S_@IYK#_
M``Z^/GP9U32O'?B.SM3XJ3XX31ZLEE9ZWI]['H=GH4JG>TD8O+:,69-I<)<2
MO))O/E/^LWQON!;?!KQ6[)#*HTBZ!2;P_<>(8GS"PP^G6Q$]ZOK;Q$/*,HI!
M8&OS3_9^_9Q^%7@S]HGP]>>%_AA\+-*2Y\2VFHQ//^P]XVL+^SN#+$6:WU:Z
MG\C30'4M')Y:PVW#;2%8DP>F/A5?V5IZR=G=>BT\]-4V@Q.N$<([MW?_`&[J
MOQWO=6[61^JM%%%`'S_^V1_R<5^R=_V56^_]0CQ77T!7S_\`MD?\G%?LG?\`
M95;[_P!0CQ77T!0`4444`%%%%`!1110`5YQ^QU_R:+\+/^Q0TG_TBAKT>O./
MV.O^31?A9_V*&D_^D4->?4_WZG_@G^=,\NK_`,C&E_@J?^E4CT>BBBO0/4"B
MBB@`HHHH`****`*&C^%],\/7FHW%AIUC8W&L7/VR_EM[=(GOI_+2+S92H!=_
M+CC3<V3MC49PH%7Z**`"BBB@`HHHH`****`"BBB@`HHHH`*_(^R_8+U?X^_\
M%5?&7Q#\)^%O#VM>,?"WQ*2>[^,4GQ!UFPU7P59VQL'D\.R>'G@2&=IK"6:&
M*5"UM+;S[VD#$*WZL^/O%:^`_`NM:Y)"UPFC6$]\T2G!D$4;.5![9VXK\HO^
M":?[6_P/_:;_`&EVU#X]>'O^"?1^*_B>/2?%_A+Q%X(FL)]6DO;J9ECT^ZDO
M5-P=:AECB)\ERV73"J0"3":XV,H[Q7XMIKUTA+1-7M9NS<9&(TPK4MI/\$K.
M_E><=TUK>UUS1_37]J?]H;1OV3OV<_&?Q(\0<Z3X-TJ;4IH_,6,SLB_)$'8A
M5+N50,Q"@L"2`":_*GX+?\%'/CM\0O@QXE\?:]\7O%7B[X?_``KUCQ0GCKQ#
M\'5\"W#Z;'`NF3:>X35(V$NGB(ZIL>W62>4+'DR&OV5KROQ=^PM\$?B!XD@U
MG7O@Y\*];U>VU"75H;Z_\)V%S<Q7DKH\MRLCQ%A,[1HS2`[F**220*5/FA6=
M3=<MDGJD[K6VE].EUZ[E2:<%%='=^:LU:^MM7?9KNG96\&^,O[0&L_%?]KO]
MEFPD^%OQ"\.>'8_B9J-SIWBS5[G1&TS78QX+\4+$T$5KJ$UZGG1MYJB>UAPB
ML'$;XC/V;7S_`/MD?\G%?LG?]E5OO_4(\5U]`5<FG)N.QG!-12EJPHHHJ2@H
MHHH`****`.2^-/QT\)_L[^!W\1^,]:MM#T=)DMQ-*CR-+*Y^5(XT#/(V`QPB
MDA59CA5)'G'_``3P^.GA/XP?LN^$-/\`#FM6VI7_`(0T'3-)UBV5'CFL;A+2
M-2K(X!*EE<*X!1BCA6.UL><?\%<_V3_'O[4?PY\(1^!5N=4FT74IFN]%6ZBM
MH;E98OENF:65$W0F,HHP6Q=/@@!L_*__``3@^'?Q9_91UM/B[_PJ7Q'XJ\'^
M(='%AC3[B'^T!;37=NWVF&TR9YN(LJNQ5=6#[U3YJ_,,WXHS+!\2PPTL,WAE
M%WFHS>CY7*5XW5HOE35M.KU1^.YYQEF^`XOIX2>#;PB@[U%"<G9J+G.\;JT)
M<J:Y=-;M<R:_6.BOG_PU\0_V??\`@J!\/K;2=5TCP/\`$BSLI4U5O#/BS1K:
M^GTVX2,(9C:7*.-T8N3%Y\89,R.JR')KS#_@E/\`L1?!?P%X!U#QKH7PA^&&
MB^,=%^)7Q"L-/UZP\*V-MJ=A;Q>+-;LHH8KE(A+'&EHJVZJK`+$!&`$&*_1L
M)C*&*I*OAIJ<'LT[K\#]7P./PV-HK$X2HIP>SBTT_FC[/HHK-\6^%;;QMX>N
M-,O)=2AMKG;O>PU"XT^X&U@PVSP.DJ<J,[6&1D'()!WGS*+Y=_N_S_)G3-R4
M6X*[Z7T5_6SM]S]#2K/\67.JV?A74I="L]/U'6XK25]/M+^\>RM;JX"$Q1RS
MI%,\4;/M#2+%(5!)".1M/C?P3^#6G3_%'Q^9M9\?7*^$_%-M;Z9%<>-M9FAB
MB&DZ9=;'C>Z*2J9IY6(E#`ARIRH"CW2N3`XBI7@YU(J-FUH[[-I]%U6APY=B
MZN(IN=6"C9R6DG+X6XO[,>JT\CY/T7]K']I+7?C[XE^'47P3^""ZWX5\/Z3X
MDNYW^,&J"UDM]2N=3MX$C8>&BYD5]*N"X*``/%AF)8+]85\__#G_`)2F_&3_
M`+)5X#_]._C.OH"NT]`***\4U36?B[IOQ=T/PK_PEGPX?^V='U'5?M7_``AE
MZ/)^R36,7E[/[4YW_;<YW#'EXP=V1QXS%_5TI<CDFTM+;MI+=K=O_.QP8_'/
M"Q4O9RDFTM.71MI+XI+=OI?SL>UT56T:*[@TBU34)[:YOTA1;F:W@:"&64*-
M[)&SN44MDA2[$`@%FQDV:ZT[JYW)MJ[5@HHHIC/"_P!L#X">!?$7AVVUW4/!
M?A.^UN^\4^&K>YU&XTBWENKB)]9L('1Y60NRM"3&03@H2IXXKUGP)\-?#OPM
MTB33_#&@:+X<L)IC<26VEV,5G"\I55+E(U`+%549QG"@=J^>O^"C?[:7@?\`
M9^T;1O#>LSZE<^(IM8T/7ET^RM"[BRMM5BN9)2[E8N19RH%W[M[)D!27&[XU
M_P""HGP7\"P?#F:[\4DV_P`5-0ET[P\_V22%[^2-;G?Y4,H2:=O.MA!Y5NDL
MWFW5HOEXG1C\U@:^6U,YK4,.X.LHQNE;FO>=_.^JOZJ^Z/D,OQ.4SSW%4L-*
MFZT(1<DN7F7O3YF[:]8\WK&^K1]!T445]*?7A1110`5\9>-?^"J/BSP[^T/?
M>![+X(ZS<6GASQ5:>']?U6_U&ZT^.&&^U.SL-.FL2UBT%]-.ET]T84G410V[
M[I=YV#ZK^+N@7OBKX6^(M-TZW^V7]_IT]O;0?V[=:#YTC(0J_;[17N+3)(_?
M0JTD?WE!(%?GA\)+Z'0OVLH_"%[>^$;;Q%X(U#2[GQ!9_P##:/Q!UI]'%S>)
M!!'-9W5BMI<3R2E52QN)%\XR1JP"RJ24-<5",M5_+_-KKVV2>SZW>R"KI0E)
M:/OV_P"';73IIU/TQHHHH`^?_P!LC_DXK]D[_LJM]_ZA'BNOH"OG_P#;(_Y.
M*_9._P"RJWW_`*A'BNOH"@`HHHH`****`"BBB@`KSC]CK_DT7X6?]BAI/_I%
M#7H]><?L=?\`)HOPL_[%#2?_`$BAKSZG^_4_\$_SIGEU?^1C2_P5/_2J1XY_
MP4?^%GP9LM'T;Q'XPB\0>&?'GB#55TKPOXA\'>&M3UC7WU5+62\C(MM,AEGN
M?+M].E?+I^[CA?;)$2&KY,_83_X*=>+?V3=0O/AG\0?AO\3_`!%8ZGKOC7QC
M9ZTGPWUWP_J,FGMXAU*^N-1N(+VUBMO+87UC*VR2-+9+Z%'8RMY0O?MD_P#!
M5+5?^"F7B#6/V?\`]BCP?I_QF\1:-=Z=J>O?$R\OWT_PC\-;^SUJWEL+P.Z`
M:G)%/9M=(D1DBE6W1TCU"(7$`\?_`."?'[&W_!0>^TYOV@]#_:'\'^+OB#J7
MB#6/#^K^"?B]I<EUI^DB">:TUBWM[NRDN&L8TUJS<);:8T-O<PV%A-(R[%LH
MN/$Y'3=26(P<G1JRLW**5I-7MSQ:M+?5Z2[26AP8OANBZL\5@)/#UI6;E!*T
MFKVYXM.,]]793M9*:LK?KU\$?VC/`_[1_AY]3\$^)=.U^VAQYZ0L4N+7+.J^
M="X66+<8WV[U7<%R,CFNUK\9/C5\0?VH?A-XNT7Q9\2?V+O$&@>-M+\0W%O/
M\4_V?]1A\1_VHX>\ECN$\,;S/);W"8266\GB<[P9"-PLWWOV._\`@ZT^'=UX
MJA\"_'B#4/`_BFRNY=*U"XU#2Y=,NM)N('$,J:C;N/*BD!CG>0QR9!VQK;A_
MEKGI9MB\-)4<TI>E2FG*#_Q+65/SYKQ_O]%RT<\QV$FJ&<T?2K34I4W_`(EK
M.EY\UX?]/'JE^FWP/_Y*;\8O^QOM_P#TP:/7H]?#G[$/_!6GX3_'_P"-^NV.
M@RZJ;?XH>)%O-&U*5K/[!^[TNSM/*>5+AAYCSV4B*J!\L\:YW$@?<=;</9EA
M<90G+#34N6<T_)\[=G\FCHX6S?!X_#5)8.HIJ-2HG;H^>3LUZ-,^?_AS_P`I
M3?C)_P!DJ\!_^G?QG7T!7S_\.?\`E*;\9/\`LE7@/_T[^,Z^@*]X^E"O./$_
M_)W7@?\`[%#Q#_Z6Z'7H]><>)_\`D[KP/_V*'B'_`-+=#KS\S_@K_'3_`/2X
MGEYO_`C_`(Z7_IR!Z/117E_[1G[7O@S]F6UM(M:N;G4_$.IS00:=X<TA%N]9
MU)II#&ABMMP)4LKC<Q"DKM!+E5.^+QE#"TG7Q$E&*ZO^OPZG3CL?A\%1>(Q4
MU""W;=OZ?9;OH>H5X'\>_P#@HEX'^$/B&3POH4>I?$?X@-YL<'AKPS";VX$L
M:S%EF=`RQ;&A82*-\J`AO**\UP%YX$^/?[=FD/;^+9+;X'_#35H52YT.R87O
MB+5[=UMW>*:9@!`KKYZ_=1URT<L$BG-?0WP1_9S\#_LX>'GTSP3X:T[0+:;'
MGO"I>XNL,[+YT[EI9=ID?;O9MH;`P.*^?^O9CF+M@(^QI?\`/RI'WG_@INS7
M^*I;_`T?+_VEFV:NV60]A1_Y^U(OGE_U[I.S2_O5>7?^')'YH_ML_L)?'#XO
M^+M1^+FN^'?#FEWGBW6+/31X=L]72:[TWS'CL+022-B!]Q%NK.DI^:8,4C7<
M(_J']E__`((]?##P9\*M`A^*O@7P+\0O&NDZG/JOV^^L8]0@M7;,<<4)EB1F
MA$:Q2&.167SU$@^:.(I[W^U/_P`DRTS_`+&_PQ_Z?]/KT>O+R+@S`9=G57,*
M3E*JXI\TFOBFY<TM$K-VZ:*[LDCQN'?#_+,KS[$9A2<YU9P3;FT[NI*?.[))
M7ERJ^EM[)(****^]/TP****`,;XC>+_^%??#W7=>^Q76I?V)IUQJ'V2V7=-=
M>5&TGEH.[-MP/<BOR^^(7PTT76]-^"G[2<GQ$UN;P)\;?%7AJXNOA=I^JZ=>
MV$FKZIJ^FWO^AZC_`&>;JYAM[FT^T36@"-)Y$I$T$:/"_P"I?BG7#X8\,ZCJ
M2V-_J9T^UDN19V,8DN;K8I;RXE)`:1L84$C)(Y%?G+:_&G]A[X"_MC>#O$_@
MKX(>$[KQ]\1;FQL[3Q#I&E:'IMSI-])?S63Q+I]]=6U_'J$4L\GVQ+.S>ZC1
MD^T#Y8U!A?=QD*B^).-NZ5WS+_N(K*[^%Q36K"OKAI)[6?I?3E=]TX.[LOBY
MK.UC]*:***`/G_\`;(_Y.*_9._[*K??^H1XKKZ`KY_\`VR/^3BOV3O\`LJM]
M_P"H1XKKZ`H`****`"OE_P#X*D:9\0/A_P#LL?%;XK>!OC/\0/`&H?#KX?ZO
MK=CHNE:;X?N]*O;RRM+FZCEN/MVFW-R=[*B.L<\:[(QM"L6=OJ"OG_\`X*Q?
M\HLOVEO^R5>*/_31=4`>@?`OX-^(OA)_:G]O_%CX@?%#^T/*\C_A)[/0[?\`
MLS9OW>3_`&9IUGGS-Z[O-\S'E)MV9;=Z!17P!^UI_P`%B/%/BO\`:.U/]GK]
MD7P#_P`+?^,VB:K9:;XF\3:E:S-\/OAYYC3O<+JMY!(LAN(X[:1?)0K\Y=%>
M2X@>S8`^C_V\?^"BOPC_`.";GP:O?&?Q5\6:?HL:6D]QIFC)/&VL^)'B,:M!
M86K.KW$F^:%6(PD0E5Y7CC#./SK_`&=/V7OVA?\`@MY\'?AII_QNTU?@M^QU
MX:CMC!X$@ENK/QC\3TL(+2.U?57X%OI\L\<TZ+&8WP$VK(?LNH)]&?L3?\$,
M_#_@GQ6OQ8_:9\0S_M-_'_6M.CBU'5/%R1ZIH'AB3[7+>-;Z)931!;6%)90$
M;:"OEL88[19I(3]E^!/@)X%^%NKR:AX8\%^$_#E_-";>2YTO2+>SF>(LK%"\
M:`E2RJ<9QE0>U<=2G4>(A5BDTDT]6GJULK-/;NC@K4JKQ4*T(II)IMMIJ[B]
M%9I_"MVAGP!^`/@W]EKX->'OA]\/O#VG^%?!OA6T%EIFF6:D1VZ9+,2S$O)(
M[LSO(Y9Y'=W=F=F8^7_\$T_^3=?$?_95?B/_`.IOKM>H?&O6_'VA>%;>7X=>
M&O!_BK6VNU2>T\2>);G0+6.WV.6D6>"PO7:0.(P(S$H(9CO!4*WA_P"POX`^
M/OP.M7\,>-?!'P@M_#.J>*_$_B>\U?1/B%J.H7]I_:VL:CJ\<$=G+HEO'+Y<
MEXD!=KF/*HTH7.(J[#O/J"O*_P!LG]C[P1^W)\!M5\!^._#^@Z[8W(-QITFJ
M:<E\ND7ZQND-[&C$?O(][=&7<C.A.UV!]4HK.K2C5@Z<U=-6?HS*O1A6IRHU
M%>,DT_1Z,_$7]FO_`(-<-(OOVD=9UF3QWXA^$S>#-2>TOK[X8^(;BQU&\O)+
M>SOX1"\T!2"&/SXF!15PT941XV2)Z?XP_P""4'_!1?X-^`[WPY\,?VW],^(V
MG^*-&N-&U6;Q[IUWI-_HRF-8X;FPO(?MUR+G:\Q,WF1,K+&W[UL-'^DGP/\`
M^2F_&+_L;[?_`-,&CUZ/7@Y'E=&CA>1N4VI3M*4G*6DG%>\]=E;?8^:X;R:A
MA\'[-N4W&<TI3DY3TG**]]^]I%6WVNMC^:'3/C)^U!\*O''A[1O&'P`_:#U'
MQW<ZB-.\5:MX*^,?B[7O&&I66@:A;7-[8SV=IJTGV6U>/5DCAEF0*MOK<=U;
MM,9DEE_0']GW_@[>^`_Q<EEDU[2Y?"=K%:)*ZR:Q";J.9\8A*7*6T;8`?<T4
ML@4JHP0X:OLWX0>$]+\.?\%7OCU>:?IFGV-WKWPU\`W^ISV]ND4FHW"ZAXMM
MUFF90#)(((((@S9(2&-<[44#L/VE_P#@G[\#_P!LC[7)\4?A-X`\<:A=Z4^B
M?VIJNB02ZK:V;>8?*M[W;]IM]K32LC0R(T;N70JW-=-?*ZW*EA,1.G;O::?K
MSJ4ONDN_>_7B,FQ'(HX'%5*5N]JB?K[12GMVG'77O?B-*_X*W_!%K5DUS7=:
M\(ZQ;S2V]YH^KZ#>+?:?+'(R,DHACD0-E<X#DC.#A@5'BGQ3_P""P_@7P[^V
M'IEW;:%K6K^&_"NFZOH%WJ5G/;R-=RSW-JPFMD#E)8,V$>UC*A9;@M@>6!)S
M/CS_`(-A/@WH.D>*8O@5\2?CM^S<?%.B?V9>Z=X,\:W;:+JLZ+<"&XU"WN&D
MGNU7[0RM"+F-#&&5?+9W=OBOXW_\$8OVSOV;OB,^A^$?$?PL_:"L;BWDUG38
M[B,^&?$.J6L$NG07<(C8BQMV1[TLA>XDW1QNQ.\I`?D.)L-Q6L/!8*M2E:46
M_<<)-IKE6LIQ=W:]N3RT>GPG%^#XVCA::R[$49VE%OW'3DVI+E7O2J1=Y6NU
M[/RT>GZ@Q?$OXU_M[QSGP!]I^"OPPN(8T37]9TXMXBUA9;:1F>UB#;%@)DAQ
M*CJW`>.8D/$O,^`OB1^S5^PY\4FM;G0?C1J?Q$U/6[O3$\1:O\)O%NLZAKFH
M*MY-,+.[CTMH9V,"7;E[/B:&%I"TBJ7KR_PU_P`%UKW]B_PBGAW]H;]D+X__
M``'T/P9<Z?HLNO:5:KXR\&Z'ILB6L-M<W&M1&-7VM,$>.%+AP4"@O,QB7D?#
M7_!8G3O^"COQ%\%>+?AOKG[,&G:3\%_B!X@UVTL/&7Q@OO#FNZ_IUGH>MZ>;
MQ[&;0BUM;M8WXU$RJ\Z11PO'(5=)O)^FP'#].$XXO'/VU=:\TM5%_P!R.T4M
MDTE)K=L^PRSA>E3J1QN9/V^)6O-+51?:G'X8);)I*37Q-GZ?_"WXEZ=\8/`E
MCXBTFV\06FGZCYGE1:WH-]H=^FR1HSYEG>PPW,7S(2/,C7<I5ERK*QZ"OA_]
MA/\`X+6Z%^UM^T!IGPA\3>$#\//BU<^'X=:U'PRVJO>2Z),RSSS6,\DUM;*;
MB"V_L]I88P\T<M])&\2BUFD'W!7T2UC&:VDKI]UW1]4])R@]XZ/[D_R:/./B
MO^S]>?%F^?S_`(A>-=)T[[99W\.FV$.E?9[:>UEBGA=6ELI)CB:%)"&D8$Y&
M-IVUUG@3PK?>$-(DMM0\2ZUXIF>8RK=ZI%:1S1J54>6!:P0IM!!/*ELL<L1@
M#;HKDA@J4*SKQOS/^])_@W;2[MIIT.*GE]&G7>)C?F>_O2:ZZ6;M97=E;2^E
M@HHHKK.T****`,3XD^']3\6_#O7M*T767\.ZQJ6G7%K8ZJD`G;3)WC98[@1D
M@.8V(;:2,[<9%?'7["O_``3*^(_P.T/_`(2KQM\18=/^,$^OI<WVH>&=2U?5
M],UK2(EBB33M1.LW-Q<7Y9(Y)%FD=9K1[AH[>1(0R2_8OQ*U74="^'.OWNCP
M-=:M9Z;<3V4*Q&4S3K$S1J$'+98`8')SBORK^`]OXL\$2_!;QKIGQ+_;M\6_
M&G4/$.D-XXT#Q9X-\61>#KZ/4[FUBU:)[:YTR/3K*WLHY+J2!H7C$83EY`$V
MF&5\0XQT;Y(W_P`4G;Y)I\[Z1>MT[!7?[E7U^)V]$KZ[7VY;]5=-6;/UOHK@
M/VI]>\<^&OV<_&=[\,]#_P"$C^($6E3#P_I_G6\0FO&7;&Q,\D41"$[RKR(&
M"%=PSFOQ%^'G[(GBSP9X4^)?AOXA_L[?'#5_!0M_'=KX(L]9\*_\)%=-XHNU
MTY;+4G6QENDCN72.;;J9VP(YF*77S,:R]I[\H6VBY>K7V5YO9=Y.*ZZ6XI1C
M*^\E'T3^T_);OLE)O;7]>?VR/^3BOV3O^RJWW_J$>*Z^@*^$[^\^.MA\:?V-
M=$^*_A7X?V5II7C>>W?7=*\;76K:IJE['X%\3(7GLWTNWAA\P>;(Y2ZFV.`J
M^8K>8/NRNFM!0J2@G>S:NMGYF%&;G3C-JS:3L^GD%%%%9F@5\0?\%5M-EN/$
M=UI/Q)^,WQ`^&_[.OQ#^'^NZ)K47AC3='E\N\L[&\O[V*8W&FWU[)]LT9-0D
M5K<P+;_V&Z@R37L*K]OU\_\`_!53_B7?\$X_C/K\/R:MX$\*WGC;0Y^OV'6-
M&3^UM-N=I^5_)OK.VE\MPT;^7MD1T9E(!^:'[,W@?]JW_@O9X+UB\F^-?Q/^
M&/[&/C&T>P2?6D\+7OB[XAV\6JSV]U#$VE:?9G2XY(+9XI5F\X!FV@7L$T@3
M]7_V0_V+_AA^P7\&H?`'PC\(:?X,\*0W<U^UI;R2SR7-Q*07FFGF=YII"`B!
MI78A(XT!"1HJ]A\)_A;H7P.^%GAKP5X6L?[+\,^#]*M=$TBS\Z2?[)9VT*0P
M1>9(S2/MC15W.S,<9))R:Z"@`HHHH`****`"LWQ;XQTCP!X>N-6UW5=.T72K
M3;Y][?W*6UO#N8(NZ1R%7+,JC)Y+`=ZTJ*F?,XOEW^__`"_-$SYG%J#L^E]5
M?TNK_>O4\#^`O[2GPZO_`(M?$NV@\?>"IKG7_%]K_9<4>N6K/J6[1M)A7R5#
MYDS*CQC;G+HR]017OE%%<>`PU6A!PJR4KMO1-?$V_P":7<X,LPE?#TW"M-2O
M*3TBX_%)RZREW/G_`.'/_*4WXR?]DJ\!_P#IW\9U]`5\_P#PY_Y2F_&3_LE7
M@/\`]._C.OH"NX]$*\X\3_\`)W7@?_L4/$/_`*6Z'7H]><>)_P#D[KP/_P!B
MAXA_]+=#KS\S_@K_`!T__2XGEYO_``(_XZ7_`*<@>CU\`?ML?\$V_A8O[=GP
M3\4Z3X)\`:%_PN/Q7>>&/'9M/"MH-1\0;-/U+Q`LXNR/W7VG^S;[3]03RV_M
M*QUJYAG8^5;M']_U\W_%[_@G]K_QC^)FC>)KO]HSXWZ9)X5\07/B3P[8V%CX
M3%KH%Q-:7EELB\W1))98TM+^YA47$DQPX9F:10X]`]0^@;/POINGZY<ZG!IU
MC!J5[#';W%W';JL\\4;R.B.X&YE5YIF`)P#*Y'+'-^N?^%O@W4?A_P"!+'2-
M6\6>(/'&H6GF>;K>MPV,5_>[I&<>8ME;VUL-BL$'EPI\J+NW-N9N@H`****`
M"BBB@`HHHH`P/BOH-OXJ^%OB33+O5)-#M=1TJZM9M2CE$3:>CPLK3AR0%*`E
MLDX&W-?CI\'?@G\*?'_Q8L+C3_VBO@%\5_BYX"\3>`O#O@B]\-WMGIDNB^&-
M(^QS7,>CV4-W=N7G,]U'<$2>4VZ7(5$\JOVDU'3K?6-/GM+N"&ZM;J-H9H9D
M#QS(PPRLIX(()!!X(-?.'@7_`()0?!+X4>-=;\1>$?AE\+/">MWNKV>I:7?Z
M/X*L+*ZT.*%+59+>&6)%=5E,$A;:5'^D/E6YW%']W6]K_A?G>#;COIU:TU:<
MELPJ^_2]GY27E:7+?\D]=+I,^E:***`/G_\`;(_Y.*_9._[*K??^H1XKKZ`K
MY?\`^"C7C+4?A_\`$_\`9=U?2?"?B#QQJ%I\5;KRM$T2:QAO[W=X,\4H?+:]
MN+:V&Q6+GS)D^5&V[FVJWJ'Q'^/OBOP/X5\,:AIGP1^)_C&[UZT^T7VF:/?^
M'(KKPV^R)O(NVO-5MX7DS(RYM9+A,PR?/M*,X!ZA17G_`(_^,GB+P=\4]%\/
MZ=\)_B!XKTG5?(^U>)]*O-#CTK1O,F:-_M"76HP7C>4H$K^1;2Y1@$WOE`?\
M+D\1?\+V_P"$1_X5/\0/^$?_`.AV^V:'_87_`![^;_JO[1_M'[_[C_CR_P!9
MS_JOWM`'H%?/_P#P5B_Y19?M+?\`9*O%'_IHNJ]`\`?&3Q%XQ^*>M>']1^$_
MQ`\*:3I7G_9?$^JWFAR:5K/ES+&GV=+749[Q?-4F5//MHL(I#['PA^</VJ-&
M^/W[=/P"^*_A#2O"^H?!GPIKW@J]T&YTCQ;X3TCQ#K_B)[RVNX9QIEWI_BM+
M2&01F)$6]2-%D=6,KH7$0!]GT5\W_LY?%KX_6?P:\5>)_BEX#U#7-;L[N"WT
M7PCH/AS2/#^LW29433B23Q1J-A)&?-!`DN[9U%K/\DA>('T#6?C[XKTOX-:3
MXG@^"/Q/U'6]1NVM[CPC;W_AQ=9TM`90)YI)-52P,9\M"!#=R/B>/*`B01@'
MJ%%>7_$?X^^*_`_A7PQJ&F?!'XG^,;O7K3[1?:9H]_X<BNO#;[(F\B[:\U6W
MA>3,C+FUDN$S#)\^THSZ'C_XR>(O!WQ3T7P_IWPG^('BO2=5\C[5XGTJ\T./
M2M&\R9HW^T)=:C!>-Y2@2OY%M+E&`3>^4`!Z!17G_P#PN3Q%_P`+V_X1'_A4
M_P`0/^$?_P"AV^V:'_87_'OYO^J_M'^T?O\`[C_CR_UG/^J_>T>`/C)XB\8_
M%/6O#^H_"?X@>%-)TKS_`++XGU6\T.32M9\N98T^SI:ZC/>+YJDRIY]M%A%(
M?8^$(!Z!17E_PX^/OBOQQX5\3ZAJ?P1^)_@Z[T&T^T6.F:Q?^');KQ(^R5O(
MM&L]5N(4DS&JYNI+=,S1_/M#LAHWQ]\5ZI\&M6\3S_!'XGZ=K>G7:V]OX1N+
M_P`.-K.J(3$#/#)'JKV`C'F.2)KN-\0280DQB0`]0K/\6:S<>'/"NI:A9Z3J
M&O7=C:2W$&F6#P)=:BZ(66")IY(H1(Y`53+)&@+#<ZKEAY_K/Q]\5Z7\&M)\
M3P?!'XGZCK>HW;6]QX1M[_PXNLZ6@,H$\TDFJI8&,^6A`ANY'Q/'E`1((SXC
M_'WQ7X'\*^&-0TSX(_$_QC=Z]:?:+[3-'O\`PY%=>&WV1-Y%VUYJMO"\F9&7
M-K)<)F&3Y]I1G`/`/"?Q=^+6A?MH>/OB++^RM\;VT3Q5X*\->&[2!-;\%&ZC
MN--OO$%Q.\BG7P@C9-5MPA#DDI+E5`4M]GUY_P"/_C)XB\'?%/1?#^G?"?X@
M>*])U7R/M7B?2KS0X]*T;S)FC?[0EUJ,%XWE*!*_D6TN48!-[Y0'_"Y/$7_"
M]O\`A$?^%3_$#_A'_P#H=OMFA_V%_P`>_F_ZK^T?[1^_^X_X\O\`6<_ZK][0
M!Z!7BFJ:-\7=2^+NA^*O^$3^'"?V-H^HZ5]E_P"$SO3YWVN:QE\S?_9?&S[%
MC&TY\S.1MP>K\`?&3Q%XQ^*>M>']1^$_Q`\*:3I7G_9?$^JWFAR:5K/ES+&G
MV=+749[Q?-4F5//MHL(I#['PAS_AQ\??%?CCPKXGU#4_@C\3_!UWH-I]HL=,
MUB_\.2W7B1]DK>1:-9ZK<0I)F-5S=26Z9FC^?:'9./&83ZPE'G<4FGI;=--;
MI[-?YW.#'X%XJ*C[244FGIRZM--?%%[-=+>=ST?1I;N?2+5]0@MK:_>%&N8;
M>=IX8I2HWJDC(A=0V0&**2`"57.!9KR_1OC[XKU3X-:MXGG^"/Q/T[6].NUM
M[?PC<7_AQM9U1"8@9X9(]5>P$8\QR1-=QOB"3"$F,2:'C_XR>(O!WPLT7Q!I
MWPG^('BO5M5\C[5X8TJ\T./5=&\R%I'^T/=:C!9MY3`1/Y%S+EV!3>F7'6M%
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M#J@!V%%>?^`/C)XB\8_"S6O$&H_"?X@>%-6TKS_LOAC5;S0Y-5UGRX5D3[.]
MKJ,]FOFL3$GGW,6'4E]B8<^@4`%%%%`!7XM>-_A9\&_^'QFN>)OB'\/_``M\
M1/&K_%73SX?\8W'BCXA0W'AW;-80VUH4MM$ET65[>Z=55#=I"IEB@E<%6<_M
M+7Y#_&[XZ?"[Q'_P4MD\-ZOHNAZ?JGA/Q_:1Z3X6T?XGW]IXA\7:E>:SIL5U
M)J.FE1&;'Y[/5(;1`R2'3&E:5$DE0F#US.C'NGMO\4'H^CZ7O?7MS!B?]RJ/
MS6^VJDM5U[V?NZ7>J1^O%%%%`'S9^W]X/T_XA_%C]F70-6MTN]*USXD:II]Y
M`XRLT,O@3Q9&ZGV*L1^-?.WA/XT^-M`^$>OZ]=6M[XL\8?L:>"]6T*X@>U-V
M=:\0_-!#?LIDB,CC2K6.Z*B1"\>M$;T/(^G/VR/^3BOV3O\`LJM]_P"H1XKK
MZ`J;/WK=5^.J3\[*4K+NT[^[K5U[MUL[_+1M+_$U&[[*UM;K\TOAU\<?$O[:
M5G\%)/#OQ;-RJ?$R^L++Q*]UX5U_Q)IL9\,ZH\Z3C199]&6X&]OLY*/M1HC-
M!*5;S;GA[]M7Q=9:#XJ\6:QK7AKPW?2:'X-T;7_&@T2TA.B6DNNZWI]YJLLK
M(0HCBB,L8N3+:V\LA=H_*,H;](:*N;N[QTU3];6NO).VMK;]]2%>SN];6_\`
M)G)/L[=+WV[:'YO_`!9_:SO/@#_PM'Q_X;\:GXEV<WA'P)8MXYT,Z,[-IUQK
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M'[9#HFIZMX6TR.UUFYM;>&(V@%L9%M898C<1RH`HV(8OW9XW]IC]M;Q!\4O@
MW\4M#C^(.B^)-:U72/&.F>+OAS'':)=_#C3[""_2SOG2-!>1R3-%:)*UT[PS
M-=JUNL28#?J+14P]U13Z)+U:BHW_``O;SWO=O1R;J.:ZR;^^4I6^5TNVFJ:T
M4-A_QXP_]<U_E4U%%-ZNYG"/+%1[!1112*"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`S/&=MJ=[X/U6'1+B&SUF6SF2PGF&8X+@H1&[#:W`?:3
M\IX'0]*_$KX7_&+]IG]G3_@I9\+/!W[4W[4^CZ'\2-8U2+2=,BT;X5>$]>M_
M%&ES7ELW]GQWUJ\>M:?#>NFSS)].@A5X&;>QC!K]N_$>C?\`"1^'K_3S<WED
M+^WDMS<6DGEW%OO4KOC;!VN,Y!QP0*^2/V-O^"-WAW]@R>Q7X;?%3XA:)8P_
M94U&VB\->"X9/$4-NV5AO[R'08[VY!!<-(UQYW[QR)`QW48;W,4JLME;?5=;
MZ=';2]I)IV<78*_O8=TUOKY=MWU76UT[K22/L2BJVL:S:>'=(NM0U"ZMK&PL
M87N+FYN)1%#;Q(I9W=V("JH!)).``<UY!J/_``4A_9XT?PCI.OW?QZ^"]KH6
MO2SP:9J4WC;3$M-1D@*B9(93-LD:,N@<*25WKG&10M7RK<+/<Q_VR/\`DXK]
MD[_LJM]_ZA'BNOH"OG[]L602_M#?LFLI#*WQ4OB"#D$?\(/XKKZ!H!.^J"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`.4^.5M->?!_Q'%;Z+K'B&YDL)5AT_24T][^XD(^7R!J
M#+9F4'#+]H;RLJ-V1P?RZT/]CK]I;X?:AXU\<^$O"?QLT?XL:UJNN3^%-?;4
M?`;W%VNH1:6'?Q9')--:A?/TZW"#180RVUL`565R#^N%%*"Y:CJQ>MN7Y/?[
M[6?=;E.5X*'1._SLU^KL?$G[47['?Q7\8?'+]G_51\<_C*Y/Q#O+[4(]'T7P
MU-IW@E7\+>(%\ZV=]%:18!+)'9(U\\X*WBABT[12KZW_`,,;?$7_`*.Q^/\`
M_P""CP1_\SU2ZW_P4%\,?#W]J'5/AOXZTC7/A[9^47\/>+/$"1VF@>*Y(K5;
MF\AM;AFPLD$;9(EV>8(YS'N$,A'O,<@EC#*0RL,@@Y!%5S<Z]HMF0ER?NWNC
MP'_AC;XB_P#1V/Q__P#!1X(_^9ZN?^)?[&WQN_X1RV_X0[]K'XO_`-K?VKIO
MVC^V=(\&_9O[.^W0?VCL\KP]N^T?8?M/D9^3S_)W_)NKZ@HI#/G_`/X8V^(O
M_1V/Q_\`_!1X(_\`F>KR#XL?LZ_M,?"C]@7Q+XI_X:6^+_B7XV^&OA_=:K_9
M&A>'/"=YI6J^(8-.>7[-:0?\(^MU+;R7:[(TR)F1E&0YS7V_7BG[6W[;&F_L
M<ZOX7N/$OA7Q9=>"M5:9O$'BZQM!+I/@J!#%''<7[9W+$\DR@LBMY:+)(^V.
M-F"NKI/J.S=S*_X8V^(O_1V/Q_\`_!1X(_\`F>H_X8V^(O\`T=C\?_\`P4>"
M/_F>KV[PIXQTCQWHRZCH>J:=K.GO))$MU8W*7$+/&Y210Z$KE75E(SP5(/(K
M2JFFG9BO?8^?_P#AC;XB_P#1V/Q__P#!1X(_^9ZN?^$_[&WQN_X59X:_X3K]
MK'XO_P#";?V5:_\`"0_V%I'@W^RO[1\E/M/V3SO#WF_9_.W^7YGS[-N[G-?4
M%%(#Y?\`!O[&WQN_X2/Q9_PD'[6/Q?\`[)_M6/\`X1C^SM(\&_:?[.^PVF_[
M;O\`#VW[1]N^W8\KY/(^SY^??6!^S3^SK\;OB5\.M1U'QC^TM\?]`U:W\5^(
M]*M[7_A'/!MKYNG6>N7UGIUSLE\/ECY]C!;3[P=DGG;T`1U`]S_:Z_:)'[+7
MP/O?%W]GV>HRQWMCIMO'?Z@=.T^*:[NHK6.6[NQ%+]FM4>56DF\I]B`D(QP#
M2_9,_:F7]I7P[K=MJGAS4?`_CWP5?C1_%GAB_E$TFD7GEK(K13J`MS:2QNLD
M-PH42(>5C=7C0C[U[=/^!_FOO7<'I:_7_@_Y/[F<Q_PQM\1?^CL?C_\`^"CP
M1_\`,]1_PQM\1?\`H['X_P#_`(*/!'_S/5]`44`?+_@W]C;XW?\`"1^+/^$@
M_:Q^+_\`9/\`:L?_``C']G:1X-^T_P!G?8;3?]MW^'MOVC[=]NQY7R>1]GS\
M^^C4OV-OC=_PM/1OLG[6/Q?_`.$)_LJ__M;SM(\&_P!J_P!H^=9?8?(QX>\K
M[/Y/]H^=O^??]EV<>97U!4.HWHTW3Y[@I+*((VD*1(7D?`SA5'))QP.]*4E&
M+E+9#2;=D?(WAS]G7XW:C^U/XR\+7?[2WQ_@\$Z/X5T'5=)U?_A'/!J_;M1N
M[O68KZV\\^'_`"G\F&STY]B`.GVO+DB2,#O_`/AC;XB_]'8_'_\`\%'@C_YG
MJP/V-/\`@I$G[37BK1]&\0^#QX,G\;Z._B7P3>VNKC5]-\2Z<FQ9XC.(8OL^
MIVKOLN;)E/EGE)9E5RGT_5N+CO\`U9V?W--/S)33V_KK^1\__P##&WQ%_P"C
ML?C_`/\`@H\$?_,]7/ZE^QM\;O\`A:>C?9/VL?B__P`(3_95_P#VMYVD>#?[
M5_M'SK+[#Y&/#WE?9_)_M'SM_P`^_P"R[./,KZ@HJ1GR_P#$O]C;XW?\(Y;?
M\(=^UC\7_P"UO[5TW[1_;.D>#?LW]G?;H/[1V>5X>W?:/L/VGR,_)Y_D[_DW
M5@?&3]G7XW>#OB+\)].\/_M+?'_5=)\5^*Y]*\3W7_".>#9_[&TY=#U6\2YW
MIX?"PYOK2Q@WR@H?M.P#?(A'U_7RUXV_X*7Q_#C]I+7?#6L>#)(OA[X8URQ\
M*ZUXK@U3S;S0=2OH;>6SFO=-\D-#I<YN!"E\LS@31N'B2,&8"UDH+=_YI?FT
MO5I`](\SV_X=_DF_D=+_`,,;?$7_`*.Q^/\`_P""CP1_\SU'_#&WQ%_Z.Q^/
M_P#X*/!'_P`SU?0%%`'R_P#$O]C;XW?\(Y;?\(=^UC\7_P"UO[5TW[1_;.D>
M#?LW]G?;H/[1V>5X>W?:/L/VGR,_)Y_D[_DW5T'_``QM\1?^CL?C_P#^"CP1
M_P#,]7T!10!\0?%C]G7]ICX4?L"^)?%/_#2WQ?\`$OQM\-?#^ZU7^R-"\.>$
M[S2M5\0P:<\OV:T@_P"$?6ZEMY+M=D:9$S(RC(<YK[?KP']L#]L[7/V</'WA
M3PUX8^'TGQ!UOQ!8W^M2:<FLIIEW=6-BUO\`:HM-5XG2]U$1W!E2T:2`.D,I
M,R8`;U?X+_&'P_\`M!?"?P_XV\*WIU#P]XFL8[^QG:)HG:-QG:\;`-&ZG*LC
M`,K*RD`@BB/O1YEM_P`.OS37R?8'H[/^MO\`-?>=/1110`4444`%?-W_``4\
M^*GC+X-_`K3==\.>(O$7@GPY:ZI_Q5_BGP_HEOK>I^%]-^SS[;];.XAFCEMH
MKG[.;G$;.EMYS+M(WI](T4I*_P!Z_/;Y[%1=GK_7WW7IHSY)_94FD_X*9_`'
M2==^+MA\/?%_AO1-<#Z;%HEM<R:-KFIZ7=W$:ZU;7#731W>GSXBDA@DA(BDC
M?,EQMC<?6U%%4WT7J_-V2;TLKNR^226B1FE;5^GHKMI:W=E?J[MW;NVVRBBB
MD4%9OC#PG8^/?"6J:'J<<LNFZS:2V-W'%/)`[PRH4<+)&RNA*L<,C!AU!!YK
M2HJ91C*+C)73'&3BU*.C1S_PJ^%7ASX&_#C1?"'A#1=/\.^&?#MHECINFV,0
MB@M(4&%50/S)/))))))-=!115RDY-RD[MDQBHI1BK)!1112&?*?_``4%_8]\
M5_$._G^)?P[N]3\1^-K+3(?#TO@+6KR*;P=XPTB29Q>6%[:3E8D\U9M[77S2
MI]FC"I*NZ"7U']C']DCPW^Q[\&[+0-#TJVTZ_N8+:36'AU/4-2CEN(K:*`)%
M-?S37(MHDB6.&)I-L<:*JJO2O6Z*(>XG&.S_`.'MZ7=[;<S;W<FR7O-2?3_A
MOO2TOO:RV22****`"OS'_;V^)UE^UC\?+#0-9^'6O1:OX`O;RSL?"/B+5;;P
MSK'B*QGO[:UM_%GA+4)I8X(]4M+R%!&DLT,ABN<;H_M$?F_IQ7&_$+]G[P=\
M5_'_`(.\3^)-!M=9UKP!=37WA^:Z9W33+F6/RWG2+=Y9E"9"R,I9-S;"NYLP
MX7G%O;K_`)KS_1NUI<LXTI6B[;_Y='Y/\TKWCS1EXK^P)^P1H_P'\-:%X\\4
M^'K2V^-6L:7YGBF[M;Z7[&^H3QP"[NELDD^P0WLXMX/M-Q:PIY\B,Q9E(KZ<
MHHK6<^9]ET71>2[(SC'E7]:^H5'=7<5C:R3SR)##"I>21V"JB@9))/``'>I*
MQ/B1\.]&^+WP^UOPKXCL5U/P_P"([&;3-2LW=T6[MID,<L3%2&`9&(.".":B
M5[/EW+C:ZYMCX;_X*_?M4ZQJW@/Q-\/O"O@[2/%VCZ'H>E>./$=Q>7YG@NM)
M-Z[@G2T@D;5-))M/+OS#*)(H+I62*Y),1C_X)]?\$X]`^(&GQ^-?B)\,K_PS
M8:3<6C_#[1K[Q:NI76D:1Y=I>'3);K3KDP:EHT-_&9;&WO/-\E%!$<0*QKTO
MA7_@C3X=N_BAJ&E^*KB/4_@EX7,TGPZ\-6U_=6VJ^&OML*IJ%HNHP&"YBTMA
MYD:::)98&25A(618(8?MBPL(-*L(;6UABMK:VC6*&&)`D<2*,*JJ.`````.F
M*JC:"<UN]5W6OYV44NRYMN9HFI>34>BT?9Z?DVVW_P!NJWNW<U%%%(85\W?M
M6?\`!0#1?AW-_P`(=\.[OP7\0/B=>ZU'X8DT'_A,H-*_L6]FM+FY@BO+A8KE
MK.>=;9TMDEA_?3,BY52SKW?[77Q3^)7P@^'UAK'PR^',7Q,OX-15]7TLZM'I
M]PFFI')).UKOXFNFV)'%$2JL\@W.B@FO@SX;?L+^%O\`@H[XZL=;T6\\%>./
M@+:^(M1O9KO5;/4-+\8:*M^)[O5/"T\9A$=W"NH7$%PLSS17%A<1,JJ9X$D3
M/E]K+V?3KZ76OI9O6W1V][EC.^94X\_7IUUU]-;VTNM[OW>9QY+_`()K?L8/
M^U+J&GQ>)/A;J'AGP'HLMW#XLNAK(TQM7\2Z=-;QV6LPP6MPNI:/XG0K<17\
M\3)%<*NY;BZCEB<?JU\-?AOHGP?^'^C^%O#6GPZ5H.@6D=C86D19E@B084;F
M)9CW+,2S$DDDDFL[X*?`_P`-?L\^`8?#7A2RN;/2XIYKMVN]0N-1N[J>:1I9
M9Y[JYDDGGE=V):261F/<\"NMK=S]U17S\WU?Z+M&R6B,8Q=[R^76RZ*_HE=]
M7=A1114%A1110`4444`%%%%`!1110`4444`(6VC)X`ZFOFGP7_P4WT3XF7D&
MI^%OA?\`&3Q5\-+O5VT6V^(.BZ';7^B7<JN8FFAMHKEM4EM1,&B^U1V+094O
MYGE`RU]#^+/#Z>+/"VI:5)))#'J5K+:/)&2&02(5)!!!!&?6OCW]BH?'S]C[
M]G[P!\"[CX'GQ5=^`4M_#</CF'Q7IVG^%+_28%`CO7!DEU2.Y\D*K6XL'0S@
M@3"(^:I2UJ-2_NV[.[?-=]+:6[\S>JBPGI"Z\[^5EI9=;Z_=;>2/M*BOS"D_
MX)[_`!.3XP:D8?A;CXO7OQ?_`.$N7]H)M;L!Y?AO[:EP+%6\\ZJ,:<HTS^S1
M;"R."3)Y9W'S7XE?\$:?C#%H'_"1?"SPWI?PZ^-OB/XN^.]5U#QU;W]G;:C9
M:%J=IJL-A)+=PN;@VY>2R811[Y868N(PRG$QDW&+:W5_F_9JW?[;OHFE"3LR
MY02DTGL[?*TW?_R16\YQ3L?L/17YP?#3]B?Q"OPQ\8:!\*_V;+K]E;XBZM\+
MKSPVOQ`7Q3IRP7>L.J+&9(M+NYIKTAQ)(NI7D:W<1;<L>Z205XE\&?\`@DCX
M[\+_`+/7Q7TW0?AG\7/`_B;7/@S?^%#I^IZMX!L='\5ZO/;M&L+QZ%;Q279C
M?+17^HS)*/-<,!YDA)4?*IM:VBVO-KGT777E6ZO[RLGIS*DE-Q4M+R2?DGR:
MOTYGM=>Z[M:V_4#]K#]JGP]^QU\++;Q=XFL]9OM-NM<TOP^D>EPQRSB?4+V&
MSA8B22-=BR3*7.[(4$@,<`^F5^//QW_X(H^*K:;7?"?@'X.>&8OASJND_#&:
M;2X7TJ"ROM4TO5Y3K-Q)`TBAI_L#L)92N;A7909"2M-^!W_!'SQ%\!KOP5X@
M\5?LV:!\4?#$>O\`C.;Q-X`LY-!,U[<7>HSR:'J\L=W<16-XD%D9($2:;S+5
M;PF.//F`:-*/,F_M32?E%12T5])/FY6KW5ME=K)2D^5VZ0NO.7,WKI\*Y5):
M6?=M)_HK^TQ^WMX>_9C^*.G^#+KPE\0/&'B75_">L^+[#3_"VEQZA<7T&F&W
M$UM%$94=[J0W,8BC52&(;++QGVC0-6_M[0K*^^S7=E]M@2?[/=1^7/!N4-LD
M7G:XS@C/!!K\,[?_`((A_&+6_P!C?P!H=U\#M'L_$_AWX5?$O0H].N-7TB[E
MT34M4U0SZ-;)<F<JS>1-/MF5ML?F2;F0N0?>/A+_`,$VOBSX4N-*TVY^%'D?
M&R/XDVGB2?X_-KNG'[/X?CGBF-@KK<-JGRZ>G]E_V<MN+)L$^:8SN+HQ3ER3
M=O/3_GY./>VD5&3U>EFK\Q59\LI.&J3:];0@[][-\R6F[MT/U?KRC]H7]KWP
M_P#L[_$?X9^#KK2]>\1^+/BOK,FDZ)I.C+;-<!(8&GNKV7SYHE6UMXU!D8,S
MYDC54=F`KX4^!W_!*WQE\'OVAOAY\2],^'&EZ1XU;X_^+?$OBWQ#;W.GKJ,W
MA6^CU)+82S+)YDUN^^T(M@69&8L8U(;'L/\`P4"U&W^$/_!3+]F7QYX@N(K/
MPKK6E^)_AW#>7#A(+/6=2AM9K%'=OE0S_8YH5)(RQ4=ZPYW[.G4MJ]X];^S4
MU%=?>DU2VOS725T6U:=2'2-[/I92<>;Y17M+7MRVUU/L[QIXML_`/@[5M=U)
MS%I^BV<U_=..J11(7<\X_A4U\C:5_P`%V/@=JO[&7PJ^.0/BJ'PK\7_%D'@S
M1[&2TMQJ=I?R7$L#?:8Q.8TCC\EW=ED?"%2`Q8`_'/PU_P""2'Q?_9=_9Z\#
MI\,OA1INB>.-1^`'BSPGXX.G:CI5I/JGB.]:U:P2[F$RK<LCFX*3%G2-4VEP
M"H//_&;_`(((_%_4-4^*W@_0[*TO/A7X1\&W&O\`PFL8[ZU@,OC*\MM-CN$8
M-*`@2339'5Y51`U^S!R2^W56C5:J?"M=/[DY\T?^WX13@]-912W)DFU%0W;:
MU[2C#EE_V[.?O*_PQGVT_5?]FS]L?P_^TMXZ^)/A6TT?Q'X7\6?"K6DT;7M&
MUV.WCND$L*3VUW'Y$TR/;7$3[HWW`G:P*J5(KUNOA7_@F_XU/[0W_!1?]I/X
MEZ7!`/#]OH_A3P/=WMK<)<6U_KMA;W4^HQI)&[)(;8WL5NS*2NY&`)P2?NJG
M*/+&/71:K9_WEY27O+R9$9\SEI;\UHFT_.+;B_.+OJ%%%%26!&169X-\%:-\
M.O#-IHOA_2=,T+1[!2EM8:=:I:VULI)8A(T`5022>!U)K3HH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
9BB@`HHHH`****`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>table4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table4.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$A`>4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"N?\4^-XO"=\OVRZL+.S\AY&EN7$8#
M!T4?,2!T8\?2N@KXQ_X+26%SJO[.D$$5U=V47VR&5Y+55:4D3)A0&XP<GG/8
M>M=>`PWUC$1HMVYG8WPU.$ZJA4=D^I]"S?M/>#X;CRCXN\)"0\!?[2BS_P"A
MU;7]H3PT]H\__"3^%O)C7<S_`-HQ;5'N=]?B/X:\"7FFVL;7L\K1L<B1Y-LS
M@]S&!C]:O1>%P;I_DNXXAP)#"K;A[U]>^#NU0^G_`+$RIK_>9+_MQ?\`R1^O
MUO\`MY_#6Z\1/ID?C'0&G3AIA(?LP/IYOW,_C6E=?MG_``YLHV:3QWX/PO)V
MZ@KX_(FOQCN['59+=HFT\[(SA(/MRN[@]"%4#'YU?T3P\VG*?-M[ZVDDR`OG
M^4CK]235RX/ANIO\/\A2R3*]HXB7_@"_^2/ULTW_`(*-_";5=?.FQ>-M'2XV
M[U::*6*&0=/ED90IK6LOVWOAYJ.ERWT7C#P\+2#=OWRE)#MSG:A^9AQP0.>U
M?DM'HU_=V0CE>\$`&%669YU4?F!6:GA1=7U1H(=5>"5.Z;"QQZ!N<?2G_JC3
MMI)_>O\`(<<CRQO7$R_\`7_R1^H7C7_@JG\,=$\,17FB:PWBF\NP/LUGIMG(
MTAS_`']Y0(/J?PKAX?\`@J#XB\5V3MHOAG2+2XLSNN(]1E)$JGHL920?,.,\
M$5^>]YX/;2;D%]?U"XFE;"AHCA#]4QC\<T:AHDJ>2O\`PDDD,F=F';>SGT`)
M%=%/A:A%:*[\V_T2/0PV49#%?O:E23_PI?\`MQ]\:I_P5D\3:9J!W>!='^R!
M-HSJI\V23@`J-N-I.>.HQUK#F_X*G?$N;5VBL=%\"7D,KJ(V^SW<8@7^+>YF
M^8C_`&5%?%4/A>[$)\G6KF9NFZ0E&5OP_P`*;_PB&HF+_2-8U2Z91D);2C&?
M]H'##\*Z(\.8>/V(_>SL>$X>6L(R^:_^V/NWP[_P4P^)%_)/:)X;T#7KA`RK
M=V.EW=M`7YP%C>=WD7ISE<^@K8\%_M_?%V#PEXJN=?\``/AZYUW38[=M(T9)
M7T:XOPSXFE8W$LF(T7!X'-?FUJWP^O\`5IIOL.HW=O>P*',+OA%_VLER1^58
M>IVOBJ>=!J?B>]<;!$L)N68L!U"9;`'MTJ7PM"6B4?QN>74RG+6O<J/YPU^5
MIV/U7^%W_!5[1-1\.7][X]LM+\(WT3JMKI5E?G5;J88^8N418UYZ`,>.IKG/
M%?\`P5SO-5O'/A#PC:O8PDCS]6NBKW&/[B19QGW;\*_-#P_\-]0U%!<O:&XL
M(V*;S>#SB>YROIZ5U<7@=KBQ$"RVPN=N442RQ.B^I&23]<"C_53#0DY-7\KN
MR+HX#(TVZGM']UOSO^)^EG@3_@JUH]_HN[Q3X:U#P_?>5E3;G[=;32?W0R8<
M#W*U](_#CQ^/B#:R7,7D_9O)AD0H&R&=26!SCI@=A7X:MX,O;'5%LY-<F,RI
MN2.*8Y_$D<_G7[._LI0?9O`%NG.196FXGJ3L.37@9_DU+!PYZ?7SOU1X6>8;
M+Z3@\"Y:O52MV?8]3HHHKY(\,****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`*^2O^"N=RNG_`2"XFMY;BUCO(O-\O/[L>:IWG'88KZU
MKB_B_JD>EZ+NF6U,;'!^TJK1@[AU!X]:[<NQ'L,3"M:]G>Q=.3C--'XFVFLV
M/B2%(+\QW+7JL]B8%D;S1C<`#]X''/3\*V;?5M1L[U-/_L[4Q,8@T%Q);L81
MCZ`#(]&Q7ZJ6VOP1)NL['2P!\V^"RCP?0@K3[_4WO8/-OL;&`&1&,GUP,8K[
M9\4R>GLM/7_@'H_6I]C\H[[Q%):H0_DWD\<Z(J6@"N<CEB7P%P3R,U-=>,]/
M,ZR[HIA;(WVF0QC]RP[$@Y]N`:_5*3PS86MFA@T?33$QW,)(DW$GNP(YK(O_
M`(6^%M:\R75O"GA>\(SACI\.&!ZACM!%5'BF.[I_C_P!+%/J?F6GQ1>'2X)8
M[JZM+*XC5G@D59I%7/&Y!D@-U'MZ5FIXPM].U/5'WJ;B*-3.DEPJ(B]>"1CI
M@[>^>M?IY#^S'\-]XO!\./!@E9-A>.Q5=P[`XZ_C3D^"/A'1;XRV/@;P$JL,
M-"^D1%G^K8W<?B*K_6JE]FF_O0OK;?0_.CPAI=UXYT&]O].AFDCM%63D%5B4
M]G&2`QP<#)KGWU".RG\N_N/(,CN]I,UMY"L(\E^3D#I]XXSD8)K].&\":<VK
M>9!X&\#1VJ(0D:))""3W8`!#_P!\DURO@UO#%_J/B)_^%<:9;ZCI=V;%KN]M
M!!;AP`<VNY?FB&1\XZDXIPXE<K_NW]Z*6)FNA^?-YXBTNX"O?JJQP@7$;/\`
MOA$<9#J5R#GMSG%5+?Q[HD]W+8W%_$;J6U^U3R0DC9$<;3DKC.#G`K]2/^$4
MT4:;&][I>E[`P9XIK..2/=ZCC^=7KCPMX?&F)#+X<\.W5NF!'"NG1$D=@JA:
MA\4+_GW^/_`$\7+J?EEHVLZ,Z1+9ZUIUVLR[E%U<JTTJ#J50#H.Y(%4]6\C5
MKHW%B(9!&H\VR1`+G821YGS$`*,=ADU^J'B9O#/AF+3R?AI!J$DLZ6Z'3]$M
M[IK0'/SN,`K&.Y&?I4T_@_PY=3EO[`\.0%#D>9I<.8SWP=HP*:XK>_LW]Z_R
M*^NR>R/RILM?M/".DQB[2Z&FVH+EK9`[(6.,;0-S-SDC'`YS71^$_!'BWQ7?
MR'1O"VMWT$>X"Y^PS(%XX\QW`#+S_"3]:^^?&DGA+P]JVCQ:?HT>O:Q=7OE6
M>G:<$MDE[2R/\NP1QKEB3Z`#DBO0V\/K97F^WF2-6S\CQ;D`Z!03R`**G$S6
MU/5]V1];;/SNT?\`8R^*/B6WG^TV*16ESA[>]L]/F#,H/"%=I4_[P.:_3[]F
MG2Y=#\)_8I]_G6EK;0R;E*G<J,#P>1R*Y./3V\MLW$^TGEA(5&?8#H*].\!+
MLU;41@\0VPY[_*_->!FV:5<72M42LNWJCCQ4W+E]?T9U%%%%?,&(4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5R7Q119=)VO$DJD@
MD,,_Q#M76UQ?QBCOY?#A&G"T^TF1<FY9@@7//W><UK1^-#6YYL^H"VOU@^P2
M&S"[A-'M(3';8.1^58OQ'\>MX6\++<Z;H6J>)I[B>.V@L+51YDK,VW<7?"HH
MY9F8@`#N>*ZRS0QC$GELT?\`&1C)[TTH8K4Y\P-(,DGN/PKTE))WL;[&/X?3
M4)+!6U"**WDV@M#'.950^BL0,_E4=S=WZZU]EBMKB:UNXV?SO*4I;8P#&<<D
MG)*Y'KSQ4FC>++S5/$&IZ>VC:I906(5HKRZ5/L]YG(/EL&)^7`SN`^\*UU4&
MW^9_WF[`PW6FY.]VAW3W..T7P!X4^#^F3ZH)KRPCL+:26YNKW4)WBBC!,CLX
M=M@QR<XX`K2TCQ';_%;PFU]HLMU#!<C$%ZL>PS)@%94##E"#P>A%/LEE\7SZ
MW9:G80S:5_QYF"[M67[2I7]YN4Y#QG(`(X/-7+?2H]'AMK;3UMK2VM$2)(57
M$21JN`B@=,``#TQ3ZW>K!6O=%BTN2TR0;(YKM%RPQM)`ZG'0"K;!HXC^X>4D
M9V\<>W-<KX]TK5]>M],;0=5M=`O;&^BGFN)[/[5]IMP?WMOC(_U@XW9^4@'%
M="][=17\4:VDCV\I+27'FH@B]!M/)_"EMJ$BQIMA;0P.8[-8_-(:7'S,S`=_
MIZTILT^V^<D>R8+M!R!QZ9[U7EG9KAPB;^1\P.,>U4->\-ZAX@TJ>VAU&[TC
MSUV"YM%C>>WY'S*7!7(]P14Z,$C<>%YSC>T)(SO0<CTQQ2R1_*-_E7!'7S%R
M3]17.Q_">%+,"Z\1>)]6:,8_TG4=N\^_EJG/Z5J:/86VCV+0K;M;A>?-8,YD
M'KN))S]:+1Z,EZC)]0M5N3&I,$D9(!*!1@\_+[>U6%N9X+5F<>?QRP"@R'T]
M!3BL-P`R(FZ0=1AF(I6T\E#Y+[<8)5EZG\.E/39CT*5E?_VW%^\@DMSDKLD`
M)'Y>M>G_``_93JFHA2"%BMUX]@]>8:QKT6EQ2R7#1VV/FD9V&W`[D@5Z=\/"
MCZC?O&!MD@MG&!C.5<YJ*W\-^GZHPK;Q]?T9U5%%%>6(****`"BBB@`HHHH`
M****`"BBD+8I-I*[`6BF[Z/,J?:1[CLQU%-,@`IL=P)!QFCVD.XB2BFF0`4"
M4-1[2/<!U%-WT;Z/:1[CLQU%-WT;Z/:1[A9CJ*;OHWT>TCW"S'44@?)I:I-/
M804444P"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*X3XVZP/#W
MAN>]E\R6"&,G[-%&7EN'W`J$QR6."`.Y85W=<C\4HA)I0.,X<=O>M:'QH:W/
M+O#GB"Z\2Z)9W=YI=WH[7$*R2V-VRM<6FX9V2%"5W#O@FK]XTD[F-#E0O+_Q
M?AVJM+<^3=I%''/+U._;A4^I%2JOV63]XKL^>3NRI'M7H,U\T.CADBM<H>&X
M?(Z#WK$U'PI;7NM)JR32IJ44?D1R(AX7.<;3\O7OC/O70-<@0$+'\HYV@9+&
MOF3_`(*[:_JNA_L#^*[BWN]0T#1+V_TFP\1:G8S&*YT[1)]0MXM1F#+\R;;9
MI`SC[JDGM6?/)/3^O7R[CC>^IT7AK]L3X?\`B#XQ3>%++]H'X7:GXDFN6LHM
M!COK)[OSU!WPJ5E#-(,<J.1CI7KNJ7UW8Z'>2(T.JZK;1%X[.#]VT[XX49/R
MY]2>*\O\:_L;_L_:I^S*?"6K^!?A[8_"JTLD:"1;:WM+*TMUVF.Y2\7:T;<*
MPF60-DYW9KR;^R_'?[87[47Q2\,>&OC!JWPS\+?"9=-T72;3PK;6=S?7]S<V
M*70U.]FN8Y2T`#B.*-,*_ER%F)K5U7?E:N_+3^NW7\Q)W2D^O]?,^L[&UEEM
M+>2:-X;FXC5F@$^?*.,E<CC(Z9JIXMUK2OA[86^I:[J5GI-DT\=G')=WBQQR
M3S.(XDR_5F<A5`.26Q7P=\+/CC\</VPM>^$/A6R^*J>!'O--\7VWC#7O#^FV
M\O\`PD<FC:G;V4-Y8><KK`)B2Q/(`:0`9VD<O^T%I/CGXL?L@Z_X3\3?%;Q9
MJ.L_"WX\Z1X677X(+2&ZUJV>^L9+:2X3RS'YL(N00R*H+1*6!&09E-[KKJO3
MF4;_`(Z7'*=DWVO]_*Y6_`_3/R"[;6V<<G80I_#OFF7MU!HFGS3W4B16T$;3
M2O*Y79&HW,Y],`9)]J_/[Q=\3OBS\%O!OQW\?)\7+^_;P?X]3X;^$].UNTM!
MI&EB=[&U;5=0*1*\[Q2732J-R("H!X)%=1\9]!^*7[$GQ,\(Z1J_QE\2_%O0
MOB[IVL^&]1TSQ-96<%[87,&E7-V-2LC;1IL@_=%)8F#`"6/!S64JGN<Z[77J
MU=+\5]_K:TES\OF_P=F_P?W>E_M'0_$UOXIT+3M5TF>/4M,U2!;JSO+=@\5S
M"ZADD1APRLI!![YJ^MI*TI=G)/8;L_F*\L_81N)3^Q)\&U>.+:G@?1]O)/\`
MRYQ=>U>EWYND?+3P[@<IE3^`P.<5T2BXS<>QE2E[2"D]VDR$6=EI=\;T644-
MW,@6:Y"_-(JG(R?0<_G3VNGU&5)(BDUM*2TCER/+'^R.YIS?\?/G2(SM(/E1
M3DM[TV\U"2.$A556SC!7YA]?6EY%EAK;[#$H14SV?';WKTCP$,:MJ7_7*W/Z
M/7FD$;S*%7C`QGGCZ5Z5X`;=JVH\@XBMP<>N'K.M?D?I^J.>M:\?7]&=1111
M7F@%%%%`!1110`4444`%%%%`!39*=39*SJ_`-;C:A:3R9.><G@U-2$9KC*&&
M3!P1QZTP#R9/EP<]JE>(/UI=M`$=TC/'\IP?6H[>&6,\GMCZU9HJ;Z60K:W"
MBBBJV*"BBB@!&&10J[!2T@&*`%1LM4E5[=M\ISVZ58KJH?"9L****V`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KB_BK=*]N+3CS'C,RY[A75
M?_9A7:5SOCOPQ%XFT\QLPAESM64+\ZKD$@'MR!^5:4VE+4#R?4]'^T:5<K-<
M/;Q-&06@D,4B>X;L:J^')H[+2[=+>[DO[6-?+6YG)+2D?[6/F/O6[KW[/-OX
MANO]-U2:[A4@I;NS>4I'&2HQN_'-7X/A%+`BK#J,,0C7:H\H[0.PQ7H>VIVU
MD:\\=KG,WMO+)+#+#-DP2?O$7^)",,`?7ICZ5+KMAINK:)=:=J$%G?6&H0/;
MW%G=(LL=U$RD/&Z'(96!((/&#S75M\/+QH"#?V8;&`1&U0V?PFD@QYNHPS2=
M-XA*\'M4NI3>@<\;Z,^2M#_X)"?`BWBMK=?"FJ7GAJPO?M]KX5OO$^IW7ARV
MESE=NG/,8-BGE8RI1<#"C`KL_CO_`,$XOA+^T3XOCU_Q#X<OK76(]/&DRW_A
M[5[O0IKZR'2UG-I)'YT2Y(57SM!(7`-?1G_"MI?E(OX4*_=VQ']:>OPY>.0D
MZAC/8*>*CFI[?U_5@YT>,>"OV8_`'PNN/#$_A;PQI^CS^"]'GT#0X[1G2'2[
M"9XWEA6/=LP6BC.2"V0>>3G+U/\`9+\!ZE8ZY#J6CK);^)_$UOXPU,"XG'VK
M58&A:*X.&RNTV\/R+A#LY7DY]I\3?"G4KFT:32=6LK:[!!3[7;M+%(.ZL`01
MGU'3TJ30OA]J<MG&=4ETR"?:!(EHTCQLWL64''UK3VL6KM_U>_YZ^NHU4@H\
MO];6_+3TT/*[GX%>!+OPKXP\.W?ABTU?1_B)?W.H>(].N4-W!JTUPB+,75R0
MH81I\JX`*@C!YKB?@C_P3D^%'P,\2W>JZ5X:U"74;C2)-`@N]=\0W^M7.FZ?
M*"LMI;/<RO\`9XV&`?*()``)X%?2S?#AA_JKV.(@D_*IY_K574_AM?W=ML76
M(;=MNW<L+$X^M3S4GIY6^6UO2VGH)S3W]?GW.>\`^"-)^%/@+2?#?A^R%EH^
M@64.G6$)F9Q;PQ($C3<Y+-A5`R22<<FF:.VJ)=7?]H112J7_`'.W@@>YKJ=.
M^',D,F;F^@GX&U/+8*I'?'K5N?P8\C?+>0(&](S@4W55[ID>ZM%L>.?$#XKZ
MKX"^(6A64OA^>3PEJF8KG6(0TO\`9D_\(G`^Y&>/GY`)YQ767EY8VK+)<W=M
M&F`8V:5=LGXYY_"NU?P#YRLCWL9C8;64H2&!]?6LN\^!.CS7EI<1Q6*26((A
M(A8>7GLN.!6BQ%)V3_`OGB8]PCW07=O54.,;N#7I/@%=FJZD./\`56_3Z/7(
MK\-ILX>^M2O8>6WZ5V?@ZU^Q:]J<0.0L5N,_@]959QE"7+V_5&-22;C;O^C.
MCHHHKSAA1110`4444`%%%%`!1110`4V2G5#=[CM"_C6=7X&"'4@;FFKD)Z>E
M1DCS<D__`%JXK%W)CTH`XJ(+F3ACCKCTI4F+O[4]0N2T4@-+4C"BD6AFVC_"
MF`N:;(2%XZTR-]\G1QQW%.D^8=_RH%<7=M4;L4C-EA@\=Z8`>`5W4/O5>$'Y
MTQ$D8Q+^%356M$9).1USWJS771^$D****U`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`K,UMML1^O]:TZY+XK_`!$T+X8^'AJ/B'5K+1;!YTMU
MN;N3RXO,8_*N[H"<'\JJ*;=D-0E-\D%=L\*_;L_:WO\`]E;P]X1.E1^%'U/Q
M;K#:>DOB2_DLM-LH8[>2>6:22-6;@(```<EA7>_L[?$+5OBA\(-'U_69_"EQ
M?:FCRF7PS?O>Z7(FXA#%*X#-\H&<@8.1VKE_C7<ZS\1K'0-5^&7B#X<:GJFC
M7;SM9:Z([JRU&)XRFWS4W2P.I(8,@YP0>#5?]F7P;I/[+WPLN=(UWQ1X9;5-
M3UB_U_4?LUPEO9VUQ>3&9X;>-FRD*9PH/7D]Z]*2IO"I)>_?YO?[DCBC2Q'U
MIQL^6W;8]H\_BG(^^N('[1'@(R%?^$R\,[E['4(Q_6KD7QO\%RR+L\7>&&W#
M(QJ<//\`X]7%RS_E9WO#5EHX/[F=9)*RCV[<TUY&'/;M[5S:?&+PC)R/%7AP
MY_ZB4./_`$*KMM\1_#EZ/W&OZ'-_N7\3?^S46GU1#I36\7]QL-*5X]*;YV1_
M]>L*Y^*7ABQO%@F\1Z#',Q`6-K^(,Q^FZKGACQ9I/B])9-)U.PU-(',<C6LZ
MRB-O0X/6BS6Z8N2=KV9H-,>W_P"NDDF.,^W-/*&-O7-5[B5+==TDL<2CDEF`
M'YFCS()`YS1YI!ZUG2>+](B0DZMI8V\G-U'P/SK+U'XP>%-)7=<>)M`A'O?1
MG^1--1D]$BU3E+X5<Z03$-CGFE,A![]?6O*=:_;2^%^@$B3Q;97#`]+9'F_]
M!%10?ML_#>YB1TUR9@YP`MC,S#Z@*<5M]7K[\K^YG2LNQ35_9R^YGJS2;G/!
MXK5\*'=XCU4XQ^ZM^/P>O'+S]L'X?P6^]=7NYAG@1Z=<$G_QP5Z[X$U"/5M2
MO+J+<8KFVM94W+M;:RL1D=CS1*E.,).:MI^J.>OAJM*4?:Q:UZ^C.FHHHKA`
M****`"BBB@`HHHH`****`"O'_P!J;]L[PG^R5+I)\56GB&:'5DE:&33+'[7M
M*%0590P;)WC&`1P:]@KXU_X*PVD-W-X+\SS-X%U@;(RA7]WG)8YSTX'O6V'H
M*M45.6S/2RFA1K8J-/$7Y7>]M]F:MM_P69^"DH3[9<^--'C<X$MYX9N@@Y`Y
M**V.M>H>%?V\/@WXY=8-/^)'A>2=@3Y4MV()!@9.0^",5^:$N@2M%+%$=X8L
M%6&`$GTR".GXUSVH?#*XUJW_`'.EKJL\8Z+:,"@ZY?)&/Y]:]1Y#2?PRL?8U
M>&\KE\%2<?5)_H?J?=_MT?!K2G(G^*7@=.Q_XF\1.?P-9&J?\%*O@3X?@W/\
M2="N6YPEIYERS8]`BFORV3X;-IJR-/IEE:2PN0-UM'L)Z`#/(..I]:U-.\`Z
MH'^2P59G`!4QQ[6;KQVQ@'OFG_J_#K,Q_P!6,NCK[:7W(_1F\_X*Q?!>/_CU
MU;7-3;^[:Z)<Y'_?:J*S=2_X*X?#FUC!M=$\;WK$\`:?%%G_`+[E'2O@23PS
M?H\B0R1R%''R!4;COC''.>O;-:MIX)U58?-CTZ.Y1"-VR0`J"#C`[X[XZ=ZO
M^PL.EJ_Q-5D&5Q5Y2D_G%?H?8][_`,%?='NY=FD?#[Q1=>DEW>VMM&Q]!M>0
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M`\-YXG\-Z]-%E4?4?#BKYAS@9:&6/_T&NHL_^"E7Q/@FMQ=Z9\/KM1@2QQQ7
MEN9#W"MO;;^*FO,;F_-K$-D,/S'*%%WH.QW=Q_\`6K.N+JYDN!M;2@N/F!4@
M!N2.>F,>Y[U/]GTG]E&/U;**C;EAU\FU^3/L3X&_M^_\+;\13Z+#X#UQ=<6S
MGNX(;?4;6:"[:-=WEI([QE2W0%U`]2*]9^`GQS/QNLO$0G\.ZOX6U/PMJ[:+
MJ%AJ$MO+(DPMX+@,KP221LICN(^0V<Y!'%?(/[`D\\W[3]ANETB9/L%T7-O+
M&SJ=O&`H_K7MWPO^,.C_``:\6_&:[U47\\NI_$@6-A9:?9R7=YJ$YT737\N*
M)`68A$=B>@5&)(`KR\5AXT9\L3X7/,-AZ&)Y,*FHVOKJ?1M%>0S?MQ>`(+^S
MA:?7ECF2U>\N6T.[2#1#<OY=NEZS1C[,[N,!9,$<%L*03BM_P4>^&;Z2E];R
M>*[RSDM[R^CE@\-7SK):V;HEW=#]US#$S@,_0D';NQ7,>,>\45\Q^/\`_@HW
M8^%OB!_8UAI"ZA8V\6KW=YJ_^E?8;2"P%H-K.L#?O':\BS@%5&.6+@5V5Q_P
M4%^%EGK&IV<FOS!]/\]89%L9GCU62"=+>:*T*J?M$BSR)'L0$LS#:&&2`#VJ
MBO'?`/[9FA>+/#?Q.UW4M/U;PWHGPONC#J,FHV<L5T$6P@O)7:`IO7:)B`!N
MW!003FJ=G_P4,^%T^L6UI<:Q?Z7]H*(\^HZ9/9PV<DD9EBBG:11Y3R1`2*K@
M95TS@LH(![=17A@_X*`^!+S4H+2.?4--F+V4\O\`;>F7>FJ;&[,PANHV>+#H
MWV>0CD`!3N*\9E7_`(*"_#OR;4.?%,-[J<ELFEV$OAV\2\U=+D2FWFMXC'ND
MBD\F0!^BD#=MR,@'MU%<_P#"WXG:1\8_`6G^)-"FFFTS4E<QF:!X)8V1VCDC
M>-P&1T='5E(R"IKH*`"BBB@`HHHH`****`"BBB@`KY?_`."J=@NM?L\"RE.Z
M"34()#&#\VX/@-C&<<D9]Q7U!7R9_P`%5[N?3OAE830VU[?;I4A:WM86=\-/
M%\X(Z8QWXYZUZ>36^O4K]T=6"JRIUXU(.S3O<_.<Z-XU^&TLD_A?6+*6U9MP
MM;YC"T;'LK`$$?4"J.G^(?BEKMVT]S+I`&XJ?LB^8_O@NN`>G(%:T'C9+"_N
MM)?4)[N:S=7G#^7&YC?)#+YF%8``Y'48KI)O$-G+KWV:VEN,+")D+0E8\?[Z
MY3-?J?L:5[\B;/KO[<Q.\9:][*_WVN4]&\4>/=`LTC^W&Z5<L(GCC^3ZDJ<F
MI4_:!\3Z-*\3W=A;78(`SIMLTI!]S']WZU-!J_VZ$,\OD>6=K,\6`?1O7::K
M7M@VH00W4S:?]H0B)7.(X9GW<*,\DGTQFH>%H-^_!&#S6LW>35^]E_D:1^-W
MQ)FE+$:,RQGY%N[&!4/_``$18K5C^./CBXCDFN]#^&FH7%NBLT<NB1L"/JFR
ML8RQW0F\B:W/D-Y<CJ2?*D_N^A/J*LZ9>1:+H7GWLT#D#`E-N$:4CT5:R>!P
MK6D$4LRJ];/_`+=7^1N:+_P48M/"SM;>(?@C\.-10?*9;6(P,Q]?F#8_.LW7
MOV]O!MZ&&A?"'^P6FYFGTO590X]D4.J_F#7'^/\`1]-\21P26_\`9OFR-E4N
M$8/(/5`.1SD5G0>"1IM[!:V26MOY;`RK;*&)&.^>0!W)J5D^"^))KYO_`#)^
MM0O=07WR_P#DCI-%^+A\5>?<VT'BRV`.?])UB42@'H-B9_G2R^.?%,<973[V
M]O%;@V][?7(5AW&?_KU8L&>TU.\L`\4]Q#L?"ILVH>,;A]XCJ?:IKB[MM8M`
MIO)X8T9FC,4Q5F*<MSW%6L%AXNRB3+,ZRTN84_Q6U&PBEMK[P%9P@\;[?6;M
MBWUR3CZ`U1\/WTWC"[DN/[.M]-M$7:J-'*ZL><C+N3QZG@UT?B+Q,;."W2W1
M;JZGPT*<E2.I.[@=.G--MM>AU/4_[.EF,-Y#$LCCRR4;/.`>]:+#45&ZA^;_
M`#95/-\1%+DFU\V97_"/W2LS0Q7"*_W6M<1>G3YAS3#\1OBA\%=1CN?#OBRZ
M>*8E=L]LEQ)'QTRP;'UKH=5\0QZ'!.[7EBT$*`Y1PQB;..5^\:BDUJ/4[1[-
MI;9M0F3<DB0%?*!Z-L?G\^*MTJ4E9P37H93S*O)7G*_KJ<OXA_:_^./B4R&?
MQ']I&``\]G"0/I\H-?KS^S'K\WB;P/:W=S<07-TVG62S/"/EWB,[@?<'K7Y!
M>(M!EM?$TEM+=9:P@2:Y;81&P;H`H_C/Y5^N'[(UO';?#V,1#:K6UL^-N.2K
M$Y'K7S'%-"C"A%THI;[>L3R<WKNKR7MOT273R/6****^`/)"BBB@`HHHH`**
M**`"BBB@`KY5_P""E%I=:A/X2M[.UNKR>?[0@AM]@D?[F0"W]*^JJ^&/^"T/
MC9/">E>#EE0&.5;MP9`#&K+Y>,^_/!'2NS`1<J\8QW/:X>I>UQ\*=[7O_P"D
ML\7FU/2M,9E73K8W$)V-%<:RNG2C!PV20`K<]SFI_P#A:GPMN1]EU3X;:FDB
M\R30>*089/<R'&[GJ<FOGS1OCU-KT"F.XL[V.(!7BP69#Z'<#GMU.:W;3XEL
M-DG]FZQ%-MWA5G\L!0O088#L!@CC/'2OHZF$FM)I_>T?I3R*G4]YU?N_X<]2
MU7XB>"IEB30[34=)A"[XX[V\.HM;YQG9(@*JO3@Y/>JL/CS2Y(RJZGJ%WL.&
MADMT"D=W9BHP/SKQ;Q5\4_%]J(9-%L[CR7.7B.J1YA/8`MG)'(_X"*L^"?CM
MX@U+(U#PEJD4H.&E2]MF9R>"V#U'7I5_5I*.FOS_`,PCE-*+Y9-L]OTKQ_\`
M97D^SW%A<6I;`233H_W(8_=+[`6Z<'BK<_B^TEOP7NQ&2^Q_)C0(A]1A-I'U
M.3SS7F)^+02R>.YLM0"(V#YV,-T`!YP?;^=-M/BA8QO]L@T6TB\@GS'V>4%`
M')8[P".#U^M1[.7\OY#ED5-VE?\`$]FTGX;V_C^[EAC\3Z3-$%+&+49HK0*W
M]Y2TF6!]AZ5+<_LK1Z5I+74GCWP+I%J>NSQ"I"GN,[LY_$]ACU^;M>^/7AU;
MV*&Z=5EEC#QVXNE50I8#AL[!^?KBL676-*UN<W*^%+.Y>"7YV@O/FB.0<MY;
M`$]QW/%3[#$+JTO1?YC_`+%G+2G75O2_ZH]ZOO#VA>'V46GB;3=?;S`5N=+N
M7F4?['S!54_0G/<TDNK:,;^(17&H_)R!''!;J"3R9'&XEAQS@=Z\9TOXE163
MN6TVY@MHX]NV2[/SGLIW.?K_`/JI;WXRWD%I<"PTFUO+A-I`FNN&R0<YR>PZ
M?I6\:51Z/]!5,E4%:4[V['NMOXXN;&V\G3?$&I+:./WJ6]S'&C#_`&VQA\>I
M`)[T^*\\.:J=XGNUE4ARK:3$%#C^'>LAR.^=O>OF?3OC5XNU'5;F,Z#IUG!'
M\R2K.P4\_P!YE(^N"*Z*Z^(FMW<>VRO;6S?<-WEP0L5CQR.W?/\`^JE+"33[
M%1RJDUS1DU\C[8_8/U/3;C]I6T2V$!F^QW)+_9@C'Y.QP,_4=:];^&_P9L?C
M%XY^+@N-0U?1M2T#XF?VEI>IZ7,L5W83_P!A:=$S*75T(:*61&5U92KGCH1\
M??\`!-&?5_&G[3:Z9J?B35B-6TB^B\VVD@MI[<>5@21E,LK#L1T]*^DOA?X_
MN_V8[OXA:)I=U_;.H^(?BH=&M=5\6:JP@MF.@V5R9+JX"EC\L1CC4`%F:-<C
MK7SV:0<*UGV1^=\34HT\6HQ=_=7YL]7O/V$_"VH7>Z;7?&TUK>K9C6[275_-
MB\3/:OOBDO&=#(S=`WEN@=556!50!IV7[&G@VP\-V^E)_:_V6V\-:AX43-X=
MWV*]=7GR<??RHVMV]*\/\#_\%,_$?C3POJ^L_P#",^#;+3/#^FBXO;MO$$LT
M,]U+JM[IEM%;^7;DR(\EJK[\`D2!0I/(BTK_`(*6^+_$>@:\^G>$?##7O@O2
MM>U?7#=:I-#')'I4\*,D"")G5Y4FR/,(V%><YKS3YP]ANOV!/`-Y8ZA;M_;@
MCU.VU"TFQ?8.R^-D9\?+P?\`0+?;Z?/_`'JS8_\`@F[\.H+[5)(?[9M8;Z::
M[M(;::*#^Q[F2Z2[^T6\B1"7S%G173S7D5.0H"DBO._CI_P4<N;#X(Z]-HD-
MAI/B.8^*;&R+7J2W%@=,T^XN8KDQ%?FW&./*D8&\<D$9I>/?^"IFH^!_$FMV
MMGX;T/7[6"SU1M)>+4Y(#=7.GW=M:2QRR/$%^=YVSY881F,@ENP/4]YT']D/
M0-+\`>/M`OM8\4:^/B8[R:]?:C>JUW.SVL=J?+*(B1`11(`J(`",XYK%\9_L
M!>!/&?C_`%'Q%-%<_:-75'O[-UB>TU"9+<6R22G9YW^K5`RI*BML4D$C-2_&
MK]H7QA\(9_A_I2^'M!U37O%/VV34Q%?S+;V$=I:M<RF`>49)V*KL12J99@25
M&:\B\`?\%-?$?CV'2K;_`(0_1]&NO%OV*;1]0U+47@TRRCN8[B0)=L4W^8JP
M%5*#9*[A05VF@-3:^$O_``3BFN?$%[?_`!.UR;Q+']@TS3+*QBU&>XA2"R-R
M5W-*JL%?[2X,?)P,M(['->B>$OV%?"OAKQ9H.NW>L>+O$.J^%WMAI%QJNHK*
MUA!;I,D=NNU%W1XG8L7W.Y5"SG:*\7^'_P#P4FU_X@^(;*SM-)\.6VK:_)%I
MEK)<ZYOT"TE6[U:)YS.L(D82+IWR`??:1%&W!)U--_X*/^)M;M]1U"U\)>&_
M[(\))IYUZ;^V9)#=FXU:YTQVL"(MLD6ZV\U)'*AU<+@'Y@!J?3GPL^&.F?![
MP5#H.C_:/L$%Q<W*^?)YC[[BXDN),MZ;Y6QZ#`[5T5%%`@HHHH`****`"BBB
M@`HHHH`*XSQ]J8T;Q%#<20R20?898V8+E,F:+"GW.,X]`:[.N/\`BRGVC0?+
M/*;PS*.^#6E&W.KC6KLS@==\%_#_`.+>(-;\.>'-1;&Y4O+*(M^#8SW[&N3\
M3?\`!/CX3>)IH9%\.3:8T`^3^S;Z6V4_50Q4\#'(Z5-XB\!6VLRD+E<L6$1)
M^1N`<8I;6QUKPK*DVD7,L:QKAK>1S)&Y^A[UZT74IZT:C7S?^9T*D[7C(SC_
M`,$V?@[+$5?PW=2`HT?S:G/P&SG'S<'D\CUJGK/_``2^^#&LHRMX=U"#<X=_
M(U:=/,(``S\Q["NSE^-&O(+>*/PV1=D'SVDF`@7Z-UR3VQ5J^^)FO:A:^5:Z
M='92L`/-9MX'J0/Y5*KY@GI4?_@7_!,FJW<XFY_X)E?!2Z@E2;PG(XG"^:QU
M.X#/MZ9(<?GUI+__`()U_".[TU;6SM-4TU?X'M-7D+`=."Y;\ZZK1;B8W;S7
M]Q-<W3D;F+$8QQ@#IW-7?)MF0M;^3N8E'V,"0._3I5O%8M/6K+[V-<_\QYO#
M_P`$N?AS;:>;6&_\61VN4,:?;U;RL$D@$KGYL\_08Q4-M_P2O^']CI_D+K/C
M'Y2P#R7R.2I.<-E/F_&O1;OPZMVJH+Z\BA('[I;ATQ^M8TWPYL[363=O]MN+
MG9@,]W*XQ]-V/TK18W&V_CR-+S_G.$D_X)F?#>POV6Y\3>,"74[8EOXTQR.>
M$R<8`';%5--_X)G?!;3-7T^Z;4?%+2:=(S0+)JA12S?>!P@KVBTLH8K7;'!&
MHC7&7R?R-47\3V$UJ_E7D3JG!$)\S&/IT[U7U_&R=O:R^\7O_P`QR-A_P3C^
M#!L9?+T:\EM[EBTX_M>?;<?[V&]NE68/^"=?P3TZX7_BD;?S)I1.I?4)]S,`
M,$?/S@`<5%<3>)=9U%3I5I;6=L)`QN;XL,#ID1)R3]375,MQJ=K%'=SV\TL(
MX/ED<^HR<BLYU<4MZK^\BU1;,SIOV)/@QI@N)9?`_AT/?`++<3EFDDQT^<MG
M\JH?#K]A#X7>&=)U"-=,;Q$M]*Q%UJ4_GW%I$3D0Q2C#",'D?SK5URWGDM/*
MM[B""Y9#Y+20F:,'ME<YP?:J/PJC^(&DZ1=MXLU32)KV:5A`MA`R0V\7\(Y.
M2V!R>E1[7$.%_;/[WJ'+)K<Z.#]EKX:W>FP0KX0\/W=O;@I&7C\XJ,Y(W$D]
M?>N^^#>D'0KC6;7[.+6**51!$HX6++[,>V,5Y)X@N)?#'ABXEEUB?3;&$%SY
M.$`R>37LOPLG^TO=/YC39MK7$C')<;6P2>^:RK>T]G)RE=?\%&55-.-WU_1G
M7T445Y0!1110`4444`%%%%`!1110`5\:?\%9OA59_%(>#8KQ_LR68N9/M322
M+'!GR^650=W;J.*^RZ^:O^"A%N;P>&8&D"V\K2JZLSQJS$IMS(H('/8]:Z\#
M-PKQDCT\GFXXJ,EV?Y,_/3PA^R3X0\)2:Q)&^LQOXB8RZ@1J/FQW(8YW`8PN
M<`C`&,]JJ_$PZ)X1U)-)0W*Z9%;CR;J4/<+<D(7V@Y^5BRA`3P2#DBOH!/A[
MJ]K="W6)PRL!@0`AN`=V[.,=B"?6N5USX:_%'1M2FB/Q*TZWM%)00KI*7+0[
MC\J[C@$C*CD#/O7TL,0KW<OZ^YGVDL3-/EIO[CQ/X4>/=1^)7AG2WOH[_P`)
MWE]YB-:?9=^QU#$*S@$`':,,>"64'K7I-CX!OK6=8YVM?$\+$,-L<:.",9!.
M`>>>.E=Q<:;J1T%T>\^WWD3Q[YYK:&"*<*VYE_=8`+$#GH,?6N)\9W'Q#T[Q
M+YOAS2(YHUMD589)U_<RABQ8[AA@^1GD$`9&:OVG/M9?U]YK]:J)W6IPVL_#
MWXAW'Q'\0RP:+H%[X:N;,QZ)IUK-'#/'/N'SRN<X`4D8;)W=L<UW.@_!2[E\
M.Q0>(+#PQI=RR".9756W9QZ#`.!R>?UKK=(N_%OC73G.NZ+I]E=K*Q6XM702
MF,C^(1\'GO@'ZUC?'7X(ZC\3-`@MF\77FE27]G):^;`BK*$;C=O#@;E/W21R
M#@YJ?;:J,FEZ:F/UJM%7COYLR-5_95TTVGFMI7A6X\@AEEM8+:[51G:"VTX'
M89/'-,F^"IT:S,N;2UMR-SPI81PO@DC("DY&<>AQVKG/A)\*?"'[-L-AID6N
M:K=-I;FRCMK6W:WM4EEW%C(XSYD[#<=NXC@X7->QZIXBT^'38[V&.[N%G03V
M<"A9/M>0?F5B#D*>HSP1C`/%*<JB:M=KTL;T\PJ+6;7R.;\._L_Z!JDZ6]SJ
MYED8A`BA8U=NGWFZ?4X%</XI\7_`WP7XOA\.WVHW']KW2EHX8D+-*1E0!A0`
M"W')YSQ7<:%JYUK4=MUI=Y:R.OF0RR1QM$3W#CY<=?4'T-7_`!'\+?"5A+IL
M]UX>@BU1H!([Q)AK?#':5DPQ8=QGD=.M--J5JC?R9C5QE6<KJ;2]#%LO`'AJ
MYTY+W0'M[FR4#?;LK"2+<H;YUYX((Y!P?KD5<N/#:VZQ;M$T2)7W%I3"G[H*
M=O)`P.,&M?2?!]E")!$+V*U@7?%"DX\@YX!9MJD`>_7-4+'XU>%?#WBZ&QOK
M'4HY)0PBN+>&.0N00I*QL=VWOD<X!J/?E?DNRI8UQ7OML]8_9#^&%E8?'2QL
M97M-#O\`Q!I-\MG>:2J1W:+Y8WR0R[2%(W+V/N*]7^`W[..G^/=)^,_A#6=>
M\4ZE!:?$5;@:C<7J/?3.NDZ8R^8?+\N11G&QXRN`O&0#7)_L27>@:S\?+.YT
MB-6'V2YPQB*E&QAB%(RA/.17M_[*_P#R4?XY?]C\?_3/I=?/Y@VZOO;V/C<Y
MJ.>(YGV1UOP]_9T\&_#7X9Q>$K'0;"?15@-O-%>PK<M>J9'E;SBX/F9DDD<Y
MXRYP!6OH_P`)_"WAZUGAL/#6@6,-U$\$T=OI\,2S1N%#(P50"I"J"#P=H]*Z
M"BN$\@YR3X/>$9M:NM2?PMX<;4;V,Q7-T=-A,UPA3RRKOMW,"GRX)^[QTJ/_
M`(4IX-_M>>__`.$2\,_;[J1I9KG^RX/.F=N&9GVY)/<D\UT]%`%>XTJUN[VW
MN9;:"6XM"Q@E>,,\)88;:3RN1P<=17!^/OV7/!WCKP=>Z+%ID/AV#4+R._N)
M=$ABLY+B9"2&E`0I+U.1(K`YSC(!KT2B@#@_`W[,_@?P#\,X/"5OX=TR]T6*
M/RY8M0MTNVNSYKS%I2X.\F621^>`SG`%=+;^`="M+#[+%HNDQVWDQ6_DI9QB
M/RHCNB3;C&U"25'12>,5KT4`'2BBB@`HHHH`****`"BBB@`HHHH`*\E\5>.S
M\4_"&M?V,3I]YI&JW6D,;I`Z^=;RA20`>58$$=^<'D&O6J\OU'X;1>`="U5;
M2\EWZMK5SK$SE0/GGD!*`=,`!1GJ<9ZFNG#N*>N^E@7-SJVQR,4]]IL=N+BU
M$A(RTL+9"GOQU]:L"9G/[MCGLK1[?UK.\7>/-,^&XTS^U]5T72HM5O8M,M#J
M%T(9+Z[ESY4$98@-(Y!VH.3CBH_%/Q?\)^"&L8M9U?3M-GU"]CTRV2>=5:ZN
MY`6C@09RTK!6(0<D*?2NUW;V.A&R(9V@3B.W8C)&?./YGU],4DMC>6D)9+D#
M(SEDR<YJC;>-GOCFQL+VX7&$9HO*0^^YL8K,T;5;3XJQ:[I\>LH9-(N_[-OX
M-.N@9K&X"I(8I7'*N4D1L`?=<>M3L]1^\EJ=/IL]I>2R)&\<I0[9CQA21G!_
M"L'3/A)HND>*+C6[+3_L.J7"[;N2WF9%N!G/*9VEO?%0Z)\4/#FK?$#5_`NE
MZ]I=QXJ\-6<%YJ>D1S!KO3[>;(AED7J%?!P3UQ3O%7CS2_AQX<U?7->U=;#1
M=&MGO+V[N9@D=K&@R[N3@!0.I["JC)V]UZ"47>QJ:CKL5AYI,%[=^6,E88&D
MD/TQUIFB^)8=8W9LM2L,,5$=U;-')(/[P!ZC\:D\.>*(+^U6X_>10R@,C.OW
MU(RK`C/!!SFM@308WB59/EP3D_+2=UI8GF,S4-:M;:,F1)L`?\\B?T%>4_%[
MXC>);(6VE^#/!NOV\VJ31K-K36T?V;3T)&YFB+!F&/:KGQ-_;G^!OP8^(I\,
M>+OBK\.?#OBB$(DFG:CKD$-Q!YC802(6^3<<`;L9->GO/)J=@DM@UG(LR++#
M,K;XI%/*L&'!!&,$&G0KQC+G:O\`D4FKZG'QZ#_8*&YNM8U+5;QD+10A3!#-
M)C@84$@$^_%:'AK4;V#PG%<^(;#3=%GB1I;MHKW?;V^.3\[A3C'4D#O5WP<G
MB)(=0.NII33BX_T)[%I&22'')<,,JV>PS4OCF70W\)7S>(O[/70X;22XU)KT
M#[+';(I:4R[N-@126+<8%5*HK^\)N[T+%O?07MFD]M*+J%U5XI(R&CV]B".#
MFG/<2Q\Q89Y.F\DJ?K4GAV\TZ;POIEYH!L;G0[^VBEL7M&7[/);LH:-XR."A
M0J1C@@C%+<W"M-A45>=N2>OTK-/6Q-T]486J>`I/%6MVESJ%_-+:VC>9':!%
M$7F]G;CYL=A^-=O^R_\`%$?%S3=0U>VTJXT_2IHK?[%--<1NUX@\U2VQ.8_N
MCAN?F]C7)>#_`!9IGCK2[RZT'4K/78--OI]-N/LDP;RKN!MDUNQ[2(W#`]#7
M4_LM?"ZY^$=GJFD?VJ;_`$NWBMEL+=[5(GLE_>LRLZ\R?>')_N^]54J)T)*6
M^EO2^OWZ?(YZZE[2/97OZV_X<]9HHHKR2PHHKYF^(^C?$Z;]JG5YKN'X@7GA
M62?2?^$./AG4[>TL+,+M.HG4E<_."W($B29CW+'M<@T`?2EY?PZ?$'GFB@0L
MJ!I'"@LQ`49/<D@`=R:D1Q(N001Z@U\0:CX.^-OQ6TWP?X=UO0O%Q@\/);KK
MMW>7=LD.HWL/B#3YEN(2LA9]EG%.ZO@<'&-W%9_@[P1\;?@7\$KKPUH>B_$:
M\N[KPW>:;IN=3M[DV.K#5+B3[2TLLWRQO;21%&YR$8;0W!`/O"HKF_@LGB6:
M:*(SOY40=PID?!.U<]3@$X'H:^(?B-\*?C_IOA^SO+;7O'UX=5U/7I-0@MK[
MS;BQ?[4PTD0I'-"%MQ!N)!9@6*&56`XNZ%\+OBUXA^-?P[F\9V7CO5M=T'QK
M_:NJ:BE];IX733!I]U%"T=N),+,'DC5@B;_,:0EC&5H`^UJ***`"OG3]NO3(
M-2U'PZ96VO;P74L1=&,>_P#=@;B,XZY!QGBOHNOD[_@I+\?M4^#GC'X=Z?8^
M'9]9M/$,US#>W,<@0:=&H3YR<^_3!SC%=.#C*55*&YVY<W[=65]_R9Y7/JL>
MD^'K=X=5>`%/W;NHE$NWEBS#YO[WZ55TBP?QQX@EMTN,&6W8JSR"1;EOE*L1
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MR`96)$)540\?-VXKN/%3S^(-(1()H3J%MN`03!3<D-NV$KRCC'T-<R-:U#4M
M-:PL[*^MM01'5VO8\-`^WJ!_&/XB>A!'K6M"*B^:6OJ=,(J2\_4\MU;P7I'Q
MYU[1A?:%J\>KQ+;W][;7NEM;'2[S`8`2?ZMR&'49S@'IFO4OAS^RR?A#X>_L
MJUUB.#3+FYGU6WM;F0;K62Y*M(%W,>6(!QCK^-=IJ.@1Z+IVBW5O-+>VL4"V
MUT'1DD>Y"@JKXSA7^8C'ICH16+\0OB==>!]'M;B?2[BX6YD0H&E'FJSG'E;@
M#QG!'IW/%:*M4J)1@83J<EHQU9HVG@FRL([9+I);AHW67+2K+"P!^Z5&`59>
MI[9%6M<\]M<8V=S']FVJK6]N'\Q0!G<&(QCT`].E<[XJ\=0>#?!EI>WD%\L.
M][BXE^S-L4E<A68`@XP<?3CK7CGAK]L36/$_B77K>V\.S6L>C7L5KIXN+59%
MUA74LTL:$<HN4&=P[C/%$*%2=Y(?M)-W>I[EJ-^)X;Z.,2'%KYD\9?:)%/=\
M@?Q=>.M8%S\'M$CUV&:Z3^T;IR,!Q%'$I!SL#N=S#(YPN:Z6^U&_?P4MWJ&A
MQ66I^(Q;PK96TW^J"KEBV6)1&DRP4\X6N*^*'@2;QE/%=+<S1,D)B2XBA5$E
MPV5Y8\J>01QFE2;O92LA>T:A='N/[''@VY\/?M):;N6YLHH-/N!]DGAVX5ER
M"AQ@KGD'J1CDU[A^RO\`\E'^.7_8_'_TSZ77C?\`P3Z\)ZOH/C&U@U'5+[4H
M].M9!!YL06*%)$4A4SSM&WH#@9]Z;XXTGQ?K-M\7X_!\_BFWN4^*:27AT+F:
M2W&AZ?\`)(%FAF\LN4R8)`X(4D,NX5XV/=ZMMSY[,I2E6O+>R/LJH=/U"#5;
M..XM9HKFWE&Z.6)PZ./4$<&OA7X>:M\9?%OQ1UBRF3XF6_B[1+WPS##&=9@G
M\/:7&;.UEU%+P`HLS/&TK$^6Q+NGEE2&-;'PU^#?QYTSPO:ZE/J7BJS\0:7>
MZ!!8:>^IQ+I8M]JKJ+2V\9"2+\S%LY(V@QX/7B/./MBBOB7PKIGQS\.C2-1@
MM?BE*FD)I<_C*UU;4;:ZDU>]COX6N_[+02%1";?[3E%,<;H855=X:F7]M\?=
M2\?Z+K0T_P"(L<3Z]>3VVC27]O#:+9MK,CQ?:)89B(V6Q\L;)HYHRAVH4D!-
M`'V[17S-^U?\.OB_XF\?>+]5\#ZUXCLK>P\+Z?'HEE;7L<5G=7C7DXOV\O*L
MTXL]@CW,JAV0@[E!'S_\6OB#\3/@]\.M0'C#Q/X^L[6YT;6[OPG;6NKQ:9K$
M-X@@^SM<&>Y>2>)2S[$>25\MAHVRF`#]$[34(+_S?(FBF\B0Q2>6X;RW'53C
MH1D<'UJ:OA6/PC\<%T:[FU2W^)$T&H6U[-HR^&M0MK.Y359(K;[//>Y=-T'#
MX\S<@(D\Q#E:](^#?PT^,>C?$SP_K_B;6/$E[=7/BO4(-;M?[25M(CTDZ>_D
MM%;9VJOVM8RK8\P;B#\IP`#ZBHHHH`****`"BBB@`HHHH`****`"N2^)TH33
MMI7=N/'_`'T*ZVN2^(]U"0ELS)YS(951L\J'52WX%A^=:4OB0UN?-?[;'[-$
MW[6W[+OB[P5$8;#7KB!;[PW?H#G3=5M76XL;@'J&6>-,XQ\I8=Z^7/V2?VA!
M_P`%,_VC_#WQ(O\`1IK70OV=_"TC:KIK6QB#>/;F!X[N#D?,;.WBE56`.&N\
M@U]TKI^N7O%Q?I8[)69!;*'S'_"-Q[]_QK,^&?P?T'X30:Q_PB^E6FDR^(-5
MN-?U/R(]@O;^X(,UPWJ[E5R?:NIK5M/_`(#V3^YW]8Q[&KLTK_TM_P!+>CEW
M/S#^'_[5/[4_C?\`9RT7X_65O\2OM.M7<6KI;WVJ^&+7X<MI\MP(AIS(\PO(
MCL.T3LWG>=U3'R5[%=_"?XDZKXO_`&O_`!GX8^,/B3X=Q^$O$=SJ&A:1H]G:
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M>_\`AYJ]K>:#XOM[*2ZO+A(@PN[.6%(FA`.?,C"NF&7&W&3[7\2?^";GP>^)
M'@.^\.:EX2MWTZ^T.P\-NRS3%X[&Q5EM(5W,W^K#M@]3P220*PO`G_!+CX0_
M#;2KV./PU?>([O4]"D\,/?>(->O]3NTTQQB2VB>>9S;HX^]Y.TG`R>!6U2FG
M"?LWOS?<[V7RO_5D323@XMZVM^%KOY_IYL^<?%WQA^.?Q^_:'^)WA_P;;?&B
MS\,?"G^S_#FD#X=W?A^!8[MM-M[E[[41J3B6;<9`$C"K%L5OF9LX^E_@G\2?
MB#\7/^";\'C;6M,TF/XJ77A#4)E71[F*[M+J_A698986A=XF\QHHWVJS!68J
M"<5I?&C_`()^?"/X_P#BL:QXO\.3Q:U<Z='H=W=Z9K5[I3:O9)@16MT;:6/[
M2B@842[B!D`X)%>Q^&/`NF^!_".E^'M"M;'0=`T2WCL["QTZ%;>&RA0;4CC5
M>%`'3%3.+E"<+VYO^#K^/Z=$*-X2B[7M_P`#3^OU9\W_`/!,#X&?"'4_^">7
M@FY\-Z%X>\7:=XPT5+[Q)J6HV<-]<ZYJ4J9OWOY)%9FF$QD5ED/R;0```*Y>
M\C@UGXV_";]GSX*?$&+X9?":+P9?^+A?^$[F*^U'6(;>^%JNG:?//YJ)$CN\
MDK+O8*%4!0*[WQI_P2?^!/B;7-<U0^$=7TX>*)3-KECI'B/4=+TW6I,Y:2XM
M;>9(G9OXVVC?_%FNO\<_L*?"/XN?#OPMX;U+P9866C^"&#^&ET6:71I_#OR[
M2+2:V:.2(,.&`;#_`,0-7/WO?:MY?)Z>B=K+Y;"BK1Y=_/KNOSZZ^>I\L^+/
MCA\:-`O_`!)\%]*^,)O?$GACXK>&?#-AX]DTRUFU`:9JMK+/+:7T(3R)+NW"
M$;@J[@T18#D'6^-MCXN\,P?M.?!C4OBUX[\3:);_``A_X331M8U".S.LZ<[K
M>07-F9DA5)+>;R%.&CW*)'"L.,?47PU_8D^%?PE\#:'X:\/^#[.PTGP[KZ>*
M;4M<SO<2:HNXB]FG9S)<3?,<M*S9X!X`K=\3_LY>$?$_BOQ/KVI:1%?:CXL\
M.'PEJTK2R@W>DEI&-L-K`*,S2'<H#?-][I6'L[P<;ZN]_3D27_DVOGN[MV-*
M<XQFI-;6_P#2[O[XZ>6VVI^?W[,&B^/_`(1_V1!+\:?B)J7@/X:_`[0O'XT.
M::U$NO:E*ETZ6+R^072S$4"Q!$^8_+SGD]%KNH?%+X??L;_#K]J34OCG<^+]
M;O9M(UF[\+26EHGA/4;75)X(FTK3T1!/'-&DVV*7S'=I(SN')Q]L^`O@IX-^
M'NOP:KHWA>2UEM-!L?#\=V6=P-/LMXM;;8['(C\Q_FQN.>2>*\Z\)?\`!,WX
M(^"OBKIWBS1?A\+>]TO4I-:TRPEU&[DT;2;YSEKJVT]Y3:PR9)(9(QM))7!-
M=4Y\];F7>]_^WF_1W5EKVMLV81BU!+K9?^DI?+6[TWO?=(?_`,$];?[!\//B
M0J3-%L^*WBH`2>GV\]?>OKOX?MOU74VR&#)`01T/#UXUX*^&^E_":SOK'P_I
M*6%OJVJW6M7D9F>1+B[N7\R>7+$D,[\XX`[`5[+\/_\`D*ZE@`?N[?@=N&XK
M&2M14>T8K[N5"K.\[OK)O[[LZFBBBO/`*^<_BI_P40TWX>?'_6?`=GX2\0Z[
M+X3DTU=?N[:&0K9B^VF$Q!8V63:C;GWO'@`A2QXKZ,KQ[6S\(OB=\?M9L=6T
MK1KCQGX!73I[RZO;7RA&;HEK,&5L+,=T654[MK`8`)%`'EU[_P`%'KZ[^'&D
M:U>>#KWPS:>+H9+G0+J'4;?4);A8+^"VF66+"K$2LP8?,W&0=KX4U/'/_!2C
M5/"6I^&O$MQX3DM/AYK.D:UJ5HZ7<=U?ZP;::U@MU\I0#;EGGR1E\!AN*L-M
M>@?"3]G/X$_!7PC?Z;9#P;=?V6!9:M>7UU;R3QMYYN-DYSB-C*F\C"[FC!()
M7-/\5^'?V<_ADWBSQ9JD'PWM'MK2;^W[EF@E:"WNF7S1(@)*),Q4L`H#L02"
M>:!G%2_\%-;Z.;5;7_A5VN?;O#FDZIKFL":^%K#;VEC%!*7B:>*.24R"X15'
MEKAE8'`&X[6D_M^ZM#XS33=?^';Z'9PZOIFDWU[_`,)!!.+0ZC;^?;2!0B[@
M!Q)R-G52XR:Z_P`-^'/@GX3TB]L8['P=HUI.+G19/MSPQ?VG%<"$S('D;=-'
M(#""<G=M4=A74W?ASX:ZMXLO=)GA\(7&N(UOJ-Y8N\#72_9T"P321YW`1H0%
M8C`!%`CPOPI_P43U#XI?$7PUH.G^'O[`>\UK1OM$LTINX;[3=1M]4>,Q/LC`
MD#Z?RR>9'@C:[9./K&O'_A-\%?@CI%_;:IX-TKP*US!AH+K3I89V3[-NQM96
M/$/VA@!TC$V!M#8KJ-$_:8^'WB*'79;3QIX:D@\,WZ:7J<S:A$D5G<O$DJ1L
M[$+EDD4C!P>0.00`#N*^<_V\)+NPU'PM>6VD1:LEL9MZ;`9<'9PIP2.,GCN!
M7NL/C[0KCQ*-%CUK27UAH1<BP6[C-R8B,B3R\[MN.^,5X7^W9;P:IJ7AFR/V
MQ+J5;AX98'VX`V!EZ@\ANWH:Z,+_`!4=>!_C(\,TW51J>L6T*F80B97CC==L
MZ\\*1U!R3^7M7+_&/5]/^)?PV\;Z%%J%I83>(IBEO=L^Z2T,>Z,GD_,QRIP>
MNPCN*6/5H/A3X?U+5)XHYM4O9?[/ME>;9Y80LF]2Q7#R,'(YP`IXS7.?!K]H
M#P3\:M(OETF".\MK'46L',FGHJW,F567[+(J*6V,R*Q(4@G@L,U[<8M/VD4[
M+J>_/EE+E>ISG[%O@SQ!\%/@OJ=CJE[%K%TQM(P9E\M-0N$@D2281I]UF0KD
M\G@`YX->I^'O$=KI>GRZQ<0VSV%O;_;)EN[LVUO8Q[RB%W4%FDD=20@&0-O7
M.*P_B-XNB^#>H^&O#-A!!IHNH=S&[1FF24!W8`C@,0H4;O05D_$S53X]\*6>
MH3V4DDT<]M>B%'\E?M<(($;D$*W!!`!P"0>U:M2J2YY:*3#V:LU%'<^"+KP_
MXX\6C5&T_P"S.US%#+<VNHAXK21B!&9(V`;#-@9Z$DBO,C^TWJ^L?$B\>/2M
M!G;4;N>WBTC4+E4O)K6V?8TR?,"%+!L%06R>1A<5H_`GX;GP?JEKLBU&&V$C
M3WL-Y>-=7(BBD^T"-G8D<2JJJ/<]*S/$/P`\.>*_&=OXCU06EOJ-I;,+B\2=
M862#S-[Q9^_DR,/NXRS'FB*I1J/FU70T]E+EU=CUWP#\2;+Q]J.HZYI-MJ7]
MGS65M->6UQ&#+#/^\7RGVG:2#M"D?>`STK(C\,ZEX?L;G6-9L3<1V5K+<(+M
M"Z02;<H'7/`ZGD#.TU#X9\1Z!9>`3I7A,VTJZ8YE1[8M\DC'!ED)P7("LJN.
M-J&J_A+Q)]IT^20:6NF7VGR/8W%W'%(/[4C,9\Q)0<F3<<8))P1GUKGY91OR
MK3\;$6M;E^\YRS^.%QI_Q0N?"^NV&I07JK"MI*]T96F$F0LK(5\EHF!X$9R`
M22.*Z[PSI&G1>);BPT>PL=-NMW[Z2<R,LAV@MY8SR,Y.T<"J7AGX+)I^JV^M
M)),D5O&\,/VXB:.-=H";1C<6&6Q@=,#-8&H_'E/`_A^#4HI--LO"4T\EO;S:
MK?O!J&KR*<2211HI,,()PN<9.">*V<5-\M%:_J7.]*-G(]#^+%U9^`O"D%W/
M&6AEN6D_>@KNBC4"1BV203N4'T7=BO+=<_:.N]#^(NF7.BZSI=Q<PPP-Y46V
M[BOQ(PWQ20G(4*F=Q(!)9=A)&*W/B6=5^,7[.VHM\+K@Z%J?B%(#I,NHP+(@
ME#@3%2V`^U0P#XVMGO77>$O@EIOPOURT'V73I=7NX8X'O([0!XY=GSW`*KMX
M&[`Q\I-90G3A%\ZN]5;_`#,G2C.//)Z=CU_]C1KO3?&NFV]Q!';27HFNG1Y_
MWH06ZJ@$?\*_>///2O2_V5_^2C_'+_L?C_Z9]+KYN_8>^+6I7G[5FF:'-:6S
M)>VM\]P40--9O&"1YDGWF+<=<\D^E?2/[*__`"4?XY?]C\?_`$SZ77E8ZFX5
M+/M<\+&ZU+^1[$D2HQ(`!;J<<GZTZBBN,XPHHHH`*KWVEVVIM$;FW@N/(D$L
M7FQA_+<=&7/0CU%6**`"BBB@`HHHH`****`"BBB@`HHHH`****`"N5^(R_Z%
MG;N/0#&?XA755B>+%4VF6`)##!(Z<T<ZA[S*@KR2/(Y/$KW=G=C2!#?7-N[Q
M;&)2-)EXV,W;'?%785F\E=TFR3:-R(?NMW'K71VEK:Z?YBP6T,2S2M-($C`W
M.W5C[FG;+9WYAC]_EH_M.DG9)G2Z$CF1-/%,N=TG''3*UEZ_XNT+1]1L+'6K
MJ*QGU"0169N'V>?+_<1NA8]AU->@.T#H%\J,C/\`=JEK7A71O$L-NE_I=C>"
MTN$NX/.A#>3,ARDB^C#L::S.DW[R=@5'2QP'Q)^(UM\-=`2\AM]4UR::YBL[
M>QL\/+))(VT98X"J.I).`!6_IS?:6YV;Q@G!SLSU`KK18VGVOS?(AY&"GE#!
M/K0+:S1]RV\`;U""C^U*=M(L?LWT.2NK%9)"A$CJS9#,1A?I4=]&XD7]TT^/
MO.@&['8'^]7;F2%SDPQD_P"[3=\`_P"648_X"*7]J0["]BSS^WU6V:=HHKG$
MZ<&.4E&7MDCKBI;;3IQ+NDN9!R-J[1MS]>IKK'\/Z9<ZC%>SV5K-?0!DBG,?
MS(IZ@'WJ]N@$>WRHL'J-HJI9K3MHF'LY''W375C`7BB6_<,/W6\(Q]<9XR*?
M!K;73X"O$8^"K)C'UKJVN(XF4K#&3G&=@^6G*\.[/EQ9.<_*.:E9I3ZH7L9'
M):C>RE@8I(SR#M<<8]CVIRWP+!95<NIR#V-=+=6L,\)"+!&^[)8H.:D8VC.J
MF.)SC(.RB.94UT8>Q?0Y6ZU22,`^3)(KX4JJ@GD]@>U=_P##[_D+:GQCY(./
M3AZR7>#C$,7'3*]*W/!K;M=U(\#,5N>![/6U/%QK1DHKI^J.:O!QY;]_T9T=
M%%%8B"OF/XA_\$_+SQ=^UWJOQ>M/%`MM4\_1Y=+TZ6%Y+%1:QS0W(N(MVV1W
MBG;RI0`\#@,I/(/TY10!\6^`/^"3G]@:SX=_MG6=,UK3O"M[9M$+M;F[?5[>
MWN_M/^D1RR&)9"0I^56&XNV0&VTOB?\`X)C^*/&/B#Q-<W_B?PQ)'K.E:WI<
M1_LZ3;_IMW%=02-`&$*>4851@@R^2V[/%?:-%`[GRKJ__!.-_%'B/X@:KJ>I
M>'YKGQIH6M:9;)_9>]-)FU".S42)N.<1FU/3!(8<C%97C'_@FCK'C;2[WP_-
MXET*RT:34=3UF'6K?37_`.$@FGO;6>!K>>4OM>V4W#9'5XXHHSMV[C]?T4"N
M?(?QE_9$\8^*M#T>W@L_#&D^)=8U]+:XOO".DK8V>EZ-+:"TU%9Y'<22/+;;
MO+(!*2QVP`Q&6J;XD_\`!-N\USQ?J>I:#J>AZ?9'Q`VLZ?IB13V4/ERZ5;Z=
M)#,T#`GRQ;*\9`Z2RJ1\VZOK:B@#Y8^"?_!/S5O@K\9_#FN:?K>BP:3HB0BY
M\F"X>XU,)8"T".D\DJ(PPN)XV638BHP;ECH?M\:1)?>*_!=RLKHNGK=3%(VP
M\AQ&,?3!.?PKZ7KYT_;GU6WTGQ#X->=S$K/<(SGE4#!!\P],D=JZ,+?VBL=6
M#?[Y'SI\>?#.EZ_96,DOGOI-K;1N,2`/;7"RE]Y8`<#)Z_TKF?A;\,]*\#:?
MJFHZ8]]>ZM)#L=KB]#M8JV%&Q,#RU;<A##(;.<Y!`U_BE%H^IC5O!&OWVMZ3
MX7\1V@\K5](<)=:3(ARDJAP0Z\X9,$$5D?!/X6R_"[QWXJL]4N?[<U.?1(]/
M:^BM4C-]"DHDA?*Y#MCYN2/E;```KVHSM2Y+OOZK^MSWHS:EH9O@?P9XA^)$
MD]EXFN+>:?S;C-S9R3I]FT_<XBC<R$LT^TD,>Y(QT-=]X&U+POXGL1X;6YDU
M1K.Y=[B9+A"+$C;&A\O/F,B\*S8[EC@8IWAWQ=!X/T'6WOWDWV^K6D6I^2H;
M-N95SCGD%1GIP`>^:\FT?]E&?P;\>O%VL:/KU]+969GN+*W"`Q*\L1"^45PH
MA(;>V068XYI\ZJ<W.[66@WSJ7)'8[+7/%%Y:ZP]A8-LB^VM80K<1*%=\B,SY
MSESD\#L%Z5YG\>OA=XBU#X9WDVE:M<:#=V&KVME/K4=F;J2SW2G,RQ<EC\@&
MT\#<#7J-CX'M[/XP6][=O-*BW`E4.Y>)`"/GV'N"3VKJO&5]);R:_'H\L45U
M;?;=8$FX@27;JZQJ"<_<!7GU.<<5HJ[IM*FC2M4VBSRWX*^(?"WB[XEZQING
M7`T@W&FFUE@N-SRW,V\RW%V=^?*+G<J0X&XLQ`6NBM_#VHSZU(7E\O3;0!E:
M9P9/*7`8QH<EL$$#/89Y%>>_"OP%XH^%?AJ[\<ZHT:W>N7=MINEQ:@8GGT>)
M][2W$OEC:[*.$/4@Y;;T;L_@K/XMUKPSJ]_KM\QTR_NIO["6;.ZVM6&QKJ8@
M#]Y,-J)&H^50Q_B`JZRBI.<'IHOPU,Z4I*/)_2.ZU/XBVWB&\6UTJW8008):
M:1GD`&<%VZ`XW`+CHU>+ZSX6^&VO^++@:E]LU^:S:28:9<WXCLK59"2Q:'(D
M>,[.Y"D+@#!Y]$^(^K0>!O#`L;.PQ%=H$_?-^]DSP6(4Y4#/3[WK7._#3]F[
MP8+J[\=ZEI\-C>7-JJZE<ZI-(B7D$9P@*QC>5Z#!QWZU$.6G#G5U?:VYM[EK
M]CJ[ZP@\EKG5==L6MM3MH?(BCG:V\F$9V^6H3;'M``"\<5M:5H-MI5_I<,$Y
M:R2%TB8S%-BR!E=AS\V=V<].HQ7G7Q4^#3_&#3GN?!VK>&!]E,;2P6_FQQVP
M20%1M^1\$`J.H^O2NS^$T<FK^`YO#&J7+?VG;2_:;25R<VDF<E5)Y*\C'J.W
M:LYQC[--/7JNQG&JFN==";]BOPOK_P`&?VD=7/V&Y\4+IMIJ%WID%O>A[[4@
MZ!A&!,52/)4!0S!1NZU],?L(>*K_`,;:G\9=3U/P]JGA2^NO'CF72M1DADN;
M7&DZ8!N:%WC.0`PVL>&&><UY%^R#IOE_M?0W+W%I-,=/FA_=L=V$C`.,X)&<
M]1QBI/B!\5];^$OCCQ-<:+XBT;PO_:_QR@TV]O=7#&P$#^&[9BLP5D)&Y$(&
M]`6"Y8"O+S"3E53?9'BYE9U=.R/MFBOASQ+_`,%2O$&@+I)\CP=,;:^M[;4B
M@D6#5X)=7?3UO;*629,0-&C3+M6X/&&PN':Y:?\`!3#7X&\06>IR^";34OM=
MO#I+VT<EY:11R7KV^9)EN/+9MBA@)FM&#E@5`&:X#SC[7HKY9_89_:J\0?M.
M^-];U/5)H+>W3PG92FPLW#VD%VFJ:S:RRI\S8,BVL)*[VQ@#<>I\N^#G_!1?
MQE+8_"GPZEUX<UG4-=M-%T74)=55X[PZC>Z3]K6YD;S4++YC0@K'`ZD2,/-5
M_E`%C[WHKXI\0?\`!2_QCJ&@Z3?:1X6TK2[+4+QM$N;_`%3_`%6FZK:6C3:A
M;2"2>W0A9RMNA\P$M!<'#X5:]<_8U_:.\:_M)ZGXAU#6](\/:!H6DK96T-I;
M22W%[+<S6-K=2,TN1'Y2^>RKM4EA@DKC!`/>J***`"BBB@`HHHH`****`"BB
MB@`HHHH`*Y7XDZ[:Z%9VWVJ=(!>7*VT18X#2-DJOU.#755\X_P#!36"74/V=
MA;6LZ0WCZK;-$QE$94AB`0Q(P<D<^]5"DJC]FW:YZ&587ZSC*="]N9I7>R/-
M_P#@H7+JFO6OP[\):(^HWNJ^)?$#[O#]IJ1TMO$5M!;2230M>#F!4RDF1][;
MM[UT?_!/SQ'>Z_\`LS:=;ZIJUWJ^M:#J-_HVI-=-YDME/!<NIM&D_P"6ODJ5
M3S?XPH/>LWPE%X%_:O\`@GH.A^/)[/4]?T6-/ML4]RUEJ.GWJ@HSJRLKHQ'!
M93A@?>O7OAC\.]"^%'@VTT+PO86FFZ+9;C'#`=RY8EF8MDEG9B26)))-1BL1
M&.#6"DO>C+>WF^M_3ITW>QE4RZO2QTJL]K6Z_P"7SO?;HCHF.U2<$X!.!U-+
M;2F>W60J4W=CVH5O2G@EAS7AG4T!)%-+&E6,"0MD_-VQ2,K9Z'IZ4(0CS%`#
MMSDXXI67<*K:MJUIX?M&N+^Y@LX%&6DGD"*,>YKQ)_\`@H5X%M/&#:;<?VC#
M9B0QKJ1B!MV(.-V`<[?>MZ&&K5E>G%LZ:.#KUDW1@W;L>ZXHQ5;1M:MO$&DV
M]]8W,5W9W:"2&>)MR2J>A!]*M#(7O^76LCGLQ-I_#THI<\\\_2J6KZY:>'--
MFO-0NK>RM(1N>:>0(B#U)-"U=D"6I;:DVA1P`#ZUE>'_`!SH_BW3OMNE:KI^
MH60.#-!.KJI]"<\&I-0\7:5IWV<7.IZ?;_;#BW\RX5///^SD_-^%/DE>UBG%
MWM;4ORG;%\QQQUKH?`?&J7_);]S;\GOP]<C;^)--U.?R8-0T^XDSM*1W".V?
M3`-=9\/[A;C5=2*]%C@3D8Y&\5Z6!32G?M^J.''1LX>OZ,ZFBBBN@Y@KC?$W
M_"P/[3UO^Q_^$.^Q^3!_8_VP7/F>;N7SOM&WC;MW;-G.<9[UV5%`''M_PGW]
MLG'_``B']G_VIQD7/G?V?Y?_`'S]HW_\`V^]4H_^%G?V:N__`(0/[9_9\^[`
MN_+^V[_W&._D[/O_`,6[IQ7>T4`<;-_PL'S)?+_X0W9YEGY>X7.=F!]LS[YS
MY7X;J=!_PG_VJ+S/^$/\G[3>>9M^T[O(V_Z)CMOW?ZWMC[M=A10!P4W_``L[
M^RVV'P']M_LN+;N%WY7]H>9^]SW\CR\[?X]W7BKK_P#"?_VLV/\`A#_L/]J1
M[<BY\[^S_+_>>WG^9T_@V]>:["B@#A;7_A9?V2/SO^$&\_[)=>9L%UL^T[C]
MFQGGR]N/,[Y^[7+?'OPO?:[#X:EO=&TG5]2@MV%U\VV"-SL+^7O!.W(.,]NM
M>QUS_C:%9'MRQD'4?*1Q^=5%V=QJJZ?OH^;=;\%P^(K2&WN/!=B_V*3"98)]
MF3)XROWO7TYJUIG@Q;&>X;_A&HX[FZ<%FED^1#@*H/.=I3'!!&`!4WCSX\WG
M@K]J7PMX*M]$BOM(\0(8+K40H62PEVEU#9'*$#J*]G73HO+<>4IC(P0Z?2MY
M3:7J.69S2/!M2\+7E]IUU!'X=T]K?S%4IMA$9?<3D@\C;V!!^\<5<;X(V&N6
ML]Q'INHVMW<.6=%G&P@XY"XX`P``.@]*]>^QM;[]L2=-VSKG'X>G3FBXLMQ6
M=(XMY4861R@4?D:%4:V)EFU31Q/%+/X&)I^HR3O8ZK<W32@I*YB9&^[R1U`7
MGUZ5JV/[/MI"7FGT^/SI"P9F;YLL3GG@9.2<#UXKTQ[B]@ED,2:>ESCY=\[N
M&7OT7/\`D5X1^TY\"OBE\>XO[-L?&Z^%=`W9%KIB&.ZG;KEIOO`9_AZ5K2FY
M2M*7*N[N;QQ]6J[.229L^./V>-`M+*S&J2VUM!:_/_IESLA5B""</QGT)XXZ
MUA7'AOPCXK81Z+XDL;BZLU%O:RV@2Z%DI[J?NA^.3G)]:POA+^P7XA\/W"OX
MN\96OB"*.0`"YMC-(Z]<%V.?3^=?1O@7PW:>`/"ZZ-IA@FAB;>59C$2Y.3[?
MA3JS44E3GS?*WYG1/'^SC93YF?./B3]FR75[T175Q+J,VQF2;[.&1R.>#G:"
M<YZXZTW2_P!D!+O4S=7%T#)]G:)R]P&:-2`-H51\I&<8Y`/3I7TYK^DW6IQQ
M+LD43R+OYW@+W"XQ@U8C\&Q6L,:M`L,<).0Y5?E[\_KR:7U^JDE<3S>:C;J?
M+UC^S]X8\&6'F1^)-'L]7C7R);J82NSJ"1M9CM`Z'H.<9ZFIK+]G1FNO[4GU
M*/4@\(DM5AAD7<,;AASSN[@FO</&7Q&\`^`K6;^UO$&@6(4;MJ3!W+#VCW'/
MX51\'?M"^"/B+>&'3=>MKU9"753:742OSP0&C'(Q^G%4L16M?6W]>0?VA52O
M&)S?PD^%&K:-XL>_T"\L8O%']FW,5M<ZG;B6V-PR?*TJ1E7=`>NU@3SS6_\`
ML+Z+X@N)?C+:^/)O#NKZ_P#\)XXOI-+LI(;"7.DZ;MV13/(P^0J#ECDY[&O1
MOA[=Z7=^+5^R0W/FQ1NOF26SH@Z9"LP&<Y[>E<]^RO\`\E'^.7_8_'_TSZ77
M)6FY2NSDG6E5?/(]6G\-:=<^3YEA9/\`9XS#%N@4^4G'RKQP.!P..*1_"VF2
M172'3[$I?-ON5-NF+AAT+C'S'ZU?HK(@@M=-M[$-Y,$,.[EMB!<]^<>Y/YU6
MNO"^GW;L[6=N)C&(A,L8655'*@,!D8/(P>#R*T**`.;\%_"3P_X!\"P>'-/T
M^,Z3`[RF*Z9KIII7D:6261Y"S22/(S.S,22S$YKHDA6(DJJJ6.20,9[4ZB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`KY%_X*\Z9_:OP&@B^[NNHOFST/G)
M7UU7RE_P5@9F^`ZHOF;C/&P"=6Q*O`SW/I7;EJ3Q,$^YZ&4XB=#&4ZU-V<6F
MCXE\'_M97.AQQ6?CSP?I'CVPMT6!+J2(0:G&BC`_?KR^!W;GCK7L'@C]N#X*
M^'M-/]BW?C/P!>`;A$(C=K*1VPS,ISTZ"OG>'35N-/MYGB>-IH\LB-\R>H)_
M*N9U_P`%>']9LVN;[S[4,?*69G?>C9P,#G%?38C)*%1Z-KYZ?<?H=7'X;$*]
M:E9_W79?^`N\?N2/I_7/^"I?BKP=)%.^G:*VG7X9K)=5E6&ZEC!P'*1G*D^A
M'-9\'_!7#QG-,LIT?PPMJPSL02D@?7_&OF/P-\*QX8\2_:0$O-H`2XN!N,?N
M*[&6T?5(KJ6UE?45C!\VW15+HP[=N?;WJ'P[@]FCG6)P,';ZM!KSYK_@T>R>
M/?\`@JC>^*?#[V@FU71//(!N+!H(G&.H5B&/Y8-<';?MO^-=?A5;"_UV9D)$
M4SZB[L?<XPI_*N.;P7I/B6"&:]LTLI=@+>9&`^>F,^HJU%H,&E2_9K1)_LY7
MY\*#D?7KCZ5I0R;#05DOP1OALSP=!WI86%O-R?YL@\9_&WQ5XOO!)KM_J5VL
M;[=U])*\4.>I[C'OBL__`(6N+O2);--,-Q.7!4L&P#GJH(&0<<58N9[?2YXQ
M%%!;1;]C3JXD*OG(RK=?I4VL^'_[;E-Q<@W-Y)R;J.%;8#C'"#C!KH6`AMJD
M>O1XUQ-.\:=*FH]N6WZFMX)_:I\8^`+)+/1=4UO24ZK`LK^5&2?X49<"FZ[^
MU_\`%?P\SWT_C>>Q@9M[?:[MB,COLQ_+BLK1=*U31S-'*L$D,O\`Q[M)(YV>
MQR:LS^`#=6,S2/%;S21'=%%<[HY/8ALX_"H_LZC=MJ[\TO\`(\[%9U2Q*;GA
MJ?,^MK'0>,/^"@?COQKX<@TZ\\7NT4X!?[(H@EE_V3LZ_48S6!IW[1;Z_:I:
MZYKNJ36B?=B*B:,\8PV3D]:X'3?A3!9:C<>1"MIJ(W2[\EHV5A@G>1PWM6YX
M2\.12V)1E5%7_EJRK(\K<Y!R!@=,$5<<NIQC:-EZ)!A<WPF']VEAHW[O5I^6
MB-O3/B%I6C,\%MK%]:0,^2J;XLGH"5!P3BO2]9_:&M/''@_PYHM[+X<U"/P[
M$8[-IH94=0?0C!5L>N>E>/0:/%:W[E=+:4!L"8S1N![G_"LO6-$U6?43Y,D`
MC#[MB2JN5_W2.:)9=&6M]4=E3B'"U:GM*V'5_+?UV.YU768M"O([S3GETR>!
M_,6:RD?.0<Y]>?>OU*_8V\0W?BSX566HWUS->75Y96\CS2_?DSOZU^/^MZ0S
M,GD7E[;3XSB!2%/U4G^5?KE^P>Q/P,TC)D8C3[<$R##9^>O-S;#N%!R>O_#G
MSG&N9X?%4*,:5/E:EOI_*^O_``#VRBBBOE3\^"C-%?,GQ+^#OQ%U;]J36M:G
ML-;\2>';N;2F\)S6'BMM)M_"?E;1?-<0A@9O-8;L!)MZKY9\L,30!](:YK]C
MX9TUKS4;NVL;1&1&FN)1'&K.P1`6/&2S*H]20.]&B:]9>)=,CO=.N[:^LYL^
M7/;R"2-\$J<,.#@@CZ@U\3R_LI_%OQ#HJV$]AJL5]LC/B:^U'Q1]NL_%UVFK
MV=Q%<VT!=A;K'##.PRD14.L05@`1DQ?LP_'?PKJ/A*+2-/N]-_X1J]LI(KRQ
MUY6MUM3>SRWBO"9U7<4E7*"%_-50#("`M`S[Y!I,U^:G@#0/B;\:=7N;#P/<
M^*8&T[PUIR>+))?$ES>1:_?+J*F\"":2,6UQ-$DAV%X7V?(PB!!/INE?L@?&
M&]\)ZS<WFL>)SJVGZ-:?\(E#-XG>'^S;Q-5NYF61(YFC8K:O`@,CRC9^[+.`
M30!]OU4UW7K+POH]SJ&I7=M86%G&99[FXD$<4*#JS,>`!ZFOCK_@J)K^M>'=
M7G\A_$%ZFH^#-0M_#5EI.MW.DSV>N!\1W*F+'VB4J\:I&"SKL;$9$C,.2\1_
ML@?'?QG9^,;74[_4M1N-;TS5+<RS:E&MAJ5O/;[;.T9&G8JT3%03Y$>UHW;S
M'\P@@'WX#D5@^-)&CDML;?XLAC@-TK=A79$H/8`5XU^V!^U=X6_98TW0[OQ.
MNHO%J]R;6$65M]H9#Q\S+G(7D<^I%7",I2Y8*[,ZD)3CRQW.@\6ZAINGR6UW
MJ5G"7@.89C9-/+`<<X95)%5M$\=6/B"?RK,WLPD&Y9C9R1Q`>@9@/UKYDU[_
M`(+$?"_^UI+/1-*\5:Y?V[!)7DT]X(83D#<'((?&?X?Y#->P^"_VK?!7Q"\.
MP7D$VIVR2K@Q2:=(F"#\P#(".V<GJ,>M:SPU6DKSC8SGAJG)=P=STA;^&=WV
M8=$)5N"""/KU%,M$'D_<.6&W*Y(%<YIGQC\+WZKY.H--*^3M_LZXSQU_Y9\]
MJM:;\5_#NJ7CP1:M$EY:_++;W"/!,F<$?*P!_&LT^QQNE4ZHWO(6X0#RD5B"
M6).1_P#7JGJNGRF,?9KQ[<L,!D52<],\@_E[=J73O%VGZFLC0WUF?+.&S,F`
M?S]_K5R>2&9=^\/_`!`IT(_E09VE'5'DGQ4U#XK:3=6MIX;L[76ENW\M[JZM
MXU-L.F\]O8\=ZZ?P?\,_&5I")O$GCZ]U"[D!9]-M[.W%E$3U`)0N<<]Q7:I>
MPL=Z'*S=\\#`J1KQ5BR-QYQD#./>FVVDK6^1W/'/D45%+S,Q/A\C)F21B<8W
M`LHQ[@'%3Q>`=&1=LFFV\V[KO!;^=:'G&YAR&*9'4$&DDF*N,9Z=JG4Q=:6Z
M9E1_#GP]!)F'1+"(QL'^6`8!]>G6K[V5O#<JJ0[2I[J``?\`ZU5M4L/[6MC`
MTTT2LP)VN8RV.V5(/ZUDZ1X5DT^=S%>7@!'&^9I0K<]F)_*GON7S3E&[F=UX
M;9?[37:H4E2"1WQ7GO[*_P#R4?XY?]C\?_3/I==EX1ENT\2I%*D#Q>6W[Y05
M8G`[9(KC?V5_^2C_`!R_['X_^F?2ZAZ&]"_*>R4444C4****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`KY7_X*UV-M_PS5;WT[S)]DUJT&8X6E9E+
MDXVCW`Y[8KZHKQK]M+X,0_'CX5'09]6O-%4W45PMS:J&<,K<`@\$'/-=6#JQ
MI5XU)NR3-\,[58L_*8?;['47N8XFNK9YBD8M;D"*TC/>09^<_3I37U,>&=.C
MGDFN+TROD^3:[@V3CH.1CUKZ63_@F'?:7'!;:/\`$BSFD0.6MM6T[:)"W3)1
MN=IZ"LV/_@E7\1_"B/?:3XL\)7VKL`9#<P3+%,P4@?*<A>OZ5]9'/,"]ZB^Y
MK]#Z98J"T;/#UTS[+&]Q)<W#LGWD7E3D]A5G1M:CM+*0DP6_[TY;A"Y/0GGK
M]:]1L/\`@G!\9'FLS=+X3G:.`P32_P!HLFW/=0%Y'7KZU<@_X)6>/KSP\+2.
M[\+Z?'9R_:(('N'G\Y@V<%MO`/Z54LUP/6J@^M4[W/'-2OCJ-G]KDN7MC9RL
M7$:B1;A5R&7Y@.<^GI6'?:JEEJG]IQRW$FFW,2B5Y"_[O)`78@'!^M?4FA?\
M$H_$?BG37C\3^*]+LHY%*^38QR3-&"<[=Q*C'`YZ]:DU3_@E%XJTX)_9/C[3
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MRC9GFAO52=W9H]N5;C:`>0,<5!K?_!(_0=4#!/'GBI5?;Q(D3A-O3;P,<]:G
M_67+^LG]S(CC8)W/C+4$%G>&#[3'9O<H)+=AQ+,V?F&T\8I);F>22\63:L,4
M@DBDG5=BIWP5.?Q-?64__!(Z\6_DN%^(]U<RO)O$ES8_ZH;=NU5W$8^F/QJK
M)_P2;US3[B9+?QS87FGSQI&8;FP*'(SN?"DC)X_*M8\0X![U/P?^17UR#ZGR
MRNIQ1:E<6NU0?LWVAI(VXQC.-N,M^&:G-SIT&BP:CYNVV(W^8X(?TZ$9Z]J]
M?^)G_!/GXH>!;RXGL[32M=L-,@,MI-ITY2<`+\R-$>6)[`5YYX7_`&</BSXJ
MMQ=0>!/%-I]J\NYD,I'E3Y;;L5)?FCPO)X%=M/,,-4CSPJ*WJBUBXVT.3U#5
MULYD>2^NOL,[[X_F#B3<!@8Q\H'7@U^MW[&MM%:_!_1A",*^DV<A_P!HE7)/
MXU^3'Q.L+WP#JYTJ_CGTVZCNA#);WT#&5`1QRH``)Z'WK]:/V-UV_!O01C;C
M1;$8/;Y'KASUIX=-;?\`!1Y6<2O&%MK_`*,];HHHKXT\8*^:_CQ^W\?A%\=F
M\*66CZ;J]II.IZ+IFMRK>R"YLFU2>.*$E1%Y<>!)O`>3,@!"@=:^E*^>?B5\
M;?@Q>?M1S^"]6\,:'X@\=Z=:6<]]=3Z=9N]A'<7$$5LC2S%79BTB,%3<0!ZE
M00#B=+_X*1^)#HWAVYU'P7H%FWCRR6Y\/!=<=HK=CJEOIV;Z0P`1INN8I-R!
MN`4QG!/2_#[]KSQ#H7P1^,_B_P`50Z3JUUX`\4W.E6UII5XK6B1I;V>U/M&Q
M2$$DS,[NNZ,%@<[*Z3P!^T?\"?C-\+'U.+4?`\>B0:9MO;/4Q:Q?8+2:55:*
M:-B52-I0@9?N[PH/.*L-^T#\$OA;\/\`Q#8Z-?\`@S^S=)TF?6;[1-%6VW3V
MRP"24B!<*Y,6TD'G:1GB@9XQJW_!0/Q[X`^-7BGPG?Z)H/B+6#?6=IIEOHUU
M+=:?8J-.:\G+R)#YQ=_E`1EX`+9VBMWPU_P4-\9?$22WDT;X>:/9VE_KVD>&
M[;^U-?*S+=WVF1:@S.L4+J(X5D*_*Q,A`(QFNSL/&_[/FH>#-&TW2='\`:IX
M=\2:RE@UO8:;9R65K=+:3W2R7*`!4`A@E(<@]>."375V_P`>/@Q9^%TUJ+Q%
MX"BTJ+4$1;E9;=42[CA`0CT=8`N&[1@<[:`/&=#_`."DGB$^&M-O-8\)>&M.
MG\3Z;)<:'%%K4\_FW4.JP:7)#(%M]QWR3K)&(U9B%*D*>:Z;]DG]L'6_VE/C
M$D-S!#I.G1^';UKC38R)0E]::S/8/*LA4.%9800C8V[L$9&:Z/4?CO\``+Q1
M!XIT35+WP&]GX0O4T/4X-0MH!;QR3Q1WPC0.NUT8%9"5R-T3$\ID>J>!_`7A
M;PM:1W/AO1M`TZ"ZBW1RZ;:11)+&Y#Y!C`!5CAN.#UH`Z"N-^+/AVR\0QVR7
MEC;7H"MM$T88+T[GI795RGQ,U,:<+7(?#;LE5W8''O0S&O)Q@W%V9QVG>`_#
M]C&B1Z3IL:H,;4@''L*T!H-BDC!;:V4/\Q58PO-+;SBZ^8+.GJ9(]H;TILVK
M065YY,K^66^[D':WT/3-$;M6/.^L5K_$_O9:G9UE'E-Y3;2N5/0=<?2JBZ+9
MZG&9);:VDER5:3RAN8CODTD,BW<7R.3GDD':0,TZZTNUU546X7S`AW+N/!/T
MZ'\::5MC/VT[W;9!<Z9I\]F8IX[*3>V!N179_<^X'>IK?R[2R$%H(HHH,*BH
MH&0.W'>B6UMU0K#:687/41@8IAL>%*(@.W/[HX&:T6UQRJ7TNR2YM]]SAD!C
M/SD$G@5+9HQ60F$Q\G&YL\'^50)(+>5%WMT(VG^(]J>9S<NVUB,D]N!5;[@G
M?8;J.NG2K9F^S75P^/N6X#;?Q)`K-D^(2?8]TNCZ]&C84,(5D!_`-FKD-R@E
M[ELLJDJ2N>W3VK074&`574*",=#C']*31UTW"*U7XF=HOC73=3EVE;^V?&W;
M<VKH#]#@C]:N3ZE;FY"K<KTR048%3V[8J:\\2:?I-PB3WEM:/-Q&DL@4OZXI
M3JUC(V(KRS9\Y"F4?RS4=;E3LU=+0TO!MQ%/KR[9(I"(R!L/3U]ZXO\`97_Y
M*/\`'+_L?C_Z9]+KL?!VH6>I^)`;:>WF:!2L@C=6*$CH<=#]:\3\$_&6?X3_
M`!%^)MGINC?V]KWB_P"*?]D:9:27BV4!D&@6%P[RS%6V*L4,AX5F8X4*2:EF
M]"UG8^GZ*^-/`'_!4:_CA:QUSP;?ZCK-A?7;ZRFG%I1IEK_:UU8P)$8HWCGD
M5;=BQ9XE(7@[CMK<NO\`@I5K?_")S:W;_"J\DL(]%UGQ(OF^(;>*633M,G2&
M:0+L/[QRQ,<9/('S,F:1K8^KZ*^7?&__``4<NO`.DZ[%?>!`OB+0)W:?3$UQ
M9?-M%TZ*_P#/C:.%I&;9,B%1%M1S\T@4ASL^$_VTIS\%/C+\0[S39M0T?P%Y
M>I:9IL`2*[EM&T#3]2$+,25\TO=2#<3@9`Z#-`'T317RMJG_``4XC\'>+=5T
M_P`1?#_7+"W\-7'V'79K.9KYM.N39B\VC;"(I(Q&\:L_F@AW.%95WU%XI_X*
M.7/@[7K>T\2^$[GPV+>'3M8F>PU*WU87-A=6]_,%(`4I(!9-D`'DKM9E):@#
MZNHKYGN/V_->L/%GAWPQ<?#0Q^*_%YL9](M$\10R6KVMU#=R+--<"/\`=LGV
M-U9%1\[@49P#7L_P`^+T?QX^$6C^*H["72_[3659;.2596MI8I7AD3>O#`/&
MV&`&1@X&<4`=C1110`4444`%%%%`!1110`4444`%<A\5D5M$R1G$BX^NX5U]
M<;\5X#+I\+B5X_+D!*CHXST-*6SN;8;^+$\UN;2+4!(L@!/)&.J#U]_\:IV>
MK:[X=B.RX6Z3AE6?G=SR#CD']*YS]H'XEV7P<^'T^O:E<FVC2Z@M5\N!I)96
MDE5-J*O+'D\#TKI([J6:+=Y+)S\H<Y./>N9P?+S-:,^ALGHS:T[XL6_V>=KN
MRN8#",[D'F*_'8]OQJR_Q)TZ33I;D>8)81Q`PPSD@$`>O7K7(2:*;_40R2SH
M\Z[67>508[@>I[FDUAX-(EM[4JDLU[*(HD!)WL`203V&`23[5FJ-.^AE]7IM
MFI9:KJFI%IOM\T<KL,Q1X"(/059FU:X21C=W6\1G"&3"^6WX=ZY:Z\)1S,CN
M766,\!6(53[51\+62^$W2UN2WD>?)Y*W,[2/-(Y+<LQ)..<#TK3V<6M#H]C%
M*\=CJH?BS>W!\RT,=U;K)Y9=X&0>_/?ZUJ6_Q)OK6X'VS3,P$']Y"W/UP>U9
M\<JNY:!._3;V/>C3PEC,Q+RNI/S8&0*S<(/H8>S@^AOZ7\5-)U*^EC:Z\C"D
MK'-&4.!R3FDE^+&BB9DBFFN)`WE[8XSDGKWQ7-ZY8?VS,LL4;KM8%9"V"0/7
MU%%GH<7V=VEAB9Y\_.F,CTP>OY5/U>GN1["!U(^)FF&W\UWN($#8/F0,":CB
M^+6AR7#Q^?-$4[R0.@/?C(KCH_"]]J>HL?/6'3(BOEQQ,?-=OXBY/;T`JUJ>
MBQ65R@\R1Q)@`,V=Q^E'L*5QJA3?4Z2Z\?Q&`2V%O+<N<<R`Q*!^6:E@^(]C
M),JS&2U?&3YJGK]17$7.G7.C3^893)$QYC#[&4>WK4<WC&Q34K738)8);J?,
MAB,@5]@'S-@\L!W`H>&B]AO#0.L\1?#7P7\4IENM3TG0O$$UOE%EGB29XLCD
M9Z_G7>_"G2;30?M-EI\,5M96MM;1011#"1H`^`/:O%I/#XG)DM1:6SR\>8J$
M^9]17LOP?@>UMIHY&1Y$M;8,R#"DX?H*[\+S*$US-JWZH\S,::@H6?7]&=K1
M113.`*\3^*/[&EM\3?BMJOBE]?GM'U1M"8VRVBN(_P"S-1BOEPQ8$^88@AX^
M4'(SC%>V44`?*&F_\$RI;WPAX6T#Q!XSM=6TKP/;+::.L'A^.V>2,W]M>2?:
MOWC++G[*B``*/F+D,U:7Q)_X)U3?$K2=9\/S^,DM?"EYJ.L:U8P1:-&;ZTO=
M1@N(I#)<%\2PH;F5@A12PV*S%4&?IVB@#YC\2?\`!/C5?'=__:VK^/Q;^(X(
M+>QM+W2=!BM8H(+>QU"TB)A:1U:7=J$DA8G'[M4"A:YH_P#!+K4&CU>9_&FF
M2W^KW<-[YSZ1=>993)8_8FD@G^V_:4<QX/\`K=IRRLI4@+]@T4`?,'BS_@GA
M?:[:W\:^-+>\:[U"SU5)]1T=OM<%W%I$.ER3I<6T\$D;O'`D@\LJ,O(K!U8!
M?H7X<>$Y?`7P]T+0Y]2N=8FT?3X+&2_N559KUHXU0RN%`4,V,D``9/%;5%`!
M7)?$X`O8[CA`6R?RKK:X_P"*OW;4%!(K*X*D9R..U".;%_PG<YZX5(`D?FL[
M<GG'//I[?TIBDS+A]K*S?.-Q*GCKBJUM:1V\#,(55NHX`/7_`.O4Z3>8VW:`
M5&3N'6K/-4K>]$L[H@I"9!SZ<&FF\33R"XW9SC`+9/H,4V*)8),@YZD<YJO?
MZQ%&PW/$F#T)`&*&]#&_<SM;\5Z?<+LEL]8F7!#0P:9*X;C)!.W^M5=-^*VD
M:</LPM]6M8H1LC62S.>,#:1G(^M:4VI>7*5AZ<8`ZX]NU&GZW#N<,4:?^+>0
M&ST_6G<ZH5(->\F_G_P"32/$5OXA@\Q;6^BP<#ST`_(`FM6PG\V!@4(*ID_+
MC=SCBL[2[K+LJE/*)SUS@$^M:%K><NN3C.T$<4$72;:V*EQJQL)<-:7)&<"2
M)58*#Z\Y_2M))%8`D]1CD=JC1_WF$1OF/4J:F>3RH]_EL1W^0TVRU;ENB*XT
M#3[V822V\$S]=Q7KBFBS@M#^[2.%589`C!+"JTUQ<"3Y8\J.@R%_*K%L"Q);
M:2?0YQ2Z%QG+X;Z&QX,,"Z]B&.-00S95=N3WKR_X-_#+0/BUXC^.FD>)-)LM
M9TYOB$LPAN8]P21=(TLJZGJK#LRD$>M>B^`UV>*%W8YC8*`:Y?\`97_Y*/\`
M'+_L?C_Z9]+J'N=N&DW%MG06_P"R5\,[.WT:*'P-X:@A\/LS:?'%9(B6^Z4S
M$;0,,#*3)ALC>=W7FMH_`WP<VE_8O^$9T7[(;"YTHP_9$V?9+E]\\&,?ZN1@
M"R]">M=512-SA/&?[,/P]^(E]]IUOP=H&I7!<.TLUHI>3]TL.&/5E,2(A4Y4
MJB@@X%:&D?`SP=H'@C4/#5GX:T>#0-7A6VOK!;9?(NXUMX[95D7HP$$4<?/\
M,:CH*ZNB@#BO$7[._@SQ/XPD\17/A[3?^$AD@,`U)85^T)F,Q!P2"#(J,55R
M"0#@''%<#\`?V`/`_P`"M2O[\V\7B#4+XVJK->:?:PK;I;+,L.R.&-$W@3R[
MG(R=^.``*]SHH`X3P/\`LP_#WX:RQR:#X.T#2Y(;M;Z)X+10\4R1R1HRGJNU
M)9%4#A1(P`&375^&/"NF^"M$BTW2+&UTVP@9VCM[>,1QH7<NQ`''+,Q/N36A
M10`4444`%%%%`!1110`4444`%%%%`!7BW[;OQXLOV<_A39:_?6-[J,5]K^F:
M"D5IMWK+?7D=M&YW$#:K2`MWP#CFO::^.?\`@M]X-F^(/[%EGHL-QK-F=2\=
M^%X&NM)E:&^LU;6+8&:&103&Z=0^/EQGM45-DN[2^]HUHNTN;LF_N3(/CC\=
M=.^%GQ8\*>&K[POJWBSQ-XKT[6+_`$:VM?)"*VFVRSR1#S6`664.$1O[QY(%
M<+X3_P""E7@?Q_H/P@N?"VE:]XDO_C1>26FD:/;(@O\`3!;@F_DO49@(DLV4
MI-U.\JJY+"O*X/V0;C]G3_@IS\!;]_B-\7/B#;ZCI_BJ-E\7:_)J\.F%;.$J
M8R4`C9\X)/WMN.U=O^RA^S5X*^$G_!3G]I#QAIVBC2+R_MM%9+MB1#;?;8)+
MB^:W!^2/SIHHY)2G5E!-81Y;J^O_``&]/GI=]+:'NS;3T6KT^_K\K:+KU+6L
M_P#!0N^\8?$+Q/H/PJ^$GQ!^,]OX)N9-.US6-!DLK#2K2\CP9+.&XNY8Q<3I
MG#+$"%;@D&O4?V8OVC-,_:>^'$FN6'AKQ1X<O-,U"72]0T;Q'ITEAJ6E7<07
MS(V0C:XPRD21LR,#P>U?(O['W[9?@/\`9/\`@#JWP4^('BVT^%/C#PE=:O'I
M7B-M/DO='\1P2W4T\.K6LR(T5Q(?-!EA8A_,5A@@UW?[%WQ&_:.^/_PQ\9^(
M+/QMHS>'Y-?CM_!.M^-?`<EE=:WI*6_[ZZ^QPSQ-%')<-^Z9SDQQDE1NJHQ?
M*WY)W]6E_2>OGHR?:MR5^[T[?UWV^]'LWQ:_;+T[X1?M*_#_`.'-[X6\1W!^
M(4TMK::["]NNFV%RD,LWDS!G\W<R1,040J,C)KS3]J#]NCP_H7Q&UO2_^%8?
M$KX@Z7\';BSUOQ=KGAEH!9^'W:/S5C=)'62\=('\Z2*`,50C/)`K6_:3T'6[
MCXW?LN_VW!I=YJD/CRY-W=Z=:R);$?V)>`N5.3&K/G`+$#*C)->6ZQ^TSX4_
M88^('[4OA+Q[;ZLGB/QQKT_BGPC8PZ5/<_\`"807^F6]I%;V916$LJW$1BD3
M(*;@3A>1$9\O,X_%&]O-^[9?<WMKIZERDG:+T3M?R7O7?;=+?N>D_$K_`(*;
M:3I?B'78O`'PW^('Q7T/P7I%KKGB36O#'V9+/1K:Y@%Q$B">1&NIOLQ\\Q1`
ME4QGD@'Z!\)?$KPSXN^#ECXUM-:A?PEJ.D)KL>J3-Y,*V3PB83L3]T"/D@U^
M;WQF_;*\.?L\_!;X<_LJW?BF+X4ZN_A#3;'XJ>,(]*N;G^PH!9Q1S:?9F"*0
MRZC,F8P[96",%B2P"C[>\:_#72/C3_P3WN_!_P`)H[-M`USP=':>$S/YD-K+
M;B%/LT;;PKA7544[E!^8Y`YK6I!*,FMD[)[][O3Y<MM79^3,*=7FDEY7:V[6
MWU[WOMIYHX%O^"C%S'J43V?@.]GTN^@BO=/TZ_\`%NE:;XKU*RD.([FWT>60
M3D2`J8XI&260,N%!(%>Q7_[27@7P_P#LTW7Q>N->A@\`6FCMKCZE-OB:*W52
M2I1@&64,/+,9&[?\N,U^7'BOQQ>Z#XKGNK_P3\.M3\26WQ@C^(U^VMWTMIXX
MGE4F2VTK[`;629S;2^5"KV[O#)!&OECDD>_?M.?LK?&OX@_"/X=:6OASPAXM
M^'7A72;WQ?XGT35]8?1+C7?$,ZSW$:S6Z13#[-:2RF1("Q\R15W'Y:SJZ4FU
M_7NI_/JNBNNTM'2JR<[;KM\[?Y/J[/O'7W37O^"D$6HZ-X"_X5_\-OB%\2?$
MWCWPDGC==`TA[6*;1M)?A)KJ:>1(EDD?Y(XU8L[!L<*37K'[.WQZ\.?M)?"3
M1O&_AR6\;2-;A:1([Z-H;NQEC9DF@FC/,<L<B.CKV*GFO@K]@G]HR/\`8HO_
M`(?^-OCC9R>!-&\?_!?P]IFD:A&D]]9>;I,ET[6\TBQYBNI8)XY5A*\D.H+,
M.?IK]@WP[J\O[$NJZI>Z++X9N/'&K^(_%-I8WUNT-S9V=_>7%Q;K+&>8W,3H
MY4\@OBM<3"-+G<=4N;\)-)?=^5]F&#J2J<G.]6H_C%-OY-V[:^1]!:GXATN6
MUM;V34=-DM[R15M9?M"%;EF^ZL;9PY.#@+DG!KB_A+\>O"O[36L>.;+P_BZG
M^'7B*?PUJL,R@26MW$J/N4#G:ZN"#WP?0U^<?[+/[9/PS^,WP`_83^'7A^\U
M?5/&OASQKHD^L:>^BW,2:/%:P7:/++(T8B",9$\ME9MXR1T-:_@/1_B)^S'\
M(M#^/OPG\-:EKOB#]HN]UG0?$.F[61K;4[[5KMM!UB9",A+?<8I"1GRWC]*<
MZ;A)VVNXKS?N\O\`X%JO77:X1Q<90BUV3EY)\U_FK)^E^MC[Y^!7[1?ACXQ7
M_C6T\+:M)>K\/_$LOA74Y)G#1"^2..1XXVZE5\P+_O*P[5]2?"QG9KHR`!S;
MVQ8#H#AZ_.#_`()^?LF6?['G[2?Q3^&=I'+J&FV^D>&?%2ZE/$<ZIJ4EO<6U
M_>LQX,LD\'F-W^<>U?I!\+3E[KG/^CVW/X/6]'E49<KOHM?.Z3_&YQ9C*4H0
M<E;WGIVT;7X6.OHHHJ#SPHHHH`****`"BBB@`HHHH`*XWXKJ6-CC=D%C@-CT
MKLJHZOX=L]>,9NX1-Y6=F6(QGKT-!C7IN<'%'E4UUY<8&?,?=R!QCW-32#%O
MYF41V7)`Y'K7H?\`PKS1MX/V)<CD?.W^-/D\"Z5*N&M%(_WV_P`:6MS@^HU.
MC1YO:SQO*K#R]O(.WNPIFIR0JV=B\'DJH[?A7I0\`Z0H/^AKSU^=O\::_P`/
M='D'S62GZNW^-5<7U&KU:/-$N%N$+``IUSGI_C5>"TB0'RE5=Y+9<#->I+\.
MM&7I9#KG_6/Q^M/_`.$"TC:1]C7!ZC>W/ZTA_4:G1H\UBTV.ZBW^5&6!P2$Q
MS^%0SZ';S9.WR7[M$[*??&#Q7J2^!M*1`HM%P#D#>W^-">!]*C)Q:`;N3\[<
M_K3N4L'56S1XQK_@%O%%D8TUW7M,!;_6VMTZN#[')XJ/PK\(X-!OH9;G5M<U
M2:%PP>YOI77/N"Q&/PKVN'P/I=N,):@9_P"FC?XTYO!FF-UM5_[Z;_&GS/:^
MAU<M=+E321PDL)EF&Z3"D]^GXU2O;P1?NH3COC..:]'_`.$*TS;C[*N!ZNW^
M-,_X0+2//\S[$GF=-P9L_P`Z+F4<--.[9S/P^B\OQ##EMQ*.>3R.*YG]E?CX
MC_'+_L?C_P"F?2Z]&U3X:Z1JVF7=JT5W;I>0/;O+9WT]I<(CC!\N:)UDB;T9
M&5AV(K/^#_P-\._`G2M2M/#L6J*NLW[:G?3:EK%YJUU=7#1QQ%WGNY993\D4
M:@;L`(,`5+.FC!PC9G74444&H4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!7-^/K2[O-.VVB[I"V#D\8SWKI*8]NDGWE!^M!4).,E)'BX\"ZS>Q
MD36PCDSAMLJE3SVYZ5C^)/@9<?$32+_2]?LA>Z->1&V>TDEPKQGJ."#@U[]]
MAA_YY)^5'V&$_P#+)/RJ%32=T=_]I5+621\T_#S]D'2_A9906GA_0_[*M;7Y
M(XX;@E`HZ`HS%<#MQFNY;X=ZDI^:*69B,[FE!R??FO7?L47_`#S7\J/L4/\`
MSS3\J<XN;YI-LCZ_46R1XW'X1URZA!;3S$ZMS\R_,/SJ>'X9WNY7D@WNN2H+
M#"$^G->N_8XO^>:_E1]CB_YYK^51[&/0'F%3LCRJ\\$ZDMIB**7TVB4`^OK5
M&?P5KLUG^[MS'(3G#.I)^O->QFSB)_U:_E1]BB_YYI^5/V2$L=471'A\_@OQ
M(NH1%=.CDC"$,_F*KACV'M5V#P-JT:KBR,1'82+Q^M>Q_8XO^>:_E1]BB_YY
MI^5'LHE?VA.UK+\?\SR7_A%]4DE`>QW989+%2..<X)_6H]<^'=YK.F7=K):R
M,EY&\3_.N2&!4G.?0UZ]]AAS_JT_*C[%%_SS3\JET(-6)6/J)W21X)\&_P!G
M]?@#\'?#7@/PW9WJ:!X6TV+2K(7-R)IO)C&%WOQN;WQ6S#X(\0)=2ET3RWZ`
M,-V.G)SS7L7V*(?\LT_*C[%%_P`\T_*K=--\SW80QLX+EBE8\AD\&ZK$2B6Y
M/H=ZXYZ\9KN?AU:/8WU[%(NV1(+8,`>^'KI/L,/_`#R3\J2VTR"TNIIHTVR3
MA1(<GY@N<<=.YK2G:"DNZ_5&&(KRJ\J?1_H3T444C$****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
7`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>table5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table5.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`"L`2`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#][==\4Z9X
M6BC?4]1L=.25ML;75PD(<]<`L1DUF_\`"W/"G_0S>'O_``8P_P#Q5;TL"3CY
MT5\=-PSBF?V?;_\`/"'_`+X%:1<+>\G_`%\C&:K7]QJWH_\`,Q/^%N>%/^AF
M\/?^#&'_`.*H_P"%N>%/^AF\/?\`@QA_^*K;_L^W_P">$/\`WP*/[/M_^>$/
M_?`IWI=G]_\`P"+8CNON?^9B?\+<\*?]#-X>_P#!C#_\51_PMSPI_P!#-X>_
M\&,/_P`56W_9]O\`\\(?^^!1_9]O_P`\(?\`O@47I=G]_P#P`MB.Z^Y_YF)_
MPMSPI_T,WA[_`,&,/_Q5'_"W/"G_`$,WA[_P8P__`!5;?]GV_P#SPA_[X%']
MGV__`#PA_P"^!1>EV?W_`/`"V([K[G_F8G_"W/"G_0S>'O\`P8P__%4?\+<\
M*?\`0S>'O_!C#_\`%5M_V?;_`//"'_O@4?V?;_\`/"'_`+X%%Z79_?\`\`+8
MCNON?^9B?\+<\*?]#-X>_P#!C#_\51_PMSPI_P!#-X>_\&,/_P`56W_9]O\`
M\\(?^^!1_9]O_P`\(?\`O@47I=G]_P#P`MB.Z^Y_YF)_PMSPI_T,WA[_`,&,
M/_Q5'_"W/"G_`$,WA[_P8P__`!5;?]GV_P#SPA_[X%']GV__`#PA_P"^!1>E
MV?W_`/`"V([K[G_F8G_"W/"G_0S>'O\`P8P__%4?\+<\*?\`0S>'O_!C#_\`
M%5Y+8_MP^%K[]M&;X,KHMR+R*!@NL_)]CDNUA6=K0=_,$3;C].E=3X6_:W^$
MWC;XE#P?I7C'PW?>)VDGA&G1R#SM\)82IC&-R[6XSG@UT/"R23<):J_R[['%
M#,(R;BJL+J7+LU[W;5ZO7H=C_P`+<\*?]#-X>_\`!C#_`/%4?\+<\*?]#-X>
M_P#!C#_\57C$?_!07X=:[\>+#PGH&I^'=;TN+3-4U'7-5@N<KHHL@C$,NS#*
MP+_,&_Y9G&:Z"Z_;Q^!]GX0CUY_'_A7^R9KQ[".X63<))D17=5`7)VJZDD#`
MR,FJ>$FK?NY:Z_BUV\F1',Z<N:U:'NNS^23?VNEU?ML>C_\`"W/"G_0S>'O_
M``8P_P#Q5'_"W/"G_0S>'O\`P8P__%5Q'CW]LGX/_#`:6==\;>&+`:U9IJ%D
MQE#B>W?A)05!`5CP"<9P<=*T'_:=^&$?Q23P4?%7AX>*9`-NG%QYA)C\P)G&
MW?L^;9G=CM6?U=VOR2Z_AOTZ=3;ZZK\OMH7T_';[77IW.G_X6YX4_P"AF\/?
M^#&'_P"*H_X6YX4_Z&;P]_X,8?\`XJN1^%/[5_PI^.7BM]#\)>+_``YKVKQV
MWVMK6UD#2>4"`6`P,X)&0.1GFO,_VC?^"A%C^SQ\2?%&C2_#[5-<TSP5866I
MZUJEK>6L8M8+IBB%8I"'D((.0M7#"2G/V2@[^;2_-(RJYE&G2]NZL7':Z3E^
M39[U_P`+<\*?]#-X>_\`!C#_`/%4?\+<\*?]#-X>_P#!C#_\57*77[4GPQT[
MX@:5X4N_$VAV?B768X'M=-F(6=O.7=$C#&$=AT5B">P-5H/VP/A#<ZKXELD\
M;>%C<^#XGFUA?/7%BB.$<L<8.'(4[2>2!U-1[!_R2_KY&OUU?\_H=OGO;XM[
M':?\+<\*?]#-X>_\&,/_`,51_P`+<\*?]#-X>_\`!C#_`/%5PS_MG?!Z+P!;
M^*7\:^&H]`N;U].CO)'V)]I1"[0D$95]H)P0#C'J*Y[Q%_P4/^#?A_6?`ULO
MB&PU"V^(#S)IU]9H)+:+RSLS*>&3=)^[`P3N/(`YJXX2<G94Y7_X%^W8SGF5
M.$>:5>G;?Y-VO\6UVE<]:_X6YX4_Z&;P]_X,8?\`XJC_`(6YX4_Z&;P]_P"#
M&'_XJN2TG]J_X4Z]\3+SP=9^+_#=QXFT_P`X3V"2`R*8EW2J#C:S(,EE!)&#
MD<58^''[2'P^^-'A?7-5\&:WI'BFW\/1[[PV)#>4QC,BH20,$J*S='ECS.$K
M;_)[/;J:QQ7-+DC5@W=JWFMU\6ZZ]CI?^%N>%/\`H9O#W_@QA_\`BJ/^%N>%
M/^AF\/?^#&'_`.*KYM^%7_!333OB?IMX[_#Z\T*:3PA=^,=*:\U&UDMKZVM\
MJRRR1EC;G</^6B].?3/HFF?MS_"JPT_PY!XF\4>%O#GB/7K&QNSI<EVLIA:[
MB62-0X4!E.X8?@'CIFNB>`J0?*Z;OY-/OV7DSDHYS1JQ4XUHV[M-=GU:Z--=
MT[K0]._X6YX4_P"AF\/?^#&'_P"*H_X6YX4_Z&;P]_X,8?\`XJO)OCQ^W%X'
M^$GQ!T;P=I]WH6N>,M0U_3](NM'6XV7%G%=2!3,<*P)0$-LX/(SBH_#G[>'P
M^TWPA=:KXYU3POX,`UK4]*LT?4$NQ>)93")Y`R*,/\R[H\$J3CFH6#DX*:@[
M/;S]%:YH\SIJI*DZL+QWT=EZN]D_(]=_X6YX4_Z&;P]_X,8?_BJ/^%N>%/\`
MH9O#W_@QA_\`BJX?QO\`ME_![X;Z7H][K?C;PS86OB"R&HZ?(TFX7-L>!*-H
M.$)XR<<@CJ*],TTV.L:=;W=LEO-;74:S12*@PZ,`5(X[@BL94U%<TH22_KR.
MFGB)5).%.I!M6=EKH]OM=>AFV_Q4\,74Z11>(]!DEE8(B)J$19V)P`!NY)-;
M]0BP@4Y$,61R/D%35A+E^R=E/VB^-KY+_@L****DT"BBB@`HHHH`****`"BB
MB@`HHHH`*1L[3CKCC-+10!\1V7_!,WQY80Z3XP'CM)?B/:>-CXPN+)YO^)"7
MDGQ*$/D^?O-KMCR3MXQC'-:_AO\`X)V^)-*O?"\\EUX9BGTKXD:QXLO;B!I/
M.>QO(YDCC1O+!,J^8N02%^7@G%?8M%>B\UKM<KM]W3MZ'AQX=P<7=)_>]][^
MKZGPA\,O^"<'Q/\`#>E:?I.IWGPZ33_#7@S7O"6FW.GB=+N_-\A$4]R3'C@D
M9`)V_,1N)KJO%/[!GC?PI;?#+5/!4?P_GUGPGX*F\(ZK8:HDL5E,\T4:R7<3
M1QEB^]3G<H+`\FOL6BJGFV(E+FE;KTWOS7^_F9%/AO!TX<D+]+:ZJW):WIR1
M^[6Y^4WQ7_9N\8?L_?%30_#$/ASQ!XWT_P`.^'=`T\65K97D5GXNF@N7G9!+
M"C(J0R/NQ*R\+7T19?\`!.OQ1#^TWJ_B2Y;1M4\,ZSXK_P"$NB:;7+ZVN-,F
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M05^VB7SU/BC7O^"=7C+Q%^T3J/B74SX=U;1/%.K:5KVH0_V]J%G_`&9=VR1B
M3RX(T\NXVLK&)I"I`.#@9%4KK_@G5\3=4_9OU_X5SZA\/8M%M+J2_P!"U>)+
MD:EJ$IOQ=JEV0H$:XRK%"QSL(^[S]R53U+Q#8:-=6<%Y>VEK/J$OD6L<TRHU
MS)@ML0$Y9L`G`R<`T+-<1HE;2UM.VS^27^9$N',%[SE?WKWUW4MTWOJW?RZ6
M6A\$?$G]DOQW\.-*\!&R\.Z'=>+=9^)<&M7"S:GJ&NZ>Q2Q9%EO9YD$B@E2"
M0N!\G)(KLO!O[`/Q#\!67PXUNVN?`=WXH\.^,=6\3:O92+-'IRQZBNQXK=@A
M;]TO*@J`6],5]HU!J>J6VBZ=/>7EQ!:6EK&TLT\T@CCA11DLS'@`#DDT_P"U
MJUK*W_`M:WI82X;PL9<S;\NEG>]]%O?4^+?AY_P3J\?>'O%'A?2-0U'P7_PB
M'@37=7U_3=1MA-_:^J/>+,(XK@%-BA3+\[!FW!5`'%>\?LM?LX7/P&_9'T?P
M)<)HZZW;:3):7MS8J1!<SMO_`'A8JK-][J1GK7KEG>1:C9Q7%O+'/!.@DBEC
M8,DBD9#`C@@CD$5+7/B,=6JP]G/;3\+_`.;.S!Y/AL/4]K2O?7=WT?+_`/(J
MQ^?OP6_X)4>._`^DR)=3_#[0;FV\%ZKX9:31'NFD\2SW<3(DM\SHH"QL0?E5
MCQ[#'3>(_P#@FEXLUWX=^/M-:Z\)2:EXD\&^&?#VFW$K2'[+<:<B+<.6\K<J
M,5^4KDG`R!7VY174\ZQ+GSMJ^G3L[_G_`);'%3X6P$*:I13MKU[QY?R7Z[GQ
M;K7[`/Q%_P"%UWUS97G@2?PC?_$#3_'4EW=+.-90PB-9+92$*;?E)!SST^7)
MK3^&W_!/CQ+X<^(?A74M7N/"]_I^AZWXNU.>$F27>NJD&UVJT>"R8^?/3L6K
MZ_HK)YI7<>33:VW]WE_(WAP_@XS]HD[WOOU4N;[KGY-_&/\`9L\??`S6_"WA
M>[\,ZKXKCT'P=8Z9-8Z1;WIL/%<J:E-<_9!/%&<*A="?-V`8]*_5K1)I+C1K
M1YK?[',\*-)!G/D,5&4R..#Q^%6J*6,S"6)BE-:IMW]==AY7DM/`U)RI2NFH
MJW91T6N[_KJ%%%%>>>T%>8_M"_M7>'/V<[W0=.U"TUW7/$'B>9X=*T71+(WE
M_>;!EW"9`"*",L2.M>G5\Y?M6_"#Q_!^TG\//BOX`T33?%EUX5LKW2+_`$2Z
MOUL))H+G:?-BF<;0RE>A]?RZ,)"G.JHU'9:^6MG97Z7=E<X<RJUJ6'<Z"O*Z
MZ7LFTI.W5I7=NMCU#PG^TIX1\1>$]"U2^U.+PK)XB4FSTWQ#(FFZ@S!S&4,$
MC!MP8$8&>V.M;6H_&'PEH^NG2[OQ3X<M=3$GE&SFU*%)P^T-MV%MV=I!QCH<
MU\1?M%_LB?%SXY>+/%^MZG\-/">KZE\2?#%EI$$DVN1/_P`('<12MN*,Z[I`
M05D+1#)88Z=9_B7_`,$U=?\`&FN>,;V\\+Z)KVHZCXM\-SV>I7-Q%Y]UI=K!
M#'?$DG<@;:^4/+Y[\5Z2P.%;7-4M?S3MJEWZ7?K:ZT/#>;Y@DU3H.5NK4HW]
MV3VMN^562O9R2>NA]I?\+K\&_P!@0:K_`,);X9_LNZ=XX+S^U(/L\S("7"ON
MVDJ`20#QCFGZK\8O".A^&;/6KWQ3X<L]'U`XM;^?4H8[:Y/^Q(6"MT/0GI7Y
M]?&W]F;6/@]XV\*Z*/`&AZWIFM?&+4]7\/>&GN(H["\L&TY=J'@I`-R.0K#&
M5&1@UJZ'^P%\2O`7A'P%>77P_P##7C=--M/$4%SX2FU6%+;0Y-1G,D#1O*#&
M_EK\AV\C^'UIO+</R1G[3?;;LW;?OI?9,G^W<=SRI^PUCO;F=O>2O\.JLW*R
M]YI;=3[[NOB-X>LFF$VNZ-$;>R&I2A[V-?*M3P+ALMQ%_MGY?>JMW\8?"6GZ
MQ#IT_BGPY#J%R\<<-K)J4*S2M(H:-50MDEE((`'(((KX1U_]A'XR_#OP%:Z-
MH6@:'XNGUOX4#P)J5Q+K"6JZ7.+B28D;QNE0*X1<8Y')`K:^+/\`P3O\5>-U
M^)^JKX3T:\\2:A;^$H_"][)=PB>W:RCA6]V.3^ZQY9&>-X`QFDLOPO-K65KV
MZ?S)7M?L[^A<LZS#E]W#/F2O9\UOA<K7MJ[KETZM)ZGU7\8?VJ?#/PB\4>'=
M#DNK75-;U_7K30SI]I>PFZL3<;BL\L1;>(QMYX_B%>F5\$S?L0_$.U_:>_M+
M_A!/#E_:#XHIXR/C,ZG$+]M.8`&T$1^?"=QG'`V@]:^]JX\51I4Z<'3E=O?[
ME]W7?4]++<5B:]6K[>'*D[+1]WK=I7OH]+KS"BBBN$]<****`"BBB@`HHHH`
M****`/A_PIJ=E\!OVK?C)9>._AAXG\57WQ`\06U[H&HVOAXZM;7UH41(H3*0
M5B$3C)#$`8)_A&?-_@W_`,++N/BWI#O_`,+;_P"$[6X\1_\`">?;_M8T86?E
M3"S%ON_<_>\GR_)^;-?I117JK,K1:Y=7%+?LN5:>FZZM+L?.2R!N:?M-%)RM
M;O+F>M][Z)]$VM;W/S0^%W@KXB^"/!>BS2>(?B_:R>.?A-?76O7EPE]J4NDZ
MDLT2PF.$_-'*J,WR+B0J&(R:SKOX?:GXP^$_P:U_Q-X<^)$6G^%_']U97MS8
M7&K7$UQ9M"-M_#'-FZA6250!G!4&0`A6Q7Z@45O_`&W+GYU"SOW\W^CLO+H<
MW^JL.3V;J75K:J_2/=]7'F=K-M[GYL>'O$7Q%U7]KG6+BUTGXC:)!<1^)[6_
MM;BXU6Z5PMM(;1G>0"U7<P4PBWY7@$DXS5TS]G[QO=?"B^T:>Z^*NN#QQ\%Y
M=6U.VU*]NYA_;44B-#`H?B-R!M,/5UR"#DU^F-%9_P!K-)*,;:)?=S6_%W^2
M-/\`5F,FW4J-W;>UOBY;]>JBT^_,S\T?#K:QX<U[X#OX7M?BOK.GVEC865QX
M;OXM8L?LT[71^TWB7`_=%8RK*8;@;?*"A!@\?I=117+C<;]8MI:S?7N[GI97
ME?U/F]Z]U'I;X5;N]_N71;ME%%%<)ZP4444`%%%%`!1110`4444`%%%%`#7A
M61E+*K%#E21]T^U.HHH`****`"BBB@`HHHH`****`"BBL/Q=\1M'\"ZEH=IJ
MEU]FN/$=\--T]?+9O/G*/($R`<?*C')P.*:3;LB9245S2=D;E%>9:%^V#\/_
M`!-\2O\`A%+#69[O4C>R:8LT6G7+6+W<8)>W%UY?DF10K97?U!'48KTVJG3G
M"W.K7(I5Z=6_LY)VT=G?4**YK4OBKIFF_%;3/!I%S+K.IZ?/J@$<>8[:WB=$
M+R-GY=SR!5X.2&]*=\5OBQH'P2^'NJ>*?$U^-.T+18Q+>7/EO+Y*DA?NH"QY
M8=!WI<DM--]OR_,;JP2DV]([^6E]?EJ='17"^.OVE?!'PV\#:!XDUC7[:VT7
MQ1<6UKI5RJ/(+Z2X&80BJI;YASG&`.N*U?`GQ5TSX@Z]XFTNS%U#?^$]1_LZ
M_@N(]C!C$DJ2+R<QNC@JW?!XXJO8U$N9IV_RM?\`-?>0L31<E!25W;KW3:^]
M)V]&=+11169N%%%%`!116)XT^(FD?#Z31UU:Z^RG7M1CTFQ_=L_G7,BNR)P#
MC(1N3@<=::3;LA2DHKFD[(VZ*YSX8_%?0?C)X=EU;PW?#4],BNYK(721NL4T
MD+E',;,`'0,"`ZY4X.":;X"^*NF?$?5?$=MIHN67PQJ;:1=3R1[8I+A(T>18
MSGY@F\*3@?,".U4Z<DVFMMS-5J;46FO>V\^OZ'2T5R'CWX\^$_AAXT\*^'M=
MU>+3]6\:W#VFBPO&Y%[*@!90P!53\RXW$9R,55\3_M%>%/"_Q'N?!KW[W?BZ
MWT27Q!_9%M"TEQ):QG!(.-FXGA5+`GZ<TU2FU=)VU_#?[NHGB:2;BY*Z:6_5
M[+U?3N=S16-\/?'>F_%#P)H_B/1Y3/I>N6<5]:NR[6:.10RY'8X/(['-;-1*
M+BW&6Z-(3C.*G%W3"BBBD4%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M7DW[2G@W5?%7CGX3SZ;87-Y!H_BQ;R^DB`(M(?L=RGF-[;G4?4BO6:*NG-PD
MI(RKTE5INF^I\I_`/Q7XU^`OP1;X:3>`]<TS7?#R:DB>*)U@_P"$>52T\\5^
M\Q?<02R%D\LL"6R,"HO#/[3GBW5=1\-6_P#;SB<3P6ZQ/;6]Q'XLF;41;W0@
MFC15:&*'+JT04CEGR!7UB>::$``X'R]..E=GUR#DYS@FWJ_7\=SS%EE2--4J
M=5I)67II;:VUM_O/F_XR6MPG[4'CJS57>^\3_"R6#14&`9Y89YQ+$A)'S[IX
M#@>H)Z5X[J_[+FI^#?`VLZ/X9\,W8LO$'@/0/[2MA<"8:AK,6IH+CS-[DM.(
MPRL>X&,D@"ON'Q+X,TCQE:M#JVF6&I1M#);E;F!9/W<@`=1D<!@!G'7`]*Y$
M_LG_``S(_P"1"\)_^"R+^YL]/3]?FZ\U$,QK4E%4HIK2]V];-VZ>?WG8LAR[
M$\\L;5G&3;MRPC*R:2>KG'71_(^3-;_9L\:7]KXB\/W6G)?^&_AE<1VO@$1S
MH[ZC%>ZE#,TH&[@VT"M;#_@8%?17P(NX=?\`VK?C/J5CMEL(WT?37GC;='+<
MQ6KO(H/3*K-$#Z9%=2_[)_PRD!!\!>$_FR#C3(AU4*?X?0?@<D<G-=CX:\*:
M7X,TP66D:=8Z7:`[A#:0+#'G`&<*`,X`&?85+Q]:I!PJQ6W1O=N+;>G6S?JR
MIY)E^'FJN!J3D[JZE&*LDI**5I2VYDO2/=MFA1117*=04444`%>"_P#!07X'
MZM^T+\-?"OAK27U6U-SXIM6N[_3N)M,@\BX5I\Y'R@LH/J&([U[U16E*HZ<U
M4CNC#%8>->C*C/:2L>'_`++'BOQ+;MHOA/Q!X<'A.X\/Z%+9SV%K&BZ=+);W
M"0I<6Q`SY,B8906&`2",C->0^'OAK'\3OAQ%X2U*U;4DT;XQ:E+XCMO/\K9;
M//<SJTIW*3$R7%O_`+PD"\YQ7V=7,>+_`(*^$/']P)M;\,:%JLHD,N^ZL8Y&
M9RFS<21R=H`Y]!Z"MWC))N<(ZNS^=[^?]6.:EE5&?)1Q$WR*Z;23?*XVM:\5
M>Z7ROH?&FJ?LHZ_XGT/P[X=ATV?2H/#5QXO;0;B2="NB/]NMY-)*DL2J%X]J
M#L`5XZ5VO[/W@SQ+9?%OP_\`%7QWI<6CZWXCT[6M1\2J9T>/0(Q]CAM+-FW9
MPL<$A]-QDSSFO?!^RA\,P,?\(%X3_P#!9%_<V?W?3]?FZ\U/IW[,7PZTB^CN
M;;P/X6AGB)*.FF1`C*;#_#T*YX]23U)-2\SQ4H\CC'JKW=];WZ=;I_)>9VKA
MW):<O:TJU6ZLTO9P2O&W*M*FB5FEV4GH]#F/V`]/FT[]D'P5YT30B[MIKV%&
MSE8)[B6:'KR/W<B<=J]AIEO;QVEND42)%%$H1$1<*BC@`#L*?6=>I[2K*IW;
M?WF6$H>QH0HWORI+[E8****R.@***\K_`&A/VBM7^!6HZ6L'@+6?$UAJMS;:
M?%>6=_:0JMW<2^5'"4ED5N6*_-C:-W7@U=.G*I)0CNS*O6A1@ZE39>3?Y'JE
M%>?Z5^TCX8B\0:+X<\0ZGI7ACQMK,22+X=N]1@DO(F;.U#L8J6.#C!^;MFLG
MXA?MM_##X;:'XCO;SQ;I5RWA21(=3MK.=9KBWD>3RU3:#][?D8SP0<U:P]5O
ME46_ZM^9E+'8>,7.4TDM[NUM+ZWV=M;;GJU%>>ZI^UA\--#_`+!^V>.?#-K_
M`,)/&LVE>=?HGVV-FVJZ9/W2W`)X)XJ#XA?M=_#KX9)XG34O%6E&^\'V37^J
M6$$ZR74$:[>-F?O$N@"^KKG&:7L*NW*_N^0WC,.E=S7WKJKK[UKZ'I-%>;-^
MV!\,;?PIH.M7'C?P[::;XFR--EGO$C%R5;:^,G^%OE8]`>":VKCX_>";3QQ<
M^&I?%6A1Z_96SWES8/>()K>!$61I77/RH$=6W'`P<T.A46\7UZ=M_NZCCC*$
ME=373JNNWW].YU]%>>Z'^UA\-/$O@Z^\06/CKPQ<Z)I<\=M>7JZA'Y-K))PB
MNV?EW9^7/7M4Y_:?^'@^&*>-/^$S\/?\(K+,;9-3^V)Y#RABOE@YY?(/R]>.
ME#H55HXOMMU[`L90:NIK:^ZV6[]/,[NBJ'A?Q3IOC;P]9ZMH]]::GIFH1":V
MNK:42Q3H>C*PX(J_6;33LS>,E)<T=@HHHI#"BBB@`HHKDOCC\8],^`OPQU/Q
M/JJ7-Q!8(!%:6R[[F_G<A8H(E_BD=R%`]_0&FDY/E6Y,YQA%SD[)'6T5P_P^
M^-(^)/P"TWQWINAZI-_:NEC4K?24,9NW)7(A!+!-^>,E@/>L_P"`G[0;_&;5
M_%.D7_AO4?"VO>#[J&VU"RN;B&Z4>=$)8V26%F1OE/(SE3UZBM7AZBYDU\._
MWV_,PCC*,N1I_'\.CUTO^6NIZ11116)TA1110`4444`%%%%`!17!?'KXOZQ\
M'_#\=]I/@G6O&>V.:XNEL+FWMULX8DWLS-,Z@D]%5<DD'I53Q)^T[H?A[]F!
M?BK]FU"XT*;28-7AMT15N)$G"&-#DA5.9%!);:O))P,UJJ,Y14DM&[?,YY8J
ME&;A)V:5^NW5WV=NMMCTBBO!+7]NZSC\*Z[)?>$M:M_$FC:Y:^'8]$@NK:Z.
MH7ES"LT*Q7"/Y.WRVW.S,-@5L].?7OASXGU'QAX2M[_5=$E\/WDQ;=927<-W
ML`)`821,R,&&",'OR`:=3#U(*\U^7:_ST:)H8VC6?+3=WZ/NUKIH[IZ/4W:*
M**Q.H****`"N`_:%^&FH_%#0?#EMIC6JR:5XGTO6)_/<H#!;722R!<`Y;:IP
M.Y[BN_HJZ<W":FMUJ9U:<:D'3ELU8^6?%'[&OB&]_:=UW77M8M=\+>)M>TW7
M79O$UQIYT^2U6)</:I"Z7!0Q!HSO7K@XQDY^H?LB_$;5-&^*VDV2Z%H.@>)[
M6672=(?6)=0M7U)KW[0UTNZ!7M(Y`/GB5G&]RPZ<_6U%=<<PJQ22Z)+[K6TV
MOHCS)Y+AY.3=_>;;VZWNKVO:\F]_PT/D_P"+7[,OQ-^(.H^-I8-&\"8^+?AV
MQT;6#=ZC+(WA>2%9$<P$0?Z2FV4NH_=$2*#[U.?V1?'+^*_']A82:9HGA3Q3
MH.H:?+&VK27L>KWLT"0P7IMVA'V23:N9=DC!^..,U]4T4OK]2W*DMK?UZ6T^
M_?4?]C4>;G;=[WZ>;?3JV[^MOAT/C[XD?LB_$/XB:IH>NW^D:1-<W'A`^$]:
MT2Q\77.G01JLQ8.LZ6Q,T4BGYXRBX(&"V,UVGB;]C&_\1_#_`.,VBP/I&FS>
M/[>RM=*N<M,8HK?3[>`13L5#%/,B<8R<JQ/4D5]&T4WF%79:?\/S?F*.289-
MN5W?O;^7EW23U7X[6/E2^_91\=?%7Q-J7B3Q+H_@G0KJ^F\.6?\`8VGW;W5K
M)::;J'VJ:61VA0,S`E$CV8"J`6YX@^)'[%7C#4]7OM9TF:R-S;?$.[\5V5C;
MZQ+IC7%K<:?#:G%PD;&&=75V&%8$$@GYJ^LJ*:S&JG[ME_2_^17XB>1X>2M*
M[??3^]Y6^T^ECA?V;/AF?A!\&=(T%].BTF:V\Z6:UBU&345BDEE>5OW[HC29
M+DDE1R3@8KNJ**XZDW.3F]V>I1I1I4U3CLE;^K:!1114&@4444`%>7?M(_LY
M7'QZG\.W5KXKUGPS>>%IY[VS%G#;S133O"8E>1)HW4E%9]I`RI<D<XKU&BJA
M.4'S1W,ZM*%6')/;YKSZ:G@GP/\`A'\2O@K^S[X<\$G_`(1CQ)_9_ARYM[N7
M4+IXA]LROD6R^7$`;;:74N1O&%.&YH_8N_9SUOX'>(?'&HWND:!X0TGQ/<6L
MUGX:T:_EOK6QDBC9)K@R.B?/-E,JJ@`1+U)KWNBNF>-J2Y[V]_?[[^APT\KI
M0=*S;5/X;]/=Y=[7V\]_E8HHHKD/2"BBB@`HHHH`****`/$_VV?AU\1?BYX+
MTWPYX*CT:30]2N&7Q/%=:I+IUS>V8`_T6&9(I/+$IRKMMW;,@?>R*7Q?^&/Q
M)^)?P%O/!>E:;X0\*VMYX;@MO)M]0ED6&X6=!+8JPA7%L]JK1B4*&4O]WBO>
M:*Z88EQC&*2T=_\`A^_]>9P5<OA4J3J.3]Y<K]/+2Z^3_2WQ99?\$_?$=M\-
M[VSM?#/@S3]*M?%UAXDTOP++JLUYI82&!H;F-KEHMRF8MY@'ELJE!D')KWW]
MCKX):E\!OA/=:7JB:99SZCK%YJR:;ILCR66C1SR;UM(68*2B#OM499L`"O5J
M*TK8^K5@X2V?^27Z;[^9CA<FPV'J*K36J5NG5M]$N[T5EY!1117$>J%%%%`!
MG%)NKQW]L1V3P[HF&9?]*?H<?P5\E?$_XOWO@OQ[X6T.RC%Q)K`N[R]+LQ:*
MTMHB[E`",NS%5&>*_$^(_%S$Y?Q)5X<P>`]M.$'/F=7D5E3]K+3DE:T4TM=7
M;N?*9MQ0L#7E1=.]K:W[V\O,_1?=1NK\M/"W[5'B/X@_!?Q%XMTO1=)B33+$
MWUH@U;[6[;&.^">-0K1R;%)';D5WWC7XQ?\`",?`FZ\<6T,E[##I::G%;F<I
MY@95(4MSC[WIVKS\P\7\[P6+A@*^4+VLZWL.58F$K5;0:BVH.*O[1;NUU).W
M*SRX\>4Y+F5+2U]^G_@)^ANZC=7YE:U^U,TVN2Z=X;M+3Q+=1>&7\0%;;5,_
MO$=0UME0V&VDGGG@#'-9%O\`MPV6IZ)JNL6&E7M_HVF6EFJRQ7!\VYU&Y(V6
M2KC&5S\S9XQTKNP_B7Q37IJK3R)V?+_S$037.XQ@I)P3BY.2Y;VO:36D96G_
M`%^HK>G_`.3?_:GZF;J-U?G3\*OBAXE\8:Y>6.NZ+IVD-;PB4-9:ZE\R/NVM
M#(@`9''KC'!&:S/C/^TM_P`*J\<:%H-MI\^KW>I3P+>LMR8TTV*:411NQP<E
MF)PO&=IKR*/C5F]?-'DV&RE5*RBYOEQ5.4>51YK\Z@X;:?%?F:C\32+_`->X
M*'.Z.GK_`/:GZ4[J-U?FC??M216_QXD\(0V-Q/IUI#<FZU;[00B3P0^=)"J8
M^8JNT$YX+8[56^#_`.T_J'Q'\7Z5IVI:!)HEOXETR75M%G%_YS7$,;[2)%P-
MC8(;J>#7;6\6.(J.#ECZN2<M-4XU=<3"_))2::CR<S:4)2E%+FC%7DDA?Z^4
M[\OLNMOBZZ?W?-'Z;[J-U?$7GR?\])/^^S1Y\G_/23_OLU\'_P`32+_H6?\`
ME;_[D;?ZZ+_GS_Y-_P#:GV[NHW5\1>?)_P`])/\`OLT>?)_STD_[[-'_`!-(
MO^A9_P"5O_N0?ZZ+_GS_`.3?_:GV[NHW5\1>?)_STD_[[-'GR?\`/23_`+[-
M'_$TB_Z%G_E;_P"Y!_KHO^?/_DW_`-J?;NZC=7Q$)Y#_`,M)/^^S7GNC?'C4
M-7^.6J>#&T"^L19:;)J%M=W-UM-^%D$8*H,[8V;.&)SQG%>QE7TAL7F,*]3"
M94FJ,.>=\1&-HW2O[U-7U:T5WUV)EQO&-KT=]/B_^U/T?W4;J_-'P!\?/$_B
M'XSOX-UKPM%I%Q!IQU*XGM]7^UBW0D+&K`*,%CGC-:/CCXZ7W@[XR^&?"O\`
M8=])9^(93#_:LESLA5PA<I&O)<@#G.`,CK7MUO&;.*6->7O*8NHJ+K^[BZ4D
MZ2BYN2E&+C+W4Y**;DUJE8S_`->Z?+S>RZVW>_\`X"?H[NHW5\1>?)_STD_[
M[-'GR?\`/23_`+[-?&?\32+_`*%G_E;_`.Y&W^NB_P"?/_DW_P!J?;NZC=7Q
M%Y\G_/23_OLT>?)_STD_[[-'_$TB_P"A9_Y6_P#N0?ZZ+_GS_P"3?_:GV[NH
MW5\1>?)_STD_[[-'GR?\])/^^S1_Q-(O^A9_Y6_^Y!_KHO\`GS_Y-_\`:GV[
MNHW5\1>?)_STD_[[-'GR?\])/^^S1_Q-(O\`H6?^5O\`[D'^NB_Y\_\`DW_V
MI]N[J-U?G-^T-\;[[X&^"1J]OHE]KBB0+,4N/*AM$RHWR,<GDL```<GZ5!\4
M/CW??#OQ5X2T]-"O[RU\37=O:2:@UQY=O:O+G"#JSN`I.,`8QSS7UN7>-F;X
MZA0Q.%RA.-;VO)_M--7]BE*IHX)II--)V<K^ZF92XZA&ZE2V\^__`&Z?I!NH
MW5\`_%?XF1?"GP/>:Q<"XNGB*PVMI'(1)>W#G;'"ONS$?09/:J_P4^)UQ\6_
MACIGB&6UDTR6_P#,#VHG,GDE)&C(W8&?N^E>9_Q,%CUE/]N/*']6]I[+F]NM
M9\KE9+V?,]$];6Z7OH5_KQ'FY/9:[_%_]J?H-NHW5\1>?)_STD_[[-'GR?\`
M/23_`+[->+_Q-(O^A9_Y6_\`N1?^NB_Y\_\`DW_VI]NYI:^,_!L\G_"8Z1^\
MD_X_H/XS_P`]%K[,K]B\,/$M<84<166&]C[)Q7Q\]^9-_P`L;;>9[^39Q]?C
M*7)R\MNM_P!$>-_MC?\`(NZ)_P!?;_\`H%?&_P`6_"6KR_&KP+XATJ&65;6*
M^TJXE2,2"P\^(&.X9<C*JZ`'ZU]D?MC?\B[HG_7V_P#Z!7@>:_F7Q;SVKE''
M^+Q5**ES4N1J6J:J4.1Z>2E==+I735T?!\51YLPFO\/X),^>[[]GWQ)X&T7Q
M]XD?^Q]4\0Z_H1TB#3_#^GM;0W,CG!GD4MR^3DD<``UU&J?LHZ;=?".^TNS/
MV3Q)J6@QZ1-?RW$TD((2-6/E;MN/D[`&O7,T5\=B?%[B2JZ=6%7DJ0G&=X+E
M4E"-.-.$HJT7"'LTU%IW;?-?0^9^JT^J_I[L\Y\(?L_VO@CXP:;XDTY-*L;.
MT\/G2+BUMK7RFN9C(K><2..BXYYK#LOV41'\#M3\)MJD-I>W.MRZY:7]G!M^
MS3>=YD.5/WMH`4^W2O8J*\J/B3Q%&I&JL0^:+I.[46[T>?V=[I\UO:2NG=2O
M:5[(KZO3M:VG^:L>+>!?V6;I_%OB'5/&4^@7X\06<5K<0:+;2Z>)I$E\TSNR
ML#O9NN#S1X__`&,-+UVXCN="U?6-&G:\L99XS>R20-%;8"A0<MY@7[K$G!)-
M>TT5Z'_$7.*XXWZ]2Q;@[17+%)4[148K]W;DVA'6U_=6NA/U2E;E:_S^\\67
M]C+3]*\>Z3J.FZ]KL6F6K7TEW:W%XTC2R7*X8H<``,22X/WN/2K/P5_9PUKP
M!XNT?4-=UZPU:W\*Z5)H^C1VUJT3B*1\EYB206V@#CBO8**SQGBOQ/C,'/!8
MO$<\9QY&Y0@Y<K<V[2Y>9.7M)J33NXNSV0+"TD[I?UI_D@HHHK\Y.@****`"
MBBB@`%>7Q?"7Q=_PTA_PFDFL^'SIHM#I?V-;.43_`&/>9`-V['F;OXNF.U>H
M45[F3<08O*XUXX7E_?0=.7-&,O=ENES)\KT6JL]")P4U9^IYOX(^#FM>#H?'
M.JC6+&7Q?XNN7FAOC;LT%DBKMMX]A.2J#J.]9GQ'^#OCKQKXR\':M!X@\-1-
MX4VW&)K"4FXN639,QVL`$/\`".U>MT5[M'Q#S>EC9YC^[E5DG&\J5-VC*FJ7
M(KQT@J:Y%%:)-V6K(="#CR]/7SO^84445\,;!1110`4444`%%%%`'G_[2/PN
MUSXR?#Q_#^CZEI>F0WKC[:]Y;O*S(I5E$>TC!W+SG/%8'Q1^#7COXAZ?X/1-
M>\+6\_AF>'496:PF*SW<6X*5&[B/:1E3SD'FO7Z*^WR?Q`S;+,/0PV%5/EH2
MJ2AS4J<G>K'EFVW%M\T4EK?1*VQE.C&;;EU5MSSKQ/\`!&^^*%XY\5:Y,T.G
MZBFH:&=')LYK!A%L;>_.\[BQ![9J_P#L^_":;X*?#&UT&XU&34YHII9GE+-L
M&]RP5`>5&",C^\6/>NVHKCQW&N;XO+/[&JU$L-S1DH*,8Q3@I)<MDK7YY.5O
MBDW)W>H*C!2Y^H4445\H:FEX,_Y''2/^OZ#_`-&+7V=7QCX,_P"1QTC_`*_H
M/_1BU]G5_8OT7O\`<L?_`(H?E(^_X,_AU?5?J>5?M4>%M2\4Z%I":;875\\5
MR[.L";B@V8R:\6_X5%XI_P"A>U;_`+\&OKZO)OC)\1]8T_X_^`/"^E7AL[:Y
MM=3US5,*";J&UA5(X,D'"F6=&;&#B,<\FONN,?`K+N)LWJ9MB,3.$II745&W
MN1MU3>R.W-N'Z&(JO$U)--N*LK=6HK\6>-?\*B\4_P#0O:M_WX-'_"HO%/\`
MT+VK?]^#65^RS^U?\1/VDKB_T*/Q-I^H7&H>#)M5N+RTT)M-E\*W[2&.V13(
MS+<H^'.0N!Y1YYQ7KOAW]K:T\0?LHV>OG6=#L_'E]X,DUV#2Y[B,7$DZ6KR%
MQ!N#&/?&QX&,`\\5\_7^BEE=)M2QE72W2/6_]W^Z_P`]FCP,)DV7XB*E"I))
MIM7Y>G+VOK[R^>FZ:/-_^%1>*?\`H7M6_P"_!H_X5%XI_P"A>U;_`+\&M?PG
M^VEJWQJ\1_#OPWX3NYK'6/$WAF_N]0N-3\.75M`EZEG&\+Q&9462,3,Q*H6R
MN.>0:P]'_;P\?>(?`^N^((?#UI9/X8@LO"EQI]_"T27/BRXND@E`DSD6L&Y2
M<<MYHY&*K_B4_+;V>,JW](=W%?9ZM6^:N1_9>6-<RJR:[I)[14GMVB[OT=KV
M)?\`A47BG_H7M6_[\&C_`(5%XI_Z%[5O^_!KO_A-\=IO"'Q&U[1?'?Q;\(ZO
M)HM@)K^WET-]".FS><L9=9I)#')"6;8.<[L<G)K(_:,_;&U71_B=X2T?X?W>
M@WNDQZII1\3:E*PGB%O?SB*WM[<JV#*ZEY2W(5%4_P`0J(_14RJ510CC*NO6
MT4OQBOZV-IY'@8476G4DK=/=;T\DW\]=-;['+_\`"HO%/_0O:M_WX-'_``J+
MQ3_T+VK?]^#70^.OVSM;M/VI[#2]'_LI_AYIO]JZ;J<SKNN=2U*TL'NW2%L_
M+'%M2-C@[G9E'W:M?L[_`!R^(M_\2/`-OXRU+0M4T[XH>%Y_$%M;66GFU?0I
MH_)D$`?>WG)Y4X!8@-N3/0T?\2IY7R\SQM3:^T/-_P`O:+?_``=!?V)@74]F
MIS?O<M[*V\5]UY)>ODKG*?\`"HO%/_0O:M_WX-'_``J+Q3_T+VK?]^#7U]17
M'_Q+#DW_`$&5?NA_D>I_J;A_^?DOP/D'_A47BG_H7M6_[\&C_A47BG_H7M6_
M[\&OKZBC_B6')O\`H,J_=#_(/]3</_S\E^!\@_\`"HO%/_0O:M_WX-'_``J+
MQ3_T+VK?]^#7U]11_P`2PY-_T&5?NA_D'^IN'_Y^2_`^0?\`A47BG_H7M6_[
M\&C_`(5%XI_Z%[5O^_!KZZNFD6UD,*HTP4F-7.%9L<`GG`S7B7[/OQ-^)/CO
MPW\3;+5W\)7/B_POX@ETO3Q!'-#ID8^RV\R*YYE95,QRV`6QT%:0^BYE$DY+
M&U=/*'>W8PJ\*X6G.,'.7O7Z+HK_`*'F7_"HO%/_`$+VK?\`?@T?\*B\4_\`
M0O:M_P!^#5K6_P!K7QQX?_8>\.^--0U'28-;N_$G]CZSJ=KIAG6UMQ?S6[36
MUF7W3.`B`("S8).#C%0?"K]ICXE_'[P_X)T;0_$'A[2]3UVTUK5IM>?2/.,U
MG9W*06JM:&0"&64R!I$+$H$Q@$\=?_$J&5V<OKM2R;6T>BN_L]OGY'F_V3@.
M:,%*=Y1C)*T?M-)+[W;LNXS_`(5%XI_Z%[5O^_!H_P"%1>*?^A>U;_OP:]__
M`&6OBM??&_\`9\\*^*=3@M[;4]5L]UY';Y\H3(S1R%,\A2R$@'D`C-=_7'4^
MB[E%.;A+&5;IVVA_D>I0X3PM6G&K"I*TDFMNI\@_\*B\4_\`0O:M_P!^#1_P
MJ+Q3_P!"]JW_`'X-?7U%1_Q+#DW_`$&5?NA_D:_ZFX?_`)^2_`^0?^%1>*?^
MA>U;_OP:/^%1>*?^A>U;_OP:^OJ*/^)8<F_Z#*OW0_R#_4W#_P#/R7X'R#_P
MJ+Q3_P!"]JW_`'X-'_"HO%/_`$+VK?\`?@U]?44?\2PY-_T&5?NA_D'^IN'_
M`.?DOP/D'_A47BG_`*%[5O\`OP:/^%1>*?\`H7M6_P"_!KZ?^)>D:]KGA.6#
MPWKUIX;U3>KK?7.GB^C1`<L#$73.1QG=Q7R1J/[8GQ#\-?L_Z5XJU3Q+IBZ+
MK_C6XTFU\06GASSKDZ5''(L=Q%8"4M*TL\1^Z6VQ,&VGMTX?Z*^45E[N-J7V
MVCU_[=_#?38\_&\/83"O]Y*=K-W7+TWZW[:[*ZNS8_X5%XI_Z%[5O^_!H_X5
M%XI_Z%[5O^_!JQXC^/WQ-NOV*M"^*5OXP\.Z7J$^E@+IL&A)?C6[V6<Q6BH?
M/'E/)NB5HQNV,6&?EQ7U%X*358_!VE#77MI-;%G$-0>W7;"UQL'F%!V7=G'M
M16^BQE%)7EC:FC:VCNO^W?ZNAX7AW"5Y*,935XJ5WR[/;:_GOV9\J_\`"HO%
M/_0O:M_WX-'_``J+Q3_T+VK?]^#7U]17-_Q+#DW_`$&5?NA_D=_^IN'_`.?D
MOP/E#PI\*O$UIXJTN630=42.*\A=V:`X50ZDD_A7U?117ZGX=^&^$X0HUJ.$
MK2J*JTWS6TLFM+)=SV\IRBG@(RC"3?-W"O-/BO\`"+4O$_QJ\"^*M+DMPFC)
M?Z7JT4C[&ELKJ$?,AP<NDL41QQD%N>.?2Z*_283<7=>?XJS_``/2JTU4CRR[
MI_---?BCQ$?LB0?#;PSH=YX.O+Y_$_@SPM>^'-+:[N$2+4HY@&C6Z(3E8Y55
MUV@8);@YKH/!G[,&BZ!^SOIO@:ZC@>:V\.?\(_+J<4*?:0K0&*1XW8$KDNY`
M/`STKTZBM9XJK)6D_/\`-_\`MS^\YZ>7T*;O"-M+?^DK\HQ7R."L?V?M+L-?
M\`:BMYJ#2_#O3IM-L%+)MN$E@CA9I?EY;;&"-N!DGBJFL?LM^&?$WPY\8^%M
M4^W7VE>-=4GU:[S-Y<MO/*R.&A=0"A1XU9#R01U->D45/MZE[WU_X-_SU-/J
ME&W+RJW_``.7_P!)T/(_AI^R3:^#_'-SXA\0^*O$GQ`U&72ET6$Z^MJ\=O:B
M43;=L4*!V+JI+OEN*C^+O["7PP^,NHP7VH^%-&M]3CO[2^EO;:RB2>Y%NRE8
M78J<QLJ!"/[O`(KV"BK^MUE-34K-=M/R,O[-PKINC*"<7WU\NMV>->(?V!?A
M9KWQ&T7Q,OA/1["_TBZN+QUM;.*--0DFC9"TWRY8J6+J000W-2_`S]CG2_@C
MXILM3_X2/Q-XD_L'3&T70+?5IHGBT*R9E8Q1;(U+'"1KOD+-M0#/7/L%%'UN
MMR\KD[;?G_F_D[!_9N%4_:*"3O?3373[]D]>J3W"BBBN<[0HHHH`****`&3Q
MF6!U#M&64@,O5?<9KR#X7?LGWWPLF\836WQ*\;7USXR+W%Q-=1V!:UNV2./[
M5$%M@/,"1(H#`I@<KGFO8J*TA5E!-1ZF-7#PJ.,I[QVU:\NAX!HG[`UGHGPY
MT[0!X]\:SRZ!KG_"0:)J$HLC/I-T3*9-BB`(ZN9I21(K8+<$8%/'[`NEZ=IF
MGRZ1XS\9:+XGM;S4;VX\0VLEM]LU!M0*-=K(C0F$*QCC("HNPQ@CG.??**V^
MNUM[_@OZUZK9G)_9.%LER[:+5]'===UT>ZZ&#\+_`(;Z7\(/A[H_AC1(I(=*
MT2U2UMUD?>Y51]YF/WF)R2>Y)-;U%%<TI.3<I;L[X0C"*A!62T04444B@HHH
MH`****`,3XD^#/\`A8WP_P!9T`ZA?:4NM6<MDUY9,JW%NLBE2T98$!L$X)!Q
M7"^-_P!DW2-?\.>!K/0]6U?PA=?#A?+T*]TP0N]M&8/L[HR31O&P:/@Y7/<$
M<UZK16D*TX?"S"KAJ576:OT_&_RU2?R1Y#X9_8R\-^&?#7@;21?ZS=6'@?69
M_$*1SRH1JE_*97,]P`@!*RS/(JH%4-CC``KUZBBBI5G4=YN__!"CAJ5%6IJV
..WX;!11169N%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>table6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$(`.L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]SOCY\:]#
M_9N^"7BSX@>)I)XO#W@S2;G6=1>"/S)1!!&TC[%R-S84X&>3BO"?`O\`P6$^
M"GQ'\8_`/0M*U?4)M1_:-T>ZUSPM&;=0(8+>(R2"Z._]R^4DC`^;YX9!GY:]
M%_;Q_9>N?VT?V5/%'PQM_$7_``BR>*_LL%W?BS^UD6J74,T\/E[TSYL4;Q$Y
MX$A.#C!^/1_P;K^&=(\?^*=<T7Q[?:9_:GCBSU_0(AIV_P#X1#1%^U->:)8G
MS?W4=P]]=-O0*%W1Y1BI+*-^;7;3_@]'W3_[=:ZHIVY=-]?^!^37S79GV=X'
M_;A^#GQ*?Q(-`^*/@/5O^$/MWO-;-MK=NZZ9;H65YY2&PL2LK`R?=!4C.:YW
M0O\`@IW^SIXF\$ZUXDL/CA\+;O0/#;6R:MJ$?B2T-OIC7+,MN)GWXC,I1@F[
M&[!QFOBGX7?\&S^C^'/AIXI\)^(_B)!JEG<>"W\$^&M4LM'N8-3TNW-VERLE
MQYU[-;S#,40>&.&*-_G.%+<=CI/_``1C\0_$/QMXNUWQW\6_`7B#6/$.M^"K
MN]M=!\"Q:58PIX=O9;K[,\`NI`S7"R["7/R#'RLH"BXI.2BWIIK\]?PL[?BQ
M:6_KLOUO]VQ]9>/?^"@7PG\&?L?^)_CG9^+])\4_#KPM97%W<:CH-U'?K</$
MVPV\91L&9I"L80D?,Z@XS7GWPO\`^"K/A[XC_M/Z?\'V^'?Q,T[QN-&L-7U^
M%M-AFMO"?VRV:Y@CO9$E)'[M2K2QJ\2R$1E]YQ7GOQ[_`."4FM)_P3W_`&G/
MAOX)UC3+[Q!\7_%^I>/M$MY+);*UM+J6>UNHK!OG*E2]H$,ORC][DJ,5;UC_
M`()Z_$7]IO\`;(^%GQ[\5>,;+P2OA9+74CX5A\.6_P#;VDO]D>*ZT<ZQ!,!<
M:?+-(9'22-\LHVE<\&FZ\OEI^.O_`*2OYM5/2Z7G;SU7W:?GY%C1_P#@N1X!
M\2_LY>(OBQIW@#XFR^!/";VTVJ:C+9V:&*RDNFMI;U(A<-*\<#*7D&T-LRRA
ML5],?&C]JWX9_LY>"-.\2>/O'OA/P=H.KNL=C?ZQJD-G!>,R;P(V=AO.S+<9
MX&>E?GO9_P#!'SXG_LA?L(?%WX<>`W^%_P`1/$'Q0TG_`(133KRP\$6WAC4;
M6*ZN)3/>:KJ'VB5[U(8IG(7:&RHP#GCZ0_:H_P"";VL_%R[^$7B7P/X]T3PO
MXV^#FC76@V=QK_AJ/Q!I%[:W-O##.9;1I8BDH\A"LB2`C+*0RL141OR7>^GY
M.Z^6FO\`>>]K%2MSV6VOZ6^_7[EM>YVOPQ_X*2_#WXS_`+;6J?!#PM.=>U;2
M?"5MXOFUFRO+6;3'MKAE$4<;+*9)&*,C[E0H%=<ME@#Y]\-_^"U7PX^*7BO0
M].T_PK\08+7Q%XT3P+8:E=V5M':W%^TUS"2`)VD$:M:RY9D7C&`<U:_X)L?\
M$JM'_P"">7B.^U+1_%C>)[;4?"FE^'E:;3HX9=]M/>7$MP'1BH25[OY8E4+&
ML:C+=N1^''_!$7PC\,O#/P_CTS4?#UGXN\+?$MOB#KOB.T\.QV^H^*(OM%_*
MEE-(LF\;!>!5D9GQY((49XU7*IQ3VZ_^!_\`R/\`PU]#&3ERRMOT_P#`?_DO
MZL?0.E?\%%_@)KOCO4/"]G\9/AK=>(M)^U?;-.B\0VKW-N+9&DN2R!\XB1'9
MS_"%.<8KE=7_`."L7P,GT[0[GPGX[\/_`!&CUGQ=I'@U_P#A%=2M]2.FW6IR
M/';27&R3Y(24?+_[)P#@U\L>"?\`@@'KGA>'PGX6_P"%R>'[CP3\,])\3:1X
M;LX_!,46LI!K=E<VVZ^O5N<W#1&?<,1H)-G(!.X;/Q5_X-ZO#OQ7\%^&?#.H
M>-HK'0-.\.^"_#6JP:;HWV&?58M!>Y,LB2QS!HI+E;@@-\QBVYR^<5*Y;J^V
MGEUE?OT2T5_BW=C;W>9KIK^EOS?W>9]B>.?VZ_A-X#_9L\2_%V;QQH>I?#[P
MH98[[5]*N!?PF:.00FWC,6[S)C,RQ!%R2[!>M>7_``Y_X*Z>`-:\?1>'?'WA
MCXA?`^\U'1KGQ%I,_P`0M)32;/5K"V027$J3B1XT>*,AY(I621%.2M5=*_X)
MFKXB_P""<=S^S1XS\<QZGIUA#%;>'];T32(='U#3+:UN(Y].EDA1FADN(9(8
MB\BHB3%"2@+-7F7QE_X(_P#Q2_;)\,ZC;?'7X]Z=XQNM.\+:OX>\*#1O!B:/
M9Z==:C:-:3:G=Q"YD:YG$3$*BO%&-S8'/"=DW;7_`(;\[]-O-[J-6E_77\K=
M=_);/Z)U[_@J/^SAX6LM&N=2^.?PKT^W\0VIO=,DN?$MI$M]`)&B\V,LXRAD
M1E#=&*D#.*VO'O\`P4!^!OPL^)MMX+\2?%SX=:%XMO!;^1H]]K]M!>2&XQY`
M$;.&W29!08RP.0"*_-K_`(*+_P#!)_X]>+OB'X^\+_!KPWX?F\(?%KPSX=\/
M:SJFHIIDEM`=-CC@,L8E*W-@JPJQV1+<!VP5V-DU[;\;_P#@B#X@\>_$CQ)'
MH/Q;\-Z+X+\=^,-&\=:OI>I>"8=2UHW^G?9=\=MJ/GQO'!(+6/`V,8]S`':Q
M!:47.WV;[^5^WIK?Y6%+F4;K>WXV[^NGXW/L/X?_`+<GP;^*WQ=NO`/AGXI>
M`M>\;6+7"7&A6&MV\]_"T#;9U:%6+!HS]Y<97N!7,_M$?\%(OA?^R]^U!\,?
MA%XKU&^@\7_%B5HM(6&V\RWMOF$<;7,F0(A+*?+C.#N?(XKRWX*?\$F=,^#7
MQ>^&WB6+Q3I<^J^`_&OB[QI<>7HB0W.KKKOGJ(6<2%E\@2HN\[M_E@87C'$_
MM7?\$)K/]L_XS_%3XA^*OC'X\T[Q7XL%G;>&$T"8V.F>&;>P"RZ>D]ON;[:T
M5Z&N22T>6<A0G6LZ4F^5S5MN;[E=+SN[:Z:-WU1I-+WU!][?>[-_)7^:71GU
M+K7[??P2\.MXI%]\5O`5LW@F]CTS7E?6H`VDW<C,B6TPW929F5@(S\QP>*A\
M;_\`!0OX$_#3P/X=\3>(/C!\.-&\/>+ED?1=1O/$%M%;:FL?^L:)R^&"'AB.
M%/!P:^3?B9_P0P?XE?!C3-(U'XGV(^)&G_$Z\^*D6L1:+):V>H7MS'Y<L4UM
M#=).5`+%)([A70XP<9!R=*_X(":K\+O"^DS?#WXE^%/#_BNY\-ZMX9\33ZIX
M(.M:5J,.HW+7,D]K:W%XSVLZR'!;SG$@'SKFGKR^?_VM_P#TKW?*U]259OR_
M2]ORU^=C[#_:%_;M\$?L_P#[.FC_`!/3^T_''AKQ)?:?IVC'PI''J,NL2WTJ
MQ6WD?.J.KLZ_-NQ@YKQJ\_X+D?"/2]'%QJ.D^.=`O-.U;4='\1:5KFFQZ7J?
MA>:STR74F:YMYI%9DEMXB8WA\Q7SG.`2+GC7_@F#KE]_P33^%WP*\.?$2ST;
MQ%\*Y=`N].\3W6@?;+>>XTJ:.9&>R\]/E<Q\KYO&>IKS34?^"(6I_$?QU/XY
M\8_&-/%?Q,UC4=2N_$NK#PW';6ERD_AVZT6TM+>U28BWBMDNFE^=Y'D.06&0
MPJ22]HHO9OE\U[MOO]Z][=`I:\O/IIKZVEI_Z3WZG6?L9_\`!?3X(_MBP^*+
MN.YD\"Z/X/TC3=4U/4_$>J:?%;0O?DB&US'<.3-]W(QC<VS.\%1]$Z5^W9\&
M-<U'PO9V?Q3\!75WXUAFN-!@BUNW>35HX2PF>%0V66,HX<C[A4AL8KXH\3_\
M&]VE^,_A*FE6?Q(LX]9T?5?"FKZ3?0:&8[9+O0=)732MRD-PDKI,0\O[N6-X
MG(PQ()/1_`W_`((%>'_AKI_B2#5O%EM<?\)OX#U_PAKK:1I4MJ[7.KW2S37]
MN]Q<W#QNJ+LP2Q<_,QZBG7:4FJ2NE>WGI=>EWIY6OUT5.[2<]-K^6MGZV6O2
M^W0^H['_`(*,_`34?`VL^)H?C'\-V\.^'988=3U(^(+9;6Q:9ML/F2%]JB1@
M0A)PQ!P31J?_``4;^`>B_"O3?&]U\9/AM!X1UB\ET^QU9_$%L+6[N(L^;#&V
M_P"9TQEE'*CDX%?%'PQ_X-X]/^'_`(>2/Q1\0/"^I7MC-X<MK.[70+J,2Z5H
M]]'>O:3I<ZA.CB;R5R$5(XN2J$$BNWOO^"+FJ:)\<+_XM_##XF^%-)\4ZGXA
M\0:O9QZOX-BUK0TT_6?LK20K!YZ$3H]LI%Q&Z[U<JR$5FV^:R6FNOW6^_7TM
MUZOI?T_6_P!VGK?IT^LM>_;J^#'A?6/#5AJ'Q4\`6MWXQMH+W1(Y-<MQ_:D$
M[;8)HCOPT<C<(V<.>`2:W/AM^T[\.OC'X\\1^%_"GC?POXC\1^$)/)UO3=.U
M**XNM+?>R$3(K$IAU93GHRL.H(KX1^/W_!OF/CO\8)?%%_\`$'1;B'Q9HNB:
M/XST^Y\-3Q6E_P#V;MVO906E[!#;)(%_U4B3+&V&7G.?<_V$O^":&H_L8_M.
M_%3QT/&FFWF@?$%LVOAG2-".F65D_GO+]JEW3RA[DHRQL\8B5]I=DWL36D+/
MXO[WX6Y?OU_X`G>VGE_P?N_JY]:T445(PHHHH`KZJ\Z:7<FV`:Y$3&('H7P=
MN?QQ7X:_"?P3X2\4?LF?LJ>*?%OP^^(?Q/T#4/%?CJ]^+%OX3TG4M8U*7Q!,
MTL(>]2TQ,LBS*BH7(V*B8X`-?NE6'X-^&GA[X=7&K2Z!H>E:*^O7KZEJ1L;5
M(/MUT^`\\FT#?(V!ESR<#)J)0YK_`"_!WMZ/KZ(I2M^/XIK[UT]6?CWHGBO]
MJ[]G?X,_#SPYJ5Q^T'\/_AZ=$\27OAM_#_A>+QIXJBO/[1<Z)I.KEXIS&B6)
M!RVW)"H\H*G'<_#S]IW]K74OB+\#?A'=^(]47Q/^T#X(T/Q/J^J7^FV=MJOP
MR&GE1K[/:&$?\?2M`D/FH0D\K@=`!^L]9:>"=&C\8OXA72=-&OR6@L'U(6R?
M:VM@^\0F7&_R]QW;<XSSC-:QE:U]=4_-VYM^]VU?NHKU<O:RTT_-K;T2=NUS
MXI_X)(_&;XV_$+XY?'71_BK<?$;7-$TG5Q)X<U?7O"P\/6"0M<72_9;>%[>*
M5I$C6'>P>:)AL97!8Y\#_:'_`&6_&'@CX*?M?:)X2\$^/SX1OOBKX:U>72='
M6[-UK^@*FFRZPMCEM\X=1<[TB;YSYBCDXK]9J*E:6:Z)+ULXO7O\-FNP.SOZ
MW]-&M/O/SY_X(Z>-['X*OXM\'-X?\<^#_"WQ0^(FN:I\*O#>MZ5>07&G:#;6
M=H9I6AFR]C:FY\WRTEV9:50H^<5VWQ&^#WB3P!_P5GU;Q]X$\'WNH7FK_!K4
MM\]Q-/%I.JZU'?6XL[:><YBB<QIC@!@FXXK[.\L&3=@;@,`XYQ3J<M7&2T:5
MO_)7'_@^HNC3ZM/[I*7Z6]#\D_\`@EK=?&?]BG]K?X[>+_VFO"OBFSU/XB6_
MAE;O6X[_`/MBTU36[J\N;>&RTR&WBQY*I,@\M"Q@2`&1B&##ZO\`^"IGP/N_
M'_Q`_9G\4:'H&M:KKWA;XOZ']HN]-2>0Z=I3M*UV\RQG:(,QQ;V<;1A<D5]=
MO&),9`.#D9'0TZBF^1P?\K37HG=+]/3H*<>;GU^)?I9_UW/Q<^'WPG^+5O\`
M\'`,OC"7PA\08XY_B?J0N8V\/7R6D/AO^Q_LT%ZVN[_LDMFT@61=/";DD;[V
MX8KTC_@J_P#M&?M1?#?X[?%.W\%:I\<-`32]+TI_AAI_@7X>P>(M'\2LY7[>
M^HW36\S0RH[%=A:/;&JLH<DU^K=%3&ZA"#?P_P"27Z7Z[ORM<FG.4[;_`.=_
M^!TT2ZW;_,'Q)XW_`&P(/VE/$_B?2?$7C^?0]*^*^F^%M'\'7'A:U71;_1)]
M'66>\>X^SBX\I;QMIG$NR,J03U`X+_@GYKGQQ^,__!1_X">(_B;<?';6=6T+
MPMXF3QI#XH\"#0O#_A/5YUMP;6QN8H42XB8QE4+/("L:,KY=@/U[HK6%3E=[
M?UR<K^_63\]K+?.4;JU^WX2YO\EZ'Y.?$SPSI7C+_@NEX4.@?#CXY^'WT3Q8
M-9\0_$JZ\.ZQ=VNOW`M#:PZ'9SA?LUMHZAO,ED?Y&=`%_OGZL_X)H_!"Y^!7
MQP_:?T^+P_J^@>&;WXA17F@K=K/]GNH7TNS,LMNTI.]#.9<E25W[N^:^MZ*S
MI^Y'E79K[W%_^VI?\'5U-*4N;S3^Y-?^W?TC\>O`_P`*?!FC^/?%NE_M#_`+
M]HKQ[^T+J/C^YOK/Q1H-CJ=U#>6+7Y;3IM.U2WFCMK*TBM1$KPM)%CRG#*Q8
M9Z?5_P!I#]KVU_:HU2QLS\59_$">+]9M-0\*OX&A7P3IWA..WG-EJ%IJWE%I
MKP[;5U7SG9Y9I(S$`M?J]12:]U16EE;RZ:V[Z:^KM8OF]YR:W=_S_#7\%N?D
M`D'[<-C\)I]0;XP?%ZZU<_`V'XC>2W@+3A)_PE2RL/[#51:9`*8WV^#,Q`;(
MY!P]&\9_M%_"O]LKXHW/@D?'*P\6>,_B?H>HZ=X6/@$3>"->L9K#38]4N;K4
MYH<VX2);C[LZ!'MXPH9G;'[-T4Z=X3YWKY?]O<UOR7HNY+LX<G];)?YO3JV?
MCEX9\)_M0>'%UOPU\/\`4OB9\*-`MA\4_%I;2/!UM-_;&HP:TS:/"QN;9_\`
MCXB?<@3#3*,C.<U:M/VHOVZ_$/[8OAG3[F#7?#L5[?\`APZ;ILWA&[E\/:GI
M<UE&^H/>30V,@@E\XS!VDN86MRB@1D$9_8.BG!J*BK;6_!O]&EVLA.[;?>_X
MV_R;[W9^-WP0UKX]_'[]O+X!2?%Y/C1J&JZ%XQ\3R>-O#^I^!$L_!7A>V:PO
M[>S^RZA'`%N(9(&C&7FE5S(22K``_7/_``05N4C_`&,O$^F:1,USX!\/_$KQ
M5I7@:42F6%M"BU.46PA<_>A4^:J$$C:H`.!7VCJFF6^M:;<6=W#'<6MW$T,T
M4B[DE1@0RD=P02#5'P1X&T7X:>$[#0?#NDZ;H6B:7$(+.PT^V2WMK5!_"D:`
M*HY/0=ZN,[1Y;=+?BG?Y6LMW9O7NY^]+F\[_`)_Y_@M#5HHHK,`HHHH`****
M`"BBO!OVD?VP=9_9^_:B^"_@;_A#8=4\._%S5I]#_MW^UEBETR[CM+B["_9O
M+)D0QV[?-O&"P&*<4Y245NP>B;?0]YHK\\+3_@N-XFU;Q#+>Z9\"]6UKP1XD
MU'Q-H/@34-/UR.;4/$6I:&)/-CFM!'F".?R)_+*M(^(6RF2N>G_9._X*C?%#
M]IWX\>'O!L_PI\+^%;3][=>)-3NO$=SOTZVW.EHJ6LUG!(+B]V&6"&0B3R$:
M1T0%`RA[[2CU2?WZ_EJ$_<NI=';]/ST]3[HHKS'X._M<^#_C?\3?$W@W2?\`
MA(++Q+X3C2XOK#5]$N]-=X'EEB2XA,T:B:)GAD`="0=ON*].H`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K\0!^W)^V/H
MW[?_`(U\*D_%F;QGK&O6=IH_AE_!F_PG96L6OXD6&ZV^5]EDT95E>\9_,WLR
MC!Z?M_7XL^+_`-NGXR>%O$&K?L[3^(/&UG\>9_C@-:M_%DWBK3%\+PZ`VI+(
MML9&N/,2W^R8B^P&/?YAQU.RG0=L3#KY/9W<5^"=_1,5;_=Y=//KM)_BU;UL
M?M-7G'QJ_9@\/?'?XD?#/Q1K-QJL.H?"K7)?$&CI:3*D4UQ):3VC"8%263RY
MW("E3N"G.!@^CT4)M.Z'NK'R7\*_^"/7P_\`@Q^T6OQ%T+Q1X_WZ1>ZSJWAG
MPW>ZE'<>'O">H:J#]MN[2V\H/N<LY"R2.J^8^T#/%?Q/_P`$8_AEXV_X0>YU
M;6?%]YK7A.^FU74-5>XMVN_$][-=6UW-=73O"Q29IK2`"2W,3I$IA5A'\H^O
M**4?=Y;?9V\OZ_R[('>3;?6]_G_7XONSYV\+2N?^"K7C1<R;!\+M&('G#8#_
M`&IJ7_+/J#_M=#T[5]$U\Z^%4_XVM^-6Q_S2[11GR/\`J*:E_P`M._\`N]NO
M>OHJ@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"OY__@#JOA+X&_MH>/\`0;76?V7_`!#X=T7XD-K-SXL\6?!N_P!1U&)]
M0UTVXMK75RVZ1H+DF'[2RF*.1/\`6$`5_0!7X0_#+X&_!SQ;^W5K=EXO\'?M
M=>&+^/Q<\.H_#?2[`ZIX1G@76WO+6X\\1+<QZ;+=LEX8VVJ&<@%E`R\/98J#
MEM9^N\?Z_P"!<5:[PTK;Z?D_Z_X-C]WJ***0PHKY1O\`_@M7^SYI/Q`\3^'[
MOQ3JMLWA==45]1ET.[73-4GTS;]OMK*Y\OR[F:`LH9(R3D\9P:O_``:_X*U?
M#+X^?%3PSX+\-:/\2KGQ#XGN+V".&Y\)W5I%8+9-Y=Y+/-*%C6.&4K$Y5F_>
M.J@$G%$?>LH]=?EW"7N_%I;3Y]C3\*,/^'L/C4?N\_\`"K=%./.._P#Y"FI?
M\L^F/]KKV[5]&5\D^'OV@/`EI_P5(\;W,OCGPG':1_#C2;1W;6;011SIJ>I%
MXBV_<)%')0]!@XYKWW_AIWX:G_FH7@?KC_D/6O\`\70!W-%<*/VH/AH1G_A8
MG@;'_8>M?;_II[C\Q2#]J+X9L./B)X%_\']K]?\`GI0!W=%<+_PT_P##3'_)
M0_`W_@^M??\`Z:>Q_*GI^TO\.)!E?B!X)89`XURU[X_V_<?G0!V]%<4?VE/A
MT/\`F?O!7_@\MOK_`'_>D;]I7X<J>?'_`(*'UURU]_\`;]C^1H`[:BN%7]J+
MX9L<#XB>!3SCC7K7KG'_`#T]:=%^TW\-IVPGQ!\#N<9PNNVIXX_V_<?G0!W%
M%<4/VD_AT?\`F?O!7')_XGEMQW_O^QH'[2?PZ)_Y'[P5UQ_R'+;_`.+]J`.U
MHKAF_:?^&JG!^(?@8'WUZU]O]OW'YBB/]I_X:RCY?B'X&;Z:]:GW_P">E`'<
MT5Q/_#2GPZQG_A/_``5C_L.6OO\`[?L?R-+_`,-)_#K_`*'[P5Z?\ARV_P#B
MZ`.UHKAY/VG/AM$V&^(7@=21D`Z[:C(_[[]Q36_:A^&BGGXB>!1]=>M??_II
M['\J`.ZHKB?^&E?ASNQ_PG_@K.<8_MRUZ]/[]"_M*?#ICQX^\%'/3&N6O/3_
M`&_<?G0!VU%<._[37PWC.&^(/@A>,\Z[:]/^^ZZ?PMXOTGQQI"ZAHNJ:=K%@
M[,BW-C<I<0LRG#`.A(R#P>>*`-&BBB@#A?VD_P!I+P;^R-\&-7^(/C_5AH7A
M+03`+^_,$DRVPFGC@1F5%9MN^1,G&`"2<`$U_/M\./"N@_%+]MOQ)+X8_:"_
M9UDTCX@^,[>1O'<_CV:S\4WCVWB0ZE#,-.DVR2710K91*K"W:,*ZY!!'[??\
M%5OA?XD^,G[`GQ#T#PC-/;^(+BUMY[::+7H=#\@0W4,SNUW-')%&BI&[-O0J
MR@J<!LU^(/\`P3[\3_$;2_VH-$^&O@KXU?#WQ/9S>-I]0@2U\7>'HAKD4M\9
MIC;B;0RUQ*5+%H[>YZY">6,8K"7^MQEU6WS:_K^F+$I_5FNCW^2?^9_2'111
M4C/SK^!__!(/XB_##XW>&[?7?$GP^\3_``6^&6O^*_%/AC1?[/G&L:S<:VL^
M;347DW0""(W4XS&IW@KN7CC0\/\`_!*[XN?#KQ1X.\3^!?'_`(6\!:[>3K)X
MRM-$M#::;:6\=W!+;:=IT*Q$-8V]N+N$6[^4)9;M[EV\S`'Z"440]SE<>EOP
MTU[Z?D$FY.3?6]_F[_GK_2/C+PA^R=\*8?\`@JIX]MD^&GPY6*[^'.DZC<1#
MP[;9FN9-4U+S)W'E["[8Y;[YQR<8K+_X)4?L]_"/5/V/H9=4\#_#>XO!XM\4
MH7NM'LGE"KX@U!54EDSPH``[`"O6?"I;_AZMXT&9-G_"L-&X\T;,_P!IZE_!
MUS[].W:MW6/^";G[/_B#6;W4+WX+_#.YOM1N)+NZG?P[:E[B:1B\DC'9RS,2
MQ)Y)))H`UO\`AF?X(X_Y)_\`"O\`\$5A[?['L/R%>`_\%4/V=_@]HW_!.+XT
MW.F>!OAI:WT'A*]>"6VT:RCEC81G!5E0$'TQ6]JW_!./X!1?M1Z)IR_!KX;B
MQF\,WMP\`T&W\MI%N;95<KMP6`9@#C.&/K7H2_\`!,C]G96!_P"%(?"XX(8!
MO#=J1D'(X*8H`W?"O['_`,))?"^FLWPM^'1+6L1)/AJS.3L'_3/W/YU^;?\`
MP4%_X-+_``K^VW^UCXG^)>C?%<_#2Q\1BV(\/Z7X/A>VLVA@2$E66XB'S;-W
MW!R>]?KQ'&L,850%51@`#``I2,B@#^?7XE_\&9.F?#_4O"D`_:)UBZ_X2;6X
M]'9CX01/LX:">7S!_IAS_J0,<?>Z\5U?_$$+I>?^3D]8/RE.?!49X.?^GWW/
MYU^Q_B']E/2_%5W83W_B?QY<2:7>C4+/.N2`6TX5T#KQV61Q@\8-=IX%\"CP
M)9SPKJVNZMY[A]^IWAN7CXQA21P/:@#Q/]D[_@F/\*OV9/V:?`OP_NO!W@?Q
M==>#=&MM*EUN]\,6:W.J/$@!GD!5R&<C<<LQR>IZU^&G_!WY\'_"/PU_;<^$
M-IX=\-V7ANUN/!KRRP^'M)A@$S"_D4%T38#QQDY["OZ5*_G!_P"#TIIU_;H^
M"WV?[3N_X0R3=Y!(;']H2]<=J`/R,U?0+%;77<+XG&-011MT]?E'[_@?/]W_
M`.M5K6?#NGKJ'B+$?B5=MO$5VZ>GR'S(>5^?KR?S-8FMR:E]B\18&K?\A2/;
M\[]/W_M5W7GU$:EXHP-6_P"/6';\[_\`/6#V^M`'](W_``:F?LY?#WX@_P#!
M*&WU#7O`OA77K_\`X2_5H_M>L:';3W;*K0[0[.K$8P.,\8%>9_\`!W%\`O`G
MPV_9\^"<GAWP9X>\/277B^ZBG?0]%M[>:9!I\I"G8J[ER`<$]J]Y_P"#0XN?
M^"/MEYN_S/\`A,-7W;_O9W1=?>O+?^#R4N/V;O@7Y?G;O^$TNO\`5$AO^0=-
MZ4`?SR:-X?L&M-`ROB8[M2=6W:>OSC,/#?/]WD_FU5[O0;'^P+LX\49&H*`1
MIZ[A\K\#Y^G`_(57T*34?L?AK(U;_D*R;LL_3-O[?6JU])J7_"-7N!J^?[3&
M/G?ILD]J`/W4_P"#/7X%^"/B5-^TP?$7A'1?$9L=1T%+8Z]HUO/);*RZEN5`
MX;:IVKTQG:/2OKS_`(.6/V9OAOX)_P"".?Q0U+1OA_X-T?48)]*\J\TW0;6&
MZBSJ5N#L9$#`D,PX(SD^M?,O_!E:92G[4GF^?N_M;0,><26QMU/UK[._X.B-
MW_#E#XL[-V_S=)V[>N?[2MNE`'\G<VAV0,9_XJW.SK_9RYZGG_65''H=DC+@
M^+>#VT]?;_II["J$\FI?N?EUG_5<_._7GVJ*.34R5XUG[W/SO_A0!^IW_!IO
M\*O"_P`0?^"HVKV.O:#'XALAX'U&06_B#2898D87%H`RH^\9P2,X'4^M?T^^
M#?`VB_#K0DTOP_H^EZ%ID3,Z6FG6D=K`C,<L0B`*"223QR:_F1_X,[FN3_P5
M=U[[1]LQ_P`(+J.W[023_P`?-ITS7]0=`!1110!XW_P4(_9KU3]L;]B;XE_"
M[1=6M=#U/QUH<VD07]RKM#;&3`)<)\Q7&00.N:^+_B-_P2H_:2^-_P`/OACX
M(\2^(?V:-*\(_#3Q%HNN:>WASPKJ%EJ%H-.GCDV6[F0K&9%0JV!SN-?H7\:O
MAY??%CX7:QX>TWQ1KW@J^U.(1PZWHK1K?Z>0ZMOB,B.F2`5^93PQK\2?V&==
M_:.UWXHWEAX8^)_Q+\1^"O#?Q+U#1[VY\1?%K0],O[A8=2*3^?IDEG+.NX!C
MY8F&\'Y-@(P4?XZBM]'Y>Z]/N<@JZ46WMJO/5:_?8_=^BBN-\;?M#>!OAM\2
MO#/@[7_%>A:1XJ\9M(FA:3=7:QW>JL@RXAC)R^!GIZ&CK8/,[*BO'3_P4(^!
MP^(WBKPB?BMX%7Q)X(MI[S7=/;5HA-ID4`!G,@SC,61O`R4R-P&:S/A__P`%
M-?@'\5_&GA_PYX9^*7A?7_$'BFYDM-,TW3YFN+J>2-2\@,:J6C"*I+%PH7C)
M&10KO;J#TW,GPJG_`!M>\:MA?^27:*,^1S_R%-2_Y:=_]WMU[U]%U\Z>%6'_
M``]=\:C*[O\`A5VBG'G'=C^U-2_Y9],?[7?IVKZ"UF6\ATJX;3X;>XO5C)@B
MN)C#%(_8,X5BH]PI^AH`\\UK_D[[P_\`]BI?_P#I5:5Z97C%[X;^*EY\9=.\
M5?\`"/>`1'8Z1<:8;?\`X26[W.9989`X;[!C`\K&,?Q5ZMX5N=6N]$B?6[/3
M['423YD-E=O=0J,\8D:.,GC&?D&/?K0!HT444`%%%%`!7\Y__!Y=:->?MW?!
ML+;ZI<D>"9#BQE$;K_Q,9.2=IXK^C"OYP/\`@]+M7O/VZ?@LJ6SW1'@R0E$S
MD#^T).>/\\T`?DYK&C2FTU[_`(EGB\YU)#Q=KS_K^1^[Z?\`UJM:UH\AU#Q'
M_P`2WQ<<VT72[7YOWD/3]WU_^O7*ZUHTQLO$7_$IN3G5(R.6Y_U_/2KFO:--
M_:/BC_B4W)S:P@<MS^]@]J`/Z>O^#1Z,P_\`!(RW4I<1%?&>L`I<-NE7YHN&
M.!D_@*\N_P"#Q6$W'[/'P*41W<I_X3.[^6V?;(?^)=-T.#_*O3/^#0Z,P_\`
M!'VR0QF(KXQU@%#U3YHN*\L_X/)H3<?LW?`M1$TY/C2Z^1>I_P")=-0!_/GH
MNC2BU\/?\2SQ<,:FYYNUXY@Y/[OI_P#7JO>:-+_PCUX/[,\7_P#(0!Q]K&3\
MK_\`3.LC0M&F%GX9_P")3<C&JR$_>XYM^>E5;[19_P#A&K[_`(E%S_R$QQEO
M[DGM0!_0!_P9A6YMIOVHU:&_@/\`:?A\[;R3?(?EU/G.!QZ5]D_\'/R^9_P1
M9^*HVROF?2!MB.';_B9VW`//-?%O_!E9;M:K^U*K0-;G^UM`.QLY^[J?/-?9
MW_!T0I?_`((H?%D!2Q,ND@*._P#Q,K:@#^4J;0Y?W7_$J\:?ZO\`Y_%]_P#I
MG42:'+Q_Q*O&G7_G\7_XW6%/H4_[G_B377^J]7]_:H8]"GW+_P`2:Z^]ZOS^
ME`'ZW_\`!H99-9_\%7-8W6NLVV?`FI?\?\PD+?Z3:?=PJ_C7].5?R^?\&=UB
M]E_P5=UW?9RVF?`FHX#Y^;_2K3UK^H.@`HHHH`*_G%D^)]GIW_!3_P`<6EY\
M%/A7=?%B]\863:#X'E^%/[^VN%\2&.9UO0@:6:73E%\;YI/*7<2J],?T=5^0
MFE?MZ_'_`,8>%=2\`>&X?BEKOQWG^-TC6.KV'A>.\\('PQ'J@WP#54C-L+!;
M-&#@R>>LH*G!S58?3%0EOY>KBOPO?T38JUWAYKO_`)2?XVMZV/U@^(VAZSXE
M\"ZI8>'M<_X1G6[NW:.RU4V27OV"4])/)<A9,?W2<&OG']IG]D[Q]\3/%O[+
ME\;ZP\8ZI\+/'D>N>*-<F@ATR2>U&F7]NTL<*D@$RSQ?NT/OVKZIHJ5I)271
MI_<[E7T:\FOO5C\G_@]_P2>^)D?QH\,^$?B'\-?".J?"GX=>)_''BBZ\4Q:Q
M'<:EX\M];$QAL1;!4EAD!G`D:1\$VT15A@5V7PZ_8B_:&^`?Q(\$>-_AYX<\
M,Z;=Z]-/'JNE:IJ*ZJ?!6GS:A;S-9FXN)3)-)<1-=SWEW$9)YKI8%'[F):_2
MZBBG[CBX[I)>J2MK\K+_`(>5U4?.Y.76[^;=[KYZ_P##*WR9\`OA'#\)_P#@
MJE\2A;ZUXRUJ/5_A[I-\[:[JLNI+:NVJ:D3%`\K%HHQGB)?D'&*^LZ^<_"C1
M_P##V'QJ/W/F_P#"K=%)'S>9M_M34O\`@.W]<YKZ,H`****`"BBB@`HHHH`*
M_#__`(.D?^"8GQQ_;C_:S^%_B+X7_"W5?B#HNA^%I+"\FL]0M[46MQ]L>0*?
M,D4G*,#P".?:OW`HH`_D`\;_`/!"+]JKPOX>UB_U']G'Q/;6<]]#*9&UVS(&
MYW1<@2DY+2J.G?VK6U'_`((!_M<7EWJ[C]FKQ3B_A2-?^)_9<E7C;G]]Q]PU
M_4S^V3_R;OK/_7UI_P#Z7V]>H4`?`O\`P;;?LF?$#]B__@FG:^"_B5X4N_!?
MB0>)M3OAI=S<13R102M'Y;%XV93G:>^:[K_@L'_P23T[_@K;\,/!OAR_\;:A
MX'/@W6)-7AN;73X[S[07@:$HRNRXX;.<U]@44`?A9>_\&5/A70-&6>/X^>)&
M_LDR7L*MX;@^_A2<_O>G[M?UK&^&'_!F+X5^)?PFT+69?COXCMQXBLK;5Y($
M\.P,(I)80^T-YN2!O(_"OW;\6N!X6U/D?\>DO4_[!KE?V8'!_9M^'^"#_P`4
MYI_0_P#3M'0!\N_\$:/^"+FE?\$?K3XDIIWC[4_',GQ'NK&YG:[TV.R%F;47
M`&T([;MWVALYQC:/>N<_X.?X_-_X(L?%52GF!I])!0OLW?\`$SMN-W;ZU^@%
M?GW_`,'1`S_P10^+/`;][I/!Z'_B96U`'\H<WAR#]U_Q3]O_`*OC_B?1^_O4
M:>'+?C_BG[?K_P!!Z+_&LF:UDS#_`,2S3O\`5?\`/8_[7_32H8[:3*_\2S3_
M`+W_`#V/_P`<H`_6O_@T&TU-/_X*MZQLT^.QW>!-2SMOENM_^DVGH>*_IUK^
M7S_@SNC:/_@J[KN;:WM_^*$U'B)]V?\`2K3K\QK^H.@`HHHH`*_F]\(?M'>%
M_AM^WA\0WTZ"^T2T'CRWN=*^'6E_$S7++59[Z7Q2;&\$UHDWE/=R*&NQ;)#Y
M0B?+,P&#^\7[?VM_$KP[^Q=\2KSX.6LE[\48=#G/AJ&.&.9WO",)M23Y"PR2
M-W&0,U^>7_!/+Q/\<?A5\:]7U#XQ_LJ_$GXD:U>:S9#PS\0]9T+PVGB/2;5X
M(XKG[9<P.KLD<N\H4W,(OE[`4\/;ZRIO:*^^[6E_E^O0*_\`N[BNK];63Z?/
M]#];:***0!1137D6/&X@9.!D]30!\\>%=_\`P]8\:<R^7_PJ_1L#S%\O/]IZ
ME_#][/OTZ5]$U\Z>%<?\/7O&O"Y_X5=HO/D'=_R%-2_Y:="/]GJ.O>OHN@`H
MHHH`****`"BBB@`HHHH`\J^,WP,\7?%[2M3TO_A.[;3-&OYHI8[=-`266W$<
MJ2J/,,OS?,@R2O0FNK\">&?%6B:E-)KWBFTUVV>/;'##HZV9B;/WMPD?/'&,
M5U5%`!1110!R?C7X%^$OB-JWV[7-"LM2NC&(3),&R4&?EX/3D_G5;P;^SIX(
M^'NJ6EYHGAO3M,N+!=ENUNI40KMVX49P!M.,8KM:*`"OS^_X.@%W_P#!%CXK
M`B(@SZ2,2-M0_P#$SMOO'(P/QK]`:_/O_@Z(;9_P10^+)PIQ+I)PPR#_`,3*
MVZT`?R@S:9`?*_T;P9_J\?\`(1E]_P#IK42:7`,?Z+X,Z_\`01E_^.UESZI)
M^Y_<Z+_JL_ZF/WJ*/5)25_<Z+][_`)XQT`?K5_P:"6R6_P#P5<UG9'H\>[P)
MJ/\`QX7#39_TFT^]EFQ[=*_IVK^7S_@SNNFN?^"KNN[DLTV^!-1Q]G15!_TF
MTZXK^H.@`HHHH`*_(3X3?\%O?B%\7OVF=:\.ZM\<?V9?A<--^(-UX4C\$ZQX
M<U>[UZ:W@OOLZ;+I9TADDG495U38&89'!%?KW7X.ZM^R%\;G^.NHZ5_PAW[6
M!^.,WQD;6[37XO$MQ_PK5/#9U,3@-*;C9Y/V3(\O9YN_"Y_@HHZXB"EM_P#;
M1^6BOOTN*M=4)..__`E^MMNMC]Q_B/JVN:%X$U6\\-:/;>(-?M[=GL--N+[[
M%%>RC[L;3;7\L'^]M./2OR;_`."S?C:W\7?%[X9Z7K^B?&3PS\6M<LM.6]UC
MPX=9UCPS\)[9+WSYKRV&GP`7FHS+&T*_*1L(W^6OWOU_HI6M)2[._P"?^?\`
MD5]EQ[JWY?U^9^'?P7^$'BKXL_M2+X3UB_\`CGX4^*6MZWX^A^+_`(FD_M*V
MTNW\-R)(=)D267_0R@7[(8%@.5S,#MS71?LY^`[;]DKX^?"KQW-\,O'?Q$T+
M6KR[C\!RL;VS#^=>P0R:JUD_GQPR&.Y8V-HQC$5E;S2O(99`%_:%E#J01D'@
M@]Z6G2]QQDNB2];:?+Y=6WU5E4]_FOUN_FW?_@>B2[W^3/@+HGC#1?\`@JM\
M2AXO\1:'X@>?X=Z1)IW]FZ<^G?8[4ZIJ6V*2-II?,<=Y05STVC%?6=?.WA7=
M_P`/6O&G$NS_`(5?HW/DC9G^U-2_CZY_V>G>OHF@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`*_/[_@Z`('_!%?XK9,:CS])R9`2@_XF=MU`!)'X5^@
M-?GW_P`'1$IA_P""*'Q9=?O++I)&1GG^TK:@#^4":YMOW7^G^#O]7_T#YO?_
M`*95&EU;''^G^#NO_0/F_P#C594_BV^_<_Z1;<Q?\^T?'7_8J&/Q=?DK^_M?
MO?\`/M'Q_P".4`?K9_P:"2QR?\%7-9\N?1Y\>!-1S]@MWBQ_I-I][<BY]L9K
M^G:OY?/^#.S5I]4_X*N:]YSQOL\"ZCM*1JG_`"\VGH!7]0=`!1110!'=7<5C
M;/--)'#%&-SN[!50>I)X%?SX>+O"GQ;^%/\`P41\407WCOP]IFL_$;Q5I\</
MQ*?XOV2VDBP^(_ML&+`3&X5?L/EV(L%BV,X!)*\U^W7[=FE:/KG['OQ$M/$'
M@'7OBCHMQHLR7GA/1`YU#7XSC-O!L96WMVPP/%?@?^PSX>@_9R_;KT:3PIX8
MU7]D'PGJ.N6UL_ACXE^![_QEJ7B$M-&H:"Z_LW_0<Y\L;[K"$[LG'+PS:Q<)
M=OU?_`Z7?D+$?[M)=_T7_!ZV7F?TDT444AA1110!\Y^%-G_#V'QK_J?,_P"%
M6Z+D9;S,?VIJ7;[N/UZU]&5\[>%6D_X>L^-!^^\K_A5^C'[Z^7N_M/4NWWMV
M._3&*^B:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K\_O^#H!PG_!%
MCXK%G\L"?2<N4W[?^)G;<X[_`$K]`:XO]H/]G?P5^U7\)M3\"_$/P[8^*O"6
ML^6;W3;S=Y4_ER+(F=I###HI&#U%`'\.,VLV?[K_`(J*'_5\?\2).G/M42:S
M9@C_`(J&'K_T`T_PK^N3QG_P1!_84^'?V;^W?@Y\/M)^U[A!]KO+F+S=N-VW
M,W.,C\Z\U^`/_!)C]@_Q5X7N%U/X9_#:?4G\1:O:VZ/?W`D>%-3N8[95!FR1
MY*Q!3W7:><YH`_+;_@T$O(;O_@JYK'E:@E_CP)J.[;8K;;/])M/3K7].U?/O
M[+__``2L_9[_`&+OB--XN^%WPM\/>#O$EQ9/ITE_9M,TK6[LKM'\[L`"R*3@
M9X%?05`!1110`4C*'7!`(]"*6B@#$^(_CVS^%W@35?$.H0:G<V6CV[7,T6G6
M,M[=2*O41PQ*TDC>BJ"37Y[?\%3?^"A'CCX5Z%X6^(/PI^*%KH>FZ/!I.J>(
MO`VH:#:1:K9Z9=WPCDU748;R1;T6HB5XE@MH1-YK*V[`('Z25YU\7/V0_A7\
M?O&V@^)/''PZ\%>+?$'A=@VDZCJ^CP7ESIY#AQY;NI90'56`S@,`>M"NIJ79
MK^O/T_&^STY6NZ_KTZZ_I=/\R?A?_P`%&?VC/CG\3-`D\(_$_P`&RZK\9_$7
MCGPKHO@:^T2!3X*&D";[!>-(N9V;$(,OG@H?M,6$P#GH?V;OVX/B7X:_:/\`
M#5G\:?CSJD'@_1+Z]M[F"QT"SNX=?O5O([..V:]M+,?Z)9O<V\5U=D11/=S)
M%'@1R&OT.TC]C/X3>'?BSK_CW3OAQX,TWQQXIMY+75O$%GI,-OJE_'(H60/<
M(HD.X*N3NR=HYXI9OV-?A1<Z/X,L)?AWX0FL_AV%'AF*32XG&B;2I'D9!V_,
MB,?5D5CR`:=/W7%O6R2?^?ZZ[WMHEJJGO<UM+W:^_1>EM/E?=Z>#P3?'/1/V
MWO%GQ&A^!4%WH]_X7M/"]F%\96"75P;6]O)Q.<C"QNLZ80_,#G->E']H/XV!
MO^3>I\9Z_P#"<:;Z_3TY_&O>:BO9S;6<L@V9C0L-[;5X&>3V'O2`^8=1_;F^
M*NE_&;2?`<G[.^L'7M9TBYUN!E\7Z>;5;>WEMXI0\N,+)NN5VIU8*Q'2NE_X
M:)^..S_DW6XSC./^$ZTWK@G'3UP/QK2_99_;2TW]H#7=4\(:]I$_@/XJ>&XE
MGU?PG?7*SR&V9B([ZSG4!+RRDQ\L\8P#\KJCC;7ME'1/N'D>"G]H7XV[C_QC
MS/C)P?\`A.=-YY/M[`_\"]J<O[0?QL)_Y-ZG'/\`T/&F^WM[G_OGWKWBB@#Y
M<^(W[<OQ6^%NL>$K'5/V=]8:X\::PNAZ?]F\7Z?,J7!MY;C,I'^KCVP2#>>-
MP4?Q"NHD_:'^-Z@X_9WN&ZX_XKG31G[WM[+_`-]>QKU/3/C'X<UCXO:MX#@U
M%6\5Z'IMKK%W8-&Z,EI</-'%*I("NI>"13M)VD`'&1GJ*/,.MCP0?M#?&XOC
M_AG>X`SC/_"<Z;TSC/3TY_"E3]H;XW,HS^SQ<*<#(_X3G3>.%]O<_P#?/O7O
M5%`'RW\;_P!NCXJ?L_?"W5?%^O\`[/&L/I.CB(SI8>+M/NKAO,E6)=D:C+?.
MZ9]`2>U=8W[0?QL#X'[/<Y&<9_X3C3?4^WL/SKU'Q5\8O#G@KXC>%O">J:BM
MIKWC7[6-&MGC?%\UK$)9E#XVAEC.[:2"0K$`[3CIZ`/!/^&AOC=D?\8\7';/
M_%<Z;Q]WV]V_[Y]Q35_:(^.!3/\`PSK<`XSC_A.M-ZXSCIZ\5[[10!\]>(OV
MH?C+X7\/W^IW7[/-Y]ETVWENI?+\:Z<[E(U=CM4#))"C`_VAZ5G_``N_;&^+
M?Q>^&WAWQ7I/[/.III/B?3;;5;,7?C'3X+A8)XTE3S(SRC['Y4\@@CK7MOQ5
M^,GASX*:9I5YXFU%=+M-:U>TT*TF>-V1[RZE$4$;%00@>0A=S87)`SR*Z@<4
M=+_U_6H'@O\`PT+\;<?\F\3]/^AYTWV]O<_E[TV3]HCXWJO'[.UPQP>/^$ZT
MT=F]O9?^^O:O?**`/G^?X\_&B]D`F_9R>0*2`7\;Z8V!G&>GIS7*?"']LSXF
M?&G0K[4]'_9LOX8=+U>]T287GBO38)!<6=P;>4J"/F3>C[6'#*H(X(KZ*^+/
MQ3T/X(?#37/%_B6[.G^'_#=G)J&HW0A>7[/!&-SN50%B``2<#@`FMK3=1M]7
MTZ"[M)8[BUNHUFAEC8,DJ,,JP(Z@@@Y]Z`/#?^&A?C;M_P"3>;C..G_"<:;Z
M'V]<#\:]6^%7B?Q!XN\'17OB;PPWA#5GDD5]-;4(K\QJ&(5O-B^4[A@X[9P:
MZ.B@`HHHH`****`"BBB@`HHKA/B7^TMX'^%-AXJ?5/$>EMJ'@O0;CQ+JVDVU
MU'-J=O801F1YOLRMYFW`P#C!)`SS2;25V-)MV1?^.?Q/D^"WPA\0>*X]#U+Q
M(WA^S>].F:<T2W=XJ<LD7F,J,^W)"E@6("CD@5\`_%_]L.?_`(*=V^G>$?#D
M-CX>\#>)]2TS4?!-SK\=RNG^/KVPFE?5?#>M"+,FGR81<6\B;W$>_P#>+F*L
M_P#:$\7^*/\`@H[\:/AMI>H?#>[%@GA\^-+7X=Z_X@M'TOQGHEP\5NVI17EF
MY>RU:S^TH\2RLT1$C;'#CS%^UOV4_P!BWP]^RNVL7UI?ZGXA\2:^T::EKVI,
M/M^JPP%UM?M93;'/<10L(3=,GG2JB^8S$9JO9M.]1:?Y/_/IMHT]=!<VC4=_
M\[/\OST[G#?L.?L`6?P"^W:YXHT+P=#KH\1WVM^&--T<275EX!MKNWA@FLK"
MXG591'+Y32R*J1QF29ML8`!/T[17/?$;XK^&_A'\/]:\5>)=:T_1_#OAV![C
M4K^XE`BM$3[VX^O0;1R20`"2!0Y:*^R_0#5\0:PGA_0;V_E,*QV4#SN9IEAC
M`52QW.WRJ..6/`ZFOS=^+/\`P4\N_P!MG0=`TCP+XA\;_#3PP$OK7X@ZAX4T
M7_A(?$_AB_0QMIR1)"DJOIUWMN-M_#'-%+Y:Q[HS(2.U^)?[2?PW_:VUS77=
M_%>D^&=?TV3X??$SPOKUI<:)JEMI%\\D6FZ[';RX=;?SI607"C'EW;;\&$JO
MM/[./_!/*+X1?&32?B!XP\;:G\2?%WA3PX/"'AK4+S3;;36TG2]P9XV6V"K/
M+(53=(XQ\@V(F6S,8MW<]OUU_P"!\_\`"XR'*WP[_P##?\'SV[IKPG]@?]A3
MXI>%=6^#7QBU2\U#PMXJM+2\T/Q1X3U+6KN]L)M!N5,L;P17'F365WY\5K,U
MIYSPQ,9E4KG%?H-15>ZU>UL8KEYKFWA2SC\ZX9Y`H@3!.Y\_=&`3D^AJI2OO
M_7];_,2CKI_7];%BOS__`&AO^"KLWQ*N_$_PV^'9U+0O&7AOQ6ND^([K28(]
M?U"'PY\ZW&LZ/'"62[EA?RDEA4/-:EI&>%M@W=)\2_\`@H)X&_:&U^PNOAM?
M^('\8^!&;Q1X:@O;"?3[+XGZ0D6W4XM*>4*E\H@=P"HRLJ0N/W9#G3_9X_X)
MD^$GF^%VNQ>/]8\9_"OX>7<WBKX<>'I[&W@71Y[M7>.5[M%6>X6-9Y1&DF,>
M9^\\PJ,)0<M9?#_P4^G>S5NOO)N.C+?NK3?7[[?\%._31V>J/!?@-^P-\4?C
MOX#O?&</BSQK9>*/`OCJ'Q#\/M=\2W]Y91^/([<JAN]7T>5&%G))"UQ;F6W6
M%IT?S6B&[#?J$I)49Z]\4M1M=1I<+"9$$KJ65"PW,!C)`ZX&1^=.^EEM_P`!
M*_SLO+LB-WS/?_@W_"Y)7QE^V5_P5-_X5-X]^(/PE\&V%E)\7;+1X+GP@9[F
M&[LM;NY`&DL]J2+Y5_''NDBM)VC:Y`3RR0W&E^TI^VW\-?C#XMN?A%I?B;5]
M#\4RWWV?PYXQ-A/'X:@\46<OF0Z4;_`A>ZWQ_-;Y.]/,C!W@H./^'W_!/_P[
M^V'X9UC6;KQ/K>G?#GXC>*8_%?CSX:W%A;RJ/$EF\<=U#]L9?M$,?VFTB+HI
M^;R049%D(,Q][7I_7_!?_@/\UU>D=&M?Z_RMTZ_RGC/PW_8H\6_MZZW\4M#U
M?QS\9+WP9?Z-:MIWQ"UN*[\+:N^K&1[C^SFTJ6);>[M+27RI$G,,<D3GREDD
MV;E_2_X0V_B6T^%7AN+QG+IL_BZ+3+=-:ETXM]DEO!&HF:+<`VPON(R,X(K?
M@@6U@2-!A(U"J/0#@4DUS';%/,D1/,8(FYL;F/8>IXJ[I*T=O^'_`,_RO=ZD
M;N[_`*V_R_.UEH25\[?M9?\`!1_P9^QU\9_"OA#Q>]OIT/C*SE-IK,M[%]ET
MV[W!($OHP3+;6TK':+ME\E7^5F4G-5?VS?VY_A!\,;K5?AMXWU#Q!)%J-BL/
MB>\T6QN)X/!=E=I(L5[J-U$-MC&Q4[)&.1PY`0%QXWX%_9!NOVLIO&$[?$_5
M_#OBJ^T*W^'/Q*6TL+34K7QMI42R26.H0-,K>0]S97;L)8RR_P"D.-A:,-46
ME+5;?\#OKUMT?>SLT7[L?BW_`.&?XJ_^:O=>,_##X9_&#]MG]H7PP?'&H_%<
MW>OZ1?6WQ'TN6VN_">G_``Q8JL:Q:/=(K6^I1W!&QH9?M,=Q&!/NB/!_0']A
MCX(^)_V:OV8_#GP^\4ZU#XCG\%B71],U0,QGO=+AE9+%KC(`%P+81+)MRNY2
M0>:[SX4_"[0_@E\--!\(>&;+^SO#WAJQBTW3K7S'D^SP1*$1=SDLV`!R2370
M5=TERQV_JW]7>^Y&LM9;_P!?UTV6@4445(PHHHH`****`"BJVLZS:>'=(NM0
MU"ZMK&PL87N+FYN)1%#;Q("SN[L0%50"22<``UX5^U;\<],\5V'A[X9^%-;\
M9GQA\4;/[?HNJ^!_LT]QHMC')`6UB269A`+-&EA!R6\X2;$5MW$RE;U&E??8
M]B\0_$WPWX3\0Z?I&J^(=$TS5M7R+"RN[Z*&XO2.#Y4;,&?_`("#7PE\&OAQ
M\:_V7OAOXR^&WAOX)VVJ?%CQ7J>IR?\`"VKB[L)M$UA+NZDDCU+46DD^V&2&
M*15-GY3J3`J(PC(*^>^%/V%OB]^U_P#M0>)O%OBG7?"EO=VATU(_$<.F1ZOH
M=]/9[X8-:T202?N[F,)*&L;O=%:7;M,OG;E(_4>TM_LEI%%ODE\M`F^0Y=\#
M&2>Y-5R:7EUTTZK\UZ??9K1._-;MK\_Z_JV_F7[./['7P[_9:MKB7P=X0\.Z
M!JNIV\4.I7FG6*VYN]F3M503Y<6]G81)A%+'`KU&BN$_:-UCXC:'\+KF;X5Z
M+X6U[QCYT0M[7Q#J$MC8>7NS*6DB1WW;00H`QN8$G`-$I=6$8]$3^,?B+X9\
M1:_J/P[M_'6DZ+XYU'3)9(+&UU*V_MJSB=2HNX[=RS$*>0Q0KE><U\)?!W_@
MFQXW\;_M3?$;P]\9+_66\'^(]#B;6)?#+26GA_XI7(WPIJUY%_S#M5B4P;X[
M=E$LD$<P.$`K@;O]GS4OVQ/$WQ>U#X>>$_#\?C/Q-J<>H>)/#OB^_?1/&WP:
M\6K:QPP:E8ZE#%,T]@ZPQ2HJ$1R*I\MBLLD:_J1X`TS5M%\":+9Z]J,6KZY:
M6$$.HW\4/DI>W*QJ)95C_@#N&8+VSBFX)P][^O3_`#V:LUU2.:T[+^O7_+=:
MWZ-_*_PK_P""64W@_P#;<T_XM>(/'NL^,#X;TR33-,N-7;[3K>HPRP&%K>]N
M0$B-I'NDD2WBA4-+(99&=P,?7]%<I\<M>\6>&/@_XCO_``+H5EXF\96MA+)H
MVEWEV+2WOKK;^[224_<3=C)]`:3D^6W848J^G4L>+?C#X2\`^)='T77?%/AW
M1=8\0N8M*L+_`%*&VN=3<8RL$;L&E(R.$!ZU\'^/_P!A#XL7_P#P4%T"YUSQ
M1XEO/!VN"[MY_&_AY$@U+4M*):=/#FNVZI]G>W1R_DWH0/L9H2`S[CY=\6_`
M_P`2OB1^VA9Z+\5?AE\//'GC#QII>H^#;C3]06*UT#QOI%AB]BN[";S;F]T:
M^B^U3#,B>3,$4ATD$9'Z&?L-_"_QS\%OV4/!?A;XCZ^GB;QCHMDUO>WZW#W)
M9?,<PQ-.ZJ\[10F.)IF4-*8RY`+4)*5.[^[[_P!+-^MAMVE[O]?T_P#/T^=M
M5_X(RV2_&#X73:;X[\0?\*_^%5W;W^A:=JMPVH:AX?%O<+-'8:9,=JVUJPB@
MBD>033M!%Y(D5&-?;UO;QVD"QQ(D4:#"HBX51["GUSOC+XJ^'_`VM:3H^H:U
MHMGK_B1I8M$TR[OXK>YUB6.,R-'`K'+D*,G:#@<FFYOEL_7YO\V%M?ZV_P`A
M?B/\6O"OP=T:'4?%WB;P_P"%M/N+A+6*ZUC48;&&69_NQJ\K*"Y[*#DU\1?\
M%&/V1?B]\1?CAX6\4^&/$^L:CX7GU^RGT_6]#C6/Q3\+O,\N&Z>Q\M=E_IUU
M$`LT$X8QEO-!95POS9\5_P!H?XG?M/\`BWX2>._%EK\%]5UC2/&%SX,OO!&I
MZ?.)/"%_J8^S-HFKVLS2M-'-Y48CU*")2A(<126\CX_0K_@FS^SSXQ_9I^#&
MMZ#XGCL]'TJ?Q!<WWA?PQ;:J^K1>#M+=8]FG)=O'&9(TD$SHNW$:2K&"0@HB
MG:[_`*V_1WTZ>5FQM)V6_P#P^OWJW_!NEX[\??\`@BK8?$/P6/"GAOQYX@LO
M">M:G+JFN:5KDYU.QANYTQ<ZG96^$"7\DC2S*TCM!%/,TR0[P,?;GAW08/#&
MBVUC;F1TMHUC\R5M\LQ``WNW5G.,ECR3S5VN0^./Q^\%_LU>`)_%/CWQ-I'A
M3P_;R)"][J,XBC,C<*B]V8X.%4$X!.,`U*M"-MEI^&B_R0W>4K[O^FS=\7>,
M-)\`>&KS6=>U33M$T?3HC-=W]_<I;6UK&.KR2.0JJ/4D"OC?_@J+\$O&W[5_
MP/@\5_"G6M-^(GA8Z>LP\/65XJ2?:(W:6UU[1-1M_GCU&U<AE3<T<Z*T?RL0
M3\U_\%!?VQ?&G[07@?XJ07NK?#6S\'?#/7-/\2VNBFU>76ET2"6&[T_Q5;&:
M3[)K5C*P!DM%10462-91.J@_5W_!.W]F7XA_"'XU^-?%NK:)X(^'W@KQEI5E
M))X6\*ZG/>:5J.N*[F?6K:&6&+[`D\)B1H`&+LF]SN&6J";5WI_PU]?7;^GR
MJ>FW]:]/3?\`I<V#XE_X)33^.O@I/?:;\1_'-YX\\::'9V7BNZ\32-!9>-HT
M8NBZQ8PJCYCBDDA\N&2%C'^Z=V45]'_L;_LR6/['G[-WA7X>6.I3ZTGANT-N
MU_-`D#7!:1Y"%C3Y8HE:1ECB7(CC5$!(7->GT4)M+E!W84444@"BBB@`HHHH
M`***^!/V_O\`@IAK/[*_B3PSXK\0Z!\0OASI/@/Q(4URSU#3EN]"\;:'<-]F
MDF@O;8RQ)<P!H[J.&9HG/ENF"6X+JZ3Z_P!?UY#L[-FC_P`%"?V\?$'A;Q#J
M_A[X;^*OAUXDT&*S^P^,K6SM!K7B/P7`DX6^U1-.WE-3@AA?9-;*N^$X=A("
M8ZY+]D[_`()Q^)_B?XP3Q!XU\2QW7@N"VN)O#&L^$=>N].:Y@OTAD:?2I8)E
MFLM/N8P!/IDWF0Q31H]LZIA1Z5^R9_P2CT[X`?&*T\9Z-\3-8UGPG'>SZMHM
MA]B2.\2UN-\D6GR7P<F73XY)I9Q"L<9EE='F>4QK7V7%$L$2HBJB*,*JC``]
MA0J<8ZO66N_2_3Y?Y[^[RJ;4G[K]W^OSZ]_+6^%\+?A;X>^"?P\TCPGX4TFS
MT+P[H-NMI86%JFV*WC'8=R2222222222236_113;;=V"22L@HHHI`01Z;;PW
M\MTD$*W,ZJDLP0"215SM!;J0-S8!Z9/K4]%%`!1110!R.@?`/P1X5^*6K^.-
M-\(^'+'QEK\2PZEK<&G1)J%ZB@`+),%WL,*O!/\`"OH*ZZBBCR`*\U_:4_9#
M^'G[6WA&;2?'/ANRU5O(,5GJ2+Y.IZ0V]9%FL[I<2VTJR(CJ\;*0R*>U>E44
M>8'C/P*_8]TWP)%H>L>.SX>^)?Q*\.(]G:>.[_PY:V^N2VH)6`2S("3,L1"M
M(NT,=Q"KN(KV:BBG=L.MPKFOB+\(?#?Q7?1I/$.BV.KS>'+TZEI3W*;C8W1@
ME@\Y#V?RII5SV#G'-=+14M)JS`^,OV,/^"4VC_"'7M9OO'OA3X:WFEPO91^$
M_#%C#<ZSIOA<6HD!NH)M1WRQSS[X]Z1!(Q]GC/S-EZ^S:**?2P6UN%%%%`!1
M110`4444`%%%%`!45W9Q:A;/#/%'-#(-KQR*&5QZ$'@U+10`B*(U````&``.
ME+110`4444`%%%9_BW1[CQ%X5U/3[34;K1[J^M);>&_ME4S63NA59D#@J60D
M,-P(R!D$4/8%N:%%?C%^R3^WI^T7\%OB;/H,_C6\^/?B+QK\9=?^$&@V?C"[
MM]$TW1X=)@CNAJ+O:6K2/-(CN&7&/E4*`37K?AW_`(."_&/C7]I+4-*T#X#Z
MYKWPUT?Q^_@"\U&P2_GU821.89]055M39^2DH_U1N1+L^;`Z548\RBX_:2?W
MJ+7X2C]_D[$_<DXRZ77W.2?XQE]WFC]0J*_,EO\`@N;\4=47PWXYTSX.>"V^
M"OB_XJ1?##3-4N/&I77UE-\UFUU+8K;E`"8W81B7<!M)X.ZO-_@Y_P`%9?VF
M?AO\1_B#X<O_``9X0^(NM>*OVAM1^&OA2WO_`!6]C;Z(L=F;AH"Z6C'[/"BQ
MLKD%W,L@QE1F:?OVY>JNOO@K?/VD6.2Y;WZ?Y3;?RY)7/U^HK\S?@9_P6V^,
M?CCQEX*;Q5\#?"6B>$-5^+,OP6UW4;#QDUY=VFN)++&T]O";90]H&0#<SAR=
MV!C!.=^SQ_P<'^+OVA/CIHB:9\"-<NOA5XE\77/A2UU>Q2_N-2L%BD,(U"X_
MT467D>8IWI'<M)$H)(.,41]ZSCU_X'_R2^_U);L[/^M__D7]WH?J'17Y8_"?
M_@MS\<?CKX3\*WO_``IGP7X?T;XQZ5XPM_`VI6_C*2:Y34=$AN"6NXVM0(HG
M>!L%2Y&,D=`?2?V3/V[OBQX8_P"#>NV^/WB^PMO%WQ%T?P%=^(;<BX-P=9\I
M':&XN-J)M8@!Y$0?*%8!CUJ93482F_LJ[_'\=-BDFZD:2W;L?H+17X\2?M5>
M*_V3M!^"'Q@^(?[7GQ=\5Q?$LV6K:E;Z'\/[/6?`VHI=,,Z/:^2BO:SY.Q',
MK.-A8H"2!Z?\-/\`@N#\7?C#X7\`1Z#\&?`__"5?&KQ5KGA[P%9WGC*2"T:#
M16F74+G4)C;9B<F-1%#$DC/DDD8`.LH.+Y7NFT_567Z_KMJ1SIKFZ;_F_P!/
MZ9^G%%?GW\#/^"VFJ_%3XA?"7PCJGPYT_1/$7BSXF>(/A=XL$6O"\L]&U#2K
M%;LRV<ZQA;J*42(%W>602PP2*X[P/_P6Y^+W[1GQ1\*^"OA/\(?A]K&O>)H/
M%%ZLNN>-)=/LXK;1M7?3MZNMLYD:4!9-JCC<>=JEJAK;SV^Y2_)IEV:W_K5Q
M_--'Z:T5X5_P3@_;6A_X*`_LF:%\2%T&3PS>WES=Z9J6F&Z6[CM+VTN'MYUB
MG7"S1>9&Q20`;E(XKW6G)-.S$%%%%(`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`\<T+_@G[\&_#/C#3M?L/`6DVVL:3XJOO&]I<I)-N@UF]B$-U>@;\
M;Y(P%((V\<`&L>X_X)>_`*X_:03XN?\`"LM!3X@I?#4_[4B>:-6NP,?:6MU<
M0--W\PQEB>2<\T44+2UNFWELOR27R02]Z_-K?_@O\VW\V8FJ_P#!';]F76OC
ME+\29_@]X7_X32;5XM?;48S/%C4(Y!(MTL2R")9=ZAF8("QSNSDUV]I^P/\`
M!^P\7PZ_#X$TE-8M_&$_C^.Z#R[UUV>'R);_`._CS&C^4C&W_9S111'W;*.E
MO^`_T7W+L#]Z[?7_`(/^;^]]Q=._8*^$&DV%M;6_@;2HX+3QL_Q'A022GR_$
M+NSMJ(^?_6%F)Q]WG[M8'A+_`()=?`#P%^T0_P`5M&^&.@:9X[>YFO?[1MVF
M2-+B4$2S+;A_(21LG+K&&)).<DFBBA)+;^M$OR27HD#UW_K=_J_O9L^$O^"?
M/P:\">'?!>DZ1X!TBQT[X=MJC^'($>4KI)U(2"^V9<D^<)I-V[/WSC%=S\*/
M@?X3^!WPATGP#X5T.STGP=H5D--L=*0&2""VP1Y7SEBRX)SN)SFBBCOYAUN>
M(?##_@C9^S!\&/C);^/O#'P:\)Z3XGLKMK^TFC$S6UE<,<^;#:M(;>)P>C1Q
MJ5[8K>\9?\$N_@!\0?@#9?"_6?AAX>O_``-IFISZS9:;(9@;&\GF>::>&8.)
MHG>21R2CC.XCIQ111TMT"[O?J1>)O^"5?[/'B[]FK1_A!??"?PLWPZ\/W@U'
M3M(ACD@%G=?-FX2:-EF$K;FW2;]S9.XFO*?BK_P04^`7Q@^+G@#4=6\+Z?\`
M\*_^'/A"Z\*Z3X)MXI;:RA,UTEQ]K$\4J2B48=3DG?YK%B2>2BCK?^MK?DPZ
M6_K>_P"9]:?"3X1>&/@+\-]'\'^#-"TWPUX8T"W6UT_3;"$16]K&.RJ/4DDD
C\DDDDDDUT=%%-MMW8DDE9!1112&%%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>table7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table7.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`%E`>L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`*#THH)P*`/SK\3?\%FOB]H.N_M-VD?P&^&D
MT?[*]K%?>)I9?BS=0?VG#+9O>I]CW:%M9_*0@K*T8WD*"P^:OJ;X<?\`!0'X
M<>(?V1/`7QF\9Z[IGPC\+_$"QM;NR'CG4;;16AEN(C*ENSS.J-(55V4*QWJN
MX<5^8WQ5_P""0?Q4_:V_:N_:B^(5Q\)_%'PL\>>(]:T;QE\'/'EWJN@2SZ)J
M&DV@B-K<&TOYYXX[J0+A0CQX57?:T:J?2_VJOV>/VJ/VS-;_`&;?B=XB^&WQ
M#\':SX'T_6_"_P`1/"GAC7_"4VI2?VCI\<4FJ:4;^>XTZ2"0B2%DN&CN$5L(
M,?O3-)OV,;KWFJ=[Z6;@W+[Y^[)6_=V4K2B]*FE[>5OA3GMV4E;[HW<7?]YK
M'225_P!&OB]^UQ\*?V?-:TC3?'OQ.^'O@C4?$"EM+M=?\1V>FS:D`P7,"32*
MT@W,H^4'E@.]>9^(/V]+[PU_P5'\/_LXW'@VU:S\2^![CQG:^)H];8RH(+@0
M/;/9&V`&6Y#B<\=5%?G;_P`%(?\`@E_^T!\0_@U:?"CX<_"B[\0>$K'X*Z?X
M5TS7?[?T&'Q!/JEOJ$4JV&LZB[VUQ/:PVT!\N&W3[*]Q.K2!@HDB^F/!O[-O
MQ8G_`."O'P(^)]U\+_$&F^!?#GP6;P?K6IW&JZ.W]DZG*PG\F2*.]>5PA3RF
M>%)$WNNTLFYQ<%>JE]E2DNUURUN5^7O0@]VGSQ[V>4G)4F^O+%^CO2<O7W9S
M6UUR2[77T5\4_P#@I;\(_@]^V7X9^!NN^,?#FF>-/$.D7.L/'>ZM;VJ6"1M$
ML,+^8PS/<>8S1Q#YBD$C8P%W9/[.7_!3OX=?%+X0Z#XB\;^,/A'\/-3\3WNJ
MPZ3IR?$O1]:BU2WL9W1KBWNH)!'-^Z5)9$3)A\S:^"IKS+XQ?LQ_$[0?^"XO
MA'XY^'?`_P#PD_@*;X4W'@S4;NWU:SM)--O!J1NRTL<TBR.'@^6/RE<&78LC
M0QDRK\/_``%_X)J_M!>$/AG^RCI/B;]GOQ#?CX2?&'Q!XT\1VCZ[X9N$2QNI
M1+:RQAM2VR.&E!VCE6MW/_/,OE2E)J/-N[W\OWW)^%/W^S5]-4UM72CS<FMK
M6\_W3D__`"?W-KIVUT:?Z]>!?VQ?A'\4?$F@Z-X9^*?PX\1:OXJL9-3T6QTS
MQ+97=SK%I&\B27%M''(6FB5X959T!4&)P3E3C8^'G[0?@+XN^+/$F@^$_&_A
M#Q/KG@VY%GX@T[2=9M[V[T.<LZB*ZBC=G@?='(-L@4YC<8^4U^-'[)'_``2^
M_:)^%B_LPV]Q\$O$7A&^\"_$WQ=XA\7:Q::YX<+VUKJT*V]K>YBU$O<-'&ZA
ME`9PMJ556`C#_1?_``1(_P"";_Q4_92\6>&9_BU9?$F#Q-\-=!UGPE;ZC-KW
MAV?PEJ]A=:G]K22SCM(?[4E>1U$Q.HLC1EFP6WE%VHVGK+W=+_\`DJE^#:A;
M2^LE\+B9UKPNH>]K;_R9Q_&*Y[KX;J+W4G]Z?$W]L7X1_!3Q7<Z%XR^*?PX\
M):Y9:>-7N-.UKQ+96%W!9%M@NGBED5UAW?+YA&W/&<U?\`_M-?#?XK>,;GP[
MX7^(/@CQ)X@LM.@U>XTS2M=M;R\@LIT22"Z>&-V=89$EC9)"-K+(A!(89^`O
M^"K/[&7Q5^//_!130?''A;X.ZMX[\+Z'\'O$WA6#4X=2T2$6^L:C;W$=OY<=
MY>PRKMW;6D"``3<%AOQ\V_"C_@DE^T5=Z-\,O"5E\,=5^%<=G^S?KGPMU;73
MKFB+9Z=K]W//.)I5L[V6>2":0`O+%$\F;D,5W!RG-&I-TW-QUM+3T]M;[_9P
M_P#!B\KZRA%3Y4]--?7V5_NYY_\`@#[:_KWX0_;3^#GQ"^'_`(A\6:!\6?AG
MKGA7PCG^W=9T_P`46-SI^BX&[_2ITE,</'/[QAQ6)K'[?WPAN/`WBS5/#/Q0
M^%7BF^\*>'F\27%G;^-=.C1+5HA)!-/,92EO;R[X@MQ)B/$JMD@BO@SX2?L$
M?&N6+QUXLN/ACJ_@O['^S-:?!?3O![:OHSW7B;6(HY!]JB:WNWM8[6/=LC:>
M:*0B1\QJ!SXK^SA_P3/_`&@_A)?>%,_L^:_I=MH_[+NK?"J\CM==\-*)O$5Q
M<W5P7`34L-',T@8S'!+RY<#YB-,6G%5(TWM&5FNK2K6[K7V<-+.WM4G=[F'M
M)PE4TNU=/HFZ5]K;<\U?1/V;DK+0_1'X0_\`!7_X8^//BG\'OAUKFM>#=!^)
M'Q5\*CQ*^CV?C"PU>TTIV\@0V4=["WE7DT[S/Y(ASYB02.!C;N]Y\%?M1?#/
MXE>-?$GAKPY\1/`NO^(_!I==?TK3=>M;J]T,HY1Q=0QR%X-KJRGS`N""#R*_
M,7]@3_@G3\?O@5^T9^SMXGU7X<W6@6NC?`*3X5>([O\`M_2S-X7U./47E-W(
M(9Y3,C08:$VXE+/Y:2B`%G3<_P""=_\`P3:^-GP;^+W[,$/BGPG<>&+']F'1
M?&&GZ_KL>K:?<V_Q%GU2X8P&Q6*=K@QN<7$C7T=LP?;PQR1U3C#G:325ZFVV
MDJO+;5O:,.MY<ZY=F<\7)03W=H?>XP<E_P"!2DKI6CR/FLFC[JU__@HE\%Q\
M,;_Q%X=^+/PC\2^7I.H:KIT</CG3(K?4ULU_?8N#*8TC1V1))3E(MX+XK'^%
MO_!3'X2ZU\'_``UKOCSXC_"#X>>(]5\-6GB;4]"G^(FDWRZ1;SE$\P722B.>
MW\UUC6X0>6[%=IY`KY$_8>_X)\>,/AO_`,$\?V@K?Q3\`VTKXT>*-3\9W'AM
MKJ?0;K5[RVUE7\B*&]BO)(X%PR)(CS1KE&QN&&/S99_\$P_VB)?#OPLAU#]G
MGQ!>7G@O]F77?A8SR:]X9D-AXANH[N&&2(MJ61$8Y"#*GS!+C!'+A>*52<8M
M\NO+"7HW3JS<5Y\T80>^K5DKV?3"$922D[+FDODITXIOR<7.:\D]['["_%/]
MMKX,_`O3-!O?&WQ<^&/@ZS\56OV[19]<\4V.GQ:Q;X1O.MFFE431XD0[DR,.
MO/(KN?`_CW0_B=X.T_Q%X;UK2?$/A_5X%NK'4],NX[NSO86Y62*6,E'0]F4D
M&OP$^/?P"\3_``@T'P)\/=?^%?[0DWB75/V?M%^'7Q(L?`_@JQ^(LVG6<>H2
M,$A^S:G''I<[_8W>*XD:YCE67/V=7A<G]=_'7@Y/V\O^"1U_H/PFUW4=!B^)
MWPU^P^%]2U<O!<VRW%@$@^U%`SHV"%E*!B,N5W<9WQ/N4JU2E[W(VE;K:51+
M[U&+3ZW:MI=XT+RJTZ=3W>9)ORO&#_!RDK>2UU:7HFE_MS_!OQ-\)?%OCG0O
MBE\/?$OA3P+!)/KVIZ-XCLKZVTH(A<K-)'*4C8@<!V&:\F_X)C?\%'O$/_!2
M;X0ZWX^LOASHGAOP@T4<GAC4(/&UOK!U61O-\RTO8HH5ETZZ@"P>;&RR@?:!
ML>0*2?F_]EO]BOXR^%/'VN_$/4?A=KO@ZV\/_L[:;\(K/P:FK:+)>^)]5MMS
M&Y@,%XUHELF=D;7$\+GS'S&@'/T3_P`$6_@_\0?V8?\`@EK\.?`'Q'\&:QX;
M\;>!-/N-.NM,FU#3[Q[S$TLL;02V]S+#L99%1?,D0@H=RJN"76BHJMRN]DN7
M_P`"J)M=[J,)<O3GL[V(4Y-TURVNW?R]VF[??*<7+9\K:M=63_@G'_P5S\$?
MMS_!*TU[Q#=>"_AGXRGDU:23PC<>+[>]O4LM/N9;>:_7?';RM;9AD)D\D*NU
MLG@U[+X8_;D^"GC>]\/6VC?&#X6ZO<>+H[B;0HK+Q787#ZTEN7$[VH24F98S
M'(',>0OEMG&TU^2O[!'_``3*_:#^!OQ<_91U#5O@/KGAR/X;>/\`QMKGC/4H
M]=\.MNM]:BB@M+@^3J+23E(@J2`*75(=JAP$!O\`[&O_``38_:,_9W^)G['&
MEZO\&]:NM#_9V\7^-I_$&N6OB'0C#?VVK2,+2ZM86OA,T6TAG614E7D>62!E
MT4IJGS^ZW%7\G;WOQM^-O+:JHQ=3D=[.5O3]YRK_`,DBK_WXWV][]3M!_P""
MA'P#\5);MIGQP^$&HK=V5UJ,!M?&6G3":UM5=[J==LQW10K'(TCCY4",6(P:
MO>*/VX/@MX'^&&A^-]:^+_POTCP9XG=H]&U^]\56-OI>K,N[<MO<O*(I2-K9
M",<;3Z&OR!_9B_X)<_';X?>-?V=K[Q#^S5K'E>`OC)XG\>>)W.K^%IC);7RP
MC3Y_^0D3--"RH?[T?V?Y"2$S+\/O^"=?[5>@?L8^`/AO<_`62)X+[X@1ZS>Q
MZUX;_P"$@TV/587;34MM0^VL]K8337/^EBTD%PPM'0JT;!9^95)NCS\MI<M[
M>?+%\OWR<?\`MQNSNHJU"/M.6^E[7\KS5_NC%VZ\Z5U:[_87QM^V!\)?AJ^B
M+XC^*/PZT!O$VG2:OHXU+Q)9VIU:RCB\Z2ZM_,D'FPK%\[2)E0OS$XYKH/"W
MQ3T?XJ_"]/%7@/6/#GC/2]1M9)])O]/U5)],U)EW*-MU")5V;U*ET#[<'Y21
MBORFTO\`8(^-ME\,/^"=%EJOP(U[6W_9U>ZF\;:>=8\.RG3I4A6"W>/S=0$<
MS>;&EPAC8E552=L@V#Z5_P""(?P/^(?[!W_!*"#PK\4?`/B#0?%?@VYUS49M
M&M)[+5KO4HI+B:\C^RBSGF61W601K&65S(I&W!5FUQ"Y:6)<7K!RY7_,ELUW
MW\]K[/3*BIS]BDKRGRW7F^:Z^7*O_`UKIKV7_!/?_@KQX"_;._9H^'GC;Q;?
M>#/A)XF^)FHW^F:'X4U3Q=;S7FIRVMZ]H5M3*EN]RS,$^5(L@R*.21GU#XK?
MMM^$-#^$?Q<UGP%X@\#?$;Q3\'=+N[[7/#EEXGA$UA-;QS.;:\:%9Y+1V\B5
M1OB)W(PV\''Y`?\`!++P7\;_`-@K3?`%MKOAV\\8Z*=&U?3]5TN#6O#5W<?#
M9=1O8Y[/6-`N+>[8Z@]W'J=HLUE"9+LF6S^\ES812;/[%/[,WBCX#_LT>.-(
M\97'CWQ-\1O`_P`)_$GA'1AIWB?PO>^%_%UGK%RDMD-)%LB7]Y<SRW5C.8[V
M431_VC:X#&]@C;FQV,H^RJ2HS2:A)K5/5*5E9WN[I:7UYG;6$HGOTN',Q^LJ
M/U:I*#J)+W)?"Y+7;;E>CZ6BWI4A(_4#]G;_`(*9_#CXH?LH_!_XE>//$G@G
MX2W?QETJ'4-'T37_`!3:PR3RN$W6]O)-Y)N64R1@[(P<NORC(KJ-7_:ZM]/_
M`&X=/^#L4/A*=)O"EQXCO[UO&=A'JVG2),B1PG1RWVMX7C9Y/M0'E+LVGDBO
MQN\'?LS?$3P%\`1977AI?%FI^(_V7$^$ITFT\0Z->-X1U&6[C\NX5UNVBN[6
MZ2\L)E336NKP_:[(/;!KFU$G?_M4?LN^,?B#\=_#OAS1-<BUK2=!_95G^&=Y
M\0;76+*>SO=5O;>+[.T44<QO;I9VFLHREM;2S_\`$VL2(R+J%FTQF,P\)RE3
MDK)U+*ZLTE7Y?/>$&G?5S2ULU+EPG#N;3A",\-4NU"[Y)=71NTK6VJ25O[M_
MMQM][_#/_@KEX:^,_P#P4DTOX&>#%\!^.?"NN>$[KQ-9^-_"_C:+5XXY+:2.
M*6SGMHH#''*&?/%RYV["5!;:/H;XR?M/_#3]G2ZT>'X@_$/P-X$F\12/#I4?
MB'7K72VU-T*!U@$\B&5E,D>0F2-Z^HK\L?V#=&\6_P##S3]G3Q9K7PSM/`^A
M?#_X$V7PZUK45\4>'+BT>^D-L;62V:UOY#<6TGVBR6,1AIE.I69>&-+F&23Z
M(_:I_9)^()_X*P/\3[CX06'[0/P<\=?#`>!-2T.YNM*SX<NXM12[5Y+?4IHX
MI+29A&SF(2R`Q%O+)2-7V3IN5.$)*2O43?E&53E>FW,HQ2OMS)N[WX:^#Q5#
MF>)I2IMJ#BFFOBC3YK-VYN5RE)VWMI9-6^T=;_:#\!>&?B]I/P^U+QOX0T_Q
M[K]LUYIGAJYUFWBU?48%$A:6&T9Q-(@$4I+*I`\I^?E./A'Q;_P7HUSP7_PE
MWVOX-Z4__"%_'"S^#-_Y/C:1O--UCR]1BSIPW8S\T#;<=I#7&>,_^"87Q;UK
M_@J#\1=?UNW^(^H?"[QSXC\(^,=`U#PCK_ARTT_1+S2$"BUU$7\#:DD,#(QC
M&GJ5D2;:Z@NQC\:^,?\`P3P_:0\22?%\:?\``KQ5=#Q1^TWI7Q5TME\1>'$%
MUHMMO\QOFU(%9OW:XC?&?-3D8?9-&\JE)RV=KKM^]HIW[6C*JNS4>=/^7"KI
M":ANMGW_`'=5JW_;RIO:Z;Y9+>_Z^>"OVGOAK\2?BAK7@?P[\0O`^O\`C3PV
M'.K^']-UZUNM4TH(X1_M%LCF6+:[*IWJ,%@#R:YCXS?M?Z9\,?CYX1^&6GV'
M]M^+O$EI-KU^LEV+2R\-Z%;.JW6IWDY5MB@L(XHPI,LI"DQQK)-'\I_\$_OV
M0OBM^SS_`,%*/'VL6'@OQ!X,^!'B>TU?6;BP\4:II&LFT\07FH122R:)<6T\
MEY!:74<4<TT-RD:B5,`.1&R]?K6A7OP9_P""\;^,=9A=]&^*7P?'AOPNZN`;
MW5=-OY+VXT^,NZQK,]M)YRARNY8I""!')AT]51<OM*3EY.,9NUM[.44N[B]+
M-JQ-Z5N7[+27HY05_51DV]+*2=[Q3OYO\-?^#@U?CC\0)#X*\`_#G5/AW+XS
M7P;9^(]1^,^BZ1>SR_;4MVD.G7"JY,D/G75O'!),;B.'`*.VT>S?L1?\%>?"
M'[3_`,4/B+X#\92>!_ACX[\%?$'4O`.EZ%/XSAN[OQ7)9;-]S9Q2PVTK@E\;
M%C<C')YQ7P1%_P`$_OVEIOV#(/!$OP(\8_\`"16?[2B_%-+-_$GALK_8C737
M1"O_`&H4$P^Z8\@;Y!@E=S#L/$'_``2L^-_B*V^-/P\'P^2P@^-7[0,?Q2M?
M'D6L:;]E\,Z1;ZEYRK,HG%Z+XQVY,2P02Q@7JAI8SYH2L)K[.-7JHIM[WDL.
MV]++W>:KTM[K3U2LJ[M"I.&Z<FEY1==)6W][EI=;^\FM+W_3S0?VS?@_XJ\2
M?V-IGQ6^&VHZN=9;PX+&U\3V4UR=4569K#RUE+?:0$<F'&\!&^7@U9\.?M/^
M`_B;XD\6>&?`WCGP#XO\;^#TE74]`L?$=O+=:9.A9/+O$A,LML/-78Q:,E2#
M\I(VU\>?L3_L)ZZW[:W[5_C7XB?"+_A'7\<^+H-;\`>*M6.C:E<6BQ6368N+
M7R;F>:UF#;I%+)&2CKDA@47RS_@G;_P31^-?PG^,'[+]IXJ\+R>$;#]F;1?&
M&F^(/$7]JV%S:?$&;5;AC"UDL,SW)B8D7$C7L5NX8+\K-G&'O2I)[2<+^C=-
MRMZQFN5IJ[YE:]G>JCY')Q5U&37K:5EMTE%W36BL^9JZ/IS_`()F?\%=O!O_
M``4<^`FBZS%-X)\'_$[7(M1FA^'LGC&"]U18K6YF@$Y411SF%S%N,@M\*"?O
M8Y;^Q7_P6%^'_P"T%^QQI/Q<^*&I>!?@1;ZMK^I>'H;7Q!XRMA;37%E/)$PB
MNKA+82%A&7VB,$#\Z^,_V)?^"6GQQ^%GP]_9?^'OB'X<'PVWP%\>:I\2-=\6
M6FL:7+;ZVEQ%,\6EV?EW'VIKAS<I!/Y\,4&+9MLTB^66\[^'7_!.3]JCPU^Q
MGX#^',WP",$B7_Q`76[V+6?#8\0:>NJPL=-6WU#[:SVUC-+<#[7]DD%PRVC(
M5:-@L^M:34YN"NN31>:Y'OYWG&SO;EYK:I&CIQ]IR)Z<[U_N_O%;SM:$KZ7Y
MN6^C9^Q7Q*_:Z^%'P8\/^'M6\8?$[X>>%-*\6J'T*]UGQ'9V-OK2E5<&VDED
M59@5=&'ED\.I[BO/M%_X*>_!O7/VP?&GP73QQX6M_$_@'1(]9U=[G6;:!(B?
M/>:!0S`N]M!!YTY'$*2Q[B#NV_GM\1?^"<WQY'_!.S]F6Q\)_"KQIHW[0GP?
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M!\R^8Q6"S+2$1H%7]*OV=O$7Q`A\1^(?"/BOP'_87ASP9::79>'_`!3_`&]!
M>_\`"8YM!]JD^RH/-M/)E79B4DR9W#BJM%\W+LN5I^L4W'LI0NFUO[_]ULGF
MDE'F5F^9->DK*2ZN,M4G9+W+Z7LO5:***S+"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/,?C5
M^Q/\&OVD_$UMK7Q%^$GPQ\?:S9VPL[>_\1^%K'5;F"`,SB)))XG94#.[!0<9
M9CC)->E6UM'96T<,,:10Q*$1$4*J*!@``<``5)10M%RK8'J[O<****`"BBB@
M`HHHH`****`,BV\`Z%9_8_*T728O[.OY]5M-EG&OV6\G\[S[F/`^6:3[3<;W
M&&;SY<D[VR6W@'0K/['Y6BZ3%_9U_/JMILLXU^RWD_G>?<QX'RS2?:;C>XPS
M>?+DG>V=>BIY(]OZ_I(Z'BZ[WF]?-];W_P#2I?>^[,BV\`Z%9_8_*T728O[.
MOY]5M-EG&OV6\G\[S[F/`^6:3[3<;W&&;SY<D[VR6W@'0K/['Y6BZ3%_9U_/
MJMILLXU^RWD_G>?<QX'RS2?:;C>XPS>?+DG>V=>BCDCV_K^D@>+KO>;U\WUO
M?_TJ7WONS(MO`.A6?V/RM%TF+^SK^?5;399QK]EO)_.\^YCP/EFD^TW&]QAF
M\^7).]LZ]%%-12V,ZE6I4=ZC;?GKUO\`FV_5A1113,PJAXA\+Z9XMLXK?5=.
ML=3MX+F&\BBN[=)DCGAD66&50P(#I(BNK#E64$$$`U?HH\P"BBB@`HHHH`**
M**`"BBB@#.O_``AI.J>)-/UFYTO3KC5])CFBL;Z6V1[FR2;;YJQ2$;D#[$W!
M2-VQ<YP*T:**`"BBB@`HHHH`****`"LOQKK]UX5\(ZCJ5CHFI^);RQMWFATK
M39+>.[U!U&1#$US+#`';H#+*B9/+`<UJ4V8NL+&,*SX.T,VT$]LG!Q^1I2V8
MUN>0_LV?M;R_M"^//&GAF^^&WC[X=ZSX%%B=0@\1SZ-<+(UVDDD:1OIM_>)O
M6-%=D<HP6:(X(<&L'Q+_`,%"_#WAOX_2^"/^$0\<WFG6/B:Q\&:CXLMTT_\`
ML73-9O+>&XM[*1'NUOF9DN;;]Y%:R0@SKF0;9"B_!/\`8M-E^SC>^'/B#K&L
MW/BSQCK-QXI\5ZIX6\2ZEH4TVI3R^9Y4%[926MT;>",0VL>2FZ&VB#KU%>&^
M-O\`@FMX_P!5_;KMOB9IUCX`^W:?XDTBZTKXB77BG53XHT7P[:0)%<:"-.-L
M]O=1SJU\CS2WHWF]\]T:6"+%T]:T(U-%[M^V\5+7RO*VR:7-NE3G$[JG-PU?
MO6_'E=O.RNM[NVUYQ^C/V@/VV/!W[+_QB\*^'_'>L^&?!_AWQ'H6K:Q+XDU[
M78-+LK![*YTRW2W8S;4)F.H\$R*08<!6W_+TGQ%_:N^%OP?U;PW8>+?B3X!\
M+WWC(@:!;:OXAM+*77"2BC[*DLBF?)DC`\L-S(O]X5SGQB_9LN/BC^T_X+\:
M21:'<Z3X8\(>)=`DAO%+W`N=3DTORWC785V>59W*2'<#B50`P9L?-6H?\$Y/
MBWX2^$5YX.\.I\)];@\?_"31?A?XEO\`6[Z[@D\,?8;:YMWN;&*.SD_M&%A>
M2R+;S/9D/$N9<2'RIA=TU?XONOK4TOLK*,-=K2UUWV:C>.MEUZVUCK;KHV[;
MZ>9]LW7Q3\,V,M\DWB/0H7TO4;?1[Q7OXE-I>W`A:"UD!;Y)I1<0%(VPSB>/
M`.]<\IJ'[9?P@TE?%)NOBK\-K8>!UW^)#+XFLD_X1]?/:WS>9D_T<>>CQ?O-
MOSHR_>!%>`^*/V)_BM%\4-?T[1KOP->>`O$?CGPIXXN-8U75;S^W5;28M'MY
MK/[*EL86,B:7YJW)N!\TAC,(!\U=^_\`V*M;T7]D[Q5X1M_#GA3Q/XBUOXB:
MOXVMT'B_4/"D:/<:]/J5I<G4;.TFN8[J"-K?($+*6BV%FCY+E90YD^MMM=H7
M:7^)SM=J_*M4I<RA:Q3ZZ75]KJ3>OE:*ND_BV;7*>^'X\^!E^#__``L(^,_"
M@\`_8O[3_P"$F_M>W_L?[)C/VC[7O\GRL?Q[MOO7+ZS^W/\`!+P[\*='\>:A
M\8OA98^!_$-R]EI7B*X\66$6E:G.A</%!=-*(I74QR`JC$CRVX^4UPWQ$_9S
M^*7Q)_8O\%:#KNO^'/$WQ6\*ZIHGB2\FU!Q!I.NWNGW\-X;:::"T38C&((+B
M*S7#JLHM@/W->?\`[5O['7Q3_:<\1?#_`,=7_A[PNGB70]'U;0-9\*:5\9/$
MWA>P\F[GMY$GBUG3+**XGPMH@>WGLA&WG$AP85,A+237:5OE:Z=TM>:7N:+W
M;<ST:%"SBF^WXWU5NEE[V^OPK4]2^-W[<`^#OQ2UOPVOAH:HNCP^#)A=#4O*
M$X\0Z_/H_P!WRFQ]G\CSNI\W=L_=XWGWNOD3Q;_P3\\0:EJ$?]AIX9T#2(-#
M^&VE6>F-JUW>_P!GKX;\0SZE=0B>2'S)D^SR)'#(X#R.I\P1`[J^NZUG&"BT
MM^:7_@-HVVNM[]_4+WU\H]]^2/-OK\7-N%%%%8@%%%%`&;XP\2)X-\):IJ\E
MIJ.H)I=I+=M:Z?;-=7=R(T+^7#$OS22-C"J.6)`'6O*/A9^W#X?\:^&?B'?>
M*M`\3_"FZ^%:K/XGL/%IL1+IML]J+I+DS6-S=6SQ-%N/RS%E*,&53C/I_P`1
MY?$4/P_UMO",.BW'BI;&8Z/%K$TL.GO=[#Y(N'B1Y%BW[=Q12VW.!FOECX7?
ML/?$/XG_``%\0^&/BM=V'@'Q1X@\167BK5?%7@+Q3'K]YXEU"!T?_2(M3T2.
MWAM8_(M8HK;RIU$,"(6^5FDGWKR2[+\7TVO97;U[)+5M/1<K?=_EL][7>SMW
MOM9^]_LP?M*:9^U5\&8O&FDZ+XB\/VTE_J.FR:=KL$5O?VT]E>36<RR)')(J
M_O8'Q\Y.",A3E1S?['?[=W@']L+X3Z/K6D>)?"$7B67P[I_B#Q!X9L_$-O?W
MWA9;NW2=8[I5*O&`&(#21INQG`JO^P?^R]XH_96^#WB#P]XI\<ZIX[O]6\6:
M]KL%W>I9*88+[4KFZC'^BV=JOF.LHDE!1E6:258R(A&B^'1_\$I]<O?V:?!'
M@(ZCX0T6YT7X(ZC\,]4O;.V>>.2_NFTU_-6,QQ^=:L]K<F3<T;MYW`!=F71\
MO-*VUE;R]VHWVO[RA%^NGG22?,GOS67^'FMY_9UW>Q]/?#7]K[X3?&?PE<Z_
MX/\`BA\._%>A65_!I5QJ.C>)+.^M(+R=XXX+9Y8I&19I'EB5(R=S-(@`)89O
M?$+]ICX<?"31K[4?%?Q`\$^&-/TN^.F7MUJVNVME#:78M_M1MY'D=0DOV?\`
M?;&(;R_GQMYKY?\`&?[%WQE^-+^,/&>O6/PI\)^-KBU\(VFA^'=%UZ^OM&NQ
MH&M_VPK7E\]A!+'YSLT"*EI)]G3<V9B^Q>@\'?L5?$#Q'\2=$\6^.$^'\=['
M\7?^%D7NG:==W-[;V5N/"TFDQ00RS6\9FGBNC&XD:.(,J>8!&V(@U%.ZO;?S
MZP2];ISE;IRI-J]W"MRMO?7\(.5O_`[0\_B2MM]`:-^TO\./$7Q7/@/3_B!X
M)OO'`L5U,^';?7+675A:,JNMQ]E5S+Y15T8/MVD.IS@BNWKYV^'GP$^(O@[]
MN+Q'XKT^'0?"OPS\0F>]UFVM?%MWK$WBN_\`(MH+:Y?3KBP2/2Y(TA8,UI>,
MDH5?,BD8K)%]$U&\8R[K^OZ=FUJTKV2U4G%]'_7]=-KNUV4444#"BBB@`HHH
MH`****`"BBB@`HHHH`****`.(^.'[2'@/]F_0[2^\=>,_"/@]-5F-IIG]O:S
M;Z8-3N=I9;>$S,OF2''"KEO:N6^#G[;7@/XD>"OAK-K'B;PCX4\7_$W0-/UW
M3O"MYK]O_:4@N[=IECAC8I)/_JYP&6,;O(D.!M8#Q_\`;[T[Q7HW[1_A/Q#X
M7\*^'?%=Y>>$=6\'1:;X@$R1:I_:,UL\B6$D,4RO=Q+:*TEK=?989K>1Y?M<
M<5I=R0\A^QK;:?\``3QAI6JW=I<:_-!\)/"OPTT>?2]%N4FUK6M+DU%]0TVU
M^TQ0F-T^U6Q=9VB$9M[OS3'_`&?>FVY?K=*,)\\ES*UEZ>TNO/F2IN^RYTE=
MI\W-7QN'@W%S2:7XMP7X7GIN^5/:<3[)MOC5X.O=)LK^'Q9X9EL=2TB37[.Y
M35(&BNM-C$9DO8W#8>W42Q%I02@$B9/S#./\#_VK/A?^TW;ZE+\-OB1X!^(4
M6C%%U!_#7B"TU9;$ON*"4V\C[-VQL;L9VG'0U^9WB/1O'OAW]E:?0]1T.TUZ
MP\%_!G5_A1X47PK9ZO>:AXTOI?[.5@D4UC$\%[!#:,]Q9B*=K=H;D*UTUI>P
MVOT[_P`$CO%NL>(])^(LOB31_%,WB+Q'KLUS>^*]1>[GB\07-C%!ID\3&30M
M%2VDM?L\,'EBR19=CLDD[QW'E.6.P[<E2ES.S:\WSR4?O@E)K1JZ3^)#^N8>
M4E&G-.\K;K6R3_-M7ZZ-733/H%?VX/@LWPZU?Q@/B_\`"\^$M`GAM=4UL>*K
M'^SM-FF"-#'/<>;Y<;R"2,JK,"P=<9R*M^-OVP?A+\-/!&C^)O$?Q1^'7A_P
MYXALAJ6E:KJ7B2SM;'4[4F$"X@FDD"2Q$W%N-Z$KF>/GYUS\V>,O^";'BM?V
M(OV>/!&C/HLOB?X(I9R7NG6'C'6?!UCK<PTR>QN3%JVEH+VV.^X>8.('\W#(
MZ`2EEZGX>_L#7F@WGPSN/^$?\+^'[7P=X+\7Z)<:4WBC4?%+6NH:U=V$XFBU
M"^@2XN%8071EEE5'S<;0KJ21U5K0Y^3WN5NWFE!O_P`FDDEO:^MSMA&+K1@W
M:+O=]M;+[EJ]K]#W"P_:Q^%FJV'C"ZMOB7\/[FV^'@W>*IHO$-H\?AD89LWS
M"3%MPCG][MX5O0U:^&W[2_PX^,NE:/?>$/'_`()\5V/B)[B/2KC1]<M;Z+4V
MM_\`CX6!HG82F+^,(3L[XKY%N/\`@EGXQT/X/_"G3=#E^'L>K_#'P-X:TE["
M;S4TO7=3T;4K6_6"5EMRZVDCPS;9A&TD;R^9Y+_,C:_B[]A#XN^,?"OB_P`>
MVM]X`\)?''5?&]MXRT"RLM2N[SP_HC1:5'HTD4MVUK%/<M/9><SN+6,;S`NT
MB'S&<TH\UM;-I?*:BI>DE>5MXI:WNK\]-N5N;2Z3^;CS./ERNT>;9]E9GTIK
MO[8'PE\+ZKX9L=3^*/PZTZ]\:W4ECX>M[KQ)9PRZ]<1SBW>&T5I`9Y%F(B*Q
MAB'(4C/%<Y^T-^W5X#^`GC+1_"+>)/".I_$#5]7T?3T\)GQ!;P:RMM?ZA!9_
M;!:Y:9HX_.+_`'-K;"-RYR/G+XO_`/!*#4E^(6E_V!HUCXX\#R^"]&\&ZAH^
MH?%KQ-X%^SQZ<UQ^\>/2HIX-369;EBT=RB;&C.'83,$Z[XD?L._$C7_C1XC3
M3;3X77'@GQ%\3/#_`,2VUK4+NZ&OVDNG_P!FQRV2VXMFB8^59.8[K[2"!*83
M#AC**@H^U@F_=YM7WBIQ7JKP<I7\N5>\U8<I<DFEKRJWJXM^GQ6C:^E[O1,^
MQZ***S+"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\KOOVZ?@EI
M?Q%U;PA<_&+X5V_BW08[B;4]$E\66":CIR6\337#36YE\R-8HE9W+*`BJ6.`
M,T>(OVY_@EX0^'-KXPU;XQ?"S2_"5_J$NDVVMW?BRP@TZXO(MPDMDN&E$;3)
ML?=&&W#8V1P:_.3X2_!+XF?'[XA?%WP#J?@CQM:S>(?#_P`0M"\.7GB--0T_
M1O!?]LW<LKD[O#MM;SQW$PM@3%J^JNH&Z)3'YCI]P?'?]G?Q_H7Q>\#>._A;
MHOPWU^\\+>%+_P`&MH'B?49]%LK2WN7M)1<VMS;6=VRE39I&T!A"R1L,21F/
M#RKNE"I_,K_/WK>E[*/DY7;M'72<8J;@GJFT_1<MM?23?_;O*E=IGL^J?&_P
M7HFGW5W>^+O"]I:V)LQ<S3ZK!'';F\=4M`[%L+Y[NJQ9_P!86`7)(KSCXG?\
M%%?@]\(OVD_"WPGUSQUX7L_&GBQKB&VLY-;LHFMKB,6YCM9D>995GG^TQ^3&
M$8R<X[9\"D_X)'ZW9^%_`'A*'Q'H=YX7@\!VWA7QM-(D]O<:A=:;#='2)[.)
M-P2.&YOIWP\NY%MK507*Y7K?AU^Q7\2?AUXK^%WCAH_`VL^.;;6O$.H>.HVU
MFYL[-EUJ2$RRV<HLI'N'M(;:W@BCEC@\U(QNEC(Y5?FM+V?2]N[UM'R5[-M]
M$X::RY<KZ*VMTM=K:7>F^CLDNNO97]8_8Q_;D\#?MH?#'0M3T+Q!X4/BN[T#
M3M<USPK8:_;ZCJ/AG[9`DR17*)B1/O8#/&F[&0!TKV>OF#]D/]AG5OV<Y_@9
M)<_\(LC?#3X67'@C5VTW>#=7LLVF2F2',2;H2]I<L6?:VZ4'82S$?3]=-=0Y
MKP[R_"4DOOBD_F.7QR2VZ?<G^#NOD%%%%8@%%%%`'*_&GXU^&?V>?AS?>*_%
MVHMIFB:>T44DD=K-=S2RRR+%###!"CS3322NB)%$C.[.JJI)`KP+X=?\%3/!
M&H:-XPU[Q-=ZGI^@VWC\>!_#,%MX0UEM9U&X_L>WOS;2Z<('O%NPQNU\LP1M
M^Z5=F\C=WW[>GP[UOXC_``,MXO#\ES::EHFNZ;K\=_;6!U.?2VLKE+J.X73P
M5:_19(HQ+:QRQ320M-Y+-.L44GSY\//@S\1O"_C72/$_C?2?$6J^(-'^(S_%
M'Q+)IVAPQVJ6<WAR31([>RBBN9VFF3S?->VCDGFB6SN4#W3/8RZAC'$4X3FJ
MKMIIHVMZ;OIUM[3R25]=ESU\72I^Z[WLWL]^6=EM:S?+K?\`FV4;GU7)^U+X
M%@CU8RZS+"="U[3O#%^DNG74<EKJ6H1V<EI;LK1ALNM_:9.-J>;ARI1PO->$
M?V_OAAX[^/\`#\,M*U+Q-<^*[J34(K8GP?K,>EWAT]Q'>F'4FM18RK!(RQNR
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MB+)(TJ?ODS%EAV_BS]O[X8^!7T-=7OO%E@=<LX=082^"M;']AVTSF.*?5?\`
M1/\`B4QLROA]0^SC$4ISB-RO*_%#]A#6/'WQ>\8ZO9^--)TSPQXWUKPQXEO]
M,D\/2W&H)J.B7UA.C1W?VQ(Q!+!8K$8S;EE>3S!(0/*//?M5?\$O-+_:&_:>
MC^)\5E\$]7U"ZTNSTG4+7XC_``NB\9B&.TFFDBDT^7[9:R6<C"XE$F3,C;82
M$4HV_IH_##VN][2]$M_F]EK9;K73KJ6Y9.&_1?=_P;[>7GZYXO\`VT/`W@/X
MK2>"]53QQ::V!(()&\"ZXVFZA(EJ]T8+6_%F;2ZG,,<A6&"5Y&9&15+@K7D/
MP9_X+'_"SX@?`#P?XT\16GCCPG?^+[&\O[?0O^$)\07]Y)'9_9_M4ENB:>)+
MJ&);N!FGBC,>#(=V(92E+QA_P2DC\7_MXZ=\9Y?$'@T_V9XG@\3P-/X)6X\4
M(8].%C_9JZRUUF/3<;Y5MX[9=LC9+L,ANA^!'_!/;6/A)+X7@U'QSI.K:7X%
M\.>(O".@P6?AR2RECT[5)M.EA^TR/>3":>#[`P:1%B67SAB.+8=^474]GS->
M]9Z>:C=:_P!Z3Y?*S;>QI!4W649/W--?O_*R?G>W1LZOPI_P4I^#'CC0->U/
M2?%EW?6/A^TM;YI8]`U+_B;V]U*T-K+I@^SYU1)ID,49L1.)),(N68`VM0_X
M*%_"G2?AII7BJZUCQ!;6.M:Y)X:M+&7PEK"ZTVJ);RW)L7TLVOVZ.X:&%Y$C
M>!6D5HR@;S8]_D/Q*_X)#Z;\3_@/X.\%ZEXHTO45\%>!M'\)VW]J^%XM1TW4
M+G3;NUNX;B[LI9BDUM(]J$EM=P+)(P69&PX[3X,?\$_$^%_A[X;VJ_\`"I_#
M3?#_`,:W'B][3X>?#W_A$])U,RZ3>Z:(S:?;;C9-B\WM/YC;A"J;%^\.KEA[
MROU=O-*5D_G'6W33=W1S1<W%.2UM?Y\C=O\`P.T;]5?1*TADW_!4GP'JGQC^
M#WASP]I_BWQ+I'QAL]0N++6;'POK$B:=):SQ6_E7$:V3>2PF>1)A.T)M?*S,
M$#`U],5\X:'^PIK'@7Q-\.]:\/>,])@U3P3XC\1ZE<OJ7AZ6[BU'3M;U![RZ
MM(TCO(C#.F8TCN&:51L9C`V[:OT?62^'7>[^[I_EYM;+KIK?^OZUW\K[L***
M*`"BBB@`HHHH`****`"BBB@`KQ/XX_MJK\"O'5QI-S\*/C7XFTVWA0'7?#/A
M5M6L9+N2-Y([-8XI#=%F"`&X\C[)$TB++<1L2![911U7]?UY>?=:#_K^OU\M
MFGJ?-WC7]O'4O"/[;'AGX2IX8\):BOB":**6"U\:Q3>+=-A>TDN#J4VBQV[+
M'IJ/'Y#7,EVA\PX6-]T?F4/AW_P4%\0>+_BGX0_M#X<V>D?"_P"(_B34O"?A
M;Q&/$;3:O=7UG'=N'NM,^R*EO;3BPO#%(EU,^%A+QQ^80G0?&?\`9(\:_'CX
MR>'[G7_B'H,WPU\,^*;#QAI^AIX1VZ[;7EF`T4*:J+ORUMS,"S#[%YS1O)%Y
MVULU@_"W_@G_`.(O`_Q/\*'5?B+8ZW\,_AUXCU3Q7X3\/+X:,&JV=[>K=QA+
MO46NI$N;>!-0O%B1+6%_FA+R/Y1WNC9J+J=W?T]VVWVOB2W6EV]4E-31R4=K
M*W^*TO\`R6_*Y;/6T5H[W/C%_P`%%?#/[-W[5_B+P9X]NVTGPSI_A31-=M;^
MST'4=1DMY+R^U2VN);R2VCECMK.,6EK^_F6*-&E;?)\R@=EXI_;P^%W@WXS#
MP'?:[J8UU;ZTTNXN+?P]J5SH^G7MWL^S6EUJ<5NUC:W$OF0[(9YTD;SX<+^]
MCW9?QX_8M_X7;K'Q=N_^$E_LS_A:G@"R\#;/[/\`._LO[/+JDGVK/FKYN[^T
ML>7\F/)^^=_R\AX]_P"">OB'Q?X\\16=O\2+.S^%7C;Q3IWC+Q#X=E\-FXUB
M>^M#:-Y-KJ?VI4@M)6L+4O&]I+(!YPCFCWIY3A9RBI[=?_`EZ_9N[V>J7NE5
M[<TI4]K*WR@K^MYW5G;J^;:_LVC?M-^!_$$FC+::WYK>(/$&I>%K`?8[A?M&
MI:<;L7D'*#;Y9L;KYVPC>5\K-N7=Y_H7_!3;X0>*OA7I?C32=3\9ZQX?UZ]6
MPT>33_`'B"[N=<E:W:X)LK:.R:>[C6)'+RP1O'&8W5V5E('/^`_V!O$_A#XT
M:/JT_P`2=/N_!'A?QKKOC;1]!B\,>3?"?5TU$W,5U?&Z=9ECEU&1H3';P[4!
M5Q*2LB5OB)_P3RUK7OV(OAI\(-#\4^"(;[X>:59Z;!XEUWP?=:A>6LUM9_94
MO]--KJ=G-IMZN2R3QSNR;B!US4:\KDM_=LO6_-?III]^[L7:'M)13TN[/NKR
MM]ZY;_/3M[3\9_VEO"?P"\'Z3K7B277U@UVY2STZSTSPYJ.KZI>S-$\VR.QM
M();IF6*.1W`B^148MM`-</\`"O\`X*2?"#XV>(/"NE^&-<\0ZI?>,]&B\1Z9
M&/!^LQ`:9+)<Q17MPSVBK:0.]I,!)<&-3A.?WL>_RG_@J5^SM\3?B-\)?A/I
MOP]T[Q-XNO/!^LFYU"^L-3:VUI0NFW%JL^Z+6M"D8N9F$ACU&/[_`##,K'9V
MG[&G[).K>$/",.L^+]/T?PKJ&O?#K1O!%YX5T.V-M;:)%83ZFZ%)%NKC:[1:
MBBM&LTPB>%MMS<`B0N6U5QUY7[O2ZLW^=E>VFMT9QMRQY]&XIOK9\Z3^Z+;M
M?5K<W/#7_!3CX*^*M/UB]M_%.IVVFZ+I<NNM?ZAX8U:PLM1TZ*5(I;ZPN)[9
M(M0M4:6+=/:--&JS1,6VNK'I?%W[;?PS\$77BNWOO$,S7G@O5M/T+5;2TTF]
MO+E;Z_2.2TMX8H87>Y>594QY`DP=P."C`>3?#/\`X)JZHL.DZ1\3/'VF^/\`
MPAX.\%ZAX`\,Z99^&/['F33+V*&WF?49C=3K>7/V:VAB#PQVL7S3,8263RY/
M@M_P31NOASXY^'7B'7_B`WBS4_"OGWWB*9]#6T?Q;J>;[['=N5F;REMUU*\`
MB;S=Q\AMZF+YG))NT7IW_P"WGTZ>ZK6O+WI1=[*5EJH-_:[=-E;7JN9N^B=D
M[*[5^(^&W_!:CPYXXL/A9XFU3P_XI\,^$_''AC7]5U&T?P9K]_JT%YI\VDA%
MM(TLUEN[80WUP\D\5N\8\HGS$$4E?9_@KQGI?Q&\':5X@T.^M]3T77+.+4+"
M\@;=%=6\J!XY%/=65@1]:^>?V=OV`=8^"FK>$/[1\;Z3K.E_#[0/$'A70;:S
M\.R6,JZ=J5QILT(N97O)A-/!]@96D1(EE\X8CBV'?[/^SO\`"7_A0GP"\$^!
M_M_]J_\`"':%9:)]M\CR/MGV:!(?-\O<VS=LSMW-C.,GK51Y72UWT_&4[I^B
MY+6TUMK:Y4]X\OG?[U;\+_\``V.RHHHJ!!1110`4444`%%%%`!1110`4444`
M%%%(3@4`!Z<=>U87@_3_`!/9/%_;^KZ#J0&G6T4HT_2);$O?*9/M$XWW,V(9
M`8MD)RT>Q]TTN\;/*/BA_P`%)O@S\(_VF/!GP=U3QKITWQ)\=7)MM.T.R/VF
M>'$<DADN"F5@3$;?ZP@DXP#7MB:S:2+D75N1ZB5?\:`Z6+-%5_[6M?\`GX@_
M[^#_`!H_M6V_Y^(/^_@_QH`L50@M]47Q/=2RWE@^C/;0I;6JV;K=13AI3+(\
M_FE71E,(5!$I0QR$NX<+'874[=VP)X23T`D'/ZT_[5'_`'T_[Z%`>1)16?XA
M\2VGAC0+[4KI_P#1M.MY+J;9\S;$4LV!W.`:\T_9*_;J^$W[<_PS?Q;\*_&^
MC^+=%@;R[I[>0QS6+A0Q2:)PKQD!A]X`>A-`'K=%>*?!O_@H=\(?VA?VD/%O
MPI\$>,++Q/XO\"V8O==CL$:2UTX&7RA$T^/+:3=U5"V.<X/%>S_:4_OK_P!]
M"@"2BH_M*?WU_P"^A1]I3^^O_?0H`DHJ/[2G]]?^^A1]I3^^O_?0H`DHJ/[2
MG]]?^^A1]IC_`+Z_]]"@"2BH_M,?]]?^^A1]I3^^O_?0H`DHJ/[2G]]?^^A1
M]I3^^O\`WT*`)**C^TI_?7_OH4?:4_OK_P!]"@"2BH_M*?WU_P"^A1]I3^^O
M_?0H`DHJ/[2G]]?^^A1]I3^^O_?0H`DHJ/[2G]]?^^A2BX0G[R_F*`'T5XY^
MRS^W[\)/VSI]>M/A[XRTS6M7\+7TVG:SI);R=0TR:*5HG$D#8<+N0X<`J>,&
MIOVD_P!N[X3_`+(^N^&=(\?>,]*T37?&>H0:7H6DEC+?ZI<32I$BQPJ"VW>Z
M@N0%'<T`>NT4PW"#^-?^^A2?:4_OK_WT*`)**C^TI_?7_OH4?:4_OK_WT*`)
M**9]HC_OI_WU1]HC_OI_WU0`^BF?:(_[Z?\`?5'VB/\`OI_WU0`^BF?:(_[Z
M?]]4?:(_[Z?]]4`/HIGVB/\`OI_WU2I*LGW6!^AH`=13#<(#C>F1U&>E'VB/
M^^G_`'U0`^BF?:(_[Z?]]4?:(_[Z?]]4`/HIGVB/^^G_`'U1]HC_`+Z?]]4`
M/HIGVF/^^O\`WT*Y/XZ?''P]^SI\&_$WCSQ/<2P>'?".G3:KJ4L$1FDCMXE+
MNRHO+$`'@<F@#KZ*\_\`V;OVIOA[^U[\+K#QG\-?%>D>+O#FI(6BN[&7)0@D
M%9$.'C<$$%74$8Z5WX.10`M%%%`!1110`4444`%%%>`_\%#?VG_$G[/'P/U2
M+X=Z=I^N_%#5-,O;G0K*]D"6MG';0F2XU"YY!^SP+@E1S([1QCE\@`]^J*ZN
MX[2/=+(D2YQN<X%>+_M#?'WQ%\,?V$]4\>Z)'87/BS_A'K:?3A>1G[*;ZY$4
M<32(I!,8EE5F4,"0",CK7FGPL^-OC[2_VH?'GP4^(>MZ;XNO/#_AS1_%^E:[
M::6NG--#<R3VMS!+"K,@V7$.Z,CG9(`VXKN(!Y=\4?\`@WH_9M\9?ML^#_C?
MH.FV7A?5M%U2?4M?T2+%SI'BHS*X9IH9&/E2!G+;HR%)^\A/-?2T?[!7P`B0
M*OPX\!JHZ!;*,`5\K^/OC%^U=XS^-WQ#LOA7X<^$5WX+\(:[_8=I/KL\D5[/
M(EM#+)O^<#[TN`0.@KM(/#_[53V=J\GBOX(QSRA3<0_\(O=L+4D)N`;[9\^"
MSC(QGRQ_?&`#W*?]@3]GZY8%_AQX%.!C_CU0?UIG_#OO]GK_`*)MX%_\!E_Q
MKQ<^&OVHS>[!XT^"1M]A/G?\(E>9W`<+M^V=S@9SWS2'PU^U)Y$[?\)E\$O,
MCW>3'_PB=YB?&_;D_;/ESA/IYA_N'(![7%^P#^S[!(&3X<^!T8="MNH(_6I7
M_84^`Q&/^$!\'?\`?L?XUX9<>&_VIXE0Q^+_`()2YSN'_"*W:[,%L?\`+YSD
M!3_P/_9YEB\+_M1&]9&\;?!1+<#*S#PC>$MR,_+]LXX)/_`<=Z`/6O$__!._
MX$:WX9U*RMO!'A*SN+VTEMXYPI;R6="H;&_G&<_A7@W_``3Y_P"#?;]F_P#8
M+^%VOZ+]D;XA:UXQL)=+U_6]=N<2WMI*`'MDBB*I%$<=@7]7/%;4'AS]JB73
MO-D\7_!*.YRH\C_A%;QA@[,G?]LQQND[<^4/[XQROQM\:_M-_`[X=3>)+[Q-
M\&;RTM7MXYXH?"UV'C:62./C_2SN"L_XA<]ZF<E&+D]D88K$T\/1GB*SM&";
M?HE=_@1_LD_\&\'[/G['7[3_`(X\::!Y>J^$?&6GI;0^%-6;[3#H4RS"3=;S
MEO,,9&1MDW,/[Y'%?3?_``P%\`?^A`\(_K_\57B%WHO[45C<>2WC/X)^9*&%
ML/\`A$[O$[A'?:?]-^7[JC//W\_PTLWAW]JA+#S$\6_!&2XW$>3_`,(M=J,?
M/@[OMG?:G&/^6A_NG-&Y[=_PP%\`?^A`\(_K_P#%4?\`#`7P!_Z$#PC^O_Q5
M>*OX;_:C^VQQKXS^";VY/SS'PE>`H.>=GVSGMW[TW_A&_P!J;9(?^$Q^"(8$
M!%'A2\^<93)S]LXP&<^_EC^\,`'MG_#`7P!_Z$#PC^O_`,51_P`,!?`'_H0/
M"/Z__%5XB?#W[5"V]NW_``EWP3+R$"9/^$6N_P!R/DR0?MGS8R__`'['][B4
M^&?VH_MVS_A,O@F8-I/G?\(G>9SC(&W[9W/&<\=:`/:?^&`O@#_T('A']?\`
MXJC_`(8"^`/_`$('A']?_BJ\47PS^U*;>X8^,O@EYB;O)3_A$[S]]C?C)^V?
M+G:GT\P_W3E6\,_M2B2+_BL/@GL<G>W_``BEY^ZY;''VSYL@(?\`@?\`LT`>
MU?\`#`7P!_Z$#PC^O_Q5'_#`7P!_Z$#PC^O_`,57BR>&OVH5N91+XU^":6\8
M+";_`(1&\.X`C/R_;..,GK_#CO5/0;']J#Q#X<MM1B\8?!-?M2)+'"?"UTV5
M;8<EQ>D<;I.F<^6/[XP`>Z_\,!?`'_H0/"/Z_P#Q5'_#`7P!_P"A`\(_K_\`
M%5XK%X:_:E:2$-XR^"2*Z9D(\)WA\IL`[?\`C\^;DL,_[.>](_AO]J4?:,>,
M?@D?+4F$?\(G>#SVPQ`/^F?+R%&?]O/\/(![5_PP'\`?^A`\(_K_`/%4O_#`
M7P!_Z$#PC^O_`,57B,_A_P#:HCL=Z>+?@E)<;B!"?"UV!CY\'=]L[[8_^_A_
MNG,__"+_`+4(O=@\;_!,PXSYO_"(W@.<X^[]L].:`/9_^&`O@#_T('A']?\`
MXJC_`(8"^`/_`$('A']?_BJ\4_X1G]J4QN?^$Q^".5("`^%+S]X"4R?^/SC`
M+GW\L?WN&-X>_:H\F`_\);\$1)(0)4_X1:\_<CY,D'[9\V-S_P#?O_:&`#V[
M_A@+X`_]"!X1_7_XJC_A@+X`_P#0@>$?U_\`BJ\5/AO]J07FS_A,?@EY&PD3
M_P#")WF=V.!M^V9Y/&<^]4ULOVHIKZ\M8O%WP2>[LU#^6?"UV!(C>;M;/VSY
M<^6O!''F=]IH`]V_X8"^`/\`T('A']?_`(JE7]@7X!1L&'@#PED'(Z__`!5>
M)+X:_:E$D8_X3#X)[6)#L?"EY^[&6P<?;.<@*?\`@>/X>7Q^&?VHGOC&_C3X
M)I!QME_X1*\.[D#[OVS(XR>O\..]`&3_`,$[/^"#_P`"?^"?GQFUKXGVDTOB
MGXE:QJ%Y>PZK>7'E6^BQ7$C/]GM+=6VJH5@NZ0NYQU`.*D_;X_X(1?`;]NW]
MH/PU\6;N6?PS\0M`U6SU"[OK*X$MKX@BMYD?[/=P.=I5E4KNC*,-W).,5@?$
M;QO^U%\-;KPA!=:_\%Y9O%VN1:&BQ>&[K%H[Q[_,8_:_F`PXP,?=!_BXZ^+P
MW^U,TD0;QC\$D#J#(1X4O#Y1P"1C[9\W)(R/[N>]2I)R<5NC"GB:=2K.C!^]
M"U_*ZNOP/;&_8$^`3L2?`'A+).3U_P#BJ3_A@+X`_P#0@>$?U_\`BJ\3;P[^
MU,#/CQA\$F\M"8O^*5O!Y[88A3_IGR\A1G_:SVIDWA_]JI+0NGBOX(M/N($/
M_"+W8&/GP=WVO_93C'_+0_W3FC<]O_X8#^`)_P"9`\(_K_\`%4?\,!?`'_H0
M/"/Z_P#Q5>+/X:_:C^UA!XT^"?DXYE_X1.\^7GIM^V<\<U3U6S_:@T73Y;BX
M\8?!-466*&/'A6[_`'A=XT!YO1C[[?7R\#[PP`>Z_P##`?P!'_,@>$?U_P#B
MJ/\`A@/X`_\`0@>$?U_^*KQ#_A'OVJA!"W_"5_!$2L0)8_\`A%[O$/W,G=]K
M^;&7^OEC^]Q(/#7[4ANRG_"9?!(18R)O^$3O/F."<;?MG'(`S[^U`'M?_#`7
MP!_Z$#PC^O\`\52?\,!_`$?\R!X1_7_XJO$I/#W[5(@E*>+/@BTBL1&A\+W8
M\T#?@D_;.,[8_IYA_NG*_P#".?M4;XA_PEWP1`9B)#_PBMY^Z&6`('VSG@*?
M^!X[4`>V_P##`7P!_P"A`\(_K_\`%4?\,!?`'_H0/"/Z_P#Q5>*0>'/VI9;Z
M1'\9?!..!3A)1X4O&W_=_A^V9'5N_P##[U%%H7[5;68=_%?P12?(W0CPQ=D`
M?)D[OM?^U)Q_TS']\8`/</\`A@+X`_\`0@>$?U_^*H_X8$^`*_\`,@>$?U_^
M*KQ)/#G[5#>3GQA\$@&4-*?^$5O#Y1V@D?\`'Y\W)(S[9[T?\(Y^U.PFV^,/
M@B=JDP_\4K>#SFPV%_X_/ER0HSVW_P"S0![;_P`,!_`$?\R!X1_7_P"*H_X8
M#^`/_0@>$?U_^*KP33(OVH]:T4W=EXM^"<S":6`Q-X7NEP8WD0_,+PCDHOT\
MPY^Z<Z1\-?M2?;50>,_@EY!&3*?"=Y\O/3;]LSTY_2@#VG_A@+X`_P#0@>$?
MU_\`BJ/^&`O@#_T('A']?_BJ\2_X1[]JC$G_`!5WP1.P@(/^$6O/W@RF3_Q^
M<8!<^_E_[7#3H'[57V:!E\6?!$R2;?-3_A%[L>1G;G!^V?-C+^F=@_O<`'M_
M_#`7P!_Z$#PC^O\`\51_PP%\`?\`H0/"/Z__`!5>*?\`".?M3"[9?^$Q^"9A
MVY$O_"*7F2V"<;?MGJ`,_P"UGM4;^'OVJUAE9?%?P19T8B-3X8NQYH^?!S]L
M^7.(_IYA_N\@'M__``P%\`?^A`\(_K_\57#?M,_\$K?@E\=/V>O&G@S2?#_A
M?PMJ7BG1[C3+;6(H3,^FO*A43*F\;BI.0,CD5QT_AC]J6*:/9XS^"4L;-\[G
MPG>*8Q\W./MG/1?^^O:DA\/?M32WKHWC#X)1VZGY)?\`A%;QC(/E_A^V9'5O
M^^?>@#I_^"77_!'GX(_\$LO";V_P[M)M3\7ZA:"VUGQ-?W1DO]64/OP4!\J-
M`>BHHZ#)8\GZZ7A:^2OV7O%OQH\+_M$Z)H7Q+U/X=ZE8>)-(O[BWC\/Z1/:3
MVLML;4EFD>>164^<R[=H/R!LX.*^M1TH`6BBB@`HHHH`****`"O'/VG_`-A?
MX;_M8+=W?BK0+>?Q%)H5UX?M-91Y4NK&VG!+*NQU#+OP^UL@E1FO8Z*`/!M=
M_8<LM8^"$OPR@\4:QI?P_/@]?#,&F6D,?G6=TL@D35([B3<_G(0NU&W1Y4$@
M]*QOAA^R)??!?Q9XE\?^+_&=U\1/B'XLM[#1;G6)=.BTZ*WTZS$AAMXH(R57
M=)))+(V?GD<X"J%4?25<U\3_`/D7H_\`KN/ZT`?)'[*5SN_:0_:!B_L+78MO
MC)F_MF6<G3;K-I:?Z/%'YA`F3JQ\M<@CYFQ7OE>!?LI-$?VCOV@/^)YJ\LX\
M9/G1WBQ86J_9+3$\;^6,ROT8>8V`!\HKWV@``Q1110`4444`%>:?M?\`B+2?
M"GP`UF]UO18O$6G07-DDVG27#0"4M<QA"77D;6(8#OBNF^)_CQO`N@;K2W:_
MUF[S'86<:EFE?NQ`_A4<DUY!\==*M/A/^SUXLN=<M;KQ>+N72KNZL=2N6CWR
M/<HGWD.0(VP1@X.`#6U;"_[#/$2E;1VOUMHWZ*_S/@.)^)E"I6RO#PO:G)U)
MOX*5X2E!25GS2ERZP2;4=9*THJ7NVKN3K>E_*&S-("W]S]TWN/IT/T'6KU9^
ML[4US209=K&:0*N3^\_<MQU'0<\@].W6M"L%L??+8****8PHHHH`****`&7)
MQ:R\9_=L<>O!K*^'KF;P'H[M'Y3/9QDI_<..GWF_]";ZFM2[&;.;)P/+?)]/
ME-9'PU=)/A[HC13_`&J-K*(I-DGS1M^]DLQY]V/U-`&W1110`F*6BB@`HHHH
M`*R+!R_C755,>%6VMB)/[Q/F9'WNW^Z.O4]M>L73)$/CG5U6<M(+6U+19.(P
M3+AA\Q'.#_".G4]@#:I,8I:*`/-OV@M?TK0M?^&:ZGHD>LR:AXN@M;&1YVB.
MF7!AE*W(Q]\@`C:>/FKTDUYC^T;KFGZ+XA^%Z7VCPZL]_P",;>VM7DF>,Z?,
M892)UV_?(`(VMQS7IV>:RA\<OE^1XV`DGCL4KIV<=$K->ZMW97ONM7IH8LOQ
M#T*V^)%CX.?5;1?%>IZ?+JUII))^TW-G%(L4LZKC&Q9'13SG+#BN)U[]MGX0
M^&/"7B+7[_XC>&H=#\):S'X=UG4$DDFM[#4W.%LRT:,&F).-J;L'@X/%?+__
M``44^$GQ.^/7_!0GP3X.^%7CNT^&NN:]\&O$UO>:^]H;BYM[<ZA:@16V&7RI
M))#&AFZQH7*_-M-8NN_$C1?B-_P36^#>B?#.ST;X?>)?`_Q3\(>%M4\/W=F]
MPO@W7K>^1;B"[A#1R3'S/WI?>&F60/O)8FM3V3[`^#'[8OPM_:*\0W&D>!?&
MVG>)M3M+?[7/;6]K=1-%$"%+DRQ(",D#@YYZ5V'C^0Q>&\K'YI^UVHV_6=!G
M[R].O7\#T.5\*M-^)FF/J2_$7Q=X+\4EV3[!_P`(]X=N='%MC=O\T37,_F9^
M7;MVXP<YSQI?$B6.+PKF6?[,GVVT&_)')N$P.&4\G`Z]^AZ4`;S?>/UI*5_O
MGZTE`!1110`4444`%+&!O'U_*DH5=S@>IZ4`87PZE:;PTS-$(3]MNAM]0)GY
M^\W7KU_!>@W:Y[X8R12^%W,-Q]J3[?=CS,DX/GOE>68\'(Z]NB]*Z&@`HHHH
M`*,T44`%%%%`'*P#'[8GPV_[`.O?^A6-?15?.MN<_MB?#;_L!:]_Z%8U]%4`
M%%%%`!1110`4444`%%%)GF@!:YKXGG_BGD_Z[C^M=(3BN;^)Q_XI^/\`Z[K_
M`"-`'Q-^S[INMZ_^UG\94TOXKC2[/2/';7FH^"HM*L[A[B$V=H/->9SY\2RG
MH5Z%>*^GCU->(?LL&X7XV_'H,^B_9/\`A.9?+1`W]H[_`+':9,G./*_N]\YK
MV^@`HHHH`*H>)?$=GX1T"[U*_E\FSLXS)*^W.!TX'<DX'XU>KB/'GV_QIXUL
M=`MHU_LFR=+S5+@;'V,,M%$R,>5;`)Z\8KIPE&-2I:;M%:OIHM_F]EYGA<19
MG4P."<\,N:M)\E-6O><OANM/=CK*>J2A&3;11\#:5%J&I7_CWQ%&M@S*7LQ=
MRE3I5LHQ\P;"J3C.0>=U>)_$+]MCP7\3_#?BY_[!CURPTE;2$Z;?3O`]\OVN
M$+*R@;HMCOG:>3M!Z&N9_:Y^*.L?M8_$Y?A+X)^W1:-I5VAU*\L&B=;M0`"=
MKE0T49)PJD[BI/:H/C7X0\-_L3Z9H^E/I>E>)].UR"UM[JPOYO*EOKE9#BZ?
M;\SG@#<!@&-`>*\26?+,,RG@Z6MH3T5K0C&%1Q<W+57Y/<@ES5-:CM!1<_HL
MY\-<)PYP'7EB*E\PJ1]NE:[2;3JUJJ2:DY0<FH-.T5RVZ+[0UC<-<TGY=V9Y
M26+XVCR6[=ZOUGZRP77M&!D8,\TH10<!_P!RQQCOQS^%:%>EZ&2V"BAALCW'
MA?4\"E,;*.01^%'H&EKB44F:7-`!1110!'=?\>DW_7-_Q^4UE?#EBWP_T4M'
MY3&SC)3S/,V_*.-V3GZYK5O#BRGYV@1.2?3Y3S61\-)8Y_AWH;PRM-$]C$R2
M,^\N-O!+=_K0!MT444`%%%%`!1110`AZ5D:>3_PG&KC9@"UM2&WYW<R<;<\8
M^G.?:M@UBZ;(C>/M942LTJVEJ73?D1@F3!QVS@\]\>U`&U1FBB@#S?\`:!\2
M:;X>U_X:)J&AV^M/J7BV"SLGEF:,Z9.8I2MRN/O$`$;3Q\U>D5YK^T-XDL?#
M^N_#)+W1+76'U'Q=!:6LD[LITR4PRD7*8ZN`"N#Q\U>E9YK.-N>5O+\CQ\!*
M^.Q,;IV<=$K->ZMW97ONM79::&3/X%T:[\<6OB:72K%_$5C8RZ9;:FT0-S!:
MRNLDD"OU",Z*Q'<J*R;OX#^"K_Q#J6K3>%-!DU/6-0LM7OKHVB^9>7MF,6ES
M(?XI81]QSR,#FNLHK0]@"V3GUZUA_$1S'X8RJ>:?MEK\OF;.//3G.1T]._3O
M6Y6%\2)XX/"NZ69H$^VV@WJ^SDW"`#/N<#'?.*`-YOO'ZTE*_#GZTAXH`**,
MYH'-`!122GR8#*Y6.(=7<[5'XGBO/O&7[6WPL^':$Z[\1?!>E;93`?M&K0J1
M(,Y7&[.1@U$ZD*:O-V]=/S.O"9?BL5+DPM.4WVC%M_<D>A4J<N/K7A]E_P`%
M%?A1XE.SPOK.K>-Y\_ZKP[H=Y?X`ZG<L>WCC//<56O?VPO&EUI?GZ+^SO\6]
M0D\W:BWAL;#S%_O@22AL=,<5S?VAAW\$N;_#[W_I-SVO]3\YBTJ]!TK_`//U
MQI?^G'#[]CUCX:/O\,29C$1^W78VB7S/^6[\YR>OIVZ5T':OF#X,?&7]H+QG
MX7=[+X1>$]"@_M2X7S->\7_:9-AF?=Q;HV"AX*YXP0*[V/PO\?M<UHO<^,OA
M=X:TY6.(-,T&YU*9AVR\[H`0?;FJ6,C+X(2?RM_Z5853AF='_><31CZ5%/\`
M]->T/8@,TLJ^0,N5C![NP7^=>">+OV6_BC\0_%-I>ZG^T%XHTG3[<;9+#PUH
MT&E"<=\ON<Y]^<51\(_\$POAGI&M/J?B.?QE\1-1>42B;Q1KLUXJ$8QB,%5[
M<Y'3BH^L8B4N6%+3NY)?ES&\<HR2G2]IB<PO*WPTJ4Y._9NI[%+U5]SW7Q'X
MVT3P;IC7NL:UH^DV:#+3WM[%!&/^!,P%>!^(?^"J_P`']'^),OAC3[[Q#XLN
M;=0T]UX<T>;5;6/.<C?$"6([X!QFO1)/V,?A!(Z,_P`,?!<AC8.GF:>)`K#D
M$!B17H&A^']/\,6ZQ:9IVGZ9$H"A+2UC@``[80"BI#&2TC*,?OE_\C^HL'7X
M=H1<J].M7;3LKPI);6>U5O\`\E/G63_@J/X(2P%S_P`(3\9?)=VC5SX*NP&9
M<$CI[C\ZW?V5_P!K7QE^U)J-S>K\)-8\%^$+>7RAJ/B"]^SWUP<$YBMMGS#(
MP3D`9ZYKWPW<I_Y:/^=,=S)]X[OK4PP^)YU*=7W5T44K_-MO[K>I>)S?(_JL
MZ6%R^U26TY5I2Y?-1BJ:;\Y<R_NG)VXQ^V+\-O\`L`Z]_P"A6-?1=?.L/_)X
MOPV_[`.O?^A6-?15=Y\D%%%%`!1110`445\\_M]?M[6G_!/+0/#/C+Q7X:O[
M_P"&%Y?G3O$WB"RG0R^%FD:-;:=K8GS+B)F+JPA#.F%.U@30!]#9KP/_`(*"
M?%7QQ\&OA/\`\)%X7\1^%?!.AZ'#<:EKVOZU8OJ/DI$@,%K%:H59S/(=K/G,
M:J2%9B,0_L!_MR'_`(*`>%=>\=:!X6N]'^&)O!9^$M:O+N)KGQ3&AD6>[^S*
M2]M%N"*B3;93\Q95X%=O\=/A#XK\>>)=$UCPGXW;PS/I=O=V=WIU[8?VCI.J
MQ7"J`\UOYD?[V)D#1ONZ,ZD$/P`<GXU_:NUWPS_P3YB^+B^&[)?%-YX7L]6M
MM$DO1):K?W4<0B@:>/.8O.F0%UR=N2!FO/?@G\??B(GQQ\9?!;XL7GA[7?%W
MAG1M,\7V.N:'9/96E_8WDDT$D#0,S%'@N(F16W'S(V1B%;(KI/"__!.N+P9^
MQ;;?`FP\;:FOA"R\*_V+;W4MFDFHQ:AYYN%U$2%MNU9""MOLV@*`&P,5:\)_
MLJ7_`,.OBUXL^*'BOQ-'XK\;>+=-TSP\TMMIPL+.PL;+S75(HM\C;I)I9)7)
M<C)4``+R`>:?LD^"#)^T3^T!K,'A6,3W7C-[63Q!&5:>]5+2T(MF4#>%CSD$
MG'S<5[S]GD!/[M\@X/R]*^8_@+\-]`^)/[1'QZA\0?#X7T%KXSD>'Q#<W*^1
M>L;.T!M4B242AHQR69`IW<$U]#1^#-)AMX8EL(!%;`"%<MB(`*!CGL$3_OD4
M`:OV=]N=K8SC.*!`Y.-K9/0;>O\`G^M9X\,:=]J\XV<)EVE=V6S@C![^AIJ^
M%=-6.5/L4.V?=Y@Y^?=NSGGOO;_OHT`7-1N5TC3;B\N%D$%K&TTA5<D*HW'C
MUQ7S3\>/BS8?#/\`9^U[7[G7H--U_P`>RK'97%H\$=]%;R.$0-',ZJ54`HV.
MF\\]Z]<^,NE:2FBZ=I[O!I;ZK?1VXN"C,B)EI)-W.%4@MDGCYO3I\=^(_C)I
M7C+XO^)?BQXMTM+'X>_#>5K"PTZ*.RO?[5OF/E):A`6E;SMP=648P/:L\SJU
M*.7.$+)U;IMRY?<BKO6S>]E[J=G:Z.K@S)\/FG$L\TQK7U;*XJI)>[[U:I\$
M4FW[W*K:PM:HVGNCTSX9Z/X;_P"";7[-_P#PG/BVVO;KQ-XD6)8M.M+4)<7$
MK<Q6L48=D"J6R9,@*IY-?/VB_M;0_M0'QUX@\<P?#SQUJO@+7-*MK#2M(\R:
MPT1)9]LMO]N4#[0^65G*%@"@'0URWPH_9CUW_@J3^U1X[F\1:]_8W@+P[)9)
MJ=UX=O)FADD,0_XDVG2,0(XUC5?M$@!W$[>HKZ?_`&E?`W@C]E.X2'PGX"\*
MZ=HAL-.WZ/;6*6]C.(KU0#(J`;GY'S'L#R:PSG*(Y!E]/%8NK.&*J2I^XK14
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MXQW6**!E11G(R>:;KO[+GBKP`HN?A;XVU/0V6()+I>N;M4LKS:6*?-)EXL9*
M_+V'M7GJ?%_X:2W\FH^!_B1X:TR\1?M4>BWFIQ_9)BN5)VLP*-R<;N!FO6/A
MI\4]#\7W<NFZOI=EHNJ,%8)]I$D%YR,&)PQ#8*)W[?6O3P&7Y%FM*5;)I\[C
M\7Q4Z\+;\\9<M7U;T>IUQ\5,_P`MS".4\64GA:LG:,9I3PT]](-Q4(/32$XT
MYW^%,S+?]J:[^%-Q;:7\7=`E\(WLQVIK5GNNM!N"1\H\_`:-S@Y5U&,=:]@T
M?48/$6D6VH:?-%>V%Y&LL%Q`XDBF1NC*PX(-9NI?#G0-:TP6-[HNGWMFN#]G
MN8O-CXVC[K9'\*_E7E?B/]EB_P#`7B.7Q%\,M4&D2@222>&+_=+HEZS?>6-0
M1]G9@-H*<`G.*N^-PF_[V'R4U^D_EROU9]IRY7F"T7U>K\W2;\MY4_GSQ[\L
M=5[>8'#8V-D]..M`@<Y^1^!D\5X+X5_:8TC3-2&D?$CP1?\`PROKY7/VC4)?
M-TN\;G<J7*G&X^8YPV#R?:O8-%TS0O$EE;WFG1Z??V[#?!/;2^8C`DG(96Q_
M$WYFNO!YCAL4OW,KOMM)>L79KYI'EYCDV,P,DL3"R>TE9Q?^&2O%_)LU[J&1
M+25MC<1L1D8'W2>M9?@$SW?@C1Y)(U\V2SC9A&Q=<[><-W'7GVJ'Q+;Z#X,T
MNYU/5#I^E0%3&]U=SB%`Q^Z-S,!DD#`]17,_"K4/!5S\,-/CL[_09;2RM8EF
M'V]6\DJJG$AWD@C8G7^[76YQ3LWJ<4,/5G#VD(MQVO9V^\]$%O(?X&_*D-M(
M!G8>>!QU->6ZA^T5\&?#]X;>Y\=_#^"YLD&8SK41>)=HQP'/8#\JX[6/V[O@
MMNFCT6XU3QG+*"LL?AS0;[4`R$$%MZ)M*C<0<'@MBN>6.P\?BFOO7^9ZV'X7
MSFN_W6$J/_MR5OOM9?,^A/LLI.!&^?3%(86Q]UOKBOG37/VN]'CCL[72_@M\
M7=>%[)CRT\/R6JQ$[L,S3,HYWOWXR<XJ\?VF-6\_S?\`AGCXK>:O`?%GGKG_
M`)[^M1_:.'O92OZ)O]#K_P!3LWLI2IJ-_P":I3B_NE-/\#W[R'_NMSTX^O\`
MA0;>0'_5OQUXZ5\WZE^T?XON-4M[31OV9_B#<K=\SRW^HV5E'&PVE<L92,?(
MOI]T4_4?BM\5_P"R?+LOV:+AKB+FW6X\8V"Q*PVXR5<MT5?^^12_M&BU=<S_
M`.W)_P#R(_\`4_,4XJ;I*_?$4%]]ZNGS/HSR7*YV-CUQ67IHG;QGJ4/EC8MO
M;,FULOSYF<KV'3![Y->*:/XD^-FJ6D-]<?!KP%IUY*A#03^+G:6'J-I*1E>G
MH>]<_J7B[XRZ)XPU$P_`_P`(Z\9UMOMMK8>,-DD<9,W[P>:JKD[Y!C/4^G2W
MC8)<SC*W^"7^1DN&,4ZGLU5HWV_CT;??SV^=SZ?\B3'W'_[YI?L[_P!QO;BO
MF&/XM_'7^V8]_P"S-I_]GQRDHW_":6OVA8R6.<9V[_F/?&2:COOVJ?B/I.JS
M@?LK>.Y+A&V--!K=C(C#(.5;?@C('Y5C_:E#JI?^`3_^1.R/!&92=H2HRZZ8
MG#/_`-REG_@IMK3_``_\)_#OQ(UQXAA_LCQ7!)Y6FW'E/L6.1Y)47!W2A`X7
MV)KT_P`-_M>_"OQ1'9"W^(?@^&ZOU0QV-UK%O%>(S#B.2,OE9.Q4\@Y%>%>/
MOB<WQ'^*WPOT/7_@1JVB^%]1U9[*X'BN.":T-Q+&H0Q*DC$RHD38+#;@GO7N
M;_L:?!]^OPK^'Q(4H#_8<&<$8/.W/3C/6L:4JU2M.KAFK.R]Y26RW/+PL,OP
MM:O@,WYG4BXR7LO9/E4HK232]]Z<R]]V4N70]&L+J'5+-+BVG@N()1NCEBE5
MT<'H0P."/I4RV\C`D*6`ZX[5Y!JW[!OP@UF=&/@?3K)8D$:16$\UI$H'HD;A
M?TJ%/V`?A'!&ZIX5D02@*X75;L!QG.#^\YKMYL4MX1_\"?\`\@;_`%?(;7^L
MU;_]>8?_`"]?D=YXM^-'@SP!!++KWB_PMHL<#^7*;W5H(?+?^Z0S9!]J\,^)
M_P#P5.^"VE:!`-+\5S>)+FZNH8X(=%TRZOC,PF0&,&-,;SR%&?F->E:5^Q/\
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MNRBK_>F33SS`4:LYT<!3DI:)3E5ERJ_E.%W;2]K>1Y;JOCKX^/I\HL/A3X"^
MULO[CS_&$FS/;=B#..>U<!J_PT_:Y^*,A6Y\=?#CX96;2!RN@V#ZG=HA/*>;
M-&%!4=&'4FOHY_!VE21NAL(-LK%G'S88G=GO_MO_`-]&G?\`")Z9E#]A@S&<
MI][Y2<DD<^K-^=%3`^TTG4G;UM_Z2DR\%Q3]4][#X.@I=Y0=2WRJRG'_`,E/
M%=1_X)O>$/'C1S_$76_'_P`3K[RA%)+KFM30V\V#D?Z/`4C'3WY&:Z?P9^P=
M\'_AR&71OA=X3M#(%\QFL/.>3;T),A8YZ\]Z]$B\+Z=!.TJV4(E?&Y^<MC'O
M_LC\JCB\&:3#`(ET^`1`@A,MC(VX[_["?]\BG#+\+%\RIJ_>UW][U.;$<6YW
M6I^QGBZG)_*I.,/E"-HKY(TK33?[/B\NVM8[6,')2"$1+GZ*!4HMY#(N4?D_
MW>M92^$M+39BP@'E+M3EOE&`,=?0#\J<OA+3'=\V,!,PV/G=\X.01U]&;\Z[
M+(^?NV[LJ_#LW%[X=9I(P7^VW2_NV,@P)F`Y]<8R.QK<\E^NQO?@UQ/PT\(Z
M)>>#&C2RCEMQ?WHP[L?F-Q+NYW>K/^==(WA?3GN1+]CA\Q>`WS9'.?6@7D:0
MMW_N/_WS1]EDRWR-\O7CI_G!K,_X1/3!O_T&W_>$%NOS8VX[_P"PO_?(IK>#
M]+:&.,V,!2''ECYOW8&,8Y_V5_(4`:@@<C.Q\>NVE^S29`\M^>GR_P"?45FG
MPMIIN?.^PP>9MVEN<XP1CKZ$_G4;>#=)=)$.GVY29BSJ=WS$[L]_]M_^^C0!
MK?9WY^1N.O'2C[-(!DHX'J5K-D\+Z;-(K/90,R'*DY^7DGU]S^=)'X5TV&X:
M5;&`2N02_P`V3T]_]D?E0!C)&T7[8WPU#`J?["U[@C_:L:^B:^:]#T.TT']K
M[X;QV=O';1MH6NDJF<$@V"CJ3V`'X5]*4`%%%%`!1110`5\6_P#!6"*^E\5?
M#C4/"WP\^'_CKQ[X*L]<\8:7<^-KVXCTGP[;64$!N+I((0S7%X6D@CB&,)ND
M;<O6OM*O@O\`;R\%?$/]J'XF>%?A7XH^#7P_\0VFOR:G=Z7K5C\1;_1=2T&Q
M@6..>Y,L-H)5\P3P1-#$SA_,^8%5)`!Z#_P3T\):?X$^/WQM@A\!>%O`^H>)
MY](\6,_AR[E:SURVO(9O*NY[=\+;WWF17"3>6-L@CB;)Y-?6=?)'_!,;X9G]
MG?Q+\2OAK=^`M-\(ZIH,VG:@=3C\77?B>\\4VUQ'*D5S/=74:3+Y9@DB6)ON
MB,D`!@3];T`&*YKXG_\`(O1_]=U_K72US7Q../#\?_7=?Y&@#Y(_93EB_P"&
MC?V@$%UXI:<>,G9K>5)1HJ+]DM,-"Q7RS<$_?"L6QC(%>^5\Q?LZ?%G3_"G[
M6WQMT'5/&#C^U_&YBTWPX-"D(@N&L[0F<WJ*0WF#C8Y`7;[U].T`%!HH4;F`
M]3BC;4-7HCYU_;D^-<_PZ\$Z])8:IH22BR_L>.VOI%C_`-(N>)64EAED@R2!
MR`V:^(KN>]DU+1/@O\./%WARX\93:@FF:0^B/;/;:M(1YM_JLZ3J=TFGV[-'
M#R`Y9BN=IKT;_@HA\<H[OQ-]DTFUU#2)=%O[C5;FY70/.N#<,WDI(C2`*RK%
MO?J0V"!R,5V'_!.SP/IWPL^#6N?&Z:"^\1ZKXQ:#2O!K7EUYESJ&G1A8HKI8
M9$4V]Q<R%Y9$'.T`$GK7M4(TL%4K9QF-/_9\'&,ES1?OU5=PA).*YH.:E4DH
MN?/&ERW7,K^A4S+^QN"J*Q4^5XR53%U?B;]G=PH6O%/2E%6C>_-+X4U$^DM"
MM/"/[#OP8\.?#SP;I/VR338/LVCZ)I\02>^D)S)<.@)V!G9G=N@W&OD_]M7Q
MKKO@#]HKP%)X[M+#6/%/B'2IEM-,MOFTFSM(KVVD>.5,@R2;L8D&<9QG!KZD
MU;Q!X3_8Y\(:M\0?B?XBTR+7=89IKN_=`KR.L>?LEI&<M@`?='4_A7P?^VS^
MT?JO[5LWP[^)47@/Q;X&T/3);O3-%O=0C1_[5N702J1A=R1[`65G_=EU`Y85
M^99CB,7F.(>*S.K-5)MR5-:[M^_5_FES6G*[Y8I-*[U/F,/PQQ!B<IK\48J3
MPV%A&<-;>SA&4)Q<I1WKU%%\SIPYE"W+9R]X]#_;]_;:AM=7\1^$'F\./I$E
M[="]U2!YKCRHT*JT<\8C.P(58D@YPO%>#S?MR>$;+Q?:>$/@MX1\:KX$DTM4
MU/Q%X>\'F\\2ZS<2HOF+;-<$"!&V[590>[`=JU?BC\`_$?Q?\*>!/`O_``D/
MB2W\>?%W5)9;VQOUCNXX-/C?=/+)+&""'58R=V&(SQ@FOTY^`_[,_AK]GW1(
M;;2HOM=Y%%'%]NN$5I56-`@6/C]VGHHKZE8^-',,1A<OI0]E.I^_]G.<(S=-
M>RO*<80G4DW&:LGRQ2B[N+][]#XMXC^HX+!\)<)RO1IQ4ZU;VCE"I*>MU:*5
M3F5^2SY4GS;64OQP^-'BWPMHOA+4;BP_9+^)FE:9=W+23Z]XHTJ\GO@R[G=V
ME'W"%)8[5QQ[5[9_P3__`&7_`(8?M3_"R8^'/B9867C*S<.EKX3\4SS7MI$6
M^4RVMRJ_.S#HHP<=<U^L\DK31E'.]",%7^8$'KP:\4^//_!/#X,_M&6DK>(/
M`>BVFKE"L.M:-"-+U2V8YPRSP!6X9BW.>:G'<&<)YG!\\L7A*[:<:U&LI<C[
M^RE&-_-<^M]CXRE3]G0J4*T?K"J.\O;2G.ZO>R@Y>Q7JJ2;ZL^4?C5X>_:Y^
M#4-C!X5^)=QXKT'3;=_-=H8;/4+?:<!)=R?O/E`P>Q)S69\+O^"@>KV&NZ1I
MGQ5\7_%CPG?R6P9(V>TL4U+H"\;LF)&#-R`<].*]`M?V%/C_`/LC:M'J?PX^
M*%]\:_"5M'Y$G@?QM<>3?/%CK;ZB2P#*1P'`!SMKGO@Q^U#X7^._B*[T?Q%X
M(B\$>-=,>2TU'X?^-+*(+?$8\U[661=DW.`ICYSM..1GQ,1@N*\@PK5?'QKX
M2GMC*5.,H1O9)8K#U82KT&W=RKQ<\/=J//`^>SO,\]P$85,JF_815G3C3I2J
MQ5VW*#G"4:L8K3D2C6LKQG)V1ZE'KOPG^,VF-<:O\5/BK]DU,&/=J.I&*T5E
MQQE8S%NQ6;:?\$]_!_BC0;W3_AO\;/$^DZ?K%N!-I]IJD<WVECG879"K[<$Y
M7%27/[%_PO\`V@3;_P#"(/KGP6\9:;G%MHDQAAVC&6>U;$<G`'.`>N:CU_X#
M?%7X*Z%;IJW@?P1\=--A\Q)+W05'AGQ#;QX9O,;_`)9RO]U?E.<@^M<F98KB
M.</9YM"C7A9.,XIK1K1QG#G:32TE!6?H>YPOXG<95,*L5DN8T<30O\+INEK&
MVDHOVL5*+[P3B]TCY[\9_P#!*_XJ>![TQW^@GXG>'[60W$EI<Z]<&&Y"\@,-
MZN/7[N:ZCP'XR_9_^'OARRM?B=^S4GA>[DAC2*ZM;5[RWU$`8>7<75F'?=@Y
M%;'@[]K7PEE[2_\`'GQO^$DVZ2VDLO$VBW-Q#"?W@V+<`;/E`ZY[BO?/A#8>
M*_&OPHT&33/$?PU^+NCPVRF.'4((S<VPV\HS_/AR,*0V"">:\_+\_:]V>`52
MW5QIS:2M_P`^I4ZC\G*$GW/TE_2'S[%<M/B;*:T81^WAJ[B^FO+"I[U[6_@W
M-S]E;7_V=M:MFL_A3;>`+23[C6=M9)!=N"2<;)1YC<Y]:]W@B_LR$00HEK&O
M2.*,1!?P&*^(_C+^SEX2O)[IM=^"_B#P?J!E$HUKPK>BYM[12<>8$4`\=U&.
MY&*@^%>H_$GX?0F#P'\:M"\2Z;IRMLT3QG:/9W4@)!"^9.1C.>"'(`KW*7%F
M22K>QC>@[;23>JW5G"G4]+4VN\KGAUN).#,^Q#CA,XE2Q#_Y=8Y3IS;\JCC:
M6NBO&/J?<AD9OXF_.DSBOG2^_;>\5?#JSM)O&WPFUBTLYV2*2_T*_CU:&-\`
MLQ6,%E4+D\_2O1/A9^UM\._C)I1NM&\4Z;'L.)+>_D%E/&<XY20@G\*]:EFV
M$JNT9V]4XW].9*_R#%<*9IAZ/UETN>EMSTW&I#YR@Y)?-H]'S1CBH[2YBU"'
M?;S17"9QOB<./S%/_BQ7H'SSNG9BUD:=(6\;:LID5T%M;,L>[+1D^9DD=LX'
MY&M;.:Q]+C1?&VK,JOYIMK4.3(2I'[S``Z`\G/K^%`&SB@FBB@#S#]I'Q1'X
M<\0_"U)=,TS4SJGC&"S1[R,LUBS0RGSH<$8D&,`G(P3Q7I_>O-_V@_&A\'Z_
M\-(O[.TS4/[;\6P:<6O(1(UGNBE;S8<_=E&,!AV)KT@\&LH-<\E?M^2/'P-O
MKN)2E?6.EMO=3WZWW_#H%%%%:GL!6+\07>/PSF.9(&^V6HWLVT8,Z`C/OT`[
MYQ6U6'\1(HIO#&)0[+]LM2`DA0Y\],'([9[=^E`&ZWWC]:2E;[Q^M)0`4444
M`%%%%`!2I]\?6DI4^^/K0!S_`,-9))O#3M+/'</]NNAOC?>,"=P!GU`XQVQ6
M_7/_``R2./PLPA61$^W79P\AD.?/?/)[9S@=NE=!0`4444`%%%%`!1110!RL
M/_)XOPV_[`.O?^A6-?15?.L/_)XOPV_[`.O?^A6-?15`!1110`4444`%?$/_
M``6$^'FN?&G4OA?X4\!>"=;\1?%);G4-;T+7-*\;'PA<>%[:!(8KJ1;P)(S^
M;]HA3R1&P;J0-H-?;U?#'[9OA[QC^T]XST0:Y^R[\6M3_P"$!U&YGT#6O#WQ
M,TS0I6,B^4TRF*]CEVN@'ROT!Y&:`.E_X)&?LW_$#]G?PIX[7XD^"1X=\1^(
M=3@OI]<O/'<OB_5O$["(H7NKEXH]@B`1$15"@$X`YS]A5\W_`/!/#P#K/@/1
M?%2ZOX`^)_@-KJYMVCB\9>.T\5R7@"."T#K<S^0J]&7*[B0><5]&RS+",L0H
MSC).*`'US7Q/_P"1?C_Z[K_6NC#^WM7-_$MQ-X=C*L"//'(.?6@#Y1_93\0K
M)\>OCYI8U[2I'@\;27#:*@7[=:AK.T'VB0[RQB?HN4`R#R:]TKP_]EC3;B/X
MW?'F[;2M&CMI/',L2:E&_P#Q,+AA9V>Z&0;`/*7(*_.>2?E%>X4`%8/Q0\5K
MX'^'FL:JUU#9&SMF=)I5+*CXPO`Y//85O5YA^U;XJ'AGX=PF,Z7]O-R+BU74
M&D6$M$"V?W8)+9*[1CEB*/;TZ%Z]6+E&"<FE:[45S-*]E=I=7;N>?FL*M7"R
MP]"2C4J6IQ<I<BYJC4(^]9V]Z2L[/6UE<_/CXZ>"[[]I7XC^$_"^F:EX]\9&
M_P#%5GJ%]XDL1;VT'ANPMCNDDD\T`^5Y1N,I]WE.<D@_5WQ^_:A\)_!B&X^*
MFNB&;5\OIG@C2;EU@CO84*HUP-A.8F<MME`^48&.>/G'X/ZKJF@>,?B7\7O%
MNAZCX<E?4W\$6U[:W4]_:ZE!&X.I/-9<M`#M1`P0_*Q8#O7M7[#WP#_X7UXK
M/Q9\8-=W^FV,KV'AC0]0M`D&FQQMA6\EHXR-@^5"5(=6!/(KXNK:K2PN44X1
MYX+VU1VA_%JVEKR:/V<.1VLDJCTO9L^OPV49;F^=UL?FL7_9N7.G%1W=:K&%
MJ--2C&*]V$54E*R:YH25VM#X*_L?^/OVKO%]E\3?C_J\\46^*_T#P1I[&.RT
ML`AD,ZN&+$KPR_Q?Q'I75?\`!6CPS?Z_^SQX?DLM2AT^ST[Q#:Q7%LR`B=)0
M8DV#UC+9VCC;G-?40X4#L.!@=!7AW_!0NSMK7]G-M?EM=-N+KPKK&GZG:O>P
M"9(&$ZH[;3Q]QCGV%>GF&7PHY;6C3C[233;N]9-:ZOY::678X^.>,L=CJ%3&
M<RH1H0FZ4817)125_=AL[-7;E=R:O)WU/'?V;/"%UJ/_``5A^)M_=6MY'!X&
MT>RT2*^A@CL]/U*>YMA+*PB5V)DV(FW'"HN#SC/VG7RQ_P`$Y/%=OX]M?B!X
M@L].U!;#6_B'J5U9:G/'B#58#;*%FMY,YGCR&7)`VME1]VOJ>NG(,%##9?1C
M&G[-RC&;3;;O.*D^9MM\VNO1;*ZU./%2G.O.=27,[VOM\*44K=E&*BK:62MH
M%%%%>P8"8S7$?'G]FSP'^T[H5O8>/?"NE>)HK`LUC+=QYGTYSM)D@D'S1OE5
M.5/517<45MA\15P]15J$G&2V:;37HT#L]&?,NM_L:^)/AQH6EVOAK7]9\<V.
MG3D`Z[?+_P`)!:1LPVB&\PJ3*C$L1,`VT85LUV^E_&[7_A;<0V'C?3II;*,-
M&FK6ZEWEQT=UZ\^O%>QU6U'2+;6+8Q7,23(01AES@5\]/!XK!+FRCD4;R;I2
MNJ;<FVW#E_@R;=WR1<'O*FY6DOE,SX5IUL4\SR^K+#XIVO.*4HU$K)*K!Z5$
MDK)IQJ+I-+1U=-\4V'C_`,+27-E=6^HV4\+@,<.N-I!!!Z>^:^<]<_X)E_#7
MXL6>A^*K"76_!'C/;'?S>(O"E]]EN;Z?`)EER"DA)YS@=*[KQ-^S]JG@N274
M?!FIOI;X8R6X),4O7[RY/0$U3\'_`+66A_#WP_;:9XNMKO0%TY4M([X!KJVN
M0./,WHO"@<ES\O.<U>"KX'.ZGU-T90Q"U]C5256RZP<6XU8_WJ4I-?;43AH<
M78G+9PPO$T%0E*RC5B[T*DNRD]82O]BJE_=E/=YE]\)_VC/`$,@\+_%KPIXL
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M5(V2QR1$P4\MG!'85XE#AF6$FZF#A%7_`)'*EY:Q3<);[2C;RZ'EY7P_@,JQ
M/UW).?!UNDJ$Y4G?O:#47V]Z+5M'H?))_8@^//[.][.^GV%QXET#:)+A=$U=
MK6^8*&^;`(WR#<>,'/'%>K?"W]M+39M:@T&?XS^(/"6M&$QSZ3\0O#R+<V;#
M.T^:-J<]RW7CO79W?['GQT^&\C3?#_\`:(U.]$L9B^Q>,]+348(D#$IY;K\P
M8+M4DCG'-5O%-E\;P(8?B-\$_A9\8;4VA^TW^C7D=M<HHP6B\JX0%B0"1@X)
M],5[V#JY=32IYG@I)ZWJ4K4YZ[-^Q_=R2_Z]1D^LC]8P_'6-Q5&.&SUK%6O^
M\<:<:KNK+F_=NG*W_7N,GUF[';:7\0?CJ=/CO;'2/A=XXTV)C&T^DZG+#)>`
M8^9=V45L'.TGO5C1/VB/%NA>+KMO$OPN\7VL=S;6Q9-+FAU);'_6#<\:-N7>
M3CW"'TKXC^+7Q%T[X/ZM<R^$$^,?[.&H;1//HUYI<]WH,DB@?.)X3(%!W!<;
M2,X!Q6M\+/\`@L1XE\%7]I<Z^="\8PW-I']JFL+A49HUW;6/`*2@%BRD=",X
MK2O@:+J1ED>-GB%+>#]FJD&NDJ<[3EY.DYM[:/<SB5"?)4RO`PQ<)+54[TZT
M.K4J7M;3\G1C5OM:.B?VUIO[=?PNNKO[+?>)!H%^A*RVFL6LME+"PZHV]<;O
MH3FO1O"GC_0?'5G'/HFMZ5J\4K,B-9W23!BO+#@]AUKYV^&W_!0/X9_M#^&?
M[3U'PG>&T5F1I9=/CU!%D"G*DJ"P)7."1@C/-=GX8^`7P4^+FFI>^%]-TFSE
M)WQW.B7#Z?>VS#N`K!D/J".1UKQ:.;XGZS+!.I3E5CO"2E2J+R<)7:?JD?&4
M\^X2Q.+GERG5H8F#M*G/E<XOLZ<U1J+INF_S.E_:'\:R^!_$'PRA73],O!KG
MBZ#36:]@\QK4-#*WFP]-LHVX#>A->D=#7SE\2OAW)^SY\4OAO<Z3KNL:IIGB
M/Q3%IMW8:_=G48[5G1Y//MS)S%+\NW<#D`GUKT?XW?$[7M'UFR\'>#K'SO%O
MB""26VO[F(OI^DQ(0KS3$9^8`Y5#C=CK7L1QDJ=.=;$QY6FERK6][62MO?IY
M[G#EN7QQ.<8C"8.KSKW'>2Y%!<EY-ZO1;O5[Z7/1UC++G!P.OM0T+J/NUXIH
M_P"QF_B&&1?B#XZ\9>/=X&RV:Z;3[6,@<D1PD%N<XR:UI?V(_AS<PR(='U<B
M50K8UJ['`R./G_VC4K$9A)<T:"2[2GK^$9+\3Z&>"R>#Y98J4FNL*=X_+GJ4
MY>MXH]3MG6\4F)EEPQ4["&P1P1Q6+\1EFB\,@QSFS?[9:?O"VSCSTRN?]H97
M'?.*X"3]AWX?6!>;3K37?#LWEF-YM-UNYMR5Q@Y^<CGJ3WKEOB/^SUI/@_30
MUE\4_%^F1W$D"K8W/B-)4?$J!YE\PYRJD-QP#@T3Q>-IK]Y1C\I__)1B"P.4
M3UIXJ2_Q4O\`Y"<T?0C*2QX/7TI,5\]2_!O26@@,/[17B=76(HDA\16K!WXP
M^"W./3WJCJ?P[U#PO>:.FJ?M/7UI>:PACTX3O91I?H%Y,:EL.<X.[VQ7/_:]
M=*\J#MY3I_\`R2-?[&RY[8Z*]:=5?E!GTG17@GA_PM\;X-,@AT7XI?#[Q+9;
MW:WOKW3P]S<1X.`QB)5B".2/>N@3Q%\<_#\<37?@[P1XC3D3)INLO:RJ`3\P
M$J8.1C`SUK6&<)_'1J1_[=YO_2'(F?#J?\#%49_]O\G_`*<4/N/6Z*\5U+]K
MW5/"-Z+?Q%\)OB)IS&4PB6SMTU"%CU&&C//'?IFH-/\`^"B/PSD5?[2NO$&@
M,7,3+J>BW$(CD&,QEMI&[GI[4O\`6'+K\LZJB^TO=_.PX\'YS.//2P\IKO"T
MU]\')'N-+'S(/K7`^&OVH_AQXP:)=/\`&_AN5YAE4DO4B?MP0Q!!Y''6NWL]
M5M+R8+#=VLK9'$<RL?T->E1Q5&LKTIJ7HT_R/%Q.`Q6'?+B*<H/^\FOS,3X9
M-(WAB3S+K[8?M]V!)OWX'GOA<_[/3';%=#6#\-8F'AA\VY@_T^[P-^_/[]^<
M^_IVK>Z5N<N^P4444`%%%%`!124M`'*P_P#)XOPV_P"P#KW_`*%8U]%5\ZP_
M\GB_#;_L`Z]_Z%8U]%4`%%%%`!1110`5^</Q7_X+/_$WX?\`Q/U_0[/X>_`V
MZM=)OYK2*:\^-&E6=Q*J.5#/"_S1L0.5/(/%?H]7YT?\%5/V6O!6CZSH^F>"
M/"7P/\#^)?$VFZ_XHU+Q+KG@JPU>\OAIUO',;.UAG41R7$[S!F9R2L<4C`$]
M`#W_`/X)Q_ML^*/VT-&\677B;PYX$\/2>'[FV@MU\,^-[3Q.DZR([,96M^(2
M"HP&^\"2.E9__!33POX&U_2O#;>*/#&O?%'Q*T-];>$/AY8R$P^(+^1(P;F5
M`5"BW3K<2.J0)-(<[F6LG_@F;X>TWX;?%;XN^%=(TWX<6VG`:'X@M7\)Z);Z
M7)8Q7MHY&G7P@^62>%XI'5S\QBNDR!Q7KG[4'_!/_P"#?[:.K:-??%'P#HWC
M*\\/12P:;->M*'LTE*F14*.O#%$SZ[10!Y%\:?`_B?\`9N_X(Z7?A3Q)XXO]
M6\3^'_!]KI6N>)(KEDN"C/%#=SI+G>`D3RA9"=V$#$YS7(?L_P#@S2?@#_P4
M(^+GPT^'\?V'X:6?@GPYKTNDP3/+9Z3J\L]Y!F/<3L>>UB1W&<OY2L>>3]/^
M"?V,/A;\.M!M]+T?P5H]KIMKX;?PA';,K2Q?V0\C2O9E78AHV=F)!R3D\UC_
M``]_90^'7[(7PMET#X;>$],\):3>:@+NX@M-[&>79M#,[LS'"J%`)PH```%`
M'RI\+-;\5^!OVC/CQJOA/X.KXNNKWQI):W&NIXAM[!YT2RM"+<QRGHA.<@<Y
MZU])P^(M>?3K.5_#+)-.$,\)OXS]F)$98;NC;2T@XZ^5_M"O)?V4EA'[0_Q_
MQ::^MQ_PFC[KJ1G_`++D7[':82(%MHF'\>%!P1R:]XQ0!C'7-76^\O\`L%C;
M["?.^V1_>`R!MZ\G`S[U\<_\%7OBU#H/A!5\0Z/X\L'TN!Y=!F\/S<7.HR%Q
M;QEP"ID;RXRBXW+O-?;X&3_A7YI?\%3_`(H^*K/QWI^AZUXGM=,T75/%*_V/
M)I%J\U_&;95N4!B*%)5#0(';MYHZ<UCBYTX8>7MXWA*T9:.7+!N]27*M6HTU
M-M+7\TZ%>=#%4\13J2@Z2G4]UV;Y(V4;6DW><H:*SZIJVN/^R+^S9<_$#_A%
M_`NI>&_%5U)ID(U_Q9/>:U9ZA-%>SYF>*Y25RT6Z=3$5B7&QB#DY-?I5IE[J
M%BT=E%X>%G86D216^R\0JB#:H0+U`"YQ[+[UXG_P3T^#=_X7\"7_`(Z\02Q7
M'B3XAL-0N/.\/+I-_8J2<V\G.YDR`RY``R<#!KZ'Q7GY3&K4C/'8E6JUI.<O
M*[NHZZVBG97UMNST,1">"P=#)N?F]BFYV32=:H^:LVFDVU)\B?*O=A'U>#!X
MBUR73A*_AUX[C*_N/M\39SY>3NZ<;I/KY7^T*\/_`."C^KZU=_L=>(8WT9K1
M9I;"229;Q6:V=;B)U`4#+GS`%]#SZU]'UX]^WI>S:?\`LNZW/`Y26*\T\@^H
M^V0Y!!ZCVKNQ;FJ,Y0W2=O6VGXGS6>2A'+J\JDG!*$FY)7:2BVVE>-VMTKJ_
M=&+^R%%XD\+?LU?#BSU'PGJNAZK#9SW,^GZC+!;W<]S(D\LBO&GRQEG(;';S
M`2`017KD_B+74T[S%\-EY]Y'D?;XP=H\S!W=.=J<?]-/]DUI:S,R:WIHV*PD
MEDWDMRN(CC'KS5S%=+Y+_NX\L>BU=ET5WJ[+OJ>M.I*I)SEN]=-M3%DUW6(]
M3BB70&:%B-\WVR,>7UYV]3_]>D37]:*3'_A'CF,J%'VZ/]X"4!/MC<Y_[9_[
M0K;(S2TB3`3Q%KI@@8^&SOD*^:GV^+]R#LSS_%C<_3_GG_M"ICK>K_VCY8T(
MF#829OMD?#8R!MZ\GC-;.:/_`-5`&(=?UGR+E_\`A'VWQ;O*C-['^_QYFWGH
MN=J=>GF?[)I!KFLF6''A]RKD[V^VQ_NQEP..^0%/_`_8UN9HH`Q9-9U:2:YB
M?1&AA$3$3_:T..G;J,`D_P#`?>N"TKPO+\0_@YHPU#PZEW.;&%5<WD4AN%*Q
M`N7/LTGN?+_VA7JEQ\MM*<`XC8@'Z&LOP!.]WX&TB614CDDM(RRQN653CH">
M2*\W-<HP>94'AL=#GCOV::V<9*THM='%IDSA"I!TZB4HRT::NFNS3T:[I[GR
MUXJ_9-\1?#+6-/\`%7@G5]:\':_;'+VEM<K)8WBX.()H1^[G3IG.TX`PU9/A
MS_@J3KGP-?4].^/OA-/#ZV7F&S\6:+#*^CZA@':DT0#RVTK''8QC!.ZOLV[L
MXK^V:*9!)$XPRGO7G/Q+^!VG^)+1A<V$>IV)!!@P?-0'/`/=>>]>/'C#-^&7
MR<24IYKEEOXD;?7L.KWNI6M7IK;WU*:3VE:Y\<^$L3EZ]IPM4C3M_P`P]1OV
M#_Z]RUE1EV2YJ?\`<6ZU_!GQ?_X67X%M?$/AFST_Q#IFH*);:>PU>":&>,AR
MKK(,CE1&<'G][_LFMPZSJQU$1C1"82.9?M<?RG./N]>G-?`_B/\`87\;?LS:
M7XAUS]G3QCJ7P^GN)EOIM)LT6YTG4KA<*GVRSD5RJ;=P9X/4<5U/A?\`X*Z^
M(/@?IWF_M%?#.\\+:+Y>8?%_@P2Z[HSN,Y2=%7SK9B!D!E_*OUG+^&\)G^"C
MF_!N+ACL/4ORJ+2J^G)?WI7NK0<I:/FC%Z&F5<987$XEY;C82PV*2NZ516E9
M?:BTVIPV]^+:UU:9]F#7-:,<I_X1YLHP"`WL?[P93)]L!G/_`&S]Q40\2Z[]
MEMG_`.$;/FR$"5/M\7[D?)DY[XW/T_YY_P"T*H_!OX]>"?VA_#0UCP-XJT+Q
M7I^Q7>33;Q)V@W<@2*IW(>HPP!R#Z5UP-?+8C#U</5=&O%QG'=--->J9]<FF
MKHQ;G6M6N+OR7\/^?:["?,>[C920,A=I]^/UKS#Q5\$_"_Q'\2:Y!KGPL\+Z
MX(+>%8K*9+;Y5+3DN"`-GF%(\]SNY^Z:]H(K+L)G;QEJR%$$:VUL5;=\S$^9
MG(_"N6K1IU%:I%/U5QZH^3?'_P#P2.^&WB6Y^T:#X<\7?#^[F,GF2^&_$HM8
ME+-)M9XB"K@?+@#'RL!_#7S1X\_8+^,7[-OB0ZEJFO>.=>\+VKR7LNN^'KE)
M;JR0+C?-&X!."<D=,#K7ZO=:3&0<C((P0>XI8?+<G^''8*G7AVDK-:6O&4;2
MBUTUMW3/5PV-P<HNAFV#I8JD_LU(IM=+QFK2BUTU:[I['YH3>,O$'C?PA\,;
MW_A<EUXV\(V7C6QEFM[D16NN:9.!O4O*@R(`AE4AAU`(.#7K'PO^*/QN_:G^
M*_Q$U#X;0>#?"WA26\CL9?%L]A)+>:B(P`L=F"WER>6I;,I&TDCVJG_P5(_9
M,\&Z3\)M(?PAX2\.Z'XE\5^)K?3I+Z)/))$BL2<EMB=.3@=*Z;PI%X,^"6D0
M^!_&GQ`TCX?Z#HD$<.E^$]$UDNL,9Y:2:XY=G9PQQNP,GIQ7@YODE\SCA^&L
M/7JTMTNL;1LTZB<ERI/>RD[V2W/*K8R%/&XG+N$\+B<3[1Q2@X1Y:,8PA)IU
M(N2:<N5_#&6R4':ZTM8_81\=^)8-5AU#XT?'.ZMKI"RPV^M65N)9`&90I6/Y
M`'5..GS#L#5+5O\`@GUXGUO397U7XK?'G59I2N^!?%-M:[V3SA')N1,`;=H*
MCKYF3]TUZCX+^!/PT\::3/\`\(AXJU.YLK@!I4TGQ0TZ@X'S,`Q(.,9S6M+\
M!O%MEE-*^+/BJS@V!1'<6L%RRXR!AR`1QC\LUPU\#B,/)QQ.`;?:-6[^ZHZ9
M\_B,USW"MPQ6`?,ND*D&_NJ*EI^74\8C_P""5_A#5-=MY]=NOBQXL94"33ZI
MXX=DGCS@1/&@7<H&>*GUK_@G'\)/"FB74Z?"FR+FYM($DU'5VN1L-Q;[E7+?
M(6RZG^\%(_B%>E7/P]^-VDS.UEX_\.ZO&JE434-+6,MUPS%%//3\S3M7\;_%
MK1=&/]M>!_#FJP1RPL9--UL1.Q\Q0%59`.<\^^<5E2Q.!@_W^7U(/NZ?/_Z;
M=3\;'+3XPJ)\N*P>(I_]P^=?^495%]]CGU_8.^$T$%HX^`/@_>K`/$SQ'R0?
M+)).<-C+?]^_]H4OA']@#X4>"=3U06GP:T.Y@U2()(]]<)=I&/G8QQ*Y)B7)
M`^7'4>E=E<?M.OX?,,>N^`?'6G7,N01;6(O8MXQ\H9&YZCG%4U_;>\#_`"^9
M%XI@4+F1I-$G"PMU*-QP1STR.#S6SSCAN#_>RIP?:2Y7]TDOQ!\>9'#2MBHP
M?:=X/[I)?D>4^(_^"6?PKU."[>Q^'FN^'[E;IYH'T7Q2]FX!\W*H0<(APGRX
M_P"6@_NFJ=K_`,$N=$\/75M<>'=<^,_AJ[\XO+<6GCKS2,,Q3<LBD,`0C8_V
ML'O7OVC?M7_#G7K".XB\7:9$CL5VSN87!'JK8('I77Z1XUT7Q!`DECK&E7B2
M'"M!=QN"?08/6NO#4\AQ7^[.G+_#)?\`MK/8P?$.7XS7"8F$^ONSC+3Y-GS/
MHG["?C#PUK-RVD_&7XYZ8DTZW4TMQKUI>1W4V4)8HT>57[V4'!"GU%2ZG\!?
MVA9=`^T6_P`5YKC5EG26*TU71=/EM6/[K=YA7DKS)TY^3_:%?4ZKYAP,-CT(
M.*4Q'T->A_8V%M:*:])27ZGK*I)._4^.?%'[._[1FOZ;+]J?X$:Q+.@G:VN_
M"4:QR2A5.UW!SRV1N'89[UP?B7]AGX]ZC::Y!;>$_P!GZW"1I-936#ZA:RW;
M@']VC;\QXP`2W!S[5^@+#`YHC.6'UKBK\+X&M_$3?J[_`)GJX7B+,\,K4,1.
M*\I27Y,_.+0OV-/VH+73M0O_``=XN\%:)`\4L:VNG:O?1Q37"R2+)"H<L%.X
M`[LXRWUK?_X5]^W1X>N&LXM6\.:K#%;>4EU_:P59&Q]X!EW;N<<_W:^XOAY<
MRWGAQWF1(W^VW2X1BPP)G`.?I^5;G05BN$\+#^#4J0])M?\``.JIQ7F=5WK5
M%-]Y1C)_?)-GQA!8_MS:+9:,JWWPFU7[1&HN%EA;S+`Y7_7-D>8<$Y*?W3W(
MK5\/^(_VW-7OXX;O0O@EID80EKJ8SNC$$#[J.2"1D^G6OKK_`/72#KWZYKMA
MD:AI&O5M_C_X!Y-3'U*C]]1_\!BM_1)GR#>>/_VVO#VH$'P1\'/$,(##%K=2
MVP;Y<A@6D!Z\8QR1V'-9%GXS_;D\5Z;%*?#WPV\.L)6!0VJO*RX/+!IB`N<8
MQR>]?:N*!653(ZDW;ZS52_Q+_P"1N=-+'X>GK+#PD_-SM^$UO^GF?$VL_$3]
MMOX>P+>76@?#_P`26YEVR06^FEI(E!)W;8I-V#@#/.-PKM/V0/CS\<OBI\5-
M7A^(-CX9TO3M.BD1-&T_2;FVN"V^/9(T\_`P&;Y>2P'/)KZFSM%!8EO\\T\/
MDU:C6C-8F<HKI)W_`!5OQNO(K$9AA*U-KZLH2Z.,I6^:ESW_`/`D<'X3U+4-
M4_:X^'#ZCI9TF4:)KH6(W"3[@?[/).5XX8E?^`Y[U].5\ZP#_C,7X:_]@'7O
M_0K&OHJO?/'"BBB@`HHHH`*^./V<O%R?\%8]%\?W_P`2/A_\/M2^#&D^(;SP
MYX:T?5+(ZAJ5S>6%P]O=7T[/^[C5I%=(TC&[:"6;Y@*^QZ^6;[_@G=XE^%?C
MKQ'JWP-^+^K?";3O&>HMJ^M:!<:%;>(-)>]<*LES;1SE7MI)-H,@5RCMSM!H
M`A_X)Q>'+_\`9^\9_$CX+:GX7^&^AOX-ELM:T[4?!>B_V/::[8W_`)XCEN+4
M,XCNHVM7C?#L&"HPP#BOJRO(/V5_V2H_V<+SQ5K>I^+O$7C[QOX[N8+OQ!K^
ML>5&]R8(S'!##!"JQ6\$:EML:#@NQ)).:]?H`*YKXG?\B_'_`-=Q_6NEKFOB
M=SX?C_Z[C^1H`^1_V42#^T?^T`O]O:C,W_"9N?[%:$"TM!]DM/\`2$?9DN_0
MC><8'`KWW-?-_P"SE=7.N?M/?&S3M/\`B5:V4FD^.GOM0\(1Z9:W-PT#6=HJ
MS/*S>=$DI&`P&/E.*^D*`,SQIX@M/"G@_5=3OY3!9V%G+/-(,Y154DD8YSZ8
MYSTK\A?`WPVF^//[;5M!X9N?B%KGPZA"69OK*;S=6L[IF66>13<?ZN.-1%ND
MV@N"N,D8K]-OVS/B5K_PO^"%[?>'+/3;J^G?R7:_N?(AABVEG8-@_/P-H/!K
MY@_X(S?#RY\;VWB'XNZWHGB?P[X@\173XRPMM-U>`J$25H<EFDV!"-P4#AL9
M8UY&:TJE>5/#Q2<&WS:II-Z1TW4N155&^C3>G6/?EN*C1YJR:<E.*M=?93JS
MO'E;W]C9W4;2:>JT^\;*T;3[*&W:XFNWMXUB:XF;=).5`&]CW8XR?<U+117K
M^1PMW=V%>9?M@^/=4^&7[/VK:UHK1+J5I<V21&6W6X4![J-&RA!!^5C].M>F
MUYI^U[\1-6^%7[/^KZYH<L4&IVUQ9Q1/)$LJA9+F.-_E((.58UE7_A2?DSQ\
M_J<F68B;DXVA-W6K5HMW6JU6ZU7J=UK)6/7-(!=P3/*%`)P_[DG!]>.?PK1Q
MFJ&L2/%KFDJN-KS2!P3U`A;'UYKP']KW_@I[\/OV*/B-9>%_%FD^+;_4+_3T
MU*.32H8'B$;NZ`$O(IW90]L=.:RQ6-H86E[7$248]V?9\.<,9KGN,679-0E6
MK6;Y8[V6[^1]&T5\-_\`$0#\%O\`H6_B/_X"6?\`\?H_XB`?@M_T+?Q'_P#`
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M75K0Q6Q\J2/87E^5@N<#J/`/O^Z_X])O3RG_`/0361\-I$E^'NB/'*\Z-91%
M9'8LSC:.23R?QKSW]F#QWXWUL_$?PI\0;O0]8\3?#K7?[).KZ18/8VNJ6\]C
M#=P2-`SOY4ZI-MD0,0"%(^]7H?PYFDN/A_HLDQ4RO9QERK;@3MYP>_UH`VJ!
MQ110!A^(?!::K<?:+5S:7@&X.G`<CUQ7FWC#X7V_B#6+B;SW\.>(I5`-R!NL
MKL@8Q+'C:01D$\U[+575]&@URT\FX7<O52.J>X-?G..X0QV68^>?\&UEA\5+
M6I3EK0Q%NE2.O+)_\_(*_P#,I7TX<ZR?+<ZPJP.<4O:03O%[3A+I*$E9Q:N[
M--/4^'OC1^PQX.^(WCQ=6T^]U']F[XK:7&K6&O\`A.1;/3=<=9#(C74"@1W`
MW')W'@,16IXQ_:H_:F_8WELI/B%\+=$^-W@:VMU>^\5_#_?!J*#@-(]A(26(
M&6.P8/7(%?3?BOP(KZ5-:7]A#K>B\GRYANE@!&"RGJI'8CTKFM$U37/@Y"+K
M3);KQ%X+M4W-;L0=1T\=RO\`>5?KT-?JG"'C/A\]JQR+/\*HXRFO]VQ%[N.S
MEAL1%QG*&BY5S.*;UBMG\/7_`+9X:7/CY/$X+_G_``7[VFM_W]->[*,5>]2"
M3TO*.\E<_9G_`&V_A;^U]I9F\`>,--UB]@B22[TIR;?4]/+*&VS6[X=2,X/!
M&>]=[I[`>/\`6$,CF1;6UW1ECA`3+CCH">_T%>`?&_\`X)\?`S]OK6K'Q[=Z
M=?:=XKMX-D7B'PW?MI6IPD[643-%PS*0,;P?3O7GFD_##]K+]D'X@0Z;X'\3
M:/\`M&>`K*RA6YL?&5U%I/B.VR7"K#<H-LJ@?\]#DX_&OJJN0Y/C&UEN)]C4
M6]+$6C9]HUE[DGV]HJ5_/=_:8+,(8BA#$T6JE.:O&4'=-=_^&N?;5%?+OP?_
M`."M?PV\<?$Z/P%XWT_Q1\%_'KQEUTGQQ:+IT-VP9E(MKDMY<PRN0<C<#Q7U
M#&?/MTF0AX91N21#N1QZ@C@U\WFN28_+)JGF%)TVU=7VDN\9?#)><6UYG=3J
MPJ*\&>*_MI:'8^,+;X;:!JFEV.K:3X@\8P6-]!<P>9^Z:&4DH>L;\#YP<XKK
M_AA^R_\`#WX-)/\`\(WX/T/3Y+HYFF:V$\\GL7DRV/;-4_V@OB#JO@37OAI!
MIDD<<?B'Q=!I5]NA63S(&AE8J,CY3E1\PYXKT<]:XJ.8XJ$)X:%62@VKQNU&
M]ETN1EN<8VG5Q6"IXF?L[PO#F:@O=6R3L[[O1:G@'QH_X)[^'/'/BL>*/!.K
MZA\+/&.0'U'0AY4$Z\Y$D*E1EB02P.3M'%8GP>_:]\5>`?B?:?#?XO:-_9FK
M7#.FF>(&GMK>UU"WCPBS2*92VZ1NZ]SC&<U]-UP7[0O[-7A']IWP.^A>*]/^
MT1J=]K=PG9=6,F,!XWZ@\\CH1]:^FP?$,<1".#SJ]2DM%*UZE/LXNZ;2TO&3
M:MLC]!RWBJGBH1R_B*]6@E:,[7JTKZ)PE=.26GN2;C;1)'>*=P&,'/(QS6'\
M19D@\+[I))(5^V6@W1L5;)G0`9'J3@^H-?+>B^)/B=_P3MN;;3/$-O=?$#X,
M6;FVL]2LHA-K&EQG)C61,C(!R#U&!P1TKZ.N/B!9?$/X4Z?K^@W`FL=3FLY8
M7?\`=-L:=,A@>5;!^Z>>?>O/S?(:F"4:U.2JT9?#4CL_)]8RMO%V:/*S[AFK
MEZCB:,XUL//X:L/A?7EDMX32WA+5=+H[4NRL<$CG/!IAC4CE5/\`P$4Y^'/U
MI*\)]F?->IF77@O1;Z3?-HVD3/\`WGLHV/IZ5R.N?LI?#KQ#([R^$]+MY''+
MVBFW;//(VD<\GFO0:*\_$Y1@<0N6O1A)><4_S1Y>+R/+<6K8K#PG_BA%_FCQ
MNY_8C\*P[CI>L>,=%8MO'V76)"%<=&PW4TL/[+&NZ;+YEA\6?'<4V[):X>.=
M"IQE=IP,\=:]CHKR/]3<FO>%'E_PRE#_`-)DCPO^(?\`#Z?-2P_(_P"Y*</_
M`$B43RRV^#OQ"T623[%\5+FY67:6&HZ1',4(Q]S##`QG-2_\(Q\7]&\[[-XL
M\':OR'B%YI+PNS=T)0X`..ON:].I5^\,^M;+AK#05J52K'TJU'^$I-'3'A+!
MTU:A4K0]*]9_A*<E^!X7X4\<_%G3O#S_`-F^$/#VO0-<7!$G]KLCQRB9Q)'\
M_4!AA?1<"K</QQ^*EL\GVGX0RL`A*>1JT9RP^]G/;/3')%>D?#2XFNO"[M.5
M+_;KM1M?<-HG<#GZ8^E=!64LAQ:E>ECZR7_<)_G3;_$PGPSCKWI9G7C\J,O_
M`$JBW^/Y'C2_M-^+-,+1ZG\(?&"3A0Z_8WCG0@X_BSUZ\=:ELOVN"&1-1^'O
MQ!TR9U#*IT[S@0<<Y7W_`)5[!DCN:<LSH.&;\Z:RG-8_#CY/_%3IO\E']!QR
M/.H.\,RD_P#%2I/_`-)4/T/)(?VO=($D9N_#'CG3[=OOW$^C2^7#]<`G\JFC
M_;&\#RQ(WG:[AR5'_$FN>W_`*]5$[@?>;\Z#.Q/7BM%@<XC_`,Q<'ZT?\JB-
MXY?GT?\`F-@_6A_E51Y?!^V!X!:YCCGU.^TY)7,8GO=-GMX`V2,%V0`=*ZSP
MI\7/"WCS4'M-$\0Z3JMU&I=HK6X#L%'!./2M^^@CU*U:"XBBN(7!#1RH'1A[
M@_6L_0_!6C>&9Y)=-TG3M/EFSYCVUNL;/GKD@5T4*6;0JI5:E.4.MH2C+Y>_
M)?UL;X:AGE.O%5ZU*=/K:G*$MNG[R2^;_$R(?^3Q?AM_V`=>_P#0K&OHJOG6
M'_D\7X;?]@'7O_0K&OHJO9/H`HHHH`****`"BBB@`HHKS7]JC]K?X?\`[%WP
MO;QA\1O$5KX>T7[1'9P%U,D]]<.?D@@B4%Y9#@G:H.`K$X`)`!Z57-?$_P#Y
M%^/_`*[C^M,^*GQ?T'X+_"G6/&OB.]_L_P`.Z!8/J5[<&-I&CA5=QPB@LS'@
M!5!))``)-><>%_VK/"W[0,NNZ#I<>MZ3XE\*-97.JZ+K6G26&H6L%W&[V\QB
M?K'(%<`@G#(RG#*10!Y!^RNDR_&CX\,4T46[>.I@LD>?[1+"RL\B3C'E?W<$
MG.>*]NKP3]DOPMN_:5_:!U./P<D4\_C!K=O$ZF-IM05;2T(LRH_>!8L[@6^4
M[N*]\VE`S,"%0;G)X"@=2?3H?RH!:NQ\!_\`!;+X@://I7AWPDGB/6K'Q!J6
M+`V%HLK6[1W;;!-(HPCN@&57.>@QS7TO^P9\+$^$O[-6BV":UXHULW/^D2RZ
M]:M:744@41LODD`QCY,X/4Y/0U\7?%'Q9XJ_:#_X*<:;HUAXGAC\-:%JXGU&
MZLM+%Q+;VQPENH5%<2,SD#S&P@4$L1Q7Z;F*0GY@[-W)Y)/K_GUKQJ$(U<PJ
MXA24E'W59QE;1)ZJ,9)=>65_BNFTTWO4J.<*:;OR1MWLZC55KWJ<)1;IN@W%
MZPES+6+BVVBE\IO[I_*C80N<''TKV3`2O+OVR_%NK>!_V=M8U+0GDCU2&YLD
MB9(A*P#742OA2#_"3VKU+RVS]T_E7FW[7GBCQ!X%_9_U?5/#,EY;:S;W-FD4
MD$/F.JM<QK)@8/\``6SQTK*OI2EZ'DY^^7+,1)R<;4YZQW7NO5:K5=-5ZG<:
MQ&C:WI&[?N6:0IAC@'RFSD=#^-9'C3X)>"_B3J:7OB/P?X8\07L48A2XU+3(
M;J5(P20@9U)"Y)./<UMZK&ZZUI84[5>:3<#GYQY1Z>O..M<K\2KWQG:Z]"GA
MZV\VT,`9R8D;Y\G/WCGIM_.O+SW,Z>`PGUFK1G55TN6$>>6O7EOLNK.S&9]5
MRBG]=HJHWM^Z3<]?1IV[E;_AD_X5_P#1,O`'_@@MO_B*/^&3_A7_`-$R\`?^
M""V_^(K'_M7XI8_X\!_X#Q<?K1_:WQ2_Y\!_X#Q?XU\1_K]@?^A9B?\`PG_X
M)Y/_`!&#,?Y<;_X#/_Y,ZWP7\#?!'PWUY=3\.>#?"N@:FJF-;O3M+AMIPIQE
M=R*#@X&1[5S/AO\`9L^#_ABVUZ73/"W@J%-0MKC3]5E!23%O<$F>W9F8^5'(
MQ)9%*ACU%;GPLU#QO)XT@'B"U\G344LS"%%PX(Q]WGUKY$^&W_!,@V'[./C"
M?QS!?I?^,]-BTJ[T7PIH%L+V."'7)-1CENA([)?W&[8"7P/*9E`))K[7(,UI
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M79YW7#2RMN9VE8*!N<EOE'H*U?AU'%#X`T58?,\I;*,)YCEWQMXR3R3[FOB#
M]F_]DWXC?LY:3XI\'?#O2?$7AKX?W%_H#6VOWFF6.E^*[AGU6:36%DDBW">V
MCM),I-(-X+,%SC->:_'[]I?XC?"#X@_"?P%XB^,6O^`[6S47^LZC]O\`-U76
M+"?Q');6(@C1=U_+-:(D1W#]VC^81NS0!^FP\1:>WB!])%]:'58[87KV0F7[
M0L!<H)2F<A"P*ANA(([5:>5(ER[H@SC+,`*^(]*N/B=^U)HGBKXF>!;GQ!X>
ML?'GQ6TCP_I6H:,\=KJ">!]+FDM;FX#R`[1+,UY+G!;!0@5X+^T#^SC^UKX]
M^$^E:'K2?$?XBZ;-8Z%KFIV6HW-G--!JVG^*]V+?;LP[Z3''(ZY(D8YSN.*`
M/U8HJOHFN-XNTBVU/^SM3TO^T$\\6>H0B*ZMLG[DJ`L%8=P">O6K)C;9NVG'
ML*`&D;AR,@C!'K6!K'@;[1=-<V$YLYR/N*,(_KGTS^5=#L8X^5N>G'7_`#@T
M&)L?=/OQ7SG$O"659_AEALTI<RB[QDFXSA+^:,HM2B_1^MT:TJTZ;]UGBWBG
MPA>Z%XG35M&=?#.LJF+A(X\V>I8R?G48`8XQD>M;?PF^+UGXL\67<.J1-HGB
M.YABA>RFE)23R]QW1G&W!WGH23CV%>E76GIJ%LT<T/FQ-U5EXKS'QW\#+7QQ
MK=U;!(_]!@ADMMK,+F%WW98/V'RKCCUKY^ACN*<@BJ&87S/!QT4]%C*4>S22
MAB8KJKTZCZ-NQ\1B^%9X/$2S'AB2HSD[U*$K^PJM]5NZ%1_S13@]YQ?Q+I?B
M[\!O!'Q]TN.Q\<^#_#?B^U@W>2FKZ='=&`L-I,;.-R''=2*^6+G_`()4>(_V
M=/%UMXF_9R^+7B;P:]E<-<_\(;XGOKC5_"]\&60/$8]VZ/EP5QD*5'UKVOP]
M\5?$'P6OH]+\<02S:0@\FWU6.,LZ8Z>;Z@Y'/TKUW0M<L_%&F1WNG7,-]:2C
M*2PN&5J_6N'^-\31PR_LO$JIAZEUR27-"7\T9TIKW9K7FBXQG&]]+IG3DV?8
M3-92H5(.CB:?QTIZ5(^>C]^#^S4BW"2V=]%\>0?M;?'$_M#_``Z^'?Q"^%(\
M%S7>O@MXHTC4DU#1/$5M&NUDC4KYD#MO#[6P0%/O7V=TKY9_X*X:5JK_``1\
M$:CI6BZSK]]X:\96FMQ6.FR/%<2_9DDD8AU(V_('Y)`XYKJ-$_X*M?LW>*-%
MM]2@^-/P^@ANXEG$5QJL<4T.0#L=#@AAG!&.H->A5RRMFR^O97A&M>6<:<9R
MC&22=U>4Y+G3V?*KI\MUMU9?54,;B83FWK'>R7PK;77SVU^\]^HKF_`7QD\'
M_%75)++POXM\,^([R&(3R6^F:E#=2I&W1RJ,2%]\5TYMY%;&QL^F*^<K4:E&
M7)5BXOLU9_B>\FFKHHZWH5GXETR:QU&UMKZQN5VS03QB1)![@\>_L17R%XZ_
M9C\>?L;Z;J&O_#_Q9?\`B'P,+^&\O/"%Y`TMPJK,'"V\H)/7AB`&;@8-?9/E
MMC.TX^E8_CP3Q>'5:%Q#)]LM1N8E1CSTR,CU&1[UZV49YB,`Y4XI3I3MSPDD
MXR2]4VFNDE9KN?19%Q)B<LYJ45&I1J6YZ<DG&:7JFXR[2BU)=^AQ/[.7[7/@
M_P#:=TMWT6[-CJ\#,MSHU]B&^MB.I\L\E3V(_&O3:\,_:@_80TCXWZY+XP\/
M7-UX1^)UKLEL->M79`TD8P@G49##`QD#./7&*XCX<?MJ^*?V?IG\-?M#Z5=Z
M+=Q2B&P\56ED\VF:JO0%W085NY.!WR`>*]BID.&S&D\3D;;E]JC)_O%?^3_G
MY'S24EUCU/?K<,X+-:3QG#4G*2^+#RUJQOUIV_BPZ)I*:ZPMJ?55%4/"/BC3
MO'OA^VU71+ZVU;3;Q`\-S:R"2-P>G(_D:T?*;^ZWY5\?.$H2<)JS71[GP52G
M.G-TZBM):-/=/LT-HI3&P&2K`'U%!B93C8V?3%20)2I]\?6CRV(^ZW'7BECC
M8LORL<GC`ZT`<]\-HHHO##B$2",WUV<2.7;=Y[YY/.,YP.U;]8GP[$\WAMC*
MPF?[;<KNC)<8\YL#)[@8&*W3"P'W6].E`#:*<('(^ZWY4@B;^ZW'48Y%`"44
MIC8#.T_E2B)C_"WY4`-HIQB<#[K?ETI/+;&=IQZXH`Y2'_D\7X;?]@'7O_0K
M&OHJOG:)&C_;%^&H8$'^P=>ZC_:L:^B:`"BBB@`HHHH`****`"O#_P#@HW\*
MKKXO?L7_`!&TG2=#77?$D_A^\AT>%;=9;@3R1%,1$\JS`D9!!P37N%%`'SW^
MVGI'B'XJ?L^>*_AUX?\`"FL:GK<GAF#6+29ECBTZ^F@NHF_L[SF8!;A_*.`P
MVX8$L*\O^">B^(/C-^V5\0?CE=>$?$W@?PQJ_A+1_!NG6'B.S^PZI?7-M<W5
MU<S-!DE8XS,L2L3\Y#E<K@G[4KFOB>?^*?C_`.NZ_P`C0!\5_!+X.>&_BG\?
M?CN_B'P1->K#XVD\K6Y;]D@N3]CM`;=8XYE<,G4ED`.>&->S_$?2M)\%_#;4
M;Q=$CU"+2;-FBM/M0A#A45=N^5PO1%X8\[<=3SYM^RGIJ1_M%?'^[&I>)Y)9
MO&31G3Y1)_8T`6TM,20?)Y?VANCXD+8`RHKBO^"NWQZT_P"%_P"S7=:3%J-R
M/$.HR1SP:=:NH>[@#%6WAA@QDGG!SQ2E6A1C*O55XP3D]+Z+5]5Z;K?=&M##
MU:TU3I*[?=3<5=VO+V:<U!;RE%7C&\KJUSR[_@C_`/!:V\3_`!"\?_%!]NE-
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M=3OO#=O>0ZU9W%BMJ]CYCS1I]IA5]J@G(V#!XZ5[%7FW[7&H^)=)^`6K3^$9
M=2AU];BS$#:>K-<!3<QB3:%!."F[/MFLL1_"EZ,\CB"7+EF(=VO<GK'XOA>V
MVO;5:G4:YX2TO^VM.7["K?:I)4E8R.,@P29R,^C,.W7U%7)?!>D2VOD/9Q>5
MDML,KCD[^?O9_C?_`+Z]AB;621KND[9=BF:7<F?];^Y;CCC@\_A5J:S6=\DM
MTQ7SO%F-SS"Y?[7A[#0Q%?F2Y)U/9KEUN^:SU6FG4]VA&DY6JRLO)7*,GA73
M);F.8VT9FB.4?S&!7_QZD'A+2]KC[+'B4AF_>MR1M(_B_P!A/^^?K5S^S4_O
M-1_9J?WFK\P_UG\5_P#H1X?_`,*U_P#(';['`_\`/U_^`E2V\"Z3<R6UNEG"
M!&X$7[V3"'Y0#][_`&%_+ZU\OK_P4?\`!D7A?Q+XBN/A]X@A.A:3#JULG]JV
MDAU.UEU3^R@2RR[+4B8AB)]I\O+9^5L?6%C%_9UTLJ$DH01GU!S7FWPF_9>T
M7]G_`.%$GAOP%/%X5U"XG:ZN=>@TJUEO;Z=IWE,EPK+LF;]XR?-SMQ@@U^H\
M)XW/,5@/:\0X:.'KW?N0G[2/+T?-9:OMT.*O&G&5J3NO2QYO\1?VQ=/^&7@S
MPCKM[\*]:O\`PQXYU>RT.74M%\2Z=JL-G=WUV]K%&/(G9KGEVD<P9"(YYRI`
MV?@3^U3X4^//QAN/"UKX9N=+DMXM4N-.O)M5@N/MB:??_8KDO!%(9;9O,EWH
MLPRR-GC&*Y;X8?\`!+C2O@KXF\':EX6^)GC:Q_X0V[U;58K*[L[&\LKO4]3G
M>6\U!H6C58YV5WB0I@11LP7EB3ZWX&_9KL/!WQXU;XA3:B+_`%C4K.;3XHH=
M(M-/BMXIIHY9&=H5#W$S>3$IEE8G:F,<DU]*8G#Z?^U7IE]X2\5ZBGPU\3V7
MB31?%]MX&M]"OK^W@N]6O;J."6W</YC10Q,DR.=YW*$;(SQ7'_"_]L_X#2_#
M?P*/&<&E>#/$EW$L$>D:S`U]=Z+*M\^G@O=(K)'&;JU\M92Z*Q"<@M@^@2_L
M;7+_`/"77ES\1=<N=3\0^)[+QO;7?]C649T;5;..*.&6-`NV2/RH$C:-^""Y
MR"U>?>'?^"77A#QK\)Y[?5?%_BG4KGQ;X9LM'U;44\G=>F+6VUMKI04P'DNG
M92OW1'@#D9H`]3\#_M+_``:\:_$+6_#&B>(=-FU/P797%WJ0AAN$L[&UMF\J
M>03D"!TC="A*N?F1AU5JX'X4?\%%?@GXS\#>'K_Q=XA\,?#[7?&FGQZI!H.K
MZD\-T+"Z-P;&23=@*9[="X']Y]@R=N?)_P!GS_@F5\4/!'@#XM^#_$=_\,;;
M1OBI!=6NKZGID4\NKZN+K5'GGD:8QJ8T6RFGB6)@V9I`Q(`.?9?B[_P3`\%?
M%;XY7?CB76M?TFXN+CPG/%IUK#;_`&:V3P[/)/91KN4MMD\W;)ST4;<&@#J?
MAI^T3\-OC;\5T\%>%]FOVMSX4B\:6^K6DY?3[JUEO)K38K!M_FK*)=RD#;D@
MX(P/5V\+:>]V)OLJ^:!C=O?USTSBO!/@'_P3IT[]FGXI6OBCPIX\\10R+97>
MFW]G=Z99W$6I6UQJMSJCH6*AHF$UTZ!TYV*N>>:^BSUH`S?^$/TS#C[&F)2"
MXWO\Q!4C^+U1?^^?KE@\$:2L42"R3;`08QYC_+C;C^+_`&%_+ZUJT4`9K>$=
M-:Y\_P"R)Y^TKOWOG!!']['0FL6Q\&Z3)XSUJ$Z>NV2"V>0^=)^\+&?/&>/O
MOT/\7L*ZP]*QM-D8^.=8'V@M$+6VQ#D_NCF3+>@SQT_NT`%[\/M$U.%([G3+
M:X2,[E64LR@Y)S@G'5C^=>=^(OV?+_P/J4>I^`+N6V*DF?2;BY/D7(/]UCP.
MIX/YUZ[16-3"X>K"=.M3C*,U:2:WM>VJM).-WRR34HO6+3/G\]X9P6:J$ZUX
M5:>L*D'RU(.Z?NR[-I<T6G&6THM'RUXK^(M[?^+_`(>>&!I5[HUXWBN&#6+9
M!(4EL_*8,KGD&,E(\GI\H]>>XU/_`()K?L]:S=W,US\%/AM/+=E?.=M%CS)@
M`#]`.E6/VS;CQ'I^E^!;SPU;ZA<W%OXFB-^MG"TA:T\F0N),#/EDA<YXR!4^
MC_M9:5<W/E3R0+(3T=&C;!Q^%?+4>)\?PEB*E&BL9+#RUC4IJM7<>\*CIQYU
M&*:<)3YW).2E)N+;^=RS.,+EV-KX#B#'T_;7@XNIRT5.+CIRIRY'/1^TY.57
MLU%<UEY_XG_X(V?LX:[93KIGP[B\&WTY).I>%M1N=*O4S]Y1)&_W2,C;C'/2
MO,_&7_!,GX\_#_4G7X3_`+3FN)X=C1)+71/&]D=9$4B>:!']HSO\H))CH22,
MG.!7V)I_Q3T^]A5W61%/'F`;U_,5J6_B_3;G&V]@R>S':?UKZG)?I#8+%2]B
MLVIUWLZ>)<)M?]N8A.2?FDGVL?H+RR\%4A!V?6/^:T/CS2K']MOX<ZJJ7_A#
MX$?%%%L_+BO[769]#=95YWNC#DOQ\H&`1U&:QOB;^WMX\^%?AK;\2/V2/B1I
MT<DEM<27/AG5(]:@RDL&`?*;<&,B@!<<[5SU-?=<%Q'=?ZMT?OPU9'Q`N)+?
MPUF.[-DWVRU_>;F7CSTRN1S\P^7\>:^UI<799BO?Q.6T)I]:;J4W\N2HX+_P
M"WD8?5ZD?AF_G9_F?(WP_P#^"QO[-WBF33[77O\`A+?AY=R?/';>*?#]]9)%
MM"`YFYCX*JN=W)7WY]GTK]H;]GKX^Z-]CA\=?##Q':ZY:;FLI]=@)N(2#PT4
MD@(.">"`17LVN:;:^)+9K?4K6VU"!F4F*ZA69"5.X<,"."`?J*\3^(7_``3*
M_9Z^*8)UOX->`+B1YGN'EBTM()))'#!F+)@DG<3SWP>U;1Q7"U67.J=>A_AG
M"K;[X4GV^TWYHJ#Q5*2G"2NMGK%KYI[GG/B[]B34_!'B*ZUSX`^--)TRU=_/
MO/"%Y>?:=,NY-K*VTJYV%E)55QA>Q%:G@_\`;J\):-J$>F?%7P3X@^%NM0RB
M%)=0M[B73IY23GRYQ\N-S-UR,'K7"3?\&^W[/^D2P7/A.;XC>`M5MI&FBU#0
MO$LD4R/SM;YE(.W)QT]*TM2_X)<?$72/"R:%H7[4'Q#U7P^\I672_&>F6FN6
MZP$LP5-R@F0%OO'MZ5]97Q'#&81C#&XUU&M%.I2G2JI><J7MXU/^WU?M)'VG
M^N/U^,:7$>%]NTK*K"2A62\Y-<M3_N(G+M-;GUII&D:#JH_M"P^QWB3X;S[>
MX,J/T(P58CLOY4Z'P)I$5H(%L4\E2"$\R3J-N/XL_P`"_P#?/US\`?L__L$?
MM6_L7^.[EO!OC;X?>)O#5U*TTMG+Y]JDP&502P$;6?:<Y5ACIDU>^-W_``49
M_:O_`&>Y?MNM?L^>'M0TC:79+>ZG62,#;N)E1WBXYX)'4>AKQZOAT\5C/89%
MC:.)B]5^\C3EZ.-3EL_F37X:IXB+KY'6^L0_E:Y*R_[A7;E_W"=3OIJC[T3P
M9I2&/%FG[I0J?O'^48`Q][T`IX\':7)))FS3_2`4D_>/\P(8$'YO1F_.OAOX
M3?\`!=&/XDW<]N?V?OBY<7GE^9;6VAK;:I+,JJIE+*CY4*6&"1@_7BO1U_X+
M)?"CPY=7$/C?1/B=\-YM/7.H#Q!X2O$33B>565XT906&,8X^85YF*\..)</5
M]A/"2E/M%QF_N@Y/RVWT/E,5&>%JNCBXNG/M).+^Z23/>?ASX,TB]\&/"VF1
MQPB_O"(_/D;DSRY;)(/.]CCMN]A72'PIIQNEF^RIYJ#`;>_'.?7'6OE[X=_\
M%AOV9;7PWMO?CAX7\][N>0"[2[AE5'E<H"LD088''3'3'%>I^$_^"@OP(\=W
M,\.C_&/X<:A+;1">58M=@_=H>C'+"O*Q7".>X6//B<%6@N\J<TOO<3%8BD]I
M+[T>ECP9I8#_`.AI^\(+?._."I'\7^POY?6D/@C26AAC-BA2WQY:F1_DQM`_
MB_V5Z^E7=)U:TU^,/87=K?*460-;S+*"K`%6X/0@C!]ZMFVD7.8WXZ\5\\]'
M9FN^QDMX/TUKHS?95,A7;G>_3!']['0G\Z:W@?2'AD0V*%)F+./,D^8G=G^+
M_;?_`+Z^F-4@@]#QU![44/3<-3-E\'Z9-*CO:*SQG*GS'X/S'U_VC^=$?A#3
M8;IYEM%$LF-S[WYQM_VL?PK^5:5%`'$Z!H%GX>_:]^&\5E`+>-M#UUF4,S9(
M^P*/O$]@!^%?2U?.L/\`R>+\-O\`L`Z]_P"A6-?15`!1110`4444`%%%%`!1
M110`5S7Q/Y\/Q_\`7<?R-=+7-?$__D7X_P#KNO\`6@#XE_9V^+FC>#_VO/C;
MH&J>-"+G6O'!@T[PR=).(9S9VA-P+M5);S!QL<A5V^]<1^V9XDOOC'^WC\-?
MA;#>:#;_`-ER_P#"06Z7_GFWGEB7<8YMJ@%F'"H&P<#.*]:_9U\=V_A?XH?M
M#RW6JV#VNC^,KB_ETVWA,FHVZBQM29656+,C8PH"#D'DUY-_P3;\'V/Q=^._
MQ%^,%O,KP7=])I*:5?VDZW&E,,.LL+2';ME^8GJ5P!QR*\_,8QJ1CAY1O[1V
MVNK+67WZ1[^_=:JS<*=*K/DK0YHV;?N\T;)6M*TXN/,VDKQG&6L9)71]K-@<
M`!1V"C`'T':DI`,"EKT!!1110`5YK^UWK7B3P]\`-6NO"3ZE'KZ7-F(&T^,O
M<!&N8Q)M`!.-A;/'3->E5YA^V0=?'[.^L_\`",-JJZW]ILO(.F[_`+3M^U1[
M]NSYL;-V?;.:RKNU*7IT/(S]M97B7&Z?LY_#\7POX?/MYGH.J2&/6=+"IN5I
M9`QS]S]TQS7@'[7WQ;^,'@'XCV5I\/\`2+K4-'DTY)9I(M&^VA9R[@C?@XX"
M\5[_`*QM&NZ4-Y7,TN%&<.?*;KV]^:TX+>:5,QK(5SU4&O9R;,Z6`Q"Q%:C&
MJK-<L]8Z]?5&'$F35LUP3PF'Q,\/)M/GINTM.GH^I\+_`/#2G[37_0LZC_X2
M_P#]C1_PTI^TU_T+.H_^$O\`_8U]U_8[K_GG-^1H^QW7_/.;\C7UW^O>7_\`
M0KP__@)^=_\`$+<U_P"A]B__``(^9?V0/B_\9?'WQGM]/\?:-=6/A]K:1VDE
MT3[&IE!78-^!UR>,\UY7\.?$WQK\7_LX>(/&.K_$L?#S1=3L8[>PUSQ9XF@2
M!KQ-<(>YBE6,_P!GP/9H]L%<$[W1MN5W'[L>SG#*&20%F`7=GK7D?_#7_P`(
MM6\*:W=/XJT*72-!B274%FM)#&D3W/V9'6)H_P!\AN?W0:-6&_C.:^3SK,Z6
M/Q'MZ-"%%62Y8:1]?5GZ%PSDE?*L']5Q&*J8F5V^>H[RUMIZ+IZGQX__``4-
MT_XS:;\'=.\-_%/Q5\*?&7B/Q%+*Z^*/$L5SH][H.G:DT5[=O/+$@O5O0#!:
M#Y78,&``1F/M7[*GQ<\6Z_\`MCZ_X3U3QE%XIM].TS6[S6!:>*+?5K"R;^TX
METT);QH#ITB0-+$T+MN?RF8@[=Q]7\3_`+4?P@T";PS%KVL:)IY\23166C'4
M]&EB7S&E,4,9:2$"WWR@I&)"FYN%R36W\-?CO\/OB!\0-<\.>%]2TZXU[3C+
M+J$5OI\EO]H\J7R9764QJESY<O[MV1GV,<$@FO)/H#XS^&?[9D'Q2LO'?B;P
MY\=M5NOA1+XS\/\`AT2:MKL*:[X?LENY+?5-59RHDLK*YE,<,9D`PJ,Z[0PK
MF](_X*6?%KP)\,[&[T/_`(1GQ/X<\+Z%;>);J]UJ&>2_U_3KGQ7<Z/!%!+'M
M0$6PBD65E.[8#@ALU]LZM^T?\(]&MO'T0UKPN[^")K?3/%$%EIXN)+2YN0?L
M]J\<4;--*[<+$@=MP(P",5M?`/X@>$_B9\%O"VMZ!JFDZOH^J6,<=E<N%4W(
M1F784E57W*Z."C*"K(WR@@T`?*WP-_X*9>-_'&G?&_QOJUKX&/A#X:Z;JL^D
MZ#IURLFN7=U;7LMK;(ZF8R>7)Y<99I(8_P!Y.$`.,GR[5_VT?V@_V.?'VA_"
M6&T\`^*+[1K?P@GB+4-=2]^T7FL^)KF[%PZR1-@0P7/S8QD)&$`&<C[3^&/[
M"OP6^%_B?5IO#W@SP[;:EJ)47,3W!G-H@NA>")(W<^1%]I"3%``I=58CBNU^
M$/Q0\._M"^`[+Q?H(@OM+U>6;[)=30IOO$@GEB69<\E&:-GC8]5(88S0!\B?
ML6_\%$];^,/[46C:5\1O$F@>%QK?@>6VMM#6<6]CJNO6OB&\T^6:S67]ZSRQ
M6ZL(MS$*1UZU]SD8-<X-?\)W?Q&_X1H2:#+XIL=/7618B*-KJWM))6C6Y'&5
M1I`PW`\L#71T`%%%%`"'I67I\[/XQU-#'A%MK<K)G[Q)DX_#'ZUJGI6/ITB_
M\)QJP$KLPMK4F,Y(C'[WD<8R>^/3F@#8HS110!YQ^T!K7B+2->^&J:!)J207
MOBV"WU<6<9=7LS#*7$V`<1[@N2<#..:[/Q+X*TCQ?:20:EIMG>12$%A)$,\?
M[0P?UKB/VB3KR^(?AA_8AU00GQ?`-5^Q!]IM/)EW>=M_Y9;MN<\9Q7I9ZU%&
MI*%63@VGI^2V/GJ>$H8O$XNABH<\&XKEFDX_"KV3NGY^=SS2\_9IL].,A\-Z
MWK'AOS>6BB?SXB1TX?D?@>]9%WX!\>^'E=Y(O#WB>.(^8"K&UN)ASE0.!NZ'
M\*]BH[49KA<#FT%3SG"T<5%?\_:<)O[VN;\3QUX?9;AI>TR>I5P<O^G%24(]
M?^7;YJ6[O;D/#9_BYHVESF+6/#OBGPR^S/FLC2(6&<@?EQ6W_P`+"TS5]&7^
MS_%<5]"98&^SG:)@3(H7(;C`)&?8&O5G02+A@K+Z,,_SKA?BQ\*_"^K>&'>[
MTBQA>2ZMT-S##Y<R[YT!`9!D;LX/U.>*^0J^%G!$W[3!X2>"G_-AJLZ7_DL'
M%??<THPXWP=^7'4<7'HJU+DE_P"!TVU\_9FO'>^(K5-YCLM2CZEH9!S],42^
M.+FP8B[TBZ3&<E,D#]*Y"?\`92TS3KH3:)KWB/1)XB#&5NO.1>?[IQUP._:K
M4'@KXC>&(P+'Q9I>L1HI`CU&U99''4989&<Y_.LJGAMCJ4?^$;B*O%K95X0J
MK[Y0YG_X,^84N-,[HNV:Y))K^:A5IU%_X"W3GWV@^AT\7Q-TYGVN+B+/=DXK
M0M?&&F7KX2\BSG'S';G\Z\\OO'_Q$T-0NI^!;'4T+$>;93JP(/(&W/&#U-4I
M?C+'))&-6^'>O6G)626*V8A3SP,#D44^%?$K#KFH8S!XM=I0E2;]'"K/_P!(
M?H1_Q%7A>,N3&JOAW_T\HUHK[W3Y?FI->9Z[#>13_<EB?L-K@U*PW(RD;E;J
M",AOPKQV'XM?#J[G(DO-0THD\&:)U7/H./\`.*U],U_PIJUMYEEXTA5<@`23
MA-N>@P2#WKEK8SQ#PB_VG(HU+=:>(5ONJ4X/\6>U@>->$L<[87,Z3?;GC?[N
M:_X$7Q,_8O\`AA\7]7?4-;\(6/\`:;1+`;ZPEDL+D(,X`>%EQU]*XNZ_99^*
M'@"WEM/`7Q?:;0PHCM="\7Z1'JMK;IV3SC^\8+@`$@^]>K00S22%+/Q3:S,>
M0CRAB>_/)[5>6+Q+%M*7&G7:GCI@`UZN&\8.),'%4,QRC%<J^RXT<1%*_1>T
ME;UC%,_2,!Q3C)4O8T\7"M36G)4M4BDNT:BDH^L;-=SYF\06NN6O@UK[XD?L
M[>%_B/'<M)IVH:CH*07=Y/&K/&<V[QAPARVT(?E5L9!KS6T_9_\`V%OB9XNT
M_1_$/P9TCP3KSJ;>&TUO1[O10<`[@TF]8SMQC<3U/7FOLKP+KVK1^'R]E9S7
M,*W=P#)<R#S#()6W@8_A#9"CT`J;Q)<-XGLVMM=\(V.L6L@V-'=6ZW`8=<88
M'`KV<'](_*\'IB*&-PC_`)J=/%TDOER3C9?W7%6T5C=O*,5%_7,#%2=_>I5.
M3_R2?M(_*/+?;3<^;-"_X(E_LS:C:+?>$K'Q7I4%S%Y33^'_`!U?!+I,J0"R
MRL"%*C&.E:,7_!(K1_#J6=EX9^-'QZ\*Z%IZ[+?2[;Q,T\<62I;#R@O\Q!/)
M.-W%='XT_8O^&7B<3-:^#-7\&WKIMBN_#=[-I[P$=U1?DR>_'-1^'?A'XY^&
MFU/#OQ=\9FU08CM?$^FPZM'@<XWY5\9[CH.*]3_B9/A^M&\N(JB=[6Q-"M9>
MKE"HO*[4?DCGEPED]6G?"XGEEVJ4W'_R:E*I^*7<Y:+_`()S?&C2@D.F_MF?
M%^VLK4%+6";1["<Q(,[%9V&7QD`D\G%8\?[''[9NG0F:V_:\TJ^NX6+QP7W@
M>V^SS=<+(5YQR,X%>IZG\7/C5X/@WKI_PY\;@'E('N=(N2,9/RN&3V`W=2":
MI:?^WUKNA3"+Q?\`!GQWHV?F-QIC0ZI"H.-H_='=GKGCBO;R[QDP&.ER8/,<
MNQ#ETM@>9_\`;LX1J7[Z7^9$?#W'U%SX3EJ+^[55_E"4HS?_`("><+\!/V\X
M)D<?M`?!FX\J0R&)_!S(LV#G82$R%/`R.1GK7J7[,.E?M36'Q2G?XP:K\';W
MP:]K*(XO#D-RE]'/E?+P74`K][.X]_I73:/^WG\*-2D$=WXJ7P_.W*QZW93Z
M>Q'KF5`OMUYP:[SPK\8_"/CN[\C1/%/A[5YVZ16=_',Y.,_=4YZ<UZN9\4XF
MKA72Q.$H04]%*-"$'_VY**BF[^KU\SR<5PSF>$][$T*L4OYE*WXJQ#;G/[8G
MPV_[`.O?^A6-?15?.EM_R>)\-O\`L!:]_P"A6-?1=?''GA1110`4444`%%%%
M`!117@?[5?Q9\<R_&+P7\+/AKJ^A^&?%/BG3M1UZ76M7TMM3MK6TL3;H81`L
MD1+327,:[]_R*KD*QP*`/?*YOXH#_BGD_P"NZ_R->!>"_P#@H+=?$7_@F):?
M'S3/#5O'K.H:298M$FNB;>/4!=&R,32A=QB%P#R!DH/6L3X;?M!_$32_C3XZ
M^#/Q%ET+QCXO\*^';#QGINL:)9'2;?5K>ZEN(#9-`\DGE/'-!M$OF$.DBDA2
M""#2N[?\#\7I]Y\L_M%?'75_@\/V@M*T;P['=:[XW\:RZ7HEYI5PK:U=3?9+
M/?$8-H=XUR-H1FSE@54<U]6_L2?"6[^"7[+/@_P_?ZEJVJ7L5I]KGDU.V6VN
M;=YOWK0-&/NB-F*@$D]<U^?WP1^`'QI^/O[:.L_%OQ#\.1=KX1\9RS:AH?\`
M:=GILBW\4,82,,\F/E3R6,BY5B!C.3C].H_$6NW-M;3/X;99Y]IN(CJ4)-L2
M$+9;HVTLXXZ^7Q]X5YF$4JM5XJ<;?96^W>U^KMT3LE=)MGHXNAAZ%-0IRC.;
M>K5]$ME=Z;MO1+I?7;<HK);6-5^V^7_83>3L8^=]MBQD#(&WKR<#\:9_;6K_
M`&>Y)T(^9'N,*?;HOW^-^.>BYVIUZ>9_LFO3/--FBL6?7=:C5=GAQI2<[L:A
M$-G+8Z^H53_P/'8U+%J^J/>LK:(4@XVRF]C._D#[O4<$G_@..]`&K7FO[747
MB2;X`:LOA%-5;7_M-F;<:=N^T[1<Q^9MQSC9NS[9KL+?7M:>RWOX=,4^5Q!_
M:$38SLR=PXXW/_W[_P!H5YS^UDWC/7_@/?6GA[1=5M]5GGLVWZ?>J]Q"!/$T
M@4)AF&-P)!Q@$]*RQ'\*7HSR,_3>68BU_@G\/Q?"_A\^WF>I:JY&L:4%5&5I
MI`6)QM_=,>!WYK\Y?^"LG_!'/XP?MV_M6+XY\#?$7P]X6T1=#L]--E>ZA>P2
MF6+?O?;#&R8.X8.<\<U^@6L:WJ3ZM8,VA2>9&\QM%74(Q]H?R9"0>,#HHRV!
M\^>QKS;XY?MOZ9^SYXBMM*UWPUJSZC<VPNUCMKB%T$9>1%)?.,G8#CMO]C7T
MG#7B7B>!,7_;V%JPIRY7"\XJ4;2MI9W5]%J>]ALAKYO/ZEAJ;J2WM'?0_*[_
M`(AI/VD_^BT^#O\`P<:I_P#&:/\`B&D_:3_Z+3X._P#!QJG_`,9K](7_`."J
M'@X7"J/#GB-HNADW1`C\,TG_``]2\'[6_P"*;\1\$8&^+YA\OOQU;_OGWK[W
M_B>?.O\`H/PW_@F'^1Z?_$(LY_Z`JG]?,\%_X)!_\$AOBY^P#^U/=^-_'OQ!
MT#Q7HL^ASZ8MG8W][/*LKR1.K[9D5,`1MSG//'>O=='_`&"?^$._9HN-/DT/
M1_B#X^N;)=.EM?$'B2^M=)%HNJM?K!;S0H9+55<12#9'DR1*"<#-=G\#OVZ-
M)_:`\>6OA[1/#>LC49XC,XN+B&-$16C#'=GDC>>.^SW%>3?`W_@IGXH\=3>.
M+G5/!NG7ND^%="&M"6*X.@E)GU*:QALQ)?E8KA9/*+?:HF\L,"G+%17Y_P`1
M>)5?CK&//L35A4DTH7A%1C[O2RLKZGG8O(,3D\_J>*ING+>TM[/K^!@0?LF_
MM17F@_"W0?&6J_#+XJ>%O#>K3>)]?TW7?$.HK*^HB^,VFP)=&V>6YMM/B"&/
MS=K32@&3Y4%>O?L^_LQ^,/`7[2.M>(]2M]*\.^$M-T[5K#PS8Z?XGO=8<2ZE
M?)=7%V8;B)([/)A1O*B9QO=N<*M>'ZS_`,%\-#T72=5N?^%*_$"ZE\,:3?:W
MXDCMM7T]AH5K9:H=-NG9RP$VR7RV'E`EUDX&5-?0'P=_;G;XR?'O4O`UIX&N
M;=+6WN[NSU=/$5C>6^H16TL44Q*1,7@<&>']W)AAN((!4BO#.8\)^%7_``2X
M^)/[+>I^*=2\+?$33?':V^I^'O$.@:9K]A#I"ZC>V%U<SW4E]<6L3.'<7,NV
M0!R[R;G&56N1\2_\$A?%7QT\+1^)-8/@7_A,9_#=C)H]Q]KNBGAS6#XIEUFY
MD@D\O.S[-,85EQO8@@J%.:^J/CY^T5X[^%_[2_P4\(6OA;0V\)?%'7KS0;^_
MFOV;4(&BT^>ZS%&HV!<1CYB2W!^7H:^9=!_X*J?$#P9\!O#_`(DE\(>'6TWX
MA"VLO`UF]Q*\^B[];BT82:E*/]>NZ0S958SNC*="&H`XS]C_`/9=^*.BW?[1
MCO\`"W6/#/Q!\96>IZ1I'C*Y;R)+==0U>4LGSH/.(@F-P9XY)PJPI'N'RK77
M?M(_\$,K;XJ_M!V>K:1:^$U\$^';3P3HFA6EW?WD-S:Z9I,LZZK`1&-O^E6\
MB(/F);Y@Q3.3T/P^_P""SVO0R:MH/BGX-ZOK&O\`@BYU:'Q3JOAW6;1-*M+/
M3=4CTV>_2.=A(09)4;R$WM]X*3C->U_#[_@H6OCS]I3QG\/_`/A7FJ65CX&M
M-4O;_P`1R:[9-8QK82B)Q-&I,EN93DQ^:!E%9N@H`\H_9!_82^,/['?QK\)Z
MAI2_#;6O"5KX=N?"&HQ76LWT=UH^FG7;S4+862^0PE,=M/%&$D=0"A&2!FON
M(]:^$_#G_!3+X@_!WP;ID/B;X5^+/B=X@U[3+?QS>2:/J6FZ?#X<TK5]5EL]
M(LMLSJ97"^0I*Y/S,S8`-=;\%O\`@I1XG^-_[5O@OP)'\.7\+QZOI'BA];TO
M4M2@N-0TS4=%U*"RD19XF,#Q'S7;C);:,&@#Z_HK%_MO5\2_\2%OW9&P?;HO
MWH)3)]L!GZ_\\_\`:%-_X2#6V@MW_P"$<;?(1YB?VC#^Y!V9.?XNK]/^>?\`
MM"@#</2LFPE<^,]50H@1+:V*N&.6),F01T&,#&.O.::=:U9;WR_[!8P[2?.^
MVQ?>QD+MZ\GC\:Q;+7-47QAK;1^'Y9+M(+<>7_:4>)$!N-A&1A<[5[_\M!G&
MPT`=E16,=;U=9(A_8!P[$.?MT7[H98`^^0%/']_V-.AUC59+QD;1&2%>DWVV
M([N0/NCGH2?^`X[T`<?^T#!XAFU[X:_V`NIF%/%L#:N;,':++RI=_G8_Y9;M
MN<\9Q7H_0UX[\>+OQOJVJ_#*72_#NIPBW\6P3ZK%::BC`6@@;<92AQY>]B#G
MC,8_O"O28M:U=I(0V@,H=-TA_M"(^2V`=OOR2,CT]ZQA_$E\OR/(P/\`ON)W
MWCOM\*^']?.YLT5CMKFL!9R/#S-Y2EHA_:$0\\@,0O\`LY(4<_W\]C4<WB'6
MX[#S!X;=Y]Q'D_VC",CY\'=TYVIQ_P!-/]DUL>N;E8WCN=[?P[NCB25OM=L-
MKL5`!F0$Y'<9R!WIQUC5/MJQC1&\HCYI?MT?RG/3'4^M87CS7=1/AF076@31
MQK>V839J4:F0_:(<<@'');(/7R\<;A0!VK\,?K25AOX@UOR(G/AIA*[`21C4
MH3Y0^3)ST."7Z?\`//\`VA4K:UJOVQD_L(^0%R)OMT7S'!XQUZ@#_@7M0!KC
M@THD8?Q,/QK`E\0:VEO.R^'"[(Q\N/\`M&$&8#?@YZ#.U.#_`,]/]DT_^W-8
MW1_\4\Q#DAS_`&A%^Z&6`/OP%/']_P!C0!KSV<-V`)8()@.@>-6Q^8KF=6^"
M'@_7+EI;KPYI<DKYW.(MI.>O0CFM*'6]5DOWC?0FC@!PLWV^([^5_AZCJW7^
MY[BHH?$&N/9!G\,LDV0&B&I0D@'9D[NG&Y_^_?\`M"M:=>K3UIR:]&U^1YF8
M9+EV/CR8_#PJK^_",OS3.=D_9@\#,ORZ*86SG=%=RHWTR&JNW[,6B(DJV>I>
M(=/\TC;Y=ZSB(CI@-U_&NLCUS6-T.?#Y7S%S)_Q,(CY+;0=ON<DC(]*=_;VL
M*\VWP\6\I=T)^WQ?OVPV%]LD*,G^_GL:[?[9Q]K.M)^K;_.Y\Y+PVX4:]W+J
M,?.,(P?;>*3_`!/./!7P?\176BM<6OCS6+"8W5Q"RI"C(425P&'3#GJQ]35V
M\^'OQ.TVZ9M/\<6EY"`"JWEJ%+GONPI_R*V/AYX@U*/P6SV'AZ:Y_P!/O`8I
M-5BW!A/-GYV`XRJX&.`_?::Z,ZWJPODC&AL86',WVZ+"\_W>O3)_"M(9UB(_
M$HR]81?Z'+5\-,F?\"=>E_@Q-=6]%[1KSV.#CL/C#82A_M_A6]&W;Y0S'G_:
M)VCTZ>]6;+5?BS93QFXTCPW?IMPPCO1'@\<\_C78'7=9*R8\//\`*0$_XF$7
M[P$ID^V`SGW\O_:%#^(-:%O`Z^'&9Y-OG1_VA#^XSMW<]&QE^G79_M"B>;<_
M\2C3?_;MOR:)I>'RI24J.9XQ6U_C*7_IR$[^FWD<I_PFWCS3YU^W^!;.[WKD
MM9WB2;3WZ^]4V^*6K64Y;4_AKJWFORILT$X(Y^\1T[?K7=?VWJZWQ7^P&,.W
M(E^WQ<G!.-O7J`,_[7M44GB'78H9MOAN1G5CY:?VE"/.`WX.>V=J<'_GI_LF
MO/Q-+*L5#V>+P-*:WLTWKWU;.F/"V<TO]VSBNNW-"A+[[4HM^6JL>?ZU\4M)
MN85_MKX;:]]ED;:S3Z8)@.N/E/\`GFJ'P8\$_"J+XBPW?ASX96_AK7+9));?
M4&T?[.RYX;:XS@D$]>V:]6N-=U>*6-4T1Y4)P[_;XAY8RW.#UZ+_`-]>QIL.
MN:O-?-')H)CA!&V;^T(FW_=S\HY'5O\`OCW%<^%RO(L)&3R_`PHRENX6C=]V
ME%7^9ZN6T>+L+5499S*=!_%!TE'G6S7-"45_Y*_.YF6X_P",Q?AK_P!@+7O_
M`$*QKZ+KYF\,:A?:E^UW\.'O],.E2C0]="Q&Y2?</]`).5XX.5_X#GH:^F:H
M^D"BBB@`HHHH`****`"O%/VK_P!FSQ9\5O$GA?Q?\-_%^D>!OB#X5CNK"WU+
M5=$.L6<MA=^5]IA:W$T)W[H(71]^%9#E6#$5[710!\WZ3_P3VM_#'[+L?P2T
MGQ/<6/PUM?"?]B6R?9%?58M3^T>>-3-P6VGY_F,7EX+<[L<50^#G[)/B3X3^
M,?$_Q)^)7C+3_'GQ,\76MEH,^HZ9HYT?3K33+1I9((8K4RS$2-)-))(YD.XE
M0%4+@_3]<U\3_P#D7H_^NZ_UH`^3/V4M,@C_`&@OC]=C_A(?M,GC1XF\R20Z
M3L%I:$>4I.P3?WR!G&,FO>*\"_92N5/[1W[0$7_"2SSRCQDS'P\8HQ%8@V=I
M_I0<+O)D^Z07(&W@"O?:`"BBB@`HHHH`*\Q_;#T#7O%'[/>L6/ABWOKG6IKF
MR:&.S;;,56ZB9\'(X"!L\],UZ=7FO[76G^(]5^`&KP>$AJK:\]Q9_9QISE+G
M:+F,R;2"#C8&SSTS65?^'+T9Y&?QYLLQ*=W^[G\._P`+V\^WF=[J,;/JVFE"
M=BRR%L-@?ZHXXQSS]*YWQ[\`?!/Q3U>/4/$GA?2=;OHHA`D]TA9UC!)"C!'&
M2?SK?UJ*.3Q!H[-RT<\ICPN1GR6!YQQQGH1_2OD#]O?_`(*=^-/V0OCROA'0
M?A@?&%@VEV^H?;Q]JX>3?F/]VC+\NT=\\U<LOIXZ/L*L%-;VDDU]ST/7>;3R
M[_:H5)0>UXMIZ^:U/H7_`(8W^%/_`$('AS_ORW_Q5'_#&_PI_P"A`\.?]^6_
M^*KX1_X?N_$W_HA#_P#D]_\`&J/^'[OQ-_Z(0_\`Y/?_`!JLO]2\%_T"4O\`
MP"'^0O\`B(N)_P"@RM_X%4_S/T(\!?L_>!_A7XA75_#GA;2-%U)(VC%U;1E9
M`AQE<DG@X'Y5SNN_L<_##Q7X<ATR[\-64UA#HTNB0K'>2+Y=E)>)>E597S\M
MU&DRR`Y1U!4BO"_^"?7_``4Q\7?MB?'6Y\*>)?AA_P`(CI<&E2Z@;QOM.)2C
MQKY1\Q%7Y@[=\\5\U^,_AS\?-#\76\N@^!O'<>B?#LZE\$(K*W5MNN:'JQO&
MCUR,9^:&U8V&7ZC8>>M:PRZE@5["E3C!;VBDE^&@_P"UIYC_`+34J2J/:\FV
M].GO:GU'?_\`!%OX$Z_\>-,\8W'AR"^T#3-*EM8?#<LTTUE->2ZC_:$E])*9
M"\K/+]Z-RR-@$BO<?AM^R5\/_A#\2-3\8>'?#_\`9VO:NUYYTXNYY(H_M<J3
MW*Q1,YCB$LJ+(P11ELFOD?QE>?'3X9?%7Q[X4\&0_%BSMO!FC:W8>%=-LM*M
MY/![:);:"$T::VG*&1]4:_5,H7.6,@*A0#7>_LK^!?BMX,_:+^"^I>.O&GQH
M\3P^(/A:9-;CU-+;^QK;7O-CGFAODBA00.B2LL1^\3$%)."#0'MOQD_8T^&W
MQ_\`BEX<\:^*=&FU/Q3X)(FT6ZBU:Y@_LZ1"S*ZQ12!-V6(+%22#M.1Q7*^%
M?^"=?P:U+P=XF74/`.GW3?$FUB/B))[J:59V$_VH>4-P%OBY)G_<B/\`>_/U
MKXU?PO\`&[X4:Q^T(GPE\'^-T;51<:E'XSU?PI]@\16FH76N1%M.LC)+-%J-
MHMHTKAO+0(BKUR0+?[1?QJ^+/[/_`,*M!\)1_$/XF:';6VM:\FG^)HK:S6_.
MC02Z:+6]N(E@"W$"+/<HJ11H6XY.R@#[.T?]C[X%>`GL/`UGX8T#3[C4O#%U
MHMMI*W4@N;_21>1W=UD;]\F;HQR22D[B[#+<UP&L_P#!*W2_$OBGXHW%UX\U
M^RTGXJ6FHV&IVNE0"TN98+^Y2>X6>5G:.5@JM%&RQ1E$E;[Q.:P_'^H:Y^T%
MKWQ^\;?#7^W+7Q;X,BTSX5^%-?T^W26^C"W5M=:Q<VJRJ8SEIU5B5(/V0Y'&
M*\@_:+_9\_:7A^`_Q:\/Q^._C/\`%*'Q'X;\;:#86&IVUBNTVUQ:KHES$UK!
M$YN;F-K@[L[7"G"KB@#[XU3]GOP/K-Z]S>>%]+N;F73K#2))74EGM+&?[39P
MGD?+#./,7_:]17)^,?V!/@K\0O%^D^(-;^&GAO4=;T#5;G6]-OI%E6:SOKFX
M%S/<*5<?/).!(V>"W:NC_9J^(=Q\4?@CH&J7?A?QCX-NEMDLYM+\46`L=3C>
M%5C9WB#OA7*EE.[Y@0>.E=U0`LCF60LQRS')/J:2BB@`K,L?,'BO4V.X1FWM
MPN6R,CS,\8X[=S^'?3K&TVWBC\=ZQ*,_:)+2U5R5&"`9=N#C)ZGN?;'<`V:*
M**`/-/VB/#VNZ]X@^&+Z)!>S1:?XO@NM4-N^T16@AE#-)R,Q[BN1SVXKTNO.
M/V@+#Q%?^(/AJ=`74VAM_%L$NK_9'*JMD(9=YFP1F+<5R.><5Z/6<?CEOT_)
M;'CX&*6-Q,M=7'?;X?L_KYW"BBBM#V`K*\:QRS:!B'=YGVFW/RL%)43)NYP>
MV>WY=:U:P_B-!!<^%MEP&,?VVT8;4#$,+A"O!!'7'../4=:`-QOO&BE;[Q^M
M)0`4444`&:***`"E7[XI*5#AA]:`,3P#%+'X=;SMQ?[9<GYF#?*96QR`.WM^
M)K:KG?A=;06?A1TME=(OM]XQ#(%^8SN6.``,9SSC)[D]:Z*@`S1UHHH`.E%%
M%`!1110!RL/_`">+\-O^P#KW_H5C7T57SK#_`,GB_#;_`+`.O?\`H5C7T50`
M4444`%%%%`!1110`444A-`"US7Q/_P"1?C_Z[K_6ND)KF_B?QX>3_KNO\C0!
M\A_LVW^H:A^T#\;;&Q\6:/!#9>/9+F\T(V*3WAC:SM!YGF>:&C5R.#L[=Z^@
M<YKQ']E:RE3XT_'FY^P:6EO)XZE1;Q#_`*;,PL[/*/\`+_JU_A^8\D\"O;J`
M"BBB@`HHHH`*\P_;'\*:WXV_9VUG3?#=M>7FLS7-D\,5HY25E6ZC9R"".B!B
M>>F:]/KS7]KOPKK_`(V^`6K:9X8CO)M9N+FS:%+:7RI65;F-GPV1@!`Q//3-
M98C6E)>3/)SZ/-EF(C9N\)Z1^)^Z]%H]7TT9WNJ`OJ^F[678)I"05&3^Z;IQ
MD<^A']*PO&7[0O@[X7ZQ_9>N^+-+T:^\M9A;W$Y1]C9PV/0X/Y5LZU;K-K>D
MN5=O+FD967&$S"PR>,]\<$<UYA\<_P!B/PA^T)XX'B#7;SQ!#?+;1VFRRN4C
MBV)G!PR,<\G/->GEL,'*K;&R<86WC9NY]KPW0R>IC.3/*DZ=&SUII.7-I;1]
M-[G0?\-E?#7_`**%H/\`X%FC_ALKX:_]%"T'_P`"S7EW_#K+X;?]!'QC_P"!
M\7_QJC_AUE\-O^@CXQ_\#XO_`(U7O?5N'/\`G]5_\!7^1]__`&;X:_\`0;BO
M_!</\CVGP/\`M`>$/BMK1TO0/%>EZS?+&9S!;S[V5`0"Y]@2.?>O.?`?[>'A
M_P`7Z)KGB34/#_BWPO\`#W3R%TGQ?J=H#I_B0&8PEK6.%GGVEU)3?&-ZY8<5
MH_`7]BKPA^SGXXDU_0KG7;F\EM7LWCO[A)8C&Q4GA44Y^4=^YK@;'_@GWXIT
M/X>7O@_2OCMX]TKPE8W\5SX9TVTMH(#HENMT;AK&6:/9+<VY#-"%++B,@$MB
MO!S"&$C6M@I.4+?:5G<_/^(Z644L9R9'4G4HV6M1)2OU5EI;L=KJ'_!1?X%Z
M4ND>?\5_!\::]9PZCIQ^UEA=6\V\12*0,`.8Y%4'!+*5'S<58\2_M^_!;P?X
M<T'5M4^)'AZRTSQ5;->Z9/(TNVZ@68P-*0$)C19OW;-(%"MPV#7CWP3_`."/
MWAKX(^$-*TBU\8ZWJ2:7<>&IQ-=6D/F3_P!B:K=:E$&QQ^]>Y*OZ;`1S53XE
M_P#!+76_&OB>;3]+^)>H^'O!VN:%KFE>(7BLX+F_U5-5U[^U+BT59%*Q1[&:
M-95;<.ZG.1PG@GM/[6_[8UG^R'I&FZIK7@WQQKWANYEA@U+7-'M8KBRT)9YT
MMHC*&D#R,TLJ8CB1B5)/M7G]E^W)\.CH?CM?%OADS:=\"X7&I:Q?6FG7<+7<
M3Q1;+.WW&>-WDEC5&,,2L3P1BNF_:S_8^\2_M#^-?!6K:'\4M6\%Z7X&4W$6
M@KI4&I:=J%VG^HNYHI2`\L('[O=D(V'`W#-<)>?\$N]`^,LOBG5?%FMRR0^+
M_"\F@6<-AH5EIE]I<<TMO<>;<7$2!KV:.:VA,?G#:@#?+ELT`='X0_X*G_"*
MUTC4H_'NI_\`"G?$FA:E<Z9J?AWQ1LCO+:>&.&>5U,.])8_*N89#(IP`Y+8P
M37JFA?M4?#SQ+\7H?`>F^+]+O_%TS%(]/MQ+)O80+<%1(JF+<(720C?D*ZG'
M(KYV;_@C[IFM^)M9\3^(?B+XBU[QGXJTKQ-8:[JTMA;PK>2:W806#210J`(E
M@@MXPB`G)+;CS47P4_89^+'[.7QA\6:YX7UCPW>6=Y#J":+_`&GJ,AA@9M*M
MK.TE6!(AY$QEM8FF<%P8P5&>,`'7Z#_P5<^%^E?V_>?$#Q!I'@#1QKVJ:?X5
MN;YYY7\3:=ITB6]UJ>$C(BA6Z\V/).-L88G!KNO#7[=GP]^(7B_P!I?A/4V\
M4P?$#5=2T:WOK.-XHM.N;&Q^VRK.DJI(-T17;A>=ZD94YKB/$?\`P2[\&_$'
MP1X7T_5]6US3[K0?AG>_#6?^R&BC@N(+]H);VZ`="?.::$LI/'[QMRDUJ?%[
M_@G3I?Q.\:6WB;2OB3\2?`/B>R\0/XCM]6\/R67VB&9])M])>(">"1/*:VMT
MR"N=S-@XP``?0]%-A0PP(A9I"BA2[?><@8R>V3U_&G4`'6LK3XW7QAJ1)3:;
M>W"J%`8']YG)QDCVR<=@,\ZO6L?3K)8_&^K3>6^][:U4R$#8X4RX`.`<C)SD
MGJ.!W`-BBBB@#S+]HKPKK/B;7_AA)H]O>7$6E>,(+[4C;OM$-JL,JL\G(RF6
M7CGMQ7IO>O-OV@O"^O>)M?\`AF^B174D.E^+8+W5##+Y82T6&569^1N7<5XY
M^E>D]ZR@K3E\OR/)P4;8W$RLU=QWV?NKX=/D]]0HHHK4]8*Q_'2/)X>_=E`_
MVJV/SH&&/.3/!5ATSCCKT(ZUL5A_$.R6_P#"YC>*29?M=J^V,`M\LZ$'!!&`
M0">.@X(ZT`;C?>-%*YRY^M)0`4444`%%%%`!2H<,/K24J-M8'WH`P_A\LB>'
M764H7%Y<_<15&/.;'`51G'4XR>Y/6MNL#X:V$>F^%VCBAE@4WUV^R0`-EIW)
M.`JC!)R..G<]:WZ`"BBB@`HHHH`****`.5A_Y/%^&W_8!U[_`-"L:^BJ^=8?
M^3Q?AM_V`=>_]"L:^BJ`"BBB@`HHHH`****`*^JZBNCZ7<W;I-(EK$TS)#&9
M)'"@DA5'+,<<`<DU\B_\%)O&^M_'7_@G'\0]<\%>)O'/PR70K.XNKUY-$DTW
M4]1BACW&V0W"J\,4A*AI8QOVAE5E))K["ZUA?$KX;:)\8/`.K>%_$EA'JF@Z
M[;/9W]I(S!;B)AAE)!!P?8T`>2?M^>+-2\(_L#^-[[2]5N=#O7T:*T_M.W?9
M-I\<[Q0RSHW\+)'([!NQ4'M7@_[-?@:T_99_;C^*?P5\'7>M7'PVT_PAH'BN
M"RU/5KG56T;4Y[B[M956>XDDE_TB*!)65FQNC)4#<:^O?&?[/O@_XB7&I-KN
MC1:K%K.@R>&;ZUN9I'M;K3W8L\+0EO+.23\VW?CC=BL+X)_L>?#W]GG1-2L?
M">BS6/\`;$T4U_=7%_<7U[>&%/+A62XN'>5DC3Y40MM09P!DY`/FS]FVXM?#
M'QL_:*UR_P!$&FZ?:^+Y'N/$TLRB&9%M+3,#+G<HCSG<1CYNM?0-Y*-.N[*"
M?=#/J,C16L;J0UPZH7*J.Y"`M]!5#QQ_P3M^$_Q$U77[O5M#U25O%,IGU>*'
M7K^VM]0D*+&6DBBF6,DJB`_+SM&:BNO^"<GPKO;BUEFL?%4LMB[26TC^+=6+
M0,RE"5/VC@E21QV)H`M'7[);W5[?[1'Y^@1)/J4?.ZQC=#(C2#^$%%9AGLII
M;?7;.ZTK2[Z.='L];,0T^9<E+TRKOC\L_P`6Y02/4"LW_AV;\(C=ZE/_`&3X
MD\[68TAU"3_A*]5W7J*A15D/VCY@$9E`/8D4L'_!-'X26NGZ?:1Z5XD2UTDQ
MFQB7Q9JH2T,:[(_+'VC"[5)`QT%`&NEY%)XB.D!LZF+9;PVNT^:(&<H)-O\`
M=+J5SZ@U0M/&ND7W@^#Q!#J-M)H5TRI#?JV;>4M+Y2@-T.9/D'OQ3$_X)N_"
MF/6O[273O$XU'R!:_:AXMU7SC$&+B/=]HSM#$G'3)-4K;_@EW\&K/PO#HD6@
MZ]%HULRM%8KXIU06\163S%(3[1@8D^8?[7-`'23`P:K'8NKK>31O-'`4.]T0
MJKL!Z`N@/^\/6O&_VS+K_A./V4_%CZ%>0RKI=_##>7"7`BCLWMKN,W"/(2`K
M(`=P)SVKU&7_`()U?"^;48[QK/Q6UW$CQI,?%^K&1%<J64'[1G!**3Z[1Z5B
M:S_P2M^#VH^%[_28M,\365IJ=RUY=+#XFU!UGF=P\DC)),Z,SL/F+*2>O7FH
MJQYH.*ZH\_-\*\5@:V&BKN<91WMNFM[.WK9V[,UO$^I/IWB[PI:F&Y/]MW5Q
M%"4BRIV6KRY)(R!A>,$9SSD5>BUFTGEU9$G1WT)MFI`9S8MY8EQ)_=/ELK\]
MB#5.;_@G-\++N>UFELO%3RV3,UL[>+M5+0$J4)7_`$CC*DCCL:AC_P"":?PC
MADU%ETOQ*C:RV^_(\6:KF]/EB+,G^D?,?+`7G^$`59Z!97QCI;:/HNH"^MS8
M^))(8=)GS^[U%YE+Q+$?XBZ@D8Z@5?MKE+S7;C3(CYFHVD44\]LJDRQ1REA&
MQ'8,4?![[36`O_!,+X.)I>DV8T3Q!]CT&2*73(/^$JU3R]/>)2L31+]HPA12
M0I'0&KMO_P`$X?A7:ZS-J,5AXICO[B*.&6Y7Q=JHED2,L44M]HR0I9L#MN/K
M0`S_`(6'H8\')XA_M6S_`+"DF%NFH;_]':0S>0$#],^=^[Q_>XK7=_+UDZ<0
MPOQ!]I-OM/F"+?LWX_N[N,^M<T?^"67P5/A9=#_X1[6_[&243K8_\)1JGV<2
M"7S@^S[1C/F_/G^]S6HW_!.GX7/J9O39^*_MAB\@S_\`"7:KYACW;]F?M&=N
M[G'K0`2>,M*AT'6=4>_MUTWP[)/#JER6_=6#P#,RR'^$H,;L],U=6_A>ZL8`
M_P"^U.%Y[2/!W7$:!69U'<`.I)_VA6&__!,#X.2Z/JNG-H>OM8:Z\TNI6Q\5
M:IY5^\PQ*TJ_:,.7`^8GKWJT/^";GPI6ZM)_[.\3B:PB:&V<>+=5W01L%#(I
M^T<`A5!`_NB@#0N;H26VK+%NDETN-Q=(BDM`WD^:%88X)1E8`]F'K7(?!3XE
MZ?XK^#?P\U62=[9O&VGPOI<5TBQ37LC0&;8JJ`I<1JS$*``%/%=#'_P3D^%D
M$EVZV/BI7OVW7)'BW5<W!V!,M_I'S?(H7GL`*H6O_!+SX,65EHMO#H6NQP>&
MSNTF-?%.J!=-.PQYA'VCY/D9EX[$B@#I8`;K5)K*-7DO+9(Y)854EXUDW>62
M.P;8^/\`=-94WC?1[;0K/5)-1M4TW4+Q-/MKHM^ZGN7E,*1*W=S("@'J,4MM
M_P`$Z_A=;ZA+=QVGBQ+J=4229?%^K;Y%0L4!/VC)"[FQZ;CZUG2_\$O/@S<:
M/;:<^A:\]C972WMO;'Q3JGEP3K(9%E5?M&`XD)8$=R30!O?VE`OB;^Q?,`U;
M[+]N^QX/G"#?Y?F[>NW?\N?6JFL^+]+\/>']3U:^OK>TTS1I6@O[J5ML5G(K
M*K*[?PD%E!SW85`?^";/PG.O_P!J_P!F^)_[3^S_`&/[7_PENJ^=Y&[?Y>[[
M1G;N^;'KS5;5/^"8/P<UO1=0TV\T37[K3M6D::^M9?%.J-%=NQ!9I%^T88DJ
MI)/<"@#:O-6MM.\0V.DW$RPZIJ<<TMI:.");E(@IE9%[A`ZD^FX4R77;."WU
M>5[B-8]`W?VFQSBPVQ"4^9_=Q&0_/8YJA=?\$U_A/?:W9ZE-IGB:74=.CDBM
M;I_%NJF6V60`2*C?:,J&"J#CKM'I39?^":'PCD@U.-M*\1F/6L_V@I\5ZKB^
MS&(CYG^D?/E`%Y[#%`%N7Q9IL5OH<K7UNL?B:1(=(<M\NI.\9E18O[Q,:LPQ
MV!-97AS7CJOQJ\5:"D-[Y^CZ;IUU(&A`3;.;G;@[=Q/[HY!)`XQCFI9/^"8O
MP=E@TB-M%\0-'H#K)I:GQ5JF-.98S&K1?Z1\A$9*@CL2*LV__!-[X46>KW.H
MQ:?XHCOKV..*XN%\6ZJ))TCW>6K-]HR0N]L`]-Q]:`);OQGI-AX5L]<FU"VC
MT;4)(8;:]9L0SO,XCB56Z$NY"CU)JTVKVR^+AH!F4:VUH;\6//GFW#^69=O7
M9O(7/J:Q9_\`@F!\&[OP[;:1)HFOR:58R12V]FWBG5#!`\3AXF5?M&`48!E/
M8@&K)_X)I_"4^)AK1TSQ,=76V-D+W_A+-5\\0%_,,6_[1G9O^;'3/-`'GO[3
MB/J4'PZUZUN88]#\,^,DO-8O6N!##:P0K-#+O)(W;9"%*C)SVXKU/4-9M=*U
M_3M+N9DM]2U@2FQMI,B6[$2AY=B]]BD$^@-<QXJ_X)3_``;\7Z1#IMWI/B1]
M,2[:\ELV\3:A)!<NS,[[U>9L;G8L2NUL]ZU;W_@FI\)=4UFPU&YTOQ+<:AI0
MD%E<R>+-5:6T$BA9-C?:,KN4`''4"HC&TF^YYV%PKIXJO7:^-QZWVBEM;3[W
MWZV-&VUJTO;+4[F*X22WT666"_E7.RSDB7=*KG^$JI!(/0&H[KQ-I]C::-/-
M>0Q0^(IXK72W8X&H2RQF2-(O[Q9%9@!U`-4;?_@FE\)+6SO[>/2O$L<&JR2S
M7L:^+-5"W;R+MD:0?:/F++P2>H%,N?\`@F1\(+RVTN&71_$4L6ARQSZ<C^*]
M5(L9(T,<;Q#[1\C*C,H(Z`D59Z)L:?J=OJVL:CI]M*MQ?:0T:7UO'DR6AD3?
M&''\.Y/F'J*Y#XR_$*U\+_"*V\21&>ZTV\U/2K>WN+6)91+]JO8849=RE2I+
MC)QG'((.#6Y8_P#!-;X3:7JE_?6^F^)H+S5&1KV=/%NJK)=E%V(7/VC+;5X&
M>@JO<?\`!,3X.77ARWT>31O$+Z3:-$T%FWBK5#!"8F#Q;5^T8!1E#+Z$#%`&
MTNK6L_C&YT".='UJSMDO9[%<F>*!W9$E9>H5F1@#W*FH4\26#^'+C5Q=1'2[
M-I4GN\_NH6B<QR!FZ`JX*GT(JE#_`,$U/A+!XFGUE-,\2IJ]U;I:37H\6:K]
MHEA1F=(V?[1DJK,Q`Z`L342_\$R?A!'H<^EKH_B(:;=-(TUJ/%6J^3*9&+N6
M7[1@[F)8^I-`&O>:S:Z?XLM-!GG2+6K^WFN[:Q;(GGAB95ED5>I5"Z`GL6'K
M46E^)M/UNWU:6SO(;J/0;F6SU)HSN%C-$H>2.3^ZRJ02#T!JE<_\$T_A)>^(
M[76)=+\2RZM9026UO>MXLU4SP12%3)&K_:,A6**2!U*CTIFG?\$R?A!I$&IQ
MVNC^(K:/6IY+K4%B\5:HHO99%"R22?Z1\S,H`)/4"@#1N?$EA9W&C12W<4<G
MB(E=+5C@Z@1$9B(O[V(@7X[#-.T_7K/5M<U73+6YCN-0T+RO[1MH\F2Q\U/,
MC\P?P[D!89Z@5F2_\$ROA#<3Z5+)H_B)Y-");36;Q7JI.GDQF(F+_2/D_=DI
MQ_"<4ZQ_X)H?"/3-7U+4+?2?$D%_K'E_;[E/%FJB6]\M=D?F-]HRVU25&>@X
MH`GMO'.CWGAK2-9BU*TDTGQ!+#!IEXKYAOY)B1$L;=&+D$`#KBKMOJUK<>,3
MH"SH=:2T2_>QY\]+=G,:S%>NPNI7/J#6';?\$N?@Q9^'=+TB+0-=BTO1)(IM
M.LU\4:H(+%XB3$T:_:,*4))!'3-64_X)J_"2+Q0VM#2_$HUB2U6R>]'BO5?/
M:W5RZQ%_M&=@<E@.F230!SGP&^)=GXU^$D_B%C<VMA#KVI:6\MW$L062'4)+
M7'RJ%P9`%4XR<C)).:[6^UBUTSQ-9:-<3)#J^I133VEF^1-<QP[1*Z+U(3>F
MX]MP]:Q;+_@F!\&M,T)]*M]$\00:;-<-=O:Q^*=4$+S-+Y[2%?M&-QE^<GKN
MYZU8N_\`@FO\);_Q!9ZK/IGB6;5-/CEAM;M_%FJF>W27;YJHWVC(#[$W`==H
MSTH`LQ>,=*GLM<N4O[9H/#$SV^KR!OETR1$$CI*?X"J,K$'L15Z\NX]/O+"W
MG;R9]4=HK.-P0URRH9"$'<A%+?0$U@)_P2^^#<=KK$`T/7UA\0RO/JB#Q5JF
MW4I'0(SS#[1\Y*JJDGJ`!5RZ_P""<'PKO;FSFFL/%,LNG.9+1V\6ZJ3;,R&,
ME#]H^4E"5..Q(H`G;Q7IJZMK-B;ZW^V>';>.[U6'=\^GPNC.DDH_A5E1V!/9
M33[7Q%8WNA:7JD5U%)INMF`:?<J<Q7IG&8?+/\6\'Y?6LM_^"8?P>?4M4O#H
MOB$W6NP):ZE,?%6J;[^%%9$CE/VC+J%9E`/0,1WI]M_P3,^$5GI&G:?#I'B.
M*QT@PFQMU\5ZJ(K,P\1>6OVC"[/X<=.U`&NNHPOXE.C"0'5EM5OC9X/G"!G,
M8EV]=I<%<^HK-MOB'H5YX'A\30ZM92^'KEUCBU)),VTC--Y`4/T),OR?[W%*
MO_!-SX4)KQU4:=XH_M,VXLS=CQ;JOG&$.7$6[[1G8&);'3))K.M_^"5_P4M/
M"$7A^+P[KD6A6[B2+3U\3ZH+:-A)YH8)]HP")/G_`-[F@![6LMI^V/\`#82Q
M21G^PM>'S*1SNL:^AJ\O^&'['_@3X1>.D\3:/8ZN^M1VLMG%<ZAK=[J!ABE9
M&D"">5PNXHF2!D[:]/!H`6BBB@`HHHH`****`"BBB@`KYW_;4\/V'Q%^,OP.
M\'Z_>7</A7Q!XBOI+^TBOY+--6FM]-N);:VD9&5G3>#)Y><,81D$#%?1%<3\
M>OV=O!W[3?@4^'/&^BPZWI0N([R%3+)!/9W$>?+G@FB99895R</&RL`2,X)H
M`^+O@Q\=_&O@O_@D+^T/J6C:OJ>H:O\`#B]\>:9X'U.:5KN[ELM/GNELY$=L
MM-Y&/+5OFR(%R35K]DK1K/X&_MU_"#PUX%\1:UK7AKQ]\%9=?\217.LSZI%=
MW$%Q9"TU9C([A99_M%RI=<"3;WV<?7_AS]EWP!X2C\*)IOA;2[.+P/IUSI.A
MQ1(1%86MPJ+/&$SM;S!&NXN"6.23DDG-_9[_`&+_`(7_`+*=[K%Q\/?!ND^&
M)]=9?M<EL&9C&N2D$9<L8K="S%((]L2%FVJ,F@#U"BBB@`HHHH`*;(,H<=>W
M%.HH`_._X"^#-5?XB?MV^$?'7QP\8Z?8V^HZ/)<^-);Z"PG\.VT^CQSS?9=P
M,%I$BL47:,@#<27^:O7/^":FFF]UCX@>*]$\.Z_X(^%VL36-AX3TS6[V:6ZU
M=+='636C',[-;I=[T6-<@R)`DK`-)BO9O'_[&OPQ^*6C?$#3]?\`!^EZE9?%
M3[-_PEL4A<#7?L\:1P^;A@?E2-%&,<+S6)\&_P#@GA\&OV?]&U?3_"'@>ST:
MSUZ>SN=0B2[N91<R6DHFMV/F2-C9(`PQC..<B@#X^\9>*]=T7QIX7^)%G=ZL
MGQ&U+]I9O!%U`+Z8BYT/S9[4V)@+&/RELHTN?N<%!)GDD_I57FMO^R%\.K7]
MH2;XIIX9M?\`A.IHO+;43+*R!M@B,RP%O)6<Q*(S,$$A0;"VWBO21P*`%HHH
MH`***1AN%`'P9_P4+^'VF_$?XY7O@_P)K7C&\^.OC5]*:SU6SU"X73_A/IUN
MZN^H2^6RQ0^8$F*1N"]U(X0_N\[>&^-G[6FLZ_\`\%7?@7_;7B/5_#GA70/&
M>N^%;/P]#87L8UM5T>8-J=X1&$DWW2A8(TW(D8,I/S_)]9_&G_@F'\"?VB/B
M??>,_&7P^L-:\3ZF(%NK]KVZA>X$"[(MPCE53M48'%>J^(?A#X<\6>*/"VM:
MCI5M=ZKX*FEN-#N7+;]-DE@>WD9.>K0NZ'.>&-`'RU^UII]I\</^"E7PB^&W
MBO5;^+X=7/@CQ'KPT^VU2:P@UK58)K*`*\D3HTC6]O-/($W?*27Q\H(])_X)
M9^+-0\;?L#?#B_U+6;SQ%-]CGM8=5NYS//J5M#=S0VT[R?\`+0O!'$V_G=G.
M3FMOQU_P3W^#GQ*^&\/A/6O`VFW>AVVK76N6\0FGBFMKRZD>2YECG1Q*GG&2
M0.JN%9792"IQ7JGA+PCI?@'PSI^BZ)IUCI&CZ3;I:65C9P+!;VD**%2.-%`5
M550``!@8H`TJ***`"FOR/QIU(PR*`/SD_:^T)/A[\>-)^(_A/QO=^(;#3OBY
MI<?CK68_&#R:QX59I;6UA\.VFF+M@:UE\U/-CD;S0EP\@65MI7S7]A'QSX^\
M4^+/@K\5/'D43W_Q`^*/B/1;VZM/%MT-9@G!U&..SN+%@;=K&-+8)]F"J]OY
M,4NXEG%?H7KO["7PC\3?'ZW^*%]X#T*Y\<6TL=PNHM&V)+B,;8KJ2$'R9+F-
M?E2=T,J#`5@`*L:'^Q/\+/#?QYN_B;9>#-)M_&MX97;4%W[8Y95VS7$<.[RH
MKB5?EDF1%DD'#,10!\^_M6Z1!\:OVP_&_A[Q5=7T/A/PC\'G\1:$;?4IK*..
M_EN[E+B]5XG3,D*V]L`V3L$AZ;^?IG]EKQ3J_CC]F7X=ZUKZR+KNK^&=.O=1
M$@PPN)+6-Y,CUWDUS7Q*_8&^$OQ>\)^%]"\0>#[:]TKP8IBTFW2[N(!#"=NZ
MW<QR*9H'VINBE+1MM7<IP*]>@A6VA2-%5$10JJHP%`Z`"@!]%%%`!1110!F>
M-?%,'@;P=JVM74-Y<6VD6<U[-%:0-/<2I&A<K'&OS.Y"X"CDD@"OS9\`_M):
MCKOB;]H+Q)XC^(OBP>(?%WP@37HM)M-/NK:V\"B/^T%6ULDF2,>=&AC:69V!
MDF+$%50!?TX/(K`UGX6>'_$.L:G?W^DV5]=:UI8T6_-Q'YB7ED&D86[H<JR9
MFEX(YWF@#X7_`."75SXK^$G[9/CKP-X_AM/!VK7/@#0-=M?#&C>)9_$6@>2L
MLUK)J/VNXQ)'>32_(T6P*ZQHX>5BS#SSQ/K%P;3QA\5_^$MU\?%;2/VFK7PG
M8Q+K4X":<-3MK)-&%H'\HP26$CRE/+RV\RYR`P^WO!'_``3E^"WPZ^'VL^%]
M)\!Z=!H_B"XM;G4$DN+B>:Z-K*LMJC3R2-+Y4+HOEQ!_+0#"J`2#LWO[$OPK
MU']H.+XJ3>"=%D\>PD2+JA1N9E3RUN3%GRC<+&3&LY3S50E0P7B@#U,<"EI%
M&T4M`!1110`5X!_P52^+?BGX#_\`!.?XS>,/!/VA?%6@>%;RYTZ6W7,MM)LQ
MYR\'!C4LX.,#9D\5[_5?5-+M]:T^>TNX(+JTNHFAG@FC$D<R,"&5E/#*02"#
MP0:`/S-?1/$'PBGN_!.IP66G6GC6W\"?VC<^'O%-_=VLVEW6K?9KJ2<RMNAN
M7_U37,;@7$<A.%9*^H?V)))?`OQR_:`\#:>)U\%^$/$NGCP]'-<23);276E6
M]Q=6L;NQ.U96W[`?E,Q``&!79>!?^">_P=^''P]\6>%=*\$6":%XXC$&M07%
MQ/=/>0J"(H1)*[21Q1`GRD1E6+^`*:W_`(;?LE?#_P"$G@31?#>A>'TMM*\/
MZI_;EF);J>YG^WG<#=232.TLTI#L"TC,2,#H!@`^#OV<-2N?`GCC]C7Q=X>\
M1Z[J_BCXRZKXA@\="?5I[M=:A-I<W-P\L3.RI]CNXH8TVJHBW>7QNQ7Z<UY;
M\+OV*OA;\%OBUK7CGPOX-TK1_$^OF5KJ[AWE8S*_F3F&(L8[<S/AY?)5/-8!
MGW$9KU*@`HHHH`^+_P#@KCX!T?QP?AUX=TW1KR_^*'Q2UI/!F@W\6KW]K'H%
MF4EN;[4FBMYD20VUO'+(N\$&0Q`G;Q7&?MI?`JPD\?Z/\,_AQX@\=W?Q:U:V
MT2ST;54U*>2S^$^DV#*7U&XD#!=\ZQS82<N]U*P0_NP=OW)X@^&&@^*O&_A_
MQ)J.F6UWKGA7[0=(O'!\RP-Q&(IMG./G0!3GM7DGQE_X)B_`K]H/XI7OC;QA
M\/[#6O%.I"W%UJ#WMU"\_D*%AW".55^11@<>OK0!A_M]6=GX]\<_`SP=J^KW
M5CX4\3>.C;:Q':Z@]F-3:'3;RXM[*62-E;;)-'&3'GY]@&"#BLC_`(),>([^
M^^'/Q9\/MJFH:WX9\"?%+7O#GA:]O+Q[QVTR)XG2$3N6:58)I)X%8LQ`AVDY
M6O7?'W[&7PR^)_A+Q)H>N^$K"_T[Q;JD>MZFK22K))?QI'''=QR*P>&9%BC"
MR1,K#;P>376_"CX2>&_@9X!TWPMX1T6P\/\`A[1XO)L[&SBV10C)8GU+,Q+,
MQ)9F8DDDDT`='1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%>(_MX?M$>-?V4_@7KOC_`,,>$-`\7:3X
M1TF]UK6X;_7'TR:."WB\W$&V"42.P5QAB@&!R<\>W5Y3^W3\'-7_`&A_V,?B
MGX#\/FT&N>,?"VHZ/IYNI#'!Y\]N\:;V`)"[F&3@T`>?^`?VYM1T.^TP_%J+
MX9?#RUU'PQ-XL*1>+I;R[AL4>V03F-[6)?*#7`5WW_(Q08;=E=VQ_P""GOP!
MU">TBC^*7A@27NI+I"))(\3)<N4$:R!E!B5S(@1WVHY8;6->&?M;?\$Z_'WQ
MP\7>'[K2_P#A'FM-.^#UUX&N5NKHKNOY+_2[@`#8<Q>7:39;U*C'/$W[6G_!
M/+Q[\9S^U1)H@\/>9\8D\&KH!N+DQG&E2(UR)R$.P<-LQG.>U`'TK:_MJ_"J
M]^,Y^'T7CC0W\7BX-G]@$APUP!DVXEQY1G`ZQ!]XP?EXJQ\3_P!HK3OA_P#&
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MV9N"!Y.,9&=PYKY6^!G_``3>^(?P[^`OQ,\.Z@WATZEXM^'?A?PO8F&Z9D^U
MZ=;W,=QO;9Q'NE7:<<\\"OH[]L_]FZ3]INP^'&FR:;H>L:-X?\<6.O:S9:M$
MLMO<V<,-RCKY;JRNVZ5"%88XSGB@#(M_^"B'@9?VA?&GA.XUCPY%X7\$>#[+
MQ9J'BE-:AELX1<75Q;^0^W(1E\@$9;+>8`!TSVOPZ_;'^&7Q9\-:=J_A_P`8
M:7?V.K:P/#]JQWPR2:@4:06ICD5760HC,`RC*C(XKY0_:<_X)'W/CSXQ>-=7
M^'.D>`O!&CW.A^%[O1K.UL([2TU#6=&UF?4?)O((44&"56CC,G+#(.#L`.SX
M@_9F^-?C"PU;XN7'A'PE8_%.7QGHOB6U\"IXF:33Y+;3;2:R$+ZG]G`$\J74
MTF\0%5\N),'EJ`/HWXA_MN?"GX5P6[Z_XWT?3_MFL7'A^!27D>:_@95FMU1%
M+%XRR[N.,Y)Q3OV8?VCF^/,'C/3]1TAO#_BCX?>)+GPWK6GF;SD#HJ307$3D
M*6AGMIH95)4$;V4\J37CG[-7[*'Q'\._$_PEXO\`&EKX7L]0M_$GBW7]3M=,
MO7N8K,:KY!@BB=T4R%-C*[87.,@8.!TW[#KWOCSXS?'_`.(,FGW.FZ/XG\8Q
M:3HPN(6ADO;?2[*&R>Z*,`P#W"3A<CYDC5AP10!](4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
=%%`!1110`4444`%%%%`!1110`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>table8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 table8.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$Y`5D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_**_,?\`
MX.VM,GUC_@D5>6]NBO(_B_2,!ON_>EZU_+A:6KIISIY"6LVDHS2LQW&X<MQ@
M^@']*`/[QZ*_A)LH)H])@DDCMKF0!PY$F`ON<=SZU4U"[74=4B6=UF\F%6.Q
M0-DAX&3W4#K0!_>#17\%U_!YEROE%&=1Y85%P1SR<],5OPW#6=E=+.=WV&U"
MVRJ!F-V;J!ZC\^:`/[LJ*_AK^#/P4U7XY>()]#\.Z1>Z_JD-NVHK:6S(AM(D
MQYDK.[*@7E<DGN*S_$'@#Q3\)=<UBPU73;RRU/169M7L[J(*UL@9`.2><[TQ
MM)R&!&1S0!_=)17\'"3S_8/.MU-O<M,([A8HF5RK-_JS[DX_2M+5=!?P_P",
M9[75;.?1+R*1[:XLKI'#V]PI*LC*1E6]CS0!_=K17\2E]^P'\8O#UUX<L%^'
MNM6=SX@5TACE\J03$1FX9G/F8BQ"I?$A4[5)[&J<O['?Q7O3YMIX!U_5-'N-
M7.EQ/:VVZVO;I7*;$V$C;YBNGF#Y-RL-V10!_;O17\*_CSPEKOPE\0:OX;UC
M2[OPYKFE@R2V%S]Z#>`RA>H(*D$$$@@@@\USEKI]S8V+(?(N(9T$S22J=R`\
M'G_&@#^\NBOX+9-(_P"$5_T:Z>)S<@-$P!R!GGD>M6XXX(+F7SKI;5Y8C&5$
M9^0=ASQGWH`_O'HK^$/7_L&AI8M;1"5U"^=N`+R2$<E>^,=^U9]Q,C:D+189
M/-?'E!SD$GG#>U`']YE%?@S_`,&7UF;7X5?M(C)^8:/E<8V/Y>H9'\J_';6[
MN^T^[MU>$ZA=W1-N=@'`4YV9Z`\4`?VWT5_$)>>'?^$EGLX'@DLM+>YWJ[D"
M6$+R4Y^AY]ZL:3)_8E[J2)-;:?;3KYEL@4EI<?=!_+D>]`']N=%?P[>&==L]
M1LH[Z_11>M(T9$2;?-;G!(Z$`=J[/X6>#?$GQCU:;P]X4\/W_B646[7UU969
MC3[-&K*/-?>RH$#.@Z]6`[T`?VK45_$E\0--\0?"K5YO#>N6=S:ZM;R?9[VR
MECV&RD7.0W;=TX[YR.*3P+\,O%?C+^PM,TG0-5GA\874NG:;%9QY74;R/:SQ
M@MA=X#IN&>`PSB@#^VZBOXS_`!7^R;\0-*\,ZQ!K'@C5[%M`TU+W4[B"YA2&
M*W?>8W$F_8^[RY!B,L<QL.H(JMIW["7Q8U#QE!IX^&.O2`:3_:5O%#&5_P!%
M&T%G&?\`6;F4>6?WFY@-N2!0!_9S17\/^D>$M6USQ@(QIR7%S?%8HK'=M<R.
MP6-&7J7)P`*ZWXI?!#Q9^SVVFZ?XC\-:UH%QJ6\1&=4<S$$B5$D1G4[.C+G*
M\9`R*`/[4Z*_B3\":0NN:/;VNEP:C>7\UUY`L8E+//YC?(J)C+%R0`.]=%X]
M_85^*/A?Q-KEG-\.O%\5MX?L4U+491;;4TV!@Q7!!*O_`*N0D(6(V/D#:V`#
M^TJBOX:[2W7SYX3&^QI./GX8=]PSSQ5[P_90Q:/-%#&K"2-R-D>/*V<E5)Y;
MZT`?W#45_#BB8L!K)11=OBWC\V$YME`YP*BU6-M0F>QDN%GM7:.":X3(DD7K
MA3Z9/3KQ0!_<G17\A/\`P2#@^P?\%._@%86QGO4L_&^F"XGDQ@DSKMVCV_2O
MZ]J`"BBB@`HHHH`****`/S)_X.UX/M/_``2'OT-PEJA\6Z3O=VVC;NER,U_+
M;+8I.[QPS2R232J(@YYD3MGV-?U%_P#!W3:M>_\`!'S4HU[^+=)SD=!NEK^6
ME6C$R8A8O$VQ?+?YBW1<GT%`%JXG6WT86Z%H;FT=A)\AQ+&#Q@_6BXT@:U&E
M_'<06%Q<C>ML">@/;ZU8OK.2!8HUN%WL&\UY?F1W8_*JU6M+V[74+)=]O=?8
M9'B4QXRI_O`GM0`J7/VS2;K>=EREPK_9Q'MWJ.IS]1FH[J.Z61[A[G,'$O"_
MWO0^O%2/<-=O;FS=EF8L96W9VCOGVI]W(VHZ?'86[6RV]QPKE\E-N=S'Z]J`
M.Z_9S_:*?]FC7O$&JKIVD>(YO$7AV?14CU*SAO+&)YGB;=)!,C1RA1&1M(ZL
M#VKVOX<?\%*;S25T;_A*M*A\43Z<UU-+9L(;>PFD>]LKB&1(DBVQB*"T\A`%
MPJD`#:"I^4Y)[I;"UTQ;07#V4OF`^6>2>@!_STJY<:)>20[KQ&B>:56?8I61
M8^^/;/\`.@#Z'_:E_;PD^+WAC1_"OAZWUVWL;/4(+Z;6=2U**>_\1&"(")[V
M2*-`TB29P<8"J@Y(S6M^V%_P4%MOVB/A1XHM(_#_`(E2[\0ZFTADOM5@N+*V
M8WK7IN@BQ+(;WYC;^9NVF%0,9XKQ+P%^S=XF^-(^S>%=`UFYMD4QK=&/;$XR
M<_49KLX_V"OB"MW%!)I]Q]EEVI=I$"RPLH.,MV]..>:`.UUC_@J)JGB#XX_;
MYX)?#GA;4(\2CPI:Z?I^JJ[68ME:>Y-NRW;JA<$S`G;*X!!.:T]*_;[^'_AO
MQ'_;/A[PKXIT/6;W69+G6H[;4[.32]4L&ED(T]8WA)CMPLC,8@/+DE=F88VA
M?&X_V&?'D%W(!I#^1$Q\]63+*,_*I^N!S5C1_P!@OQ]+J%I;/X0U%7OF\U9Y
M(SLB0'N.ZD_CB@#&_:O_`&CK?X[_`!X'B>U\/P:!I]KIMIHEEI<<:(EK;6D"
M01`^6JIDJF<*`HS@9QFO.+?6!'93R.7_`'XP44$A$!X/\J^P_#O_``2+\>^(
MXS+JD<,+B0M+$X*@)MZICD^PIFM?\$9?'>B/'Y5PE_\`:8P(Y?X(<MPS#T`[
M4`?*LOB&"_M1%<VT2SF,/;2^6=J]\D>GI5+[<=3@A-W<VUTL<18`+M=6R>OJ
M*^Z-)_X(WZ_K;64=YXAA+V\(240QD$*,@Y!Z#-=9=?\`!&OP[-J;K:WMO;K;
M6"J<Y_>R+RS#/=NE`'YU!5@32SY42W'*;7/RR*PR#39GN=*A1(PZ;)!-))MW
ME%Y`9CU'%?>`_P""0+^-$BN5+0O"A`$*$Q)CA1S]XU'IG_!&/6ID1K*\NI);
MAB+@N2`4)Z%?Z4`??7_!F!&)OAG^TK=I+N%T='."V2"(]0YQVSZ5^/FE:I);
M^?Y>4WS2/+,PRKN/0^Y`!^M?T/\`_!O#^Q1)^QYX$^,YDEMV_P"$CATYQ#"<
MB'R8[P;?_'Z_G*\0SSWWB233IE^RV\<37(CB?"1AB3G'4MTS0!)#+)/J,5W>
MSQ?:_,:5@6R(57D8'IU%-FT>Y\6Z].]Q:P6NEP',F9,'9CDIW!/852CTK^QF
MVVL<DZB".X,VW"RXZ#G\0<4[1KMKC4?M=S'>?9)Y'+1H.,%<`8_AYH`VK.[M
M-4TZ)=/@@,*$",RC88PO'/HQKJO@O\:9OV?;SQ?=6&BZ/K</B+29-$@&HV,%
M[;6[M<6\Q=[>X1TE&(&'(ZL".E>?WNL0ZM9K`)W<(ZRRQ[-I?'168=CBEN;@
MWFCPW\-W/832N&-JL8/VCDX`ST(Q0!]5?"7_`(*50:=I]E-K6CWVI>);>[-Y
M,HEM/[*NMEXMR;P6CP$+=JBBW0_ZM8@%`&!5GQC_`,%&-#U;XF>%M<T;POJ%
MMH_A[Q1?^)X].N-16]MKC[596\$B-%*K?/YD!<C+)MD*U\7P:G/9F6V,4J7"
M+OGDP!(ZL3M`;I@9Z5HVVMWUY+;Z=]G>)MI<S;0@4+CC/?CL*`/H#P5^W%?Z
MAX?U;2]>M+O6;66U$5EH6B0:?I>@QQ;)U5)K);?&U&N'E!A*-YA8D\Y'6?"G
M_@HAX#^$7CB!-$\)>+]1\,6MK'<QZ%K][8W;7FKPW45PM_(YA+23/*AW3-\Z
M@J$^5=M?*[ZG+J\EQ+8":6.'-N\R((U!/W6R.2`>IJ?PWX6@\::T5NXYHM0C
MC"VSVO&\CJ<]0!UYZYH`[-OCE+:ZMHGB:XT70'O]$\5?VO?SP6/DW]^[3B9K
M=IRQW(O*H-OR^]?1GP+_`."CW@+X%?$>TC\-?#;Q?<Z!<:O=Z_LOM8@%S_:%
MU+;M(IV1K']G$4'EE6!+&3<0=H%?(>K7VC^$;Q]!O8+W6)IY3++)&W$,G<>_
M:DL+&UMI;::XNV2WC#RN4E.4)/&3WQTQ0![Y\:?VD=%^)4?@I[2TFAOK35'U
M+Q=<:4S:?<!(9Y$LK2*1D`\RVM'9/-52A=U(SMKK](_X*A>&O#5WKMMX3\#Z
M_J^BV$"IX9T[6KBRN(O#<PANH&G4B+?@K<L[.K>9(V_<?F!7Y5L[>]N9;P6L
MW]J,Y`M"21F,C@-BIO#GAR73/#,MQ<VJV8D:0R2`?,S#C:H[YP>*`([#P_I5
MY'%9RRRVUX)3Y%T6P,XSCW!QC%9G]M2:OK-C8B9M'MH&=+>YF4C>_3`]C4]]
M=_;K#RKK$<DSAK9<X/"\[O3/.*A@\-ZAJJVBM;/]H@,BH[DR+&Q&1CU/I0`L
M/C*XO&&GM!(;ZPE,:^>N`R\Y=O8]:F\/>$Y]=L9M0@C=19$SRNWRJQ/<+^'%
M6M#TKQ0Z"UM-#U::UN6V7=XUIND4XX&>N!V[5)#X+O\`X?SP_P!L7=XE]J3[
MHT"MY:H.A8=/PH`^B?\`@D#H;C_@IQ\"-0=DACE\<:6RB23:[9G7Y57Z]:_K
MSK^0G_@DGX?N(/\`@JY\"&/VK6_^*UTR4OY)5(!YZDNO'`'>OZ]J`"BBB@`H
MHHH`****`/CG_@NE^S1%^UI^P7>^#I[P6,%QK5G<23$_=">9_C7X7ZI_P1:\
M):1H<:#6+V2[+[96/&]\8)%?T$?\%3I9(?V3;QHK@VS?VC;_`#`<M]_C\:_-
M`S_VYHMJVI2S2SNV8HP`F1C@#U)H`^$?%?\`P0TB\1Z#'_9^N7%M)*X"SS8"
MP>AQW-6-!_X-]9I=:*7/B\-:QVZ(_EQA/.QR/F[$U]Q:5ID44#)*TK1V9\P6
MSS85&]QU.*ZGQ'K0U?P_8VNE"8SH`]Q_"@YYQ_>IV*Y7=JQ\8>%/^")W@KP1
MY,=Y+=R%79;L7$H(D!X^\*].^&'_``2>^!OP\@6ZN].MKFZ,F^W9Y,HR9[@]
M37M-D//GN7UG48=CL(PBKU0]R/45SEWX?L=.\6B\M8;V_P!/5]]JK_=?'7(S
MT]J+65V7*C424I1:3\C+N/V/O!%AI=Q>VWAS3I%D1@8EM5*H!W!QZ8K/^$G_
M``3U\!>-M7L%N=&L##.K&:5PI:90<[?P]*[7P/J%PGB"[$UU?+:N^P1@9^S[
MB<8'I[5:O533-1M+6`WUS%;3.A4'R]P;MCUR<YI:6,O,U'^$OAC]GW3)4TA+
M.'3&N1#';1!0ROT+'`XKDO$NA0>+O&-M:8D"73%8O)7:I9C@-QWS79^#_![V
MFKK':076MRF0".Q9/-E9F/0*,G(KU#1/V3;GP^XUOQ)%9_#U&)-L->U2.*1"
M2.D"[I3_`-\B@.IXOXN^$D'PBN;2POH`^I-&%9`PDC9NQ<]^*ZJUU31?"4UH
MFJV\?F2[(+=XAF.88Z`]B*]!\9?"[X6ZMXUBOKGXLW1NT@V1K9:'/*C/C!;+
ME0PJ]J?PO^$?BC1;2>X^(M[:163JS3W.@30*S#@G*L<?E5<K-EAJUHOE>NVC
MU]#R+XC_`!6T?4-2E_L2#;/;*(DD(W;FZ'Y3V%4-#FU/6;:#S+:1Y+G*?*N%
M0>O'YUZSXY_907Q=9K'X!U_P/XCE9O/CCM;]8K^X0C.%CFV%B1_=S7`_$/Q!
MXH^%&LPZ3-X?D\.2V=L(Y([R)HY\>HSP<^U23[&HK\RVW\CFH-4AT^^U%;DK
MYIW1"-3M\S)X/3IQ7-VNEVLNL6=\9F>>%G\Z,8V(G9#_`+7UK3\+.VM7\NH7
M\<BRF0SJJ)\C`?>4`]<UJ3_$72FUAA8^'K.RMI@(KD8/F-_M@D\DT:&?F03^
M-9O#=]#,UM;P:<%83Q!1^Y4GAA_M&K6A?$:U\.:G/<W2!]+O$)$*G,D@;I[\
M5'I=O:R7U[->6K);7:%0!\[2KT"X]1658Z!HJZKJ-O*+B22-4%O\A#$'DC/M
M0!]Q_P#!*7Q5'X@\,?%.*")XX[*.V5"PP7!2X(-?RO6-_<ZOJMUYEK+%K#[Q
M(R1EF,(;^+@XSBOZCO\`@C%:21^%_B;:3;R?]$P67&`RW.!^%?"GP?\`V5?A
MY\$H_$(MM!L+B]N8#;W%[<_OC.Q/`'<4`?C?#\+/%_Q`NX;1]%U=M/A0O&]M
M`R)&G9F_&NL\,?LP?$?5#I^GQZ7-Y3`B19XRAE4D8'/?%?L#>>&=&M[8V2:<
MUH+FW4(@4!G8'IT_2J%E\*M=\>^-=.TOPYH6I:A>VZ9\NTMC</@GC)48'N3T
MH`_)C2?V'/B58ZU+)#X<;S+^810),<+;1@@Y^N<UZ"?^"=GC6[UNRO;F1+BT
MC)>.+:4R_'(]1G-?K_:?LB77AH1GQAXG\!^#;J,,3;WFI_:KU<CJ8;<.P(]"
M12:MX(^%?A_P6MK+\73!<3*9$O(O",\B0(AP2!(ZGKW[U4(N3LCT,MRZKC:Z
MH4EKJV[-V2ZVBF_P/R&3_@F7XO\`%FMW%Q!>VRS2.-UM%'E7(X.3VXKV+X=?
M\$:(]4\'7-QXI\37MH;U6>SMTA&^%UQA?I[U]OZ/\#/`T>BO=>&_V@;.TCEE
M:5Y-:\)744$C'@G=&SXY]JW?#7[+'Q&U_1=2O=+\4^&OB?I*1@V__"*WL=Q<
MDCKF!MLR@=_EJW2M&]SU*_#RI4*E:5>-Z>\;23^5XI:[VO<^##_P2^\,>#;N
MRT^UOKV=;H&"=)#\NXGDD],UW'A[_@EU\/\`PQKJ3B.>:6W7:J13G?<XZ_4_
MTKU?Q/HVH>`+LPZKJ9_MF%/.ETUH&26,;L;\$9SVP14&F^*-/E:XU*7761Y8
M76Q)0C8PZ@#U%2H2;V/-P^38ZNU&A2E)NUK+OM]YYSXA_8B\(:3\.?M]CH<4
M!^W'S7(!FQG&U3U8GO\`6N:\,?\`!-_P)XFU9;B^M_LT:,S)9QGYXI"?O,/2
MO:;CQ1I<VEZ-$NL.DT\PD3DE2?5C_"2?6K7B74;?2?$$H2YCEN[H)',%7_4*
M.K,5Z]:4H2CJQ8[*<;@K?6Z4H7VNK7,GPE^RQX*^&NBO;QZ3I?GSH52?8#E!
MTY[5B:A^RGH.KQ6@ATG3ETMYS-"\R@LYZ,1[>E=5XDN[>&**"POY+ZS>/$DD
M2?(AS]TD\\UM:AX9U#0]+@2:_B>YE`%G:LW^H0CEMW0=:D\X\UN_V+_!$.G2
M_9].TF5IV\VW>2/.=O;/KFK7@K]E3P98ZJSE+:3400AMI`$AE/M7H6K_``MU
M.+P7I>U%6UMT%PKQ7`+J6.-S?[)KD[/7(8_$T:W$+2VUO,$D9$_=S'N-U`%S
MQW\&M/@U&YTWPQ;6YOKB!6+18VHV.1GZ5B:W\$+"\T?0WN;+3;I(45+E2JDK
M(.VX]Z]'T_QIX;M_&VKRFQN?(DA"VRQ-L(DV]/<5P.N^';R^LXK6"Y^T?:9/
MM,<;G8MNF?O,>YS0!Z]^Q7\!M.TG]KKX:W^CV]G:/9Z_:2/Y:*"$$JEEW"OV
MXK\:/V"O"5GX;_:/\!+<>($DU";7+9H[;<"P`D7*$5^R]`!1110`4444`%%%
M%`'RW_P6"\71^"?V,[V_EB\Y%U6U0IZYWBOR(M/CGJ6MVABM-.4/:L)(B&R`
M<X&?I7ZL_P#!<77++P_^PS-/J$T,%N=>L4W2G"L27POU-?D?JGQP\.?#F&RL
M[*"!3J`5IE0?.A?M],4&M"K[*K&HDG9WUV^9)8?'*\T#4=:@BE;4[R\N.)&'
M,8Q_".@&<BH[3XXZU9^,[1[VX:ZACMC&;>/A`,YR/]KWH\+^)[/P:MY?7NGZ
M5<//=?:8MW5E(PHSTQ45I=Z9K&M/?W&GV]E;V]I(/+)QND)R,5W^T@ZLGY'Z
ME7SS!RS/&R]SEJ4M'9;V6D>P:I\3;+QMXFDN;^UNYR0L:K#,T:!%')(R,DYK
M?T3X_P!IH*+IL<D4$%J\9MVF)8;6/*Y/3WS7+ZU?V5CHUM9K<:;<G4F&%9S%
M+;$]5P.H'K6#KWPD34HPEM*MX(D"2FW?+(OJ0>]14DG325K^1'%N8X7%9123
ME%2CRJ$82;TMJY)KW6CVVV_:LT:!]6#!X6LP3&(4^6\`QMY[9-=1^R_JM[\=
MM:UC6M4>T\.>!_#"1W.K>([LEX[21S\MO&O!EN)!PL:\]S@5\X^!_A+JOB_Q
M/IGAW3HD;4=9OTTJT1OO&9V5%!'U8?K7JW[47Q:L='\<6'PG\),C?#OX7W#:
M:?)8!M;U$$"]U%_[SM(&5,_=C50.IK2I"E#8[<ZR/)<MC)7A*HTVES-VCRQ>
MJ_F<F[)Z;MW2L_7?$G_!3+3O`5G=:9\+_#=QX:T=I'@NM6FE5M=O5SR[R_\`
M+,'M''@`=S7.Z!^TGIGC/4Q'>7$]E(R>;'<W&9/M>.2"QR<Y-?&WQE^-WAKX
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MON=(_P`0M*_X1B:TM&N[;S;J.9;5Y/GA1<9BC8'(W<=*]/\`A=^W1J^C)-X<
M\8::?%O@4P_+H&O2---;<_>M;DDRPL!Z';TXKY^\&^'?"_C^W5[;Q7I=O?H#
M))'*"JQL/E$>:CL'O-(U%[A5M]1?2Y&BB;>6AF/3.>XQ2G4@X/6_]="LXSO(
MJ^`K4O:0F[3=V]5-QC;E5O>5UI)V:/IWXKZ?93>#(/'WPTN)_$7@:2X2PU"W
MN&VZCX1E<<0W2+P4/\$P^5NAP:\DN?C''<V>H6LF&;2K020RH,;VSRK<?K5S
MX4?M.Z?^SIXKTC6=/M7NK#4B;/Q7ITJ?Z-K-C)Q-`5[X'*G^%E4BL#]L?X*'
MX&?%'6=/T#5H[S1-6MXM4TB3I)?Z=,HF@+#H6V,%)_O*U9THTU"\SXKA_+<I
MC@Z6)S-Q2:E;5WD^:*M;NEUZIZ;,Z7PK^T0\>O6NFS6-F1>JNPM<'*/LR-Y[
M+]*ZO0?BK%=W=XFJ6]E;W5A*C-+;2>9"RMDAL]<<<U\`>#I=8\,1_;=2^UI<
M7,A$:ESF-6DXY[<8KU?P%'K&IZVUO;^9"A&UY[@%8F&/NY/!.**CI<KL:9SC
M.':V#J1PU*$9\KLU>]U.R^^)^R7_``1[\3V7B70?B3+:.9R#:$SG_EJ"+C&!
MV'!KXDU3Q)'?:1?3MY5FOF`MY2Y\S'.37T!_P;\>(_[0OOCE91,#;Z;;:0(U
M4Y7)6^SC\A7R=\`=*E_:>^-^G>'M1OCH_AF.SFU;Q`+$_/;6%JIDF&[L[@;!
M_M.*X3\L/:?A=X"T9O"=A\1O'&M7NE^&)96@TBRM0/[1U^5>&6W#<+&#D/,W
MRCH,FJ?Q(_;7'B[1)?"O@Z,^$/#4*XDTS16:)[C'4W$_^LF/J6..O%>$?''X
MPZQ\8?BY?ZI=:=<6MFUHFF:!HMJ/]'T2SB.V&W0=``N"QZLQ8GDU@Z-\.;RQ
M6&XEO;>SGN=R;/,XXXR3Z^U`'7:7\=-`BU:6#>J3J"@C8Y8#N3[FN<3XO>'?
M'_BFXO[^RF-EID+6KP!2R1\Y4X[]ZYK2?`FEZ[KEY>6TS7=W:%A(NS:B_+@Y
MSVXKGM&T32M4M+N2TN9UF-P(IE#?*5'4#USSQ6E*IR2N>]P[G<LJQ?UF*;5G
M%I.SL^SZ?<=G'\1])T^_U06$4S6')MD(PL'&-Q'0<]*G\-_'>P\/QZ;-IDES
M;7%IEM\#F-U8=]X((YKE!X9TO2+@-`\WV>\/EI!/\OG'L3[#VK<NOAMX?\+:
MR+-HX;R=;432-!-O)F;D$KV`IU*B>QW9[Q/+,8.$8<MY\SUNVDDDF^MM[];G
MNFE_MX6_C#6;?2?C7HG_``E.ESVBK9Z_;1+'XBT=&/!2?_EXC'4QRYSC@BO/
MOC/X#7]G;7?!^KQW0\7_``_UL32Z+XETU<07R%OFC93DQ7,><21-R#TR.:\W
MU;2H-2\,7.JW^N6]SJU\@CM;<X^0*VT@>@`Z5['^Q#J-C;2WGPE\0:Q"?"WQ
M*<0(+A=_]AZP1MM;^+/"$2%8Y!_$CG/05T/$0BDHKU/=?&.&P="%++:;3=.*
MF[Z.2C;16O%IMW:=GK=7U//8_B/X=O/`OBI!(MO)<7#RVID^\V2NT9]>]7?#
M'Q!TJRNX;"TMY;F\GC,S7#)]\`?-Q7AOQ3^&^N>'=5\2Z9J;)!<^$[B:"_MG
MX*7"%@PQW(*Y^E?,'AGX\_$JS6VMK"^M([Z[NC9[_M`\QD<GY5!/<<5,YRJ(
MY,RS/&Y_0E>.BDY)N[^RERK0_2S0?%WA[6)M2W:E'$T(#^6$"JS`^O;`K8\4
M>)K2[TFPAN+BQ+7Z>=;R&3<SQ=M_I7RF_AS4_#7AB-[\O']EC6W9MXVLY`WE
MO7K7*_%/XA7'A:&&WTZ<R_N1ON=WSHG]W!Z`UR/3<^#G%QDXO='UEI7B^RGA
ME1M3,KHODPP6\N[9@'&?05FCQ#%J-AYCSO:1H2%7>`2V<9*]_K7S-^ROK6L+
MI&KZCKUM>&UB:1[-E3'F$CG=Z>U='J_CVQ\4ZZBW$_V`H@&(R7^SG.`,#KG-
M!)]`:EK-G=Q_O)X8YXH,)(),[5([CU/Z54TGQ%!;>'XA,;9XK5<H^_YR3W_"
MO''\,2>,?'%U96>J27=EI\07S/\`5@$@9S["I;O0==ET&6]TNYLV\EC;^4OS
M!^><D]\"@#ZJ_8)MY)_VROAS=^7@3^(K23[20<RYF7*X-?NS7\Y?_!.W7O%,
MW[>?P<BU1;S[+:^);**,%6571IE^8]N*_HTH`****`"BBB@`HHHH`^)O^"_>
MGQ:A_P`$_I_.M$O4A\1:?+Y;+N&09.<5^`?Q`\)C5=?$D;W]M+;1^=$%W`PY
M/0D]J_I/_P""G'P6O/C_`/LQ/X;L;EK2>YU6VDWA<\+O)'XU\1>*/^"5<EO\
M$A>RO-'KD$0`=X`04SA1P/FR>:`/S!BUW6Y$TB'38KF6\@A6VO%NAYJ/N'WE
M4CTYKV7PIXWT^]T?57\<:/>7UU%;QV]JMI'Y:QE!P6QU!%?96C?\$:KKQ/X$
MTW4I_$US;:M?.GF0R6_DI;[>OS#U%=WJO_!*KP!J:R:=;>,9K'45\MIFBE#)
M-*,9&3V^E`'Y>R>*M`U354+VD5J\4+SQM<L5(3H>OI7H7PXU?2_B'9Q2QPZC
M%8PPEI+RQCY*#@ACV_&OI7]H+_@C_>V=V;BROK?Q3NS&J@*FWGA<>F.M</IG
M_!/#XA_##PU>W4-GJ.DVMRZ13P63>9$\>.`1QCGTH`B_8BM;*/\`;=\)_87.
MI;&O;^WFD7:T4\5G,\#'WWJ!]17CND^#[J'29[F],4D\DSSSS*P+W+D$\9X^
M;O7T#\&?#/B_]G'XK^'O$TGA=-4.DW<=W(=IW",-\T8/0L4+<=.:7X_?"B/X
M-_&?7=*B@@;PI?VIUGPVQA8I=V\YWQL#V*C*,.Q0BCK<TG5G.?/4=WYGXX_M
M,^)+F?XPW-W?V85+FY$<,C2,K0*.,<Y&1ZU@VUEHL_AN^E:74;2=IA`)58.4
M0G/`XR#C]:^O/VFO@/H_Q/URXLI4M]]Q/O618]BH3C@'M7D&N_\`!/[6=5\+
M>5H=[;W7V.X>0Q.^UH>V-W<#'%:J6\F>YA,QE.4ZM9QNHZ76IX3X?U73-+NY
M)M)U^6SOH,+9W!B9&C]3QD#W^M>YW?[47B#1?!ULWVIM9O38LC21GNW21AZ#
M'ZU@_"C_`()M^-_'.CSZC]MT#3;6TOF,[7%P0SD#.-E=AX=_9)L?#OAG5$N=
M3C62[C-OA6YE'.&7T`%1[K5K'F2Q-&5)J--*3Z_F?/D7C?4=/\3+JT5]>027
M;%B%D)A8-Z#V/>OK[_@GM\=;W4_!NM6MUJ$M];6T^V/[0-WD^@'>O/\`PE_P
M3@&OO;W6K^-M+L+3R04MU0^<4_NKS@<<\UZE\&_!6C?!`:IHNASG42-TPF2/
MBXP,!6]#4G$>C^,_CYNO],MK[22]NV(H)HT"!,$\D8YKWG]O#7M!L/@-\"M4
MU)V@N;CP6\8*."\D,5[.L0)]-I(KY9\+?#KQC\=/B%HGA/1M-N[K4_$%W#I]
ME"J_ZLN>,]P!R6;LH)KVK]LG3=(^+'[0<'A6SD@U#P5\.]%M?!NF7=QE;>=;
M96$]XC#_`)Z7+3,/]G;1TL6ZDFDF]$8^FZ-I'Q!TO1YH;!'`82R%1N$3!1M!
M-/\`B/'KWB?4+73)H;6W2T!\M(F"@J.OU)%>$>&/$FJ?"V_N-'L=3O9K&>X,
M<GV8YR$.%QZ@BO7_`/A++[4+C3($T"[<%HU6[E4EP_\`>^F.M!!^BO\`P;N^
M%(M"T3XTS1VTB7%ZFF!I6.1,JI>!<?3)_.OG+]DS1[WP1\+/CW-<V4$6KVGA
MVRMF*G_EE-J$(E&?HH!^M?67_!!9M0C\+?%W[<8_,B>R1`G8!;K'':OS$^$/
M[3M];?MAVWPS\4ZO=:+X5^-^B7_A&_O7APFG7%R`;*^+_P!V.[CAR?[K-0!J
MS>)K[5[^]\FW\J:YG"V\*L<$9YVGMTS5*?QA<P-%!#;7]Q?9$31YXC)ZE?45
MCZ]\/?%/PVUGQ%X7UW[?#XV\-%K&2S5O]6\7#MG^Z1R/4$'O7>?LL_"Z[^(>
M@:EJ]SKBV\NDQF%$D*F:9B.D:^W3)H`\T\?ZOXJ^&&F:E=PPP?9HH7VHK@YR
M-QWXY)ZUYS\$_&.H_%2-W"VUGI-@6NY[DR&-I2`,QJ.NXYXJIH^H>)[#Q]K?
MA>_U!+V2Y>:3RI)!YD0S\O/XXKMO!6J6.C>#(K$:3;F2972XD4\HX/4>P]:Z
MX4H/D\]S]`R[),HJ_4)57.U63C/;>Z2MY:GJ'C']H&Q^)/P`TF"'3+:'Q!X:
MF2VT]HH]A>$L27D_YZ'U-<EX2234=`O=5U)+I]?N[P)_HZ822+^[GI]!5/0+
M_P`0Z]XE<V/A2XU>U>Q>-%";(K%<<.#@9.`3CWKU[X"_`'QKXF^&^H:C%:.;
M9-OV>,D%Y"?XD],>]9SIQ]G?K<\W'95@J65SQ%*_M8U7#7:W2WGW.`\;6&@7
M^B:9/ILCIJ-R2+BVE^5XBGZ!3_.KNIZ(FB>(-+U"RNI9K@M%<$[L1I*N#M4C
MN..?6NZO_P!DXZAXWU>.?'FV.F1W4D+DAE+(6R1U*@BNF_9!_94U+XD?%[PA
M'J.\>#X+%M>UB:)2?*L;>4-*#_M2$+&H'4N!6GU5VNW;2YZ=#@.4J#Q5>MR0
M4%-NS>\5*R[O6Q%_P45ABE_;+^)I<QVUL\L%Q/%$%4M++;Q22D_[6]FKY:\3
M_L^^$_B;KKZU':O87FG2QK`JC"HRX^?CO[FO?/CWX&\:_'_Q)XQ^*$VC7"6F
MMZU<LZF(XBE>7;'`?<#:OX5YM/\``?QS;"6UO+2[MY+())>6S(8V=2<_*W0G
M%1.G*FE9[G)GF2ULCIQ]E64N>ZEIL]&UK^9Q?B/QK>^&O"E_>7FG?:-#TNYV
M3WK9E:0]]H/&17C&NW-O\3=$NO&.E:M&]A->FR%BV/M#QJN0^/2O<M5DUG2M
M&CL]0TK^U-,%R;DV*/Q,/]OL..M>9?$!]*\(>'?*T_P^=-M[^3!0Q;=K'!;!
M]*Y]SXIN[N:?P0T[6%\&71$D[V*W21F!I=S3+P<@=NM=MXW\`16OC31[;1[>
MRB6[&/M%O\W[P\D.2>HKG9/'6EZ%X8TV&U!TQ4E"NUL"S*X7N?3IFN7B\<R7
M&M7C6]U?7$4"->D!<^6V,+CMSG]*!'6Z9XFUG0]<\816DEK!%9PAKN6=-P;'
M\*D?Q&M6SDCO]#TFYOKJZTRRUC+I]G?;O<=R.W/Z5X_X/\97DOPVUJV(NXI=
M3O$9HY`")W!R0W]!7JGP5\(^(/'>M7D-[)86>F6=E-Y-U<IYB,P3[H'KZ>]`
M'U1^Q+-=>%_VSO@OX=GU;[9*GBFQ=Y@`P9?-5@F?T-?T!U_,E_P3%T3Q)I?_
M``4*^#T$\,\MK#XOL7:9I=V5\Y0?TK^FV@`HHHH`****`"BBB@#Q/]O_`.+U
MQ\#_`-G2\U^VXDANX8B<#Y0V[GGITKXF\+?\%,+KQ#ID<.H7.?+(E2+?PP!Y
MY],\U[__`,%T=4_LG]@Z[D,;2JVN6*,B_P`0)?CZ5^&7_"SKS3;J6<:@;>VM
MG7"-@["3@ICTH`_43QC_`,%(;C4;=[+^T]\D[!XRA.5[$"O%+O\`:B?3?'JK
M%J37$]R[(7DEQL#<@X'<=J^'6^,(@N-DWG1R!V87#9&XD?*2/0U7T7QZD>OP
MR2WB-?1$S*S*3O']!0!^F?P?_:1U#5=;LH1K\]G/>,Z%Y1N(*]"2>QQUKTC7
M/VL[C^S=1M-;O8;F\LI=PN86P9U"G:N.AK\T+?X[:I/_`&+#=7,;F"0Q.X4H
MV.V,=N>M=#K7Q$GLOB'$D-]YJR_((@^8^G)&?7.*`/N_PM^T;I_BJ[_LS4=7
MW6S0!3,BJ5MP?;^M=_;+X0\2>$K+P;XGO+:;3(Y6.EZLC!I=)>3GRRHY:!_X
MESP3D<U\.?#B3S?`H<PM$AN66:4I\R`=`3Z<YQ6QJ/B2;2M,OX(;S?-$0-YX
M23H0<]B!0!]+?$_]C/P%X-0R^(M*1+:0"73[ZT(DL;QA_$DG3'J"<CTKS'Q/
M^QEX*?4-7<SQ6UJ46>!()-IO(RI)''IG]:YOX-?'[QQX1UA;/2]?AO?#VI`+
M=:-J=NMY87?'(:%\C<1_$N#[U[IJ&M?"S4--674=$UCP=<O$)&N?#][]JMK=
M^V+>?E?]U7Q0!X#\#?\`@EC_`,)]X7\47$^JR>']%MW,MO,Q\S>2.%.3GIWJ
M*Q_X)8^%K[X9PP7&JYUHR,L<J2Y61,=<?@!7:Z7XH\!ZK#J.E:3\>KJP2;='
M)%JWA.]26,@Y.3"TBDUE:5/X'\*:2QN?VA=+NK),8%AX3U&2X7GTD"#GZT`8
M^J_\$CK^Y\.Z6GAT1C571A=BX/F((P,AL_RI?AQ_P2:U_5?'UWHT,UM<?:#'
M)?36\7_'N,88*W0>Y/2O28_VR_AG\*M/\[2G^(?C[4^[7$ZZ-8KC^\L9DD\O
MOC<*\=^(W_!7'QQK<-]I5A%H7ASPY*S#^SM'B,2S^N^4DR2'W<\^E`'U#X=_
M8N\)_L\>&=8T/P!K8U#QUKUI)IMUKQE#?V':MQ+%:G_GHXX:3.=N0.M>87G_
M``3K^'/P3MWN?$7C#_A)4\L-';1-M5R1RN,_P\U\R7/[1&N^$[;3]8AO9</*
M7$:W)VCC^(9S[56/QF\2>---N/M#0NDD@97&28U;L!UQF@#ZDU__`()??#"_
M\-CQ/H7B26#PY<HEU`)"GF@C_69/4`<X%=;X+^%7P`DM+*WNKS48;I9-JWT4
MVX2`+A2PZ<GK7Q%XT_:D\9Z%I4&@P-%9VX!!5E.9E([#TK.T34=9TSP8MS'/
M,UU)\S0OG^+^+V`H`_:/]A#PMX4\*Z+XTM_"RH1+#!)<R;`&E8B<`GVZU^)6
MM?"#Q#>:C]LNK!99X085<Q[]B;LY0GICBOTG_P"#?K5-9UKP+\5Y]6:ZD.^R
MCB>9RV["W6<9Z#I7S[I$EE9>%;N2_21[^.1!;1K\P'][=[8[T`0O\&/^&VOA
M_IL'BO5(?"OQ=LK1=*TOQ/.VRV\6VB#Y+>](_P!7<(,(DYX90%;H#7F6F_L7
M^+O@AXE72]1T^[T/Q(LP\ZVDW,ETHR=X?H4(Z%<@YZU[9XO^,ME:W$3R6MFL
ML$:K'*1D*<#Y0!ZYZUL6/[<>L>`]$.EW<-AXNT2)OWMAJT1EAM$89/DRY$L0
M_P!UOPH`^<OC-^SCX4MO$UIJ.H:-%;ZS>G$T\,XX1L?(P'09SFO7?!/[/GPG
M\(^!4EO]&TQ/MB&`CS2-GH=WN<<BL3QO\8?V>?BCXKMH98OB+X`U/SM\DUBL
M.MZ>2>IQ(8Y0OXM4_BKPY\']<6RL$_:!M--AM'\]8K_PEJ*RNOOY:NOZU2G)
M6L=4,;7AR<LW[CO'R?='7?&;XJ^$?!7PY@TZSN+&&2<(OG6D0'DQD;2K'J21
MTKFO"7Q*TWPOH\6GZ1?OI^FSQ;+0RN0)`.<D]>M<UXK^%'P2T;P<[:M\;[^\
M34KT3^;I'@^\D\U%'$8\\QJ![GO3/#?[0'P5\"Z']F\+^"?%/Q*OM.7]W?>,
M[Y+?3X3_`'A:6O+#V:2E=VL0\56E!TW)V;NUW??U/2/AA\";G]ISXE^(=<O[
M1=,\/PZ7;B77;B[>&QM$0%9!)-P#G)^7DGTKU/5_B[X4\%:-H/@?X6:Q;1Z'
MIQC:]U2XX?5"F=@(/*PHQ+*G<G)YKY<^/G[<6N?%'X=V=E>:I;R:?!)NM],T
MNS6STVR&,!$A3"\>IR3W-?/FO^.M2U?4=&O;.\C2Y>0I)&@Z]<+M'M6DJ\Y)
M)O1'LYAQ-F&,HT\-5J/DIQ45%/2R\NY]I1>.?#J^(M3\'RZ[+)X9DO#J,L,$
M_P`_VPMYC-ST^<9K<\<_M$^'_&FC:;9S:E!K,S2&1X%148H@R<MUK\T_&7Q)
MUZSU&8!%6<2969')9^VTUVWPF\37%GIL]SJUS)92P6Y)V)YKMG.%&.Y/Z5#D
MWN>5B<=B,1_'FY>NI]YW'Q!^%'B_PK%I\?A'3+.U,'F75R"OVA%#9.?3/\J\
MI^,_PY^$_P`:-;T:)Y[;3M+T^0QV4<3!2ZYRTC_[1/`KY3U#QY>:IX@@L;2\
MEBMYMCRQ,NSS@><'O7&ZOXTGN_'TL<4[_9;7<VW>>&ZC%2<A]S3?L,?!WP;X
M)NI=6U?]YK%ZK6RQN&=$8@G/X#]:SK[]DKX`>$KS7KK5I'E5@@BMTG\M&4C`
M!QSD>E?(NB_%Z774NOMC7?E11%4D\XGR9,$@`US4'Q7O;GPM<S7,]_>-)+G,
MK#Y1VS0!]PZ9_P`$M?!MC:6&I6&HVR6%[BZM+:XN0[L6_B_"KOA_P;\&?@I+
M!H,\/VCQ"]T6OKN27,"+GA(E_F>M?$>G_M7:[H%M'YEW>7#A?LUO&SMMA9N!
MM(]#7-?'3Q5?VWA[2]6CU<W.H[W9HTR)(G!P`?J:`/U<_9B^'7PT^%?[6W@B
M_P!*6WU37->UNT8#?D6)>4891V/2OURK^;+_`()'^(M7\4?MA?"N^U'4+FZN
MSXGL$E1Y,A09AD>^*_I-H`****`"BBB@`HHHH`^(?^#@Z?[+_P`$Y-6D^TI:
M[-:L3O<X!&7R*_GW?5K7SBL:0&UE.5+-\QR.')Z=<XK]YO\`@Y:UO_A'_P#@
MF'J5QA21XBTY0K#.XEI.,5_.OX=\6KKZQB".(^:"6&_Y;8+GMVY!H`[?7/B)
M!!>VMM>SQI<SQF")5.?M*#MCL<4][Q+&_CG_`':S(`JA'W84C@9]<UYA-KTW
MB/Q"M[#Y-JL;"-%E3&X]]A]:Z'1-33_A)D6XF2S$#DNIQMD;'7-`'NND:U*;
M32))X0H\S:ZYR0WU[UUEKXDBU?Q=;-<2I!9K-A$>(8=A@@YZ]J\XAUVQCTRU
MDE`*7SJMO*KY5G],=J<_B9$\8Z=`&\R/)*12'`^5O7\Z`/NOX3SVUWH5TU[:
MSS;@LQ=7V+[@+W.*Q/B?XLM;?2I$LG(M[J[!92H:11Z5R/PP\53:S81S/*)R
MC+%'Y<FU",8;ZXK(\2^*(H;ZX::YM,1WJM&I;<=O(P!_.@#O=%\3Z9/+-)DI
M=Q,&A=1_J\=!QT/K7JGC#QM%=:?8:BMIL5+)A/NY1R!C=[$#)KY@T3Q'I;:]
MY44\@%[-@S$;8PQ[_2NU^,7Q,O\`P+X0^Q6=Q;2Q;#\RM\CGOD'ZT`</HGB"
MQEU:[:+419S7,KNROQ(A!X9?KWK(TKQK::F^L)/J.)(65`9"HWY/WO>O&+3X
MCV]KKMW/?O&6W-F6)_WA)X`*^GTK)D\7Z7#'/YTGG3EMT(5>G][CO0!]+:AX
MG%OH*PV6H!?M"JL@9ONGH<^QZUYUXGU&&ZU.^A20?O2J^:F.!GKBN*\0>.FO
MA;;;F%;1E173'ER%NR@^E<U+JUU?:[<[HKB.)8V9'!Y<C^$>OUH`^A=?T6UG
M\'6SKJ:R_9XPBQ;<L,^O8G-1>"_$*QS7N^7SIX<1XD`1$(QR/_KUYO??VK!\
M.].N%N@)V8$*/^6HQE<GU%8>@6USJ"74LMV83=2>;O+X)/<$=Z`.Z^+OQ6CL
MO$UO-?:A"K@;%7`RO'#5ES_M2V&@WGD7-\TC1P^6,D_/NP2<#UKQCXEZC$OC
MJ*WO%@8QNC-(QS@=<$=P.U=Y8^(/!^A:#<W.I6D6I75W&0LD>,J#PN/2@#]?
M?^#;SXES^/O"WQHWRSR6UDVF^2KCY4#)=DA?7I7S;XF^-VFZUJ'V-KNT9$')
M7"N@.`HQTSN('/XU[K_P;$/I,'PE^-":2)E$+V.])'W%?DNR!G\Z_&?6?VF]
M9TSPCXAL[2\LIKK5I7CD@*!FAC8X*[CWH`_7/X@_LTCP1I<D)U<Z[KUE>6-I
M=:>EJJ.\]S;37`\I@YWJB0OU`)P3C`Y\_P!9T/P_KOP?N+TQW)L%62[AN(;9
MG^V1Q311.&8$$(KRJ"QR`2!CFOF3X/\`_!4+PU<_&76]0M]'\3-::MXXT?7Q
M"$C66&QMM'N=/NOXL>;NG#H/ND+R16OJ_P"W_P##WX/^$M`\):!>^)O$]UH6
MA7UDEWJ.GQ6?VVYEU:POH]T*R.4B"6KHW+')![\`'J?Q]_9GOOA;8'Q;>V5Y
MI]G9ZG:Z1!!-;;6G,T$LI8$'Y3&(\%&&[YU)`KS+6O@+XQ\5V]YXLTOPOXAE
M\.06LEW!?!`T5U'$Q6;`SN<(5;=M!VXR<"O+/BO^WEX(D\$?$"#P%JOQ`UW6
MO''CF/Q;<IKME%!!I*^5=*ULK+*YGD#S@>;M4,JKP"*]7\/_`+8'@OX8?!W]
MG_QSJ^M^(;CQIX:T'7A!X;TZ"&>RO)+B_O(HQ<R&0-;CY][@HQD3:!US0!:^
M+?@#Q[J'P?\`"VLKX6U=-#FB3:XA\Q6$YVPX0?,!(>%)4!CC!-=)X(_9;\:>
M$8;U=>LKOPN]MH5WK8%Y`'CO([4HKVWR$A7S(`03E>XYK.TK_@IQX(^%7Q.F
M^)EG;>)=4\5ZMIFD:3=^&KJTB@T[3UMGM#-*ESO)E!6U'DIY:^6TG)^49N?"
M?_@I/\+_`-F75KZ7P%JGBOQ)JES8ZB;5];L8C:VMU<F(P*UKO=7(*,9)<_,=
MN%^6@#+\8?`OXH:L;_0]"^'VIE[,J+Z/`3R#*N]$4$@EV7D(/G_V:XGX]?#C
MQ%\"/#_P\U;Q`;:&U\:Z>=4LA;_NWC2.1XS$XZAP$W$^C`=<@>R^._\`@J=\
M/(%O+)[[4M#@C\0P>*U8^&;/7[J*X>!!<6D7VAQL*R+F&XY(#D.N1S\G_M??
MMVZ+^T5IOA;4EL=;M_$NF6U[8ZK:W]K$(`DFHW%W#<131D;G=;C:Z>6@4ID9
M!P`#HO'?PD\6^.?">B^)?#O@?Q+>Z%K%]'IUA>PPY34+AY"@2-0=SG>I!P#C
M'.*]&\-_"7XFV-G>:/'X#U./5EL?M,D**A#VP;9YHEW>65+_`"YW?>^7KQ7D
M7PN_X*6^'/AM\5?@9?R6-]>V7PPTC6-*UBU*1R!1J4EP//M5<E'=(YU;:X`8
MIM/!S7L?Q'_X**?"CXD?L_S?#*\U/Q%9>"M2M4D36](\*6.G&SO([HS;$T^&
M09A<?>9I2?,PP``P0##^+?@;Q=\&/C</"K^&K[7+VSU&UTFWOX[/RA)>SVEO
M<BR"DY\Y!<*"#UZ]ZX;6O@QX]\9VNJ^*K+P%K;:)I3S6TUU%`JK$T+B.<\D,
MRHYVNZ@JAZD5ZOIW[?WP@^(_Q2CUF_F^(UIIGACQMI?B_2?)M(+F[UE;?3;.
MRD@N"TJB)RUF'#C>"'88SBO&?C#^V#\,_C;X?&O7VH_$#2O$WAO2M6\/Z=HF
MGQI#::H)[R[N(+B2X$FZ)0+HB>'RV\WR\!L,<`'??%']C/Q?\'=/U+PA)9:E
MJWBB;6K72[.VTZQ,T%UY]J;A0LH)^?`(V$9PK-D`5Q%]^QO\4;2ZDT&/P/JM
MYJ$-M#J$MO&BB.."1C&DK2[O+V;U9=V[;N!&<UZ[J/\`P5`^&OA6:>_L+;Q9
M?P>+]0CO=6"6L-O=:2D^@S:5<_9CYA$DD;R"1"=H<9!V]:\8^,W[=G@4_L8Z
MQ\%?"Z>*]8MWM8H(-=U&S2P-],VHK>31-`LCF*W58T"C<VYRY(`(H`XGQ)HE
M]\./$LFB:UX?O]/UK2I?(U#3KM"D]BX;YLKV_P`,$5Q7Q22TTOQ`CR74N)C\
MJ$D[16K^TO\`M+V_Q_\`VD+[Q-X=:]LK&[L;%"MV0)E:WL8+=MV"1R\;$<]"
M*\(^)?B1KG6Q)J$L@ER%4E\^83P,#TH`^^?^"2OBBQTG]NOX*P(<3W7BZR@"
MK+N+9F7)-?U"5_(A_P`$@;U;'_@I;\`85!F$OC?3F+%_]43.HX]J_KOH`***
M*`"BBB@`HHHH`_-G_@ZSU$Z7_P`$F-1E5'D/_"4Z4-J#D_-)7\R6E>.FLIQ]
MGMF6*[CVSLW!'<`^N:_IB_X.SIY+?_@D/JAB7<?^$JTH$_W1NER:_EK_`+5G
M>)@'3R^-J.<'WP?:@#L-3\6ZE<I'?/)#&;;/R1OG8#]TE:TQ\1IM>M#'')$M
MQ:C,['(`''KU/O7$WM[:ZC>MY9Q9*@$CQG!5O?U^M4I?$<-A<3+S<02,KPRG
MY25';W%`'L^B_$JYTK1HHX[KE)<Q!I-PA?/WA_2MZZ^)I@\2VL[WTMRT**3(
M&^8GKM/H?I7DUK)#;6$).R19#YBY/0GD9K<TS7[>7Q!I^5A9H'#RE1\O`_6@
M#Z_^$?Q%N[71)=1^SG4]+@!W+YK)L=OX%]JK^)/BI;V=M?I*]M')<;98%>8#
MR@3@@>N*\@T/XV7>B>'KVPTQF^QW&998PN0F[CCWKBE\*:EXNU=I6G62WMW!
M4,WS*I'-`'T9IGQ?1K&.PTJ>%[I<,9PQ8*@^\`*N_%;XOK/;6\5W<RSA(,>8
M1A5_#U/2O)?@YX1M_#>M6UY+(K6]J<SQ,^XRCID>U=I^T1JOANYOHI;:*X1C
M;@VXSA"#UR*`/'T\7I=^()I3]L\ZTE$BP@<N3G!SZ8K)O?B0^I:[-'%#-9F"
M10^3\K9.=N>HK'TSQ7)H4AMHY$?S78.KGYCW^]UV_P!:R+WQE!--?R3K)%!L
M_@8'<XZ?A0!Z]>Z?K#WT$T]V/LKJ&61Y1OC.>@[<5EZ_\4)=%O$CDN7ECA8I
MY@D("^F!WKAI?B!-J]C:7'VE)5#J!"Y^XN.1CN3ZUD7OB&"?6TEN$>6+/R1Q
MC'E<X)/M[T`>I>*?VE@_AN!#<7)"/D+&I*[L8'T%8VC_`+2-Q/I:R6ML?.DF
M\B5BQ8@=,XJ/6]:TB7X<I#:16]M/YBDJ0-VT'D9_6L?0O"MC=ZRQ63"1X>18
MWP2">N:`#5OBG=7MVK3LMSJ[G*$MGY!P5'O[U<@\9:U=`2Q6\D+6Y_<R;-RS
M<=&'I69XTTW3O#VO6LO"O$I##<,1Q^HQU-36OCQ8(I);:X^T;055".^/O8[T
M`?N1_P`&CNEWD/PH_:!O;N3+7S:6?+#D^6PBO=W';D_I7X0Z]X<U$>(9'@+P
MJ)6#DC&>>_OS7[N?\&C/C'_A)/@Y\>8]Q)LX]*+97!RT=\2<?A7X+:U\1;L>
M(I`L[31).7!)^_S]V@#Z&^&O@G4/!OBG3Y]MM$UY;+L6(^8S#'\0['%<G^T#
MIQ\,?%7^W7DE:41':I`79_LX]*P_#7[1NKP>+_-CAA%YMCC0H,`CH!Z?6L#X
MP>/M5\7ZGJ=SJ!M?-4%513G`QUH`I>%_$4DFIS37$XLX),MO4#<V>U:MO<W.
MHW\*:;<$R/("K<;I`#QDUYGHMK<#3`Y20JJ[W=_NGC@"M/1OB%_8\T!6#9)&
MV$E5ON@CN/K0!Z)J.O:OJWB)GU6[_P!(,GD>6&"[%7C''>ME=/U'3$DEM+0Q
MS(YD++P$7L2?\*\<T;Q'<ZKJC[Y6#!F=I,9+$GM7I7@#Q!?7$BK<74T=B(RL
MJ,WS,H//%`%-O$-WK_CD+(SK,4)>1>DC#ZUD:MX@N1>S>8)(<@PK-(V2Y[]^
M*W=9\5QZ)XDGNK;[.8?)9&QC.#TP*\]OKZWUZ(/("LC2%V;?CZ4`,TW6+2;6
M'CG618(@#&8V/SGIQ_\`7KK]:\46]AI\3EA%9VPPIQGGV'UK@=-MMVMQ2.WE
MQ@[-RKG!'/2N@\56C:I;/\W^J3,2N!AO4L*`-'0?B3_9VFW5QF1&NR(E$;9W
M>_L:RF\1W?S2I(QF:0\CE`!_6L:]D:R\/K-(8F)8HD:\-GCD#\:HQNL:0P&4
MA8#G@_B:`.M77+^9$AN=1C5-I82EN4;L,5EOXHD-_M,TC,28Y'R?F]\5G7WB
M>&51Y<*L-QY<<[:S[F1D965F\F8EUR>?SH`ZZQ\27S7D?D1*\L?#;1C:/>LS
M7=:FO=:5KH!P7)0E@6+#T/8>U1V'B*WTRPEMK=F$VT'>6YYZUDB<7NLJ&D'V
M?&,%>Y]*`/L/_@D#XA:3_@J9^S[;;!%YOC;2N,=0)U[U_8A7\:7_``2"U*WO
M/^"L'[.<8C8-'X\TL)CCI.O)%?V6T`%%%%`!1110`4444`?F7_P=IW7V3_@D
M3J!R0K>+-*5L=P3+7\KB6NZ9_.=7CD4^65'<]"*_J9_X.Z[C[+_P1ZU)L9/_
M``END@?]]2U_+':7HDCWMS,F6*YQ@]L4`32ZC%]GRZ,DKKY6.F_'0E:K70D>
M6.-V&Y8B,8R,>@QVJJ4EOK@+F/>J[B<]?K[U)',SI$O)D4$`J,9'?)]:`.I@
M%NI@;SM^P*IB7N3T-:EYK0TR[AGGW1M%E9,#D@^E<9INKG3K+,0,<JD`=RH]
M<U:M+SR]:MQ=/++$3\P8_*_OF@#V'P%XC2-9WCCD<N,#Y=H"XX./;TJYJ'Q3
MDL+8+:0F:60[7"IL\[T)/M6)HWQ/BTQ,-9I'+]V&1CG<O3+`>M<IXF\5/>:M
M(ZX2,D*50Y"D]?TH`]2\/_$J"WU=9]_F3X*J`<JF.WUS72?$7XMPZSH]NTD4
M*@KMW.1NA/0$>V:^=[B]BM9I+DM*&D?:BC)\M??%:TNO1+HL%JK-*I7?E_E8
MXZB@";5-/DU&VFN1\R"4QL\;<8S^?>L%[A[73S!$J&R4F68M]X]A@U1AU.:\
M=I8;B8.CX"J3M*\Y/UI8G@DL_,+2MM&YX\$@MT/U[4`6;*2/3X`7C$F`3@`Y
M(/W?QQ528S:<[S[MRW)VHQ;[Z]2/K2AY8E2$R,J38,9*8+$9SGVJK>-Y,OEG
M#I@AG/0YY.#VH`VXM4CLM#W>8TTTIP=K=_0"IO#_`(IN-,GECE<E[SY"0/F"
MCMGTK"CEA6P?[,WS1M\Q8Y+GL!1I2-<3;%9W9&^>/=W['/\`2@#<\3>)6:_A
MG+)+Y*8E51\T:@\?G265\+F*6=F2-Y,S+)Z'&`,>E<YJP,-WMCQNQ\V]L?\`
M`3ZUKZ5JOFVBV_V7;<7&2[.V(]O8"@#]W_\`@S%BG_X5#^TC<2L629])\O/4
M`17^>/K7X+ZAJ!NO$TR;`4EF+`="AY_*OWK_`.#-+77UCX7?M+`H$CMVTA4Q
M_P!<K_/\J_`J_;S=0N+DXVB1D#8^;J?SH`T'\0"UU!V20R'9M&T88'V[5)8Z
MW-8K<3O$CVMPPB)<Y96'0^M9"3V]P4DC#>9@#!/:B\,VHF!/.VM`Q#%N/_UT
M`:E]XM=],-G@S0<`!>JGO61'*LC8C,[./F`/?Z"J\D[WDX5G`C7DL>,GWH6>
M83$1D`QXVL>]`&CH=U<27)DR(0BEE0'D$>M;>B>*+BUF=O/8RQJ>6;IZC%<_
MH]];E7:96^4[G&?]8W4`U#/J'G033JH7>,_>_2@"_)JK75_/<Y!,@)0`XX/!
MSFJC%H4\OS(@`1(4!^8^Q]*SK>3-KOE)#(>`3]ZB28)\^!(9A\S8[T`:>E7D
MDMV3D^4C!E16^YW.:M:KJ[:I&^+IO+R`JXQS6):(8H%900<['VG[^>E+<%]H
M_>$C!+`]OH*`-RWGC32(5\HN^[AV.>?6LDW'E./+^YG)0'.3ZU!>7Q4+M=]S
M#!4GC'I4?F--$L;,JX`Y`^Y0!>NE$\4?F3>6AR^T]6_SZ57@NY+>--F-H;A3
MT85!<S@GY4!1>H)S]:>]U%Y0QZ8Q0`P72W$4N_Y2?N@#\N:FBG>W>,K\S8'(
MY"FH!M$*L!D@D@>M-MKMTR00I8_A0!]5?\$9)GO/^"MG[/#R8\S_`(3S2B6[
M\3KQ7]HM?Q7_`/!%QMO_``5P_9W#,6)\>:5SGJ?M"U_:A0`4444`%%%%`!11
M10!^7_\`P=W9_P"'/>HX*`CQ=I)&[I]Z6OY6(5/ENTA/)!<XSCV%?U3?\'>`
M+?\`!'K4=N,_\)=I&,C/\4M?RM21@;E68Y5@FW'0$<F@!D<A_>[5+!@!EC^M
M-\]FG*("#P=P/)%1J<PB/[N6/S'IBDVXD3:?,"+VX_"@"\MYY[R&2-`P&WC[
MWUJ2TE9I8H+AU6$#.QAD*>HP?>JQG=U8M@EL<#^$?6I4NH()#`7;"Q?>;^]V
M'TH`Z33HR+,>5N9F(9M_/'8K52X$LMS,R.!(`06;@YK+M]?-K`B1MAFR2XZK
MG^E2M*]BZ[G1O+P[9/WZ`+EEKK*5/F,XA7?M$?WV'K5N.Z_M?33B+R&=BQ8G
M..YP.U8]EJ/VF4!1C.0"O(SUR:)K@K*LB&.0$X<`XWT`26^JR6S?NXG+$[F*
MGKVX%+%J<CO@W`1C\P&WE>:IRZANG(`3R\8C*G&WM4,+(\QW@.0"/[O'KF@"
MW!*S1AC,X<A@K,<A1GI5?[;,MF(F0!0Y8>N/>D6YE;"#8Z)@`$>O:HUD_P!*
MX)8!2OS'G%`%J>U6:W655E'G*&95/OQ5J&21;A!&8Q/L!#@=,536>22+"2A5
M50`2<;C[5#;7`B)C?$B%2J[.JT`:%Y<([2K-MFRP?)&&R?3TJ:XCAL[=?N$@
M@!6.[:,YR/>L2YECDC5TW@@8&\]*9&_"ON;&<EO>@#^@K_@S,D0_#7]IA$"C
M9_8^2!C>3%J'.*_`F6Y:/4+M6P&\UPH/;FOWE_X,K)'D^&'[3991@C1BK8^\
M/*U&OP*U`$:O=XY*RNV0?>@#1?5@T/,"Q2$A0R#E_>HI+Q(PD;`2,,EFZBJ2
M3/'`2&RS''/:FF?8V#NS@#IUH`DOI%<JJR1LN>3Z4R2=55]N'W@+G/*D=ZB<
MJ(^%VACDC%,.=PX&V@"2UN#%"WR@X^\W?%77FCD",G`09"G[K'ZU3AQ$0Q!P
M>A]#2;CAL;3D_,!T%`"S+YTP>-2PSP">E0EB[,!N"GM0LQC0KR`3VI48%#SM
M7'''6@"6.X,8''4;2<]*:SJLV[<>N?FY/XTV--Z\9.X8QVX]:(UVOT4DC-`$
MLUVDK*5`4ALYI4NS:#=L!+'CO@57+A01^)^M.<E5W'@'@$4`2E`RY90)&/!!
MZTB!0/+()4]6`Y%011L\;#T]>U.!+KZ'C@4`.$A8$<^@)IT<R+'L'&[J<<YJ
M/S?FY4#TIL;@;B>-WIVH`^IO^"*TD8_X*V?L[`@EO^$[TL;O?[0M?VH5_%7_
M`,$4L?\`#V?]G?/)_P"$^TK!_P"WA:_M4H`****`"BBB@`HHHH`^(?\`@X)_
M82^(/_!1?_@GE=_#?X9P:7<>)YO$&GZBJ:A>BTA\F$R%SO((S\PP*_"V/_@T
M;_;("DG2?`(?/!_X2:+D>_RU^]'_``7@_:B\<_L>?\$[M>\<_#O7F\.>)['5
M=/@BO%M8;DB.2<+(H25'4Y7/;-?A$W_!Q9^UW#*P_P"%QZB0))$8CP[I;",8
MR#Q:]LX[\U[&"R6OBJ7MH-)7MK\O+S/.Q69TZ$_9R3;M?0I/_P`&BW[8Q1?^
M)-\/"4Z?\5+'S_X[22_\&C'[8TA8?V+\/PI'0>)HAS_WS6RG_!PK^V%=3"*#
MXS3>8D1F8-X=TO.WC!Q]FZ>M5[+_`(.&_P!LF#38YYOB_)-+O*SQ?V%I8,8)
MPA&+;C\>#C&:ZWPQBEM*+^__`".1<089]'_7S*#_`/!HS^V,(@JZ/X`_VO\`
MBIH__B:1/^#1?]L5"S?V-\/]_&"?$T9#?^.U-)_P<3_MD2Q;_P#A<-PD9B#(
MX\/Z4,MC."#;=N]2)_P<6?M?WP@AM?C-.RSR%6N9/#VE)M!P!Q]FP!G/)]14
M_P"K>(:OS1_'_(T>=4.S_#_,A;_@T;_;#9VD.B?#_P`S'`'B:(*?_'>E./\`
MP:0_MB>7_P`@3P`S\?,WB>/C_P`=JNW_``<4_MGF\E*?%^Y\B(C@^'M*W,,X
MS_Q[8']>U=-\/O\`@NY^VY\4_&.D^'-&^+IN-:\1S+%8HVE:/!$F<DEG:V"K
M@#DDX&*7^KF)M?FC][_R*_MFA=))Z_UW.>'_``:._MCP%MNC_#\YZ8\31K_[
M+4T7_!I'^V&'.=$\`#*8!'B:+Y#_`-\UZAXE_P""O'[>>DZA;QQ?%'^T(KJT
M:^M[[1],T;4]+>%2ZES=Q6[1??BD0KN!#`CMSQ5M_P`%T/V\!/+]H^(7B.+=
MIYU90WA"P7R[49S./]#PT>.C9V\=:%PYB&TE*.OG_P``A9Y0L[Q:MY?\$YH?
M\&B_[8_!_L;P!\O`'_"3Q8_]!H3_`(-%OVQ6#[]&\`X;ICQ/'Q_X[79:U_P6
MP_;X\*:.MYJ7C[Q-%;I86VK2R?\`"):<4BM+A=T,SL+7"JXQM)(SG'KCJ?#O
M_!5S_@H3XYT70M1TKXGZ?<+KL-M<6MC#%H#ZC)!/=_94N7M/)\Y(3,5CWD`#
M.3QS2EP]7C%2E.*OYO\`R-(YO2DVE%Z>7_!/)C_P:-_MD`'&C_#\DJ!G_A)H
M_P#XFHA_P:)_MD%=O]D?#\#LW_"3Q_\`Q->S3_\`!4S_`(*%M>Z_;6/Q3T;5
MKCP\PBEAL5T"XEO)%C\Z:.V00AKAXX2'=8P2@/-<]\5?^"V'[<GP!OK*U\7_
M`!9B@>_\QXWL-.T2_C'EN8I(S)#"R"1)/ED3[R$8.*<.':\Y<JG&_J_\B9YQ
M2BKN,ON_X)Y\O_!HO^V-Y>#H_@`X&U0?$T?Y_=I(_P#@T6_;&6;)T?X?D*."
M/$T?/_CM7(O^#BC]KZ^FACM?C1/-)&2;@?\`"/Z5P#@K_P`NW3MGU-6#_P`'
M%?[7Q)S\6KJ%T;#(^AZ5MY;"D'[-DKZM5?ZM8BUU./WO_(S>>T%IRR_#_,RH
MO^#1/]L16RVB^`.1CY?$\8Q_X[3H/^#13]L/C?HW@'Y!\N/$\?\`\36M<_\`
M!PG^V3::8N_XO2>9N8O(NB:6"$`W#`-M@FJME_P<5_M@W=A;M_PMV]:624Q'
M9X?TL\C.[C[-CC@\53X8Q2WE'\?\@CGV'DKI/\/\S]2O^#;+_@D9\9?^"8?@
M;XUZ?\5;+0+2?QP-._LK^S=56]#F%+P2;L`;.9H\>N3Z5^55Q_P:,?MB23LP
MT7P"-[EF_P"*HCY!/^Y4VF_\'%'[9,KXD^,+,I4AF.A:4AC[*Q'V;C/UQ]*G
MO?\`@XK_`&P;:U%S)\7KF&!.'"Z#I;F0Y'"G[*!QWQSUJ%PWB.7FYH_CT^13
MSR@I<MG^'^9G-_P:*?MBN>=%\`?+]W'B>+/X_+3!_P`&B7[9'F;O['^'X_[F
M>/\`^)J6'_@XO_;*O%=E^,-U#G!3?X=TK;@\]?LWISSVK]?_`-D7]M'XH?M"
M?\&\_P`0_BGXG\87=Q\0K;0?$36^OV\<5C-`]NL@AD3R%559<##*`>*Y<3DU
M:A!5)M6;MUW?R.JCF-.K)PBG=*Y^/I_X-$_VQR1_Q)OA_@`_\S/'_P#$TUO^
M#1/]L@X_XDWP^X_ZF>/_`.)KR2+_`(*Z?M,QP6\D7Q\^+,CEW0J_B6Y*<\`$
M[^QY_&H[/_@K5^TY%:1/)\?/BQ*YR64^)[L``]"?F^[QC\:V_L&ITDOQ,?[5
MAUBSV!_^#1']L=CC^Q_``3.1_P`5/'Q_X[36_P"#1#]L<`@:/X`YQR?$\?\`
M\37D%]_P5M_:=BU)E_X7[\6(X=J+N'B:Z;DXSC+\=>N":DTW_@K/^TW"),_'
MOXP,R$1#=XDN9`93TYW@8..E3_8=6]N9?B/^U:?+S69ZT/\`@T._;'!_Y`WP
M_(_[&>/_`.)I3_P:'_MC<_\`$E^'_M_Q4\?_`,37B^E?\%=_VH9O-CE_:`^*
MZK$2"?\`A)+G([@YW_I6CJ/_``5G_:DT.6:WO/CC\8;6YB1&V7/B&\C)5E#*
MP4MDAE(8'N&!':G'(YO[:"6:13MRL]7_`.(1+]LGMH_P_7Z>)X__`(FE'_!H
MA^V,HXT7P!^/BB/K_P!\UXQ)_P`%:/VH1.^/V@_BO]F/S$_\))=F1>OR@;QZ
M']*)O^"M/[45NDS6O[0'Q;N;=%&;EO$5VRQC(`S\^!R<<]<^HJ%DM3K)%_VE
M"]K,]F3_`(-$/VQU'.B_#\^O_%3Q_P#Q-++_`,&B'[8[GC1_`&,#C_A)X_\`
MXFO%K[_@K/\`M/G$4?[0/Q<3&T;O^$FNRNYL$C._].U6H/\`@K%^U&3,5_:`
M^+3K$/F\SQ)<@'Z?/GH,_B:K^PZO-:Z)>:4DKV/8/^(1+]L<R@_V-X`QW'_"
M3Q__`!-,_P"(1#]LC/\`R!OA_P!?^AHC_P#B:\GC_P""M7[4+VWR?'KXJM)M
M\N9V\2W6(#P2V-W7G%>[_!WX[_M7?%G]G\^.+3]IGXPK]L;4ULH'N-3:T=K/
M:VR6\$GEP/+N"QJ5)9BJ_P`5-Y'45G*:L$<TA+119A-_P:(_MC,O_(%\`9]?
M^$HB_P#B:/\`B$0_;&*X_L7P!USD>)XN?_':L:O\8/V^+#0-6U+_`(7)\0;B
MQ\.V,EUJ=Y!\0E>WMPDCQR1F1)BIGC:.1'C'S(5Y'(STG@#XA?M<>*/'GC+0
M+[]J'XJ;O!U[IEA<3:!J>I:]%-)?1O(DA>&4>5"@0^8[<+GI6,LJL_XB-5C;
M_99Z#_P3;_X-A_VJ/V7_`-OGX0_$/Q1I'@F/PYX-\5V&K:D]OXBCFECMX959
MRB!<LV`<#O7])=?RX:M\9?VGO!'AKPM?ZW^V'\08;'7@?M%Q9:C?:I'9R$2-
M#;HT$[/+<3!/DB*1[@3\WRMBK\8/BY^V#\*/AIK7B6+]J/XB>(8M#N3]I%CJ
M^I_97MQ??8@RW1/E>>9L;K;_`%B*P)STI_V3*R?,M?47U^-VK;']3-%?R;_"
M_P#;>_:A\4:MXNB\8?M-?%SX>VO@G3(]6U(WD^HW%SLFN8H(T$`D5P29E()P
M`!TY%=5JGQ+_`&YM0759?"OQW^(GB?2M)FMH5O[?QI+&;P70A,$@ADE61(W^
MT0A2P!#.`><TWD\EO-$+,HO:+/ZGJ*_E$^!7[2O[87Q=\:W6@7_[17Q9\-WD
M6CV.L"#^V-0U*]V7<L<=O_H\#EP"9D=RW^KC.YAT!L_&W]IW]J[X#>$9;K4_
MVG_B)?:OI%S:VFN:/!KNH+)I,MW%+-:XF+;)]Z0MG;C8<<'.:2RF3ERJ:*EC
MU%<SBS^K*BOC?_@W_P#BMXH^-O\`P2.^$WB?QGX@UCQ5XEU+^V!>:IJMR]Q=
MW/EZU?Q)OD<EFVQHB#/9`*^R*\NI!PFX/H['="2E%274_/'_`(.A[A[7_@DE
MXE9&"?\`$_TD,3Z&Y`K^95M)>[TXW$-RWV1+A<'.US$S$*0O\;<#H?K7].'_
M``<]0"7_`())^*F96<0ZUI<FU5!+8N!Z\5_,/):7#V=K<V_E.)`K0QI)EEVG
M!VCIG.?>ON^&],$VUNW^A\IG;3Q*2=M%^IIQW=O>W2Q+N3!8$=-Z*N"`SCJ3
M[^M9J&YMKV2;S'#1E81-YFW><XWG.0<`@5HZC<&+3[J:.X97+(<.0BC:>C#)
MYZYX]?3%216T=ON$B0Y;#\.0;9>H/(Z8X/'.3TKZ"G"[_K]#P(S45>WD5I;.
M*TBE>;S4\E_];M7=-N!P3QCC`XQ[UF^>)EA\I)2\Y82)$=I0)M.<#C!(!_#-
M:C6R7MTR;7N(1&)`T9W10@XSD8.0!U)R>];_`,(/A!XG^-'CO2/#W@OP]J/B
M?7]1E6W@L-'MOM%R58`,W'`C')+'``'S$8I2IJ3NM$M[_P"9K"3VZG(Z7#''
M;R2W<L4CX3"$85AN/#9XP,?AFNU^"7Q%E^"OQMT#QUI<,,][X;O5OHX9<()'
MY12&ZMM)!Z<X.>*]YU/]COX0?LP:T?\`A=GQ@AF\3#*R>"OA[91^(-1@QP8K
MJ\9A90/R055Y"I/3(I#\6/V2_"JQI9?`?XH^)PN'2]U[XA_99G?G@1VUJ$'X
M$C/'-8RKPJ0<%%S7E_F[&[C*,N>4N5O^MDF<YH?_``4"\9^&&(UF:3Q)?-J"
M:A,]Y/)#'MBL[RT%OY<06/9BYDEQC&X>I)J+XT?M^ZU\6OA=KN@6NA+HMMXB
M2:YU*:/7+BYF,\LMO++Y6\_N[8BUC`ME)1-S'G-=+;^+?V/?BW=>0WA+XW?"
M>Y5UB2]TO7;/Q);QC.`SP31PR%03SB2D\3_\$W;W7_"]WXC^#?B_PS\>O"VG
MQO<7HT")X-<T:,!O^/K2I<7"K\W,D0DC'<CK7/'V'.G4CR]G;[MKH2G6A!I2
MYN_?[GJ9%O\`M^:A'\.[/09?#D<L\.C+H]E>G7+M0KFP^PO-<0C"3EH-I2)C
MMCDRX)W$5DV?[9WCKPYH7@#0HM7:#0?"=A#`=+LIVMDU%8;B6?,D\0$Z,3(#
MA7^5E1@,BO$XYFT>]6=PSPP[5,`;;L;9@G'4D,3[\$58D\/@1V;K'':2;]D:
M1;MW0#>21PQSG`!QCK70L+3:^&_]=-UWMJO0PEB:FEY:?+7R/<]3_;BTGQ3)
MJ4=U\/G7Q#>VMMI>FZV/%=TNJ6%I$#^YGN&C+3,S_,[Y1W4(F0JX/(?M<_M1
MZA^U]XKTF6YT32O#%MX6@GAMX(I#(&DGE,LTTC&./<TDA],XVEBS$L?*O$UK
M'?2+%F)8Y"-JV\Q8O(.H.>>/;C@\T]((9[I'?D;FB4,^1(,[LG/'4^YX'>B&
M%@I+1:>;_P"#L;O$3:O?=?\`!*D=A]G>2.#R+IT=9@HC(W)R>O\`^OIUK0OM
M,;R;9?,D2+<99(A$7>,[L_+GTX(P>F:DMXH+QD6*'[<EQE4CD0F5MO?KQW&/
M3%=)X?\`AUK/C+Q!!IWA_2+[6YYR"(Q;R$`M@E3QGMTSC@FM9QA!.I/W5^"_
MK<X*^-C"TJCM;5WT_P"&.2FU%;B^GCB:24W>\.X<LKA?[JL.#PV,]P<5)IUK
M%I.G@O'YJRSD(PE\LH-@'YG.,=S7U9X-_P""7WBS5X_.\4WVB>`?LZ-(K3YF
MG1`3A45`1O9R.IR!VP:]3^&/[)WPT^%1@N=.BU#Q5K98,MQJ4)"J.@9$'R*=
M^3SV'OFOFI\89;S6P]3VK7\JO%7_`+WP>OO7\CXG-/$7*<+3M1;JO:T==N\M
M$E\_D?+7P^_8@\=_$K2BTVFCPY99#&XU=FM"JL57Y(SS(<,O3KVZ&O:/"W_!
M-C0-*TJ\FUZ[N-8;3%7=&ETMG!.V0/-4\R!,,,YZD&OJ#Q=XENM!M5GN-=@U
M%LF-)"=QM,KO5)6&%C(4%<C@`CJ>OA7C']H_P5HWB>\_M;Q#-=ZE;0#$^GQF
MY@1CA62.2$JAX"_*>,,3UKYK!Y]FV8I35E%V^%2;M=7T:C*UK^_I:_PNUS\Y
M_P!<N(LVJ..%O"*UM!-OIUW^XQ]+_95^'GA#6[.[M++0H40E\W]Q)>B=,,$Q
M&6P%P3D<D8'RC!S^MOPF\(Z%X+_X-U?BG8>&TL+?2!X6\220-:QE8CN69BVT
M].2>/IP*_('1_C1\+-1N)H['4)=%EU*("2YO]/=$,B`L0.6*9;EF*_,02,5^
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M#]3\,217WQ*\/7GB;6M=;5;EKN^E@EU%8-/MX$PJ^?\`9(D+`-(68!,$\_'E
M[?:U;13I;ZEJ$*:JZ-?6HNY'BO67G,@W8=A]X%P<9R#46IZC<0)"(KV^1HEC
M*#?(&LB)&9?+Q]T#.1C&"Q/K6;PTDFF_ZMZ]'T-?;P;32/M_4_V7?AGJ5_XF
MU?0?AEXD\4>(/"?@:#4I/`QL-7TJWU"]EU1+-I[>.;_39+>*V?S'"GB4,=VT
M$5UG[:'[':_&_P")?B*[TGP-X@N/$^B>(_`6B2Z7:2RWEQI6E7.@(LL4NT9^
M26)%,S`8(Y(S7R/\$OA7\8/VM/BXFE^!!XP\0>)1;M+<:R=5F3^S;==V9I[V
M1PMO;@=6=U7&>]>JZ?X(_9^_9+U>\MO'/QD\??&?Q3=6_P!FU+1_AM?OIV@Q
MA0`;>?5Y\M<*"`#Y$++P,-652,HSMS7=O^#]VF^AK2<9PYDK+^OQ\C9_:0_9
M!\'?`[P-XCU#PK\)M5^(<4WBKQ1IUYJO]I7IB\%PZ9=^5;P,8#L!,/[YWN"=
MZ.`NW&:]'_:<^"WA_P`:?&SX[VT6@+\+?#+:-X1DMY-/GN(-+O[>ZU#3XWO6
M1R8YHU25MNW]WNC#'YLFO&I/^"@GPF\(:;<V7AS]EGP=_9&ILKW46O\`C?7M
M2GU,@[MTX2XBCD8$DY9.O:G6O[8?[/GQ8L4T[QO^SWXE\+V]Q#]C6[\"_$._
M8VL2DN%^R:@9HF1&Y$>Y5R#C'6LXTY\RYHO\/+SL:.4+/56_X#\CUR#]@KP!
MXH^,&GZ-K_PV\0?#FPTWXJP^#[59-6NS<>.=,-O=M).'FX\Y?L\$GG6X\K%R
M!M^[GY?_`&HO"7A67X)_##QWX0\'GPA_PE[ZSI^HZ=%J<U[`TEA<0K%.LDWS
M;GCE`<="R94+G`]!\1?L1M^TZEOK7[.'Q@U/XN7&@6S2IX(UR272_&>AVRX)
M%M;.[1W48`P39R%N^P5\PWTNHV]Q<V-^+V*6R9X%L9O,1[65<[QY;\*^0-PP
M.1S6V&CS3YE-Z?Y/H_,RQ#486<5K_P`#L9MW=W4>II,8K<(J%BZ$G>Q[M^)/
MY5N?\+7UN\T/1-+DU;RK?PQ/+>Z:@7RC;R2/'(SJ1G)+1H1GH5]ZQON7;"92
M6E0,N[`*ELGA1CU]._`K6\->`_$/Q)U9+70]&N;CSHPVU$^1VW8X].3C&:['
M%M7^?]=CCG5ITX\TVHI+>]E8]3;_`(*(?$^>34I[.\\/:>\EG<VOG0:#:P.O
MVAW:>=`B`":8R,9&Q\QP3]T8\\\=_M!^,?'%OK-IJM[;&V\13V=[?"VA2V$\
MEK`T,#G8!SM=]W]YCD@UZ;\.?V"?$^NZG;S>(E;1[9Y_(>")1).DI(PI1B.N
M>N>.>P->^Z+_`,$_/A]X8>TLK^TO=;O5E62:ZCG.`^Y`L8C''S*3DG(`Y'J/
M/Q.)PU%J+?OOHET[^FGWGQ^9^(F3X&7(ZCJ/^[[WXWM_PY\Q?#;]N#XA?#^R
MT73],F\,&UL$%NH_X1VTF%\!"]NC7!"!II(HI)$1F.Y`[8.3FMVU\2_&GXY?
M#V?P-X>\)W$V@7EV]_)::3H$=BG[N0S[`P4$0K(0XCW<,/88^MM+\/VGPNM?
M%&FVOAKP@DVF1I,)180S>;B1A%O165D*JQR1U9`#R*UO#WCF_P!>N=/!O+**
M)E?]W):K)*2P5GV#+,9!G'&.&4GIBO/EC:M2E.IAH1TMJVVG[O-=66N^U[ZV
MWN?)8OQ7K-<V$H+E[REY7VBKZKS/E_X=?LW?M`?#'4-?U*#P1::HVN6L>EZE
M9>(#:ZM'>0B:*5`R3,V[$B1L#U&WL*]0T/3/VJ)M&N/#VK:?X?UC0=3OTFU2
MP.IV&G7<RM<Q7!B2X7YK>))8HCF+A`$48&!7>?%_XOK<>%K:VBU:\FU"WO(S
M:"2+9'*I0"3Y5`VY(.6]0>F*S-1U`W^F+9W5\UQ<PR/+MN-S,KA%.]D!#,A4
ME@`>203SQ6%".:U</&I.5.,F_P#GW)Z>7OQ_']#S</XCYZZ:G5A!)WZ3^_66
MJ^[J>4R?#C]H2']J/Q;X^T^W\/1^,O$+27=^)S;7=M9[I$=$7>"D91UB\L#Y
M@$7C&:XCQWX/_:*^*O@FU\(^(_#US>VMA,LLCQV=O]KU&2-3'&\\R#?/Y4;D
M(7+;0YQUS7U`;FU\"V5O=:I>PR*ZW#75M.R$-.%`<C&,MEAQR5.#UHT^-O"O
MB*PU$^+=#D2TGEE2-X#-++`X1!&I`R)<E^6XRPZ`5W4ZU>G&51*,K)V]UJ[2
M=^K=K^6BMJR8^)^;NZDH236GNSU:W2:??NOF?M#_`,&\WA+4_`O_``1Y^#VE
MZQ;FTU*V35_/A9BQ0MK-\X!)YSAAGWK[1KYI_P""0&6_X)X>`78R[YI=5F82
M.696?5;QBN22<`G`YZ`5]+5\S6FYU)3ENVS^C\BQ4L5EN'Q,E9SA"6GG%,_/
MS_@YJGD@_P""4GB$1]9-?TE._(-R*_FAFTB.QNXI)=\<'[P#RN7)X;'/W>@&
M>/ZU_3!_P<T6DEY_P2=\4K$JLRZSIC89L`@7`R/\^M?S(P1RZKILLZ-&9[20
MMEU_=EL8*!._&/Q'2OO.%Y-83KN_T/GN(%_M=[VT2?SO8LVJ6\^ESK)(Q5D+
M-%+$1]I!;)8'^`CIT]?:J[V8BT)6EP+U`L4DIDW97&5`X_GQAJ[SP1\!?&?Q
M,\/F\T;PAJ^K01A8I[N*/98+N?8!YK8'WF`&,X(/8BO6OA[_`,$RM92[LH?%
MGB"P\/7LS1S-I8/VFZN`7`_=L/ERQ(5<$CD9'%=N,SG`86?LZE6/-U2U=[)O
MW5=Z7UTZJ]KJ_P`7F'$679>KXNLHN^V[?HE=_@>;?LO_`+.?B']K3Q_;>&_#
MD=CI"VT,E]KNK7X\K3]!L8UWS7UY)C`BC"GCJQ957)85ZO\`&/\`;)T;X,^!
M+SX3?LYVU_H7@V[A\GQ#XQ,?V;Q#\0G7AS*Z$O;69;/EVD97Y2#)N;(K[(\>
M_L\>'OV2/A!;_`OPE8S:SXF\3NNI^-IM1Q*VM7<,?F1Z4TH8;8+4,,J2`9B3
MD[,5PGA/PQH?PVDETV&P\/Z?+=9DMHK6Q$L5G/&#@"7JTBL#R2`21Z5\[BN+
M*,JC5.#J26JCI&]M.9K5VO?I:Z[[?,YOXDX7+FZ&'HN<NKO;7K'9OW=I>::O
MIK^>>B_"#Q+-.7LO#6ORI&#.#%82%8TX]$SDY''J0:Z#1_V2_B-KAC7_`(1J
M[B:*)9<7LP@?83N#NCMG'.1^)[&OT!T^WNO&>I)JEE<>*+/SV/FV=O:$+(=F
M)<H&'0;0HZE1QG(%6_B%H=EXBTK2[FVT%WU:YEN_+\YFC&H$%8T+D$X7.X%>
M^7P.17DUO$"<:\,-*FD]4[/X79O7FY=';=7>]]$V?)U?%'%MVA2A'36]Y6?9
MZQ7J[V/AW2OV$OB+?K/=7<&@6$$DT2%S=*7<G/(V<MC!8C.X@9P:]$^$'[%?
MB+X5?%2#6=*^):^'=?\`#\8OH-5TA6MKBUF"[CL=9.0>!U^;=@KUKZ]T?POI
MSW'VF+3VE6_N?.`<B2)9%B\MLHR]6;[G(`!R,DTZUMKG2?!NJ6UUHUI8/+?)
MJ&98XC%&455&"WSIN92.!T)-?/8CQ'Q4[JG97:5O=7Q-)NSYF^76ZMK;IU^?
MK>)V;5;N$E3T^S%7OMI>_P#3,3Q-^PY\/O\`@H#<&XGD30/CS]E2YEDTFVBT
MZP^(ZJ/,>4P;3'!J&U265,"8_P`(;KYI8_\`!/7X;V'VVWO]%UN:ZT^:..4/
M/.1>2=6C7HR\D9PHQUXP17KWANUU6\\2:-JBQV.@:Q8^?*);61K6ZNMFQD?Y
M]H0;L`[23P>Q%>W?'?19OCM\.M0\?>'I;.UU][J'3_&NGZ?L=H[]H\Q7Z'<-
M@G1=K!C_`*U"`?FKSL3QAC6E2I8CDLKRU5E[RB]4G96UVLDVW9H,7Q-FV98=
MR6(DJ]))RY6XJ<;ZR]VWO1Z]UK9.,K_&WAC]F7X4)>W4=QX%M;B.SMWD+6V9
M6MKA%'SJC$9BZ`CJQ8'M6E>?LW>`TL1K=[\+-/2WM[E(X#;W&ZV2[0\0J[`'
M>2"2"-I+`<X%>KZ7I4O@>"^O/$&L07#6B1W+R!$)VF-&?<F<$JRC&>1@YKS3
MQ-^T]\-OAS\-GTV\U'5;"350;JR?RFD>5)'".SQG/E[0A`!SGCIQG"&99EBZ
MO/@/:U8N4%+EE4Y;/=K6-FM&TDW;HK-GAX;,<UQ=7V,)U)R6GNRD^FU[^MU;
MH=GX3^$_@CP1?V.JVG@7P]+>W!^VD@*9K)WRA5BO"A=K,!@9QTQ73>'YKBVL
M7720;&TO90J;G1S(0A1MSC+-\C%5],DC`%8\GC?P9XT\,+>:=<S:K+JX5K<1
MH99;A`2)MHBVC>J98]@(SGK@Y]]XPT?P?`;:TAEQ"R1+:O,Y,1WB59Y0"`<N
M2=OWB7Y&*^9K8/%XY2IU:=656]FJG,TDM=%*;6CLE+E2WUO8\.;Q=22]M)W=
MTM7?31WZ[VLG^96C:^\50V1U36LVH6YMY;B:V#/=0#/`0G>_W4'4$`/WYKF?
MV@_VC-*^`WA/38[F<NE];%8-&A?'VKYMKIN7!3/!RPQ\V`3VY?\`:9_:I'@S
MP?')83Z5/>W,(LM*2YMI!)=*^99;D[OF90Y*;'QC`QU-?#?BKXC:EX[\976M
MZ[=I=^("Y::27YXU7.Y>..A(`'.!CM7Z9POP;/%3IXO'P4(1;:@HI*[OT25K
MIIWZ-:6=V??\)\#U<RE]:Q6E%:VM9R?Z)/1O?HK=.P^(7[3NM_$>*8:GJ5W%
MI[#FR1EBCE.?^6FT9?@]\\@&N)U&ZBTI4DAM)Y)22(HC^\A8\DEA@>HY`YP.
M]*;:'5+*5&:WCCO1N>X*_O`<D$-Q@\G/KS^4T5@5C9+JX8?:#Y43!=VT+[DY
MQZ'_`&:_7H4XTHN%.*C_`%_EZG[3A<+A<-%4J$.6/9+_`"^90T[3O[2U!KZ[
MD>[BX1?,4[0=O3;G[HP0/7FOWD_X)Z+))_P:]?$?:ZL[^'O%.T[!&!Q-CBOP
MDMK@"`"49:"(@!4;>'^8EAC&T;?UQZFOW<_82G+_`/!KO\2F6/;M\-^*,*0"
M,`2XXZ'BO$X@_P!WA_BC^I]3P_*4L5-=.5_H?SSG5)T,7F/'*ZQD(58$HV?F
M8CIUQQ5(*83=).VT`?NHU!=7((Z#MD9/7FGVVM1V<L@E5)$W`B8C:%(8X48&
M"<'I3KW5[>U*JRIMD5G"HQ\S(`/S'H%/_LOM5WC**=[?U8[%&2=E$IF1);Z0
MYN%APQ8,=K]AR!D\<8'O7L?[(?[*NI_M7>-=4M[C5K3PCX(\+VHUKQGXIN3O
MM/#FG(W^L.#EY)"0L,*G=)(R@=#CRW0/#.M>+-?T[3O#FG7&HZAJ3I#;P0Q&
M61IG98T16&<EG8*/<BOL+]LK0-:_9S^%=M^S9X"TJ_U'3/!MS%J'Q$U>S@8_
M\)+XI,8+Q/(!AK2Q5A!&H."XF?J01S3G*,O9PW?W;?.YI*K1IP]K5DDEW:6O
M8\^_:/\`VW]-\:_#U_@_\'[74/A[\$+*4[[$L/[6\73)_P`O^L7`.99'(++#
MGRH0<`9&ZOG@(EB/M-U`!'+@+A@8B<G[Y''`]^]=SX;_`&?/%GC33O.M?#5Z
MT2K(MRWRPMA2,J`Q!)R2,`9.17K7@7_@G=/<W_E:KK2W-S;3Q0S6M@HBB,1V
M_.68=0/E*XZLM5>G0C9KYW_/^O\`@^#F?%6685MXFNEY)W:^[;YGS(MJ8+[Y
MEC;SE.!Y@\W!4X&.@ZCIGVZ5;@\,:O=RPE-*U*^:4`EK.!Y=Z$%B1\OH>3[&
MOM#3OV1M&^'&BSZI:Z#9/_9]TGV6>[NE,R2(X\M,ON52>KX&5.T8QQ7H=S=#
MP_KD8V>'-,>W@>:4!W0WKA!)L)R-Z@,W4C@'.,5G&K1GI1?,^EFO+3??5??V
M/D,7XF44[8.CS[K5VV797?4^-/`W[-WQ0EN]'\2Z=H^O:,C3)+IFJP,T%S`X
MD($JLI$BE-O)&"./45][0?L91?\`!3WP7:6WQ(\3>%O#W[2.F;8;+Q!:;;8^
M/8#E([;4TX47S;,17(`,GW9,G#5K7'Q=T/5O`4EKH%CL@N)8%NH8;@12^6B[
MMHP"T<3,A;*\D$9-:/Q&O)KR^36=,T*.TN<1W1BC\LS./.PAB8[6PQ(.0O&&
M;!&*^,>>XZ56-+$T/9:M)N4>G+925[ZWMLUI=[JWQU7Q4S?VL8JG&$7)IKK;
MM>5[.ST?=+1K0\?\/_L+?#7X?6%O8ZSH6K7FJ-</!%]L$B7+3IL!1F4XC^<2
M(`0,8;VSUWB&\T>'18K?PJEIH5YIF];29X4-Y>.6=)9PBMRA7)+8P%Y^]7T)
M^TG<7_[6_P"S=IWC>*7/B[P;.+/QI;6]N474=ZLMIJ#[2`8Y/+V2L@.9%!_C
MKYBN_'GA+PCXDT[4M4O+:'5=%@^UWMO8B7[-;G86=2S=)$S@J>I(R.:O"4L1
M6;JUY2G).?NI\T;7T]VUO>CIJK)M^5OF<R>+JXCFJ59UT[RCJY:.]O=>B3^&
M6EDTUZ3126?C:XTV;41K9TS4DACN5A812*PR`5PN\?,2V"?F#Y/MK:?X4FN]
M2\07B:F^E6T/DK''<H@OWCE^7Y5!\P'RPY<$D$-QWQRJ_&NP\6Z?%)X8OM/T
MAHYTSKM_,5M9'1OE)&2J`INSN^4D8ST%<KXDN_"WQD\,:M=:SXVLEDMH+@2W
MHN4F60AE)8RJ^?ERVU2F.<CFO8E0JN:C*7)HM+<S^)7]W6*4DK=TM;(RH8"M
M?EJQE3C\-K.35VK/E2MKMWMND=)H/CG0M1\0,+6&ZO;+4;)[8WUO(K6T<J!A
MY0DZH0J#[V>&!-:G@7Q5K[Z?>2_\(II4SQV*P(YNT+PLCB0N`%&>N-H.26(/
M&`/C?Q/\3H/!/A.'POX#O]4@L]V[5;AV5C?RC)5XAC,:A>,@Y(-<O\.OC+XF
M^$_B.:_T;7KM9[M3&QN7:5&VGT.<.&P01TQ7KXO+J<H>SM?;=OH]'HUY>OX'
MWT?#RI6H3J4I*[^%3YKM+9RL_=NO71+3='Z)ZMXELO$6EO>>)HM-6>QN$*HT
M*6L_EQ[2[1/&1\Y3#;&[L?05Y?XB^*3'Q;<R7'Q(\.:9K4"-:6]O?3[9+D-(
M=PDD57&=HYSQ@]>E?*^L_M/>-M3T6ZL9M3W_`&E6$MVT*&XF+#YLO@,"0J@G
MT&.<FN"M-8E@N()X[MOW3^8-F</@$[MI!`./P]JRP^5TL.G&#LK6M96BNJBG
MHD]GW.C*?#25)2EB9KR25U^*T3ZK?S/MW4OB5X8O_!MUJ_B+0%F28!_W0`:^
M#JS1M$R-@?=)W$9P%!Y.:\R\)_'K2=7U5+BSM5E-S;"VCLM7E>06I9VS@@;L
M_*2&)W`#'.23XSX;^-=Q;Z#;:==K#>:5IUQ+=3);P*LF9&&YBIR#MP/3`)'>
MO0/"'PXTF30M4\2V>KRRV<%C+>1+"&;$[)A&;^[_`*S[I)/7'2O>H0I*]WH^
MEWIL]-?+IZ'6^&,/E].HL5S>\[1LVUV2MK9O1OR\D?TV_P#!#77X_$__``2U
M^%]]$FR&;^UA'SG<JZO>JK<\\@`\\\\U]9U\0?\`!N(2?^",GP<);?DZV0=Q
M;(.NZ@1R>3QBOM^OS/'6^LU+?S/\S]]RNA&A@Z-&&T8Q7W)(^&/^#BCP!XA^
M)G_!,C7])\,67V_5YM<TMHXO-6+`%RN6W,0!CU)Q7X?_`+.G["/A9-2EOO%=
MYIOB34XKMXA:1S36UM;SI&"R2*.'9F)!?=MP.*_H*_X*]QO<?L/^((4BFG,U
MW;*8X?\`6N-^2$]^.W.,XK\:]$^&\-QH4=S+;6MI$VKM+9V=NO[Y\@R>3+G+
M;78'D#'W00.M<N(SN=#"RPOM'#:W+9RO+3OIMIIT=V?SWXP<1XW#9C]0P]3V
M:<(NZ^)W<KZWO96Z6ZW;V-NUTZ*%;?P]<W=K9:3I,9>#0],:*\-L'F.R-<?*
MIY^Z0V2"<Y(KVCX0:!HJ?%KQ%\5_L;7VG^`=/77;:"]MEMDN[QL16,/&%`^U
M'<<@<1MP*^>M(^,?@Z]\27N@VE]86/B"-TDO8[N(PQ*F\+B4`%MR#)PI9ACD
M`=/2?CIXMC^%'_!/;1K33M5M=4U;XK^('OIY'O5:"'3K#$<9@CZO'YD_(/?D
MY->%E^4XJMF5)-3A+56<?=:G:3D]WJUS-RFV[==>7\ER+"XGZX\1437*N?5=
M4DHO97CSRB^[6BN>;^.OC3X4L_$>H3^(O%-CKVOWK/-)87\VYW:4Y8(R\'<-
MX^]VYYQ4$W[0VE^`)K^_T^2/5GO"\36G]G_9+JS4%D\MA@B38[+C'+`'!R17
MY\^.=>M=0\;:I+_:EU+.)7'VG4%\HMMR"^$PH)Y``[`5]9_LZ:=J'B'X::;-
M=^6)[2V#&6X9DDN81M8Q1[LD2!MKJP_QK[O'\$X*E",\3-U5LT[*+OT44M$F
ME:VNOO.6Q[&=<'8?+,)3Q5>I*?-;F3T\]-+[_/N>J:O\<+O2XK&;4/$&DPR-
M(;R?[+&T>R*W1FV3MT4LJA1@@,``1Q7!?"W_`(*!V?B_QLFEVXN-(NHBLVFZ
M8DR/:$`@,[R!=[/E<[,!>1G-<S^T!I\MK\+-=26VB>RU/'V:25][P%B9"V['
MSE-Q!'0;CQFODG1;[RM:M+AKAC.CJ?+AE+,H##/S=0"#R.G/2NK`<"Y/.G*5
M2A'7162V\NETFHJZNDM+79Z/#?"6`S+`5:L_B6B:Z.U[V7W/KIH]3Z=_:O\`
MVJ?&O@_XJ-HEMJNEW%I]DM[@SZ9<?:'@G`&Q@X(6-B`%*D$#ICFM#X0?MFWQ
M\*ZEJ^L7L]F;..&68,NY[N9Y,$(#]T$GD<#"\=:\+^/Z/HWB3[;+JPNXY852
M">V5F;R^6"<@%S\P&3S\N:/":Q:A\.O%<MVUBES:6MM)`)824F5I4``R>",<
M9YKW(Y%@%@8T*M.+5HJ_*NEE\DTDK;'T,N&LMGEM*/LE]E.23NVY)/IY_+<^
M@_VK?B_JNL?#^[U#SW:;4EC>1#"$F@$A4A!)P54H-^T8+'.:M_\`!'3XC2Z%
MXWUO1]19(_!/Q"FC\+Z_=^>[2VXNB5MKI?>&Y$,N>RH_8G/G'[-WQ&D^(DU]
MX>U,VLVJR36\^GK=>:WVP(HRJD-_`0.<%ON]AQ[+\/\`X>MX/^!MOI]I<1P7
MNHZZ@N+2"Y6-99(S*5C"CJ5?`VL<CL2K5Q5_9Y?@U@*,$DW&*26EG:\EZ+:^
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MSA<Z[>VS6[7LRQRE/-*;7;YSM"$`G:.&R.M?)OPRO6\->,M#:SG%LT6I1217
M",P-H"V"X]AGGDD;>`:^C/CG\4;A+[7-+U9-'U.RT](;J-;>W+QI(%4&*0C#
M#D9R&4';CG%:X_+YXBNJ<(JTK.;7Q-1::5_7SOOW.3BS+I5L9'#T4N6I9S_F
M?([?JNJV?<\8_:=\67GBKXH>)IK\[QIEP]A!%:3.4C16^5E8Y."1E<]1UQ7#
MV6D?VAJZ&5;2U9U9I5E3&>`V<\Y+'M^%5H?$O]L^)+B\:WLU6:0>8CJ60KNX
M(ST4$$'/.,5J:Q#;ZE<6!B@97,<BRRH^(F4!1D#V/3U_"O>HTH0A&&]K(^]P
MN'^IT(8:*LE&U_EZ_,BCN#+#>/*(1'=Q[$V\?:6'H.@Q@#.!T[FETS3$N)#O
M^RM/;\97<J8(S\P[G/<=-I]:K7=LB7IC"?9W)V2JRX1R#M`!]?K@GM1=PMO\
MF(M!&[^<2KE5@0\'J,D9!XQC!SUZ:<B:.AJZLG:Y?TB%]-O/L]O:LMR0QD9Y
M0S*HQE3SP<`GD=O2OWF_X)M^'[WQ_P#\&U/CG2M.6S^WZGHOB6S@`F$4+2-Y
MJ#+-PH)ZD\#K7X#Z)*/MHAT[/VZ<%C."O&"<AL\X&<$YZ5_0G_P1W$MO_P`&
M]FLF^$,LHL_$#R`!0K9>0\[CMZ8SGBOF>*&XX.,T]>9>BT9Z662E0E7K1^)4
MY-7W=OGMIW/Q*^&W_!+[6GTZ*?Q1KFG6^GSZC]C%KI$@O;E)57<Q^@'&1N!(
MQ7K'@?\`9-\)>`?%(\2:5X=B30_LD^FQ7>M-)>&WGCA&)C%P?F=6X*G`/"UZ
MS\2+G2?`4CSW.JL)-0MW@$-LS/%)'N,VS`([`#(QE5&3\W/%:Y\>/[-\4Q6G
M@+3M0DN#!&PN;U"B"X&'V!3D%3G<<D=N<9KXS#XC,\93]I0O*+3L_@BE>^KU
M5UI9ZWM\-I,_`ZO%>>YO%VFU&2=[+DA;KK?\[[;'T)^P+X#M/@-H?C/QYJ[Z
M%86_@6-9;)(X4BMWUJ5I(K%@,`%(]SR8;!'D9QP#7AWQ#TVU+67B&]U:2[\0
M.=MWJ+2L\1W%V9T0$*,JP&6!V%SNKW#XS?'";P+^P_X'M?[-TF_U3XFZY>ZQ
M<2.X(:"VA%O#+L9<2+YDESUP.,9/6OEOQS\3'M=:M+>#PXK>7?\`D%C$\LPR
MS;U,:87)P#\IP$`#`DUT9=A,?4K*K43Y97;4>6STMU^SLK>FG=5\-C)^QI5-
M';GE9K5S5WUO;DY(M/2ZV+_AKPE<ZW>*NE:)(_V]E:65G^RCRE&/E9<A"[!'
M.2"23SVKN_%<GB+Q%H\-TDFFZ7!<3FVO$N(-Z,Z$JC;."202-XR,HAR1P.-M
M_P!KWPMI6G:M/YTUD+"_CL[.&YD+68ED`+HTBC<40D\$#IM!J]X8\>ZO\7H8
M=9MXT:4H\.GPVTT<8EG+#>HA?#^6H4DD8!!(]SV8N&,Q%:-6M2C3A%V3E9O7
MIJ[/IKLFNRT\C%X3&Q_VC$4N2$.LO-7ZNSTMKTM?4=X[F\"_#^^M;75/$US?
M:1IQ6&X:V@,AC#K)YBF7!0`ELE6YRW7@"N1\3_M3>"M#9-,LM#M]9N-,M+G>
M1C:\8(VM'YKXD8`$]N^!@XJCX^^"VLZUIL8DT\VTB7)M8X+`R2PWURW[QI'5
M"W*[5R&Z!ACA<U\Z?';X9ZWI7C.\U>VM/M&CQ1>6TT$2O$Y0*I(;JOWOF/!R
M&X%>GA\KHU84Y2KSJ/33F27:]H63^=^^Z/K>&\CRS&N-.O7<I)/JDF_^W;:N
M[V?ZGOU]^WWJ6M:%K4L&EQ0:=;0)$C-(@N+IBQ>(E/0D8?#$C)Q]ZN8\)?\`
M!0/Q?8>()[*RTJSFN[N<6UO#<1BX:RBD146-02,!<$`9VG/3/-<W\-;)-`TV
M]M-9VQZ<IL;J."2R2X8NL+[-LA;(!.SHW).!T.9?A7X032?&VK3R:>+M;K7+
M<),B>5NB*ERN_</*616/(S@`X.>*ZUD&6PI/#RH1<?-7OI^;LE9_D>^LFR3#
MQK)8=.R36KL[\O5Z:/>SL?0?[+/[?_\`9W[6&G?#'7M:FG^'WC*.X\$ZV]JG
MD_9%O?W:SJ44?ZFZ:.9<?<V$#@<_*7Q;^#]]\*/CYKGAOQ5-=FYT34+O1KW8
M0KK>02.K-*"&W!MN[<2=P(Y[CLO%'PTC^'OQ-TC6](DCM;2^U20PPBY6XO+/
M:VW<^1G?G`4=3CJ<U]$_\%H-4A&HZ;XW4PFV^+/AW2]55%C:.6>Z:V\NX9F'
MR[Q<6SG`Y!+9'-:8:C0PLD\/%1C*[T22[]-V[N[VN>]EV(PE/#TJ&`AO9=$]
M6U+9;J5G:_5_/XE^*WQ_N/%WAFS\*V,DVG>&[*(02P)M07N#\OF%`?ERH.!D
M#(ZXS7FXL[-CB5;A-[#S?W8+..0`N.G#>OI2W-P;6$(I6#R@8Y+8?*0,<9ZY
M]L\YJ2]C5-8MX0]M'(6,I5G;=)\H/?Z'`]J+Z\VFK_K^M#[G!8.CA:7LJ"Y4
M[O3KU;?F^_IV)KB"'[,\/"Q3%AO`Q+E!@=^G;MDXJ>>>'3K/88C:-(N6!;E'
M#\%3],]>],>RCGU037$I?)5\)'EV4<D]>I`XSUP*MZ:TGB*]GCT_3WO3&SW$
MSQH;B2..-=Q9@H/"#YBV,=SQ6NK33T&_>UWZLB"NL2<QW5O<;I&;=@KM'4YY
M(Z\=LG%1S7<CPQ"'*-$@ED<$%0H((X[9..#Z=JT=8\#ZKX=AL-6O_M<-IK%H
M=0M)'V;;J!)7BR`#]SS(V4Y_NGBL#4;X-=YDEC2W$K2^6F#OZE2/7T%'.E'?
M0(QO(ISP"+4##'\R,6#`$_/N'))`QC(_E6SX2\=ZEX*BBBTS4)[6*RN/.CA5
MMT9E"D!V7HS`9&3V-3^)_AAJ7A_0]!UC4K.:STOQA%)>:5,TB$7T<,SP,ZX.
MX`2(5P?[OXUBZ%8VUXD@E=(MLF)%C?MT/7OP>?0US_;]VQU5H4YPM55UI=-7
M/ZOO^#<_7YO%'_!&OX.W\[*\US_;;.RH$!/]N:@.%``'3H!7VW7PW_P;<1&'
M_@BU\&`P`.-;.`.F==U`U]R5\'C;_6*E_P"9_F?6X11C0@H[67Y'S+_P5W\2
M3>%/V'/$EY;6D5W=+<6R0B101&[2`!^>A'J.17X*>)?%.IZ_XSO8SKAUF[F0
M2FU2-D;+HT@C'"^8F&Z`#E5R3DU^Y_\`P6SB^T_L%ZS#]MEL!-J=DC21XW,#
M(<H`>#NZ<_SK\2[+Q3XAUOQY%I7AS2;2W^T6L5O#>ZBWF17&U%+EGV\$J-F<
MX`)!.3D=F68>A0A5QWLTY6]Z3LDHJV[:V5V[*WG;0_F_Q737$/,DG^Y6^EO>
MEU:?_DNO<^,--N9="AU*+%SI]_<VLD$OV2??(P9P3ECC(.WMDY(YQ7TG^VU=
MPZ'\&OV7M(N=4^S3Z+\.XM66V!9FG:]U*\E8Y.0``D?4Y/;I6)\5/V4K[X61
M>.V1;#5M!O"5CO+:_@D6.X1RY$94G*H"P('7G@[>*?\`P46BN]:N/V>_L[[Y
M;CX2:$(8XUVVTK)+=QMD]!RA/)P/J:_0,-F5+&JEB,.^:+VL[_9_X+_0^GRC
M&8?'8>O*D]K)]ULVG>]K/1IZJQX_\1OA3?:.MIK%_;12:?JDC2K$LHD&%=MP
M..B$\#/H37TKXL^(<?B3X+>#A?7=G`\+P+:".=P+)(8&:&,%0?NG:-QQDCYL
MXS3+3P8VE^#M0\)2VZZC_:%I"["%53R9VC20L&VDY/+;/X@6''6N`_:0T-;2
MY\+WEO=731Q6!L]0CCLF@@BVLX$;$#:'8+W/39ZYJ+X;&5Z;<?ADW&7R?7?5
M::Z-ZK>Q^?SS!9M4H8>L[.,I.+5]8\MXZ=.UWNUYFM#\3-*\6_!Z;2]0F^UZ
M]JUI<6>FQR*9UL_,D+!&#8,3YVE<9XZD]!\TVL3^&;\70C1S#(`[LK;T.!^\
M7/X=1QCWKT/X+V+:E?0P:=;K/=I.S?9F;;=3[D)5A+@]0H7U(R!UKSZ\MX;/
M6+]6N%AE;,<D.&9F=2"5Y^Z.,'GK]:]&GAH4VW!ZO7TNNB_R\S[7)<%2PE6O
M0I/1OF:>N[?3HK>IZ[X+_LW6/@KK=UJ;^3]GC;8[S-YUS*C(P$1*[LG)R2.F
M`.^&?`TKXH\-^+;2189;Z\T^-[>-H_/='1E;RRIP$'``/^-9OP/\=I>>(E\.
MW4,307R310B8LIC9SA23\PX!..Y;'-.^!GC23PU?:]I4]G+<1:S'-:L(MHF,
MP+@-D`A>%8DGCCMP:X\2IN,O9N\G;R2M;\+J[[]SS,7AJL(8F"6MXS6O2_3_
M`,!U[GG\'B%/#6L6UYIC7.EZG;LMQ9M$RR;AN)YSR&P3T].]>\>"?VDC/HEC
MJ>HZ2;C3DN;6>^1ECA*M$^2T(7!WN,-[G/'%?/D%CJ?DI-%;^:YMV2$.!+%L
M!&<+UX^;GH,\=*[CX36]WK_PXO[:[FCB2.]M9(8Y8F?>_(+2%1PNT\#..".]
M=%:C3K6A):/3JM/)KKY'JY]EF$KT(U*Z3Y6E>^MF]M-=]?(^L?\`@IC\6M%^
M)7[%7[.NK^&SJ#V;KKENMW>1^3(1;WD<C1F)3L)_TEL-GH.!7Q']O^S7HEN@
M]R!`6=MFV/H<9'4=CTSTKZ9^/GE:/_P3J_9^L5N&6RB\2>+Y6:(L1,B26*9`
MY(4LIQG[N:^7I5N](M?M"Z@)H/E67=DB)&^[QCTP"?SKGRW#?5L.J%VU%M:^
M4GKT5_DCT</@:.&IPP]+;EC:][OW4EK;?^K$=O=PZ/J?G6\LLDEJ\4]N(GR"
MH(8J<88+VR:][^,WBJS\2^!K[5;*Q&EMJ&GQ&:WCD52[M@[AD8;>,J3R<(QX
MZUX!97/]G6I5I9/WA:,)'\N`3QZ-SM)Z^G%=KK[MKOPWAF66.VNO);87$B_:
MPBJ&C4CZ[L8Y&37I1BG:2W7Y?+^OQ.+-\%&KB*%67V7:_?9VM\CC'A9+IP]J
MWGHNT$X*/N!W;3TQSG\\&I=%N;2+2T8!#-$Y1=Y+;]S#'`Z=#QZ4RZG$6CF>
M6[C>0J&D5\YF4[@HP`",`8ST-/M].CNK0W5I:J]JS;(Y&^7S)%4\#H.Y&?89
MZ"J34IZ/I_EVW/:E;EM+T_X'S(#-<:E,OG%T@2;,L.&9`%'?\SSZ\U9N8;Z2
MPG94F)EDPB,O"(N[`+')]3T[BG:3=PPW5TYA<^3'L=V8LTP/(D`Z8Z]OIT-9
M^I7_`-@)F::)GEF,DF%8NVX')`'&,XX[YYI.[7//T*2<I\L5L7-,M#I]R\Z2
M2/.%(^SA05Q@`A23G))'3'4U_0G_`,$G9H[7_@WH\1S0A"JZ;XAD(V"5<CS"
M?EYX]J_GOM;F.VTE',5Q/<F8O%O7YBNTGC!)&,]>V*_H4_X)"V:3_P#!OQKZ
M^1#`DMIXB<Q7.#']^4D/C`P>_3J:^8XKE&.!3Z<R_)G5@G?V[E_S[G^7]?J?
MDG>:RWCSQO;78LM6O--O(;E_*-\V#(=L.]SEC&$"A\=BH`XS6YK?QQ\+?"[1
M9=)LK'5I[?3S=7UMID-U%<:BX4J?.G?[WEDJQVKG*G)X4BLOX=)X>\=>+[74
M_#]G!X7OI[D_:M#BO\PSQGYM@ED)0K\Q)R%(*G/(KX[^,OCV?Q;^T+XIUE)(
ME:6\GC@<;5"PY(1=T>$4!>``,>W-</L:5><*<X./+'9R^%O:ZNTWO[R?=7=]
M/R7*.'*>;8F6'JWA"E%/E;UO=VO9M=7:2;\GV_3;]H[XT^&=9;]G;PW:QVDU
MQJ'PWT[4+31+J+R2QN9[FZ/D38QYQ)4;,`,#C!R*^<_C?\5[[P)H5WK>G`W5
MSJ]RT4:78:*ZTF4$EURA"[P7*X;'RG/:N0_X*/2?:]4_9_U*5KJV$WP8\/26
MC0OAENHDGB7T/WHSG&,5N^,Y;;XT?`^PUI[%;&XUC3DO[QV,;++/%_HZ[V<[
MC(<,<*.2P/;-:9=@*<*GO7L]/G?Y+UTONG>Z/:XFX<PN`S*A7=W2ERQ:?2R5
METT:737W;.Z>GS'X(\276IZS=V=_:1W8U5PTS*OS%R"N?=LL>>>1[UZ#XAFN
M=!^)?AF3X?/?WOB.T+A(&F2982KL0PW8PA#'Y3UV_A7G.A76J?#OQ=-!+-;O
MY!$<QB3>L\;,#]X<CM@CD#IR*]WT;X-Z/XS\"2V6FW]I)-;VL&KDJRI/%</,
M4N8T;&Z0$8(C'KU7BO8]V-*2J?C]Q]/G=>AAYPJU/@DK6M>+YE:\EVLUI=77
M7H>GZYXGUKP]\%/$^NZGI]W;^+]3NK7['?/:,$@S&NUK01E8PDP+`AU;[PST
MJN_B&]^*O[/6LV8U-;K5-$LY-2UD):>0D#.2Q=%8!F<8`&./G.`,"KWC/X=7
M\GPAT^_O]<U:_P!7\*O%'911+)+:WS@*=F[:!'''PJAL$-(PSQ7GOBWP',PU
MC4K\:VLYT@S/=QR_:((YRI,<9&%B6+E4QEF3K@X)KP\/"@X2JTVN933V;2LH
MKW4[636UFK-WMNG^:8*GA\3&-Y14HS]UI*RY>6T5>S<;.^[LWL[6/#/COXX\
M/^*(])C\/VUW'9PV,27L;$(1<*I#-U;Y>F"<=/I78Z7\?H=-M4TM(GU+4+-K
M>5-1RWRHH'EA0#]Y"2"S9^ZN,`FO!?*OT$\C('MGFW;G^Y(`2,-@8R3VSVKJ
M/"+3YO-0>YV'"IC&%0L5()(Z8`/'?VQ7KPES+WK_`#^?7J?LF*R;#?5HTI^\
MH[:WU=M_Z_(^@E\2Z?\`&SQ59ZB9DMO$5E<R/<RFU:&[9!P)'4G:1MW''52O
M4YKT#_@HM\:#\6/^"??[..HWEL;B\23Q!I`OO-+2K'8W@,:[><\7&3SG(],U
M\K_#R^NH/B+%BZ$]S<ELD.60;U[8SUZ<]!UKWG]M%M__``3H_9FM)D,<LU]X
MNO'$,1B<0^=9PY*MCDM'G/<]*6+DXQA./\WZ/^K>1Q9/DE"ABW'>,8+E_N^\
MG9>5TK?D?)>G1@EY#%<F*:/<;A\C!)!Z\^G7K2R6L@A/F3CS7^=5ERRJP(Z^
MF<<^_P!:T!=WUO9;H#"6>,)\H#-LY'TS]*COK7R-09%F8+"0&+_O"0%`Y'H>
M1CMGK6;A%ZR5V?2QJMROL?8?[/WCWX8Z1\.?V<_"_BBU\"-H?B'Q->3>/KM+
M"&74VMH[Y/LT4]P09((,`G"[=R%\Y7@>U^$?B[IWPU_:+M=,T[0OA_X-\2>(
M_!/BG2$U>]U/P[<V>M2RP[M.AD^R*+2W`8/&C2X,B.JN2%Y^`/`?P<\0_&;Q
M=X5T[0]+;[9XQO1I&BO/B"UO[E65#&)20/DWIN/\)(]:PO"W@*?QYXBOM-LX
MK*2XL(9[JYMFU"*")A;JSR'=(RACA&P%R7.`H)(KGG0C)MW[_C?^OD:PK2LF
MX_UH?:7@_P`3>!O!OPGEUN.R^&^I>--+^#EY<F.]L[.Z4^(#XH91)Y7*27"V
MWS(,$&(*<;#7??L_:5\--6_::OO%MWJWPIA\.ZJ_A%O$.@I;Z)';;+K3XI-2
MN=]Z<06R3F1'AM%\P2.,;-HK\ULI:S[8\9D<#S$Z)R<A@?48`],5J>$O"<WQ
M'UN#2M.AL)KW4Y&AM(WN(;=58CHTDA5$4\\LP`Z5,L-=-WUU94<0TUI=:6/:
M/VU]6\.7WPJ^#ND:%?6M_P#V'9:[!Y=I.DB6<9UZ[>(/UV[HBC+GJI!Y!KP[
M2(!JFDWESA96@8[0JY*8/4]<@9(/''6J=W`+"_6*%TB=D`"B3Y>.`>^>G0=Z
MW/!MPWV^3RHEE:U@EE8H`YD7E0<#D`=><<`5V8>CROE7Y?\`!.?$U?<YUY']
M2_\`P;=Q-!_P1<^#"-OW*-:!W')'_$\U#@_2ON*OAG_@VR8O_P`$5_@P3GG^
MW#R.?^0[J-?<U?G^,=\1-^;_`#/L\-_!CZ+\CYB_X*]Z!:^(OV(M<AO4NFMH
M[VUE<V]PL+(1)PQ+<$`X)7^+&*_"70)M1\/_`!+\1>%5FL[&U\@&"T8NWV^1
MV#>6TS#,;X!X```XR>#7[W_\%1O"UCXQ_9%U6RU._&G6'VVVFFD8`JZH^_80
M<##;<=1]:_+?PC\,M"\-?#OQMJ-HD4%I'%'Y=W=(HN+J3JDJ*>5+*S?Q8XST
MZ?(YGQUALDJSP]52J2G[-*%GRIRG:+N[IN_V8QYM$_-?S-XO5)?V_P"S<;IT
M4UMHXN4F_*R6]NNC1QTGPCD\46UKH$^C?V<EK!'`[Z6D8DAC=F=I3#U)1B%#
M$!FR1CGC<^*_[%UU\;?V;_@]=V6F02MHMG?>%&GE`EM8Q;:G-,LA(#-M>.XR
M,'C%>,_&/_@I[X,\)>+IK?2UUFZDO&>XU77+39AS&6VD*""X8XZD<+D9SFOJ
M;]@?]I;4OV@?V*?B!JR0:38?\(Q?1ZS8VL6Y'2S*^1<Y9E(4[#"W']TYS7A2
MQG'.4Y57S"%*-.5DXQFW\;;;TYK^][UD[+172ORGR'#^"QF#IU8XI3A1J1NI
M67->-I?"WORPEIYZ;IOQ`?L^:IX>B4:O;3P:9`WF:9)+;[%DNL*%D.,;D"*<
MYQC)P.U>`_M`Z;-XA\10:+$DUAIVGR/]J(5Y8=1N<-C$9<A0,N58?+A1Z`5^
M@WA+]KG0-:T.POO[.GM]5G'V,B[MY&1,.XC$1"#>3Y848`)++SCFOD'QW\+[
M?]H?Q=K.I>%_$J:EK>C>3I^HZ9J)=+BPF^T2!MG0#'W3\N-K'D4_#3Q`SJKF
M%:IQ3AWAHPY5S._)=OENK)I+1>\Y--RO9:,XJ.$PF&Q4:^&K.HK/[/P:*SDU
MI=W>C7NM*S<MOEVR^#U[X5_:&TSP_-I\UQ:3-;R%W/V=9HW&2RD$D`@XX/88
M(/7SKXI_#F^\`^/==T2ZM9=(U"T83*K0",HCX*9#<C<I)WY.Y2I[U]-_$V[U
M71/C3X>L[F=-,UY;:WAN;.>%@EU<8+,Q?.8VVN$)48^08'-?/_Q'^%_B>YNO
M$+M'<:\;.=;>Z<2-=%5?!CC96.\@*`.<;0!CTK^E<!C)U80K2:Y903^=[)JV
MB3^^UMM4?H609K4J5HSQ,XJ\(KJKOF^+6R\O._D<5X<\02:;XML[N.]BLKHW
M,9%P(OEC'RC>@YYYSW[\5Z1X;\#:AX,^+.L+HUX'M2':!IH%DEN%R"VX8ZAF
M;(P.,Y->;^&FL=.\8_9FL+B0PS(Y$:E7F5#O9/4$+D<XQD>E??\`^S5^PPOQ
M#\,6GQ0\?:_>^`_!5_=7::=;R6WF:SK<*$`KI]MD`#`*&:0^6IS]\G%=>+QM
M'#TU5KRTU_KN]-3VL[JN#M!)1<'=RMRVT:;?1+57>FO=GY[Z'H^H^)M;;3K>
MTO+V[O9/LMC86<$DMU>L2S?(FWYAD$<#.*^S_@S_`,$O/B!X?^#LNL^-'\+?
M!;2[N_CF\_QSJG]GW!14.P"U4-.Q(!8+Y8/R\<5]#VG@CQ''<#0O@)91?L]Z
M#JL;-)J%G9QW/B365+$,\VJ3L)8]ZX*QVZHN#FN8^%_["FK?%C1K/PAJ]ZNI
M^*O$=Q"9M6_M.2XDN;@\!9UDR1(-Y#-DG#'UKX+%^)>34J_L(8B,9J44U\4D
MFVK]K:-:<SVT/,SCB_*7AZ:H.55RG%62<5>Z76-Y:VVL]NAA?MX?"?\`9Z^&
M'P+^!7ACQO\`$WQOK(T/PQ<:G;Q^`?#,?V?44U*\DN4G\V\DC\HLJ1@`QG(7
M.`&Q7SI;?%3]DQ)O]'^#OQF\5M#E4EUWQ[!IXD.<-F.UMLCI_>KZN_;7_9]T
MWXC_`+1_CR&6VN;S1[;3K30_#\5@?+2SL=/2&TC8N5(5F\MR%7.3)DXQSXI9
M?\$H;BR\::99W]YXD2WU$A`-/T4EHU<X3S'=\$=06`X+#@XQ6T^+\AP\.;&8
MJV[:OOIS2M:VU^MO>T5[J_J+Q!RM5)T:?V+*+47*ZT6CUU>WGTOJ<1HO[27[
M/U]<W5M8?LH6\\,">=+=7WQ$U67RQ\VXEU3@=2,#)SQ7I/B3QM\!->\.:2?^
M&<KB\T^W-O&LNA_$F^1[?S241OWL+#;U!)Z9P>M>F^)?^"?OBCP-\,)=&T_3
M].TK0EOS-)-.0U_=(J%$MY&`*L2V3NP`-PZ9P>.\:_LN^)?!OP_TK0K*:VO8
MK;41<2745S]E:2SED#LJ[$!)#-@XR`1E>#7#EGB/PYC[1P6+4DVU_$;V2;>C
M:O?2U^M]3Y['\>U%6A>FJ;OHI12?*TUS.\5;9Z)]=V>7_$?PC^RW'X]O-(US
MP/\`M$?#W42SV_VK3M5L/$ED`HW?*LD4+%2!GANE9-Q^Q1\)/BY9.?`'[1WA
MFRE\P1PZ?\0O#]UX9:.?IM%R@FM23@#YG'`].:^Q/@C^R]X_T[QSK4#1:@FF
MQW<EQ!-/=QMY.Y"YB+8.X.Y574<\GMFNC/[(WC/Q1<R:'/;Z9'H\UY;:EY-W
M%#/&HC^5\J05Q@[0#SAR<G&*^7S#QMR#!8B6&>,I648R;=9.ZEOIRR=UO:Z?
MZ^M@>*<XKTHU%EDZL4OCA&?+=)-VLK+1[:[=C\Y/C#_P3Q^,/P6\)2ZYK'@V
MYU'PQ&JJ/$6A7$.MZ2P`^\+FT=D7..-Q&`6)`KR@K)'9-]H3_1CE%G8AI)CN
MQA0#V`SGMWR*_:'X8?LM^+_V>M:MKKP6UGX?G$,IFNM(":>E\S$`/)&!Y<HV
MD@HRE<Y..PH_'7]B_P"#'QNBM)?BAX!T?P'XLUR8J?%W@V/[/`[JF0U[:(##
ML.`&>$`@C.#FJR/Z0?#&95XX.G6BYSNE:2ULGTT>ROJUYG:N(5*$JN)PM6C"
M.O-./N:NW\311N]G-*/FC\:6U!(=3WVMQ:"X,'F1O(I8*@+'9CIT]`>M?OW_
M`,$E/#L_B'_@W"\1V"EIKC5-,\2*AA^9LN\H'&.",CBOA3X]_P#!)?P9\'/%
M&FV%POC1=/\`$=LT&FZO8ZI97EG?R9)%PCF+'DD*`>=XX7&>GZA_\$T?`N@?
ML^?\$6]2LXY+Z\T73K/6;NXFNR'>X&Z1I&^3!QD$;>O!%?19MQOA<?AI0PE.
M?M(7DHM6;M?1:O6^AZW#_$&$Q.(Q&#I-JHJ4V[Q>EDO+ST6M]T?E%\)OA'IV
ME>!V\,-<M9:]KUI?Z?>WWV7SKF>6XW=/X"1DG[_3G&1BOG?XB_\`!'7QKX1F
MT-;/Q!9ZF-<VFVB5?*<1Y8AF`8G(`^;('48S7WQJG_!1+X9>$+W5]2L]:\)7
M<$R[I8XE>.XM'/#A8T4(-P0M\OS@A<CO6K\$_P#@H-\)/B3XCL8I[WPYIUP+
MD?8Y(K9EDV.F2XDV@`@@J5)SM9AC."?Q+$<<\<86I/,<-DU5TFN:::YI.5F_
M=2C&2C&32V>BDE8_.LHQ6,P<:F)HXMQG.2YE*C+E7:3ERM?#]E2C;2[EJEXC
M^VG_`,$IM;^+7[./P)U72O$%O;Z?X0T&^\(W)OK2:>Y80ZA+/"2R@*,)<!=S
M8`P.W->27?P;?X#?#'3K!H_^$CG\.Q21W5N(@(Y)I)D8J'D48Q&5R<#!<8'6
MOUF\%>/]+_:"^"/CK3HM6MX[71[D:W:.T.Z%;1(MMVV[@$_.C,K=-AP#MKYR
M^*7PUD^(W@\Z?$EO?76L:;Y>GO?7:0?;&9T11*VX[D"CCC.TG(R:SX<\8<TI
MXBA'/(<D)*,K.\'&]U)2DXI.S4VU=:6;5B>)\WS&O4P].%3V]&RU2BKN/[N;
MO%MV>K7^):IGY'?$[X0ZO8?&JXU2WL$MK6^2.\MK'SQ,D9"<1RR?*H<$'"GG
M@>M>I?LER&[T:;^Q]/1;.WU"+^TK6>Z"R7TZ3F:**(C)`+!P0!TX)Y%?5'[8
M/['%IX:UTW.G7%\^FW%Q%<:A%"H3(4*KJGS;MD:@G:/E*C.<UYQX?\&Z%\0[
M_2-6M=0TQK#P@98;RXALY;2X>--TD5PQ&`[;4`8(1MRN><U^_99Q9EV;933Q
MN7R<X5%=MJ5XM:I2ZWNDEJG=IH,=Q7'%Y=]7Q$;."2=KNSCHD[/WFWL^;?5.
M^WHWBG7?%UIK-AYL<<&@:I";G?%(GD0R.B[&^959F0Y/3OR.M>%^./VB/&OP
MB\36UU.&U/PA<7BSQ:5>V4=Q9W]S;QK\YB9=H4@H,9&=A/&<EWQP_:6U/7?!
MOAFYT2]M6O8T,`CMKMX;FYDD8&-"DCL!%(V=R]=R.2<8KD=!\*^.==T:"T\5
MPZEI_A*Y/FP7ZVRRP*SJI\H2!2BIA=K<Y`SZUMD^64H4(_VA3IKFT<;*[LY:
MV=_>?EJ]5;17\C(,F>$A]9Q<*:6JY=IV3>JZM_"_3I<^6O%NIW/CS5KV_A>.
MT?4[NXNIK2UA^SV<3.S.PB0$@#LJ8Z5%*;J+2FAN<VBVSEKB-F`Y7`+C.3DC
M(Q[<5[#9:II'PB^-;2(EKJ%E#).`(H5:'#HR*&W@@;@^06!QA<>M8WQ9@G^*
M>JV,&AV&K:[J&O1Q16\9L"US.PS&=D<62YRJ*"`,D'CDU](Z$:<;=DDORL_2
MWXG[C0S5U:L*<*=H22:?Z=.G?7L<!X3\9-X0\3:1J=H]TDUI*+@+"VTCG/#]
M1UY_E7TA_P`%1I5TCP;^S7X1N6N!J6G_``^76KN)FQY<VK7T]\%;N#Y30]?:
MMGX`_P#!$'XR_$?X@>%-#\9?\(Q\)X/$=RL%M;^+]:@L=6OU8Y<Q6`+7+$1[
MCEHP`!R0!FO2_P#@H_X<_9=\5_M:>*O$_B/XQ_%+7(;V.TM-+T7P?X*CBM[+
M3;:WCM[2);R^F13^ZA!W+$0<DC-<57$1G:FG=+717\E]^I]#3PT(5/:OW9-6
M5W:ZO?\`#3[S\]YM+&C/#+`LJW$.6P6W;RS?Q>_7@=,"B2V&HF"Y21?-CQ&R
MQN5>8'.>3^5?2VE_%O\`9&\`^9;V?P7^-OB:9$R\FO\`Q"@L-^XXR4M+0X]\
M-3U_:O\`V<;.R:0?LBV)@!R'G^)&K-)MSM!R%48R/2G&HTK*#_#_`##V=GK-
M?C_D>H_LM?M++IWP<_9FT_5OB)X<TW0?AI\2Y+OQ#H>H31075I;O/;S6LX0H
M'EA4"?>ZG@\-U%5]%_:-\+?%GPOI>N>/-4\(W'BZRT+XA:5-(UA;P/%;R6,/
M]D1%8XU7'G23K!QE22`1@5YTW[3_`.S1=V\7V[]D^ZL5P2DFG?%#4(Y#DC.#
M+#(#CKS[U`-8_8_^*ERWVCPY^T?\.2Z@F33M9TOQ';(.V4DB@D(!SQNS7,Z2
M^+D=_EY]F^YTJI+;F5OGY'K/C[]JWPEX\\*>*?#$^L>#W\+:'X0\%W7A^&#3
M[>-DUB"73AJ+K($#M,(S=++N8Y4'.<"NLT_]K3X>_%+]HUKKQ7JO@2;P_P"$
M?C8[^''.G6L-O9^')+2\\SRTCC4-:&1;8X8-\YSU)KP>?]B?X*?$>">/X9?M
M3>$U=B/)TCXAZ#=>&Y9)3Q@72B:VR3P"7`&>37"_'K_@G)\7?V=_#TOB3Q)X
M(OY_"^3);^)?#[QZWHI7L/M=HTD:@_[>TTN2FY64K-]]/S#GJ15^6Z\M?R/;
M-._:3\-W7P,\,^`+C5O"2>%KKX/:S%J=JUA`&D\0_:KQ[$R2^7YOVE6%MY9#
MC`;'\1KT_P#X*5%O!/[/&L^&/#]S:3>$_#.L:-%KMK9S6]I/X3G_`+.\N"QB
M@^SI(8II@\L@,LF'CY)R7/YP:7JR7]I<Q[4N;:*1G9-AZ$'#$YX&>0*[6Y\2
M_$C]HWX=7-KJ_BCQ#XB\/>#H?.CL-3U::X@MHP5B4Q+(Y"GY@HQR`,#BMOJO
M+.,Z;OULSGJ8R$*4HXCW5HK^NB_$_IV_X-O&D?\`X(N_!@R[B^-:SNZ_\AS4
M,5]Q5\0?\&X*>7_P1=^"HVLG[K6.&Z_\AJ_Y_&OM^OC,<K8FHO[S_,^JPNM"
M'HOR/E;_`(+*>/M"^''[#.LZAXDM[6ZT@ZE90S0W,K10R$R@KN*\X#`'`Y.!
M7X.VW[==C)IGB"$&\;S;7[%I]O(!)Y2X*N[%N9,\+T&T8[DU^U7_``<.6<%]
M_P`$RO$:W)"0C5M.9I2N[R/WX^?\/7WK^>/0_@+8:]X\^S+<7NGZ<;7[3*\<
MT1DEY5U!,FU5;`YR<G(SZ'U\IX?RW$4*F,Q4'*3LGJ]HM25ELGW:UEHGHK'X
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M64C*BN>\!?M/>$KS4_&GB+6K/^P?$W[R]TK4XR@M;E2TQ=9#C'ER&0*`<YR/
M2HOV>/V7KG_@H!^R[9?#_4-02'QSX&BN/^%?ZUY,L2W6F/*WF:%<R%0`&D_>
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ME1QFOO?]FSXC7?Q4^']Y_;FAZB]GYR1O+->1QM+(2`9L[@RXPJLO4@D5^#>(
M_$F)X-P49<,RC4P"]DE#FTIKF37LV^534[/F3<GJGI%'@X?`X;-<UJX&CB)2
ME/6#:<KNW/9VC*7O/:T;66KM9OP?]F/]BNZ^(W[5MW)\2/"6C7'AW3['_A)]
M4NXH_LQ+H(&CMT.2<S/L0[CA=S'KU]F_:!^&I^,7Q@T;7)M1L[OQ!!;&(VMI
MMAM=.M8OF2&+&`(D5U4`D@E<XR2P]"^#/A"#Q"OQGL[N_N_M>JQP7*P0VY59
M8+.9-_ENI!?((([`*?>OG7XF?$"QL?C'8PIK!2[MV*.Y;[)+:6J+&HBD&!LW
M%RJ`DD8)'?/RF)XNS_B#$86.7UO9<N'G.2A";IN7*X*+N]DELK+FLU>Z.C-Y
MT,+E<<&Z?M8SDTVI)22A)QLTF]5&*MHU[TO=5SW[3HDT?2[:&PM-)U*ST^!5
M-W),88XWSM\R-BQZ9&!C'<UG>$_!.D?!K0KWQ]<^(FL[NW@GT3PQ]FF:;9J4
MD;*\JHX`D:WC9VW#.UW7&<BNI^''P7@^*>H>:+E;+0=/66;46>_61+*)N-Y!
M'WAV4<$X`&1D>*?M=:WJ/Q/U/PSI>@6EKI_A72[2*S\-6UU>"62>+S)%>YE5
M5_UTN`W&,$A2?3\[\)\(EBY8ZIB72YN:*O:\I6=Y:MIJ&LFXQY6VD[^\EUYL
MYX+#+&UH).'\)7=KVBE+[+M'3XY2?.EL[COA3\+O#?B&Q\7:C%(;Z[OE+&[:
M9RT;HB'<8<`+DA3V/RGIBO9/!.EZ+8Z?!!9(US->VI=9)(W9-S;3G/.TA@#Z
MG=FOD_X9^+/&WA^VN;2SL-(M]4OY9Y&W7$NZ4I(HWPKU;/<9XQVS7=1)XO\`
M&.O7$>CZ_"WV.(R1M;B[MXH7W'*R,6YR1\IX`QSFMN.N!\?B\=6CBLQ2HK6+
M<KV48QAKRII*Z2BKQ3L[:H\7A?B*EELZ//AE5FO=Z2D_>OI=ZO[[+?30]D^*
M47A+3?"7FZKI=OJ$$%Q$93/,T3K+O4C8>HVA`3T!P.YKRCX@S^'&O;&ZETV"
M*.\U>"99;N[,\$(:0NP2+>#&F5Y."`=W''/BGQ-^('Q,\0QZQINFZ[H>L1Z?
MJ"_:HY]07[7+*V3Y;<+\Y4?=!``1LY->2^,_$/Q(TWQ:UE_PC>H)J4NK1->O
M/MN8+9VD'[N-PQ^3HV.?F/0YK[[P^\$JM"E%U<SCS+FE959?"XQ:?*W&VZ?P
MM6:3U:.C/LZQ&=8A5*,*=.%E:-H)JS=FWO\`??77?4_3KPEH1@T[5H9H]-VR
M3RSJFGRXCB!56[<[3\O([<FM,,DD5H1!!J$D0\V.=9`ABD^4<$$#Y0226X.,
M\XY^-_AA^V)=M\2K/2-5\.ZG8ZCI$[&]NI+=S+/$6^ZA0$D$*H&\8^8#`P*]
MBU+]IJQU/5]3GA@U&\MXH8C#LM?L<EHTN\J[+N+,F54-D8P,]#7X!Q7X,<3Y
M=F*A6I.7,N:Z^&UU!6DI6][1J[BVNA^HY#XG9?ALF>#QDI05W:+<9Z2@[/EM
M;>RYDI):>ZCVV.R,,,\9:WG4VS2SABZ896VY))S]WDD<=?456U*[MKB2ZMVA
MTZ?3ELBWE3#SDC)&X*RYZ_-T..U>,G]IBVUCQ$ZZ;X@T!C!9!$@:YBW.YXD5
M%Y!;<H&3R><X!Q4WBG]IJR\$?#^;5_.GU.?>`19P)++>S%ONM&@W)LP,.>B@
M`\@BODJGAEQ!'$0@J3]I-Q45[R=WMT236WEZ)L^IR7Q=R"CA98/&4ZDDKNWN
M\LG>S23>JE:]I=7>VR?MGPFB\(^,O#D7PYU:ULY=/GE^W:5+'`X@L;]BI22-
M\?*))&VL!P>378?%?P=:?"S_`((E?&C2].MIK)-/\+>(=\,DC2F*39,7`W8.
M,YP.WK7BG@CXW7&O?%#P%IL-H(6\3:M;QP+"P*P'.XY(7.[^(Y`4;#SQFOIS
MXTW%E\=/^"77QJCTJ9IK/7=+\16\4J=75C,N5S]>GM7].>`V`SVCBZ>(S1SY
M+5$FY\R:4HZ/I>$E.S>MI-7LE;ZC"<9<(YM4J5,FPL:3A&7O-)-QBHN2C:*]
MU)QNKM12CWL?R:--8ZQX>?48FD%XDJQR0-NB>=3U<'[I`/R^N376:;XZ$?A_
M6ETRVD2*>U4S,75/[/C#Q8*#J9<J@R.PS7J%O^POHJ:=J$U]XDUS2;_3]9_L
MM+,V0N+F])90!"N03OR"-V!V[BMBW_8-33OACKVKV_B*WG.GV4DI6:RFB,0B
MG5!YH4L!@E>>>2/J/[DGF%&@G[6:2NELVG+IJE:[O^74_/\`$<4Y+5<8<[?O
M)+W9>3WM9^NOS1[=_P`$?/VQG^`_C(VFM3WVNVU^QN+NU%\)EU2WDC\J2T*D
M$^8T0<@':.1SQ6G_`,%#_CI\1?V0_BU:^$--\7"[TV>W34M*EO;`XN])G;S;
M24,Q)XBVHV`I#QN#DY)^7/@U^P;XY^*JQ/X?UCPLND@Q?:;@ZJ8&B5XPR.1M
M&<\KC.>F>,9]M^%GPKUC]J;X6:C^S[\2=4TVU\9^![BXN_AAXKNK^.2V@\U@
ML^B7=P6.VUN9`IAD/$4S`?=DKY66`R3$9E5J.,*LTU*<9)-Q;22EJKK1?AN<
M=#)\FQF.J4Y5H2NU)0=M)/1JS_F]UVW3BNY3^`7_``5/\;>./&^DV_B0V&IZ
M.KBTU!UL<SM"ZEF;[P&W(W#)^7RQSBO:],^,'PA^.*M=WXMY?$%S=/)%:PD6
ML<\:>>0GEG[K!5(/42%^^37Q9?\`[$/QM^&-Y>Q3>%]1T[6[-;B#4[*6-([J
MQBC?RY%9`<L&/`X^88*G!KDOAS\-/&-MX_6+2_#&KZM)92M/+$UNZ^8(\,P/
M0K@%C[9SWK*7!^15:GML`_83C:[HRC"UFY6:7\VS]%LTCQ,WX0RC%>U>"K1I
M.*VBUNKI\VUM?-;69]?:C^S-X-'Q#\/2V-]IT@EM7B*_:S/$C85FC?*KY9A'
ME-\N?OMCH:]B^'MOY_AM]+O-;C.F7%S&J3715GN)``VY8B0-@5OF8CD$''%?
M/.A_$"\(BUJ7X>SZ;K433RQR1V+W-U=$@R%HTGS'*8\AB>"H;VKZ,_8.\!:-
M\0/$7B#Q'XQTZS_X1CPBC>(]4L)+;$QAPL<5JN,@/<SO#DCH')KGSG*L34P:
MA6JW5*S3:A)\RF]=VE;3NE9IQ=C\^QV`QN+G"C.HV](IMIV=[MW5]%NY7V3\
MD8>G?\$LO#GC/Q!8^.?B#XC;PAX2CMI+RSDM/)N-5\93K*-PMK9P%\E4$<9F
M?$:$8PY.:YS]HO\`:7\<_L]>&I?"_P`"_#NB?##P7#.=/>[T+-[XONQ+O?,M
M^29<LV]C'`(U!0KC&*[_`,9?M=P_&7]H:;5O$&CQ:_+;Z;]HBBTZ!A8:7:H9
M$AMRC%66$8&V,=1\W)R:L?L?)-^U-\2IM?U6-M!^&G@C4A<ZAX@AEB:.VB6%
ME@15"8DO)'(2-%)(+<C[QJ<-F>:4ZDO;4>>G3@G>5ES2?WZ[;JRNK:'NY?Q%
MFU.K"A@(<T*:U<[*3_O7^POBT3]V-V^9:GFG[+G[-'B#X$_L_P#C7]H.\T7Q
M9>_$OQ)#=>$_"$^JWC7L\`NX@FH:E("@D4P0EX@S$Y>X`'W37S1\1_V;?%VA
MV=A#XWYL=2NK>*"TMK,V\\VR(!)A,000H)##.,KS7ZD?$S]NO1OB!JV@2P:#
M;Z/X>TAFM;&RD0M<6UHDQC&V(D%I#RSOCDRD8)Z,\2?%[0_&>MW%D=#\/:[X
M>MKJ);66^M3]FMRPP<-@_O0"A"``'9MXR:^`QWBSGV7X^4:F4MT&Y7ESV=HO
MELF[J]]8Q;3Y>B:.W$\=<U7E]JN6%DFXRU;UE)-W<4G:SM>UC\W4_8J\#7EK
MJDUC;^*KBVNY!:V5Y-J,-UY`\DR'RXT7>Y#+@[@H&]<>E<AXI_84\,S?"$^)
M+/4_&%C/!-:P1/-:QS6LHD(WD@`%6"DMC)Y(!K]:O&MK\.M7U&^LI/"&EZXT
M-O)9V]EI4,<$K$'.05QY0`0':3U`'/%3ZC^RAX)TSX:ZGHUIX1U?2;!K-5+G
M4681,P^Y*`3M'RCG!;+=NM?+Q^D;@*<*<,?@JU'FE&UW!^[=7=W-2DW=+X>N
MFNJ[XYGF2E.K@<PC54/>E;VFT5JM:;2;2T^R]7==?QIL/V3_``SXOUK2[)_%
MM]HU_JR^3',UCY]O;GRU9)9"#E4D;CG[I[FI?BS^Q;IOPT\0WMD/%5QJ&L:?
M;AKEIM+>WM\;=R^7EMQ#88!C@=.YK]E_!7[%?P6EM]-72_!<5S;(4\I[B[FF
M2262/YBHW`MM&Y2?X>F*XSX\_P#!.WX:?%3QU)906\EE>W4CW$;VNV3RTRV]
M)!(=_ECJH)`!Z#@UU9?])_A7$9M[&O2KT:<8MOFA!V=UJ^64I:*^F]NC/8JY
MCFU"G3QJQ*E1E+DY4XM\SU35X*ZM9-*3U:;ZL_$7QC\%M9^'UK;IJ^EW\$%T
M#-!<V^V2"X4'Y2&&0N!C@D=^A%;OP,_:B^)/[,/BD:U\//&GB7P;>MY@N;?3
MY66&8YP4D@),<B=.)%(.:_43Q/\`\$H;G0-:MQX7UB$:'.DJWEOJTN][G$1C
M`D]V<DD<C'U-?.7BK_@EYJ/@[7K6/7/"<MWJ]SJ%P=6N;*:01O#Y>Y?*$1VE
M%=VY'4#&.]?J62^*/"F=*,,!C(2;5^5M1DOBW3MM;7?=/J>EAN/(TZ;J8ZG*
M-NMK:N[ZZ+;I)W=K=EYY!^T?\%?VZGBT;XSZ!I/PE\>W"A8/B-X+TSR=*NIS
MP/[6TE,(RY/S3VNQAUV-6KXI_82\6_LT:1XMT7Q@^F/!<:(-7T>^TR;S]+\1
MVZRQE;FWF3Y)(F4$$9W*Q(*!J23]CZ3X-ZSJUI9^!YY9_P"QID2XELY9DWR#
M!\HNI&Y!D$D9&<CJ"/9?V3="U+X]?#+5OV;_`!M?/>:!XYMFA\*:A=6_V:X\
M'^)-JO;^5&PS%;7!6*&<`D,S(WW@37W.%K4_9^TPU12BTGHU)6OK:ST].M]#
M?%<0X;.(QP^'GR<SBU)VN]4]NEUL[WN_5K]F_P#@WBU:?6_^"._P>N;B-8I'
M76!Y:C`C5=:OU51]%`%?:=?%_P#P;V^$;_P#_P`$A_A1HNIQ-#J&ES:[;7"-
M()"KKKNH`_,.#7VA7QF.UQ-1_P!Y_F?L6!Y5AJ:CMRK\CXD_X.#K^RL/^":7
MB%K]S%;-K&FHS@@%#]H&#S].?;-?@+9_$VRM=5UB[>T6QCM;,;EMW+BY&^+'
M+XV`@$D]#D5^^?\`P<.VXN/^"9GB'>KF--7T]W9/O1@3?>`[X../K7\Z6D?#
M_4==\1W<L4OE12H%F7<)Y%'RG&?3)!P?2OM.&Z<98)N7\S_3Y?>?D''^&PU3
M,N:N[>XNOF_Q?^1](_&K4=#T_3?#<NH6IO+#7X4OGA+>7/&(V9E#;,`?+GMZ
MYKR_QUKG@S2$T/4K2_UBUD-Q+$Z1$"`)YA3Y><`;20<D'DX]:E^.>I75OX?L
M(H[:755L4_LN91'N<%%&Z7H#M(`'\.*\2DEN;`M97,DLOFPB!U?DM&N"P`X.
M1[=^E>Q@,%*G2A*=5R:OUT=]KK;1::;V1^;<.9%&IA8S]HU9O1/=:K;TMT5_
MQ/I+PI^UQ<_"KPM<V7A&ZN=-:".)5N'DD6,KN,NWD?,58'!Z*2`.`#7M&D_\
M%'?"'[4^DZ5I_P`3]1F\`_$:P\M]-\?7%BUY9WB1X\E=7@4!B"K[1=1#S%SE
ME/4?GS>R/K,$:S_:?M21_NI)1E550Q6,KW&5!R>1QZ5+:Z5>WFB6TCXMY88\
M6[W,@/[L[<@#'\(R?QIOA[`3<Y3IKGFM96U?^+OIWNK'U>$X>P5",E4BIJ3]
MY2U3\_OOJK-7?=W^XO%WPH^)?PN\86NO>.=&O=3\(7!@N;+Q9X:O&U72+DH&
M\L6]Q`618QA"1)A@%^9<FO3O@7^V1;:-I\WE?8+G^U)3*POU5&BF7:&D7<<+
MP&+#&#Y@P,U\1_LI?M7?$?\`9EU'[1\/_$NO>#SJ"NCPV\K&"])X#20'*.P(
M*\J<C%?37@;_`(*'?$7XP:IJ,NO>'?AMJ<)N(Q/-K7@;3)YY%=2^QI-J%W^7
ML&Z<FOE.+^`LNSK!+"9E3C*FDDOLI6>EE9];=>FQ\[G'#V!H5_KF&J2H."TT
M4DOL]UJ[]NFMF>T_`7]NFX\4_%=_$WA3S]3NM`U"5;/1S,TT6KB:+RS8@(I+
M+M+94'J5[$5V_P`3_P#@GS9CQ._Q7^VR?#[X:W4'_"1ZFFIV,MWXFT;SCL^P
MM:$%F577,4[;8PHY(-?-&B?M^_&K01?6/AZZT'P'$7F$,?AGPK9:,S8^3K'$
M)&W#&TJP8;3G/%?,_A7]IWXJ?!+XYGQ?IGC#Q/8>*;>Y^SZA>&Y>Z;58/-(E
M@N%FW>8CD<I(-IW``5YV1\`87+(SA@4HT[)1CJ]+;:VO?=MIN_?1)Y1D^63=
M7#NHZL7[RNDK-K5Z2O).RO'W;V5FK)GZ?^(?^"A_@KXB6.E>`O#DZ:'X56-)
M7C^UJ^J74R[62>[D48?<,\Q_*F3TQ7RSXHU[XA:+/:2Z#JEDUEJ&R19[M'D\
ML*9I``';=D!2>!D[0>!76ZU^TO\`L[?$?QA:ZA?^&]6^%?BVXMO*_M_1-'-_
MX=E=]RN9=-#"2$,!@M`S!2W"@U4E_9D^*'BWP\NI_#BY\-?%?1IK-HX-0\'Z
MREY(L62%<V<FVZ5PFY"K)P2<>E>%E'`6$R[$RQ.&C[M1*ZK).*LYOW%M&UTD
MEV6G?YW%\/YIBZJQ=%*M!I)72TMT]G9.,8VNERI7O\6YROPI\9>(;/Q)=WFM
MWF@PZC#:W"9$12Y$*J"VPJS+&P&TD#&<`C/`KZ!\`_M@:UK.H"X\%:CIWB"S
MAB-O>LVGR&Y#B(1H78@`IN7!.,G`/J:^1K/QIJ/@K7;WP_XST;4-(@MW+BSU
M?3YK)\`,'5-^U@SC(R2WW%&.`#T/A;XGV_@[XOW]AI*B;2-5LFO4O_._T3(R
M2P0*3O"J`-IXW9[XK@XV\-\#G"E]9PT92A#W$XITVO=NG]J]GS)7W6\M4>/4
MHYCE^(G*CS4ZB5UROE5EV5MTGHO7?IW/QV^,OVLSV'B<Z%_:,DBF"2&WC0VM
MP99&7S%!"ME0PSD'YL>M<+\7_B[97GB#P]+%83Z$;MA<K<KI\EL]TS2(&&#*
MP+@JC!2O4-@\9/$^*?B#HNM?$";7)7TC4EM69YH+8D_8Y%F1E=20IYRQR/EW
M*3WKFO&/C>/XB^(;!XM>U'['-KEH]E'J-NOEP/\`<(5R-Z_+L.Y3MQP0">?L
M,FX)PF$IX>;I\KIIMI7C%.22DHKLGTVTO:]SHRS*:SG&552V;DWW:MIH]?7]
M;GM7PK\<'4OVF=4L+)-4N-/O[N,/;V-J5COS%MDDRFXLNXC@;OX03UK[6TSX
MOZ?I7C76[BXL$P3$9X4$)9;8*ZQB13G`W;<]`#GI7YBZ5XZNO"7[4PN?#NJQ
MZ)?7%VY:\MY-^U"J`IY>[![@]QN88XKZ?^!GP!U/XM^*]3;2_`7C:>ZOK*"2
M2?1K6<:8TPE96*,P*KSM+;VP`7["OSCQ3\,<-G-6G5JW4%1C'W$W-OGA=R7-
M&RLE9J[NNEDGM5I8C!SI3P*;FXPE91YF[)QU77=Z:WZJS/<-)TKP_P".Y-*M
M]3\"Z+8Z3J+W,PGBLV,?GRMM"@H2"Y);`R>@`^[6%!\,]%\9Q:EIBW5O!/JD
MWV:"-+J>#5OW;D1QA`&$G(QN3)8$8Y%<;>00?L^Z'HEE\6OBQX'\!:?X<EEN
MFT?1KT^(_$%]+YA"EDMV\F-^^99%P6(Q@&J>G?\`!2O0;Z]ATKX/^'[G0-1G
M'V=/%6LLMYXBNN!N$6/DM%?)RL`W<XW9:OF\%X09S3J3K_694Z.MN64I<JC-
MRC+WW)7DFG*S=K6-)\/8RG35?,HI**=W9.>VJ4591M:Z<G&U[WE(^FO"/P@\
M.?LD>#]8&M^+!_PMC6]+N(8;*YU)99/#]@[,),+D!;EUD9<]45FZ,3CW7X)W
M5KX5_P""'/C>XTII%AM?#VNRPR>:"Y(\XA]SDCT(R<#BOS*\.Z^OQ"^%GB>7
MQ4DL&KWE_%/=7F!-<697<C$N<>7T+%<88.,>@_0[X*Z_I^O_`/!OY\2KRT3[
M7I+^'?$7V=6EWK+#B;;@[0`,=@,"OJ>'\FQ]#,*RQE:<XPFH<K25-:)W37Q-
MW>MNCLDK)?9^&]:-?-)4(4^6$*%2-KN5[N.K>BE*7>RT25DK(_"JQ\3)'\-_
M$VM:WX@O)M7U?5+:"W1'+QV\[`NY9S\QQ'LY!&<KQP*[OPC^U9KOP^^&>HZ)
MKVEVOB=6TA;*SN9YS;I*A=#F3GY@JH2,+U`!KS>R\*Z'JOP^%U9SW%O):W*2
M01*/,#.O4]A\JC`8]@/K7JWA?1?"?B+]GCQ;9?;;2XGT^!9(QJ)1I8X"[`@O
MCY6RX)^\>GIFOV?,:>%J4.3%0<X\\;6WBVXI6:M9+K\_EQ9J\%;][2<U[1)J
MUN7X8JW+LOGKKV/.O!O[3.I^#/C9I-YX>N;C1[#R_)9+FY:YB@W*69B@4X*X
M7!QG`QC&:W/C/\3_``A\0EU2^TV\5IM0=[NYEU$'R]\;*5A+K]QR8P^,;<LO
M()XWOV5_@_X)\2W<']H376G74SFYM;F&`%8WV-NCDW'YF(X()Y5EZ]:\T_:,
M_9^T+PKXAU'_`(1_6#)&M^;1H;E/*E9BP.\,/E(`.3[,,?>%.E/"5,S<8Q?M
MN17:C92C>RO*UFD]E?2_F;T)936S54(J5.<$E>VDM?M/7K;5O?T/J7X1?\%*
M=&^+GP0T[X??'NRU&V_M6R%CI_Q%M`+S4([10'MH-0A4[KB`995*OY\>`!G!
M%/\`AA^P7XG\(O<ZSX>MK?XB?"^6WN)DUOPM>'7K)1][RRGRW%M(_`9)44J"
M>N`:^5_AG\$]6U[X)WLKRVDRP!Y(6=!&Y*2%<!L<!5)'48*MFKGP`\=^*_@7
M\2;[Q-X7\0:UX<O['3FLY[RQU-HFA3'5]A#2$<8QR`!G&*B66T)*M3PEHNH_
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MB6+Q7\=/%\?PSN)0K7/@W2[F*^\7:JF)%1&AB8QV*`3')G8$`G"$GE-8_P""
MJ&G>/M-T_P`+Z=X8M?"/AS2KN5-`\/Z7?*MD;=D"?:+J4KF>Y;G,C+ZA=HKY
MK_:-_9FL9/"<WQG^!4EUXH^$>M7/GWUM,WVK5_`%Y*#YEAJ:C+A<C$5T?DD5
M5!(;(KYS7Q=<Z,EI<H`[6L<<4$8).Y,MD^G/()SUKCK9)EN/P[IXF-XO=+W;
M)+:RUT\WT1>9\'8>=-X2C'DB[;/625[)RZPVTV[JZ/T1U[]L7PEXH^&EII8M
MI!817-O$(;BP\NX@C+*'C:Y0H`-P+97(SCTS6O\`!O6O!\$P@GTF(0WFLVUS
M`(M4-Y)=2M(9/,C0L5;YOE'RC*J?7(_-C5/&>JZM=1P_\?1N)4G"-_#)]#P"
M,<#&,9KN/AG^T'-\/);BWAFTZ]^6*X$,T1VJZL>A7&UP3T'&1R<=?%Q/`&5K
M+:N`P,YTU4?-I*2][J_=:UZZW;ZO4^-Q_AY4A07U:;;[;Z:6[+3I=;'[-_\`
M"@O"?B.[\1O8VNEQZ?+)(KVWV@P+'(ZQHTZMP(R51UX&<X/<UQ/[1/Q!\3?#
MK1;?0/"OA_2DMKV#8;Q]8;?YK[HE0X!/\'RN=Q(Y/6O@2[_X*>^,+O0K^=)K
M.`S.Q$D<(C21`H0$I@$<@E@%Z\]17(_$;]MKQEKU[I&H&^0VNG881V42VY2?
MEBP*<?\`+3G=G'2OPSA[P`SN&9TL3G>*IXBC#50GSSLU%)-ZQN[KK?362>Q,
M\DS*K2G1AAXTI3NF^9VDKMVLD[*UE9-)6V/OSP3IWQI^'/B?2/$%S<#Q%HP>
M*`VUK)'*85$>UG;.ULYWCJ<C&0,\]/J_B6_U#XMZK;:]>ZU;:C<>3<6]DD+V
ML%SO`!1)0=A58\$G)(93V;CX+\(_\%'_`!%X*;PY+8S#5K!+V,W5K+(1;R!0
MR$E,@[LD_-ZA?05]>S?\%,/"'Q7\5+J"&TT@P.K7`NK;);>I4,`?F^1B=W!!
M'U->=Q7P'Q)A\?[:.7T:O/3G'VE"/))6DI0C*/O-WLTW'>Z]Y-'S^9Y)B*&7
M<M>,T[QM%*\&TG&4VDE:2]WEU5TW?1'TR?$NFZ8UC-=K<7UO-;"&S@M/,::U
M!E`>9S_%AFSP1@*2!6U8^/['7[2P?0K^VU<0W,]@MRTH*+)$<S0N<9&%(XSU
M^N*\3TCXQ?"WQ]X5DMM;U32;F\N78R2`/%(Q;Y0#)M^52#D$=05&ZM3XM_%'
M3OV=OAK;>,;3$%HLP@B>*_#Z<)7RA=AM+.$#,_.<G//:OYHS#@*M]8AE]3#U
MOK,IN$%./+3FW=)1;LW?JTM;-N]U;U,NSNM1C=\MIJ*]R-YQ6FCT:;TLKM<M
MU:5DST^3XAIX@E>_CD@M;:P27[3.S)N0M$,-(C8P7RN`"25YZ$UY[X=T2P^(
M_P`?/"W]FI;M=W^L0/<?:86/G;#$5?<I"H\&QR<@X"CTS7"_#K_@H%I?C:?^
MP+54U#7+NY\M!IUE]H;44D`C1-BAFY);!'\(X&*[_P".NH:%^Q-\,'MW-O;_
M`!,\56DVD065GJ1^S^$X9HE6X9F.1]HE7*D`'R59NYK]1\//#;-,DSF#S/#S
MP^J4;.ZE%7;5]+N^JM\*5[1<;F.-KO%SIU^=\L9*51N'([V348IMIRDERI)I
MIWF[J[7Z9?L*ZYH?BC]FO3M3\-_83HNI:OK5W;&S.86$FKWCL0>.2Q8GW)KU
MZOGK_@E5Y:_L$^`UAGM[J*/^T(UF@E62.4+J-TNX,O'./PZ=17T+7]28:WL8
M<K;5EOOMU\S^I.&JLJN3X2K-6<J=-_?%'P;_`,'(%R]K_P`$P=;='\LC7]+R
MWH/M`K^=70_%5OX.\0QEK7S9FB*QVK3%HFVL"P..<X!SGH,#FOZ(O^#E?59-
M&_X)5>)9HFE5_P"VM,4>4<,<SCH>W./RK^;[2-2DGU6YNID74%YD"RG`0<'[
MPZ9P`?7\:_1N&+?4_P#M[_(^+XRPZJ8MN:]WE76S>K/=IOCHNK:;NO5%GYEQ
MYT@MH1<11QJ,$;PQ;.`<G!&.O:O(?B3IFD:7?VL]I]N_M.7:5BEN#*&!8#<S
MG'"CD@#TX'-6O!D<]TD,LBC9#/,Z1I#L(VK\_P`W<8VC;GG(/&:=XLF9Y+66
M\2![:%FB8NP:55)`."O<X...,?G]).AR^[';?3Y;GYY@,#1P6)Y*&F]TGOO9
M=W]_HR#1]&C=)FGNI[>X?<$G8_NRH7E%(YR<#CG@=JKP>%89_#MM-+)<BZMY
MB\4WFETDZ?P^V00!VQZ4W0;NUU2W:4QX^3R;:665BJ*#MV8Z$X'/(/&.YJY_
M:T&GWDL4+-M412RNQ/E8XW`*0"OH,'G.`.*WA.[UVVV^9Z4Y5E-J+=_\OZ_X
M!3E@317?S+=[L:B0B,\SQRQ/U9P5Z<X8D=<<BO</V:_&#:??7UH8XIF^6*W+
M'#R_*6,P5_E++N;ORI`QQ7A7B:W%UL:&!X#.P$>R,LR*S*1P<[=O/;O7=?#W
MQ'>:1IK><8I+FWB0.T:`RNBKA6&2,CH,CYN1V.*\['TG7P\J$U=-?U_5CR\]
MP:Q.`<);OI?KI;_+_@GM=OJUK+XU_M"^U:2:[MO/\IEB<9D;825YV&3C[K#!
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M]0U"..22>X=)`RXP?W>0.Q)Z8;MS7S5?:[Y.M+>)`UP;=A!MN]I@MU!<KD9`
M"LIZ<`[0:X>',)5PV'=&6R;LM$M6WHNGW+O9;&/"."J*G.G+7E::5_5=E:[O
MK=W['US\+O\`@J9\5?"7ANQN=3^(3Z_"'6T6PUN,:C;QHJKAO)N%?#Y4;6X!
MW')KT_1/V]M6\=7NI3:W\./@CXGL/LC2JR^%H4>./RB75WA*`G(/3&-I!X.1
M^>KPP":2=[,(8;E$C=8R8@C<]&^[M!#'GCMS7NOP]UG^PC?S+<:9I]A=VK):
MS&YS]LN2C$R<'<O']Y>68`#'-=&-RRCR.K3A[VNJ\[;V^Z_17/5SIXK#4G.A
M5EKHDW>*VLDM5>SZ+:YUFH?M>>$9=+BO+3]E[X&:G)JF+*+_`$/48&N&WE'7
M:+K:!\J@9/!Z''-9VO\`[<+?#>-8]/\`V;/V>-'>:=99GN]'O;J6%S)A)&$M
MRRD;QQM8XZUX.=1M_$5Y^\:W:[V^0RP;H4$J,""/F^5PHX/&6R,'-0>+?&FH
M^)/#L=K+J!>UT]UM6CE1G6*13E8^^0S(!VP<D]<5ZOU2C;=VTZR_S/J:.88[
MFC&7*U?6\5?RMIK;T5W]Q[YHO_!4/XKVWQ22TT#2OA%X/A@U,0W&H:'X"TZW
MD)+_`#;9I4EE#-_>_7O5KX]?MM_$/XKWNLVFK>-O'FM6,\$-[''=ZG+'8Q)Y
MKQD".,@>40>,`<X["OEBSB^Q75Q=+=R6US//LG5IB;B"#=@D'D%7!'3)7DFO
M2;CQ_P#\(YINJV<\:G3IHX+<Q6TGGH5+,6*/D$J=S-G.,X!`/2'EE)3C-)+[
MN^FN_3^M#ESBMBJLX6DVK)<J;2>L;Z+1^72WD]?++W3I-:U%M'@=!+%ONYD#
M;C.78E'5B<$#./I^-==\(GO_``#J-[<V=IY#6;-(US$[+=63$#>S$]!M#+P.
M-V:I^`M=TVUO[:WMXXR]RRQ0N(N5A9PS*,G!'&#C^'V-=AI'B6T35[C[-=1V
M?VC;&6;&^5'DPP!`PVX*5YKIG4=W'HS/-,54Y)8;DO&W7KJK[?UIU1WVK:]J
M?B;X;Q-80C3H]3MO*F6XG,DFL20`!G#'E$3Y@%.-P8G'`%?J#^P1/=Z)_P`&
MTOQ%FNYEDFM]#\4.LL4>T,%,V"!@=P:_*K7?BTGA'PS;Z98W4K36%S,^W[%]
MHGB7;QEF^4?.X!X#?(,$5^JW[&FM7.I?\&R_Q+NKBXMI6_X1WQ48YH2-C)F<
M@GD\^N3FOD,Q52&&BG%)>T3\^N]]7]_II8]7PQH5(8BM%P2A*,K;W\MU?:W7
M\+)?AWX:\2/>>!RHG:6""8E(G;:(LKNX(ZMDD9.!T`K>\,?$+3M,^&FO6OG7
MC27,*9@^SX$9$@W*S?Q8`P3[X/05XWH/BJ]LM,GMWP(BR&&-OE7=M/?TZ=^#
MBK6B^,+CP\E_!+=)/'J4*`&(;D,BD$(Q//`/4?K7O3E"<.67J=^(R)3YHVTY
ME)6ZZI]MSZ$_9W\66VC^(;:V^T6JV2YDMK?S6\NVG8;@5+=QM9.1T'3UXWXH
M_$/9\0M<O+M8S;W-Q<3P)&PQ%(`D8VJ?NK@`9';.,$9KBO!?BO\`L7RKC-M]
MOC8""0J%@1L[5#L<94$YR3P2?6LGQYXKGU6]2>*X$:.3(5E3RXPS$;U5B.0"
M<<^H(/>MO91A4]M:[M;^K]S@PV0I9E.O)7YE9OYM_CIJ?1-C\2#>_LQ65A%]
MHM+S%[-)).NV`(LJD[6R<LQ`R<$G(SU->,Z#=WD6O*\$]L+E[DW4*%BSG;DL
MC,!RN%&X=.<$=:QM$\>WND>%I[&2^BN;:ZF87%K$P/E#`(96.2'W8`(."`:C
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MM04G>&CVNOZU^9O]:JT(<UN==O\`+_@'M?C3_@DQ\4]2T-M5^&G_``B_QGTB
MWBWQ7O@764O92G./.L6*7B'CE6B]J^</%/PZ\6_"2XN;7Q)H.M:#JI#1O#J>
MG2V;P8/W6$JJ>?QYQ77^)O-T:#^TM,DUG3=7AD26&YAF\F4,#EI`Z,&/);H1
M^8Q7K_PX_P""H'Q]^'=G_9$?Q2\3^(M+C(\S3_$4<.O10+CE!%>)(-O0#GKF
MLW2K7N[/\/\`/\B\-CL/4HW::_'MZ::]SYKM]$FD\//<0?.TL;));QEI1+DY
M.<]#R#VZ9IL%L^IM:HD0F`5=MM`=JG);<S#/4``#U],U]IWW_!2;5O%WAG[5
MJWP7_9[UN<V[-+<W/@VVM7NBO7)MGBP>37`R_M]^"-3U>W-U^RQ^S_)<*_E-
M*(=6MQ"!\QQMO!SD\9Q6M7GII1E'?S7]?@3AJT,1S>]:S?37\&_S/G76?#X\
M/^&FNHXBB^8(F=(B_D_=VDDGIN)!QT)`K,M/%&HRZO%_IB)<28$;[\"0XX4M
MG.#SFOO/4/VS?"VH>%+5-'_9[^``N?+1Q;W&D7NH++*<?*JR71XY'))Z&LOQ
M=^WA\7_A1;^=X6\.?!SX=1F18(X_#_P]TR&>U8IG:)I(I)-V.>N>G-1/VK=D
MK?\`;UORN>?A,WP$G[.O-<[;2T=WMWM_E\SS?X$_#[XW?':T.F^#OA]XXU=Y
M?FDNK?2IVL]HQ\I<KY4:G:.2PZ]A7T\WP-M-#^'I\-_'GXL^"O!%EI>EO)>^
M']%U"/Q1KK(C-M'EPDQ6ZE`J@23#GM7R7\1/VBOCE^TK:3?\)U\2OB)XJ@"_
M-;2ZR\%I:+N50PMT*Q;?;;Z]A7GWC3P\+#3;*UC'D!;<R7#@[5;&T_-CM\N!
MDG&3BIGETL3'GFHIQU3M=I][OK\MCS,5EN2SJQ5."<T[I]$^]D[_`"YCV[5?
M^"BWA_\`9NTHZ-^S7X6F\`6NKPM!?^-=7NAJ'C+58R<&-)@/*L(V.<I`-V&^
M^:K^,M<O]7^''AWQM8^-)_L&K7$PGTS4;@WMYYV$\UW55;/,B@$`-\I)S7S3
MX<\/Z9XHU"SMGNIE#3F,?9XR&V=-H7C.[`]"%Y'(KI_&&C7GA2UTZRLYKFVM
MGO!);M$V&=)5V[RPY7[N`>PQUK2.#<G&5)V2=WI=O3:[U7?T5EHV=V=4*.+J
MTH2=IQOHTK-/=6M:^BUM<_JF_P"".<MA/_P3=^&LFF10PVDD5^X2(857.HW1
MDX['>6R.QR,5]-5\9_\`!OJEQ%_P2*^$\=S.+J:)]:C:49^?;K>H*.O?`%?9
ME?FN+AR5YPO>S:_$_4LBH*AEN'HIWY805^]HI7/./VJ?V4_!7[:'P=O/`?Q!
MTZXU7PS?SQ7$]M#=RVK.\3;T^>-E;&1TSS7RO)_P;9?LBR6ZQGX?ZMA"&4CQ
M-J`((]_._P`XK[OHITL;B*4>2E-I>39V5<'0JRYZD$WYH^&X/^#=']E*VBC5
M/!&N#R7$B-_PD^H[E;*G.?._V13=5_X-R_V4-;EC>Y\#:S*8@0O_`!4E^.#U
M!Q+SGWK[FHK;^U,8]'5E][,%E."3YE2C?T1\*I_P;@?LE1VQB7P#JRQE_,VC
MQ+J``.<\?O>F>U2Q_P#!N=^R@F<^!M:?*JHW^)M0;;M(*XS-V(X]*^Y:*/[4
MQFWM9?>P_LG!/>E'[D?#TO\`P;L?LJSS&1_!>O.[;<L?%&H]L_\`3;OGGUJ6
MP_X-Y/V6--B*1>"=:P7$AW>)+]N1]9>GM7VY12_M3&?\_9?>R7DV`:Y71C;_
M``H^+=._X-_?V8-)L#;6_@S6(X2YDV_\)%?'YCU.3+G-94__``;D_LHW/WO!
M.NYWB0%?$^H`JP8L"/WO8DXK[GHIK-,8MJLOO8H9+E\&Y0H03?\`=7^1\<7'
M_!!;]F>YMTC/@W5E\NW-JKKX@O5D5"P;[PESG*CG.?SK%?\`X-U_V4Y'E9O`
MVL%KC/FG_A)+_,I.,EOWO/2ON&BE_:>+_P"?LOO9-/(LMAI"A!?]NK_(^&G_
M`.#<[]E&6%HV\$:XZ/C<#XGU#G'`'^NZ8K4T[_@W\_9<TF7?!X%U!6\G[.,Z
M]>D!,YP`9/<_F:^T:*I9MC4[JK+_`,"94LER^2M*C&W^%'Q$G_!O!^RLJ,#X
M'U=P\BRMO\1W[;BN,9S+T&.E.UO_`(-Y?V5M?DF:;P-JRB>3S72+Q'?QJ6R3
MG`EXZU]MT4EFF,6U67WL/[%R^_-[&-_\*/A>W_X-QOV3;:_>Y7P)K'GN`K.?
M$NH$D#H.9>GM["IA_P`&Z_[*N%#>"]>=(X?(1&\4:@51,@X`\[U'\_6ON*BC
M^U,8M%5E][+>4X)[TH_<CX9'_!N5^R?N4GP+K3%""I;Q-J!*XZ8_?<5=?_@W
MH_97DD+'P-JO1E`_X2*^PBL<E0/-X')Z=,G%?;-%+^T\9_S]E][%+)\#+XJ,
M?_`4?%%M_P`&^?[+]H[,GA#7@\G#M_PDU_E_J?-YKV30?^">'PW\%_L7:_\`
M`7P[;:MX>\!>(=/O=-F6UO3+>0)=AA*\<LXD^?YB1N5@#V->YT5G4QN(J149
MS;2[LTH9;A*$G.C2C%OLDOR/RNC_`.#0_P#9LCA$?_":_'`H""%.LZ9@$'(/
M_(/^GY5/+_P:/_LW31D'QI\;0=I`8:QI@*DDG(_XE^,\_3VK]2J*V6:XM;5&
M']FX;^1'Y<Z7_P`&E'[..C/FW\9_&M,DE@VKZ6ZN<8Y#:>15)_\`@T,_9N>>
M5_\`A.OCH#.=T@&M:6%8^N/[.XX)'%?JG10\UQ;T=1B66X5/F4%<_*B/_@T!
M_9IMS&8O&WQQA>!@T3)K.E_N\>@.G8.?<'I5R?\`X-'?V<+B`JWC?XX;SM_>
M#6=+#`#/'&GXP<^E?J714K,\4MILMX##MW<$?EOJG_!I)^SEJX0R^-_C=YD8
M4+(NKZ6'&WIS_9U0R_\`!HQ^SC)"4'COXYIDY!36=+!7DGC_`(EWO7ZG453S
M;&-W=1D++<*E901^5D/_``:%?LV00!!XW^.)"C`)UC2LYYYS_9W7G]!5ZU_X
M-*_V=+212OCCXW?+D@'6-+ZXQU_L_-?J+126:8M;383RW"S^*"/S!U7_`(-.
M_P!G;6$(E\:_&SYAABNL::">2>OV#U)X'%58/^#27]G*U5Q#XW^.$2R-N8+K
M6F<GUYT\U^I%%4\VQC=W49$<HP<594U8_,4?\&HW[/6QPWC?XU.TD9B:1]5T
MHOM/O_9_U_,UFS?\&C/[-DUV\Q\9_&W=+G>#K.F,&)&,G.GGFOU,HHEF^,EK
M*HPCE.#C\--(_,S1O^#5/]GS01B#QK\:0H!"J=7TW"#!''^@>]:?B+_@V`^`
M_B?3)+6Z\:_&4QNJ*I&K::6C*YPP)L#\W/4YK](**'FV,=KU'H<\N'LME-5)
M48N2ZGYV>'O^#9[X'^&K(P0>-OC"\;?>$NIZ8^[ZC[!@_C5?QA_P;#?`+QM9
MSPW7BKXM(MQG>8]3TXL<A0>6L6Q]W/U)K]&Z*/[6QE[^T9C'A?*8U/;1H14N
MY^9%G_P:E?L\V=W!/_PFGQH>>W9#'(^K:9N`0`*N?[/Z#`_*K6O?\&L'[/GB
M2XCENO&/QF9XY5FRNL:>F67IG%C_`/JSQVK]+:*?]L8W_GXSJ_L3`<W/[)71
MYY^RI^S5H?[('P$T+X=^&[S6-0T;0#<M!<ZK.D]Y,T]S+<R-(Z(BL?,F?G:.
=,9R<D^AT45Y\YRG)SENST:5*%*"ITU9)67HC_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
